<SEC-DOCUMENT>0001683168-26-001917.txt : 20260317
<SEC-HEADER>0001683168-26-001917.hdr.sgml : 20260317
<ACCEPTANCE-DATETIME>20260317154954
ACCESSION NUMBER:		0001683168-26-001917
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		64
CONFORMED PERIOD OF REPORT:	20260131
FILED AS OF DATE:		20260317
DATE AS OF CHANGE:		20260317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PharmaCyte Biotech, Inc.
		CENTRAL INDEX KEY:			0001157075
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				621772151
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40699
		FILM NUMBER:		26761524

	BUSINESS ADDRESS:	
		STREET 1:		3960 HOWARD HUGHES PARKWAY
		STREET 2:		SUITE 500
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89169
		BUSINESS PHONE:		(917) 595.2850

	MAIL ADDRESS:	
		STREET 1:		3960 HOWARD HUGHES PARKWAY
		STREET 2:		SUITE 500
		CITY:			LAS VEGAS
		STATE:			NV
		ZIP:			89169

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVILEX, INC.
		DATE OF NAME CHANGE:	20090324

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EFOODSAFETY COM INC
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>pharmacyte_i10q-013126.htm
<DESCRIPTION>FORM 10-Q FOR JAN 2026
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:us-roles="http://fasb.org/us-roles/2026" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2026" xmlns:country="http://xbrl.sec.gov/country/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:PMCB="http://pharmacyte.com/20260131">
<head>
     <title>PHARMACYTE BIOTECH, INC. 10-Q</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_023_US%2DGAAP%2D2026%2D(with%2DECD) -->
<!-- Field: Set; Name: xdx; ID: xdx_039_PMCB_pharmacyte.com_20260131 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20250501_20260131 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wNC0zMA== -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DDocumentFiscalYearFocus_2026 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DDocumentFiscalPeriodFocus_Q3 -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0001157075 -->
<!-- Field: Set; Name: xdx; ID: xdx_075_SO_pharmacyte__i10q%2D013126.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Year_0_Year -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--04-30</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000005" name="dei:DocumentFiscalYearFocus">2026</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000006" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000007" name="dei:EntityCentralIndexKey">0001157075</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2026-01-31" id="xdx2ixbrl0126" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-05-012024-07-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-05-012024-07-31_us-gaap_CommonStockMember" id="xdx2ixbrl0459" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-05-012024-07-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-05-012024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0467" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2024-05-012024-07-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2024-05-012024-07-31_us-gaap_CommonStockMember" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2024-05-012024-07-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2024-05-012024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemption" contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemption" contextRef="From2024-05-012024-07-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemption" contextRef="From2024-05-012024-07-31_us-gaap_CommonStockMember" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemption" contextRef="From2024-05-012024-07-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemption" contextRef="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemption" contextRef="From2024-05-012024-07-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0482" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemption" contextRef="From2024-05-012024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0483" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemption" contextRef="From2024-05-012024-07-31" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockRedemption" contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockRedemption" contextRef="From2024-05-012024-07-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockRedemption" contextRef="From2024-05-012024-07-31_us-gaap_CommonStockMember" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockRedemption" contextRef="From2024-05-012024-07-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0492" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockRedemption" contextRef="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockRedemption" contextRef="From2024-05-012024-07-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0494" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockRedemption" contextRef="From2024-05-012024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockRedemption" contextRef="From2024-05-012024-07-31" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0500" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0501" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2024-05-012024-07-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0502" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2024-05-012024-07-31_us-gaap_CommonStockMember" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0505" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2024-05-012024-07-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2024-05-012024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0507" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-05-012024-07-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0512" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-05-012024-07-31_us-gaap_CommonStockMember" id="xdx2ixbrl0513" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-05-012024-07-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0514" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-05-012024-07-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0516" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0520" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0521" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-012024-07-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0522" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-012024-07-31_us-gaap_CommonStockMember" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-012024-07-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0524" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0525" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-012024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0527" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0530" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0531" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-05-012024-07-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-05-012024-07-31_us-gaap_CommonStockMember" id="xdx2ixbrl0533" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-05-012024-07-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0534" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-05-012024-07-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0536" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-05-012024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0537" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:FractionalSharesAdjustmentValue" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0560" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:FractionalSharesAdjustmentValue" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0561" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:FractionalSharesAdjustmentValue" contextRef="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0562" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:FractionalSharesAdjustmentValue" contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0563" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:FractionalSharesAdjustmentValue" contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0564" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:FractionalSharesAdjustmentValue" contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:FractionalSharesAdjustmentValue" contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0566" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:FractionalSharesAdjustmentValue" contextRef="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0567" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:FractionalSharesAdjustmentValue" contextRef="From2024-08-012024-10-31" id="xdx2ixbrl0568" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0572" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0573" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0574" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0575" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0577" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0578" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0579" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0583" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0584" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0585" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0587" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0588" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0589" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemption" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0593" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemption" contextRef="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0594" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemption" contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0595" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemption" contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0596" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemption" contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0597" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemption" contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0598" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemption" contextRef="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0599" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemption" contextRef="From2024-08-012024-10-31" id="xdx2ixbrl0600" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockRedemption" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0605" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockRedemption" contextRef="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0606" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockRedemption" contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0607" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockRedemption" contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0608" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockRedemption" contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0609" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockRedemption" contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0610" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockRedemption" contextRef="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0611" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesBPreferredStockRedemption" contextRef="From2024-08-012024-10-31" id="xdx2ixbrl0612" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0616" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0617" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0618" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0619" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0621" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0622" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0623" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0626" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0627" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0628" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0629" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0630" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0631" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0632" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0636" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0637" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0638" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0639" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0640" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0641" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0643" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0646" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0647" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0648" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0649" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0650" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0652" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0653" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-11-012025-01-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0676" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-11-012025-01-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0677" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-11-012025-01-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0678" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-11-012025-01-31_us-gaap_CommonStockMember" id="xdx2ixbrl0679" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-11-012025-01-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0681" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-11-012025-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0682" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-11-012025-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0683" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-11-012025-01-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0686" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-11-012025-01-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0687" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-11-012025-01-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0688" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-11-012025-01-31_us-gaap_CommonStockMember" id="xdx2ixbrl0689" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-11-012025-01-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0690" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-11-012025-01-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0691" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-11-012025-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0692" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-11-012025-01-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0696" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-11-012025-01-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0697" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-11-012025-01-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0698" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-11-012025-01-31_us-gaap_CommonStockMember" id="xdx2ixbrl0699" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-11-012025-01-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0700" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-11-012025-01-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0701" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-11-012025-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0703" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-11-012025-01-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0706" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-11-012025-01-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0707" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-11-012025-01-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0708" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-11-012025-01-31_us-gaap_CommonStockMember" id="xdx2ixbrl0709" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-11-012025-01-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0710" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-11-012025-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0712" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-11-012025-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0713" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-05-012025-07-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0754" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-05-012025-07-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0755" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-05-012025-07-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0756" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-05-012025-07-31_us-gaap_CommonStockMember" id="xdx2ixbrl0757" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-05-012025-07-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0759" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-05-012025-07-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0760" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-05-012025-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0761" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-05-012025-07-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0764" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-05-012025-07-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0765" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-05-012025-07-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0766" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-05-012025-07-31_us-gaap_CommonStockMember" id="xdx2ixbrl0767" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-05-012025-07-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0768" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-05-012025-07-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0769" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-05-012025-07-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0770" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-05-012025-07-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0774" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-05-012025-07-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0775" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-05-012025-07-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0776" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-05-012025-07-31_us-gaap_CommonStockMember" id="xdx2ixbrl0777" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-05-012025-07-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0778" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-05-012025-07-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0779" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-05-012025-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0781" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0802" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0803" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-08-012025-10-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0804" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-08-012025-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0805" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-08-012025-10-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0807" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-08-012025-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0808" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-08-012025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0809" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:IssuanceOfSeriesCPreferredStockAndWarrants" contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0812" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:IssuanceOfSeriesCPreferredStockAndWarrants" contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0813" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:IssuanceOfSeriesCPreferredStockAndWarrants" contextRef="From2025-08-012025-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0815" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:IssuanceOfSeriesCPreferredStockAndWarrants" contextRef="From2025-08-012025-10-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0816" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:IssuanceOfSeriesCPreferredStockAndWarrants" contextRef="From2025-08-012025-10-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0817" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:IssuanceOfSeriesCPreferredStockAndWarrants" contextRef="From2025-08-012025-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0818" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:IssuanceOfSeriesCPreferredStockAndWarrants" contextRef="From2025-08-012025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0819" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:IssuanceOfSeriesCPreferredStockAndWarrants" contextRef="From2025-08-012025-10-31" id="xdx2ixbrl0820" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockAccretion" contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0824" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockAccretion" contextRef="From2025-08-012025-10-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0826" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockAccretion" contextRef="From2025-08-012025-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0827" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockAccretion" contextRef="From2025-08-012025-10-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0829" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockAccretion" contextRef="From2025-08-012025-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0830" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockAccretion" contextRef="From2025-08-012025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0831" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockDividendSubjectToSettlement" contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0834" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockDividendSubjectToSettlement" contextRef="From2025-08-012025-10-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0836" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockDividendSubjectToSettlement" contextRef="From2025-08-012025-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0837" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockDividendSubjectToSettlement" contextRef="From2025-08-012025-10-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0838" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockDividendSubjectToSettlement" contextRef="From2025-08-012025-10-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0839" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockDividendSubjectToSettlement" contextRef="From2025-08-012025-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0840" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockDividendSubjectToSettlement" contextRef="From2025-08-012025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0841" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockDividendSubjectToSettlement" contextRef="From2025-08-012025-10-31" id="xdx2ixbrl0842" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockDividendsAccrual" contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0844" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockDividendsAccrual" contextRef="From2025-08-012025-10-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0846" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockDividendsAccrual" contextRef="From2025-08-012025-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0847" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockDividendsAccrual" contextRef="From2025-08-012025-10-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0849" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockDividendsAccrual" contextRef="From2025-08-012025-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0850" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockDividendsAccrual" contextRef="From2025-08-012025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0851" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0854" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0855" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-08-012025-10-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0856" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-08-012025-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0857" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-08-012025-10-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0858" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-08-012025-10-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0859" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-08-012025-10-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0860" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0864" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0865" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-08-012025-10-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0866" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-08-012025-10-31_us-gaap_CommonStockMember" id="xdx2ixbrl0867" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-08-012025-10-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0868" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-08-012025-10-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0869" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-08-012025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0871" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0892" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0893" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0894" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember" id="xdx2ixbrl0895" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0897" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0898" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0899" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:StockIssuedUponVestingOfRestrictedStockUnits" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0902" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:StockIssuedUponVestingOfRestrictedStockUnits" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0903" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:StockIssuedUponVestingOfRestrictedStockUnits" contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0904" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:StockIssuedUponVestingOfRestrictedStockUnits" contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0908" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:StockIssuedUponVestingOfRestrictedStockUnits" contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0909" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0916" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0917" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0918" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0921" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0922" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0923" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0928" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0930" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember" id="xdx2ixbrl0931" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0933" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0934" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0935" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockRedeemed" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0938" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockRedeemed" contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0940" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockRedeemed" contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0943" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockRedeemed" contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0944" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockRedeemed" contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0945" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockSubjectToSettlement" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0952" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockSubjectToSettlement" contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0954" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockSubjectToSettlement" contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember" id="xdx2ixbrl0955" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockSubjectToSettlement" contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0956" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockSubjectToSettlement" contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0957" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockSubjectToSettlement" contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0958" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="PMCB:SeriesCPreferredStockSubjectToSettlement" contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0959" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0962" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0964" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember" id="xdx2ixbrl0965" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0967" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0968" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0969" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0972" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0973" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0974" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember" id="xdx2ixbrl0975" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0976" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0977" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0978" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0982" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0983" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0984" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember" id="xdx2ixbrl0985" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0986" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0987" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0989" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember" id="xdx2ixbrl0992" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember" id="xdx2ixbrl0993" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember" id="xdx2ixbrl0994" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember" id="xdx2ixbrl0995" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0996" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember" id="xdx2ixbrl0997" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0998" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0999" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2025-11-012026-01-31" id="xdx2ixbrl1000" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2026-01-31" id="xdx2ixbrl1185" decimals="0" scale="0" unitRef="USD">20165535</ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-04-30" id="xdx2ixbrl1187" decimals="0" scale="0" unitRef="USD">15172163</ix:nonFraction>
  <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="From2025-05-01to2026-01-31" id="xdx2ixbrl1229" decimals="INF" unitRef="Integer">1</ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_LongTermPortionOfLegalSettlementMember" id="xdx2ixbrl1489" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="pmcb-20260131.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2025-05-01to2026-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-03-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-03-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012025-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012025-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_custom_PreferredStockSeriesBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_custom_PreferredStockSeriesCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_custom_ContingentlyRedeemableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31_custom_PreferredStockSeriesBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31_custom_PreferredStockSeriesCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31_custom_ContingentlyRedeemableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_PreferredStockSeriesBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_PreferredStockSeriesCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_custom_ContingentlyRedeemableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_PreferredStockSeriesBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_PreferredStockSeriesCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_ContingentlyRedeemableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-31_custom_PreferredStockSeriesBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-31_custom_PreferredStockSeriesCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-31_custom_ContingentlyRedeemableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-31_custom_PreferredStockSeriesBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-31_custom_PreferredStockSeriesCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-31_custom_ContingentlyRedeemableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-07-31_custom_PreferredStockSeriesCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-07-31_custom_ContingentlyRedeemableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-07-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-07-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-07-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-10-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-08-012024-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-08-01</xbrli:startDate>
        <xbrli:endDate>2024-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012025-01-31_custom_PreferredStockSeriesBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012025-01-31_custom_PreferredStockSeriesCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012025-01-31_custom_ContingentlyRedeemableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012025-01-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012025-01-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012025-01-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012025-01-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012025-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012025-07-31_custom_PreferredStockSeriesBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012025-07-31_custom_PreferredStockSeriesCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012025-07-31_custom_ContingentlyRedeemableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012025-07-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012025-07-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012025-07-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012025-07-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012025-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012025-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2025-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-012025-10-31_custom_PreferredStockSeriesBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-01</xbrli:startDate>
        <xbrli:endDate>2025-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-012025-10-31_custom_PreferredStockSeriesCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-01</xbrli:startDate>
        <xbrli:endDate>2025-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-012025-10-31_custom_ContingentlyRedeemableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-01</xbrli:startDate>
        <xbrli:endDate>2025-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-012025-10-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-01</xbrli:startDate>
        <xbrli:endDate>2025-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-012025-10-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-01</xbrli:startDate>
        <xbrli:endDate>2025-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-012025-10-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-01</xbrli:startDate>
        <xbrli:endDate>2025-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-012025-10-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-01</xbrli:startDate>
        <xbrli:endDate>2025-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-012025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-01</xbrli:startDate>
        <xbrli:endDate>2025-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-012025-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-01</xbrli:startDate>
        <xbrli:endDate>2025-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31_custom_PreferredStockSeriesBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31_custom_PreferredStockSeriesCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31_custom_ContingentlyRedeemableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31_us-gaap_TreasuryStockCommonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_PreferredStockSeriesBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_PreferredStockSeriesCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_ContingentlyRedeemableWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-012025-08-31_us-gaap_PrivatePlacementMember_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-01</xbrli:startDate>
        <xbrli:endDate>2025-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-31_us-gaap_PrivatePlacementMember_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-012025-08-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-01</xbrli:startDate>
        <xbrli:endDate>2025-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_QCLSSeriesHConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-30_custom_QCLSSeriesHConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-132023-11-14_custom_FemasysPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-13</xbrli:startDate>
        <xbrli:endDate>2023-11-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-14_custom_FemasysPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-292026-01-31_custom_FemasysNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-29</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-01-292026-01-31_custom_FemasysMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:FemasysMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-01-29</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_FemasysCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_custom_FemasysPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012025-01-31_custom_FemasysPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_FemasysPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012025-01-31_custom_FemasysPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_FemasysPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_FemasysPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_FemasysPurchaseAgreementMember_custom_FemasysSeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:FemasysSeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_FemasysNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_FemasysWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_custom_FemasysNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_FemasysNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_custom_FemasysWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_FemasysWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-202025-11-21_custom_FemasysPurchaseAgreementMember_custom_FemasysCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:FemasysCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-20</xbrli:startDate>
        <xbrli:endDate>2025-11-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-202024-11-21_custom_FemasysPurchaseAgreementMember_custom_FemasysCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:FemasysCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-20</xbrli:startDate>
        <xbrli:endDate>2024-11-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-202025-11-21_custom_FemasysPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-20</xbrli:startDate>
        <xbrli:endDate>2025-11-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-202024-11-21_custom_FemasysPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-20</xbrli:startDate>
        <xbrli:endDate>2024-11-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012025-04-30_custom_FemasysPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2025-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_FemasysMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:FemasysMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_FemasysMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:FemasysMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-20_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_us-gaap_SeriesGPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-20_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_LongTermWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:LongTermWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-20_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_ShortTermWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:ShortTermWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-192024-05-20_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-19</xbrli:startDate>
        <xbrli:endDate>2024-05-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_LongTermWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:LongTermWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_LongTermWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:LongTermWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_ShortTermWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:ShortTermWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSAccruedDividendReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSAccruedDividendReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSAccruedDividendReceivableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSAccruedDividendReceivableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesGPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesGPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesGPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesGPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesGPreferredStockMember_custom_QCLSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesGPreferredStockMember_custom_QCLSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesGPreferredStockMember_custom_QCLSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_SeriesGWarrantsMember_custom_QCLSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesGWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_SeriesGWarrantsMember_custom_QCLSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesGWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_SeriesGWarrantsMember_custom_QCLSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesGWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesGPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesGPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputMaturityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_custom_MeasurementRedemptionPremiumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">PMCB:MeasurementRedemptionPremiumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_custom_MeasurementInputMarketInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">PMCB:MeasurementInputMarketInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-01</xbrli:startDate>
        <xbrli:endDate>2025-09-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_custom_MeasurementInputRedemptionPremiumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">PMCB:MeasurementInputRedemptionPremiumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_custom_MeasurementInputMarketInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">PMCB:MeasurementInputMarketInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_us-gaap_SeriesHPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_FemasysNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">PMCB:FemasysNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_FemasysNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">PMCB:FemasysNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_FemasysNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">PMCB:FemasysNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_FemasysWarrantsMember266865281">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">PMCB:FemasysWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_FemasysWarrantsMember266865281">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">PMCB:FemasysWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_FemasysWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">PMCB:FemasysWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_QCLSSeriesGPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesGPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_QCLSSeriesGPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesGPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_QCLSSeriesGPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesGPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_QCLSMember_custom_QCLSSeriesGWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesGWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_QCLSMember_custom_QCLSSeriesGWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesGWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_QCLSMember_custom_QCLSSeriesGWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesGWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_QCLSSeriesHPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-02_custom_QCLSSeriesHPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_QCLSSeriesHPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_QCLSSeriesHPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_QCLSSeriesHWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-02_custom_QCLSSeriesHWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_QCLSSeriesHWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_QCLSSeriesHWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_PayrollRelatedCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
            <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
          </xbrldi:typedMember>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:PayrollRelatedCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_PayrollRelatedCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
            <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
          </xbrldi:typedMember>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:PayrollRelatedCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_DirectorFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
            <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
          </xbrldi:typedMember>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:DirectorFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_DirectorFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
            <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
          </xbrldi:typedMember>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:DirectorFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_RAndDCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
            <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
          </xbrldi:typedMember>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:RAndDCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_RAndDCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
            <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
          </xbrldi:typedMember>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:RAndDCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_LegalSettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
            <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
          </xbrldi:typedMember>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:LegalSettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_LegalSettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
            <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
          </xbrldi:typedMember>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:LegalSettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_ExciseTaxOnStockRepurchasesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
            <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
          </xbrldi:typedMember>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:ExciseTaxOnStockRepurchasesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_ExciseTaxOnStockRepurchasesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
            <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
          </xbrldi:typedMember>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:ExciseTaxOnStockRepurchasesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_LongTermPortionOfLegalSettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
            <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
          </xbrldi:typedMember>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:LongTermPortionOfLegalSettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_LongTermPortionOfLegalSettlementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
            <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
          </xbrldi:typedMember>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:LongTermPortionOfLegalSettlementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_EquityPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PMCB:EquityPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_EquityPlan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PMCB:EquityPlan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-10-012025-10-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-01</xbrli:startDate>
        <xbrli:endDate>2025-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-28_custom_EquityPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PMCB:EquityPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_EquityPlan2022Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PMCB:EquityPlan2022Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_custom_EmployeesMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_EmployeesMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012025-01-31_custom_EmployeesMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012025-01-31_custom_EmployeesMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_EmployeesMember_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-10_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_custom_SeriesBPreferredWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesBPreferredWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_SeriesBPreferredWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesBPreferredWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_SeriesBPreferredWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesBPreferredWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012025-01-31_custom_SeriesBPreferredWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesBPreferredWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012025-01-31_custom_SeriesBPreferredWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesBPreferredWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-31_custom_SeriesBPreferredWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesBPreferredWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-16_custom_SettlementAgreementMember_custom_FirstWarrantIssuanceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:SettlementAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:FirstWarrantIssuanceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-29_custom_SettlementAgreementMember_custom_SettlementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:SettlementAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:SettlementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-152025-05-16_custom_FirstWarrantIssuanceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:FirstWarrantIssuanceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-15</xbrli:startDate>
        <xbrli:endDate>2025-05-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-07-282025-07-29_custom_AdditionalWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PMCB:AdditionalWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-07-28</xbrli:startDate>
        <xbrli:endDate>2025-07-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-07-29_custom_AdditionalWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PMCB:AdditionalWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-07-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012025-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2025-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_custom_SettlementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:SettlementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_SettlementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:SettlementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-19_custom_SeriesCPrivatePlacementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PMCB:SeriesCPrivatePlacementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-012025-08-19_custom_SeriesCPrivatePlacementAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PMCB:SeriesCPrivatePlacementAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-01</xbrli:startDate>
        <xbrli:endDate>2025-08-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_custom_SeriesCPrivatePlacementAgreementMember_custom_SeriesCPreferredWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PMCB:SeriesCPrivatePlacementAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:SeriesCPreferredWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_SeriesCPrivatePlacementAgreementMember_custom_SeriesCPreferredWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PMCB:SeriesCPrivatePlacementAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:SeriesCPreferredWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-19_custom_SeriesCPrivatePlacementAgreementMember_custom_SeriesCPlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PMCB:SeriesCPrivatePlacementAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:SeriesCPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-012025-08-19_custom_SeriesCPrivatePlacementAgreementMember_custom_SeriesCPlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PMCB:SeriesCPrivatePlacementAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:SeriesCPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-01</xbrli:startDate>
        <xbrli:endDate>2025-08-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012025-04-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2025-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012025-04-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2025-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_SeriesBWarrantsAndSettlementWarrantsAdjustedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PMCB:SeriesBWarrantsAndSettlementWarrantsAdjustedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_SGAustraliaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">PMCB:SGAustraliaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_custom_VinDeBonaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PMCB:VinDeBonaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_VinDeBonaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PMCB:VinDeBonaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012025-01-31_custom_VinDeBonaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PMCB:VinDeBonaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012025-01-31_custom_VinDeBonaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PMCB:VinDeBonaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_SGAustriaAndSubsidiariesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PMCB:SGAustriaAndSubsidiariesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-152025-05-16_custom_HCWainwrightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">PMCB:HCWainwrightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-15</xbrli:startDate>
        <xbrli:endDate>2025-05-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-192025-05-20_custom_HCWainwrightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">PMCB:HCWainwrightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-19</xbrli:startDate>
        <xbrli:endDate>2025-05-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-152025-05-16_custom_HCWainwrightMember_custom_FirstWarrantIssuanceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">PMCB:HCWainwrightMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:FirstWarrantIssuanceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-15</xbrli:startDate>
        <xbrli:endDate>2025-05-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-152025-05-16_custom_HCWainwrightMember_custom_AdditionalWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">PMCB:HCWainwrightMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:AdditionalWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-15</xbrli:startDate>
        <xbrli:endDate>2025-05-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-19_custom_AdditionalWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:AdditionalWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-182025-08-19_custom_FirstWarrantIssuanceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:FirstWarrantIssuanceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-18</xbrli:startDate>
        <xbrli:endDate>2025-08-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-182025-08-19_custom_AdditionalWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:AdditionalWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-18</xbrli:startDate>
        <xbrli:endDate>2025-08-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012025-01-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012025-01-31_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_custom_OptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:OptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_OptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:OptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012025-01-31_custom_OptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:OptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012025-01-31_custom_OptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:OptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_custom_PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:PreferredSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:PreferredSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012025-01-31_custom_PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:PreferredSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012025-01-31_custom_PreferredSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:PreferredSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012025-01-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012025-01-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2025-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-08-162025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SeriesCPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-16</xbrli:startDate>
        <xbrli:endDate>2025-08-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SeriesCPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SeriesCPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-08-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SeriesCPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SeriesCPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_MeasurementInputExpectedTermMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_MeasurementInputRedemptionPremiumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">PMCB:MeasurementInputRedemptionPremiumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_MeasurementInputMarketInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">PMCB:MeasurementInputMarketInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_us-gaap_SeriesCPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_us-gaap_SeriesAPreferredStockMember_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_MeasurementInputExpectedTermMember_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_MeasurementInputRedemptionPremiumMember_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">PMCB:MeasurementInputRedemptionPremiumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_MeasurementInputMarketInterestRateMember_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">PMCB:MeasurementInputMarketInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-12-102025-12-11_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-12-10</xbrli:startDate>
        <xbrli:endDate>2025-12-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_TreasuryStockCommonMember266868390">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_TreasuryStockCommonMember266868390">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-10-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-11-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-11-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2026-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_MarketableEquitySecuritiesMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_MarketableEquitySecuritiesMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_MoneyMarketAccountMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:MoneyMarketAccountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_MoneyMarketAccountMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:MoneyMarketAccountMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_ConvertibleNoteReceivableMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:ConvertibleNoteReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_ConvertibleNoteReceivableMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:ConvertibleNoteReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_WarrantAssetFemasysMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantAssetFemasysMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_WarrantAssetFemasysMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantAssetFemasysMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_InvestmentInPreferredStockQCLSMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:InvestmentInPreferredStockQCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_InvestmentInPreferredStockQCLSMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:InvestmentInPreferredStockQCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2026-01-31_custom_WarrantAssetQCLSMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantAssetQCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2026-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-30_custom_WarrantAssetQCLSMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001157075</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantAssetQCLSMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Year">
      <xbrli:measure>PMCB:Year</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>PMCB:Integer</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt"><a href="#k_001">Table of Contents</a></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b><br/>
<b>SECURITIES AND EXCHANGE COMMISSION</b><br/>
WASHINGTON, D.C. 20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90C_edei--DocumentType_c20250501__20260131_z9PLJY3AYbS"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000016" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 1%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--DocumentQuarterlyReport_c20250501__20260131_zYOoysBTMftf"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" format="ixt:booleantrue" id="Fact000017" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 98%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the quarterly period ended <span id="xdx_90E_edei--DocumentPeriodEndDate_c20250501__20260131_zO7Aqts8jYj1"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" format="ixt:datemonthdayyearen" id="Fact000018" name="dei:DocumentPeriodEndDate">January 31, 2026</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-decoration: underline">or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--DocumentTransitionReport_c20250501__20260131_zcLutmd1kJI7"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" format="ixt:booleanfalse" id="Fact000019" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 98%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the transition period from __________ to __________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number <span style="text-decoration: underline"><span id="xdx_905_edei--EntityFileNumber_c20250501__20260131_zyGNEZKdcneb"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000020" name="dei:EntityFileNumber">001-40699</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90E_edei--EntityRegistrantName_c20250501__20260131_zYIQxg5U7VTl"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000021" name="dei:EntityRegistrantName">PHARMACYTE BIOTECH, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20250501__20260131_z8ums0FsAGLc"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" format="ixt-sec:stateprovnameen" id="Fact000022" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20250501__20260131_z3XunGuWVbNc"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000023" name="dei:EntityTaxIdentificationNumber">62-1772151</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation or organization)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityAddressAddressLine1_c20250501__20260131_zfKBz2wHaENd"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000024" name="dei:EntityAddressAddressLine1">3960 Howard Hughes Parkway</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressAddressLine2_c20250501__20260131_zOy5cZgz99Bk"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000025" name="dei:EntityAddressAddressLine2">Suite 500</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressCityOrTown_c20250501__20260131_z94FjcWCymdl"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000026" name="dei:EntityAddressCityOrTown">Las Vegas</ix:nonNumeric></span>,
<span id="xdx_903_edei--EntityAddressStateOrProvince_c20250501__20260131_zWScqrzLNzBj"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000027" name="dei:EntityAddressStateOrProvince">NV</ix:nonNumeric></span> <span id="xdx_907_edei--EntityAddressPostalZipCode_c20250501__20260131_znS2BBunUkbc"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000028" name="dei:EntityAddressPostalZipCode">89169</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_906_edei--CityAreaCode_c20250501__20260131_zXuEBJbSwKLl"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000029" name="dei:CityAreaCode">917</ix:nonNumeric></span>) <span id="xdx_907_edei--LocalPhoneNumber_c20250501__20260131_zBLDPKV2B0g2"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000030" name="dei:LocalPhoneNumber">595-2850</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td colspan="5" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="5" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities registered pursuant to Section 12(b) of the Act:</b></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="5" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 39%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 39%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--Security12bTitle_c20250501__20260131_z3VXiXsI8Yu4"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000031" name="dei:Security12bTitle">Common Stock, Par Value $0.0001 Per Share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--TradingSymbol_c20250501__20260131_zNldr6GgQ31i"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000032" name="dei:TradingSymbol">PMCB</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_903_edei--SecurityExchangeName_c20250501__20260131_zJL9wn9FQqSb"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" format="ixt-sec:exchnameen" id="Fact000033" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. <span id="xdx_902_edei--EntityCurrentReportingStatus_c20250501__20260131_z4SPvz3CYaGc"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000034" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405)
during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <span id="xdx_908_edei--EntityInteractiveDataCurrent_c20250501__20260131_zYqCVOUOWIud"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" id="Fact000035" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 15%">&#160;</td>
    <td style="width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer&#160; &#9744;</span></td>
    <td style="width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer&#160; &#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityFilerCategory_c20250501__20260131_zRDzIL2r8osa"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" format="ixt-sec:entityfilercategoryen" id="Fact000036" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span>&#160; &#9746;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company&#160;<span id="xdx_909_edei--EntitySmallBusiness_c20250501__20260131_zcnjkbcRvNEa"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" format="ixt:booleantrue" id="Fact000037" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company&#160; <span id="xdx_904_edei--EntityEmergingGrowthCompany_c20250501__20260131_zZtIzOKFvIyc"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" format="ixt:booleanfalse" id="Fact000038" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;&#9744; No <span id="xdx_90F_edei--EntityShellCompany_dbF_c20250501__20260131_zT4iyVIXGUk9"><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" format="ixt:booleanfalse" id="Fact000039" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 12, 2026, the registrant had <span id="xdx_90C_edei--EntityCommonStockSharesOutstanding_iI_c20260312_zuBIPZr6RIk1"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2026-03-12" id="Fact000040" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,735,649</ix:nonFraction></span>
outstanding shares of common stock, with a par value of $0.0001 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PHARMACYTE BIOTECH, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="k_001"></span>INDEX TO QUARTERLY REPORT ON FORM 10-Q</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FOR THE THREE AND NINE MONTHS ENDED JANUARY
31, 2026</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 6%">&#160;</td>
    <td style="vertical-align: top; width: 88%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I.</b></span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#k_002">FINANCIAL INFORMATION</a></b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_004">Condensed Consolidated Financial Statements (Unaudited)</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_005">Condensed Consolidated Balance Sheets as of January 31, 2026, and April 30, 2025 (Unaudited)</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_005">Condensed Consolidated Statements of Operations for the Three and Nine Months Ended January 31, 2026, and 2025 (Unaudited)</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_006">Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine Months Ended January 31, 2026, and 2025 (Unaudited)</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_007">Condensed Consolidated Statements of Changes in Temporary Equity and Stockholders&#8217; Equity for the Three and Nine Months Ended January 31, 2026, and 2025 (Unaudited)</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_008">Condensed Consolidated Statements of Cash Flows for the Nine Months Ended January 31, 2026, and 2025 (Unaudited)</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_009">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_010">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_011">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_012">Controls and Procedures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART II.</b></span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#k_013">OTHER INFORMATION</a></b></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_014">Legal Proceedings</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_015">Risk Factors</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_016">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_017">Defaults Upon Senior Securities</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_018">Mine Safety Disclosures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_019">Other Information</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_020">Exhibits</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_021">Signatures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="k_002"></span>PART I &#8211; FINANCIAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="k_003"></span>Item 1. Financial Information.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PHARMACYTE BIOTECH, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="k_004"></span>CONDENSED CONSOLIDATED BALANCE SHEETS</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_111_z4i041s48w92" summary="xdx: Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="3" id="xdx_498_20260131_zu464kfDA03c" style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="3" id="xdx_495_20250430_zsAtK38iGni7" style="text-align: center"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font-size: 9pt">(Unaudited)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="3" style="text-align: center"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">January
    31, <br/> 2026</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">April
    30, <br/> 2025</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsAbstract_iB_zGnLVub55Suf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: center"><span style="font-size: 9pt">ASSETS</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AssetsCurrentAbstract_i01B_z74GmeHsodu5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 9pt">Current assets:</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzuN5_z5GY3DqiXx7e" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; width: 66%; text-align: justify"><span style="font-size: 9pt">Cash and cash equivalents</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2026-01-31" id="Fact000048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,165,535</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-04-30" id="Fact000049" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,172,163</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--MarketableSecuritiesCurrent_i02I_d0_maCzuN5_zeUnL5bkm2r" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-size: 9pt">Marketable equity securities</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2026-01-31" id="Fact000051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">372,251</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2025-04-30" id="Fact000052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">366,316</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--WarrantAssetCurrent_i02I_d0_maCzuN5_zInXmSXI8s7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-size: 9pt">Warrant asset &#8211; QCLS - current</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:WarrantAssetCurrent" contextRef="AsOf2026-01-31" id="Fact000054" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:WarrantAssetCurrent" contextRef="AsOf2025-04-30" id="Fact000055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,917,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--ConvertibleNoteReceivableCurrent_i02I_d0_maCzuN5_zzAF5opDnIOe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-size: 9pt">Convertible Note receivable &#8211; Femasys - current</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:ConvertibleNoteReceivableCurrent" contextRef="AsOf2026-01-31" id="Fact000057" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:ConvertibleNoteReceivableCurrent" contextRef="AsOf2025-04-30" id="Fact000058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,696,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzuN5_zXVhHcw4MIya" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"><span style="font-size: 9pt">Prepaid expenses and other
    current assets</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2026-01-31" id="Fact000060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,664</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-04-30" id="Fact000061" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,759</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AssetsCurrent_i01TI_mtCzuN5_maCzNUY_zT2UMSto6Xse" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1pt"><span style="font-size: 9pt">Total current assets</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2026-01-31" id="Fact000063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,696,450</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-04-30" id="Fact000064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,375,238</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OtherAssetsAbstract_i01B_z8KY2K7VGxg4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 9pt">Other assets:</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_maCzY8x_z7cYOY4uU3G7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-size: 9pt">Intangible asset</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2026-01-31" id="Fact000069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,549,427</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2025-04-30" id="Fact000070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,549,427</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--InvestmentsAndOtherNoncurrentAssets_i02I_pp0p0_d0_maCzY8x_zWYYuFe20tya" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-size: 9pt">Investment in preferred stock &#8211; QCLS</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:InvestmentsAndOtherNoncurrentAssets" contextRef="AsOf2026-01-31" id="Fact000072" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,472,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:InvestmentsAndOtherNoncurrentAssets" contextRef="AsOf2025-04-30" id="Fact000073" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,474,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--WarrantAssetNoncurrent_i02I_pp0p0_d0_maCzY8x_z78G4stgbHr1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-size: 9pt">Warrant asset &#8211; QCLS &#8211; non current</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:WarrantAssetNoncurrent" contextRef="AsOf2026-01-31" id="Fact000075" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,242,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:WarrantAssetNoncurrent" contextRef="AsOf2025-04-30" id="Fact000076" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,701,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--WarrantAssetFemasys_i02I_pp0p0_maCzY8x_zNNihnG21Qe7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-size: 9pt">Warrant asset &#8211; Femasys</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:WarrantAssetFemasys" contextRef="AsOf2026-01-31" id="Fact000078" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">906,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:WarrantAssetFemasys" contextRef="AsOf2025-04-30" id="Fact000079" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,061,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OtherAssets_i01I_maCzY8x_zsODRKA51CI4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"><span style="font-size: 9pt">Other assets</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2026-01-31" id="Fact000081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,688</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2025-04-30" id="Fact000082" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,688</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsNoncurrent_i01TI_mtCzY8x_maCzNUY_zM1wVIij2J11" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1pt"><span style="font-size: 9pt">Total other assets</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2026-01-31" id="Fact000084" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,177,115</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2025-04-30" id="Fact000085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,793,115</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--Assets_iTI_mtCzNUY_zViP0k0bqifd" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"><span style="font-size: 9pt">Total Assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2026-01-31" id="Fact000087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,873,565</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-04-30" id="Fact000088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,168,353</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zmx0bsTmRfC7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center"><span style="font-size: 9pt">LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS&#8217;
    EQUITY</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B_zHhBRIdty1L6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 9pt">Current liabilities:</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_i02I_maCzQOd_zsZgMNlsCdq4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-size: 9pt">Accounts payable</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2026-01-31" id="Fact000096" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,200,082</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">$</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-04-30" id="Fact000097" format="ixt:numdotdecimal" decimals="0" unitRef="USD">399,204</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzQOd_z1Ywug7wVfWd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-size: 9pt">Accrued expenses</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2026-01-31" id="Fact000099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,656</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-04-30" id="Fact000100" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,515,080</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DividendsPayableCurrent_i02I_d0_maCzQOd_zM6Kvu1EHMga" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"><span style="font-size: 9pt">Accrued Series C dividends</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DividendsPayableCurrent" contextRef="AsOf2026-01-31" id="Fact000102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,491</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DividendsPayableCurrent" contextRef="AsOf2025-04-30" id="Fact000103" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrent_i02TI_mtCzQOd_maCztUA_zK6St3doZ5c1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1pt"><span style="font-size: 9pt">Total current liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2026-01-31" id="Fact000105" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,678,229</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-04-30" id="Fact000106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,914,284</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OtherLiabilitiesAbstract_iB_zTnrrOvuU9Vg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 9pt">Other liabilities:</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesNoncurrent_iI_d0_maOLznkW_zKJHHXSwb1k3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-size: 9pt">Long-term portion of accrued expenses</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesNoncurrent" contextRef="AsOf2026-01-31" id="Fact000111" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesNoncurrent" contextRef="AsOf2025-04-30" id="Fact000112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--WarrantLiabilitiesNoncurrent_iI_maOLznkW_zuYhggl3tpOg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-size: 9pt">Warrant liabilities</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:WarrantLiabilitiesNoncurrent" contextRef="AsOf2026-01-31" id="Fact000114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,657,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:WarrantLiabilitiesNoncurrent" contextRef="AsOf2025-04-30" id="Fact000115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">338,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_d0_maOLznkW_zWeS7KZebEjl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"><span style="font-size: 9pt">Derivative liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2026-01-31" id="Fact000117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,136,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="AsOf2025-04-30" id="Fact000118" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--OtherLiabilities_iTI_d0_maCztUA_mtOLznkW_zwFNEBn1jZKa" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1pt"><span style="font-size: 9pt">Total other liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2026-01-31" id="Fact000120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,793,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OtherLiabilities" contextRef="AsOf2025-04-30" id="Fact000121" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--Liabilities_iTI_mtCztUA_maCzHAA_zYc0ediPN80c" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-size: 9pt">Total Liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2026-01-31" id="Fact000123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,471,229</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-04-30" id="Fact000124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,277,284</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--CommitmentsAndContingencies_iI_zVIXVpdRbqu8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-size: 9pt">Commitments and Contingencies (Note 8)</span></td><td style="font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0126">&#8211;</span></span></td><td style="font-weight: bold; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--TemporaryEquityAbstract_iB_zjqh9JPrBrJ5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 9pt">Temporary Equity:</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: justify"><span style="font-size: 9pt">Series B convertible preferred
    stock: authorized <span id="xdx_90E_eus-gaap--TemporaryEquitySharesAuthorized_iI_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zMoM1acq26bh" title="Temporary equity, shares authorized"><span id="xdx_906_eus-gaap--TemporaryEquitySharesAuthorized_iI_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zLYGebxxxBVf" title="Temporary equity, shares authorized"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2026-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact000132" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2025-04-30_us-gaap_SeriesBPreferredStockMember" id="Fact000134" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,000</ix:nonFraction></ix:nonFraction></span></span> shares, $<span id="xdx_906_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z7SDXOyW3ZJk" title="Temporary equity, par value"><span id="xdx_90C_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z0RQhEbdVnql" title="Temporary equity, par value"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2026-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact000136" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2025-04-30_us-gaap_SeriesBPreferredStockMember" id="Fact000138" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value and $<span id="xdx_907_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iI_pp0p0_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zsiYU46wzgze" title="Temporary equity, face value"><span id="xdx_905_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iI_pp0p0_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKfJTq1qhCA6" title="Temporary equity, face value"><ix:nonFraction name="us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital" contextRef="AsOf2026-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact000140" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital" contextRef="AsOf2025-04-30_us-gaap_SeriesBPreferredStockMember" id="Fact000142" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000</ix:nonFraction></ix:nonFraction></span></span> face value, <span id="xdx_901_eus-gaap--TemporaryEquitySharesIssued_iI_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zRzq52VQzMV4" title="Temporary equity, shares issued"><span id="xdx_90E_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z0EslobBs4a5" title="Temporary equity, shares outstanding"><span id="xdx_909_eus-gaap--TemporaryEquitySharesIssued_iI_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zNqCAJEw0Vel" title="Temporary equity, shares issued"><span id="xdx_901_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zBZlIDYRo39g" title="Temporary equity, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2026-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact000144" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2026-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact000146" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2025-04-30_us-gaap_SeriesBPreferredStockMember" id="Fact000148" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2025-04-30_us-gaap_SeriesBPreferredStockMember" id="Fact000150" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of January 31, 2026
    and April 30, 2025, respectively</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98A_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pp0p0_d0_maTWz6Pg_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zY0b6IOxxSF3" title="Convertible preferred stock" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2026-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact000152" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_985_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pp0p0_d0_maTWz6Pg_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zxxKEalXVHVl" title="Convertible preferred stock" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2025-04-30_us-gaap_SeriesBPreferredStockMember" id="Fact000154" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: justify"><span style="font-size: 9pt">Series C convertible preferred
    stock: authorized <span id="xdx_90C_eus-gaap--TemporaryEquitySharesAuthorized_iI_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zDE3JTCcE9Ej" title="Temporary equity, shares authorized"><span id="xdx_909_eus-gaap--TemporaryEquitySharesAuthorized_iI_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zcHXG27ApUX8" title="Temporary equity, shares authorized"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2026-01-31_us-gaap_SeriesCPreferredStockMember" id="Fact000156" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesAuthorized" contextRef="AsOf2025-04-30_us-gaap_SeriesCPreferredStockMember" id="Fact000158" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,000</ix:nonFraction></ix:nonFraction></span></span> shares, $<span id="xdx_904_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zAAsw0eLtx01" title="Temporary equity, par value"><span id="xdx_90D_eus-gaap--TemporaryEquityParOrStatedValuePerShare_iI_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zP1YC9Cq1Yn7" title="Temporary equity, par value"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2026-01-31_us-gaap_SeriesCPreferredStockMember" id="Fact000160" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:TemporaryEquityParOrStatedValuePerShare" contextRef="AsOf2025-04-30_us-gaap_SeriesCPreferredStockMember" id="Fact000162" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value and $<span id="xdx_90F_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iI_pp0p0_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zOVEd0sjO3Z6" title="Temporary equity, face value"><span id="xdx_90F_eus-gaap--TemporaryEquityValueExcludingAdditionalPaidInCapital_iI_pp0p0_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zDkxhj6brO8" title="Temporary equity, face value"><ix:nonFraction name="us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital" contextRef="AsOf2026-01-31_us-gaap_SeriesCPreferredStockMember" id="Fact000164" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital" contextRef="AsOf2025-04-30_us-gaap_SeriesCPreferredStockMember" id="Fact000166" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,000</ix:nonFraction></ix:nonFraction></span></span> face value, <span id="xdx_907_eus-gaap--TemporaryEquitySharesIssued_iI_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zXpnhmSrixh2" title="Temporary equity, shares issued"><span id="xdx_90C_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zsuvrGaet3Q8" title="Temporary equity, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2026-01-31_us-gaap_SeriesCPreferredStockMember" id="Fact000168" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2026-01-31_us-gaap_SeriesCPreferredStockMember" id="Fact000170" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,766</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90A_eus-gaap--TemporaryEquitySharesIssued_iI_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zWq3MtUBHKdd" title="Temporary equity, shares issued"><span id="xdx_904_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z5EnFWZZQFig" title="Temporary equity, shares outstanding"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2025-04-30_us-gaap_SeriesCPreferredStockMember" id="Fact000172" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="AsOf2025-04-30_us-gaap_SeriesCPreferredStockMember" id="Fact000174" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of January
    31, 2026 and April 30, 2025, respectively. Liquidation preference of $<span id="xdx_90E_eus-gaap--TemporaryEquityLiquidationPreference_iI_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z4O2zM3XKlL9" title="Temporary equity liquidation preference"><ix:nonFraction name="us-gaap:TemporaryEquityLiquidationPreference" contextRef="AsOf2026-01-31_us-gaap_SeriesCPreferredStockMember" id="Fact000176" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,765,671</ix:nonFraction></span> as of January 31, 2026.</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_987_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pp0p0_d0_maTWz6Pg_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zVaMBIepslp7" title="Convertible preferred stock" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2026-01-31_us-gaap_SeriesCPreferredStockMember" id="Fact000178" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">872,323</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98F_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iI_pp0p0_d0_maTWz6Pg_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zDqeZWna0j6c" title="Convertible preferred stock" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="AsOf2025-04-30_us-gaap_SeriesCPreferredStockMember" id="Fact000180" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--ContingentlyRedeemableWarrants_iI_d0_maTWz6Pg_zCJgZFenqIca" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"><span style="font-size: 9pt">Contingently redeemable warrants</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:ContingentlyRedeemableWarrants" contextRef="AsOf2026-01-31" id="Fact000182" format="ixt:numdotdecimal" decimals="0" unitRef="USD">417,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:ContingentlyRedeemableWarrants" contextRef="AsOf2025-04-30" id="Fact000183" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--TotalTemporaryEquity_iTI_d0_mtTWz6Pg_maCzHAA_zTDExF746emk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-size: 9pt">Total temporary equity</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:TotalTemporaryEquity" contextRef="AsOf2026-01-31" id="Fact000185" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,289,323</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:TotalTemporaryEquity" contextRef="AsOf2025-04-30" id="Fact000186" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--StockholdersEquityAbstract_iB_zfGv4SsMMgik" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify"><span style="font-size: 9pt">Stockholders&#8217; equity:</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-size: 9pt">Preferred stock, authorized <span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20260131_zkFJYwlbvgxd" title="Preferred stock, shares authorized"><span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20250430_zQyHTg77tCx" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2026-01-31" id="Fact000191" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-04-30" id="Fact000193" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span></span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: justify"><span style="font-size: 9pt">Series A preferred stock: authorized
    <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zkmCggzDXz0k" title="Preferred stock, shares authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zOn12DctP3Q" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2026-01-31_us-gaap_SeriesAPreferredStockMember" id="Fact000195" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-04-30_us-gaap_SeriesAPreferredStockMember" id="Fact000197" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1</ix:nonFraction></ix:nonFraction></span></span> share, $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zpfQ2Gk016U3" title="Preferred stock, par value"><span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zsvpvFvOc5Qf" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2026-01-31_us-gaap_SeriesAPreferredStockMember" id="Fact000199" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-04-30_us-gaap_SeriesAPreferredStockMember" id="Fact000201" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value and <span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zf7g5ZLR8rp2" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z2mi1GKTMhq6" title="Preferred stock, shares outstanding"><span id="xdx_902_eus-gaap--PreferredStockSharesIssued_iI_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z4Fq8z8rMBJ1" title="Preferred stock, shares issued"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zlPbVWYRxrbl" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2026-01-31_us-gaap_SeriesAPreferredStockMember" id="Fact000203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2026-01-31_us-gaap_SeriesAPreferredStockMember" id="Fact000205" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-04-30_us-gaap_SeriesAPreferredStockMember" id="Fact000207" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-04-30_us-gaap_SeriesAPreferredStockMember" id="Fact000209" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of January 31, 2026 and April 30, 2025</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_987_eus-gaap--PreferredStockValue_i01I_pp0p0_d0_maCzOki_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zIUIGgFhK2va" title="Preferred stock value" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2026-01-31_us-gaap_SeriesAPreferredStockMember" id="Fact000211" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98C_eus-gaap--PreferredStockValue_i01I_pp0p0_d0_maCzOki_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z1jY8nFnJI0g" title="Preferred stock value" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-04-30_us-gaap_SeriesAPreferredStockMember" id="Fact000213" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--CommonStockValue_i01I_maCzOki_zGo1LqzYhnK1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: justify"><span style="font-size: 9pt">Common stock: authorized <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20260131_zXZKKMi0t2Zc" title="Common stock, shares authorized"><span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_c20250430_z46xDHdFPf6" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2026-01-31" id="Fact000218" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-04-30" id="Fact000220" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span>
    shares, $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_c20260131_zn5nEc1XMVJb" title="Common stock, par value"><span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_c20250430_zGjhjOjW4meb" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2026-01-31" id="Fact000222" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-04-30" id="Fact000224" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_c20260131_zqvJuZYVZqff" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2026-01-31" id="Fact000226" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,005,715</ix:nonFraction></span> and <span id="xdx_901_eus-gaap--CommonStockSharesIssued_c20250430_zCvbKxHRK6R7" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-04-30" id="Fact000228" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,672,095</ix:nonFraction></span> shares issued and <span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_c20260131_zeLHvyyuLZch" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2026-01-31" id="Fact000230" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,735,649</ix:nonFraction></span> and <span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_c20250430_zKVMj6so5Yyl" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-04-30" id="Fact000232" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,795,779</ix:nonFraction></span> shares outstanding as of January
    31, 2026 and April 30, 2025, respectively.</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2026-01-31" id="Fact000215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,602</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-04-30" id="Fact000216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,167</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AdditionalPaidInCapital_i01I_maCzOki_zkfi1561hGjj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-size: 9pt">Additional paid-in capital</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2026-01-31" id="Fact000234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183,141,663</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2025-04-30" id="Fact000235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,489,647</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maCzOki_z9992o50CaTb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-size: 9pt">Accumulated deficit</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2026-01-31" id="Fact000237" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">100,000,171</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-04-30" id="Fact000238" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">84,968,960</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--TreasuryStockCommonValue_i01NI_di_msCzOki_znyiN9dieCXj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify"><span style="font-size: 9pt">Treasury stock, at cost, <span id="xdx_90A_eus-gaap--TreasuryStockCommonShares_iI_c20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zaVMB9cIzMM4" title="Treasury stock, common shares"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2026-01-31_us-gaap_TreasuryStockCommonMember" id="Fact000243" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,270,066</ix:nonFraction></span> and <span id="xdx_90E_eus-gaap--TreasuryStockCommonShares_iI_c20250430__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zwRjnfhnDoq5" title="Treasury stock, common shares"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2025-04-30_us-gaap_TreasuryStockCommonMember" id="Fact000245" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,876,316</ix:nonFraction></span>
    shares as of January 31, 2026, and April 30, 2025, respectively.</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:TreasuryStockCommonValue" contextRef="AsOf2026-01-31" id="Fact000240" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,009,541</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:TreasuryStockCommonValue" contextRef="AsOf2025-04-30" id="Fact000241" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,607,916</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i01I_maCzOki_zEhaMe0iq87h" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"><span style="font-size: 9pt">Accumulated other comprehensive
    loss</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2026-01-31" id="Fact000247" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,540</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2025-04-30" id="Fact000248" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,869</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--StockholdersEquity_iTI_mtCzOki_maCzHAA_z2rXaDlORDHe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: justify; padding-bottom: 1pt"><span style="font-size: 9pt">Total stockholders&#8217; equity</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-01-31" id="Fact000250" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,113,013</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-04-30" id="Fact000251" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,891,069</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzHAA_zV0L2kDz5Xj3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt"><span style="font-size: 9pt">Total Liabilities, Temporary
    Equity and Stockholders&#8217; Equity</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2026-01-31" id="Fact000253" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,873,565</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-04-30" id="Fact000254" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,168,353</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying Notes to Condensed Consolidated
Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PHARMACYTE BIOTECH, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="k_005"></span>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(UNAUDITED)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_113_z4ZfZVouK3o5" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_494_20251101__20260131_zGCGBog2bwdg" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_49A_20241101__20250131_znPbck8GoYU3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_49A_20250501__20260131_zdfXtNMrU1d9" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_49E_20240501__20250131_zja4SCsyAmva" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended <br/> January 31,</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended <br/> January 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Revenues_d0_maCz0gg_zLqOnO1xQCXf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Revenue</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-11-012026-01-31" id="Fact000256" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-11-012025-01-31" id="Fact000257" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2025-05-01to2026-01-31" id="Fact000258" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-05-012025-01-31" id="Fact000259" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpensesAbstract_iB_zapHKJvsAJIg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzJde_zzbITNPLnThi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 40%; text-align: left">Research and development costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-11-012026-01-31" id="Fact000266" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,113</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-11-012025-01-31" id="Fact000267" format="ixt:numdotdecimal" decimals="0" unitRef="USD">118,196</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-05-01to2026-01-31" id="Fact000268" format="ixt:numdotdecimal" decimals="0" unitRef="USD">329,355</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-05-012025-01-31" id="Fact000269" format="ixt:numdotdecimal" decimals="0" unitRef="USD">311,682</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzJde_zwgwAbVgNj1j" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-11-012026-01-31" id="Fact000271" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,024,989</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-11-012025-01-31" id="Fact000272" format="ixt:numdotdecimal" decimals="0" unitRef="USD">842,056</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2025-05-01to2026-01-31" id="Fact000273" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,013,103</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2024-05-012025-01-31" id="Fact000274" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,024,316</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingExpenses_iT_mtCzJde_msCz0gg_z95aW1vc5XAi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-11-012026-01-31" id="Fact000276" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,118,102</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-11-012025-01-31" id="Fact000277" format="ixt:numdotdecimal" decimals="0" unitRef="USD">960,252</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2025-05-01to2026-01-31" id="Fact000278" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,342,458</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-05-012025-01-31" id="Fact000279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,335,998</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingIncomeLoss_iT_mtCz0gg_maCzamr_zS2yumiaG1Fb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-11-012026-01-31" id="Fact000281" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,118,102</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-11-012025-01-31" id="Fact000282" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">960,252</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2025-05-01to2026-01-31" id="Fact000283" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,342,458</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-05-012025-01-31" id="Fact000284" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,335,998</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_z1PEdWJ3Dfg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income (expenses):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestIncomeOther_i01_maCzBr8_z5KfqxlS81c" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2025-11-012026-01-31" id="Fact000291" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,668</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2024-11-012025-01-31" id="Fact000292" format="ixt:numdotdecimal" decimals="0" unitRef="USD">255,692</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2025-05-01to2026-01-31" id="Fact000293" format="ixt:numdotdecimal" decimals="0" unitRef="USD">654,848</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2024-05-012025-01-31" id="Fact000294" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,185,686</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ChangeInFairValueOfWarrantLiability_i01_maCzBr8_zCrK4QYm522h" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantLiability" contextRef="From2025-11-012026-01-31" id="Fact000296" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,895,865</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantLiability" contextRef="From2024-11-012025-01-31" id="Fact000297" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,487,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantLiability" contextRef="From2025-05-01to2026-01-31" id="Fact000298" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,335,135</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantLiability" contextRef="From2024-05-012025-01-31" id="Fact000299" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,400,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ChangeInFairValueOfDerivativeLiability_i01_d0_maCzBr8_z6cc0zb4Ohz8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:ChangeInFairValueOfDerivativeLiability" contextRef="From2025-11-012026-01-31" id="Fact000301" format="ixt:numdotdecimal" decimals="0" unitRef="USD">557,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:ChangeInFairValueOfDerivativeLiability" contextRef="From2024-11-012025-01-31" id="Fact000302" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:ChangeInFairValueOfDerivativeLiability" contextRef="From2025-05-01to2026-01-31" id="Fact000303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">859,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:ChangeInFairValueOfDerivativeLiability" contextRef="From2024-05-012025-01-31" id="Fact000304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,184,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ChangeInFairValueOfConvertibleNoteReceivable_i01_d0_maCzBr8_z3v0N2dRfQGh" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Change in fair value of convertible note receivable - Femasys</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:ChangeInFairValueOfConvertibleNoteReceivable" contextRef="From2025-11-012026-01-31" id="Fact000306" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PMCB:ChangeInFairValueOfConvertibleNoteReceivable" contextRef="From2024-11-012025-01-31" id="Fact000307" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">79,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:ChangeInFairValueOfConvertibleNoteReceivable" contextRef="From2025-05-01to2026-01-31" id="Fact000308" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,304,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:ChangeInFairValueOfConvertibleNoteReceivable" contextRef="From2024-05-012025-01-31" id="Fact000309" format="ixt:numdotdecimal" decimals="0" unitRef="USD">601,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ChangeInFairValueOfWarrantAssetFemasys_i01_d0_maCzBr8_zQVfD1aj3vH" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Change in fair value of warrant asset - Femasys</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantAssetFemasys" contextRef="From2025-11-012026-01-31" id="Fact000311" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">214,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantAssetFemasys" contextRef="From2024-11-012025-01-31" id="Fact000312" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">596,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantAssetFemasys" contextRef="From2025-05-01to2026-01-31" id="Fact000313" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,155,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantAssetFemasys" contextRef="From2024-05-012025-01-31" id="Fact000314" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,830,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--ChangeInFairValueOfInvestment_i01_d0_maCzBr8_zLptbsZIjjyk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Change in fair value of investment - QCLS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:ChangeInFairValueOfInvestment" contextRef="From2025-11-012026-01-31" id="Fact000316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,725,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PMCB:ChangeInFairValueOfInvestment" contextRef="From2024-11-012025-01-31" id="Fact000317" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,031,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PMCB:ChangeInFairValueOfInvestment" contextRef="From2025-05-01to2026-01-31" id="Fact000318" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,485,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PMCB:ChangeInFairValueOfInvestment" contextRef="From2024-05-012025-01-31" id="Fact000319" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,642,050</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--ChangeInFairValueOfWarrantAsset_i01_d0_maCzBr8_zG4k4rFsgadj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Change in fair value of warrants - QCLS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantAsset" contextRef="From2025-11-012026-01-31" id="Fact000321" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,200,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantAsset" contextRef="From2024-11-012025-01-31" id="Fact000322" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,194,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantAsset" contextRef="From2025-05-01to2026-01-31" id="Fact000323" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantAsset" contextRef="From2024-05-012025-01-31" id="Fact000324" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,123,684</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--GainOnFairValueOfWarrantsWainwright_i01_d0_maCzBr8_zzRWi6Xxdj86" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Gain on legal settlement &#8211; re-fair value of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:GainOnFairValueOfWarrantsWainwright" contextRef="From2025-11-012026-01-31" id="Fact000326" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:GainOnFairValueOfWarrantsWainwright" contextRef="From2024-11-012025-01-31" id="Fact000327" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:GainOnFairValueOfWarrantsWainwright" contextRef="From2025-05-01to2026-01-31" id="Fact000328" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:GainOnFairValueOfWarrantsWainwright" contextRef="From2024-05-012025-01-31" id="Fact000329" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--GainOnRelatedPartyInvestmentQcls_i01_d0_maCzBr8_znz9Asl0pGKg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Gain on related party investment - QCLS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:GainOnRelatedPartyInvestmentQcls" contextRef="From2025-11-012026-01-31" id="Fact000331" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:GainOnRelatedPartyInvestmentQcls" contextRef="From2024-11-012025-01-31" id="Fact000332" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:GainOnRelatedPartyInvestmentQcls" contextRef="From2025-05-01to2026-01-31" id="Fact000333" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,089,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:GainOnRelatedPartyInvestmentQcls" contextRef="From2024-05-012025-01-31" id="Fact000334" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,395,734</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants_i01_d0_maCzBr8_zRYWR3mIKHp9" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Issuance costs &#8211; Series C convertible preferred stock and warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants" contextRef="From2025-11-012026-01-31" id="Fact000336" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants" contextRef="From2024-11-012025-01-31" id="Fact000337" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PMCB:IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants" contextRef="From2025-05-01to2026-01-31" id="Fact000338" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,234,553</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants" contextRef="From2024-05-012025-01-31" id="Fact000339" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--LossOnIssuanceOfSeriesCConvertiblePreferredStock_i01_d0_maCzBr8_z8i0sJTlt85i" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Loss on issuance of Series C convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:LossOnIssuanceOfSeriesCConvertiblePreferredStock" contextRef="From2025-11-012026-01-31" id="Fact000341" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:LossOnIssuanceOfSeriesCConvertiblePreferredStock" contextRef="From2024-11-012025-01-31" id="Fact000342" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PMCB:LossOnIssuanceOfSeriesCConvertiblePreferredStock" contextRef="From2025-05-01to2026-01-31" id="Fact000343" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">215,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="PMCB:LossOnIssuanceOfSeriesCConvertiblePreferredStock" contextRef="From2024-05-012025-01-31" id="Fact000344" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_i01_d0_maCzBr8_zOd1JmN2xFIe" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Unrealized loss on marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2025-11-012026-01-31" id="Fact000346" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">128,939</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2024-11-012025-01-31" id="Fact000347" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,632</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2025-05-01to2026-01-31" id="Fact000348" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">294,065</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2024-05-012025-01-31" id="Fact000349" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,632</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OtherNonoperatingIncomeExpense_i01_maCzBr8_zqyNLESvusB7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-11-012026-01-31" id="Fact000351" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">632</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-11-012025-01-31" id="Fact000352" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">400</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2025-05-01to2026-01-31" id="Fact000353" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">848</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-05-012025-01-31" id="Fact000354" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">852</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpense_iT_pp0p0_mtCzBr8_maCzamr_zOdOVbmGojY1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total other income and (expense), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-11-012026-01-31" id="Fact000356" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,864,962</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-11-012025-01-31" id="Fact000357" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,085,076</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2025-05-01to2026-01-31" id="Fact000358" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,688,753</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-05-012025-01-31" id="Fact000359" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,242,466</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_iT_mtCzamr_maCz3wC_zDTBLJ5YQRT5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net income (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-11-012026-01-31" id="Fact000361" format="ixt:numdotdecimal" decimals="0" unitRef="USD">746,860</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-11-012025-01-31" id="Fact000362" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,045,328</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-05-01to2026-01-31" id="Fact000363" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,031,211</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-012025-01-31" id="Fact000364" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,906,468</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DividendsPreferredStock_iN_di0_msCz3wC_ziU1MDkY9vAf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Preferred stock dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-11-012026-01-31" id="Fact000366" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,458</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2024-11-012025-01-31" id="Fact000367" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2025-05-01to2026-01-31" id="Fact000368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">195,097</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2024-05-012025-01-31" id="Fact000369" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,129,759</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--PreferredStockAccretionOfRedemptionDiscount_iN_di0_msCz3wC_zqjqsLN4YrYe" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Preferred stock accretion</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" contextRef="From2025-11-012026-01-31" id="Fact000371" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,204,657</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" contextRef="From2024-11-012025-01-31" id="Fact000372" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" contextRef="From2025-05-01to2026-01-31" id="Fact000373" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,106,653</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" contextRef="From2024-05-012025-01-31" id="Fact000374" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,193,404</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_iT_pp0p0_mtCz3wC_zRVeX0vNP3b7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) attributable to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-11-012026-01-31" id="Fact000376" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,556,255</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-11-012025-01-31" id="Fact000377" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,045,328</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-05-01to2026-01-31" id="Fact000378" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">18,332,961</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-05-012025-01-31" id="Fact000379" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,583,305</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Basic and diluted income (loss) per share attributable to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_c20251101__20260131_zQNTf3MKJ1Z3" title="Basic income (loss) per share attributable to common stockholders" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVOQVVESVRFRCkA"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20251101__20260131_zv9MsdXElTU8" title="Diluted income (loss) per share attributable to common stockholders" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVOQVVESVRFRCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-11-012026-01-31" id="Fact000381" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-11-012026-01-31" id="Fact000383" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.17</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20241101__20250131_z98TsRLK1Br1" title="Basic income (loss) per share attributable to common stockholders" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVOQVVESVRFRCkA"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_c20241101__20250131_zm7EdsGXr8e6" title="Basic income (loss) per share attributable to common stockholders" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVOQVVESVRFRCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-11-012025-01-31" id="Fact000385" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-11-012025-01-31" id="Fact000387" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.44</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_c20250501__20260131_zGBdXkqCfFLe" title="Basic income (loss) per share attributable to common stockholders" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVOQVVESVRFRCkA"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20250501__20260131_zpdMnmxo7h32" title="Diluted income (loss) per share attributable to common stockholders" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVOQVVESVRFRCkA">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-05-01to2026-01-31" id="Fact000389" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-05-01to2026-01-31" id="Fact000391" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.41</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20240501__20250131_z2PJzDV9coj7" title="Basic income (loss) per share attributable to common stockholders" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVOQVVESVRFRCkA"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_c20240501__20250131_zzHyY8C39Ju9" title="Basic income (loss) per share attributable to common stockholders" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVOQVVESVRFRCkA"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-05-012025-01-31" id="Fact000393" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-05-012025-01-31" id="Fact000395" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.67</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Weighted average shares outstanding basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20251101__20260131_zCUM7Kc3Rmw1" title="Weighted average shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVOQVVESVRFRCkA"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20251101__20260131_z55IBm64WP2k" title="Weighted average shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVOQVVESVRFRCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-11-012026-01-31" id="Fact000397" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-11-012026-01-31" id="Fact000399" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,262,829</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20241101__20250131_zIb0EI8ZzhAa" title="Weighted average shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVOQVVESVRFRCkA"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20241101__20250131_z0CkhFZHf9Qd" title="Weighted average shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVOQVVESVRFRCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-11-012025-01-31" id="Fact000401" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-11-012025-01-31" id="Fact000403" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,960,014</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250501__20260131_zLsyD9qFctN3" title="Weighted average shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVOQVVESVRFRCkA"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250501__20260131_zX2WvjCqaJe4" title="Weighted average shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVOQVVESVRFRCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-05-01to2026-01-31" id="Fact000405" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-05-01to2026-01-31" id="Fact000407" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,618,128</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240501__20250131_zcIweOQOabb9" title="Weighted average shares outstanding basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVOQVVESVRFRCkA"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240501__20250131_zciRdDA8bIO1" title="Weighted average shares outstanding diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OREVOU0VEIENPTlNPTElEQVRFRCBTVEFURU1FTlRTIE9GIE9QRVJBVElPTlMgKFVOQVVESVRFRCkA"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-05-012025-01-31" id="Fact000409" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-05-012025-01-31" id="Fact000411" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,487,813</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying Notes to Condensed Consolidated
Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PHARMACYTE BIOTECH, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="k_006"></span>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE
INCOME (LOSS)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(UNAUDITED)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_305_113_zIDQ5wxJUK39" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_491_20251101__20260131_zc71tMwSV6ug" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_497_20241101__20250131_zf4lgMJpuQTh" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_497_20250501__20260131_zWhSI2cZQGK4" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_494_20240501__20250131_z6LcneYLoFz3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Three Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>January 31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Nine Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>January 31,</b></p></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_maCzSvL_z5sxzQ8ZY7Kc" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">Net income (loss)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-11-012026-01-31" id="Fact000413" format="ixt:numdotdecimal" decimals="0" unitRef="USD">746,860</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-11-012025-01-31" id="Fact000414" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,045,328</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-05-01to2026-01-31" id="Fact000415" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,031,211</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-012025-01-31" id="Fact000416" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,906,468</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ComprehensiveIncomeNetOfTaxAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other comprehensive income (loss):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_i01_pp0p0_maOCILNzlXW_zO84ZP9vf9oj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Foreign currency translation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2025-11-012026-01-31" id="Fact000423" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,587</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-11-012025-01-31" id="Fact000424" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,219</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2025-05-01to2026-01-31" id="Fact000425" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,329</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-05-012025-01-31" id="Fact000426" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">975</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_iT_pp0p0_mtOCILNzlXW_maCzSvL_zAJkOv0l4Tg7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Other comprehensive income (loss)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2025-11-012026-01-31" id="Fact000428" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,587</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2024-11-012025-01-31" id="Fact000429" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,219</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2025-05-01to2026-01-31" id="Fact000430" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,329</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2024-05-012025-01-31" id="Fact000431" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">975</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCzSvL_z8j8XmgdlOK4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Comprehensive income (loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2025-11-012026-01-31" id="Fact000433" format="ixt:numdotdecimal" decimals="0" unitRef="USD">749,447</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-11-012025-01-31" id="Fact000434" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,046,547</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2025-05-01to2026-01-31" id="Fact000435" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,028,882</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-05-012025-01-31" id="Fact000436" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,905,493</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying Notes to Condensed Consolidated
Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PHARMACYTE BIOTECH, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="k_007"></span>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES
IN TEMPORARY EQUITY AND STOCKHOLDERS&#8217; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THREE AND NINE MONTHS ENDED JANUARY 31, 2026
AND 2025</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(UNAUDITED)</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_114_zVSETwPxBIH4" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS' EQUITY (UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_custom--PreferredStockSeriesBMember_z2y5KXtJPeqh" style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_custom--PreferredStockSeriesCMember_zO8xjyC1L9uj" style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_custom--PreferredStockSeriesCMember_us-gaap--StatementEquityComponentsAxis_custom--ContingentlyRedeemableWarrantsMember_zIfvt443nx19" style="text-align: center"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zlwHC7xUxgAa" style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zlPcthRjPne" style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockCommonMember_z5sVpaoe4y23" style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zxElkvztd9ye" style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zATuZMDJZMPe" style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" id="xdx_4B6_zHK18kYFe0F" style="text-align: center"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Preferred
    Stock Series B</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Preferred
    Stock Series C</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Contingently Redeemable
    Warrants</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Common
    Stock</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt"><b>Additional</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt"><b>Paid-in</b></span></p></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Treasury
    Stock</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Accumulated</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt"><b>Other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt"><b>Comprehensive</b></span></p></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt"><b>Stockholders&#8217;&#160;</b></span></p></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Shares</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Shares</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Shares</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Capital</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Shares</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Deficit</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Loss</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Equity</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_439_c20240501__20240731_eus-gaap--StockholdersEquity_iS_d0_zzzXoi5yiili" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; font-weight: bold; width: 13%"><span style="font-size: 7pt">Balance, April 30, 2024</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_985_eus-gaap--SharesOutstanding_iS_d0_c20240501__20240731__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesBMember_z9fCtYB5XBai" title="Beginning balance, shares" style="width: 4%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-04-30_custom_PreferredStockSeriesBMember" id="Fact000448" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,646</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-04-30_custom_PreferredStockSeriesBMember" id="Fact000438" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,867,016</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--SharesOutstanding_iS_d0_c20240501__20240731__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesCMember_zt6Xvf7UW93e" title="Beginning balance, shares" style="width: 4%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-04-30_custom_PreferredStockSeriesCMember" id="Fact000450" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-04-30_custom_PreferredStockSeriesCMember" id="Fact000439" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-04-30_custom_ContingentlyRedeemableWarrantsMember" id="Fact000440" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--SharesOutstanding_iS_d0_c20240501__20240731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCzUmZYUqlxc" title="Beginning balance, shares" style="width: 4%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-04-30_us-gaap_CommonStockMember" id="Fact000452" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,672,078</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-04-30_us-gaap_CommonStockMember" id="Fact000441" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,167</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-04-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000442" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,334,173</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_989_eus-gaap--TreasuryStockCommonShares_iNS_di0_c20240501__20240731__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zHF1VlH8iypb" title="Beginning balance, shares" style="width: 4%; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2024-04-30_us-gaap_TreasuryStockCommonMember" id="Fact000454" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,634,454</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">)</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-04-30_us-gaap_TreasuryStockCommonMember" id="Fact000443" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,040,216</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">)</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-04-30_us-gaap_RetainedEarningsMember" id="Fact000444" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">115,625,010</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">)</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-04-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000445" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,511</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">)</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-04-30" id="Fact000446" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,647,603</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zEaytj7M11n" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Stock-based compensation options</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0456">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0457">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0458">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0459">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-05-012024-07-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000460" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,677</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0461">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0462">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0463">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-05-012024-07-31" id="Fact000464" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,677</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--PreferredStockAccretion_z8sBd6DhXMBd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Preferred stock accretion</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember" id="Fact000466" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,148,047</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0467">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0468">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0469">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2024-05-012024-07-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000470" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,148,047</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0471">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0472">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0473">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2024-05-012024-07-31" id="Fact000474" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,148,047</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_405_ecustom--SeriesBPreferredStockSubjectToRedemption_zgSc2qMullQ9" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Series B preferred stock redemption</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_98F_ecustom--SeriesBPreferredStockRedeemedShares_c20240501__20240731__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesBMember_z8tPncj1tsDc" title="Series B preferred stock redemption, shares" style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:SeriesBPreferredStockRedeemedShares" contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember" id="Fact000486" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">2,917</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemption" contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember" id="Fact000476" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,893,144</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0477">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0478">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0479">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0480">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0481">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0482">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0483">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0484">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--SeriesBPreferredStockRedemption_zh5XJssH4mD1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Series B preferred stock subject
    to redemption</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_986_ecustom--SeriesBPreferredStockSubjectToRedemptionShares_c20240501__20240731__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesBMember_z5gjAq32GPI9" title="Series B preferred stock subject to redemption, shares" style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemptionShares" contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember" id="Fact000498" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">5,833</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:SeriesBPreferredStockRedemption" contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember" id="Fact000488" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,788,805</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0489">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0490">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0491">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0492">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0493">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0494">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0495">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0496">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_iN_di_zk8xcObH0B8i" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Preferred stock dividends</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0500">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0501">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0502">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0503">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2024-05-012024-07-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000504" format="ixt:numdotdecimal" decimals="0" unitRef="USD">685,801</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0505">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0506">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0507">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2024-05-012024-07-31" id="Fact000508" format="ixt:numdotdecimal" decimals="0" unitRef="USD">685,801</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_zbGM465nbCmb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Foreign currency translation adjustment</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0510">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0512">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0513">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0514">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0515">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0516">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-05-012024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000517" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-05-012024-07-31" id="Fact000518" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zpvYjzGB29ke" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Net income</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0520">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0521">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0522">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0523">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0524">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0525">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-012024-07-31_us-gaap_RetainedEarningsMember" id="Fact000526" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,421,355</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0527">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-012024-07-31" id="Fact000528" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,421,355</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--StockRepurchasedDuringPeriodValue_iN_pp0p0_di_zFXcQ1RFAZU1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Repurchase of common stock</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0530">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0531">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0532">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0533">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0534">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_980_eus-gaap--StockRepurchasedDuringPeriodShares_iN_di_c20240501__20240731__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zYoLYyGe20Y1" title="Repurchase of common stock, shares" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember" id="Fact000540" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">320,346</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember" id="Fact000535" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">749,600</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0536">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0537">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-05-012024-07-31" id="Fact000538" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">749,600</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_435_c20240801__20241031_eus-gaap--StockholdersEquity_iS_d0_z1165B9MPbA6" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; font-weight: bold"><span style="font-size: 7pt">Balance, July 31, 2024</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_987_eus-gaap--SharesOutstanding_iS_d0_c20240801__20241031__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesBMember_zoYqYDN7oOQi" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-07-31_custom_PreferredStockSeriesBMember" id="Fact000552" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,896</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-07-31_custom_PreferredStockSeriesBMember" id="Fact000542" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,333,114</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_983_eus-gaap--SharesOutstanding_iS_d0_c20240801__20241031__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesCMember_z94k0CbBaaGl" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-07-31_custom_PreferredStockSeriesCMember" id="Fact000554" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-07-31_custom_PreferredStockSeriesCMember" id="Fact000543" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-07-31_custom_ContingentlyRedeemableWarrantsMember" id="Fact000544" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_981_eus-gaap--SharesOutstanding_iS_d0_c20240801__20241031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsBYpAsC85mc" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-07-31_us-gaap_CommonStockMember" id="Fact000556" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,672,078</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-07-31_us-gaap_CommonStockMember" id="Fact000545" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,167</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-07-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000546" format="ixt:numdotdecimal" decimals="0" unitRef="USD">182,723,002</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--TreasuryStockCommonShares_iNS_di0_c20240801__20241031__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zvAJcMsCVzy5" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2024-07-31_us-gaap_TreasuryStockCommonMember" id="Fact000558" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,954,800</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-07-31_us-gaap_TreasuryStockCommonMember" id="Fact000547" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,789,816</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-07-31_us-gaap_RetainedEarningsMember" id="Fact000548" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">92,203,655</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000549" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,328</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-07-31" id="Fact000550" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,708,370</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--FractionalSharesAdjustmentValue_iP3us-gaap--TreasuryStockCommonShares_zY4hSukxAOxg" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Fractional shares adjustment</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0560">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0561">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0562">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_986_ecustom--FractionalSharesAdjustmentShares_iP3custom--FractionalSharesAdjustmentValue_d0_c20240801__20241031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCsKTSNDUXyh" title="Fractional shares adjustment, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="PMCB:FractionalSharesAdjustmentShares" contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember" id="Fact000570" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0563">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0564">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0566">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0567">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0568">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zSOOvbAtLyPk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Stock-based compensation options</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0572">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0573">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0574">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0575">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000576" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,155</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0577">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0578">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0579">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-08-012024-10-31" id="Fact000580" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,155</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--PreferredStockAccretion_z6ph9TbL5kjk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Preferred stock accretion</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember" id="Fact000582" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,045,357</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0583">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0584">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0585">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000586" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,045,357</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0587">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0588">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0589">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2024-08-012024-10-31" id="Fact000590" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,045,357</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_405_ecustom--SeriesBPreferredStockSubjectToRedemption_zamsQjRyLG1l" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Series B preferred stock redemption</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_986_ecustom--SeriesBPreferredStockRedeemedShares_c20240801__20241031__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesBMember_zXFfvPlV7fEc" title="Series B preferred stock redemption, shares" style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:SeriesBPreferredStockRedeemedShares" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember" id="Fact000602" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">2,917</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemption" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember" id="Fact000592" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,868,607</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0593">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0594">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0595">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0596">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0597">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0598">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0599">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0600">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--SeriesBPreferredStockRedemption_zAbGLZD8baj3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Series B preferred stock subject
    to redemption</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_98F_ecustom--SeriesBPreferredStockSubjectToRedemptionShares_c20240801__20241031__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesBMember_zVACERH8Vvzc" title="Series B preferred stock subject to redemption, shares" style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:SeriesBPreferredStockSubjectToRedemptionShares" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember" id="Fact000614" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">2,979</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:SeriesBPreferredStockRedemption" contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember" id="Fact000604" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,509,864</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0605">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0606">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0607">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0608">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0609">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0610">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0611">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0612">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_iN_di_zVlLEyRO5VVd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Preferred stock dividends</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0616">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0617">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0618">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0619">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000620" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,958</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0621">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0622">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0623">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2024-08-012024-10-31" id="Fact000624" format="ixt:numdotdecimal" decimals="0" unitRef="USD">443,958</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_zHbYc2er7jX4" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Foreign currency translation adjustment</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0626">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0627">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0628">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0629">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0630">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0631">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0632">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000633" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-08-012024-10-31" id="Fact000634" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zT58gYIEbYvb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Net loss</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0636">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0637">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0638">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0639">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0640">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0641">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember" id="Fact000642" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,469,560</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0643">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-08-012024-10-31" id="Fact000644" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,469,560</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--StockRepurchasedDuringPeriodValue_iN_pp0p0_di_ztNnLqt0fPlb" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Repurchase of common stock</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0646">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0647">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0648">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0649">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0650">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_980_eus-gaap--StockRepurchasedDuringPeriodShares_iN_di_c20240801__20241031__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zQhdLillgqZe" title="Repurchase of common stock, shares" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember" id="Fact000656" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">683,036</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember" id="Fact000651" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,417,565</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0652">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0653">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-08-012024-10-31" id="Fact000654" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,417,565</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_43E_c20241101__20250131_eus-gaap--StockholdersEquity_iS_d0_zAbuY7e9Lbd6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; font-weight: bold"><span style="font-size: 7pt">Balance, October 31, 2024</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_980_eus-gaap--SharesOutstanding_iS_d0_c20241101__20250131__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesBMember_z8POEBlsk8B8" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 7pt"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-10-31_custom_PreferredStockSeriesBMember" id="Fact000668" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-10-31_custom_PreferredStockSeriesBMember" id="Fact000658" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction><span style="font-size: 7pt"></span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--SharesOutstanding_iS_d0_c20241101__20250131__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesCMember_z6zCIOUX6mDc" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-10-31_custom_PreferredStockSeriesCMember" id="Fact000670" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-10-31_custom_PreferredStockSeriesCMember" id="Fact000659" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-10-31_custom_ContingentlyRedeemableWarrantsMember" id="Fact000660" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_982_eus-gaap--SharesOutstanding_iS_d0_c20241101__20250131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgJe7dplzkF" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-10-31_us-gaap_CommonStockMember" id="Fact000672" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,672,095</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-10-31_us-gaap_CommonStockMember" id="Fact000661" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,167</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000662" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,352,842</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--TreasuryStockCommonShares_iNS_di0_c20241101__20250131__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zLDiiM74oRrd" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2024-10-31_us-gaap_TreasuryStockCommonMember" id="Fact000674" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,637,836</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-10-31_us-gaap_TreasuryStockCommonMember" id="Fact000663" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,207,381</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-10-31_us-gaap_RetainedEarningsMember" id="Fact000664" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">93,673,215</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000665" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,267</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-10-31" id="Fact000666" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,451,146</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zSumFFN5YGJg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Stock-based compensation options</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0676">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0677">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0678">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0679">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-11-012025-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000680" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,861</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0681">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0682">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0683">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-11-012025-01-31" id="Fact000684" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,861</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_zaze0Hr3Lybg" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Foreign currency translation adjustment</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0686">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0687">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0688">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0689">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0690">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0691">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0692">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-11-012025-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000693" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,219</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-11-012025-01-31" id="Fact000694" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,219</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zMV2bjASDG3j" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Net loss</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0696">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0697">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0698">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0699">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0700">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0701">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-11-012025-01-31_us-gaap_RetainedEarningsMember" id="Fact000702" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,045,328</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0703">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-11-012025-01-31" id="Fact000704" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,045,328</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_40A_eus-gaap--StockRepurchasedDuringPeriodValue_iN_pp0p0_di_zlp0JTvhEft9" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Repurchase of common stock</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0706">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0707">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0708">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0709">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0710">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_985_eus-gaap--StockRepurchasedDuringPeriodShares_iN_di_c20241101__20250131__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zWH7nSh4MYYh" title="Repurchase of common stock, shares" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2024-11-012025-01-31_us-gaap_TreasuryStockCommonMember" id="Fact000716" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">129,365</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-11-012025-01-31_us-gaap_TreasuryStockCommonMember" id="Fact000711" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">227,275</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0712">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0713">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodValue" contextRef="From2024-11-012025-01-31" id="Fact000714" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">227,275</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_434_c20241101__20250131_eus-gaap--StockholdersEquity_iE_d0_zuYiJMYs6yMg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; font-weight: bold"><span style="font-size: 7pt"><b>Balance, January 31, 2025</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td id="xdx_989_eus-gaap--SharesOutstanding_iE_d0_c20241101__20250131__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesBMember_zZoK22LDROTc" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-01-31_custom_PreferredStockSeriesBMember" id="Fact000728" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-01-31_custom_PreferredStockSeriesBMember" id="Fact000718" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td id="xdx_985_eus-gaap--SharesOutstanding_iE_d0_c20241101__20250131__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesCMember_zyg90y0qNYRe" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-01-31_custom_PreferredStockSeriesCMember" id="Fact000730" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-01-31_custom_PreferredStockSeriesCMember" id="Fact000719" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-01-31_custom_ContingentlyRedeemableWarrantsMember" id="Fact000720" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td id="xdx_982_eus-gaap--SharesOutstanding_iE_d0_c20241101__20250131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdyDvodBNTBk" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-01-31_us-gaap_CommonStockMember" id="Fact000732" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,672,095</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-01-31_us-gaap_CommonStockMember" id="Fact000721" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,167</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000722" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,425,703</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td id="xdx_985_eus-gaap--TreasuryStockCommonShares_iNE_di0_c20241101__20250131__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zSYu86fS5sNa" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b>(<ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2025-01-31_us-gaap_TreasuryStockCommonMember" id="Fact000734" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,767,201</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>)</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-01-31_us-gaap_TreasuryStockCommonMember" id="Fact000723" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,434,656</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>)</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-01-31_us-gaap_RetainedEarningsMember" id="Fact000724" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">96,718,543</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>)</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000725" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,486</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>)</b></span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-01-31" id="Fact000726" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,250,185</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt"><b>&#160;</b></span></td></tr>
</table>

<p style="text-align: right; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="text-align: right; margin-top: 0; margin-bottom: 0"><i>(continued)</i></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"><br/>
</p>

<!-- Field: Page; Sequence: 6 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 7pt"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt"><b>Preferred
    Stock Series B</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="5" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 7pt"><b>Preferred Stock Series
    C</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="3" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-size: 7pt"><b>Contingently Redeemable
    Warrants</b></span></td>
    <td style="border-right: Black 1pt solid; text-align: center"><span style="font-size: 7pt"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt"><b>Common
    Stock</b></span></td><td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="3" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt"><b>Additional</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt"><b>Paid-in</b></span></p></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt"><b>Treasury
    Stock</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="3" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-size: 7pt"><b>Accumulated</b></span></td><td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="3" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt"><b>Accumulated</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt"><b>Other</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt"><b>Comprehensive</b></span></p></td><td style="text-align: center; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="3" style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt"><b>Stockholders&#8217;&#160;</b></span></p></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center"><span style="font-size: 7pt"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt"><b>Shares</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt"><b>Amount</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 7pt"><b>Shares</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt"><b>Amount</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt"><b>Amount</b></span></td>
    <td style="border-right: Black 1pt solid; padding-bottom: 1pt; text-align: center"><span style="font-size: 7pt"><b>&#160;</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt"><b>Shares</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt"><b>Amount</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt"><b>Capital</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt"><b>Shares</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt"><b>Amount</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt"><b>Deficit</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt"><b>Loss</b></span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt"><b>Equity</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td>
    <td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="3"><span style="font-size: 7pt">&#160;</span></td></tr>

<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 13%"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right; width: 4%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right; width: 4%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right; width: 4%"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right; width: 4%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right; width: 4%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right; width: 4%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right; width: 4%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right; width: 4%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right; width: 4%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right; width: 4%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right; width: 4%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right; width: 4%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right; width: 4%"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left; width: 1%"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_434_c20250501__20250731_eus-gaap--StockholdersEquity_iS_d0_zqquogvNsWNf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; font-weight: bold"><span style="font-size: 7pt">Balance, April 30, 2025</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--SharesOutstanding_iS_d0_c20250501__20250731__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesBMember_zUUBuZr6lzy" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-04-30_custom_PreferredStockSeriesBMember" id="Fact000746" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">$</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-04-30_custom_PreferredStockSeriesBMember" id="Fact000736" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_983_eus-gaap--SharesOutstanding_iS_d0_c20250501__20250731__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesCMember_z012ZZbqMIyd" title="Beginning balance, shares" style="text-align: left"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-04-30_custom_PreferredStockSeriesCMember" id="Fact000748" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">$</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-04-30_custom_PreferredStockSeriesCMember" id="Fact000737" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">$</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-04-30_custom_ContingentlyRedeemableWarrantsMember" id="Fact000738" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--SharesOutstanding_iS_d0_c20250501__20250731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfM6qToh2fZf" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-04-30_us-gaap_CommonStockMember" id="Fact000750" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,672,095</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">$</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-04-30_us-gaap_CommonStockMember" id="Fact000739" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,167</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">$</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-04-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000740" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,489,647</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_985_eus-gaap--TreasuryStockCommonShares_iNS_di0_c20250501__20250731__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zHpVsiIGtn7f" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2025-04-30_us-gaap_TreasuryStockCommonMember" id="Fact000752" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,876,316</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">$</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-04-30_us-gaap_TreasuryStockCommonMember" id="Fact000741" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,607,916</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">$</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-04-30_us-gaap_RetainedEarningsMember" id="Fact000742" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">84,968,960</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">$</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-04-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000743" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,869</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">$</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-04-30" id="Fact000744" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,891,069</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zw87gly5eX8g" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Stock-based compensation options</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0754">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0755">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0756">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0757">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-05-012025-07-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000758" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,492</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0759">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0760">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0761">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-05-012025-07-31" id="Fact000762" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,492</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_zKvlqDUVjUK3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Foreign currency translation adjustment</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0764">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0765">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0766">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0767">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0768">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0769">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0770">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-05-012025-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000771" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-05-012025-07-31" id="Fact000772" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zZ3D0k2JueGf" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Net income</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0774">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0775">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0776">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0777">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0778">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0779">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-05-012025-07-31_us-gaap_RetainedEarningsMember" id="Fact000780" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,360,096</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0781">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-05-012025-07-31" id="Fact000782" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,360,096</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_433_c20250801__20251031_eus-gaap--StockholdersEquity_iS_d0_zub53lIOqnxc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; font-weight: bold"><span style="font-size: 7pt">Balance, July 31, 2025</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_980_eus-gaap--SharesOutstanding_iS_d0_c20250801__20251031__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesBMember_z98QaQQoDyuf" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-07-31_custom_PreferredStockSeriesBMember" id="Fact000794" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-07-31_custom_PreferredStockSeriesBMember" id="Fact000784" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--SharesOutstanding_iS_d0_c20250801__20251031__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesCMember_zjmsmIuREy5b" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-07-31_custom_PreferredStockSeriesCMember" id="Fact000796" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-07-31_custom_PreferredStockSeriesCMember" id="Fact000785" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-07-31_custom_ContingentlyRedeemableWarrantsMember" id="Fact000786" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_980_eus-gaap--SharesOutstanding_iS_d0_c20250801__20251031__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgcwoh4T2kWa" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-07-31_us-gaap_CommonStockMember" id="Fact000798" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,672,095</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-07-31_us-gaap_CommonStockMember" id="Fact000787" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,167</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-07-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000788" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,550,139</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_984_eus-gaap--TreasuryStockCommonShares_iNS_di0_c20250801__20251031__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zyUMrFOPvSue" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2025-07-31_us-gaap_TreasuryStockCommonMember" id="Fact000800" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,876,316</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-07-31_us-gaap_TreasuryStockCommonMember" id="Fact000789" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,607,916</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-07-31_us-gaap_RetainedEarningsMember" id="Fact000790" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">93,329,056</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000791" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">23,746</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-07-31" id="Fact000792" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,591,588</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zDVfQAa0Daj6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Stock-based compensation options</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0802">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0803">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0804">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0805">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-08-012025-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000806" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,492</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0807">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0808">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0809">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-08-012025-10-31" id="Fact000810" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,492</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--IssuanceOfSeriesCPreferredStockAndWarrants_iP3us-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zBYJbJseh0Gg" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Issuance of Series C preferred stock
    and warrants, net of transaction costs</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0812">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_98E_ecustom--IssuanceOfSeriesCPreferredStockAndWarrantsShares_iP3custom--IssuanceOfSeriesCPreferredStockAndWarrants_c20250801__20251031__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesCMember_z3qceo91ZHD9" title="Issuance of Series C preferred stock and warrants, net of transaction costs, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="PMCB:IssuanceOfSeriesCPreferredStockAndWarrantsShares" contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesCMember" id="Fact000822" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,000</ix:nonFraction></span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0813">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="PMCB:IssuanceOfSeriesCPreferredStockAndWarrants" contextRef="From2025-08-012025-10-31_custom_ContingentlyRedeemableWarrantsMember" id="Fact000814" format="ixt:numdotdecimal" decimals="0" unitRef="USD">417,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0815">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0816">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0817">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0818">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0819">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0820">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--SeriesCPreferredStockAccretion_iP3custom--IssuanceOfSeriesCPreferredStockAndWarrantsShares_ziU7WVOOgSl6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Series C Preferred stock accretion</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0824">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="PMCB:SeriesCPreferredStockAccretion" contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesCMember" id="Fact000825" format="ixt:numdotdecimal" decimals="0" unitRef="USD">901,996</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0826">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0827">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:SeriesCPreferredStockAccretion" contextRef="From2025-08-012025-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000828" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">901,996</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0829">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0830">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0831">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:SeriesCPreferredStockAccretion" contextRef="From2025-08-012025-10-31" id="Fact000832" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">901,996</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_40B_ecustom--SeriesCPreferredStockDividendSubjectToSettlement_iP3custom--SeriesCPreferredStockAccretion_zOdggZYWAf7i" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Series C preferred stock dividend
    subject to settlement</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0834">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:SeriesCPreferredStockDividendSubjectToSettlement" contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesCMember" id="Fact000835" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">96,639</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0836">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0837">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0838">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0839">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0840">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0841">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0842">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--SeriesCPreferredStockDividendsAccrual_iP3custom--SeriesCPreferredStockDividendSubjectToSettlement_zYyJ28x1npg8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Series C preferred stock dividends
    accrual</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0844">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="PMCB:SeriesCPreferredStockDividendsAccrual" contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesCMember" id="Fact000845" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,639</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0846">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0847">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:SeriesCPreferredStockDividendsAccrual" contextRef="From2025-08-012025-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000848" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">96,639</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0849">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0850">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0851">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:SeriesCPreferredStockDividendsAccrual" contextRef="From2025-08-012025-10-31" id="Fact000852" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">96,639</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_zFUX3TRMc3Tl" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Foreign currency translation adjustment</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0854">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0855">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0856">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0857">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0858">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0859">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0860">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-08-012025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000861" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">381</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-08-012025-10-31" id="Fact000862" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">381</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zuLaSLWPn7mf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 7pt">Net loss</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0864">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0865">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0866">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0867">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0868">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0869">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-08-012025-10-31_us-gaap_RetainedEarningsMember" id="Fact000870" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,417,975</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0871">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-08-012025-10-31" id="Fact000872" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,417,975</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_431_c20251101__20260131_eus-gaap--StockholdersEquity_iS_d0_z9sCaoEnrbw4" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; font-weight: bold"><span style="font-size: 7pt">Balance, October 31, 2025</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_980_eus-gaap--SharesOutstanding_iS_d0_c20251101__20260131__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesBMember_zNbT6BZ51eVa" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-10-31_custom_PreferredStockSeriesBMember" id="Fact000884" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-10-31_custom_PreferredStockSeriesBMember" id="Fact000874" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--SharesOutstanding_iS_d0_c20251101__20260131__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesCMember_zBJllyGUG4oi" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-10-31_custom_PreferredStockSeriesCMember" id="Fact000886" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,000</ix:nonFraction></span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-10-31_custom_PreferredStockSeriesCMember" id="Fact000875" format="ixt:numdotdecimal" decimals="0" unitRef="USD">901,996</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-10-31_custom_ContingentlyRedeemableWarrantsMember" id="Fact000876" format="ixt:numdotdecimal" decimals="0" unitRef="USD">417,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_986_eus-gaap--SharesOutstanding_iS_d0_c20251101__20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkq3hc8XnG15" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-10-31_us-gaap_CommonStockMember" id="Fact000888" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,672,095</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-10-31_us-gaap_CommonStockMember" id="Fact000877" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,167</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-10-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000878" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,611,996</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--TreasuryStockCommonShares_iNS_di0_c20251101__20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zYdm1Sdvfdt3" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2025-10-31_us-gaap_TreasuryStockCommonMember" id="Fact000890" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,876,316</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-10-31_us-gaap_TreasuryStockCommonMember" id="Fact000879" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,607,916</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-10-31_us-gaap_RetainedEarningsMember" id="Fact000880" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">100,747,031</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000881" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,127</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-10-31" id="Fact000882" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,235,089</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zlQS19joDWH8" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Stock-based compensation options</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0892">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0893">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0894">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0895">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000896" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,492</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0897">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0898">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0899">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2025-11-012026-01-31" id="Fact000900" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,492</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--StockIssuedUponVestingOfRestrictedStockUnits_iP3us-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zacLbhYBXKP3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Stock issued upon vesting of restricted
    stock units</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0902">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0903">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0904">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_98A_ecustom--StockIssuedUponVestingOfRestrictedStockUnitsShares_iP3custom--StockIssuedUponVestingOfRestrictedStockUnits_d0_c20251101__20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXbqj9DgG0fk" title="Stock issued upon vesting of restricted stock units, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="PMCB:StockIssuedUponVestingOfRestrictedStockUnitsShares" contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember" id="Fact000912" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">875,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="PMCB:StockIssuedUponVestingOfRestrictedStockUnits" contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember" id="Fact000905" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="PMCB:StockIssuedUponVestingOfRestrictedStockUnits" contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000906" format="ixt:numdotdecimal" decimals="0" unitRef="USD">892,411</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_986_ecustom--StockIssuedUponVestingOfRestrictedStockUnitsShares_d0_c20251101__20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_z75ExEx16kWa" title="Stock issued upon vesting of restricted stock units, shares" style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:StockIssuedUponVestingOfRestrictedStockUnitsShares" contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember" id="Fact000914" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">393,750</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:StockIssuedUponVestingOfRestrictedStockUnits" contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember" id="Fact000907" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">401,625</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0908">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0909">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="PMCB:StockIssuedUponVestingOfRestrictedStockUnits" contextRef="From2025-11-012026-01-31" id="Fact000910" format="ixt:numdotdecimal" decimals="0" unitRef="USD">490,875</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_iP3custom--StockIssuedUponVestingOfRestrictedStockUnitsShares_zY3bTQy8Kpy" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Stock issued for warrant exercises</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0916">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0917">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0918">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iP3us-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_d0_c20251101__20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqsKjFCPh9Kk" title="Stock issued for warrant exercises, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember" id="Fact000926" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,100,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember" id="Fact000919" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000920" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,645,785</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0921">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0922">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0923">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2025-11-012026-01-31" id="Fact000924" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,645,895</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--PreferredStockAccretion_zXRBSj8RFja8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Preferred stock accretion</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0928">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td/>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember" id="Fact000929" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,204,657</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0930">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0931">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000932" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,204,657</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0933">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0934">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0935">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:PreferredStockAccretion" contextRef="From2025-11-012026-01-31" id="Fact000936" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,204,657</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_404_ecustom--SeriesCPreferredStockRedeemed_iP3custom--PreferredStockAccretion_zaEufh6jJFhk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Series C preferred stock redeemed</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0938">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_982_ecustom--SeriesCPreferredStockRedeemedShares_iP3custom--SeriesCPreferredStockRedeemed_d0_c20251101__20260131__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesCMember_zqyLxhg9kvd" title="Series C preferred stock redeemed, shares" style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:SeriesCPreferredStockRedeemedShares" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember" id="Fact000948" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">2,234</ix:nonFraction></span></td><td><span style="font-size: 7pt">)</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:SeriesCPreferredStockRedeemed" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember" id="Fact000939" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,234,330</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0940">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td id="xdx_988_ecustom--SeriesCPreferredStockRedeemedShares_d0_c20251101__20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhXu0xh9hhbg" title="Series C preferred stock redeemed, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="PMCB:SeriesCPreferredStockRedeemedShares" contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember" id="Fact000950" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,358,620</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="PMCB:SeriesCPreferredStockRedeemed" contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember" id="Fact000941" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="PMCB:SeriesCPreferredStockRedeemed" contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000942" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,234,094</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0943">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0944">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0945">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="PMCB:SeriesCPreferredStockRedeemed" contextRef="From2025-11-012026-01-31" id="Fact000946" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,234,330</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--SeriesCPreferredStockSubjectToSettlement_iP3custom--SeriesCPreferredStockRedeemedShares_zRN4d3flR0h1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Series C preferred stock subject
    to settlement</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0952">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="PMCB:SeriesCPreferredStockSubjectToSettlement" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember" id="Fact000953" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">98,458</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0954">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0955">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0956">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0957">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0958">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0959">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_iN_di_zKU04pIwD0Lk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Preferred stock dividends</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0962">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember" id="Fact000963" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">98,458</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0964">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0965">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000966" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,458</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0967">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0968">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0969">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" contextRef="From2025-11-012026-01-31" id="Fact000970" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,458</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_zz1HsmgDtQA3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Foreign currency translation adjustment</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0972">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0973">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0974">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0975">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0976">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0977">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0978">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000979" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,587</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2025-11-012026-01-31" id="Fact000980" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,587</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zaMbGihScXR3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; text-align: left"><span style="font-size: 7pt">Net income</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0982">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0983">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0984">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#160;&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#160;<span style="-sec-ix-hidden: xdx2ixbrl0985">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0986">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0987">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember" id="Fact000988" format="ixt:numdotdecimal" decimals="0" unitRef="USD">746,860</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0989">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-11-012026-01-31" id="Fact000990" format="ixt:numdotdecimal" decimals="0" unitRef="USD">746,860</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--StockRepurchasedDuringPeriodValue_iN_pp0p0_di_zBCu18YOD049" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 7pt">Repurchase of common stock</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0992">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0993">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0994">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0995">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0996">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0997">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0998">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0999">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl1000">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_43B_c20251101__20260131_eus-gaap--StockholdersEquity_iE_d0_zr27uyiBkB2b" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -3pt; padding-left: 3pt; font-weight: bold"><span style="font-size: 7pt"><b>Balance, January 31, 2026</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td id="xdx_985_eus-gaap--SharesOutstanding_iE_d0_c20251101__20260131__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesBMember_zbEUyia6az79" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2026-01-31_custom_PreferredStockSeriesBMember" id="Fact001012" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-01-31_custom_PreferredStockSeriesBMember" id="Fact001002" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>&#160;</b></span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td id="xdx_98E_eus-gaap--SharesOutstanding_iE_d0_c20251101__20260131__us-gaap--StatementEquityComponentsAxis__custom--PreferredStockSeriesCMember_z0x5glW26dDk" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><b><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2026-01-31_custom_PreferredStockSeriesCMember" id="Fact001014" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,766</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-01-31_custom_PreferredStockSeriesCMember" id="Fact001003" format="ixt:numdotdecimal" decimals="0" unitRef="USD">872,323</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-01-31_custom_ContingentlyRedeemableWarrantsMember" id="Fact001004" format="ixt:numdotdecimal" decimals="0" unitRef="USD">417,000</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-right: Black 1pt solid"><span style="font-size: 7pt"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td id="xdx_98D_eus-gaap--SharesOutstanding_iE_d0_c20251101__20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8q4KF8k4xif" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2026-01-31_us-gaap_CommonStockMember" id="Fact001016" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,005,715</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"/><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-01-31_us-gaap_CommonStockMember" id="Fact001005" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,602</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-01-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact001006" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183,141,663</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td id="xdx_98A_eus-gaap--TreasuryStockCommonShares_iNE_di0_c20251101__20260131__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockCommonMember_zlvyGtmzQvyj" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b>(<ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2026-01-31_us-gaap_TreasuryStockCommonMember" id="Fact001018" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,270,066</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>)</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-01-31_us-gaap_TreasuryStockCommonMember" id="Fact001007" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">45,009,541</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>)</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-01-31_us-gaap_RetainedEarningsMember" id="Fact001008" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">100,000,171</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>)</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b>(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact001009" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">21,540</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>)</b></span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 7pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>$</b></span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font-size: 7pt"><b><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2026-01-31" id="Fact001010" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,113,013</ix:nonFraction></b></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-size: 7pt"><b>&#160;</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying Notes to Condensed Consolidated
Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>PHARMACYTE BIOTECH, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="k_008"></span>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(UNAUDITED)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_112_z59p05jixJx3" summary="xdx: Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="3" id="xdx_498_20250501__20260131_zKKyxp5UXsZe" style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="3" id="xdx_493_20240501__20250131_zDxO3r4nQtk8" style="text-align: center"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Nine Months
    Ended January 31,</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">2026</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">2025</span></td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z7l54jkmJ8n" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><span style="font-size: 9pt">Cash flows from operating activities:</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_i01_maNCPBUzgxT_zUoEYWmuK7ge" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 66%; text-align: left"><span style="font-size: 9pt">Net income (loss)</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-05-01to2026-01-31" id="Fact001023" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,031,211</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td><td style="width: 2%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 13%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-012025-01-31" id="Fact001024" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,906,468</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_iB_zanAbbaaDJRj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left"><span style="font-size: 9pt">Adjustments to reconcile net income
    (loss) to net cash used in operating activities:</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--GainOnRelatedPartyInvestmentQcls_iN_pp0p0_di0_msNCPBUzgxT_zqIDmvRsi6M5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-size: 9pt">Gain on related party investment &#8211; QCLS</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="PMCB:GainOnRelatedPartyInvestmentQcls" contextRef="From2025-05-01to2026-01-31" id="Fact001029" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,089,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="PMCB:GainOnRelatedPartyInvestmentQcls" contextRef="From2024-05-012025-01-31" id="Fact001030" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,395,734</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_404_ecustom--IssuanceCostsSeriesCPreferredStockAndWarrants_d0_maNCPBUzgxT_zl37emUVutw7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-size: 9pt">Issuance costs &#8211; Series C preferred stock and
    warrants</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:IssuanceCostsSeriesCPreferredStockAndWarrants" contextRef="From2025-05-01to2026-01-31" id="Fact001032" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,234,553</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:IssuanceCostsSeriesCPreferredStockAndWarrants" contextRef="From2024-05-012025-01-31" id="Fact001033" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--LossOnIssuanceOfSeriesCPreferredStock_d0_maNCPBUzgxT_zSWNoZmQYj17" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-size: 9pt">Loss on issuance of Series C preferred stock</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:LossOnIssuanceOfSeriesCPreferredStock" contextRef="From2025-05-01to2026-01-31" id="Fact001035" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:LossOnIssuanceOfSeriesCPreferredStock" contextRef="From2024-05-012025-01-31" id="Fact001036" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--GainOnFairValueOfWarrants_iN_di0_msNCPBUzgxT_zUN54BUHBuGk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-size: 9pt">Gain on re-fair value of warrants</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="PMCB:GainOnFairValueOfWarrants" contextRef="From2025-05-01to2026-01-31" id="Fact001038" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:GainOnFairValueOfWarrants" contextRef="From2024-05-012025-01-31" id="Fact001039" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--NoncashInterestIncome_iN_di0_msNCPBUzgxT_zsKmKpA8L3X3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-size: 9pt">Non-cash interest income</span></td><td style="font-weight: bold"><span style="font-size: 9pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="PMCB:NoncashInterestIncome" contextRef="From2025-05-01to2026-01-31" id="Fact001041" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span></td><td style="text-align: left">)</td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="PMCB:NoncashInterestIncome" contextRef="From2024-05-012025-01-31" id="Fact001042" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensation_d0_maNCPBUzgxT_z2nXYp9rwxE5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-size: 9pt">Stock issued for compensation - RSUs</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-05-01to2026-01-31" id="Fact001044" format="ixt:numdotdecimal" decimals="0" unitRef="USD">892,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-05-012025-01-31" id="Fact001045" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--StockbasedCompensationOptions_d0_maNCPBUzgxT_zRGKpOf9ctZ" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-size: 9pt">Stock-based compensation - options</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:StockbasedCompensationOptions" contextRef="From2025-05-01to2026-01-31" id="Fact001047" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,476</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:StockbasedCompensationOptions" contextRef="From2024-05-012025-01-31" id="Fact001048" format="ixt:numdotdecimal" decimals="0" unitRef="USD">414,693</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_iN_di0_msNCPBUzgxT_zLEKbeLNT3Ye" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-size: 9pt">Unrealized loss on marketable equity securities</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2025-05-01to2026-01-31" id="Fact001050" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">294,065</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2024-05-012025-01-31" id="Fact001051" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,632</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40A_ecustom--ChangeInFairValueOfWarrantLiability_iN_di_msNCPBUzgxT_z32qyLbt2sp8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-size: 9pt">Change in fair value of warrant liabilities</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantLiability" contextRef="From2025-05-01to2026-01-31" id="Fact001053" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,335,135</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantLiability" contextRef="From2024-05-012025-01-31" id="Fact001054" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,400,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_406_ecustom--ChangeInFairValueOfDerivativeLiability_iN_di0_msNCPBUzgxT_zDymhva9fFeb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-size: 9pt">Change in fair value of derivative liability</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="PMCB:ChangeInFairValueOfDerivativeLiability" contextRef="From2025-05-01to2026-01-31" id="Fact001056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">859,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="PMCB:ChangeInFairValueOfDerivativeLiability" contextRef="From2024-05-012025-01-31" id="Fact001057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,184,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40A_ecustom--ChangeInFairValueOfConvertibleNotesReceivable_iN_di0_msNCPBUzgxT_zT4zipcFt7wl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-size: 9pt">Change in fair value of convertible note receivable
    - Femasys</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="PMCB:ChangeInFairValueOfConvertibleNotesReceivable" contextRef="From2025-05-01to2026-01-31" id="Fact001059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,304,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="PMCB:ChangeInFairValueOfConvertibleNotesReceivable" contextRef="From2024-05-012025-01-31" id="Fact001060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">601,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_400_ecustom--ChangeInFairValueOfWarrantAssetFemasys_iN_pp0p0_di0_msNCPBUzgxT_ziDwUM5Rx6qk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-size: 9pt">Change in fair value of warrant asset &#8211; Femasys</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantAssetFemasys" contextRef="From2025-05-01to2026-01-31" id="Fact001062" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,155,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantAssetFemasys" contextRef="From2024-05-012025-01-31" id="Fact001063" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,830,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--ChangeInFairValueOfInvestmentQcls_iN_pp0p0_di0_msNCPBUzgxT_zz2nZXdtg4xf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-size: 9pt">Change in fair value of investment &#8211; QCLS</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:ChangeInFairValueOfInvestmentQcls" contextRef="From2025-05-01to2026-01-31" id="Fact001065" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,485,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:ChangeInFairValueOfInvestmentQcls" contextRef="From2024-05-012025-01-31" id="Fact001066" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,642,050</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--ChangeInFairValueOfWarrantsQcls_iN_pp0p0_di0_msNCPBUzgxT_z7D2Mt6Z67X6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left"><span style="font-size: 9pt">Change in fair value of warrants - QCLS</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantsQcls" contextRef="From2025-05-01to2026-01-31" id="Fact001068" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantsQcls" contextRef="From2024-05-012025-01-31" id="Fact001069" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">8,123,684</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_iB_zKaaQHxcmIRd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Change in assets and liabilities:</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_iN_di_msNCPBUzgxT_z3MPN1L4JRqk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left">D<span style="font-size: 9pt">ecrease in prepaid expenses and other current assets</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2025-05-01to2026-01-31" id="Fact001074" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">65,095</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-05-012025-01-31" id="Fact001075" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">52,438</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInOtherAccountsPayable_maNCPBUzgxT_zc01pI2PV7pi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left"><span style="font-size: 9pt">Increase in accounts payable</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2025-05-01to2026-01-31" id="Fact001077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">714,459</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2024-05-012025-01-31" id="Fact001078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">95,578</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--IncreaseDecreaseInOtherAccruedLiabilities_maNCPBUzgxT_z1BjFfyQGywc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Decrease in accrued expenses</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2025-05-01to2026-01-31" id="Fact001080" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,625,424</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="From2024-05-012025-01-31" id="Fact001081" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">49,470</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtNCPBUzgxT_maCzwsb_z0gRrUInznol" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Net cash and cash equivalents
    used in operating activities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2025-05-01to2026-01-31" id="Fact001083" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,760,352</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-05-012025-01-31" id="Fact001084" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,937,925</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zC7UEkkKsEbi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 9pt">Cash flows from investing activities:</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--ProceedsFromInvestmentNoteReceivable_d0_maCzV8k_zWCn5AyNKcP9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Proceeds from investment - note receivable</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:ProceedsFromInvestmentNoteReceivable" contextRef="From2025-05-01to2026-01-31" id="Fact001089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:ProceedsFromInvestmentNoteReceivable" contextRef="From2024-05-012025-01-31" id="Fact001090" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--InvestmentInPreferredStockAndWarrantsInQcls_iN_di0_msCzV8k_zYMiFk1LhOK1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Investment in preferred stock
    and warrants in QCLS</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="PMCB:InvestmentInPreferredStockAndWarrantsInQcls" contextRef="From2025-05-01to2026-01-31" id="Fact001092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="PMCB:InvestmentInPreferredStockAndWarrantsInQcls" contextRef="From2024-05-012025-01-31" id="Fact001093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_d0_mtCzV8k_maCzwsb_z5XnsGXZilq9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Net cash and cash equivalents
    provided by (used in) investing activities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2025-05-01to2026-01-31" id="Fact001095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-05-012025-01-31" id="Fact001096" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,000,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zsMdFmqJghrh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><span style="font-size: 9pt">Cash flows from financing activities:</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--PaymentsForRepurchaseOfCommonStock_iN_di0_msCzaiU_zHm0wk5jS0ji" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Repurchase of common stock, net</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2025-05-01to2026-01-31" id="Fact001101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401,625</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="From2024-05-012025-01-31" id="Fact001102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,370,733</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_402_ecustom--RedemptionOfPreferredStock_iN_di0_msCzaiU_zadBjaBxqZDl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Redemption of preferred stock</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:RedemptionOfPreferredStock" contextRef="From2025-05-01to2026-01-31" id="Fact001104" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="PMCB:RedemptionOfPreferredStock" contextRef="From2024-05-012025-01-31" id="Fact001105" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,486,875</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromIssuanceOfConvertiblePreferredStock_d0_maCzaiU_zPu7fNeEc0cj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Net proceeds from issuance of Series C convertible
    preferred stock</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2025-05-01to2026-01-31" id="Fact001107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,268,866</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="From2024-05-012025-01-31" id="Fact001108" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--ProceedsFromWarrantExercises_d0_maCzaiU_zQnfMeHCDU8i" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Net proceeds from exercises of warrants</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-05-01to2026-01-31" id="Fact001110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,046,760</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2024-05-012025-01-31" id="Fact001111" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--PaymentOfSeriesCConvertiblePreferredStockDividends_iN_di0_msCzaiU_zId0VOuFtQYa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Payment of Series C convertible preferred stock  dividends</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="PMCB:PaymentOfSeriesCConvertiblePreferredStockDividends" contextRef="From2025-05-01to2026-01-31" id="Fact001113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,606</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:PaymentOfSeriesCConvertiblePreferredStockDividends" contextRef="From2024-05-012025-01-31" id="Fact001114" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_d0_mtCzaiU_maCzwsb_zySWvrVMPAW5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Net cash and cash equivalents
    provided by (used in) financing activities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2025-05-01to2026-01-31" id="Fact001116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,751,395</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-05-012025-01-31" id="Fact001117" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,857,608</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_maCzwsb_zU0kDmpErV4i" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Effect of currency rate exchange on cash and cash
    equivalents</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2025-05-01to2026-01-31" id="Fact001119" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,329</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2024-05-012025-01-31" id="Fact001120" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">975</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzwsb_zGZyOuUKC6Fg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left"><span style="font-size: 9pt">Net increase (decrease) in cash and cash equivalents</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2025-05-01to2026-01-31" id="Fact001122" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,993,372</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-05-012025-01-31" id="Fact001123" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,796,508</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_z9gg9d5bG8g4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Cash and cash equivalents at beginning of the period</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-04-30" id="Fact001125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,172,163</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-04-30" id="Fact001126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,179,968</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_z5zz6Blfn9U9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Cash and cash equivalents at end of the period</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2026-01-31" id="Fact001128" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,165,535</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-01-31" id="Fact001129" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,383,460</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z0d7XXHAmI94" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-size: 9pt">Supplemental disclosure of non-cash investing and financing
    activities:</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability_i01_d0_z3zcUUltu6Sc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Reclassification
    of Series B Convertible Preferred Stock and dividends to current liability</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability" contextRef="From2025-05-01to2026-01-31" id="Fact001134" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability" contextRef="From2024-05-012025-01-31" id="Fact001135" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,190,179</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock_i01_d0_zhgDHTn2uG9e" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Accretion of discounts to redemption
    value of Series B Preferred Stock</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock" contextRef="From2025-05-01to2026-01-31" id="Fact001137" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock" contextRef="From2024-05-012025-01-31" id="Fact001138" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,193,404</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--AccrualOfSeriesCConvertiblePreferredStockDividends_i01_d0_z5kxlRSlfUCl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Accrual of Series C Convertible
    Preferred Stock dividends</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:AccrualOfSeriesCConvertiblePreferredStockDividends" contextRef="From2025-05-01to2026-01-31" id="Fact001140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">195,097</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:AccrualOfSeriesCConvertiblePreferredStockDividends" contextRef="From2024-05-012025-01-31" id="Fact001141" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts_i01_d0_zudx5txNLts4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Accrual of Series C Convertible
    Preferred Stock issuance costs</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts" contextRef="From2025-05-01to2026-01-31" id="Fact001143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,419</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts" contextRef="From2024-05-012025-01-31" id="Fact001144" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock_i01_d0_zFwHXhKgp0Oc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Accretion of discounts to redemption
    value of Series C Preferred Stock</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock" contextRef="From2025-05-01to2026-01-31" id="Fact001146" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,106,653</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock" contextRef="From2024-05-012025-01-31" id="Fact001147" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--InitialFairValueOfInvestmentInQclsSeriesHPreferredShares_i01_d0_z75nVD3mSh35" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Initial fair value of investment
    in QCLS Series H preferred shares</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:InitialFairValueOfInvestmentInQclsSeriesHPreferredShares" contextRef="From2025-05-01to2026-01-31" id="Fact001149" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,483,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:InitialFairValueOfInvestmentInQclsSeriesHPreferredShares" contextRef="From2024-05-012025-01-31" id="Fact001150" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--InitialFairValueOfInvestmentInQclsSeriesHWarrants_i01_d0_zoDmduYzHZP1" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Initial fair value of investment
    in QCLS Series H warrants</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:InitialFairValueOfInvestmentInQclsSeriesHWarrants" contextRef="From2025-05-01to2026-01-31" id="Fact001152" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,606,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:InitialFairValueOfInvestmentInQclsSeriesHWarrants" contextRef="From2024-05-012025-01-31" id="Fact001153" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--NoncashDerivativeLiabilityAtInitialFairValue_i01_d0_zr9jYlrsJHUe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Non-cash derivative liability
    at initial fair value</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:NoncashDerivativeLiabilityAtInitialFairValue" contextRef="From2025-05-01to2026-01-31" id="Fact001155" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,995,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:NoncashDerivativeLiabilityAtInitialFairValue" contextRef="From2024-05-012025-01-31" id="Fact001156" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--NoncashWarrantLiabilityAtInitialFairValue_i01_d0_zsrXywtD3hSd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Non-cash warrant liability at
    initial fair value</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:NoncashWarrantLiabilityAtInitialFairValue" contextRef="From2025-05-01to2026-01-31" id="Fact001158" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,220,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:NoncashWarrantLiabilityAtInitialFairValue" contextRef="From2024-05-012025-01-31" id="Fact001159" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--NoncashRedemptionOfSeriesCConvertiblePreferredStock_i01_d0_zymr4naLuEL7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Non-cash redemption of Series C
    convertible preferred stock</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:NoncashRedemptionOfSeriesCConvertiblePreferredStock" contextRef="From2025-05-01to2026-01-31" id="Fact001161" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,234,330</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:NoncashRedemptionOfSeriesCConvertiblePreferredStock" contextRef="From2024-05-012025-01-31" id="Fact001162" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--ChangeInFairValueAssociatedWarrantExercises_i01_d0_zTsEhczASwo2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Change in fair value associated warrant exercises</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:ChangeInFairValueAssociatedWarrantExercises" contextRef="From2025-05-01to2026-01-31" id="Fact001164" format="ixt:numdotdecimal" decimals="0" unitRef="USD">599,135</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:ChangeInFairValueAssociatedWarrantExercises" contextRef="From2024-05-012025-01-31" id="Fact001165" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--FairValueOfContingentlyRedeemablePlacementAgentWarrants_i01_d0_zODaZjnqpj5d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Fair value of contingently redeemable
    placement agent warrants</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:FairValueOfContingentlyRedeemablePlacementAgentWarrants" contextRef="From2025-05-01to2026-01-31" id="Fact001167" format="ixt:numdotdecimal" decimals="0" unitRef="USD">417,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:FairValueOfContingentlyRedeemablePlacementAgentWarrants" contextRef="From2024-05-012025-01-31" id="Fact001168" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40B_ecustom--ExciseTaxAccruedOnRepurchaseOfCommonStock_i01_d0_ziLvzIIBuQre" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 9pt">Excise tax accrued on repurchase
    of common stock</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:ExciseTaxAccruedOnRepurchaseOfCommonStock" contextRef="From2025-05-01to2026-01-31" id="Fact001170" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="PMCB:ExciseTaxAccruedOnRepurchaseOfCommonStock" contextRef="From2024-05-012025-01-31" id="Fact001171" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,707</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying Notes to Condensed Consolidated
Financial Statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 8 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PHARMACYTE BIOTECH, INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="k_009"></span>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(UNAUDITED)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001173" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zOOTQMet2C56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 &#8211; <span id="xdx_82A_zNQYknODog77">NATURE OF BUSINESS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PharmaCyte Biotech, Inc. (the &#8220;Company&#8221;)
is a biotechnology company focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation
technology known as &#8220;Cell-in-a-Box<sup>&#174;</sup>.&#8221; The Cell-in-a-Box<sup>&#174;</sup> technology is intended to be used as
a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (&#8220;LAPC&#8221;)
will be developed. The current generation of the Company&#8217;s product candidate is referred to as &#8220;CypCaps&#8482;.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a Nevada corporation incorporated
in 1996. In 2013, the Company restructured its operations to focus on biotechnology. The Company acquired licenses from SG Austria Pte.
Ltd., a Singapore corporation (&#8220;SG Austria&#8221;) and its wholly owned subsidiary, Austrianova Singapore Pte. Ltd., a Singapore
corporation (&#8220;Austrianova Singapore&#8221;) using the Cell-in-the-Box technology to treat cancer. The restructuring resulted in
the Company focusing all its efforts upon the development of a novel, effective and safe way to treat cancer. In January 2015, the Company
changed its name from Nuvilex, Inc. to PharmaCyte Biotech, Inc. to reflect the nature of its current business. In October 2021, the Company
moved its headquarters from Laguna Hills, California to Las Vegas, Nevada.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 1, 2020, the Company submitted an
Investigational New Drug Application (&#8220;IND&#8221;) to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for a planned clinical
trial in locally advanced pancreatic cancer (&#8220;LAPC&#8221;). On October 1, 2020, the Company received notice from the FDA that it
had placed the IND on clinical hold. On October 30, 2020, the FDA sent a letter to the Company setting forth the reasons for the clinical
hold and specific guidance on what the Company must do to have the clinical hold lifted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To lift the clinical hold, the FDA informed the
Company that it needs to conduct several additional preclinical studies. The FDA also requested additional information regarding several
topics, including DNA sequencing data, manufacturing information and product release specifications. The Company has been in the process
of conducting these studies and gathering additional information to submit to the FDA. See &#8220;Investigational New Drug Application
and Clinical Hold&#8221; below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 15, 2022, the Company entered into a
Cooperation Agreement (&#8220;Cooperation Agreement&#8221;) with Iroquois Master Fund Ltd. and its affiliates, pursuant to which the Company
elected a reconstituted Board of Directors (the &#8220;Board&#8221;). The Board has formed a Business Review Committee to evaluate, investigate
and review the Company&#8217;s business, affairs, strategy, management and operations and in its sole discretion to make recommendations
to the Company&#8217;s management and Board with respect thereto. The Business Review Committee is also reviewing many of the risks relative
to the Company&#8217;s business. In addition, the Board is reviewing the Company&#8217;s development programs and its relationship with
SG Austria, including that all licensed patents have expired, that know-how relating to the Company&#8217;s Cell-in-a-Box&#174; technology
solely resides with SG Austria, and that the incentives of SG Austria and its management may not be currently aligned with those of the
Company. The Board has curtailed spending on the Company&#8217;s programs, including pre-clinical and clinical activities, until the review
by the Business Review Committee and the Board is complete and the Board has determined the actions and plans to be implemented. The Business
Review Committee&#8217;s recommendations will include potentially seeking a new framework for the Company&#8217;s relationship with SG
Austria and its subsidiaries. In the event the Company is unsuccessful in seeking an acceptable new framework, the Company will reevaluate
whether it should continue those programs which are dependent on SG Austria, including its development programs for LAPC. The issues involving
SG Austria have delayed the Company&#8217;s timeline for addressing the FDA clinical hold for its planned clinical trial in LAPC and could
result in other delays or termination of the development activities. In addition, the curtailment of spending on the Company&#8217;s programs
pending the review by the Business Review Committee and the Board may cause additional delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Cell-in-a-Box<sup>&#174;</sup> encapsulation
technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules.
The technology is intended to result in the formation of pinhead sized cellulose-based porous capsules in which genetically modified live
human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been
shown to create a micro-environment in which encapsulated cells survive and flourish. They are protected from environmental challenges,
such as the sheer forces associated with bioreactors and passage through catheters and needles, which the Company believes enables greater
cell growth and production of the active molecules. The capsules are largely composed of cellulose (cotton) and are bioinert.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23C_zVsUe9KOPe4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_238_zx7k0Qq1zZhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zwoHtvzIBuEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 9 -->
    <div id="xdx_23B_zglV98UjtdJ3" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23B_zmeFwfR25Ve4" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zoMHUdghS417" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has been developing therapies for
pancreatic solid cancerous tumors by using genetically engineered live human cells that it believes are capable of converting a cancer
prodrug into its cancer-killing form. The Company encapsulates those cells using the Cell-in-a-Box<sup>&#174;</sup> technology and places
those capsules in the body as close as possible to the tumor. In this way, the Company believes that when a cancer prodrug is administered
to a patient with a particular type of cancer that may be affected by the prodrug, the killing of the patient&#8217;s cancerous tumor
may be optimized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until the review by the Business Review Committee
and the Board is complete and the Board has determined the actions and plans to be implemented, spending on the Company&#8217;s programs
has been curtailed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Investigational New Drug Application and
Clinical Hold</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 1, 2020, the Company submitted an
IND to the FDA for a planned clinical trial in LAPC. On October 1, 2020, the Company received notice from the FDA that it had placed the
Company&#8217;s IND on clinical hold. On October 30, 2020, the FDA sent the Company a letter setting forth the reasons for the clinical
hold and providing specific guidance on what the Company must do to have the clinical hold lifted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to address the clinical hold, the FDA requested that the Company:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide additional sequencing data and genetic stability studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct a stability study on &#8204;the Company&#8217;s final formulated product candidate as well as the cells from the Company&#8217;s Master Cell Bank;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluate the compatibility of the delivery devices (the prefilled syringe and the microcatheter used to implant the CypCaps<sup>&#8482;</sup>) with &#8204;the Company&#8217;s product candidate for pancreatic cancer;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide additional detailed description of the manufacturing process of &#8204;the Company&#8217;s product candidate for pancreatic cancer;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide additional product release specifications for the Company&#8217;s encapsulated cells;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Demonstrate comparability between the 1<sup>st</sup> and 2<sup>nd</sup> generation of &#8204;the Company&#8217;s product candidate for pancreatic cancer and ensure adequate and consistent product performance and safety between the two generations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct a biocompatibility assessment using the Company&#8217;s capsules material;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address specified insufficiencies in the Chemistry, Manufacturing and Controls information in the cross-referenced Drug Master File;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct an additional nonclinical study in a large animal (such as a pig) to assess the safety, activity, and distribution of the product candidate for pancreatic cancer; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revise the Investigators Brochure to include any additional preclinical studies conducted in response to the clinical hold and remove any statements not supported by the data the Company generated.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&#160;</p>

<ix:exclude><p id="xdx_238_zcqzgRKje1d5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zAuTmKAtBDc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_zX26bdzch572" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 10 -->
    <div id="xdx_238_zRt5UFtaSuO" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_238_zmkKOBlQUfvg" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zBtXG5FyQWk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA also requested that the Company address
the following issues as an amendment to the Company&#8217;s IND:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide a Certificate of Analysis for pc3/2B1 plasmid that includes tests for assessing purity, safety, and potency;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Perform qualification studies for the drug filling step to ensure that the Company&#8217;s product candidate for pancreatic cancer remains sterile and stable during the filling process;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submit an updated batch analysis for the Company&#8217;s product candidate for the specific lot that will be used for manufacturing all future product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide additional details for the methodology for the Resorufin (CYP2B1) potency and the PrestoBlue cell metabolic assays;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide a few examples of common microcatheters that fit the specifications in &#8204;the Company&#8217;s Angiography Procedure Manual;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clarify the language in the Company&#8217;s Pharmacy Manual regarding proper use of the syringe fill with the Company&#8217;s product candidate for pancreatic cancer; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide a discussion with data for trial of the potential for cellular and humoral immune reactivity against the heterologous rat CYP2B1 protein and potential for induction of autoimmune-mediated toxicities in &#8204;the Company&#8217;s study population.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company assembled a scientific and regulatory
team of experts to address the FDA requests. Through January 31, 2026, the Company&#8217;s scientific consultants have been in active
dialog with the FDA. The Company received communications from the FDA and responded, including the submission of the updated drug master
file. The FDA accepted the updated master drug file and cleared many of the clinical hold items. The Company believes that the technology
upon which the LAPC treatment will be based, intra-arterial chemotherapy, has been used in five clinical trials in humans. The Company&#8217;s
position is that the data available from these human clinical trials supersedes large animal study data, making the study unnecessary.
The treatment may not be a treatment of pancreatic cancer, but a method of improving and possibly enabling complete surgical resection
of the tumor. The Company is waiting for the FDA&#8217;s responses and hopes the FDA will accept that the LAPC treatment now meets manufacturing
standard requirements, which have significantly improved since the clinical hold was first placed. The FDA may require additional preclinical
studies when the meeting takes place. The Company is in ongoing dialogue with SG Austria to prepare for the next steps, including the
preparation of the syringes filled with the latest generation of CypCaps&#8482; with the working cell material.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001183" name="PMCB:LiquidityAndOtherUncertainitiesTextBlock"><p id="xdx_80F_ecustom--LiquidityAndOtherUncertainitiesTextBlock_zrHMuctJJlOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 &#8211; <span id="xdx_82F_zI5bbh6y7x9d">LIQUIDITY AND OTHER UNCERTAINTIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of January 31, 2026, the Company had approximately
$<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_dxH_c20260131_ziflwvAgMvu4" title="Cash and cash equivalents::XDX::20165535">20.2</span> million in cash and cash equivalents as compared to approximately $<span id="xdx_90A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_dxH_c20250430_zJirND3gYRc7" title="Cash and cash equivalents::XDX::15172163">15.2</span> million at April 30, 2025. The Company expects that its
current cash and cash equivalents of approximately $19 million, as of the filing of this Quarterly Report on Form 10-Q, will be sufficient
to support its projected operating requirements and financial commitments for at least the next twelve months from the date of this Quarterly
Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2025, the Company entered into a securities
purchase agreement pursuant to which it agreed to sell to investors in a private placement an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250801__20250831__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_ztvrvToq2nzb" title="Stock issued new, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2025-08-012025-08-31_us-gaap_PrivatePlacementMember_us-gaap_SeriesCPreferredStockMember" id="Fact001189" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,000</ix:nonFraction></span> shares of the Company&#8217;s
newly designated Series C convertible preferred stock with a stated value of $1,000 per share and warrants to purchase up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pn6n6_c20250831__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--WarrantsMember_zyZAqNsg79zi" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-08-31_us-gaap_PrivatePlacementMember_custom_WarrantsMember" id="Fact001191" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="Shares">7</ix:nonFraction></span> million
shares of common stock, resulting in aggregate gross proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20250801__20250831__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zgbx1xXSz2" title="Proceeds from sale of equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2025-08-012025-08-31_us-gaap_PrivatePlacementMember" id="Fact001193" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">7</ix:nonFraction></span> million. See Note 10 - Preferred stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2025, the Company entered into a
securities purchase agreement pursuant to which it agreed to purchase in a private placement QCLS Series H Preferred Stock (as defined
herein) initially convertible into <span id="xdx_909_eus-gaap--InvestmentOwnedBalanceShares_iI_c20250930__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHConvertiblePreferredStockMember_zG5udMArbW08" title="Investment shares"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2025-09-30_custom_QCLSSeriesHConvertiblePreferredStockMember" id="Fact001195" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600,000</ix:nonFraction></span> shares, subject to adjustment of QCLS (as defined herein) common stock and warrants for an
aggregate purchase price of $<span id="xdx_90C_eus-gaap--PaymentsToAcquireInvestments_pn6n6_c20250901__20250930__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHConvertiblePreferredStockMember_zyKoiN7aXDQd"><ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2025-09-012025-09-30_custom_QCLSSeriesHConvertiblePreferredStockMember" id="Fact001196" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">3</ix:nonFraction></span> million. See Note 4 - Investment in debt and equity securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_234_ze7PHN6rNj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zt4IO8TM8Nll" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zjEELpnwgGkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 11 -->
    <div id="xdx_237_zHaTkGh6Bia8" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23D_z5gXCXIX05gk" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zBMj9xOooCI5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expects to need additional capital
in order to complete a clinical trial for the treatment of pancreatic cancer. If any additional equity financing, if available, may not
be on favorable terms and would likely be significantly dilutive to the Company&#8217;s current stockholders and debt financing, if available,
may involve restrictive covenants. If the Company is able to access funds through collaborative or licensing arrangements, it may be required
to relinquish rights to some of its product candidates that the Company would otherwise seek to develop or commercialize on its own, on
terms that are not favorable to the Company. The Company&#8217;s ability to access capital is not assured and, if not achieved on a timely
basis, will likely have a material adverse effect on the Company&#8217;s business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates in an industry that is subject
to rapid technological change, competition and government regulation. The Company&#8217;s operations are subject to significant risk and
uncertainties including financial operational, technological, regulatory, and other risks. Such factors, include but not limited to, results
of clinical testing and trial activities, the ability to obtain regulatory approval, the supply of needed materials, the ability to obtain
manufacturing and the ability to raise capital to achieve strategic objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001202" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zk5BMDdRWtEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 3 &#8211; <span id="xdx_821_zAKl9Qnxushb">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001204" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zEn8a5sVwzBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86F_zF924hLUdH9g">Principles of Consolidation and Basis of Presentation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated
financial statements have been prepared in accordance with U.S. GAAP for interim financial information and the rules and regulation of
the United States Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by
U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of
normal recurring items) which are considered necessary for a fair statement of the unaudited condensed consolidated financial statements
of the Company as of January 31, 2026 and for the three and nine months then ended. The results of operations for the three and nine months
ended January 31, 2026 are not necessarily indicative of the operating results for the year or any other period. These unaudited condensed
consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures as of April
30, 2025 and for the year then ended which are included in the Company&#8217;s Annual Report on Form 10- K, filed with the SEC on August
11, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited condensed consolidated financial
statements include the accounts of the Company and its wholly owned subsidiaries. The Company operates independently and through three
wholly owned subsidiaries: (i) PharmaCyte Biotech Europe Limited; (ii) PharmaCyte Biotech Australia Pty. Ltd.; and (iii) Viridis Biotech,
Inc. and are prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and the Rules and Regulations
of the Commission. Upon consolidation, intercompany balances and transactions are eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001206" name="us-gaap:UseOfEstimates"><p id="xdx_84C_eus-gaap--UseOfEstimates_zdlBwwa553N9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86B_z5PEf66noUIc">Use of Estimates in the Preparation of Financial
Statements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of
contingent assets and liabilities known to exist as of the date the financial statements are published and the reported amounts of revenues
and expenses during the reporting period. Uncertainties with respect to such estimates and assumptions are inherent in the preparation
of the Company&#8217;s unaudited condensed consolidated financial statements; accordingly, it is possible that the actual results could
differ from these estimates and assumptions, which could have a material effect on the reported amounts of the Company&#8217;s condensed
consolidated financial position and results of operations. The Company&#8217;s most significant estimates and assumptions are the assessment
of the fair value of long-lived assets, fair value measurements of investments, the valuation of warrants and derivative liabilities,
and the measurement of stock-based compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_233_z8gQeqFf990h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zA4HoKsiGy22" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_z34E6YVbI4pe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 12 -->
    <div id="xdx_231_zghGmI5dkNE4" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23E_zvqTg1qsK5S2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zx4SrF2cy6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001212" name="us-gaap:Reclassifications"><p id="xdx_84D_eus-gaap--Reclassifications_z6JDFJSpFkTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_860_zjtxU3oKJfKe">Reclassification</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain balances in the unaudited condensed consolidated
financial statements for the three and nine months ended January 31, 2025 have been reclassified to conform to the presentation in the
condensed consolidated financial statements for the three and nine months ended January 31, 2026. In the prior year, the Company separately
disclosed compensation expense, director fees and legal and professional expenses and combined the QCLS change in fair value of the investment
and warrant assets and in the current year the Company has reclassified these costs on the consolidated statements of operations with
general and administrative expenses and the change in the fair value of the investment QCLS and the change in the fair value of the warrant
assets are presented separately. These reclassifications had no effect on the Company&#8217;s previously reported results of operations,
changes in convertible preferred stock and stockholders&#8217; equity, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001214" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zecu2pLZS4lb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_864_zPdv9rRu08qi">Cash and Cash Equivalents</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents include cash in banks
and short-term liquid investments purchased with maturities of three months or less. Additionally, the Company, as of January 31, 2026
and April 30, 2025 had $<span id="xdx_901_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20260131_zIsJD9ugzaQe" title="Cash, uninsured amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2026-01-31" id="Fact001216" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.1</ix:nonFraction></span> million and $<span id="xdx_90B_eus-gaap--CashUninsuredAmount_iI_c20250430_zPY9BRgn84Fg" title="Cash, uninsured amount"><ix:nonFraction name="us-gaap:CashUninsuredAmount" contextRef="AsOf2025-04-30" id="Fact001218" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,287</ix:nonFraction></span>, respectively, in a money market fund that is not insured by the Federal Deposit Insurance
Corporation (&#8220;FDIC&#8221;) and is classified as a cash equivalent. The Company has no significant off-balance-sheet concentrations
of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. The Company maintains most
of its cash balance at financial institutions located throughout the U.S. Accounts at these institutions are insured by the FDIC up to
$250,000. The Company has not experienced any losses in such accounts. Management believes it is not exposed to any significant credit
risk on cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001220" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p id="xdx_849_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_z5n34qUqwrFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86F_zOZQuZk62MQ5">Intangible Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s accounts for intangible assets
at cost. The intangible asset has an indefinite life; therefore, is not amortizable. The Company performs annual impairment analysis for
the intangible asset to ascertain the value at each year end and records a non-cash impairment expense should the value decrease below
book value. The asset is deemed to be an In-Process Research and Development (&#8220;IPR&amp;D&#8221;) as the asset is in the research
stage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Financial Accounting Standards Board (&#8220;FASB&#8221;)
standard on goodwill and other intangible assets prescribes a two-step process for impairment testing of goodwill and indefinite-lived
intangibles, which is performed annually, as well as when an event triggering impairment may have occurred. The first step tests for impairment,
while the second step, if necessary, measures the impairment. The Company has elected to perform its annual analysis at the end of its
reporting year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001222" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_znpaVd9AXJV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_862_zNSiRm1au4Fe">Fair Value of Financial Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting Standards Codification (&#8220;ASC&#8221;)
Topic 820, &#8220;Fair Value Measurements and Disclosures,&#8221; requires disclosure of the fair value of financial instruments held
by the Company. ASC Topic 825, &#8220;Financial Instruments,&#8221; defines fair value, and establishes a three-level valuation hierarchy
for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported
in the Consolidated Balance Sheets for current assets and liabilities qualify as financial instruments and are a reasonable estimate of
their fair values because of the short period between the origination of such instruments and their expected realization and their current
market rate of interest. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability
(an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use
of unobservable inputs. The three levels of valuation hierarchy are defined as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1. Observable inputs such as quoted prices in active markets</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2. Inputs, other than the quoted prices in active markets, which are observable either directly or indirectly; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These unobservable inputs are significant to the
fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23D_z0wCOGKtcjTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zu0eW8V1EHzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zfh0nrJQTibe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 13 -->
    <div id="xdx_23A_zrWHJrwcOEA1" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23D_zEHrUlYhijoa" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zVDG1lAJxgPb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001228" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zBHCex85zAM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Segment Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates in <span id="xdx_90F_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20250501__20260131_zASX9yMgXsV6" title="::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl1229">one</span></span> business
segment, which includes the business of research and development activities related to developing cellular cancer therapies. The determination
of a single business segment is consistent with the financial information regularly provided to the Company&#8217;s chief operating decision
maker (&#8220;CODM&#8221;). The Company&#8217;s CODM is its President and CEO, who reviews and evaluates consolidated net income as presented
in the accompanying consolidated statements of operations for purposes of assessing performance, making operating decisions, allocating
resources, and planning and forecasting for future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zRUkpy3lvvW" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86B_zo7ajKAyO8Wb">New Accounting Pronouncement Effective in Future
Periods</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2025, the FASB issued ASU 2025-11
&#8211; Interim Reporting (Topic 270): Narrow-Scope Improvements to improve the guidance in Topic 270, Interim Reporting, by improving
the navigability of the required interim disclosures and clarifying when that guidance is applicable. The amendments also provide additional
guidance on what disclosures should be provided in interim reporting periods. The guidance is effective for the Company&#8217;s interim
periods&#160;within annual reporting periods beginning after December 15, 2027. The Company is evaluating the impact of adoption of this
standard on its financial statements and disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001233" name="us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock"><p id="xdx_801_eus-gaap--TradingSecuritiesAndCertainTradingAssetsTextBlock_z219I15BXJw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8211; <span id="xdx_82A_zVblqXKVwvdc">INVESTMENT IN DEBT AND EQUITY
SECURITIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>INVESTMENT IN FEMASYS SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 14, 2023, the Company entered into
a Securities Purchase Agreement (the &#8220;Femasys Purchase Agreement&#8221;) with Femasys Inc. (&#8220;Femasys&#8221;), pursuant to
which it agreed to purchase from Femasys for a sum of $<span id="xdx_904_eus-gaap--PaymentsToAcquireInvestments_c20231113__20231114__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zLcj5u7fnul2" title="Payment for investment"><ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2023-11-132023-11-14_custom_FemasysPurchaseAgreementMember" id="Fact001235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span>, (i)&#160;senior unsecured convertible note (the &#8220;Femasys Note&#8221;)
in an aggregate principal amount of $5,000,000, convertible into shares of Femasys common stock, par value $0.001 per share (the &#8220;Femasys
Shares&#8221;) at a conversion price of $<span id="xdx_90E_ecustom--ReceivableInstrumentConvertibleConversionPrice1_iI_c20231114__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zHVzT1Kdnz6g" title="Receivable conversion price"><ix:nonFraction name="PMCB:ReceivableInstrumentConvertibleConversionPrice1" contextRef="AsOf2023-11-14_custom_FemasysPurchaseAgreementMember" id="Fact001237" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.18</ix:nonFraction></span> per share, (ii) Series A Warrants (the &#8220;Series A Warrants&#8221;) to purchase up to
an aggregate of <span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_c20231114__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_z9rFcisGttN6" title="Investment shares"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2023-11-14_custom_FemasysPurchaseAgreementMember" id="Fact001239" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,237,288</ix:nonFraction></span> Femasys Shares at an exercise price of $1.18 per share, and (iii) Series B Warrants (the &#8220;Series B Warrants&#8221;,
together with the Series A Warrants, the &#8220;Femasys Warrants,&#8221; and, together with the Notes, the &#8220;Femasys Securities&#8221;)
to purchase up to an aggregate of 4,237,288 Femasys Shares at an exercise price of $1.475 per share (collectively, the &#8220;Investment&#8221;).
The Femasys Note accrues interest at 6.0% per annum, payable annually, and mature two years after the date of issuance. The Series A Warrants
expire five years from the date of issuance. The Series B Warrants expired in November 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Femasys Purchase
Agreement, the Company&#8217;s Chief Executive Officer was appointed to the Femasys board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The convertible note receivable is not traded
in active markets and the fair value was historically determined using a Monte Carlo simulation. The convertible note receivable is accounted
for as available-for-sale debt securities based on &#8220;Level&#160;3&#8221; inputs, which consist of unobservable inputs and reflect
management&#8217;s estimates of assumptions that market participants would use in pricing the asset. The Company elected the fair value
option for the Femasys Note, therefore, holding gains and losses are included within change in fair value of the note in the unaudited
condensed consolidated statement of operations. The Femasys Warrants are accounted for as an equity security and are valued using a Monte
Carlo simulation based on &#8220;Level 3&#8221; inputs, which consist of unobservable inputs and reflect management&#8217;s estimates
of assumptions that market participants would use in pricing the asset, recorded at fair value with subsequent changes included within
change in fair value of the warrants in the unaudited condensed consolidated statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of January 31, 2026, the Company received $<span id="xdx_908_ecustom--ProceedsFromInvestmentNoteReceivable_pn6n6_c20260129__20260131__us-gaap--TransactionTypeAxis__custom--FemasysNoteMember_z3FcWOAhwI62" title="Proceeds from investment - note receivable"><ix:nonFraction name="PMCB:ProceedsFromInvestmentNoteReceivable" contextRef="From2026-01-292026-01-31_custom_FemasysNoteMember" id="Fact001241" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span>
million in full settlement of the Femasys Note. Additionally, the Company received <span id="xdx_90A_ecustom--InvestmentSharesAddition_c20260129__20260131__srt--CounterpartyNameAxis__custom--FemasysMember_z9fVH9nzhZl2" title="Investment shares additions"><ix:nonFraction name="PMCB:InvestmentSharesAddition" contextRef="From2026-01-292026-01-31_custom_FemasysMember" id="Fact001243" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">379,747</ix:nonFraction></span> shares of Femasys common stock in full settlement
of the accrued interest of $<span id="xdx_905_ecustom--SettlementOfAccruedInterest_c20260129__20260131__us-gaap--TransactionTypeAxis__custom--FemasysNoteMember_zzHliDpcSK26" title="Settlement of accrued interest"><ix:nonFraction name="PMCB:SettlementOfAccruedInterest" contextRef="From2026-01-292026-01-31_custom_FemasysNoteMember" id="Fact001245" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span>. The Company holds <span id="xdx_90D_eus-gaap--InvestmentOwnedBalanceShares_iI_c20260131__us-gaap--TransactionTypeAxis__custom--FemasysCommonStockMember_zrPDxviwDO73" title="Investment shares owned"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2026-01-31_custom_FemasysCommonStockMember" id="Fact001247" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">695,537</ix:nonFraction></span> shares of Femasys common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended January 31, 2026
and 2025, the Company recognized interest income of $<span id="xdx_90E_eus-gaap--InterestAndOtherIncome_c20251101__20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_z19F0T74GJs4" title="Interest income"><ix:nonFraction name="us-gaap:InterestAndOtherIncome" contextRef="From2025-11-012026-01-31_custom_FemasysPurchaseAgreementMember" id="Fact001249" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,500</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--InterestAndOtherIncome_c20241101__20250131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zQX2dnaYVmp1" title="Interest income"><ix:nonFraction name="us-gaap:InterestAndOtherIncome" contextRef="From2024-11-012025-01-31_custom_FemasysPurchaseAgreementMember" id="Fact001251" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></span>, respectively, and during the nine months ended January 31, 2026
and 2025 the Company recognized interest income of $<span id="xdx_904_eus-gaap--InterestAndOtherIncome_c20250501__20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zl78V5En0eT8" title="Interest income"><ix:nonFraction name="us-gaap:InterestAndOtherIncome" contextRef="From2025-05-012026-01-31_custom_FemasysPurchaseAgreementMember" id="Fact001253" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,500</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--InterestAndOtherIncome_c20240501__20250131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zb5ja9cB7XV9" title="Interest income"><ix:nonFraction name="us-gaap:InterestAndOtherIncome" contextRef="From2024-05-012025-01-31_custom_FemasysPurchaseAgreementMember" id="Fact001255" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,000</ix:nonFraction></span>, respectively, from the Femasys Note. As of January 31, 2026
and April 30, 2025, the Company has accrued interest receivable of $<span id="xdx_905_eus-gaap--InterestReceivable_iI_c20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_z4muJVXWSDub" title="Interest receivable"><ix:nonFraction name="us-gaap:InterestReceivable" contextRef="AsOf2026-01-31_custom_FemasysPurchaseAgreementMember" id="Fact001257" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--InterestReceivable_iI_c20250430__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zMWRTJ76sYB4" title="Interest receivable"><ix:nonFraction name="us-gaap:InterestReceivable" contextRef="AsOf2025-04-30_custom_FemasysPurchaseAgreementMember" id="Fact001259" format="ixt:numdotdecimal" decimals="0" unitRef="USD">137,500</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of January 31, 2026, the fair value of the
Femasys Series A Warrants was approximately $<span id="xdx_90E_eus-gaap--InvestmentOwnedAtFairValue_iI_c20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--FemasysSeriesAWarrantsMember_zPFmkAJ9fBT2" title="Investment fair value"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2026-01-31_custom_FemasysPurchaseAgreementMember_custom_FemasysSeriesAWarrantsMember" id="Fact001261" format="ixt:numdotdecimal" decimals="0" unitRef="USD">906,000</ix:nonFraction></span> and was determined utilizing the following assumptions: Femasys stock price of $0.54,
exercise price of $1.18, risk free rate of 3.58%, equity volatility of 102.0% and remaining term of 2.79 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:exclude><p id="xdx_238_zWxxLoSJpi22" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zxSdu2cHsSW1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zf3qfye5pd93" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 14 -->
    <div id="xdx_23B_z2n1oKTktoRk" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_zmXwPzS5Th15" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zoPcGqZ3VIa7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognized the Femasys Note and Femasys
Warrants based on their respective fair values as of April 30, 2025 of $<span id="xdx_90D_ecustom--ConvertibleNoteReceivableCurrent_iI_c20250430__us-gaap--TransactionTypeAxis__custom--FemasysNoteMember_zAx1e3l3CDhj" title="Convertible note receivable, current"><ix:nonFraction name="PMCB:ConvertibleNoteReceivableCurrent" contextRef="AsOf2025-04-30_custom_FemasysNoteMember" id="Fact001267" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,696,000</ix:nonFraction></span> and $<span id="xdx_90D_ecustom--WarrantAssetFemasys_iI_c20250430__us-gaap--TransactionTypeAxis__custom--FemasysWarrantsMember_zUCHdhdvSCf" title="Warrant asset - Femasys"><ix:nonFraction name="PMCB:WarrantAssetFemasys" contextRef="AsOf2025-04-30_custom_FemasysWarrantsMember" id="Fact001269" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,061,000</ix:nonFraction></span>, respectively. Subsequent changes in
the fair value of the Femasys Note and Femasys Warrants are recognized in earnings, at each reporting date. During the three and nine
months ended January 31, 2026, the Company recognized gains for change in fair value of the convertible note receivable of $<span id="xdx_907_ecustom--ChangeInFairValueOfConvertibleNotesReceivable_c20251101__20260131__us-gaap--TransactionTypeAxis__custom--FemasysNoteMember_zHxVS2TuGxNj" title="Change in fair value of the convertible note receivable"><ix:nonFraction name="PMCB:ChangeInFairValueOfConvertibleNotesReceivable" contextRef="From2025-11-012026-01-31_custom_FemasysNoteMember" id="Fact001271" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90F_ecustom--ChangeInFairValueOfConvertibleNotesReceivable_c20250501__20260131__us-gaap--TransactionTypeAxis__custom--FemasysNoteMember_zavfvQdqlWxb" title="Change in fair value of the convertible note receivable"><ix:nonFraction name="PMCB:ChangeInFairValueOfConvertibleNotesReceivable" contextRef="From2025-05-012026-01-31_custom_FemasysNoteMember" id="Fact001273" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,304,000</ix:nonFraction></span>,
respectively, and losses for change in fair value of the warrant asset of $<span id="xdx_90A_ecustom--ChangeInFairValueOfWarrantAssetFemasys_iN_di_c20251101__20260131__us-gaap--TransactionTypeAxis__custom--FemasysWarrantsMember_znfrkPMNAJBd" title="Change in fair value of the convertible note receivable"><ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantAssetFemasys" contextRef="From2025-11-012026-01-31_custom_FemasysWarrantsMember" id="Fact001275" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">214,000</ix:nonFraction></span> and $<span id="xdx_90F_ecustom--ChangeInFairValueOfWarrantAssetFemasys_iN_di_c20250501__20260131__us-gaap--TransactionTypeAxis__custom--FemasysWarrantsMember_zv0dD2FQ3mz8" title="Change in fair value of the convertible note receivable"><ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantAssetFemasys" contextRef="From2025-05-012026-01-31_custom_FemasysWarrantsMember" id="Fact001277" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,155,000</ix:nonFraction></span>, respectively. See Note 12 &#8211; Fair
value Measurements for further information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is a summary of activity for the Femasys
Note and Femasys Warrants as of January 31, 2026:</p>

<ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001279" name="us-gaap:ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock_zIJZbr9fmyab" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Femasys Note and warrants)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B6_zPFx5JpVVhV8" style="display: none">Schedule of activity for the notes and warrants</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: justify">Balance of Femasys Note as of April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ConvertibleNoteReceivableCurrent_iS_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zcVqZmWeVxJf" title="Investment, beginning balance" style="width: 13%; text-align: right"><ix:nonFraction name="PMCB:ConvertibleNoteReceivableCurrent" contextRef="AsOf2025-04-30_custom_FemasysNotesMember" id="Fact001281" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,696,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ChangeInFairValueOfConvertibleNotesReceivable_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zzRyXvMMS5y1" title="Change in fair value" style="text-align: right"><ix:nonFraction name="PMCB:ChangeInFairValueOfConvertibleNotesReceivable" contextRef="From2025-05-012026-01-31_custom_FemasysNotesMember" id="Fact001283" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,304,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Settlement of Femasys Note</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ProceedsFromInvestmentNoteReceivable_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zxwa0yFTbJP6" title="Settlement of Femasys Note" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="PMCB:ProceedsFromInvestmentNoteReceivable" contextRef="From2025-05-012026-01-31_custom_FemasysNotesMember" id="Fact001285" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,000,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Balance of Femasys Note as of January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ConvertibleNoteReceivableCurrent_iE_d0_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zfJXwdRVpvTd" title="Investment, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="PMCB:ConvertibleNoteReceivableCurrent" contextRef="AsOf2026-01-31_custom_FemasysNotesMember" id="Fact001287" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: justify">Balance of Femasys Warrant Asset as of April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--WarrantAssetFemasys_iS_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysWarrantsMember_zXIWBF6vdp01" title="Investment, beginning balance" style="width: 13%; text-align: right"><ix:nonFraction name="PMCB:WarrantAssetFemasys" contextRef="AsOf2025-04-30_custom_FemasysWarrantsMember266865281" id="Fact001289" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,061,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--ChangeInFairValueOfWarrantAssetFemasys_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysWarrantsMember_zvxqJ0ydPnb" title="Change in fair value" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantAssetFemasys" contextRef="From2025-05-012026-01-31_custom_FemasysWarrantsMember266865281" id="Fact001291" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,155,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Balance of Femasys Warrant Asset as of January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--WarrantAssetFemasys_iE_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysWarrantsMember_znNVChNbG69b" title="Investment, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="PMCB:WarrantAssetFemasys" contextRef="AsOf2026-01-31_custom_FemasysWarrantsMember" id="Fact001293" format="ixt:numdotdecimal" decimals="0" unitRef="USD">906,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_z6Hmbxx60Oud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>MARKETABLE SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 21, 2025 and 2024, the Company
received from the Femasys Notes payments in Femasys common stock for interest income in the amount of $<span id="xdx_900_eus-gaap--InterestAndOtherIncome_c20251120__20251121__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--FemasysCommonStockMember_zmlXyrGr8mh3" title="Interest and other income"><ix:nonFraction name="us-gaap:InterestAndOtherIncome" contextRef="From2025-11-202025-11-21_custom_FemasysPurchaseAgreementMember_custom_FemasysCommonStockMember" id="Fact001295" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span>
and $<span id="xdx_907_eus-gaap--InterestAndOtherIncome_c20241120__20241121__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--FemasysCommonStockMember_zEbFh4PxG7Bi" title="Interest and other income"><ix:nonFraction name="us-gaap:InterestAndOtherIncome" contextRef="From2024-11-202024-11-21_custom_FemasysPurchaseAgreementMember_custom_FemasysCommonStockMember" id="Fact001297" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span>,
respectively. The interest income payments were based on the Femasys average stock price on those dates of $0.79 and $0.95,
respectively, therefore, the Company received <span id="xdx_909_ecustom--InvestmentSharesAddition_c20251120__20251121__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zvHWQVHUhxn1"><ix:nonFraction name="PMCB:InvestmentSharesAddition" contextRef="From2025-11-202025-11-21_custom_FemasysPurchaseAgreementMember" id="Fact001298" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">379,747</ix:nonFraction></span>
and <span id="xdx_909_ecustom--InvestmentSharesAddition_c20241120__20241121__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zJXHg6pF4oRl"><ix:nonFraction name="PMCB:InvestmentSharesAddition" contextRef="From2024-11-202024-11-21_custom_FemasysPurchaseAgreementMember" id="Fact001299" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">315,790</ix:nonFraction></span>
common stock shares, respectively. The Company elected the fair value option on this investment. The related unrealized loss
pertaining to this investment is recorded in other income and expense. The value of the initial interest payment was $<span id="xdx_90B_eus-gaap--PaymentsToAcquireEquityMethodInvestments_c20240501__20250430__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zSs2my83FyPb" title="Investment interest payment"><ix:nonFraction name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="From2024-05-012025-04-30_custom_FemasysPurchaseAgreementMember" id="Fact001301" format="ixt:numdotdecimal" decimals="0" unitRef="USD">366,316</ix:nonFraction></span>
on April 30, 2025. The Company holds a total of <span id="xdx_900_eus-gaap--InvestmentOwnedBalanceShares_iI_c20260131__srt--CounterpartyNameAxis__custom--FemasysMember_zZ0APWx5Zh41"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2026-01-31_custom_FemasysMember" id="Fact001302" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">695,537</ix:nonFraction></span>
common stock shares. As of January 31, 2026, the current market value of the Femasys common stock shares was $0.54 that generated an
unrealized loss of $<span id="xdx_906_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_iN_di_c20250501__20260131__srt--CounterpartyNameAxis__custom--FemasysMember_zuuZTwMa8Doc" title="Unrealized loss on marketable securities"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2025-05-012026-01-31_custom_FemasysMember" id="Fact001304" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">294,065</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost and fair value of marketable equity securities
at January 31, 2026 are as follows:</p>

<ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001306" name="us-gaap:ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock_zvFiqG8cQ8nd" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Marketable securities)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B3_zvXzbb3lexK5" style="display: none">Schedule of marketable equity securities</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Carrying Value</td><td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">At Fair Market</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Adjusted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Unrealized</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 55%; text-align: justify; padding-bottom: 1pt">Marketable securities</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Basis</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Equity &#8211; stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--MarketableSecuritiesCurrent_iI_c20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_ztFDbwbPoEN8" title="Carrying value at fair market value"><ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="AsOf2026-01-31_custom_FemasysPurchaseAgreementMember" id="Fact001308" format="ixt:numdotdecimal" decimals="0" unitRef="USD">372,251</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--InvestmentOwnedAtCost_iI_c20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zczNH370gFRj" title="Adjusted cost basis"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2026-01-31_custom_FemasysPurchaseAgreementMember" id="Fact001310" format="ixt:numdotdecimal" decimals="0" unitRef="USD">666,316</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20250501__20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zAt1iAJWMWD1" title="Unrealized loss"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" contextRef="From2025-05-012026-01-31_custom_FemasysPurchaseAgreementMember" id="Fact001312" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,065</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zS5gpO4LWg9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of equity securities has been measured
on a recurring basis using Level 1 inputs, which are based on unadjusted quoted market prices within active markets. There have been no
changes in valuation approaches or techniques and related inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<ix:exclude><p id="xdx_238_z7oOHRGidHgl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zuaxz959QJw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zMw9b0Ehz0yb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 15 -->
    <div id="xdx_23D_zZ1xTWByWP1" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23A_zTdwKK20QFZ9" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_z4ftF5MGfZvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>INVESTMENT
IN Q/C TECHNOLOGIES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Series G Preferred Shares and Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 20, 2024, the Company entered into a Securities
Purchase Agreement (the &#8220;Series G SPA&#8221;) with a public company operating in the medical industry, MyMD Pharmaceuticals, Inc.
which subsequently changed its name to TNF Pharmaceuticals, Inc. and then to Q/C Technologies, Inc., (&#8220;QCLS&#8221;). Pursuant to
the Series G SPA, the Company purchased (i) <span id="xdx_90D_eus-gaap--InvestmentOwnedBalanceShares_iI_c20240520__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_z1uNwUsqKdVl" title="Investment shares owned"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2024-05-20_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_us-gaap_SeriesGPreferredStockMember" id="Fact001318" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,000</ix:nonFraction></span> shares of QCLS&#8217;s Series G Convertible Preferred Stock (the &#8220;Series G Preferred
Shares&#8221; or &#8220;Series G Preferred Stock&#8221;) with an original conversion price of $1.816 per Series G Preferred Share, which
were initially convertible into 3,854,626 shares of common stock of QCLS (&#8220;QCLS Common Stock&#8221;); (ii) warrants to purchase
up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240520__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--LongTermWarrantMember_z2joAwK5Kvtc" title="Warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-05-20_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_LongTermWarrantMember" id="Fact001320" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,854,626</ix:nonFraction></span> shares of QCLS Common Stock with a five-year term (&#8220;QCLS Series G Long-Term Warrant&#8221;); and (iii) warrants
to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240520__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ShortTermWarrantMember_zKRQLTc7Jjr" title="Warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-05-20_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_ShortTermWarrantMember" id="Fact001322" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,854,626</ix:nonFraction></span> shares of QCLS Common Stock with a 18-month term (&#8220;QCLS Series G Short-Term Warrant&#8221;) (collectively,
the &#8220;QCLS Series G Warrants&#8221;), for an aggregate purchase price of $<span id="xdx_909_eus-gaap--PaymentsToAcquireInvestments_c20240519__20240520__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zRAHMfPVbLrf" title="Payments for investments"><ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2024-05-192024-05-20_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember" id="Fact001324" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2025, QCLS issued securities that caused
changes to the original terms of the Series G Preferred Stock. The conversion and exercises prices were adjusted to $0.1832 per Series
G Preferred Share, the number of QCLS Series G Long-Term Warrants were adjusted to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--LongTermWarrantMember_zaLsWtEZVwT4" title="Warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-04-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_LongTermWarrantMember" id="Fact001326" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,209,611</ix:nonFraction></span> shares of QCLS Common Stock and
the number of QCLS Series G Short-Term Warrants were adjusted to purchase 38,209,611 shares of QCLS Common Stock. In September 2025, in
connection with the QCLS&#8217; <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20250901__20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zrUnZqn72I88" title="Stockholders equity, reverse stock split"><ix:nonNumeric contextRef="From2025-09-012025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember" id="Fact001328" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-100 reverse stock split</ix:nonNumeric></span> and pursuant to the stock combination event adjustment provisions of the
Series G Preferred Shares and QCLS Series G Warrants, the conversion price and the exercise price was adjusted to $3.37 per share, the
7,000 Series G Preferred Shares were adjusted to be convertible into 2,076,351 shares of QCLS Common Stock, and the number of QCLS Series
G Long-Term Warrants were adjusted to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--LongTermWarrantMember_z8PhV2jf0gY5" title="Warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_LongTermWarrantMember" id="Fact001330" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,076,351</ix:nonFraction></span> shares of QCLS Common Stock and the number of QCLS Series G Short-Term Warrants
were adjusted to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ShortTermWarrantMember_zy7W7OI7o566" title="Warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_ShortTermWarrantMember" id="Fact001332" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,076,351</ix:nonFraction></span> shares of QCLS Common Stock. On November 23, 2025, the QCLS Series G Short-Term Warrants expired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Series G SPA, the Company has
the right to participate in future sales of QCLS&#8217;s equity and equity-linked securities until the second anniversary of the Closing
or the date on which no Series G Preferred Shares remain outstanding, whichever is earlier. Additionally, the Company has the right to
nominate one individual to serve on QCLS&#8217;s board of directors until PharmaCyte no longer beneficially owns at least 20% of QCLS
Common Stock on an as-converted basis. The Company&#8217;s Chief Executive Officer serves on the board of directors of QCLS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determined that QCLS is a VIE, since
QCLS does not have sufficient equity at risk to finance its own operations without additional subordinated financial support. However,
the Company has determined that it is not the primary beneficiary of QCLS. Furthermore, Series G Preferred Stock is not considered in
substance common stock, and as such, the equity method of accounting does not apply. The Company recorded its investment in Series G Preferred
Stock at its fair value as the Company did not elect the measurement alternative to account for the investment at cost less impairment.
Subsequent changes in fair value of the Series G Preferred Stock are recognized in earnings at each reporting period. The fair value of
the Series G Preferred Stock was estimated utilizing a Monte Carlo simulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The QCLS Series G Warrants were determined to
meet the definition of a derivative and were required to be recorded at fair value in accordance with ASC 815. Subsequent changes in the
fair value of the QCLS Series G Warrants are recognized in earnings, at each reporting date. The issuance date fair value of the QCLS
Series G Warrants was determined utilizing the Black Scholes Merton Method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series G Preferred Stock shares include a
10% dividend, which are payable in cash or shares of QCLS Series G Preferred Stock at the Company&#8217;s option, and the Company has
elected to receive shares of the QCLS Preferred Stock as Payment in Kind (&#8220;PIK&#8221;). As of January 31, 2026, and April 30, 2025
the Company owned <span id="xdx_90D_eus-gaap--InvestmentOwnedBalanceShares_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zcuWseDqodl3"><span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_c20250430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zKR3zSS6yyUk"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember" id="Fact001333" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2025-04-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember" id="Fact001334" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,577</ix:nonFraction></ix:nonFraction></span></span> shares including accrued dividend of <span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_c20250430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSAccruedDividendReceivableMember_zN1HwkIkgCYe"><span id="xdx_903_eus-gaap--InvestmentOwnedBalanceShares_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSAccruedDividendReceivableMember_zN6PDxdC1L34"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2025-04-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSAccruedDividendReceivableMember" id="Fact001335" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSAccruedDividendReceivableMember" id="Fact001336" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,577</ix:nonFraction></ix:nonFraction></span></span> shares, and <span id="xdx_902_eus-gaap--InvestmentOwnedBalanceShares_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_ziDWMlK366G"><span id="xdx_906_eus-gaap--InvestmentOwnedBalanceShares_iI_c20250430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zj8sh39WEck9"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesGPreferredStockMember" id="Fact001337" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2025-04-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesGPreferredStockMember" id="Fact001338" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,831</ix:nonFraction></ix:nonFraction></span></span> Series G Preferred Stock shares, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_239_zNVYUmoQHuXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zGMKOeLlaR99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zjoIvwJ6H3Be" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 16 -->
    <div id="xdx_232_zHUgs690iBG7" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_zf7vrbq3Wnsi" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zvVzBauNWEnl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recognized a gain for the change in fair value of the Series G Preferred Stock of $<span id="xdx_907_eus-gaap--RealizedInvestmentGainsLosses_c20251101__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__srt--CounterpartyNameAxis__custom--QCLSMember_zNW87lik5PU9" title="Recognized gain (loss)"><ix:nonFraction name="us-gaap:RealizedInvestmentGainsLosses" contextRef="From2025-11-012026-01-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesGPreferredStockMember_custom_QCLSMember" id="Fact001344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,433,000</ix:nonFraction></span> and a loss of $<span id="xdx_909_eus-gaap--RealizedInvestmentGainsLosses_iN_di_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__srt--CounterpartyNameAxis__custom--QCLSMember_z9xmBNKjZ4U7" title="Recognized gain (loss)"><ix:nonFraction name="us-gaap:RealizedInvestmentGainsLosses" contextRef="From2025-05-012026-01-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesGPreferredStockMember_custom_QCLSMember" id="Fact001346" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,127,000</ix:nonFraction></span>,
respectively. The $<span id="xdx_900_eus-gaap--InvestmentOwnedAtFairValue_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__srt--CounterpartyNameAxis__custom--QCLSMember_zm27p3EQQYGc" title="Investment at fair value"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesGPreferredStockMember_custom_QCLSMember" id="Fact001348" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,347,000</ix:nonFraction></span> fair value of the Series G Preferred Stock was estimated utilizing a Monte Carlo simulation with the following
assumptions on January 31, 2026: QCLS stock price of $4.19, expected time to settlement of 5.00 years, dividend rate of 10%, discount
market interest rate of 10%, risk free rate of 3.79%, equity volatility of 135.0% and probability of default of 24.7%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recognized a loss of $<span id="xdx_906_eus-gaap--RealizedInvestmentGainsLosses_iN_di_c20251101__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGWarrantsMember__srt--CounterpartyNameAxis__custom--QCLSMember_zeFX0DJq8gyk" title="Recognized gain (loss)"><ix:nonFraction name="us-gaap:RealizedInvestmentGainsLosses" contextRef="From2025-11-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_SeriesGWarrantsMember_custom_QCLSMember" id="Fact001350" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,461,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--RealizedInvestmentGainsLosses_iN_di_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGWarrantsMember__srt--CounterpartyNameAxis__custom--QCLSMember_z9zpQ3wh8Zb9" title="Recognized gain (loss)"><ix:nonFraction name="us-gaap:RealizedInvestmentGainsLosses" contextRef="From2025-05-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_SeriesGWarrantsMember_custom_QCLSMember" id="Fact001352" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,652,000</ix:nonFraction></span>, respectively, related to the change in the QCLS Series
G Warrants fair value. The $<span id="xdx_904_eus-gaap--InvestmentOwnedAtFairValue_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGWarrantsMember__srt--CounterpartyNameAxis__custom--QCLSMember_z1qfsR1BQ7D1" title="Investment at fair value"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_SeriesGWarrantsMember_custom_QCLSMember" id="Fact001354" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,966,000</ix:nonFraction></span> fair value of the QCLS Series G Warrants was determined utilizing a Black Scholes Merton model with
the following assumptions on January 31, 2026: QCLS stock price of $4.19, exercise price of $3.37, risk free rate of 3.57%, equity volatility
of 130.0% and remaining term of 3.31 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is a summary of activity for the Series
G Preferred Stock as of January 31, 2026:</p>

<ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001356" name="us-gaap:InvestmentTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--InvestmentTableTextBlock_z2pMAY7NicW2" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series G Preferred Stock and Preferred Stock Warrants)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_z9Ya0pjiqgBa" style="display: none">Schedule of activity preferred stock</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: justify">Balance of Series G Preferred Stock as of April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zJWApdCZnImc" title="Investment, beginnning balance" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsAndOtherNoncurrentAssets" contextRef="AsOf2025-04-30_custom_QCLSSeriesGPreferredStockMember" id="Fact001358" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,474,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ChangeInFairValueOfInvestment_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zVOsyYNARIR2" title="Change in fair value" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="PMCB:ChangeInFairValueOfInvestment" contextRef="From2025-05-012026-01-31_custom_QCLSSeriesGPreferredStockMember" id="Fact001360" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,127,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Balance of Series G Preferred Stock as of January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zsTyPAX3lp3c" title="Investment, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsAndOtherNoncurrentAssets" contextRef="AsOf2026-01-31_custom_QCLSSeriesGPreferredStockMember" id="Fact001362" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,347,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is a summary of activity for the QCLS Warrants
as of January 31, 2026:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: justify">Balance of QCLS Series G Warrant assets as of April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_c20250501__20260131__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGWarrantsMember_zWMuwb6FjXK5" title="Investment, beginnning balance" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsAndOtherNoncurrentAssets" contextRef="AsOf2025-04-30_custom_QCLSMember_custom_QCLSSeriesGWarrantsMember" id="Fact001364" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,618,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ChangeInFairValueOfInvestment_c20250501__20260131__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGWarrantsMember_zX7yT8Eu3rD1" title="Change in fair value" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="PMCB:ChangeInFairValueOfInvestment" contextRef="From2025-05-012026-01-31_custom_QCLSMember_custom_QCLSSeriesGWarrantsMember" id="Fact001366" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,652,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Balance of QCLS Series G Warrant assets as of January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGWarrantsMember_zPbgi1cCOVA6" title="Investment, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsAndOtherNoncurrentAssets" contextRef="AsOf2026-01-31_custom_QCLSMember_custom_QCLSSeriesGWarrantsMember" id="Fact001368" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,966,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zEZR9p8KbHkd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Series H Preferred Shares and Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 2, 2025, the Company entered into
a Securities Purchase Agreement (the &#8220;Series H SPA&#8221;) with QCLS. Pursuant to the Series H SPA, the Company purchased (i) <span id="xdx_901_eus-gaap--InvestmentOwnedBalanceShares_iI_c20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zYbCmXXR9Xcd" title="Investment shares owned"><ix:nonFraction name="us-gaap:InvestmentOwnedBalanceShares" contextRef="AsOf2025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesGPreferredStockMember" id="Fact001370" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,000</ix:nonFraction></span>
shares of QCLS&#8217;s Series H Convertible Preferred Stock (the &#8220;Series H Preferred Shares&#8221; or &#8220;Series H Preferred
Stock&#8221;), at a stated value of $1,000 per Series G Preferred Share, with an initial conversion price of $5.00 which were initially
convertible into 600,000 shares of QCLS Common Stock ; (ii) warrants to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember_z0crNGR4mhY3" title="Warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember" id="Fact001372" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600,000</ix:nonFraction></span> shares of QCLS&#8217;s Common Stock with
a five-year term (&#8220;QCLS Series H Warrant&#8221;), for a total purchase price of $<span id="xdx_903_eus-gaap--PaymentsToAcquireInvestments_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zM8ruhAXtEDh" title="Payments for investments"><ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember" id="Fact001374" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2025, in connection with the QCLS&#8217;
1-for-100 reverse stock split and pursuant to the stock combination event adjustment provisions of the Series H Preferred Shares and QCLS
Series H Warrants, the conversion price and the exercise price was adjusted to $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember_zLYWHTya9n2" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember" id="Fact001376" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.37</ix:nonFraction></span> per share, the 3,000 Series H Preferred Shares were
adjusted to be convertible into 889,864 shares of QCLS Common Stock and the number of QCLS Series H Warrants was adjusted to purchase
<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSCommonStockMember_z8l7ZXxa9Nlf" title="Warrant shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSCommonStockMember" id="Fact001378" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">889,864</ix:nonFraction></span> shares of QCLS Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series H Preferred Stock is not considered
in substance common stock, and as such, the equity method of accounting does not apply. The Company recorded its investment in Series
H Preferred Stock at its fair value as the Company did not elect the measurement alternative to account for the investment at cost less
impairment. Subsequent changes in fair value of the Series H Preferred Stock are recognized in earnings at each reporting period. The
initial fair value of the Series H Preferred Stock of $<span id="xdx_905_eus-gaap--InvestmentOwnedAtFairValue_iI_c20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember_zT5Nspg14Dic"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember" id="Fact001379" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,483,000</ix:nonFraction></span> was estimated utilizing a probability-weighted scenario model, with the
following inputs: the fair value of QCLS Common Stock of <span id="xdx_90E_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zvCR4pKKU5M8" title="Fair value measurement"><ix:nonNumeric contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputSharePriceMember" id="Fact001381" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">$3.61</ix:nonNumeric></span>, estimated equity volatility of <span id="xdx_904_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zCM1TNaXoj09" title="Fair value measurement"><ix:nonNumeric contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001383" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">100.0%</ix:nonNumeric></span>, the time to maturity of <span id="xdx_901_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputMaturityMember_zBJyvJfZhHN8" title="Fair value measurement"><ix:nonNumeric contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputMaturityMember" id="Fact001385" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">1.49 years</ix:nonNumeric></span>,
the redemption premium of <span id="xdx_902_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementRedemptionPremiumMember_z3qEwrWcB3N2" title="Fair value measurement"><ix:nonNumeric contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_custom_MeasurementRedemptionPremiumMember" id="Fact001387" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">106%</ix:nonNumeric></span>, the liquidation premium of 125%, the conversion price of $5.00 per share, a market interest rate of <span id="xdx_901_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketInterestRateMember_zu6O3Sd2Orj2" title="Fair value measurement"><ix:nonNumeric contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_custom_MeasurementInputMarketInterestRateMember" id="Fact001389" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">19.51%</ix:nonNumeric></span>,
a risk-free rate of <span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z9qLKV5VmfFg" title="Fair value measurement"><ix:nonNumeric contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001391" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">3.61%</ix:nonNumeric></span>, and dividend rate of <span id="xdx_900_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zcatBCq9rW29" title="Fair value measurement"><ix:nonNumeric contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001393" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">7.00%</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_231_zt13cxno7eYl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_z5oCmBFs6ECa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23A_zUB8natkwob7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 17 -->
    <div id="xdx_23C_zEFLpSad4t4a" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23F_zTnpuzeiKBga" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zxVN7uReeDMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The QCLS Series H Warrants were determined to
meet the definition of a derivative and were required to be recorded at fair value in accordance with ASC 815. Subsequent changes in the
fair value of the QCLS Series H Warrants are recognized in earnings, at each reporting date. The issuance date fair value of the QCLS
Series H Warrants of $<span id="xdx_902_eus-gaap--InvestmentOwnedAtFairValue_iI_c20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember_zfEo4DWUmLf8"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember" id="Fact001398" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,606,000</ix:nonFraction></span> was determined utilizing the Black Scholes Merton Method using the following inputs: the fair value of
QCLS&#8217; s common stock of <span id="xdx_900_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zFETuWycUad8" title="Fair value measurement"><ix:nonNumeric contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputSharePriceMember" id="Fact001400" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">$3.61</ix:nonNumeric></span>, exercise price of <span id="xdx_90A_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zKJuzoU25pF8" title="Fair value measurement"><ix:nonNumeric contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputExercisePriceMember" id="Fact001402" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">$5.00</ix:nonNumeric></span>; dividend yield of <span id="xdx_907_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zG2XAEvXHb01" title="Fair value measurement"><ix:nonNumeric contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001404" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">0%</ix:nonNumeric></span>; remaining term of <span id="xdx_90B_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zq67PnSZnSGj" title="Fair value measurement"><ix:nonNumeric contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputExpectedTermMember" id="Fact001406" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">5.00 years</ix:nonNumeric></span>; equity volatility of
<span id="xdx_908_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zIOUYKeQVW4f" title="Fair value measurement"><ix:nonNumeric contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001408" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">105.0%</ix:nonNumeric></span>; and a risk-free interest rate of <span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_ztxNOMAxxwg4" title="Fair value measurement"><ix:nonNumeric contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001410" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">3.59%</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total aggregated fair value of the QCLS Series
H Preferred Stock and the QCLS Series H Warrants of $<span id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zDA9vEWXniZ8" title="Investment, fair value"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember" id="Fact001412" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,089,000</ix:nonFraction></span> exceeded the total purchase price of $<span id="xdx_908_eus-gaap--InvestmentOwnedAtCost_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zvjtqinXZTNh" title="Investment, cost"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember" id="Fact001414" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span> by $<span id="xdx_905_ecustom--GainOnRelatedPartyInvestmentQcls_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zelXRyGJYRN9" title="Investment, fair value"><ix:nonFraction name="PMCB:GainOnRelatedPartyInvestmentQcls" contextRef="From2025-05-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember" id="Fact001416" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,089,000</ix:nonFraction></span>, which was
recognized as a gain on investment in QCLS on the condensed consolidated statement of operations for the nine months ended January
31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recognized a gain on the change in fair value of the Series H Preferred Stock of $<span id="xdx_905_eus-gaap--DebtSecuritiesRealizedGainLoss_c20251101__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zBxcpU3mFzYl"><ix:nonFraction name="us-gaap:DebtSecuritiesRealizedGainLoss" contextRef="From2025-11-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember" id="Fact001417" format="ixt:numdotdecimal" decimals="0" unitRef="USD">292,000</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--DebtSecuritiesRealizedGainLoss_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zVwgIsgTKMse"><ix:nonFraction name="us-gaap:DebtSecuritiesRealizedGainLoss" contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember" id="Fact001418" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,642,000</ix:nonFraction></span>, respectively.
The $<span id="xdx_908_eus-gaap--InvestmentOwnedAtCost_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zwY2WLJPFFic"><ix:nonFraction name="us-gaap:InvestmentOwnedAtCost" contextRef="AsOf2026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember" id="Fact001419" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,125,000</ix:nonFraction></span> fair value of the Series H Preferred Stock was estimated utilizing a probability-weighted scenario model, with the following
inputs: the fair value of QCLS Common Stock of <span id="xdx_904_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z5geTJmuiFYa"><ix:nonNumeric contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputSharePriceMember" id="Fact001420" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">$4.19</ix:nonNumeric></span>, estimated equity volatility of <span id="xdx_90D_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zy1ZVYCfLcXd"><ix:nonNumeric contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001421" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">150.0%</ix:nonNumeric></span>, the time to maturity of <span id="xdx_902_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgfHluaohRk5"><ix:nonNumeric contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputExpectedTermMember" id="Fact001422" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">1.08 years</ix:nonNumeric></span>, the redemption
premium of <span id="xdx_90D_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRedemptionPremiumMember_z3YeQXgNHkX"><ix:nonNumeric contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_custom_MeasurementInputRedemptionPremiumMember" id="Fact001423" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">106%</ix:nonNumeric></span>, the liquidation premium of 125%, the conversion price of $3.37 per share, a market interest rate of <span id="xdx_901_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketInterestRateMember_zaYKClbVAnO1"><ix:nonNumeric contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_custom_MeasurementInputMarketInterestRateMember" id="Fact001424" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">16.37%</ix:nonNumeric></span>, a risk-free
rate of <span id="xdx_904_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zRn1BGFNfNyl"><ix:nonNumeric contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001425" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">3.42%</ix:nonNumeric></span>, and dividend rate of <span id="xdx_90B_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zT3iDeAmRzhi"><ix:nonNumeric contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001426" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">7.00%</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recognized a gain of $<span id="xdx_901_eus-gaap--DebtSecuritiesRealizedGainLoss_c20251101__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember_zvAYRzWziQb1" title="Recognized gain (loss)"><ix:nonFraction name="us-gaap:DebtSecuritiesRealizedGainLoss" contextRef="From2025-11-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember" id="Fact001428" format="ixt:numdotdecimal" decimals="0" unitRef="USD">261,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--DebtSecuritiesRealizedGainLoss_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember_zXzxIYLEYr2a" title="Recognized gain (loss)"><ix:nonFraction name="us-gaap:DebtSecuritiesRealizedGainLoss" contextRef="From2025-05-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember" id="Fact001430" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,670,000</ix:nonFraction></span>, respectively, related to the change in the QCLS Series H Warrants
fair value. The $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember_zpj3mZjZRmF6" title="Fair value of the warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-05-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember" id="Fact001432" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,276,000</ix:nonFraction></span> fair value of the QCLS Series H Warrants was determined utilizing a Black Scholes Merton model with the following
assumptions on January 31, 2026: the fair value of QCLS&#8217;s common stock of <span id="xdx_904_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zqfuKpJ7vnMf"><ix:nonNumeric contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputSharePriceMember" id="Fact001433" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">$4.19</ix:nonNumeric></span>, exercise price of <span id="xdx_902_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zsMjjLd31e3l"><ix:nonNumeric contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputExercisePriceMember" id="Fact001434" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">$3.37</ix:nonNumeric></span>, risk free rate of <span id="xdx_90B_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zhRtF73UUEaf"><ix:nonNumeric contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001435" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">3.68%</ix:nonNumeric></span>,
equity volatility of <span id="xdx_906_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z5apMLrDIqFj"><ix:nonNumeric contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001436" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">135.0%</ix:nonNumeric></span>, and remaining term of <span id="xdx_90A_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zn045s94KhHf"><ix:nonNumeric contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputExpectedTermMember" id="Fact001437" name="us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">4.59 years</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has determined that QCLS is a VIE,
as QCLS does not have sufficient equity at risk to finance its own operations without additional subordinated financial support. However,
the Company has determined that it is not the primary beneficiary of QCLS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is a summary of activity for the Series
H Preferred Stock as of January 31, 2026:</p>

<ix:nonNumeric contextRef="From2025-05-012026-01-31_us-gaap_SeriesHPreferredStockMember" escape="true" id="Fact001439" name="us-gaap:InvestmentTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--InvestmentTableTextBlock_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zfEVQb40lg51" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series H Preferred Stock and Preferred Stock Warrants)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_z6IJ0Rx6rgya" style="display: none">Schedule of activity preferred stock</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: justify">Balance of Series H Preferred Stock as of April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_d0_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zkLGmajUPc4g" title="Investment, beginning balance" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsAndOtherNoncurrentAssets" contextRef="AsOf2025-04-30_custom_QCLSSeriesHPreferredStockMember" id="Fact001441" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Initial fair value of investment Series H Preferred Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--InvestmentOwnedAtFairValue_iI_c20250902__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zvMRwQxuSUNi" title="Initial fair value of Investment" style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2025-09-02_custom_QCLSSeriesHPreferredStockMember" id="Fact001443" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,483,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ChangeInFairValueOfInvestmentQcls_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zW4yEHlezcM6" title="Change in fair value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="PMCB:ChangeInFairValueOfInvestmentQcls" contextRef="From2025-05-012026-01-31_custom_QCLSSeriesHPreferredStockMember" id="Fact001445" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,642,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Balance of Series H Preferred Stock as of January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zR9XFRjFULte" title="Investment, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsAndOtherNoncurrentAssets" contextRef="AsOf2026-01-31_custom_QCLSSeriesHPreferredStockMember" id="Fact001447" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,125,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is a summary of activity for the QCLS Series
H Warrants as of January 31, 2026:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: justify">Balance of QCLS Series H Warrant assets as of April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_d0_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zN1LwFG8Jbyc" title="Investment, beginning balance" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsAndOtherNoncurrentAssets" contextRef="AsOf2025-04-30_custom_QCLSSeriesHWarrantsMember" id="Fact001449" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Initial fair value of investment in of QCLS Series H Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--InvestmentOwnedAtFairValue_iI_c20250902__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zacjDXECZvh8" title="Initial fair value of Investment" style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2025-09-02_custom_QCLSSeriesHWarrantsMember" id="Fact001451" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,606,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--ChangeInFairValueOfInvestmentQcls_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zp8eUhbkLUM4" title="Change in fair value" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="PMCB:ChangeInFairValueOfInvestmentQcls" contextRef="From2025-05-012026-01-31_custom_QCLSSeriesHWarrantsMember" id="Fact001453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,670,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Balance of QCLS Series H Warrant assets as of January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zwUz1V3pxHM6" title="Investment, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InvestmentsAndOtherNoncurrentAssets" contextRef="AsOf2026-01-31_custom_QCLSSeriesHWarrantsMember" id="Fact001455" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,276,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zNLlMm3N3Wka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:exclude><p id="xdx_23A_zQXYbnn9EJ65" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_233_z8Ghn5zYlsKl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zG4wnSYdlFji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 18 -->
    <div id="xdx_23E_zMUNO5hIfJ7k" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_232_zVHyOJkCAZ89" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zn7AyC5zEDA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001461" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_806_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zZXGy1qjxGyb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5 &#8211; <span id="xdx_824_zTSYEmpOKWf4">ACCRUED EXPENSES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accrued expenses at January 31, 2026 and April
30, 2025, are summarized below:</p>

<ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001463" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z6sz1XjptWR6" summary="xdx: Disclosure - ACCRUED EXPENSES (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B6_zz4ZxbsiawG7" style="display: none">Schedule of accrued expenses</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">January 31, 2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify">Payroll related costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--PayrollRelatedCostsMember_z5Z6s3hvwP47" title="Accrued liabilities" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_PayrollRelatedCostsMember" id="Fact001465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,846</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--PayrollRelatedCostsMember_zEzO2lwRUUXd" title="Accrued liabilities" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_PayrollRelatedCostsMember" id="Fact001467" format="ixt:numdotdecimal" decimals="0" unitRef="USD">335,846</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Director fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--DirectorFeesMember_zTFrCxa1TXk9" title="Accrued liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_DirectorFeesMember" id="Fact001469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--DirectorFeesMember_z97Wn1e0mxEd" title="Accrued liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_DirectorFeesMember" id="Fact001471" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">R&amp;D costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--RAndDCostsMember_zCC1dAi5A4ve" title="Accrued liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_RAndDCostsMember" id="Fact001473" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,310</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--RAndDCostsMember_z79qi1A8c18k" title="Accrued liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_RAndDCostsMember" id="Fact001475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,310</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Legal settlement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LegalSettlementMember_zGzALkLR9NTd" title="Accrued liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_LegalSettlementMember" id="Fact001477" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LegalSettlementMember_zcTYAJpGCEue" title="Accrued liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_LegalSettlementMember" id="Fact001479" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,019,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Excise tax on stock repurchases</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_d0_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--ExciseTaxOnStockRepurchasesMember_z2VTRJAFL8kj" title="Accrued liabilities" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_ExciseTaxOnStockRepurchasesMember" id="Fact001481" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_d0_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--ExciseTaxOnStockRepurchasesMember_z0hYN3MSnks8" title="Accrued liabilities" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_ExciseTaxOnStockRepurchasesMember" id="Fact001483" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,424</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131_z0YQ0hNQSJUk" title="Accrued liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2026-01-31" id="Fact001485" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,656</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430_zQjA8i06jb6l" title="Accrued liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2025-04-30" id="Fact001487" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,540,080</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Less: Long-term portion of legal settlement</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LongTermPortionOfLegalSettlementMember_z6dZocZKBjgc" title="Accrued liabilities" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1489">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LongTermPortionOfLegalSettlementMember_zpnXjBA3TZma" title="Accrued liabilities" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_LongTermPortionOfLegalSettlementMember" id="Fact001491" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AccruedLiabilitiesCurrent_iI_c20260131_zptDgpGu0iTj" title="Accrued liabilities, current" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2026-01-31" id="Fact001493" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,656</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrent_iI_c20250430_zW3pBe71mdtg" title="Accrued liabilities, current" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2025-04-30" id="Fact001495" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,515,080</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001497" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_805_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zmtZvJpme0j4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6 &#8211; <span id="xdx_823_z53GYDCltHP4">STOCK OPTIONS AND WARRANTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2021 Equity Incentive Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective June 30, 2021, the Company implemented
the 2021 Equity Incentive Plan (&#8220;2021 Equity Plan&#8221;) as approved by the Company&#8217;s stockholders. The 2021 Equity Plan
is administered by the Compensation Committee of the Board and has <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210630__us-gaap--PlanNameAxis__custom--EquityPlan2021Member_zSQ8ZapKCF9"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2021-06-30_custom_EquityPlan2021Member" id="Fact001498" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">166,667</ix:nonFraction></span> shares authorized under this plan. The 2021 Equity Plan can
issue various types of awards, as follows: stock options, stock appreciation rights, restricted stock, restricted stock units, and cash
or other stock-based awards. The 2021 Equity Plan is available to be issued to employees, directors, consultants, and other individuals
who provide services to the Company. An incentive stock options (&#8220;ISOs&#8221;) can only be granted to employees and shall not exceed
10-years (5-years in the case of ISOs granted to any 10% shareholder). As of January 31, 2026, there are <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20260131__us-gaap--PlanNameAxis__custom--EquityPlan2021Member_z1SD9GF3Ad9l" title="Shares available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2026-01-31_custom_EquityPlan2021Member" id="Fact001500" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">154,596</ix:nonFraction></span> shares remaining available
under the 2021 Equity Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2022 Equity Incentive Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective December 28, 2022, the Company implemented
the 2022 Equity Incentive Plan (&#8220;2022 Equity Plan&#8221;) as approved by the Company&#8217;s stockholders. In October 2025, the
Company held a special meeting of stockholders (the &#8220;2025 Special Meeting&#8221;). At the 2025 Special Meeting, the stockholders
of the Company approved an amendment to the 2022 Equity Plan which, among other things, increased the number of shares of common stock
available for grant under the 2022 Equity Plan by <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_c20251001__20251031_zz9x0wnDi2ta" title="Increase number of shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" contextRef="From2025-10-012025-10-31" id="Fact001502" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,250,000</ix:nonFraction></span>. The 2022 Equity Plan is administered by the Compensation Committee of the
Board and has <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20221228__us-gaap--PlanNameAxis__custom--EquityPlan2022Member_z3Mo5siVCexg" title="Shares authorized for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2022-12-28_custom_EquityPlan2022Member" id="Fact001504" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000,000</ix:nonFraction></span> shares available under this plan, as amended. The 2022 Equity Plan can issue various types of awards, as follows:
stock options, stock appreciation rights, restricted stock, restricted stock units, and cash or other stock-based awards. The 2022 Equity
Plan is available to be issued to employees, directors, consultants, and other individuals who provide services to the Company. An incentive
stock options (&#8220;ISOs&#8221;) can only be granted to employees and shall not exceed 10-years (5-years in the case of ISOs granted
to any 10% shareholder). As of January 31, 2026, there are <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20260131__us-gaap--PlanNameAxis__custom--EquityPlan2022Member_zTWtMDzaGuW5"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2026-01-31_custom_EquityPlan2022Member" id="Fact001505" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,970,040</ix:nonFraction></span> shares remaining available under the 2022 Equity Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_238_zvPd87h3A5u4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_z9ml8ROqIwQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_z0pcfSBmU2X9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 19 -->
    <div id="xdx_23D_zmwatqeCAci4" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_z4Z9Y9OYN1xd" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zCeeCeEfMH6i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the Company&#8217;s stock option
activity and related information for the nine months ended January 31, 2026, are shown below:</p>

<ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001511" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zhN8BJ7Hr51l" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details - Option activity)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B3_zEN5pPGVLvof" style="display: none">Schedule of stock option activity</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Options</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Options</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Exercise <br/> Price per<br/> Share</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average <br/> Remaining<br/> Contractual <br/> Term in Years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 55%; text-align: justify">Outstanding, April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zU18bZQ2oYrb" title="Number of options outstanding, beginning" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-04-30_us-gaap_StockOptionMember" id="Fact001513" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,169,961</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqjjd7wljfJc" title="Weighted average exercise price per share, beginning" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-04-30_us-gaap_StockOptionMember" id="Fact001515" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.21</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240501__20250430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_ztAHF3gpWixi" title="Weighted average remaining contractual term"><ix:nonNumeric contextRef="From2024-05-012025-04-30_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact001517" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.62</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zH3YEuCSe837" title="Number of options, issued" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2025-05-012026-01-31_us-gaap_StockOptionMember" id="Fact001519" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z6b1fkdt5B86" title="Weighted average exercise price per share, issued" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2025-05-012026-01-31_us-gaap_StockOptionMember" id="Fact001521" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Expired and forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNIYCM2ch8l7" title="Number of options, expired and forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2025-05-012026-01-31_us-gaap_StockOptionMember" id="Fact001523" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,334</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zB4tdiEYEEkc" title="Weighted average exercise price per share, expired and forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2025-05-012026-01-31_us-gaap_StockOptionMember" id="Fact001525" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.78</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding, January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zgZNfkXpwA41" title="Number of options outstanding, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2026-01-31_us-gaap_StockOptionMember" id="Fact001527" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,160,627</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zR7Opdz4xT3i" title="Weighted average exercise price per share, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2026-01-31_us-gaap_StockOptionMember" id="Fact001529" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.14</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zw5CCEnpK5re" title="Weighted average remaining contractual term"><ix:nonNumeric contextRef="From2025-05-012026-01-31_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact001531" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.92</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Exercisable, January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZh3fse2DOo2" title="Number of options, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2026-01-31_us-gaap_StockOptionMember" id="Fact001533" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">907,695</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zvqSvYplALk3" title="Weighted average exercise price per share, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2026-01-31_us-gaap_StockOptionMember" id="Fact001535" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.39</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zb2OQOjkaBPk" title="Weighted-average remaining contractual term, exercisable"><ix:nonNumeric contextRef="From2025-05-012026-01-31_us-gaap_StockOptionMember" format="ixt-sec:duryear" id="Fact001537" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">7.56</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zDIvHMFEL1qd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20251101__20260131__srt--CounterpartyNameAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMYR0u7BUigf" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-11-012026-01-31_custom_EmployeesMember_us-gaap_StockOptionMember" id="Fact001539" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,492</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20250501__20260131__srt--CounterpartyNameAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z5yPYeMbXKn8" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-05-012026-01-31_custom_EmployeesMember_us-gaap_StockOptionMember" id="Fact001541" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,476</ix:nonFraction></span> of
stock-based compensation expense related to the issuance of Employee Options to certain officers and directors in exchange for
services during the three and nine months ended January 31, 2026, respectively, and $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20241101__20250131__srt--CounterpartyNameAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zRNNQhIsbc6h" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-11-012025-01-31_custom_EmployeesMember_us-gaap_StockOptionMember" id="Fact001543" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,859</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20240501__20250131__srt--CounterpartyNameAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPedYnLT1CFb" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-05-012025-01-31_custom_EmployeesMember_us-gaap_StockOptionMember" id="Fact001545" format="ixt:numdotdecimal" decimals="0" unitRef="USD">414,692</ix:nonFraction></span> for the three and nine
months ended January 31, 2025, respectively. As of January 31, 2026, there remained $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20260131__srt--CounterpartyNameAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9ie6UBeTFc5" title="Employee service unrecognized compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2026-01-31_custom_EmployeesMember_us-gaap_StockOptionMember" id="Fact001547" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,579</ix:nonFraction></span> of unrecognized compensation expense
related to unvested Employee Options granted to officers and directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value of vested outstanding
options as of January 31, 2026 was $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_pp0p0_c20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zB2elHkZAJG2" title="Aggregate intrinsic value"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2026-01-31_us-gaap_StockOptionMember" id="Fact001549" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Series B Warrant</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 10, 2023, the Company entered into a Securities
Purchase Agreement (the &#8220;Private Placement Agreement&#8221;) with certain accredited investors (the &#8220;Investors&#8221;), pursuant
to which it agreed to sell to the Investors warrants to acquire up to an aggregate of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230510__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zpnxX9KXAk88" title="Warrants acquire"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-05-10_us-gaap_PrivatePlacementMember" id="Fact001551" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,750,000</ix:nonFraction></span> shares of Common Stock, collectively,
the (&#8220;Series B Warrants&#8221;), with an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230510__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z2ElVcvjisbj" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-05-10_us-gaap_PrivatePlacementMember" id="Fact001553" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></span> per share (subject to adjustment), for a period of five years from
the date of issuance. In connection with the Series C Private Placement (as defined herein), in August 2025, the exercise price of the
Series B Preferred Warrants was adjusted to $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260131__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zlS32ZhOy5Ya" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-01-31_us-gaap_PrivatePlacementMember" id="Fact001555" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.95</ix:nonFraction></span> per share and the number of shares of Common Stock issuable upon exercise of the Series
B Warrants was adjusted proportionally to 36,780,161 pursuant to the full ratchet anti-dilution provisions contained therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series B Warrants were determined to be subject
to liability classification as they are considered to be indexed to the Company&#8217;s own stock but fail to meet the requirements for
equity classification in accordance with ASC 815. As such, the Company recorded the Series B Warrants as a liability at fair value with
subsequent changes in fair value recognized in earnings. The Company utilized the Black-Scholes-Merton Model to calculate the value of
the Series B Warrants issued on May 10, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company received Series B exercise notices totaling <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20251101__20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zRB2rWhqigLb" title="Warrants exercised"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zHTNkSXlKcRf" title="Warrants exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-11-012026-01-31_custom_SeriesBWarrantsMember" id="Fact001557" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2025-05-012026-01-31_custom_SeriesBWarrantsMember" id="Fact001559" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,100,000</ix:nonFraction></ix:nonFraction></span></span> shares. The exercises resulted in the Company received cash
in the amount of $<span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_z8LLi4MetkEh" title="Proceeds from warrant exercises"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-05-012026-01-31_custom_SeriesBWarrantsMember" id="Fact001561" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,046,740</ix:nonFraction></span> and a reduction in the warrant liability of $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_z3YTIv1hI1s6" title="Reduction in warrant liability"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-05-012026-01-31_custom_SeriesBWarrantsMember" id="Fact001563" format="ixt:numdotdecimal" decimals="0" unitRef="USD">599,135</ix:nonFraction></span>. Following the exercises the Company has <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zOLYbcSmE6d" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-01-31_custom_SeriesBWarrantsMember" id="Fact001565" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,680,160</ix:nonFraction></span> Series
B warrant shares remaining.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_232_zGQH2j8lbboe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zjNxYGPaFq0a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zoW0K5W196Sk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 20 -->
    <div id="xdx_237_zFCCRZWDvpWc" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_230_z3iACisQU61c" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_znDMiknBdm9c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recorded a gain of approximately $<span id="xdx_90D_ecustom--ChangeInFairValueOfWarrantLiability_iN_di_c20251101__20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBPreferredWarrantsMember_zgnbDfHEHlr4" title="Change in fair value of warrant liability"><ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantLiability" contextRef="From2025-11-012026-01-31_custom_SeriesBPreferredWarrantsMember" id="Fact001571" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">874,000</ix:nonFraction></span> and a loss of $<span id="xdx_90D_ecustom--ChangeInFairValueOfWarrantLiability_iN_di_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBPreferredWarrantsMember_zWe5COUedCdg" title="Change in fair value of warrant liability"><ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantLiability" contextRef="From2025-05-012026-01-31_custom_SeriesBPreferredWarrantsMember" id="Fact001573" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,182,000</ix:nonFraction></span>, respectively, related to the change in fair
value of the warrant liability which is recorded in other income on the unaudited condensed consolidated statements of operations. The
fair value of the Series B Warrants of $<span id="xdx_90B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBPreferredWarrantsMember_z5iwPDQWekjk" title="Fair value of the warrants"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2026-01-31_custom_SeriesBPreferredWarrantsMember" id="Fact001575" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,520,000</ix:nonFraction></span> was estimated at January 31, 2026, utilizing the Black-Scholes-Merton Model using the
fair value of the Company&#8217;s common stock of $0.82 and the following weighted average assumptions: dividend yield 0%; remaining term
of 2.27 years; equity volatility of 60.0%; and a risk-free interest rate of 3.48%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2025, the Company recorded a gain of approximately $<span id="xdx_907_ecustom--ChangeInFairValueOfWarrantLiability_iN_di_c20241101__20250131__us-gaap--StatementClassOfStockAxis__custom--SeriesBPreferredWarrantsMember_zS4DTrJhIFS9" title="Change in fair value of warrant liability"><ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantLiability" contextRef="From2024-11-012025-01-31_custom_SeriesBPreferredWarrantsMember" id="Fact001577" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,487,000</ix:nonFraction></span> and $<span id="xdx_905_ecustom--ChangeInFairValueOfWarrantLiability_iN_di_c20240501__20250131__us-gaap--StatementClassOfStockAxis__custom--SeriesBPreferredWarrantsMember_zGtQmNSkvveg" title="Change in fair value of warrant liability"><ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantLiability" contextRef="From2024-05-012025-01-31_custom_SeriesBPreferredWarrantsMember" id="Fact001579" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,400,000</ix:nonFraction></span>, respectively, related to the change in fair value of
the warrant liability which is recorded in other income (expense) on the Condensed Consolidated Statements of Operations. The fair value
of the Series B Warrants of $<span id="xdx_90F_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20250131__us-gaap--StatementClassOfStockAxis__custom--SeriesBPreferredWarrantsMember_zEIgkL9ceNS4" title="Fair value of the warrants"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2025-01-31_custom_SeriesBPreferredWarrantsMember" id="Fact001581" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,384,000</ix:nonFraction></span> was estimated at January 31, 2025, utilizing the Black-Scholes-Merton Model using the fair value
of the Company&#8217;s common stock of $1.60 and the following weighted average assumptions: dividend yield 0%; remaining term of 3.27
years; equity volatility of 55.0%; and a risk-free interest rate of 4.19%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Settlement Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Settlement Agreement, as
defined on Note 8 &#8211; Commitments and Contingencies, on May 16, 2025, the Company issued warrants (&#8220;First Warrant Issuance&#8221;)
to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250516__us-gaap--TransactionTypeAxis__custom--SettlementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FirstWarrantIssuanceMember_zJOKpIArpksc"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-05-16_custom_SettlementAgreementMember_custom_FirstWarrantIssuanceMember" id="Fact001582" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">343,183</ix:nonFraction></span> shares of Common Stock with an exercise price of $4.00 per share and a term of five years from the issuance date.
On October 29, 2025, the Company issued additional warrants (&#8220;Additional Warrants&#8221;, and collectively with the First Warrant
Issuance, the &#8220;Settlement Warrants&#8221;) to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251029__us-gaap--TransactionTypeAxis__custom--SettlementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SettlementWarrantsMember_zRVKgkuu28Ck"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-10-29_custom_SettlementAgreementMember_custom_SettlementWarrantsMember" id="Fact001583" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">313,067</ix:nonFraction></span> shares of the Company&#8217;s common stock with an exercise price
of $4.00 per share and a term of five years from the issuance date. In connection with the Series C Private Placement (as defined herein),
in August 2025, the exercise price of the Settlement Warrants was adjusted to $0.95 per share and the number of shares of Common Stock
issuable upon exercise Settlement Warrants was adjusted proportionally to 2,758,511 pursuant to the full ratchet anti-dilution provisions
contained in their respective agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Settlement Warrants were determined to be
subject to liability classification. As such, the Company recorded the Settlement Warrants as a liability upon issuance at their fair
value with subsequent changes in fair value recognized in earnings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company utilized the Black-Scholes-Merton
Model to calculate the value of the Settlement Warrants issued during the three and nine months ended January 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the First Warrant Issuance of
approximately $<span id="xdx_907_eus-gaap--FairValueAdjustmentOfWarrants_c20250515__20250516__us-gaap--ClassOfWarrantOrRightAxis__custom--FirstWarrantIssuanceMember_zLBIRjlEG6P5" title="Fair value of the warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-05-152025-05-16_custom_FirstWarrantIssuanceMember" id="Fact001585" format="ixt:numdotdecimal" decimals="0" unitRef="USD">199,000</ix:nonFraction></span> was estimated at May 16, 2025 (the date of issuance) using the fair value of the Company&#8217;s common stock of
$1.06 on the issuance date as well as the following input assumptions: expected dividend yield of 0%; expected term of 5.0 years; equity
volatility of 97.0%; and a risk-free interest rate of 4.1%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the Additional Warrants of approximately
$<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20250728__20250729__us-gaap--AwardTypeAxis__custom--AdditionalWarrantsMember_z8HpMF7JSCfd" title="Fair value of the warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-07-282025-07-29_custom_AdditionalWarrantsMember" id="Fact001587" format="ixt:numdotdecimal" decimals="0" unitRef="USD">164,000</ix:nonFraction></span> was estimated at July 29, 2025 (the date of issuance) using the fair value of the Company&#8217;s common stock of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20250729__us-gaap--AwardTypeAxis__custom--AdditionalWarrantsMember_zD7BwdQZIDo9" title="Fair value per share"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2025-07-29_custom_AdditionalWarrantsMember" id="Fact001589" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.02</ix:nonFraction></span> on the
issuance date as well as the following input assumptions: expected dividend yield of 0%; expected term of 5.0 years; equity volatility
of 94.0%; and a risk-free interest rate of 3.9%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recorded a gain on legal settlement of $<span id="xdx_900_eus-gaap--LitigationSettlementGain_c20251101__20260131_z1Zl42Eh5DGi" title="Gain on legal settlement"><ix:nonFraction name="us-gaap:LitigationSettlementGain" contextRef="From2025-11-012026-01-31" id="Fact001591" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--LitigationSettlementGain_c20250501__20260131_zADkI1LIrW6l" title="Gain on legal settlement"><ix:nonFraction name="us-gaap:LitigationSettlementGain" contextRef="From2025-05-01to2026-01-31" id="Fact001593" format="ixt:numdotdecimal" decimals="0" unitRef="USD">106,000</ix:nonFraction></span>, respectively, which represents the difference between the
estimated fair value of the Settlement Warrants recognized during the year ended April 30, 2025 totaling $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20240501__20250430_zfR4OThLqtxa" title="Fair value of the warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-05-012025-04-30" id="Fact001595" format="ixt:numdotdecimal" decimals="0" unitRef="USD">469,000</ix:nonFraction></span> and their issuance date
fair values totaling $<span id="xdx_90B_ecustom--IssuanceFairValues_c20240501__20250430_zciLjZyjQ825" title="Issuance fair values"><ix:nonFraction name="PMCB:IssuanceFairValues" contextRef="From2024-05-012025-04-30" id="Fact001597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,000</ix:nonFraction></span>. See Note 8 &#8211; Commitment and Contingencies &#8211; Legal Proceedings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recorded a gain of $<span id="xdx_902_ecustom--ChangeInFairValueOfWarrantLiability_iN_di_c20251101__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--SettlementWarrantsMember_zkSXgMslh5X6"><ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantLiability" contextRef="From2025-11-012026-01-31_custom_SettlementWarrantsMember" id="Fact001598" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">545,000</ix:nonFraction></span> and a loss of $<span id="xdx_908_ecustom--ChangeInFairValueOfWarrantLiability_iN_di_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--SettlementWarrantsMember_zWqsgjBVStSd"><ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantLiability" contextRef="From2025-05-012026-01-31_custom_SettlementWarrantsMember" id="Fact001599" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">694,000</ix:nonFraction></span>, respectively, related to the change in fair value of the warrant
liability associated with the Settlement Warrants which is recorded in other income (expense) on the unaudited condensed consolidated
statements of operations. The fair value of the Settlement Warrants of $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--SettlementWarrantsMember_z18hBVmQBbZ5" title="Fair value of the warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-05-012026-01-31_custom_SettlementWarrantsMember" id="Fact001601" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,057,000</ix:nonFraction></span> was estimated at January 31, 2026 utilizing the Black-Scholes-Merton
Model using the fair value of the Company&#8217;s common stock of $0.82 and was based on the following weighted average assumptions: expected
dividend yield of 0%; expected term of 4.39 years; equity volatility of 60.0%; and a risk-free interest rate of 3.7%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_239_zQtNrRsS8NH4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zxZOcCxAbKfh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_z9AiKzXoAh4e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 21 -->
    <div id="xdx_23B_zdDRl6HFlFt3" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_zUwLlmQecWb5" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zs7zAj6jnGej" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Series C Warrant</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 17, 2025, the Company entered into a
Securities Purchase Agreement (the &#8220;Series C Private Placement Agreement&#8221;) with certain accredited investors (the &#8220;Investors&#8221;),
pursuant to which it agreed to sell in a private placement to the Investors warrants to acquire up to an aggregate of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250819__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember_zlTAJSYuGJvj"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-08-19_custom_SeriesCPrivatePlacementAgreementMember" id="Fact001606" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,000,000</ix:nonFraction></span> shares
of Common Stock, collectively, the (&#8220;Series C Preferred Warrant&#8221;), with an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250819__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember_zRAB3pyO0Pv2"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-08-19_custom_SeriesCPrivatePlacementAgreementMember" id="Fact001607" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share (subject to adjustment),
for a period of five years from the date of issuance. The Series C Private Placement Agreement closed on August 19, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series C Warrants were determined to be subject
to liability classification as they are considered to be indexed to the Company&#8217;s own stock but fail to meet the requirements for
equity classification in accordance with ASC 815. As such, the Company recorded the Series C Warrants as a liability at fair value with
subsequent changes in fair value recognized in earnings. The fair value of the Series C Warrants of $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20250801__20250819__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember_zilEi7MTIc8k" title="Fair value of the warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-08-012025-08-19_custom_SeriesCPrivatePlacementAgreementMember" id="Fact001609" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,220,000</ix:nonFraction></span> was estimated at August
19, 2025, utilizing the Black-Scholes-Merton Model using the fair value of the Company&#8217;s common stock of $1.01 and the following
weighted average assumptions: dividend yield of 0%; remaining term of 5.00 years; equity volatility of 95.0%; and a risk-free interest
rate of 3.75%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recorded a gain of approximately $<span id="xdx_908_ecustom--ChangeInFairValueOfWarrantAsset_c20251101__20260131__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCPreferredWarrantsMember_zscCxlc2zlCf" title="Change in fair value warrant asset"><ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantAsset" contextRef="From2025-11-012026-01-31_custom_SeriesCPrivatePlacementAgreementMember_custom_SeriesCPreferredWarrantsMember" id="Fact001611" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,076,000</ix:nonFraction></span> and $<span id="xdx_903_ecustom--ChangeInFairValueOfWarrantAsset_c20250501__20260131__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCPreferredWarrantsMember_zCwbgfEcOeBd"><ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantAsset" contextRef="From2025-05-012026-01-31_custom_SeriesCPrivatePlacementAgreementMember_custom_SeriesCPreferredWarrantsMember" id="Fact001612" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,140,000</ix:nonFraction></span>, respectively, related to the change in fair value of
the warrant liability associated with the Series C Warrants which is recorded in other income on the unaudited condensed consolidated
statements of operations. The fair value of the Series C Warrants of $<span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20250501__20260131__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCPreferredWarrantsMember_zxMEFhIwzPC9"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-05-012026-01-31_custom_SeriesCPrivatePlacementAgreementMember_custom_SeriesCPreferredWarrantsMember" id="Fact001613" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,080,000</ix:nonFraction></span> was estimated at January 31, 2026, utilizing the Black-Scholes-Merton
Model using the fair value of the Company&#8217;s common stock of $0.82 and the following weighted average assumptions: dividend yield
0%; remaining term of 4.55 years; equity volatility of 70.0%; and a risk-free interest rate of 3.68%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Placement Agent Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Series C Private Placement
Agreement, the Company also issued warrants to purchase up to an aggregate of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250819__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCPlacementAgentWarrantsMember_zM34x6wuNf3b"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-08-19_custom_SeriesCPrivatePlacementAgreementMember_custom_SeriesCPlacementAgentWarrantsMember" id="Fact001614" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">560,000</ix:nonFraction></span> shares of the Common Stock as compensation to placement
agents for services rendered (the &#8220;Series C Placement Agent Warrants&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series C Placement Agent Warrants are classified
as a contingently redeemable warrant in accordance with ASC 718, as it was determined that the warrants were not precluded from equity
classification under that guidance, but could be settled in cash or other assets in the event that another person or entity becomes the
beneficial owner of&#160;50% of the outstanding shares of the Common Stock. The Series C Placement Agent Warrants were thus classified
in temporary equity on the Company&#8217;s condensed consolidated balance sheets as of January 31, 2026 pursuant to ASC 480-10-S99-3A.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the Series C Placement Agent
Warrants of $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20250801__20250819__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCPlacementAgentWarrantsMember_z8JZymXNJhKj"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2025-08-012025-08-19_custom_SeriesCPrivatePlacementAgreementMember_custom_SeriesCPlacementAgentWarrantsMember" id="Fact001615" format="ixt:numdotdecimal" decimals="0" unitRef="USD">417,000</ix:nonFraction></span> was estimated at August 19, 2025, utilizing the Black-Scholes-Merton Model using the fair value of the Company&#8217;s
common stock of $1.01 and the following weighted average assumptions: dividend yield of 0%; remaining term of 5.00 years; equity volatility
of 95.0%; and a risk-free interest rate of 3.75%. The fair value of the Series C Placement Agent Warrants was expensed as incurred and
was recorded in Series C convertible preferred stock and warrants issuance costs on the condensed consolidated statement of operations
for the nine months ended January 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the Company&#8217;s warrant activity
and related information for the nine months ended January 31, 2026, are shown below:</p>

<ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001617" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zlKnRnxcRI3g" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details - Warrant activity)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B3_zcALJrtgtFwa" style="display: none">Schedule of warrant activity</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise Price Per Share</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining Contractual Term In Years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 55%">Outstanding, April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJBlos8fFIj7" title="Warrants outstanding, beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2025-04-30_us-gaap_WarrantMember" id="Fact001619" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,570,847</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zP1ahsgBRuK2" title="Weighted average exercise price warrants outstanding, beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-04-30_us-gaap_WarrantMember" id="Fact001621" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.54</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240501__20250430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zvI9x1qfoP4b" title="Weighted average remaining contractual term"><ix:nonNumeric contextRef="From2024-05-012025-04-30_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact001623" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.12</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--WarrantsIssuedShares_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQ3ewShGzi9" title="Warrants issued" style="text-align: right"><ix:nonFraction name="PMCB:WarrantsIssuedShares" contextRef="From2025-05-012026-01-31_us-gaap_WarrantMember" id="Fact001625" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,216,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zStQwJ09LwF5" title="Weighted average exercise price warrants issued" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-05-012026-01-31_us-gaap_WarrantMember" id="Fact001627" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Issued - Series B Warrants and Settlement Warrants adjusted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--WarrantsIssuedShares_d0_c20250501__20260131__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsAndSettlementWarrantsAdjustedMember_zrk6zl7qbTK5" title="Warrants issued" style="text-align: right"><ix:nonFraction name="PMCB:WarrantsIssuedShares" contextRef="From2025-05-012026-01-31_custom_SeriesBWarrantsAndSettlementWarrantsAdjustedMember" id="Fact001629" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,132,422</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20250501__20260131__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsAndSettlementWarrantsAdjustedMember_zHd0FGdR57v5" title="Weighted average exercise price warrants issued" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2025-05-012026-01-31_custom_SeriesBWarrantsAndSettlementWarrantsAdjustedMember" id="Fact001631" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.95</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--WarrantExercised_iN_di_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxLNNtOa0Hnl" title="Warrants exercised" style="text-align: right">(<ix:nonFraction name="PMCB:WarrantExercised" contextRef="From2025-05-012026-01-31_us-gaap_WarrantMember" id="Fact001633" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,100,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--WeightedAverageExercisePriceWarrantsExercised_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmu9SNWDPLke" title="Weighted average exercise price warrants Exercised" style="text-align: right"><ix:nonFraction name="PMCB:WeightedAverageExercisePriceWarrantsExercised" contextRef="From2025-05-012026-01-31_us-gaap_WarrantMember" id="Fact001635" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.95</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--WarrantsExpired_iN_di0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zF2aD6730o6h" title="Warrants expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="PMCB:WarrantsExpired" contextRef="From2025-05-012026-01-31_us-gaap_WarrantMember" id="Fact001637" format="ixt:zerodash" decimals="INF" sign="-" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--WeightedAverageExercisePriceWarrantsExpired_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3x0aTXrP1ub" title="Weighted average exercise price warrants Expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="PMCB:WeightedAverageExercisePriceWarrantsExpired" contextRef="From2025-05-012026-01-31_us-gaap_WarrantMember" id="Fact001639" format="ixt:zerodash" decimals="INF" unitRef="USDPShares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Outstanding, January 31, 2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOgTvl4NlbE7" title="Warrants outstanding, ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2026-01-31_us-gaap_WarrantMember" id="Fact001641" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,819,519</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zN6gAdwQkCbj" title="Weighted average exercise price warrants outstanding, ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2026-01-31_us-gaap_WarrantMember" id="Fact001643" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.68</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxZRaHOKg9F5" title="Weighted average remaining contractual term"><ix:nonNumeric contextRef="From2025-05-012026-01-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact001645" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">2.61</ix:nonNumeric></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Exercisable, January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_ecustom--WarrantsExercisable_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zMZVcf06fIZf" title="Warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="PMCB:WarrantsExercisable" contextRef="AsOf2026-01-31_us-gaap_WarrantMember" id="Fact001647" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,819,519</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWWMcdN6Pmk1" title="Weighted average exercise price warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="PMCB:WeightedAverageExercisePriceWarrantsExercisable" contextRef="AsOf2026-01-31_us-gaap_WarrantMember" id="Fact001649" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.68</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zl6tMlzLhwF3" title="Weighted-average remaining contractual term, exercisable"><ix:nonNumeric contextRef="From2025-05-012026-01-31_us-gaap_WarrantMember" format="ixt-sec:duryear" id="Fact001651" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">2.61</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zTCo32KlALc2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:exclude><p id="xdx_239_zUgQ5lKfc9l8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zlzQZlKzKRKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zFlZUUFys2Ih" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 22 -->
    <div id="xdx_237_zya0N4R4io9l" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_zn4z6Ch94XLa" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zlN9BhoWtZTa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001657" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zABU17sipgMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7 &#8211; <span id="xdx_82E_zTsBTjEMBru5">OTHER RELATED PARTY TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had the following related party transactions
during the three and nine months ended January 31, 2026 and 2025, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company owns <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20260131__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SGAustraliaMember_zDLW0fWYJNs9" title="Equity interest owned"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2026-01-31_custom_SGAustraliaMember" id="Fact001659" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">13.8</ix:nonFraction></span>% of the equity in SG Austria
which is presented using the measurement alternative allowed under <i>ASC 321 - Investments Equity Securities</i> with no readily determinable
fair values. SG Austria has two subsidiaries: (i) Austrianova; and (ii) Austrianova Thailand. The Company purchased products and services
from these entities in the approximate amounts of $0 in the three and nine months ended January 31, 2026, and 2025, respectively. The
investment in SG Austria was fully impaired as of April 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2014, the Company entered into the
Vin-de-Bona Consulting Agreement pursuant to which it agreed to provide professional consulting services to the Company. Vin-de-Bona
is owned by Prof. G&#252;nzburg and Dr. Salmons, both of whom are involved in numerous aspects of the Company&#8217;s scientific
endeavors relating to cancer (Prof. G&#252;nzburg is the Chairman of Austrianova, and Dr. Salmons is the Chief Executive Officer and
President of Austrianova). The term of the agreement is for 12 months and is automatically renewable for successive 12-month terms.
After the initial term, either party can terminate the agreement by giving the other party 30 days&#8217; written notice before the
effective date of termination. To date, the agreement has been automatically renewed annually. The amounts incurred for the three
and nine months ended January 31, 2026 were approximately $<span id="xdx_908_eus-gaap--ProfessionalAndContractServicesExpense_pp0p0_c20251101__20260131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VinDeBonaMember_zbrGFfWuYBJb" title="Consulting fees"><ix:nonFraction name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="From2025-11-012026-01-31_custom_VinDeBonaMember" id="Fact001661" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,500</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ProfessionalAndContractServicesExpense_pp0p0_c20250501__20260131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VinDeBonaMember_zxGo0YYc5c27" title="Consulting fees"><ix:nonFraction name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="From2025-05-012026-01-31_custom_VinDeBonaMember" id="Fact001663" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,500</ix:nonFraction></span>, respectively and approximately $<span id="xdx_90C_eus-gaap--ProfessionalAndContractServicesExpense_pp0p0_c20241101__20250131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VinDeBonaMember_zgGeGAKibqs6" title="Consulting fees"><ix:nonFraction name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="From2024-11-012025-01-31_custom_VinDeBonaMember" id="Fact001665" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,390</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--ProfessionalAndContractServicesExpense_pp0p0_c20240501__20250131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VinDeBonaMember_zxKEQMVmOsO" title="Consulting fees"><ix:nonFraction name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="From2024-05-012025-01-31_custom_VinDeBonaMember" id="Fact001667" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,670</ix:nonFraction></span>
for the three and nine months ended January 31, 2025, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&#8217;s Chief Executive Officer was appointed to the Femasys
board of directors, see Note 4 &#8211; Investment in Debt and Equity Securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&#8217;s Chief Executive Officer serves on the board of
directors as the executive chairman of QCLS, see Note 4 &#8211; Investment in Debt and Equity Securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001669" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z8nQFBbELu77" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 &#8211; <span id="xdx_824_ztpgKhsbGKc8">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acquires assets still in development
and enters R&amp;D arrangements with third parties that often require milestone and royalty payments to the third-party contingent upon
the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required, contingent
upon the successful achievement of an important point in the development lifecycle of the pharmaceutical product (e.g., approval of the
product for marketing by a regulatory agency). If required by the license agreements, the Company may have to make royalty payments based
upon a percentage of the sales of the pharmaceutical products if regulatory approval for marketing is obtained. For the three and nine
months ended January 31, 2026 the Company expensed $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20251101__20260131_z3h7DA7ZsCzg" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-11-012026-01-31" id="Fact001671" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,113</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20250501__20260131_zh6SbZoLG0Kg" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2025-05-01to2026-01-31" id="Fact001673" format="ixt:numdotdecimal" decimals="0" unitRef="USD">329,355</ix:nonFraction></span>, respectively, and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20241101__20250131_z8KlzLcEmOig" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-11-012025-01-31" id="Fact001675" format="ixt:numdotdecimal" decimals="0" unitRef="USD">118,196</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20240501__20250131_zpzK5mdi34wh" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-05-012025-01-31" id="Fact001677" format="ixt:numdotdecimal" decimals="0" unitRef="USD">311,682</ix:nonFraction></span> for the three and nine
months ended January 31, 2025, respectively in research and development expenses within the accompanying unaudited condensed consolidated
statements of operations. There have been no recognized costs related to royalty payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are future royalty payments as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Four percent royalty on all gross sales received by us or the Company&#8217;s affiliates;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Twenty percent royalty on gross revenues received by the Company or the Company&#8217;s affiliates from a sublicense or right to use the patents or the licenses granted by the Company or the Company&#8217;s affiliates; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fifty percent of any other financial and non-financial consideration received from sublicensees of the Cell-in-a-Box&#174;&#160;technology; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The removal of all milestone payments.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_232_zgxU6dUZO3ra" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zosPK35yD1Ci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zUWex18uyq45" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 23 -->
    <div id="xdx_23D_zt6VMuzyLFSc" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23A_zrhqwfJFfiib" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zbY8tbeBwTMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Office Lease</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2023, the Company entered into a month-to-month
agreement of the Las Vegas office space, commencing on May 1, 2023. Additionally, the Company rents storage space pursuant to a month-to-month
agreement in Laguna Hills, California.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rent expenses for these offices for the three
and nine months ended January 31, 2026 were $<span id="xdx_90F_eus-gaap--OperatingLeaseExpense_pp0p0_c20251101__20260131_zAEhXsDu3oai" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2025-11-012026-01-31" id="Fact001683" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,196</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_pp0p0_c20250501__20260131_zG5q7T7XhKoe" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2025-05-01to2026-01-31" id="Fact001685" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,404</ix:nonFraction></span>, respectively, and for the three and nine month ended January 31, 2025
were $<span id="xdx_904_eus-gaap--OperatingLeaseExpense_pp0p0_c20241101__20250131_ziMfUhKkfADa"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-11-012025-01-31" id="Fact001686" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,071</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--OperatingLeaseExpense_pp0p0_c20240501__20250131_zbA6XCANbO7f"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2024-05-012025-01-31" id="Fact001687" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,298</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the month-to-month office rental agreements
there are no aggregate future minimum lease payments required to be made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Service Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into several service agreements
with independent and related parties pursuant to which services will be provided over a specified period-of-time related to the IND which
the FDA has placed on clinical hold. The services include regulatory affairs strategy, advice and follow-up work on the IND and services
related to having the clinical hold lifted. The total remaining cost is estimated to be approximately $<span id="xdx_900_eus-gaap--ContractualObligation_iI_c20260131_zWYTFtmsRoTg" title="Contractual obligation"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2026-01-31" id="Fact001689" format="ixt:numdotdecimal" decimals="0" unitRef="USD">543,000</ix:nonFraction></span>, of which the related party
(SG Austria and its subsidiaries) portion will be approximately $<span id="xdx_90E_eus-gaap--ContractualObligation_iI_c20260131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SGAustriaAndSubsidiariesMember_zpH8HZkuAMO9" title="Contractual obligation"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2026-01-31_custom_SGAustriaAndSubsidiariesMember" id="Fact001691" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,000</ix:nonFraction></span>. These amounts take into account some of the cost associated
with the work and preclinical studies required to lift the clinical hold.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company is subject to legal
proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims
cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect
on the Company&#8217;s financial condition or operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 16, 2025, the Company entered into a settlement
and release agreement (&#8220;Settlement Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC relating to a complaint filed on December
4, 2023, alleging a breach of contract. The Settlement Agreement resolved fully all differences, disputes or claims without admitting
any liability, fault or wrongdoing on the part of all parties. The Settlement Agreement required the Company to pay $<span id="xdx_906_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn4n6_c20250515__20250516__srt--LitigationCaseAxis__custom--HCWainwrightMember_zOZdX55ygBdb" title="Initial payment"><ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="From2025-05-152025-05-16_custom_HCWainwrightMember" id="Fact001693" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">1.55</ix:nonFraction></span> million, comprised
of an initial payment of $<span id="xdx_901_eus-gaap--PaymentsForLegalSettlements_pn4n6_c20250519__20250520__srt--LitigationCaseAxis__custom--HCWainwrightMember_zqy5goazwaH" title="Payment for legal settlements"><ix:nonFraction name="us-gaap:PaymentsForLegalSettlements" contextRef="From2025-05-192025-05-20_custom_HCWainwrightMember" id="Fact001695" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">1.25</ix:nonFraction></span> million paid on May 20, 2025, and twelve equal payments of $<span id="xdx_909_eus-gaap--DebtInstrumentPeriodicPayment_c20250515__20250516__srt--LitigationCaseAxis__custom--HCWainwrightMember_z52G52wMZ11h" title="Debt instrument periodic payment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2025-05-152025-05-16_custom_HCWainwrightMember" id="Fact001697" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> beginning on the one-month anniversary
of the initial payment. On May 16, 2025, as part of the settlement, the Company also issued warrants &#8220;(First Warrant Issuance&#8221;)
to purchase <span id="xdx_90F_ecustom--WarrantsIssuedShares_c20250515__20250516__srt--LitigationCaseAxis__custom--HCWainwrightMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FirstWarrantIssuanceMember_zSHdHlZooiuc" title="Warrants issued shares"><ix:nonFraction name="PMCB:WarrantsIssuedShares" contextRef="From2025-05-152025-05-16_custom_HCWainwrightMember_custom_FirstWarrantIssuanceMember" id="Fact001699" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">343,183</ix:nonFraction></span> shares of Common Stock with an exercise price of $4.00 per share and a term of five years from the issuance date.
On July 29, 2025, as part of the settlement, the Company issued additional warrants (&#8220;Additional Warrants&#8221;) to purchase <span id="xdx_906_ecustom--WarrantsIssuedShares_c20250515__20250516__srt--LitigationCaseAxis__custom--HCWainwrightMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AdditionalWarrantsMember_zQ8xm8VFALCl"><ix:nonFraction name="PMCB:WarrantsIssuedShares" contextRef="From2025-05-152025-05-16_custom_HCWainwrightMember_custom_AdditionalWarrantsMember" id="Fact001700" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">313,067</ix:nonFraction></span>
shares of Common Stock with an exercise price of $4.00 per share and a term of five years. See Note 6 &#8211; Stock Options and Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 19, 2025, pursuant to the warrant terms,
the exercise price of the First Warrant Issuance and the Additional Warrants was adjusted to $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250819__us-gaap--ClassOfWarrantOrRightAxis__custom--AdditionalWarrantsMember_z1lH3U3Ltx5f" title="Warrants issued per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-08-19_custom_AdditionalWarrantsMember" id="Fact001702" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.95</ix:nonFraction></span> per share. The price adjustment resulted
in the number of shares underlying the First Warrant Issuance to increase to <span id="xdx_903_ecustom--WarrantsIssuedShares_c20250818__20250819__us-gaap--ClassOfWarrantOrRightAxis__custom--FirstWarrantIssuanceMember_zTDXQpGlA5Lg"><ix:nonFraction name="PMCB:WarrantsIssuedShares" contextRef="From2025-08-182025-08-19_custom_FirstWarrantIssuanceMember" id="Fact001703" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,442,551</ix:nonFraction></span> shares and the number of shares underlying the
Additional Warrants to increase to <span id="xdx_903_ecustom--WarrantsIssuedShares_c20250818__20250819__us-gaap--ClassOfWarrantOrRightAxis__custom--AdditionalWarrantsMember_zNBdnXVHI7Aj"><ix:nonFraction name="PMCB:WarrantsIssuedShares" contextRef="From2025-08-182025-08-19_custom_AdditionalWarrantsMember" id="Fact001704" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,315,960</ix:nonFraction></span> shares. See Note 6 &#8211; Stock Options and Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Company&#8217;s knowledge there are no
other legal proceedings pending to which any property of the Company is subject.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23C_zYSBLZr2oD8c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zZjBvpXLcyb7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zJCvh13g5mwb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 24 -->
    <div id="xdx_232_zp4hY5xddIw8" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23C_zTOLBkuA4v5k" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zZA6t1RjAT94" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001710" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_80F_eus-gaap--EarningsPerShareTextBlock_z7lEbo5zFc1e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9 &#8211; <span id="xdx_829_zAWu52m9fDh2">EARNINGS PER SHARE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes basic earnings per share
using the two-class method. The two-class method of computing earnings per share is an earnings allocation formula that determines earnings
per share for common stock and any participating securities according to dividends declared (whether paid or unpaid) and participation
rights in undistributed earnings. The Series B Preferred Shares and Series C Preferred Shares are considered participating securities
as preferred shareholders are entitled to participate with common stockholders on an as-converted basis in any distributions of assets
by the Company under the terms of their respective Certificates of Designations. Diluted earnings per share for the nine months ended
January 31, 2025 was computed using the two-class method. Under the two-class method, there is no change in the weighted average shares
outstanding used between the basic and diluted earnings per share calculations as the Series B Preferred Shares represent the only dilutive
share equivalents during the nine months ended January 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three and nine months ended January 31, 2026 and the three
months ended January 31, 2025 the Company incurred losses attributable to common shareholders. Accordingly, the effects of any common
stock equivalent would be anti-dilutive during the period and thus are not included in the calculation of diluted weighted average number
of shares outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table illustrates the computation
of basic and diluted earnings (loss) per share:</p>

<ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001712" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zWXykV1ecHvf" summary="xdx: Disclosure - EARNINGS PER SHARE (Details - Per share calculation)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B0_zxLqDWzUcPOj" style="display: none">Schedule of  basic and diluted earnings (loss) per share</span></td><td>&#160;</td>
    <td colspan="3" id="xdx_496_20251101_20260131" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_494_20241101_20250131" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended January 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Earnings per share</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-11-012026-01-31" id="Fact001714" format="ixt:numdotdecimal" decimals="0" unitRef="USD">746,860</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-11-012025-01-31" id="Fact001715" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,045,328</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--PreferredStockAccretionOfRedemptionDiscount_iN_pp0p0_di0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKLTnQEC55Ll" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Less: Accretion of discounts to redemption of convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" contextRef="From2025-11-012026-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact001717" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,204,657</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" contextRef="From2024-11-012025-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact001718" format="ixt:zerodash" decimals="0" scale="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ConvertiblePreferredStockDividends_iN_pp0p0_di0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zO2jMDPdpqzj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Less: Convertible preferred stock dividends</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="PMCB:ConvertiblePreferredStockDividends" contextRef="From2025-11-012026-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact001720" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">98,458</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="PMCB:ConvertiblePreferredStockDividends" contextRef="From2024-11-012025-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact001721" format="ixt:zerodash" decimals="0" scale="0" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_z1YZW2LKWxLi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2025-11-012026-01-31" id="Fact001723" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,556,255</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2024-11-012025-01-31" id="Fact001724" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,045,328</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Weighted average shares outstanding used in basic and diluted earnings per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20251101__20260131_pdd" title="Weighted average shares outstanding used in basic earnings per share"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20251101__20260131_pdd" title="Weighted average shares outstanding used in diluted earnings per share"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-11-012026-01-31" id="Fact001726" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-11-012026-01-31" id="Fact001728" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,262,829</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20241101__20250131_pdd" title="Weighted average shares outstanding used in basic earnings per share"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20241101__20250131_pdd" title="Weighted average shares outstanding used in diluted earnings per share"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-11-012025-01-31" id="Fact001730" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-11-012025-01-31" id="Fact001732" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,960,014</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per share basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20251101__20260131_pdd" title="Net income (loss) per share basic"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20251101__20260131_pdd" title="Net income (loss) per share diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-11-012026-01-31" id="Fact001734" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-11-012026-01-31" id="Fact001736" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.17</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20241101__20250131_pdd" title="Net income (loss) per share basic"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20241101__20250131_pdd" title="Net income (loss) per share diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-11-012025-01-31" id="Fact001738" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-11-012025-01-31" id="Fact001740" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.44</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_49E_20250501__20260131_znWz4okqdtPb" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_496_20240501__20250131_zBaFV8T3dyNe" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended January 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Earnings per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_z8o8ZmHolDi4" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: justify">Net income (loss)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2025-05-01to2026-01-31" id="Fact001742" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,031,211</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-05-012025-01-31" id="Fact001743" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,906,468</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PreferredStockAccretionOfRedemptionDiscount_iN_pp0p0_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zNJIKfNLSUe4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify">Less: Accretion of discounts to redemption of convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" contextRef="From2025-05-012026-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact001745" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,106,653</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" contextRef="From2024-05-012025-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact001746" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,193,404</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--ConvertiblePreferredStockDividends_iN_pp0p0_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zF4x150XcIpf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Less: Convertible preferred stock dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PMCB:ConvertiblePreferredStockDividends" contextRef="From2025-05-012026-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact001748" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">195,097</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="PMCB:ConvertiblePreferredStockDividends" contextRef="From2024-05-012025-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact001749" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,129,759</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--LessAllocationOfUndistributedIncome_d0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzgjUJNVZCY6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Less: Allocation of undistributed income to Series B convertible preferred stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="PMCB:LessAllocationOfUndistributedIncome" contextRef="From2025-05-012026-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact001751" format="ixt:zerodash" decimals="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="PMCB:LessAllocationOfUndistributedIncome" contextRef="From2024-05-012025-01-31_us-gaap_SeriesBPreferredStockMember" id="Fact001752" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,067,733</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_iP3us-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zV9P8rWTMqui" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Undistributed income (loss) available to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="From2025-05-01to2026-01-31" id="Fact001754" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,332,961</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" contextRef="From2024-05-012025-01-31" id="Fact001755" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,515,572</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Weighted average shares outstanding used in basic earnings per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250501__20260131_pdd" title="Weighted average shares outstanding used in basic earnings per share"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250501__20260131_pdd" title="Weighted average shares outstanding used in diluted earnings per share"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2025-05-01to2026-01-31" id="Fact001757" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2025-05-01to2026-01-31" id="Fact001759" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,618,128</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240501__20250131_pdd" title="Weighted average shares outstanding used in basic earnings per share"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240501__20250131_pdd" title="Weighted average shares outstanding used in diluted earnings per share"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-05-012025-01-31" id="Fact001761" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-05-012025-01-31" id="Fact001763" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,487,813</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) per share basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_c20250501__20260131_pdd" title="Net income (loss) per share basic"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250501__20260131_pdd" title="Net income (loss) per share diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2025-05-01to2026-01-31" id="Fact001765" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2025-05-01to2026-01-31" id="Fact001767" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.41</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20240501__20250131_pdd" title="Net income (loss) per share basic"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20240501__20250131_pdd" title="Net income (loss) per share diluted"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-05-012025-01-31" id="Fact001769" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-05-012025-01-31" id="Fact001771" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.67</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zMEpQRkfKw2a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:exclude><p id="xdx_239_zpWvXupeU7x4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zJ4XeXSnABY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_z6ikTTlPWb6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 25 -->
    <div id="xdx_234_zPaV9z6Aqejg" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_zx4BcMzfOXf6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zqjLbM8qoD33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below sets forth the potentially dilutive
securities excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive:</p>

<ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001777" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zIMlQuiVdZ7e" summary="xdx: Disclosure - EARNINGS PER SHARE (Details - Diluted shares)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BD_zxhk3UkMI4uk" style="display: none">Schedule of potentially dilutive securities</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three and Nine Months Ended <br/> January 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify">Excluded options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-11-012026-01-31_custom_OptionsMember" id="Fact001779" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-05-012026-01-31_custom_OptionsMember" id="Fact001781" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,160,627</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-11-012025-01-31_custom_OptionsMember" id="Fact001783" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-05-012025-01-31_custom_OptionsMember" id="Fact001785" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">917,697</ix:nonFraction></ix:nonFraction></span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Excluded preferred shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_pdd" title="Antidilutive shares"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_pdd" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-11-012026-01-31_custom_PreferredSharesMember" id="Fact001787" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-05-012026-01-31_custom_PreferredSharesMember" id="Fact001789" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,008,061</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_z5pGw8qxByt6" title="Antidilutive shares"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240501__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_zpkZStzTy9Td" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-11-012025-01-31_custom_PreferredSharesMember" id="Fact001791" format="ixt:zerodash" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-05-012025-01-31_custom_PreferredSharesMember" id="Fact001793" format="ixt:zerodash" decimals="INF" unitRef="Shares">&#8211;</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Excluded warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-11-012026-01-31_custom_WarrantsMember" id="Fact001795" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-05-012026-01-31_custom_WarrantsMember" id="Fact001797" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,819,519</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-11-012025-01-31_custom_WarrantsMember" id="Fact001799" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-05-012025-01-31_custom_WarrantsMember" id="Fact001801" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,570,847</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total excluded options, preferred shares and warrants</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131_pdd" title="Antidilutive shares"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131_pdd" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-11-012026-01-31" id="Fact001803" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2025-05-01to2026-01-31" id="Fact001805" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">61,988,207</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131_pdd" title="Antidilutive shares"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250131_pdd" title="Antidilutive shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-11-012025-01-31" id="Fact001807" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-05-012025-01-31" id="Fact001809" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,488,544</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zOOcYe0NJb45" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diluted earnings per share were calculated under
both the if-converted and the two-class methods to determine the most dilutive amount for the common stock. The Company applied the treasury
stock two-class method which assumes the securities remain in their current non-exercised or converted form and therefore, deemed anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001811" name="us-gaap:PreferredStockTextBlock"><p id="xdx_80B_eus-gaap--PreferredStockTextBlock_zbVNKkYoPyEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10 &#8211; <span id="xdx_825_zaDnPOk3UUr3">PREFERRED STOCK</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Series C Private Placement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 17, 2025, the Company entered into the
Series C Private Placement Agreement with the Investors, pursuant to which it agreed to sell to the Investors in a private placement (the
&#8220;Series C Private Placement&#8221;) (i) an aggregate of <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_z4Qq5BaFh1o2" title="Aggregate shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2025-08-162025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember" id="Fact001813" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,000</ix:nonFraction></span> shares of the Company&#8217;s newly designated Series C convertible
preferred stock, par value $<span id="xdx_90A_ecustom--PreferredStockParValuePerShare_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_z5hy8M3ko5F5" title="Preferred stock, par value"><ix:nonFraction name="PMCB:PreferredStockParValuePerShare" contextRef="From2025-08-162025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember" id="Fact001815" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>, with a stated value of $<span id="xdx_900_ecustom--PreferredStockStatedValuePerShare_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zf9mQBr3OYPj" title="Preferred stock, stated value"><ix:nonFraction name="PMCB:PreferredStockStatedValuePerShare" contextRef="From2025-08-162025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember" id="Fact001817" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,000</ix:nonFraction></span> per share (the &#8220;Series C Preferred Stock&#8221;), initially convertible
into up to <span id="xdx_902_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zkyi08q8NQkk" title="Conversion shares"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember" id="Fact001819" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,000,000</ix:nonFraction></span> shares of the Company&#8217;s common stock, par value $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zhwHsggJkYgi" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember" id="Fact001821" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share at an initial conversion price of $<span id="xdx_90E_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zkEhX6F0fsP3" title="Conversion price"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember" id="Fact001823" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> and
(ii) the Series C Preferred Warrants to purchase up to an aggregate of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zhwp0RVdxIqi" title="Warrants to purchase shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember_custom_SeriesCWarrantsMember" id="Fact001825" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,000,000</ix:nonFraction></span> shares of Common Stock. The closing of the Private Placement
occurred on August 19, 2025. The aggregate gross proceeds from the Private Placement totaled $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zuYInITqCogl" title="Aggregate gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2025-08-162025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember" id="Fact001827" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Series C Private Placement,
pursuant to an Engagement Letter (the &#8220;Engagement Letter&#8221;) between the Company and the Placement Agent, the Company has agreed
to pay the Placement Agent <span id="xdx_908_eus-gaap--SaleOfStockDescriptionOfTransaction_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zL7VWD19NPzh" title="Engagement letter, description"><ix:nonNumeric contextRef="From2025-08-162025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember" id="Fact001829" name="us-gaap:SaleOfStockDescriptionOfTransaction">(i) a cash fee equal to 8.0% of the gross proceeds from the Series C Private Placement, and (ii) warrants to
purchase shares of Common Stock equal to 8.0% of the number of shares of common stock that the Preferred Stock are initially convertible
into, with an exercise price of $1.00 per share and a five-year term.</ix:nonNumeric></span> Further, pursuant to the Engagement Letter, the Placement Agent
is entitled to compensation with respect to any financing of the Company occurring during the term of the Engagement Letter or within
twelve months thereafter when such financing is provided by investors whom the Placement Agent introduced to the Company. In addition,
for any warrants of the Company that are issued to investors who are introduced to the Company by the Placement Agent in the Private Placement
or were previously issued in connection with the Company&#8217;s May 2023 private placement, and are exercised during the term of the
Engagement Letter, the Company shall pay the Placement Agent a cash fee equal to <span id="xdx_90E_ecustom--PlacementAgentFeePercentage_dp_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zH5pOu8SJJd4" title="Placement agent, cash fee percentage"><ix:nonFraction name="PMCB:PlacementAgentFeePercentage" contextRef="From2025-08-162025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember" id="Fact001831" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.0</ix:nonFraction></span>% of the net proceeds received by the Company from
such warrant exercises.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Transaction costs totaling $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250501__20260131__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zjLFYX6Oppe8" title="Transaction costs"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-05-012026-01-31_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember" id="Fact001833" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,234,553</ix:nonFraction></span>&#160;were
incurred related to the Series C Private Placement consisting of cash expenses for placement agent fees, legal fees, and accounting costs
related to the financing, as well as the fair value of the warrants issued to the Placement Agent, of which $<span id="xdx_900_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20260131__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zz2TAyAthFQb" title="Accounts payable"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2026-01-31_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember" id="Fact001835" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,419</ix:nonFraction></span> was included in accounts
payable on the condensed consolidated balance sheet as of January 31, 2026. These costs were proportionately allocated to the Series C
Preferred Stock and the Series C Warrants based on the allocated gross proceeds of the instruments. Accordingly, none of the transaction
costs were allocated against the carrying value of the Preferred Stock and the total of $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_ziJNsPo1Usad" title="Transaction costs"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2025-08-162025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember" id="Fact001837" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,234,553</ix:nonFraction></span>&#160;of transaction costs were immediately
expensed related to the Series C Warrants which are accounted for as liabilities in accordance with ASC 815, and the bifurcated derivative
related to the Series C Preferred Stock, which is included as a Series C preferred stock and warrants issuance costs on the condensed
consolidated statement of operations for the three and nine months ended January 31, 2026. Net proceeds from the Series C Private Placement
totaled $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250501__20260131__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_z3dkfiszPdq5" title="Aggregate gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2025-05-012026-01-31_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember" id="Fact001839" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,182,447</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23F_zkD95cpEPR7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_ziuTldqocDAe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zN7vp0wEzvX1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 26 -->
    <div id="xdx_23C_zoXY3Py2bss3" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_zxQkK9Wbh1Zj" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zQAb5ldIAkUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Series C Preferred Stock</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The terms of the Series C Preferred Stock are
as set forth in the form of Certificate of Designations (the &#8220;Certificate of Designations&#8221;). The Series C Preferred Stock
are convertible into shares of Common Stock (the &#8220;Conversion Shares&#8221;) at the election of the holder at any time at an initial
conversion price of $<span id="xdx_90B_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20260131_z4SYctm2OJ9k" title="Conversion price"><ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2026-01-31" id="Fact001845" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> (the &#8220;Conversion Price&#8221;). The Conversion Price is subject to customary adjustments for stock dividends,
stock splits, reclassifications and the like, and subject to price-based adjustment in the event of any issuances of Common Stock, or
securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable Conversion Price (subject to
certain exceptions). The conversion price was reduced to $0.95 after issuance pursuant to the full ratchet anti-dilution provisions contained
in the Certificate of Designations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of the Series C Preferred Stock will
be entitled to dividends of 7% per annum, compounded quarterly, which will be payable in cash. Upon the occurrence and during the continuance
of a Triggering Event (as defined in the Certificate of Designations), the Series C Preferred Stock will accrue dividends at the rate
of 15% per annum. The holders of Series C Preferred Stock are entitled to vote with holders of the Common Stock as a single class on all
matters that holders of Common Stock are entitled to vote upon, with the number of votes per Series C Preferred Share equal to the stated
value of such Series C Preferred Share divided by the then applicable Conversion Price; provided, however that in no event shall the then
applicable Conversion Price be less than the &#8220;Minimum Price&#8221; (as defined in Nasdaq Listing Rule 5635) on the date immediately
prior to the date of the Purchase Agreement.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2025, the Company held a special meeting
of stockholders (the &#8220;2025 Special Meeting&#8221;). At the 2025 Special Meeting, the stockholders of the Company approved, for purposes
of complying with Nasdaq Listing Rule 5635(d), (the &#8220;Exchange Cap&#8221;) the issuance of shares of Common Stock underlying the
Series C Preferred Stock and Series C Warrants, which allows the Company to settle all Series C Preferred Stock conversions into shares
of Common Stock. The Series C Certificate of Designations contains a certain beneficial ownership limitation after giving effect to the
issuance of shares of Common Stock issuable upon conversion of the Series C Preferred Stock or Series C Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company obtained stockholder approval to remove
the Exchange Cap on October 30, 2025, upon which event the conversion floor price was adjusted to $0.19.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series C Certificate of Designations includes
certain Triggering Events (as defined in the Series C Certificate of Designations), including, among other things, the Company&#8217;s
failure to pay any amounts due to the holders of the Series C Preferred Stock when due. In connection with a Triggering Event, each holder
of Series C Preferred Stock will be able to require the Company to redeem in cash any or all of the holder&#8217;s Series C Preferred
Stock at a premium set forth in the Series C Certificate of Designations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series C Preferred Shares were determined
to be more akin to a debt-like host than an equity-like host. The Company identified certain embedded features that were deemed not to
be clearly and closely related to the debt host instrument and were therefore bifurcated as a derivative under ASC 815. These features
were bundled together, assigned probabilities of being affected and measured at fair value. Subsequent changes in fair value of these
features are recognized in the condensed consolidated statement of operations. The Company estimated the $<span id="xdx_900_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20260131_z1ivcrYtcXng" title="Fair value of derivative"><ix:nonFraction name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" contextRef="AsOf2026-01-31" id="Fact001847" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,995,000</ix:nonFraction></span>&#160;fair value of
the compound bifurcated embedded derivative at issuance using a probability-weighted scenario model, with the following inputs: the fair
value of the Company&#8217;s common stock of $<span id="xdx_907_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_uUSDPShares_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zO3z69qDxM7d" title="Derivative, measurement input"><ix:nonFraction name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" contextRef="AsOf2026-01-31_us-gaap_MeasurementInputExpectedTermMember" id="Fact001849" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1.01</ix:nonFraction></span>&#160;on the issuance date, estimated equity volatility of&#160;<span id="xdx_902_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_znT6Z7A9jO8d" title="Derivative, measurement input"><ix:nonFraction name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" contextRef="AsOf2026-01-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001851" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60.0</ix:nonFraction></span>%, the time to maturity
of&#160;<span id="xdx_906_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_uYear_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zAupil9Jk1f9" title="Derivative, measurement input"><ix:nonFraction name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" contextRef="AsOf2026-01-31_us-gaap_MeasurementInputExpectedTermMember" id="Fact001853" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Year">1.50</ix:nonFraction></span>&#160;years, the maturity redemption premium of&#160;<span id="xdx_908_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRedemptionPremiumMember_zOh7F0nRoTxk" title="Derivative, measurement input"><ix:nonFraction name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" contextRef="AsOf2026-01-31_custom_MeasurementInputRedemptionPremiumMember" id="Fact001855" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">106</ix:nonFraction></span>%, the liquidation premium of 125%, a market interest rate of&#160;<span id="xdx_900_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketInterestRateMember_z4WAycjbueH5" title="Derivative, measurement input"><ix:nonFraction name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" contextRef="AsOf2026-01-31_custom_MeasurementInputMarketInterestRateMember" id="Fact001857" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16.92</ix:nonFraction></span>%,
a risk-free rate of&#160;<span id="xdx_908_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zjhWbjYK1XG9" title="Derivative, measurement input"><ix:nonFraction name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" contextRef="AsOf2026-01-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001859" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.76</ix:nonFraction></span>%, and dividend rate of <span id="xdx_90F_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zkFicZjjdzll" title="Derivative, measurement input"><ix:nonFraction name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" contextRef="AsOf2026-01-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001861" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.00</ix:nonFraction></span>%. The fair value of the bifurcated derivative liability was estimated utilizing
the with and without method which uses the probability weighted difference between the scenarios with the derivative and the plain vanilla
scenario without a derivative.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The discount to the fair value is included as
a reduction to the carrying value of the Series C Preferred Stock. During the nine months ended January 31, 2026, the Company recorded
a total discount of $<span id="xdx_906_ecustom--PreferredStockDiscount_pp0p0_c20251101__20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zzhCB6Yvr4f2" title="Total discount on preferred stock"><ix:nonFraction name="PMCB:PreferredStockDiscount" contextRef="From2025-11-012026-01-31_us-gaap_SeriesCPreferredStockMember" id="Fact001863" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,000,000</ix:nonFraction></span> upon issuance of the Series C Preferred Stock, which was comprised of the issuance date fair value of the
associated embedded derivative of $<span id="xdx_90E_ecustom--FairValueEmbeddedDerivative_pp0p0_c20251101__20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zqEiRdlAbQE6" title="Fair value of embedded derivative"><ix:nonFraction name="PMCB:FairValueEmbeddedDerivative" contextRef="From2025-11-012026-01-31_us-gaap_SeriesCPreferredStockMember" id="Fact001865" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,995,000</ix:nonFraction></span> and the difference between the remaining gross proceeds after allocation to the derivative
liability and the residual fair value of the Series C Preferred Shares of $<span id="xdx_90B_ecustom--WarrantLiabilityFairValue_pp0p0_c20251101__20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zjcSY14lUBr1" title="Fair value of warrant"><ix:nonFraction name="PMCB:WarrantLiabilityFairValue" contextRef="From2025-11-012026-01-31_us-gaap_SeriesAPreferredStockMember" id="Fact001867" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,005,000</ix:nonFraction></span>, which represents the portion of the total of the
Series C Warrant liability of $5,220,000 allocated to the discount. As the fair value of the liabilities required to be subsequently measured
at fair value exceeded the net proceeds received, the Company recognized the excess of the fair value over the net proceeds received as
a loss upon issuance of preferred stock of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20251101__20260131_ziNmSMxlwx6k" title="Proceeds from issuance of preferred stock"><span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20250501__20260131_zy1woTaUUX68" title="Proceeds from issuance of preferred stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2025-11-012026-01-31" id="Fact001869" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="From2025-05-01to2026-01-31" id="Fact001871" format="ixt:numdotdecimal" decimals="0" unitRef="USD">215,000</ix:nonFraction></ix:nonFraction></span></span>&#160;which is included in other income (expense) in the condensed consolidated statement
of operations for the nine months ended January 31, 2026. As of January 31, 2026, it is probable that the Series C Preferred Stock will
be redeemed. In accordance with ASC 480-10-S99-3A, the Company is accreting the discount using the effective interest method and $<span id="xdx_906_ecustom--DeemedDividend_pp0p0_c20251101__20260131_zEdRFFwGvm22" title="Deemed dividend"><ix:nonFraction name="PMCB:DeemedDividend" contextRef="From2025-11-012026-01-31" id="Fact001873" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,204,657</ix:nonFraction></span>
and $<span id="xdx_90E_ecustom--DeemedDividend_c20250501__20260131_pp0p0" title="Deemed dividend"><ix:nonFraction name="PMCB:DeemedDividend" contextRef="From2025-05-01to2026-01-31" id="Fact001875" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,106,653</ix:nonFraction></span>, respectively,&#160;was recorded as a deemed dividend during the three and nine months ended January 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23F_zvB7B0sC97ui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_234_zg3cLCy388fb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zHcVQE7XQdI" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 27 -->
    <div id="xdx_231_zUDPEsvjYB6c" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_230_zRVCoLQk4zt2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zazgKtZyPZCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recorded a gain of $<span id="xdx_90D_ecustom--ChangeInFairValueDerivativeLiability_pp0p0_c20251101__20260131_z3RELHctJgQ5" title="Change in fair value derivative liability"><ix:nonFraction name="PMCB:ChangeInFairValueDerivativeLiability" contextRef="From2025-11-012026-01-31" id="Fact001881" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">557,000</ix:nonFraction></span> and $<span id="xdx_90E_ecustom--ChangeInFairValueDerivativeLiability_pp0p0_c20250501__20260131_z1gSVLCj3joj" title="Change in fair value derivative liability"><ix:nonFraction name="PMCB:ChangeInFairValueDerivativeLiability" contextRef="From2025-05-01to2026-01-31" id="Fact001883" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">859,000</ix:nonFraction></span>, respectively, related to the change in fair value of the derivative liability
which is recorded in other income (expense) on the condensed consolidated statements of operations. The Company estimated the $<span id="xdx_907_ecustom--WarrantLiabilityFairValue_pp0p0_c20251101__20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zaFOys2XDHzl" title="Fair value of warrant"><ix:nonFraction name="PMCB:WarrantLiabilityFairValue" contextRef="From2025-11-012026-01-31_us-gaap_SeriesAPreferredStockMember_custom_DerivativeLiabilityMember" id="Fact001885" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,136,000</ix:nonFraction></span>&#160;fair
value of the bifurcated embedded derivative at January 31, 2026 using a probability-weighted scenario model, with the following inputs:
the fair value of the Company&#8217;s common stock of $<span id="xdx_902_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_uUSDPShares_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_z5zy8cncjno1"><ix:nonFraction name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" contextRef="AsOf2026-01-31_us-gaap_MeasurementInputExpectedTermMember_custom_DerivativeLiabilityMember" id="Fact001886" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.82</ix:nonFraction></span>&#160;on the measurement date, estimated equity volatility of&#160;<span id="xdx_90A_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zeupaYbnmpf8"><ix:nonFraction name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" contextRef="AsOf2026-01-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_DerivativeLiabilityMember" id="Fact001887" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85.0</ix:nonFraction></span>%, the
time to maturity of&#160;<span id="xdx_90B_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_uYear_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zVruSaU2mKQ9"><ix:nonFraction name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" contextRef="AsOf2026-01-31_us-gaap_MeasurementInputExpectedTermMember_custom_DerivativeLiabilityMember" id="Fact001888" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Year">1.05</ix:nonFraction></span>&#160;years, the maturity redemption premium of&#160;<span id="xdx_90C_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRedemptionPremiumMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zNurQC2Tb4T1"><ix:nonFraction name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" contextRef="AsOf2026-01-31_custom_MeasurementInputRedemptionPremiumMember_custom_DerivativeLiabilityMember" id="Fact001889" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">106</ix:nonFraction></span>%, the liquidation premium of 125% a market interest
rate of&#160;<span id="xdx_900_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketInterestRateMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_z8GBw3rkvEXg"><ix:nonFraction name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" contextRef="AsOf2026-01-31_custom_MeasurementInputMarketInterestRateMember_custom_DerivativeLiabilityMember" id="Fact001890" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20.10</ix:nonFraction></span>%, a risk-free rate of&#160;<span id="xdx_908_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zwdUG4pfSOR"><ix:nonFraction name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" contextRef="AsOf2026-01-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_DerivativeLiabilityMember" id="Fact001891" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.42</ix:nonFraction></span>%, and dividend rate of <span id="xdx_901_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zYEG0KEkT8ni"><ix:nonFraction name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" contextRef="AsOf2026-01-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_DerivativeLiabilityMember" id="Fact001892" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.00</ix:nonFraction></span>%. The fair value of the bifurcated derivative liability
was estimated utilizing the with and without method which uses the probability weighted difference between the scenarios with the derivative
and the plain vanilla scenarios without a derivative.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recognized a total of $<span id="xdx_900_eus-gaap--DividendsPreferredStockStock_c20251101__20260131_zYuGn86aADfe" title="Preferred dividends"><ix:nonFraction name="us-gaap:DividendsPreferredStockStock" contextRef="From2025-11-012026-01-31" id="Fact001894" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,458</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--DividendsPreferredStockStock_c20250501__20260131_z218shCEqrP4" title="Preferred dividends"><ix:nonFraction name="us-gaap:DividendsPreferredStockStock" contextRef="From2025-05-01to2026-01-31" id="Fact001896" format="ixt:numdotdecimal" decimals="0" unitRef="USD">195,097</ix:nonFraction></span>, respectively, of preferred dividends at the stated dividend rate, of
which $<span id="xdx_90D_eus-gaap--DividendsPreferredStockCash_c20251101__20260131_zea7dqRyAyLf" title="Dividend paid in cash"><ix:nonFraction name="us-gaap:DividendsPreferredStockCash" contextRef="From2025-11-012026-01-31" id="Fact001898" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,356</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--DividendsPreferredStockCash_c20250501__20260131_zF5HkZlw1hk3" title="Dividend paid in cash"><ix:nonFraction name="us-gaap:DividendsPreferredStockCash" contextRef="From2025-05-01to2026-01-31" id="Fact001900" format="ixt:numdotdecimal" decimals="0" unitRef="USD">162,606</ix:nonFraction></span>, respectively, were paid in cash and $<span id="xdx_904_eus-gaap--DividendsPreferredStockPaidinkind_c20251101__20260131_zislt7KY9Ha6" title="Dividend accrued"><ix:nonFraction name="us-gaap:DividendsPreferredStockPaidinkind" contextRef="From2025-11-012026-01-31" id="Fact001902" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,491</ix:nonFraction></span> are accrued in accrued Series C Preferred Stock and dividends
on the condensed consolidated balance sheet as of January 31, 2026. During the three months ended January 31, 2026, there were <span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_c20251101__20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zy7Xhk4h7nz6" title="Stock converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2025-11-012026-01-31_us-gaap_SeriesCPreferredStockMember" id="Fact001904" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,234</ix:nonFraction></span> Series
C preferred stock converted that resulted in <span id="xdx_90E_eus-gaap--ConversionOfStockSharesIssued1_c20251101__20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zGHAfHjmimx8" title="Shares issued"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2025-11-012026-01-31_us-gaap_SeriesCPreferredStockMember" id="Fact001906" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,358,620</ix:nonFraction></span> shares of common stock being issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001908" name="us-gaap:TreasuryStockTextBlock"><p id="xdx_801_eus-gaap--TreasuryStockTextBlock_z05biwOFw9D9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11 &#8211; <span id="xdx_826_z0QudCCnAqA9">TREASURY STOCK</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2022, the Board authorized a share repurchase
program to acquire its outstanding common stock for up to $10 million. In January 2023, the Board authorized an additional share repurchase
program to acquire up to an additional $10 million of the Company&#8217;s outstanding common stock. In conjunction with the share repurchase
programs, the Company selected a broker to repurchase shares on behalf of the Company. The amount of common stock repurchased on any given
trading day is determined by a formula, which is based on the market price of the common stock and average daily volumes. Shares repurchased
are held in treasury for general corporate purposes. The shares are treated as Treasury Stock using the cost method. As of April 2025,
the Company has paused the repurchase program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 11, 2025, the Company granted the
directors of the Company <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20251210__20251211__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSCY3nNp30bd" title="Restricted stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2025-12-102025-12-11_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001910" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">875,000</ix:nonFraction></span> shares of common stock in a restricted stock unit (&#8220;RSU&#8221;) transaction. The RSUs vested immediately
and the Company withheld <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20251210__20251211__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNKiFu3YEpSg" title="Restricted stock vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2025-12-102025-12-11_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001912" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">393,750</ix:nonFraction></span> shares valued at $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20251210__20251211__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7MAV44xa0N4" title="Restricted units valued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2025-12-102025-12-11_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001914" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401,625</ix:nonFraction></span> to cover the expected income tax effect of the grants. The Company recorded
stock based compensation expense to general and administrative expenses of $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20251210__20251211__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzDtIa02IHR9" title="Stock issued for compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2025-12-102025-12-11_us-gaap_RestrictedStockUnitsRSUMember" id="Fact001916" format="ixt:numdotdecimal" decimals="0" unitRef="USD">892,500</ix:nonFraction></span> related to the RSU grants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of January 31, 2026 and April 30, 2025, the
total number of shares held in Treasury Stock was <span id="xdx_90D_eus-gaap--TreasuryStockCommonShares_iI_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--TreasuryStockCommonMember_zeharu2husK8" title="Treasury stock, common shares"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2026-01-31_us-gaap_TreasuryStockCommonMember266868390" id="Fact001918" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,270,066</ix:nonFraction></span> and <span id="xdx_905_eus-gaap--TreasuryStockCommonShares_iI_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--TreasuryStockCommonMember_zJhKLAewAxmg" title="Treasury stock, common shares"><ix:nonFraction name="us-gaap:TreasuryStockCommonShares" contextRef="AsOf2025-04-30_us-gaap_TreasuryStockCommonMember266868390" id="Fact001920" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,876,316</ix:nonFraction></span>, respectively, shares at total costs of $<span id="xdx_90A_eus-gaap--TreasuryStockCommonValue_iI_pp0p0_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--TreasuryStockCommonMember_z5eQUeKLUwfa" title="Treasury stock, value"><ix:nonFraction name="us-gaap:TreasuryStockCommonValue" contextRef="AsOf2026-01-31_us-gaap_TreasuryStockCommonMember266868390" id="Fact001922" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,009,541</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--TreasuryStockCommonValue_iI_pp0p0_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--TreasuryStockCommonMember_zGUTxHAJD8A1" title="Treasury stock, value"><ix:nonFraction name="us-gaap:TreasuryStockCommonValue" contextRef="AsOf2025-04-30_us-gaap_TreasuryStockCommonMember266868390" id="Fact001924" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">44,607,916</ix:nonFraction></span>,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001926" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_80A_eus-gaap--FairValueDisclosuresTextBlock_zQasBjGXWRnl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12 &#8211; <span id="xdx_829_z6jXmNqYPeQ5">FAIR VALUE MEASUREMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value measurements discussed herein are based
upon certain market assumptions and pertinent information available to management as of and during the three and nine months ended January
31, 2026. The carrying amounts of cash equivalents, other current assets, accounts payable and accrued expenses approximate their face
values at January 31, 2026 due to their short-term nature. The fair value of the bifurcated embedded derivative related to the convertible
preferred stock was estimated using a probability-weighted scenario model, which uses as inputs the fair value of the Company&#8217;s
common stock and estimates for the equity volatility and of the Company&#8217;s common stock, the time to maturity of the convertible
preferred stock, the risk-free interest rate for a period of time that approximates the time to maturity, the maturity redemption premium
rate, the liquidation premium rate, the market discount rate, and the dividend rate. The fair value of the warrant liability was estimated
using the Black Scholes Merton Model which uses as inputs the following weighted average assumptions, as noted above: dividend yield,
expected terms in years, equity volatility and risk-free rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_232_zsbhXoMHS79k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zGkE5SfCJVj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zSaaiGK4XUU3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 28 -->
    <div id="xdx_23F_z9sM0oupuIq1" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_zzUjIaRzYv09" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zdGEbYIDOu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Fair Value on a Recurring Basis</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the guidance in ASC 820 for
its financial assets and liabilities that are re-measured and reported at fair at each reporting period, and non-financial assets and
liabilities that are re-measured and reported at fair value at least annually. The estimated fair value of the warrant liability and bifurcated
embedded derivative represent Level 3 measurements. The following table presents information about the Company&#8217;s liabilities that
are measured at fair value on a recurring basis at January 31, 2026 and April 30, 2025, and indicates the fair value hierarchy of the
valuation inputs the Company utilized to determine such fair value:</p>

<ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001932" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zF9lBkc5Vir9" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair value)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B6_zCx3vSGvWar2" style="display: none">Schedule of fair value of financial liabilities</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: justify">Description</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Level</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">January 31, 2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">April 30, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Liabilities:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; text-align: justify">Warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 11%; text-align: center">3</td><td style="width: 1%; text-align: center">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20260131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_ztEgxCLFA8Yg" title="Warrant liabilities" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2026-01-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember" id="Fact001934" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,657,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FinancialLiabilitiesFairValueDisclosure_pp0p0_c20250430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zpRAlvZ7ydcl" title="Warrant liabilities" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2025-04-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember" id="Fact001936" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">338,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Derivative liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20260131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zELHs1Gy564k" title="Warrant liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2026-01-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember" id="Fact001938" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,136,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_d0_c20250430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zTB27IoUPQug" title="Warrant liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2025-04-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember" id="Fact001940" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zl9Ml1eQruZh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth a summary of the
change in the fair value of the warrant liability that is measured at fair value on a recurring basis:</p>

<ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001942" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zjATpYIMOsv" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of warrant liability)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_zK9pFyzu0yq4" style="display: none">Schedule of change in the fair value warrant liability</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended January 31, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%">Balance on October 31, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zPinaFMb2qVl" title="Fair value of the warrant liability at beginning" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2025-10-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember" id="Fact001944" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,152,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pp0p0_d0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zRj80Tmfx8Pb" title="Issuance of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" contextRef="From2025-11-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember" id="Fact001946" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Warrant exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--WarrantExercises_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zGzvOXGHFIOg" title="Warrant exercises" style="text-align: right">(<ix:nonFraction name="PMCB:WarrantExercises" contextRef="From2025-11-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember" id="Fact001948" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">599,135</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ChangeInFairValueOfWarrantLiability_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_pp0p0" title="Change in fair value of derivative liability" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantLiability" contextRef="From2025-11-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember" id="Fact001950" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,895,865</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Balance on January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zgCPiGJi7Emc" title="Fair value of the warrant liability at ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember" id="Fact001952" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,657,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt; width: 83%">&#160;</td><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 1%">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center; width: 13%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine Months Ended January 31, 2026</span></td><td style="padding-bottom: 1pt; text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Balance on April 30, 2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zid8xXInSDa1" title="Fair value, beginning" style="text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2025-04-30_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember" id="Fact001954" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">338,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_z3f6fB8kM2Jf" title="Issuance of warrants" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" contextRef="From2025-05-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember" id="Fact001956" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,583,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Warrant exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--WarrantExercises_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zGwMiBjNtHwk" title="Warrant exercises" style="text-align: right">(<ix:nonFraction name="PMCB:WarrantExercises" contextRef="From2025-05-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember" id="Fact001958" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">599,135</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiability_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_pp0p0" title="Change in fair value of derivative liability" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantLiability" contextRef="From2025-05-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember" id="Fact001960" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,335,135</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Balance on January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_z8ZefvQM88B" title="Fair value, ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember" id="Fact001962" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,657,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_z03HtV5aCvE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth a summary of the
change in the fair value of the derivative liability that is measured at fair value on a recurring basis:</p>

<ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001964" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of derivative liability)" id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zB3WdxHNSH4b" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BE_zBPBqzsLGbJ6" style="display: none">Schedule of change in the fair value derivative liability</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three Months Ended January 31, 2026</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance on October 31, 2025</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zz6jtwY1f8ia" title="Fair value of the warrant liability at beginning" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2025-10-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember" id="Fact001966" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,693,000</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 84%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of Series C convertible preferred stock</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_985_ecustom--IssuanceOfSeriesCConvertiblePreferredStock_pp0p0_d0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zmI71ikrL7jd" title="Issuance of Series C convertible preferred stock" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="PMCB:IssuanceOfSeriesCConvertiblePreferredStock" contextRef="From2025-11-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember" id="Fact001968" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in fair value of derivative liability</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_ecustom--ChangeInFairValueOfWarrantLiability_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zuPImSdAN83l" title="Change in fair value of derivative liability" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantLiability" contextRef="From2025-11-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember" id="Fact001970" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">557,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance on January 31, 2026</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zJtanI2USiFf" title="Fair value of the warrant liability at ending" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember" id="Fact001972" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,136,000</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine Months Ended January 31, 2026</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance on April 30, 2025</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_980_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_d0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zqDxowByTRS8" title="Fair value, beginning" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2025-04-30_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember" id="Fact001974" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 84%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of Series C convertible preferred stock</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_986_ecustom--IssuanceOfSeriesCConvertiblePreferredStock_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_pp0p0" title="Issuance of Series C convertible preferred stock" style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="PMCB:IssuanceOfSeriesCConvertiblePreferredStock" contextRef="From2025-05-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember" id="Fact001976" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,995,000</ix:nonFraction></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in fair value of derivative liability</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiability_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_pp0p0" title="Change in fair value of derivative liability" style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="PMCB:ChangeInFairValueOfWarrantLiability" contextRef="From2025-05-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember" id="Fact001978" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">859,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance on January 31, 2026</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zV8ZJWF4fvzj" title="Fair value, ending" style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="AsOf2026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember" id="Fact001980" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,136,000</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AF_zDmWku3XIn9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23C_zyCKgc7YQpH2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_z0dvxEW22Z8k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zvbVfVsty7Ci" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 29 -->
    <div id="xdx_233_zdVKmbQMTYc5" style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_232_zc8MCUbIMsk6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zoJ7dOZefj42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the convertible note receivable
was historically estimated using the income approach, which uses as inputs the fair value of debtor&#8217;s common stock and estimates
for the equity volatility and volume volatility of debtor&#8217;s common stock, the time to expiration of the convertible note, the discount
rate, the stated interest rate compared to the current market rate, the risk-free interest rate for a period that approximates the time
to expiration, and probability of default. Therefore, the estimate of expected future volatility is based on the actual volatility of
debtor&#8217;s common stock and historical volatility of debtor&#8217;s common stock utilizing a lookback period consistent with the time
to expiration. The time to expiration is based on the contractual maturity date. The risk-free interest rate is determined by reference
to the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration.
Probability of default is estimated using the S&amp;P Global default rate for companies with a similar credit rating to debtor&#8217;s.
At January 31, 2026, the fair value of the convertible note receivable was estimated to be equal to its principal value the note was near
its maturity and was expected to be fully settled in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair values of financial instruments by class
as of January 31, 2026 and April 30, 2025 are as follows:</p>

<ix:nonNumeric contextRef="From2025-05-01to2026-01-31" escape="true" id="Fact001986" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zGaBW8wYEk61" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair values of financial instruments)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B3_zLyMlzDJddi8" style="display: none">Schedule of fair values of financial instruments by class</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Level</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">January 31, 2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">April 30, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: justify">Financial Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; text-align: left">Marketable equity securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 11%; text-align: center">1</td><td style="width: 1%; text-align: center">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20260131__us-gaap--FinancialInstrumentAxis__custom--MarketableEquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Fair value of financial assets" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:FinancialInstrumentsOwnedAtFairValue" contextRef="AsOf2026-01-31_custom_MarketableEquitySecuritiesMember_us-gaap_FairValueInputsLevel1Member" id="Fact001988" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">372,251</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--MarketableEquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Fair value of financial assets" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:FinancialInstrumentsOwnedAtFairValue" contextRef="AsOf2025-04-30_custom_MarketableEquitySecuritiesMember_us-gaap_FairValueInputsLevel1Member" id="Fact001990" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">366,316</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Money market account</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20260131__us-gaap--FinancialInstrumentAxis__custom--MoneyMarketAccountMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Fair value of financial assets" style="text-align: right"><ix:nonFraction name="us-gaap:FinancialInstrumentsOwnedAtFairValue" contextRef="AsOf2026-01-31_custom_MoneyMarketAccountMember_us-gaap_FairValueInputsLevel1Member" id="Fact001992" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,081,636</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--MoneyMarketAccountMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Fair value of financial assets" style="text-align: right"><ix:nonFraction name="us-gaap:FinancialInstrumentsOwnedAtFairValue" contextRef="AsOf2025-04-30_custom_MoneyMarketAccountMember_us-gaap_FairValueInputsLevel1Member" id="Fact001994" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">76,287</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible note receivable &#8211; investment in debt security - Femasys</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_d0_c20260131__us-gaap--FinancialInstrumentAxis__custom--ConvertibleNoteReceivableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zC0yzOpRIE41" title="Fair value of financial assets" style="text-align: right"><ix:nonFraction name="us-gaap:FinancialInstrumentsOwnedAtFairValue" contextRef="AsOf2026-01-31_custom_ConvertibleNoteReceivableMember_us-gaap_FairValueInputsLevel3Member" id="Fact001996" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--ConvertibleNoteReceivableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Fair value of financial assets" style="text-align: right"><ix:nonFraction name="us-gaap:FinancialInstrumentsOwnedAtFairValue" contextRef="AsOf2025-04-30_custom_ConvertibleNoteReceivableMember_us-gaap_FairValueInputsLevel3Member" id="Fact001998" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,696,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Warrant asset - Femasys</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20260131__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetFemasysMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Fair value of financial assets" style="text-align: right"><ix:nonFraction name="us-gaap:FinancialInstrumentsOwnedAtFairValue" contextRef="AsOf2026-01-31_custom_WarrantAssetFemasysMember_us-gaap_FairValueInputsLevel3Member" id="Fact002000" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">906,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetFemasysMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Fair value of financial assets" style="text-align: right"><ix:nonFraction name="us-gaap:FinancialInstrumentsOwnedAtFairValue" contextRef="AsOf2025-04-30_custom_WarrantAssetFemasysMember_us-gaap_FairValueInputsLevel3Member" id="Fact002002" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,061,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment in preferred stock - QCLS</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_c20260131__us-gaap--FinancialInstrumentAxis__custom--InvestmentInPreferredStockQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaBdqNmylt05" title="Fair value of financial assets" style="text-align: right"><ix:nonFraction name="us-gaap:FinancialInstrumentsOwnedAtFairValue" contextRef="AsOf2026-01-31_custom_InvestmentInPreferredStockQCLSMember_us-gaap_FairValueInputsLevel3Member" id="Fact002004" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,472,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--InvestmentInPreferredStockQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Fair value of financial assets" style="text-align: right"><ix:nonFraction name="us-gaap:FinancialInstrumentsOwnedAtFairValue" contextRef="AsOf2025-04-30_custom_InvestmentInPreferredStockQCLSMember_us-gaap_FairValueInputsLevel3Member" id="Fact002006" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,474,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Warrant assets - QCLS</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_c20260131__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z8xXTGJ8HWue" title="Fair value of financial assets" style="text-align: right"><ix:nonFraction name="us-gaap:FinancialInstrumentsOwnedAtFairValue" contextRef="AsOf2026-01-31_custom_WarrantAssetQCLSMember_us-gaap_FairValueInputsLevel3Member" id="Fact002008" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,242,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Fair value of financial assets" style="text-align: right"><ix:nonFraction name="us-gaap:FinancialInstrumentsOwnedAtFairValue" contextRef="AsOf2025-04-30_custom_WarrantAssetQCLSMember_us-gaap_FairValueInputsLevel3Member" id="Fact002010" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,618,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_z3I6Soh50QTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assumptions used in the valuation of the Level
3 assets include time to expiration, discount rate, risk-free rate, volatility and probability of default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_811_zRnX8g1sfBx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="k_010"></span>Item 2. Management&#8217;s Discussion and Analysis of Financial
Conditions and Results of Operations.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cautionary Note Regarding Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This Quarterly Report
on Form 10-Q (&#8220;Report&#8221;) includes &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws.
Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements other than statements
of historical fact are &#8220;forward-looking statements&#8221; for purposes of this Report, including any projections of earnings, revenue
or other financial items, any statements regarding the plans and objectives of management for future operations, any statements concerning
proposed new products or services, any statements regarding future economic conditions or performance, any statements regarding expected
benefits from any transactions and any statements of assumptions underlying any of the foregoing. In some cases, forward-looking statements
can be identified by use of terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;believes,&#8221; &#8220;intends,&#8221;
&#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;goal,&#8221; &#8220;aim,&#8221;
&#8220;potential&#8221; or &#8220;continue,&#8221; or the negative thereof or other comparable terminology. Although we believe that the
expectations reflected in the forward-looking statements contained in this Report are reasonable, there can be no assurance that such
expectations or any of the forward-looking statements will prove to be correct, and actual results could differ materially from those
projected or assumed in the forward-looking statements. Thus, investors should refer to and carefully review information in future documents
we file with the U.S. Securities and Exchange Commission (&#8220;Commission&#8221;). Our future financial condition and results of operations,
as well as any forward-looking statements, are subject to inherent risk and uncertainties, including, those set forth in this Item 2,
&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and in our unaudited condensed
consolidated financial statements and notes thereto included in this Quarterly Report, those set forth from time to time in our other
filings with the Commission, including our Annual Report on Form 10-K for the fiscal year ended April 30, 2025 and the following factors
and risks:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Among others, these include:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the United States (&#8220;U.S.&#8221;) Food and Drug Administration (&#8220;FDA&#8221;) approves our Investigational New Drug Application (&#8220;IND&#8221;) after we complete the FDA&#8217;s requested studies and submit a response to the FDA&#8217;s clinical hold, so that we can commence our planned clinical trial involving locally advanced, inoperable, non-metastatic pancreatic cancer (&#8220;LAPC&#8221;);</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the success and timing of our preclinical studies and clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential that results of preclinical studies and clinical trials may indicate that any of our technologies and product candidates are unsafe or ineffective;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our dependence on third parties in the conduct of our preclinical studies and clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the difficulties and expenses associated with obtaining and maintaining regulatory approval of our product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the material adverse impact that the coronavirus pandemic may have on our business, including our planned clinical trial involving LAPC, which could materially affect our operations as well as the business or operations of third parties with whom we conduct business;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether the FDA will approve our product candidates after our clinical trials are completed, assuming the FDA allows our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to comply with the listing requirements of The Nasdaq Capital Market and any delisting or potential delisting of shares of our common stock; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other risks and uncertainties, including those listed in &#8220;Risk Factors.&#8221;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">All forward- looking
statements and reasons why results may differ included in this Report are made as of the date hereof, and we do not intend to update any
forward-looking statements except as required by law or applicable regulations. New risk factors emerge from time to time, and it is not
possible to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which
any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements.
Forward-looking statements are not guarantees of performance. All forward-looking statements attributable to us or persons acting on our
behalf are expressly qualified in their entirety by the foregoing cautionary statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Except where the context
otherwise requires, in this Report, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to PharmaCyte
Biotech, Inc., a Nevada corporation, and, where appropriate, its subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Overview of Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a biotechnology company focused on developing
cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as &#8220;Cell-in-a-Box&#174;.&#8221;
The Cell-in-a-Box&#174; technology is intended to be used as a platform upon which therapies for several types of cancer, including LAPC,
will be developed. The current generation of our product candidate is referred to as &#8220;CypCaps&#8482;.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended April 30, 2024, we determined
that research and development in the treatment of diabetes would no longer be pursued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 15, 2022, we entered into a Cooperation
Agreement (the &#8220;Cooperation Agreement&#8221;) with Iroquois Master Fund Ltd. and its affiliates, pursuant to which we elected a
reconstituted board of directors (the &#8220;Board&#8221;). On November 17, 2023, the Board formed the Strategic Scientific Committee
(the &#8220;Scientific Committee&#8221;), chaired by Dr. Michael Abecassis. The Scientific Committee and our independent consultants are
reviewing many of the risks relative to our business. In addition, the Board is reviewing risks associated with our development programs
and our relationship with SG Austria Pte. Ltd (&#8220;SG Austria&#8221;), including that all licensed patents have expired and that know-how
relating to our Cell-in-a-Box&#174; technology solely resides with SG Austria. The Board has reduced spending on our programs, including
pre-clinical and clinical activities, until the review by the Scientific Committee and the Board is complete and the Board has determined
the actions and plans to be implemented. The Scientific Committee&#8217;s recommendations will include potentially seeking a new framework
for our relationship with SG Austria and its subsidiaries. We are reevaluating those programs which are dependent on SG Austria and the
U.S. Food and Drug Administration&#8217;s (the &#8220;FDA&#8221;) acceptance of its technologies, including our development programs for
locally advanced, inoperable, non-metastatic pancreatic cancer (&#8220;LAPC&#8221;). Our reevaluation for addressing the FDA concerns
has resulted in delays stemming from the review of the non-clinical package provided by SG Austria and changes to the FDA review process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Cell-in-a-Box&#174; encapsulation technology
is designed to present genetically engineered live human cells to targeted tissues. The technology is intended to result in the formation
of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated, grown to confluence
and maintained in a cryopreserved (frozen) state until shortly before they are injected into an appropriate patient. In a laboratory setting,
this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and
flourish. Encapsulated cells are protected from environmental challenges, such as the shear forces associated with bioreactors and passage
through catheters and needles, which we believe enables greater cell growth and production of the active molecules. The capsules are largely
composed of cellulose (cotton) and are bioinert. During the past year, SG Austria has generated data and reports to support submission
to the FDA concerning the safety of the microcapsules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have been developing therapies for pancreatic
tumors by using genetically engineered live human cells that we believe are capable of converting a cancer prodrug into its cancer-killing
form. We encapsulate those cells using the Cell-in-a-Box&#174; technology and place those capsules in the body as close as possible to
the tumor. In this way, we believe that when a cancer prodrug is administered to a patient with a particular type of cancer that may be
affected by the resulting active drug, the killing of the patient&#8217;s cancerous tumor may be optimized both by enhanced potency and
limited exposure away from the target tumor. We believe that the prodrug/activator technology is well suited to address the shift from
cure/enhanced survival to creating a zone of clearance around blood vessels adjacent to tumor. This zone of clearance improves the probability
of successful surgical resection of LAPC, which has been shown to improve survival.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to reengaging SG Austria, we are also
identifying alternative approaches to expand the prodrug/activator technology for cancer treatment. These discussions may expand our prodrug/activation
options to use highly toxic cancer-killing drugs in tightly controlled perivascular spaces.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until the Strategic Scientific Committee completes
its evaluation of our programs and we enter into a new framework for its relationship with SG Austria, spending on our development programs
has been curtailed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Investigational New Drug Application and Clinical
Hold</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 1, 2020, we submitted an IND to the
FDA for a planned clinical trial in LAPC. On October 1, 2020, we received notice from the FDA that it had placed our IND on clinical hold.
On October 30, 2020, the FDA sent us a letter setting forth the reasons for the clinical hold and providing specific guidance on what
we must do to have the clinical hold lifted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to address the clinical hold, the FDA
has requested that we:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide additional sequencing data and genetic stability studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct a stability study on our final formulated product candidate as well as the cells from our Master Cell Bank (&#8220;MCB&#8221;);</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluate the compatibility of the delivery devices (the prefilled syringe and the microcatheter used to implant the CypCaps&#8482;) with our product candidate for pancreatic cancer;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide additional detailed description of the manufacturing process of our product candidate for pancreatic cancer;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide additional product release specifications for our encapsulated cells;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Demonstrate comparability between the 1st and 2nd generation of our product candidate for pancreatic cancer and ensure adequate and consistent product performance and safety between the two generations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct a biocompatibility assessment using the capsules material;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address specified insufficiencies in the Chemistry, Manufacturing and Controls information in the cross-referenced Drug Master File;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct an additional nonclinical study in animals to assess the safety, activity, and distribution of the product candidate for pancreatic cancer; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revise the Investigators Brochure to include any additional preclinical studies conducted in response to the clinical hold and remove any statements not supported by the data we generated.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA also requested that we address the following
issues as an amendment to our IND:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide a Certificate of Analysis for pc3/2B1 plasmid that includes tests for assessing purity, safety, and potency;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Perform qualification studies for the drug substance filling step to ensure that the product candidate for pancreatic cancer remains sterile and stable during the filling process;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submit an updated batch analysis for the product candidate for the specific lot that will be used for manufacturing all future product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide additional details for the methodology for the Resorufin (CYP2B1) potency and the PrestoBlue cell metabolic assays;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide a few examples of common microcatheters that fit the specifications in our Angiography Procedure Manual;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clarify the language in our Pharmacy Manual regarding proper use of the syringe fill with the product candidate for pancreatic cancer; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide a discussion with data for trial of the potential for cellular and humoral immune reactivity against the heterologous rat CYP2B1 protein and potential for induction of autoimmune-mediated toxicities in our study population.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following provides a detailed summary of our
activities to have the clinical hold lifted:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stability Studies on Our Clinical Trial Product Candidate for Pancreatic Cancer</span>. We have successfully completed the required product stability studies. The timepoints were 3, 6, 9, 12, 18 and 24 months of our product candidate for pancreatic cancer being stored frozen at -80C. These studies included container closure integrity testing for certain timepoints.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Additional Studies Requested by the FDA</span>. We have successfully completed various additional studies requested by the FDA, including a stability study on the cells from our MCB used to make our CypCaps&#8482;. </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Determination of the Exact Sequence of the Cytochrome P450 2B1 Gene</span>. We have completed the determination of the exact sequence of the cytochrome P450 2B1 gene inserted at the site previously identified on chromosome 9 using state-of-the-art nanopore sequencing. This is a cutting edge, unique and scalable technology that permits real-time analysis of long DNA fragments. The result of this analysis of the sequence data confirmed that the genes are intact.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Confirmation of the Exact Sequence of the Cytochrome P450 2B1 Gene Insert</span>. An additional, more detailed analysis of the integration site of the cytochrome P450 2B1 gene from the augmented HEK293 cell clone that is used in our CypCaps&#8482; was found to be intact. In this new study, we were able to confirm the previously determined structure of the integrated transgene sequence using more data points. These studies also set the stage for a next step analysis to determine the genetic stability of the cytochrome P450 2B1 gene at the DNA level after multiple rounds of cell growth. This new study has been completed in which our original Research Cell Bank (&#8220;RCB&#8221;) cells were compared with cells from the MCB. The analysis confirmed that the cytochrome P450 2B1 and the surrounding sequence has remained stable with no changes detected at the DNA level.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Biocompatibility Studies</span>. We have been involved with 10 biocompatibility studies requested by the FDA, eight of which have been completed successfully. To enable the biocompatibility studies to be performed, we had Austrianova Singapore Pte. Ltd. (&#8220;Austrianova&#8221;) manufacture an additional 400 syringes of empty capsules.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Systemic Toxicity Testing</span>. We evaluated the potential toxicity of the capsule component of our product candidate for pancreatic cancer&#8204; and determined there is no evidence of toxicity in any of the parameters examined. The study also confirmed previous data that shows our capsule material is bioinert.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Micro-Compression and Swelling Testing</span>. This testing is underway. We are developing and optimizing two reproducible methods for testing and confirming the physical stability and integrity of our CypCaps&#8482; under extreme pressure. These studies required the acquisition of new equipment by Austrianova as well as validation and integration into Austrianova&#8217;s Quality Control laboratory.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Break Force and Glide Testing</span>. We are in the process of developing a protocol to measure whether the syringe, attached to the catheter when used to expel the capsules, will still have a break and glide force that is within the specifications we have established. We are setting the specifications based on the syringe/plunger manufacturer&#8217;s measured break and glide forces, or alternatively, accepted ranges for glide forces routinely used in the clinic.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Capsules Compatibility with the Syringe and Other Components of the Microcatheter Delivery System</span>. We are in the process of showing that CypCaps&#8482; are not in any way adversely affected by the catheters used by interventional radiologists to deliver them into a patient. Compatibility data is being generated to demonstrate that the quality of the CypCaps&#8482; is maintained after passage through the planned microcatheter systems.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">CypCaps Capsules and Cell Viability after Exposure to Contrast Medium</span>. We have commenced testing to show that exposure of CypCaps&#8482; to the contrast medium interventional radiologists &#8204;used to implant the CypCaps&#8482; in a patient has no adverse effect on CypCaps&#8482;. Contrast medium is used to visualize the blood vessels during implantation.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Master Drug File Information</span>. Austrianova is providing additional detailed confidential information on the manufacturing process, including information on the improvements and advancements made to our product candidate for pancreatic cancer since the last clinical trials were conducted with respect to reproducibility and safety. However, Austrianova has not changed the overall physical characteristics of CypCaps&#8482; between the 1st and 2nd generations.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Submission of Data to FDA</span>. We are in the process of providing these data to the FDA. The clinical hold did not reflect any deficiencies of the clinical trial proposed. We seek to resolve these non-clinical issues to enable FDA review of a new clinical protocol that reflects the standard of care for LAPC.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We assembled a scientific and regulatory team
of experts to address the FDA requests. Through January 31, 2026, our scientific consultants have been in active dialog with the FDA.
We have received communications from the FDA and responded, including the submission of the updated drug master file. The FDA accepted
the updated drug master file and cleared many of the clinical hold items. . We believe that the technology upon which the LAPC treatment
will be based, intra-arterial chemotherapy, has been used in five clinical trials in humans. Our position is that the data available from
these human clinical trials supersedes large animal study data, making the study unnecessry. The treatment may not be a treatment of pancreatic
cancer, but a method of improving and possibly enabling complete surgical resection of the tumor. We are waiting for the FDA&#8217;s responses
and hope the FDA will accept that the LAPC treatment now meets manufacturing standard requirements, which have significantly improved
since the clinical hold was first placed. The FDA may require additional preclinical studies when the meeting takes place. We are in ongoing
dialogue with SG Austria to prepare for the next steps, including the preparation of the syringes filled with the latest generation of
CypCaps&#8482; with the working cell bank material.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Performance Indicators </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Non-financial performance indicators used by management
to manage and assess how the business is progressing will include, but are not limited to, the ability to: (i) acquire appropriate funding
for all aspects of our operations; (ii) acquire and complete necessary contracts; (iii) complete activities for producing genetically
modified human cells and having them encapsulated for our preclinical studies and the planned clinical trial in LAPC; (iv) have regulatory
work completed to enable studies and trials to be submitted to regulatory agencies; (v) complete all required tests and studies on the
cells and capsules we plan to use in our clinical trial in patients with LAPC; (vi) ensure completion of the production of encapsulated
cells according to cGMP regulations to use in our planned clinical trial; (vii) complete all of the tasked the FDA requires of us in order
to have the clinical hold lifted; and (viii) obtain approval from the FDA to lift the clinical hold on our IND that we may commence our
planned clinical trial in LAPC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are numerous items required to be completed
successfully to ensure our final product candidate is ready for use in our planned clinical trial in LAPC. The effects of material transactions
with related parties, and certain other parties to the extent necessary for such an undertaking, may have substantial effects on both
the timeliness and success of our current and prospective financial position and operating results. Nonetheless, we are actively working
to ensure strong ties and interactions to minimize the inherent risks regarding success. We do not believe there are factors which will
cause materially different amounts to be reported than those presented in this Report. We aim to assess this regularly to provide accurate
information to our shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Developments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nasdaq Minimum Bid Price Requirement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 1, 2025, we received a written notice
(the &#8220;Notice&#8221;) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) indicating
that we are not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the &#8220;Bid Price
Rule&#8221;) for continued listing on The Nasdaq Capital Market. The Bid Price Rule requires listed securities to maintain a minimum bid
price of $1.00 per share, and, based on the closing bid price of our Common Stock for the 30 consecutive business days preceding the date
of the Notice, we no longer satisfy this requirement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Notice has no immediate effect on the listing
or trading of our Common Stock on The Nasdaq Capital Market, and our Common Stock will continue to trade under the symbol &#8220;PMCB.&#8221;
The Notice does not affect our business operations or our reporting obligations with the Securities and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with Nasdaq Listing Rule 5810(c)(3)(A),
we have been provided an initial period of 180 calendar days, or until June 1, 2026 (the &#8220;Compliance Date&#8221;), to regain compliance
with the Bid Price Rule. If at any time during this 180-day period the closing bid price of our Common Stock is at least $1.00 per share
for a minimum of 10 consecutive business days (or for such longer period as the Nasdaq staff may determine is necessary under Nasdaq Listing
Rule 5810(c)(3)(H)), Nasdaq will provide us with written confirmation of compliance, and the matter will be closed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we do not regain compliance by the Compliance
Date, we may be eligible for an additional 180-day compliance period if we (i) meet all applicable continued listing requirements for
initial listing on The Nasdaq Capital Market (other than the minimum bid price requirement) and (ii) provide Nasdaq with written notice
of our intention to cure the deficiency during the second compliance period, which may include effecting a reverse stock split, if necessary.
If we do not qualify for the second compliance period or fail to regain compliance during any additional compliance period granted, Nasdaq
will provide written notification to us that our securities are subject to delisting. In such event, we would be entitled to appeal Nasdaq&#8217;s
determination to a Nasdaq Hearings Panel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to actively monitor the closing bid
price of our Common Stock and will consider all available options to regain compliance with the Bid Price Rule, including, if appropriate,
implementing a reverse stock split, subject to stockholder approval. There can be no assurance that we will be able to regain or maintain
compliance with the Bid Price Rule or the other continued listing requirements of The Nasdaq Capital Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Three and nine months ended January 31, 2026, compared to three
and nine months ended January 31, 2025</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Revenue</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We had no revenues for the three and nine months ended January 31,
2026, and 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 36 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and development expenses</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">R&amp;D expense was $93,113 for the three months
ended January 31, 2026, as compared to $118,196 for the three months ended January 31, 2025, a decrease of $25,083. The change in cost
is primarily due to nonrecurring expenditures in our use of consultants to conduct research into the treatment of pancreatic cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">R&amp;D expense was $329,355 for the nine months
ended January 31, 2026, as compared to $311,682 for the nine months ended January 31, 2025, an increase of $17,673. The change in cost
is primarily due to our continued strategy utilizing consultants to conduct research into the treatment of pancreatic cancer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>General and administrative expenses</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses consist primarily
of costs associated with our overall operations and with being a public company. These costs include personnel, legal and professional
services, insurance, investor relations and compliance related fees. These expenses were $2,024,989 and $842,056, respectively, for the
three months ended January 31, 2026 and 2025, an increase of $1,182,933, or 141%. Stock-based compensation expenses increased by $880,130
primarily due to a restricted stock unit (&#8220;RSU&#8221;) granted to our CEO and directors, and investor relations and filing fees
increased by $48,741 due to stockholder meetings requiring more attempts to reach investors. Legal and professional fees increased by
$246,096 primarily due to an increase in consulting fees relating to capital raise costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses consist primarily
of costs associated with our overall operations and with being a public company. These costs include personnel, legal and professional
services, insurance, investor relations and compliance related fees. These expenses were $4,013,103 and $3,024,316, respectively, for
the nine months ended January 31, 2026 and 2025, an increase of $988,787, or 33%. Stock-based compensation expenses increased by $659,283
primarily due to an increase in RSU to our CEO and directors, and investor relations and filing fees increased by $138,035 due to stockholder
meetings in 2026 requiring more attempts to reach investors. Legal and professional fees increased by $198,256 primarily due to an increase
in consulting fees relating to non-recurring transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Other Income (Expenses), Net</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other income (expenses), net, for the three months
ended January 31, 2026 was $2,864,962 as compared to other income (expense), net of $(2,085,076) for the three months ended January 31,
2025. Other income (expenses), net, for the three months ended January 31, 2026 is attributable to interest income of $230,668, net of
changes in fair value of warrant liabilities of $1,895,865, a change in the fair value of derivative liability of $557,000, a change in
fair value of the Femasys warrant asset of $(214,000), a change in fair value of the QCLS investment of $1,725,000, a change in fair value
of the QCLS warrant assets of $(1,200,000), a change in the unrealized loss on marketable securities of $(128,939), and other expenses
of $(632). Other income (expenses), net, for the three months ended January 31, 2025, is attributable to interest income of $255,692,
changes in fair value of warrant liability of $4,487,000, a change in fair value of convertible note receivable of $(79,000), a change
in fair value of the Femasys warrant asset of $(596,000), a change in fair value of the QCLS investment of $(6,225,000), a change in the
unrealized gain marketable securities of $72,632 and a net of other expenses of $(400). The changes to the fair values are a result of
the updated inputs in the various calculations of fair values.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other income (expenses), net, for the nine months
ended January 31, 2026 was $(10,688,753) as compared to other income (expense), net of $22,242,466 for the nine months ended January 31,
2025. Other income (expenses), net, for the nine months ended January 31, 2026 is attributable to interest income of $654,848, net of
changes in fair value of warrant liabilities of $(8,335,135), a change in the fair value of derivative liability of $859,000, a gain on
the legal settlement revaluation of $106,000, a change in fair value of convertible note receivable of $1,304,000, a change in fair value
of the Femasys warrant asset of $(2,155,000), a change in fair value of the QCLS investment of $(3,485,000), a gain on related party investment
of $2,089,000, issuance costs on convertible preferred stock and warrants of $(1,234,553), a change in fair value of the QCLS warrant
assets of $18,000, a change in the unrealized loss on marketable securities of $(294,065), a loss on the issuance of convertible preferred
stock of $(215,000) and other expenses of $(848). Other income (expenses), net, for the nine months ended January 31, 2025, is attributable
to interest income of $1,185,686, changes in fair value of warrant liability of $8,400,000, derivative liability of $2,184,000, a change
in fair value of convertible note receivable of $601,000, a change in fair value of the Femasys warrant asset of $(1,830,000), a change
in fair value of the QCLS investment and warrant assets of $(9,765,734), a gain on related party investment of $21,395,734, a change in
the unrealized gain marketable securities of $72,632 net of other expenses of $(852). The changes to the fair values are a result of the
updated inputs in the various calculations of fair values.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Discussion of Operating, Investing and Financing
Activities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents a summary of our
sources and uses of cash for the nine months ended January 31, 2026, and 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Nine Months <br/> Ended<br/> January 31,<br/> 2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Nine Months <br/> Ended<br/> January 31,<br/> 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify">Net cash used in operating activities:</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(3,760,352</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(1,937,925</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net cash used in investing activities:</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(7,000,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Net cash used in financing activities:</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,751,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(24,857,608</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Effect of currency rate exchange</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,329</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(975</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Net increase (decrease) in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,993,372</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(33,796,508</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Operating Activities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cash and cash equivalents used in operating
activities for the nine months ended January 31, 2026 of $3,760,352 is mainly a result of the payment of $1,450,000 relating to the legal
settlement accrued at April 30, 2025 and our general and administrative expenses. The cash and cash equivalents used in operating activities
for the nine months ended January 31, 2025 of $1,937,925 is mainly a result of our general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Investing Activities</span>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cash and cash equivalents for the nine months
ended January 31, 2026 provided by investing activities is attributable to the collection of the Femasys note receivable in full in the
amount of $5,000,000 and our entry into a Securities Purchase Agreement (the &#8220;Series H SPA&#8221;) with QCLS (defined below). Pursuant
to the Series H SPA, the Company purchased (i) 3,000 shares of QCLS&#8217;s Series H Convertible Preferred Stock (the &#8220;Series H
Preferred Shares&#8221; or &#8220;Series H Preferred Stock&#8221;), at a stated value of $1,000 per Series H Preferred Share, with an
initial conversion price of $5.00 which were initially convertible into 600,000 shares of Common Stock; and (ii) warrants to purchase
up to 600,000 shares of QCLS Common Stock with a five-year term (&#8220;QCLS Series H Warrant&#8221;), for a total purchase price of $3,000,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cash and cash equivalents for the nine months
ended January 31, 2025, is attributable to our entry into a Securities Purchase Agreement (the &#8220;SPA&#8221;) with MyMD Pharmaceuticals,
Inc. which subsequently changed its name to TNF Pharmaceuticals, Inc., and then to Q/C Technologies, Inc., (&#8220;QCLS&#8221;) in conjunction
with a new focus on the development of energy-efficient computing infrastructure. Pursuant to the SPA, the Company purchased (i) 7,000
shares of QCLS&#8217;s Series G Convertible Preferred Stock (the &#8220;Series G Preferred Shares&#8221; or &#8220;Series G Preferred
Stock&#8221;) with an original conversion price of $1.816 per Series G Preferred Share, which were initially convertible into 3,854,626
shares of Common Stock (as defined below); (ii) warrants to purchase up to 3,854,626 shares of QCLS Common Stock with a five-year term
(&#8220;QCLS Series G Long-Term Warrant&#8221;); and (iii) warrants to purchase up to 3,854,626 shares of QCLS Common Stock with a 18-month
term (&#8220;QCLS Series G Short-Term Warrant&#8221;) (collectively, the &#8220;QCLS Series G Warrants&#8221;), for an aggregate purchase
price of $7,000,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 38 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Financing Activities</span>:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cash and cash equivalents provided by financing
activities for the nine months ended January 31, 2026 is attributable to our entry into a Securities Purchase Agreement pursuant to which
we sold investors in a private placement (the &#8220;Series C Private Placement&#8221;) (i) an aggregate of 7,000 shares of the Company&#8217;s
newly designated Series C convertible preferred stock, par value $0.0001, with a stated value of $1,000 per share (the &#8220;Series C
Preferred Stock&#8221;), initially convertible into up to 7,000,000 shares of the Company&#8217;s common stock, par value $0.0001 per
share at an initial conversion price of $1.00 and (ii) the Series C Warrants to purchase up to an aggregate of 7,000,000 shares of Common
Stock. Proceeds from the Series C Private Placement net of cash issuance costs totaled $6,268,866. Additionally, during the nine months
ended January 31, 2026, we paid investors $162,606 in dividends on the Series C Preferred Stock and we paid our directors $401,625 in
the form of RSUs granted to our directors for the estimated income tax effect of the grants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The cash and cash equivalents used in financing
activities for the nine months ended January 31, 2025 is mainly attributable to the repurchase of our Common Stock of approximately $2,370,733
and redemption of Series B Preferred Stock of approximately $22,486,875.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of January 31, 2026, we had approximately $20.2
million in cash and cash equivalents as compared to approximately $15.2 million at April 30, 2025. We expect that our current cash and
cash equivalents of approximately $19 million as of the filing of this Quarterly Report on Form 10-Q, will be sufficient to support its
projected operating requirements and financial commitments for at least the next twelve months from the date of this Quarterly Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2025, we entered into a securities purchase
agreement pursuant to which we agreed to sell to investors in a private placement an aggregate of 7,000 shares of our newly designated
Series C convertible preferred stock with a stated value of $1,000 per share and warrants to purchase up to 7 million shares of our Common
Stock, resulting in aggregate gross proceeds of $7 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2025, we entered into a securities
purchase agreement pursuant to which we agreed to purchase in a private placement QCLS Series H convertible preferred stock initially
convertible into 600,000 shares, subject to adjustment, of QCLS Common Stock and warrants for an aggregate purchase price of $3 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to need additional capital in order
to complete a clinical trial for the treatment of pancreatic cancer. If any additional equity financing, if available, may not be on favorable
terms and would likely be significantly dilutive to our current stockholders and debt financing, if available, may involve restrictive
covenants. If we are able to access funds through collaborative or licensing arrangements, it may be required to relinquish rights to
some of its product candidates that we would otherwise seek to develop or commercialize on its own, on terms that are not favorable to
us. Our ability to access capital is not assured and, if not achieved on a timely basis, will likely have a material adverse effect on
our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We operate in an industry that is subject to rapid
technological change, competition and government regulation. Our operations are subject to significant risk and uncertainties including
financial operational, technological, regulatory, and other risks. Such factors, include but not limited to, results of clinical testing
and trial activities, the ability to obtain regulatory approval, the supply of needed materials, the ability to obtain manufacturing and
the ability to raise capital to achieve strategic objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 39 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Service Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We entered into several service agreements, with
both independent and related parties, pursuant to which services will be provided over the next twelve months related to the clinical
hold on our IND submission involving LAPC. The services include developing studies and strategies relating to clearing the clinical hold.
The total cost is estimated to be approximately $591,000, of which the related party portion will be approximately $157,000. These agreements
are under review by our Business Review Committee and reconstituted Board which has curtailed spending on this program until their review
is complete and recommendations are made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Critical Accounting Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no material changes to our critical
accounting estimates from the information provided in Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations,&#8221; included in our Annual Report on Form 10-K for the year ended April 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Available Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our website is located at <span style="text-decoration: underline">www.PharmaCyte.com.</span>
In addition, all our filings submitted to the Commission, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current
Reports on Form 8-K and all our other reports and statements filed with the Commission are available on the Commission&#8217;s web site
at <span style="text-decoration: underline">www.sec.gov</span>. Such filings are also available for download free of charge on our website. The contents of the website are not,
and are not intended to be, incorporated by reference into this Quarterly Report or any other report or document filed with the Commission
or furnished by us, and any reference to the websites are intended to be inactive textual references only.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="k_011"></span>Item 3. Quantitative and Qualitative Disclosures
About Market Risk.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information called for by Item 3 is not required
for a smaller reporting company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="k_012"></span>Item 4. Controls and Procedures.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Evaluation of Disclosure Controls and Procedures</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Chairman, Chief Executive Officer,
and President, as our principal executive officer (&#8220;Chief Executive Officer&#8221;), and our Chief Financial Officer, as our principal
financial officer (&#8220;Chief Financial Officer&#8221;), evaluated the effectiveness of our &#8220;disclosure controls and procedures,&#8221;
as such term is defined in Rule 13a-15(e) promulgated under the Exchange Act. Disclosure controls and procedures are designed to ensure
that the information required to be disclosed in the reports that we file or submit to the Commission pursuant to the Exchange Act are
recorded, processed, summarized and reported within the period specified by the Commission&#8217;s rules and forms and are accumulated
and communicated to our management, including our Chief Executive Officer, as appropriate to allow timely decisions regarding required
disclosures. Based upon this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of January
31, 2026, certain of our disclosure controls and procedures were not effective due to the material weaknesses in internal control over
financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reference should be made to our Form 10-K filed
with the Commission on August 11, 2025, for additional information regarding discussion of the effectiveness of the Company&#8217;s control
and procedures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 40 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A control system, no matter how well conceived
and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design
of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative
to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that
all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities
that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Also, controls can be
circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The
design of any system of controls is also based in part upon certain assumptions about the likelihood of future events. There can be no
assurance that any design will succeed in achieving its stated goals under all potential future conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in Internal Controls over Financial
Reporting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no changes to our internal control
over financial reporting during the nine months ended January 31, 2026, that have materially affected, or are reasonably likely to materially
affect, our internal controls over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the January 31, 2026 reporting
process, management identified two ongoing material weaknesses related to the Company&#8217;s internal controls: insufficient segregation
of duties of our Chief Financial Officer and insufficient management review controls.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Certifications of our Chief Executive Officer
and Chief Financial Officer required in accordance with Rule 13a-14(a) under the Exchange Act and Section 302 of the Sarbanes-Oxley Act
of 2002 (&#8220;Certifications&#8221;) are attached to this Quarterly Report. The disclosures set forth in this Item 4 contain information
concerning: (i) the evaluation of our disclosure controls and procedures, and changes in internal control over financial reporting, referred
to in paragraph 4 of the Certifications; and (ii) material weaknesses in the design or operation of our internal control over financial
reporting, referred to in paragraph 5 of the Certifications. The Certifications should be read in conjunction with this Item 4 for a more
complete understanding of the matters covered by the Certifications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 41 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="k_013"></span>PART II &#8211; OTHER INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="k_014"></span>Item 1. Legal Proceedings.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we are subject to legal proceedings
and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be
predicted with certainty, we do not believe that the outcome of any pending claims will have a material adverse effect on our financial
condition or operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="k_015"></span>Item 1A. Risk Factors.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should consider the risks and uncertainties
described under Item 1A of Part I of our Annual Report on Form 10-K for the fiscal year ended April 30, 2025, which we filed with the
Securities and Exchange Commission on August 11, 2025, together with all other information contained or incorporated by reference in this
Quarterly Report on Form 10-Q, when evaluating our business and our prospects. The risks and uncertainties that we face are not limited
to those set forth in the Annual Report on 10-K. Additional risks and uncertainties not presently known to us or that we currently believe
to be immaterial may also adversely affect our business and the trading price of our securities. There are no material changes to the&#160;risk&#160;factors&#160;set
forth in Part I, Item 1A, in our Annual Report on Form 10-K for the year ended April 30, 2025, except as described below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nasdaq may delist our securities from trading
on its exchange, which could limit investors&#8217; ability to make transactions in our securities and subject us to additional trading
restrictions</i>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 1, 2025, we received a letter from
The Nasdaq Stock Market (&#8220;Nasdaq&#8221;) notifying us that for the preceding 30 consecutive business days our Common Stock did not
maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the &#8220;Minimum Bid Price Requirement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with Nasdaq Listing Rule 5810(c)(3)(A),
we have a grace period of 180 calendar days, or until June 1, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2). Compliance
can be achieved automatically and without further action if the closing bid price of our Common Stock is at or above $1.00 for a minimum
of 10 consecutive business days at any time during the 180-day compliance period, in which case Nasdaq will notify us of our compliance
and the matter will be closed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If, however, we do not achieve compliance with
the Minimum Bid Price Requirement by June 1, 2026, we may be eligible for additional time to comply. In order to be eligible for such
additional time, we will be required to meet the continued listing requirement for market value of publicly held shares and all other
initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and must notify Nasdaq
in writing of our intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary.
However, if it appears to Nasdaq that we will not be able to cure the deficiency, or if we are otherwise not eligible, Nasdaq will provide
notice that our Common Stock will be subject to delisting. We would then be entitled to appeal that determination to a Nasdaq hearings
panel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should we fail to satisfy additional continued
listing requirements, such as the corporate governance requirements or the Minimum Bid Price Requirement, Nasdaq may take steps to delist
our Common Stock. Such a delisting would likely have a negative effect on the price of our Common Stock, and would impair your ability
to sell or purchase our Common Stock when you wish to do so. In the event of a delisting, we would take actions to restore our compliance
with Nasdaq&#8217;s listing requirements, but we can provide no assurance that any such action taken by us would allow our Common Stock
to become listed again, stabilize the market price or improve the liquidity of our Common Stock, prevent our Common Stock from dropping
below Nasdaq&#8217;s Minimum Bid Price Requirement or prevent future non-compliance with the Nasdaq&#8217;s listing requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 42 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If Nasdaq does not maintain the listing of our
securities for trading on its exchange, we could face significant material adverse consequences, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 48px">&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a limited availability of market quotations for our Common Stock;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced liquidity for our Common Stock;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a determination that our Common Stock is a &#8220;penny stock&#8221; which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a limited amount of news and analyst coverage; and</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a decreased ability to issue additional Common Stock or obtain additional financing in the future.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="k_016"></span>Item 2. Unregistered Sales of Equity Securities
and Use of Proceeds.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="k_017"></span>Item 3. Defaults Upon Senior Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="k_018"></span>Item 4. Mine Safety Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 43 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="k_019"></span>Item 5. Other Information.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">During the
three months ended January 31, 2026, no director or officer of the Company <span id="xdx_902_eecd--Rule10b51ArrAdoptedFlag_dbF_c20251101__20260131_z3IY8iXQF9Uf" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_904_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20251101__20260131_zARoKDgevq9c" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-11-012026-01-31" format="ixt:booleanfalse" id="Fact002011" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2025-11-012026-01-31" format="ixt:booleanfalse" id="Fact002012" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span> or <span id="xdx_90D_eecd--Rule10b51ArrTrmntdFlag_dbF_c20251101__20260131_zPFSPl8WXid" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90E_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20251101__20260131_zZXTPKP99Ynd" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-11-012026-01-31" format="ixt:booleanfalse" id="Fact002013" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2025-11-012026-01-31" format="ixt:booleanfalse" id="Fact002014" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> a &#8220;Rule 10b5-1 trading arrangement&#8221;
or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span id="k_020"></span>Item 6. Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 53%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Location</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="pharmacyte_ex3101.htm">Principal Executive Officer Certification required by Rules 13a-14 and 15d-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="pharmacyte_ex3102.htm">Principal Financial Officer Certification required by Rules 13a-14 and 15d-14 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="pharmacyte_ex3201.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002</a></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished herewith</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="pharmacyte_ex3202.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002</a></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished herewith</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 89%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document </span></td></tr>
  <tr>
    <td style="white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted in Inline XBRL and included in exhibit 101).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Indicates a management contract, compensation
plan, or arrangement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 44 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="k_021"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned thereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>PharmaCyte Biotech, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 17, 2026</span></td>
    <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: <span style="text-decoration: underline">/s/ Joshua N. Silverman&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua N. Silverman</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 17, 2026</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: <span style="text-decoration: underline">/s/ Carlos A. Trujillo&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carlos A. Trujillo</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer and Principal Accounting Officer)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 45; Options: Last -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>pharmacyte_ex3101.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULES 13A-14(A) AND 15D-15(A) UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Joshua N. Silverman, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
have reviewed the Quarterly Report on Form 10-Q of PharmaCyte Biotech, Inc. (&ldquo;Report&rdquo;) and its subsidiaries for the period
ended January 31, 2026;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this Report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this Report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluated
the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this Report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosed
in this Report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s Board of Directors (or persons performing
the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal
control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 57%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March 17, 2026</FONT></TD>
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 41%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ Joshua N. Silverman&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Joshua N. Silverman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title: Chief Executive Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Principal Executive Officer)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>pharmacyte_ex3102.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULES 13A-14(A) AND 15D-15(A) UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Carlos A. Trujillo, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I
have reviewed the Quarterly Report on Form 10-Q of PharmaCyte Biotech, Inc. (&ldquo;Report&rdquo;) and its subsidiaries for the period
ended January 31, 2026;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this Report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects
the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this Report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluated
the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this Report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosed
in this Report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s Board of Directors (or persons performing
the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal
control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 57%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March 17, 2026</FONT></TD>
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 41%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ Carlos A. Trujillo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Carlos A. Trujillo</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title: Chief Financial Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Financial and Principal Accounting Officer)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>pharmacyte_ex3201.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to section 906 of the Sarbanes-Oxley
Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of PharmaCyte
Biotech, Inc., a Nevada corporation (the &ldquo;Company&rdquo;), does hereby certify, to such officer&rsquo;s knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Quarterly Report for the quarter ended January
31, 2026 (the &ldquo;Form 10-Q&rdquo;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition
and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 57%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March 17, 2026</FONT></TD>
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 41%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ Joshua N. Silverman&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Joshua N. Silverman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title: Chief Executive Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Principal Executive Officer)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This exhibit shall not be deemed &ldquo;filed&rdquo;
with the Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended,
or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general
incorporation language contained in such filing; however, it is instead furnished as provided by applicable rules of the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>pharmacyte_ex3202.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to section 906 of the Sarbanes-Oxley
Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of PharmaCyte
Biotech, Inc., a Nevada corporation (the &ldquo;Company&rdquo;), does hereby certify, to such officer&rsquo;s knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Quarterly Report for the quarter ended January
31, 2026 (the &ldquo;Form 10-Q&rdquo;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition
and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 57%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: March 17, 2026</FONT></TD>
    <TD STYLE="width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 41%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ Carlos A. Trujillo&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Carlos A. Trujillo</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title: Chief Financial Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Principal Financial and Principal Accounting
    Officer)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This exhibit shall not be deemed &ldquo;filed&rdquo;
with the Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended,
or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general
incorporation language contained in such filing; however, it is instead furnished as provided by applicable rules of the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>pmcb-20260131.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOaODWaPty552aYkxvmR5fbkqLycvHZiNmCb4e3s2gbkO -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:srt-types="http://fasb.org/srt-types/2026" xmlns:ecd="http://xbrl.sec.gov/ecd/2026" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:PMCB="http://pharmacyte.com/20260131" elementFormDefault="qualified" targetNamespace="http://pharmacyte.com/20260131">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://pharmacyte.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
          <link:definition>00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
          <link:definition>00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" id="CondensedConsolidatedStatementsOfComprehensiveIncomeLoss">
          <link:definition>00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity" id="CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity">
          <link:definition>00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS' EQUITY (UNAUDITED)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
          <link:definition>00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/NatureOfBusiness" id="NatureOfBusiness">
          <link:definition>999013 - Disclosure - NATURE OF BUSINESS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/LiquidityAndOtherUncertainties" id="LiquidityAndOtherUncertainties">
          <link:definition>999014 - Disclosure - LIQUIDITY AND OTHER UNCERTAINTIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecurities" id="InvestmentInDebtAndEquitySecurities">
          <link:definition>999016 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/AccruedExpenses" id="AccruedExpenses">
          <link:definition>999017 - Disclosure - ACCRUED EXPENSES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/StockOptionsAndWarrants" id="StockOptionsAndWarrants">
          <link:definition>999018 - Disclosure - STOCK OPTIONS AND WARRANTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/OtherRelatedPartyTransactions" id="OtherRelatedPartyTransactions">
          <link:definition>999019 - Disclosure - OTHER RELATED PARTY TRANSACTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999020 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/EarningsPerShare" id="EarningsPerShare">
          <link:definition>999021 - Disclosure - EARNINGS PER SHARE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/PreferredStock" id="PreferredStock">
          <link:definition>999022 - Disclosure - PREFERRED STOCK</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/TreasuryStock" id="TreasuryStock">
          <link:definition>999023 - Disclosure - TREASURY STOCK</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/FairValueMeasurements" id="FairValueMeasurements">
          <link:definition>999024 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables" id="InvestmentInDebtAndEquitySecuritiesTables">
          <link:definition>999026 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
          <link:definition>999027 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsTables" id="StockOptionsAndWarrantsTables">
          <link:definition>999028 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/EarningsPerShareTables" id="EarningsPerShareTables">
          <link:definition>999029 - Disclosure - EARNINGS PER SHARE (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
          <link:definition>999030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative" id="LiquidityAndOtherUncertaintiesDetailsNarrative">
          <link:definition>999031 - Disclosure - LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants" id="InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants">
          <link:definition>999033 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Femasys Note and warrants)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities" id="InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities">
          <link:definition>999034 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Marketable securities)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants" id="InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants">
          <link:definition>999035 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series G Preferred Stock and Preferred Stock Warrants)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants" id="InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants">
          <link:definition>999036 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series H Preferred Stock and Preferred Stock Warrants)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative" id="InvestmentInDebtAndEquitySecuritiesDetailsNarrative">
          <link:definition>999037 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/AccruedExpensesDetails" id="AccruedExpensesDetails">
          <link:definition>999038 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/AccruedExpensesDetailsDefOnly" id="AccruedExpensesDetailsDefOnly">
          <link:definition>999038 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity" id="StockOptionsAndWarrantsDetails-OptionActivity">
          <link:definition>999039 - Disclosure - STOCK OPTIONS AND WARRANTS (Details - Option activity)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity" id="StockOptionsAndWarrantsDetails-WarrantActivity">
          <link:definition>999040 - Disclosure - STOCK OPTIONS AND WARRANTS (Details - Warrant activity)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative" id="StockOptionsAndWarrantsDetailsNarrative">
          <link:definition>999041 - Disclosure - STOCK OPTIONS AND WARRANTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative" id="OtherRelatedPartyTransactionsDetailsNarrative">
          <link:definition>999042 - Disclosure - OTHER RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation" id="EarningsPerShareDetails-PerShareCalculation">
          <link:definition>999044 - Disclosure - EARNINGS PER SHARE (Details - Per share calculation)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares" id="EarningsPerShareDetails-DilutedShares">
          <link:definition>999045 - Disclosure - EARNINGS PER SHARE (Details - Diluted shares)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/PreferredStockDetailsNarrative" id="PreferredStockDetailsNarrative">
          <link:definition>999046 - Disclosure - PREFERRED STOCK (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/TreasuryStockDetailsNarrative" id="TreasuryStockDetailsNarrative">
          <link:definition>999047 - Disclosure - TREASURY STOCK (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue" id="FairValueMeasurementsDetails-FairValue">
          <link:definition>999048 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair value)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability" id="FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability">
          <link:definition>999049 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of warrant liability)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability" id="FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability">
          <link:definition>999050 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of derivative liability)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments" id="FairValueMeasurementsDetails-FairValuesOfFinancialInstruments">
          <link:definition>999051 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair values of financial instruments)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="pmcb-20260131_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="pmcb-20260131_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="pmcb-20260131_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="pmcb-20260131_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2026" schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd" />
    <import namespace="http://fasb.org/us-gaap/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd" />
    <import namespace="http://fasb.org/us-types/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2026" schemaLocation="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2026" schemaLocation="https://xbrl.sec.gov/country/2026/country-2026.xsd" />
    <import namespace="http://fasb.org/srt/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd" />
    <import namespace="http://fasb.org/srt-types/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd" />
    <element id="PMCB_PreferredStockSeriesBMember" name="PreferredStockSeriesBMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_PreferredStockSeriesCMember" name="PreferredStockSeriesCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ContingentlyRedeemableWarrantsMember" name="ContingentlyRedeemableWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_QCLSSeriesHConvertiblePreferredStockMember" name="QCLSSeriesHConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_FemasysPurchaseAgreementMember" name="FemasysPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_FemasysNoteMember" name="FemasysNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_FemasysMember" name="FemasysMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_FemasysCommonStockMember" name="FemasysCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_FemasysSeriesAWarrantsMember" name="FemasysSeriesAWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_FemasysWarrantsMember" name="FemasysWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_QCLSMember" name="QCLSMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_LongTermWarrantMember" name="LongTermWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ShortTermWarrantMember" name="ShortTermWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_QCLSAccruedDividendReceivableMember" name="QCLSAccruedDividendReceivableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_QCLSSeriesGPreferredStockMember" name="QCLSSeriesGPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SeriesGWarrantsMember" name="SeriesGWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_QCLSSeriesHWarrantMember" name="QCLSSeriesHWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_QCLSCommonStockMember" name="QCLSCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_QCLSSeriesHPreferredStockMember" name="QCLSSeriesHPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_MeasurementRedemptionPremiumMember" name="MeasurementRedemptionPremiumMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_MeasurementInputMarketInterestRateMember" name="MeasurementInputMarketInterestRateMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_QCLSSecuritiesPurchaseAgreementMember" name="QCLSSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_MeasurementInputRedemptionPremiumMember" name="MeasurementInputRedemptionPremiumMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_QCLSSeriesHWarrantsMember" name="QCLSSeriesHWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_FemasysNotesMember" name="FemasysNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_QCLSSeriesGWarrantsMember" name="QCLSSeriesGWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_PayrollRelatedCostsMember" name="PayrollRelatedCostsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_DirectorFeesMember" name="DirectorFeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_RAndDCostsMember" name="RAndDCostsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_LegalSettlementMember" name="LegalSettlementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ExciseTaxOnStockRepurchasesMember" name="ExciseTaxOnStockRepurchasesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_LongTermPortionOfLegalSettlementMember" name="LongTermPortionOfLegalSettlementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_EquityPlan2021Member" name="EquityPlan2021Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_EquityPlan2022Member" name="EquityPlan2022Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SeriesBPreferredWarrantsMember" name="SeriesBPreferredWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SettlementAgreementMember" name="SettlementAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_FirstWarrantIssuanceMember" name="FirstWarrantIssuanceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SettlementWarrantsMember" name="SettlementWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_AdditionalWarrantsMember" name="AdditionalWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SeriesCPrivatePlacementAgreementMember" name="SeriesCPrivatePlacementAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SeriesCPreferredWarrantsMember" name="SeriesCPreferredWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SeriesCPlacementAgentWarrantsMember" name="SeriesCPlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SeriesBWarrantsAndSettlementWarrantsAdjustedMember" name="SeriesBWarrantsAndSettlementWarrantsAdjustedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SGAustraliaMember" name="SGAustraliaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_VinDeBonaMember" name="VinDeBonaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SGAustriaAndSubsidiariesMember" name="SGAustriaAndSubsidiariesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_HCWainwrightMember" name="HCWainwrightMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_OptionsMember" name="OptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_PreferredSharesMember" name="PreferredSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SeriesCPurchaseAgreementMember" name="SeriesCPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SeriesCWarrantsMember" name="SeriesCWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_DerivativeLiabilityMember" name="DerivativeLiabilityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_WarrantLiabilityMember" name="WarrantLiabilityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_MarketableEquitySecuritiesMember" name="MarketableEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_MoneyMarketAccountMember" name="MoneyMarketAccountMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ConvertibleNoteReceivableMember" name="ConvertibleNoteReceivableMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_WarrantAssetFemasysMember" name="WarrantAssetFemasysMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_InvestmentInPreferredStockQCLSMember" name="InvestmentInPreferredStockQCLSMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_WarrantAssetQCLSMember" name="WarrantAssetQCLSMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_WarrantAssetCurrent" name="WarrantAssetCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ConvertibleNoteReceivableCurrent" name="ConvertibleNoteReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_WarrantAssetNoncurrent" name="WarrantAssetNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_WarrantAssetFemasys" name="WarrantAssetFemasys" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_WarrantLiabilitiesNoncurrent" name="WarrantLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ContingentlyRedeemableWarrants" name="ContingentlyRedeemableWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_TotalTemporaryEquity" name="TotalTemporaryEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ChangeInFairValueOfWarrantLiability" name="ChangeInFairValueOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ChangeInFairValueOfDerivativeLiability" name="ChangeInFairValueOfDerivativeLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ChangeInFairValueOfConvertibleNoteReceivable" name="ChangeInFairValueOfConvertibleNoteReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ChangeInFairValueOfWarrantAssetFemasys" name="ChangeInFairValueOfWarrantAssetFemasys" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ChangeInFairValueOfInvestment" name="ChangeInFairValueOfInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ChangeInFairValueOfWarrantAsset" name="ChangeInFairValueOfWarrantAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_GainOnFairValueOfWarrantsWainwright" name="GainOnFairValueOfWarrantsWainwright" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_GainOnRelatedPartyInvestmentQcls" name="GainOnRelatedPartyInvestmentQcls" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants" name="IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_LossOnIssuanceOfSeriesCConvertiblePreferredStock" name="LossOnIssuanceOfSeriesCConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_FractionalSharesAdjustmentValue" name="FractionalSharesAdjustmentValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_FractionalSharesAdjustmentShares" name="FractionalSharesAdjustmentShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_StockIssuedUponVestingOfRestrictedStockUnits" name="StockIssuedUponVestingOfRestrictedStockUnits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_StockIssuedUponVestingOfRestrictedStockUnitsShares" name="StockIssuedUponVestingOfRestrictedStockUnitsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_IssuanceOfSeriesCPreferredStockAndWarrants" name="IssuanceOfSeriesCPreferredStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_IssuanceOfSeriesCPreferredStockAndWarrantsShares" name="IssuanceOfSeriesCPreferredStockAndWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SeriesCPreferredStockAccretion" name="SeriesCPreferredStockAccretion" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SeriesCPreferredStockDividendSubjectToSettlement" name="SeriesCPreferredStockDividendSubjectToSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SeriesCPreferredStockDividendsAccrual" name="SeriesCPreferredStockDividendsAccrual" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_PreferredStockAccretion" name="PreferredStockAccretion" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SeriesCPreferredStockRedeemed" name="SeriesCPreferredStockRedeemed" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SeriesCPreferredStockRedeemedShares" name="SeriesCPreferredStockRedeemedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SeriesCPreferredStockSubjectToSettlement" name="SeriesCPreferredStockSubjectToSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SeriesBPreferredStockSubjectToRedemption" name="SeriesBPreferredStockSubjectToRedemption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SeriesBPreferredStockRedeemedShares" name="SeriesBPreferredStockRedeemedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SeriesBPreferredStockRedemption" name="SeriesBPreferredStockRedemption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SeriesBPreferredStockSubjectToRedemptionShares" name="SeriesBPreferredStockSubjectToRedemptionShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_IssuanceCostsSeriesCPreferredStockAndWarrants" name="IssuanceCostsSeriesCPreferredStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_LossOnIssuanceOfSeriesCPreferredStock" name="LossOnIssuanceOfSeriesCPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_GainOnFairValueOfWarrants" name="GainOnFairValueOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_NoncashInterestIncome" name="NoncashInterestIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_StockbasedCompensationOptions" name="StockbasedCompensationOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ChangeInFairValueOfConvertibleNotesReceivable" name="ChangeInFairValueOfConvertibleNotesReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ChangeInFairValueOfInvestmentQcls" name="ChangeInFairValueOfInvestmentQcls" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ChangeInFairValueOfWarrantsQcls" name="ChangeInFairValueOfWarrantsQcls" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ProceedsFromInvestmentNoteReceivable" name="ProceedsFromInvestmentNoteReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_InvestmentInPreferredStockAndWarrantsInQcls" name="InvestmentInPreferredStockAndWarrantsInQcls" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_RedemptionOfPreferredStock" name="RedemptionOfPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_PaymentOfSeriesCConvertiblePreferredStockDividends" name="PaymentOfSeriesCConvertiblePreferredStockDividends" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability" name="ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock" name="AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_AccrualOfSeriesCConvertiblePreferredStockDividends" name="AccrualOfSeriesCConvertiblePreferredStockDividends" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts" name="AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock" name="AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_InitialFairValueOfInvestmentInQclsSeriesHPreferredShares" name="InitialFairValueOfInvestmentInQclsSeriesHPreferredShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_InitialFairValueOfInvestmentInQclsSeriesHWarrants" name="InitialFairValueOfInvestmentInQclsSeriesHWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_NoncashDerivativeLiabilityAtInitialFairValue" name="NoncashDerivativeLiabilityAtInitialFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_NoncashWarrantLiabilityAtInitialFairValue" name="NoncashWarrantLiabilityAtInitialFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_NoncashRedemptionOfSeriesCConvertiblePreferredStock" name="NoncashRedemptionOfSeriesCConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ChangeInFairValueAssociatedWarrantExercises" name="ChangeInFairValueAssociatedWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_FairValueOfContingentlyRedeemablePlacementAgentWarrants" name="FairValueOfContingentlyRedeemablePlacementAgentWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ExciseTaxAccruedOnRepurchaseOfCommonStock" name="ExciseTaxAccruedOnRepurchaseOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_DisclosureLiquidityAndOtherUncertaintiesAbstract" name="DisclosureLiquidityAndOtherUncertaintiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_LiquidityAndOtherUncertainitiesTextBlock" name="LiquidityAndOtherUncertainitiesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_DisclosureTable" name="DisclosureTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="PMCB_DisclosureLineElements" name="DisclosureLineElements" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ReceivableInstrumentConvertibleConversionPrice1" name="ReceivableInstrumentConvertibleConversionPrice1" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_InvestmentSharesAddition" name="InvestmentSharesAddition" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_SettlementOfAccruedInterest" name="SettlementOfAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_WarrantsIssuedShares" name="WarrantsIssuedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_WarrantExercised" name="WarrantExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_WeightedAverageExercisePriceWarrantsExercised" name="WeightedAverageExercisePriceWarrantsExercised" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_WarrantsExpired" name="WarrantsExpired" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_WeightedAverageExercisePriceWarrantsExpired" name="WeightedAverageExercisePriceWarrantsExpired" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_WarrantsExercisable" name="WarrantsExercisable" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_WeightedAverageExercisePriceWarrantsExercisable" name="WeightedAverageExercisePriceWarrantsExercisable" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_IssuanceFairValues" name="IssuanceFairValues" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ConvertiblePreferredStockDividends" name="ConvertiblePreferredStockDividends" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_LessAllocationOfUndistributedIncome" name="LessAllocationOfUndistributedIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_PreferredStockParValuePerShare" name="PreferredStockParValuePerShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_PreferredStockStatedValuePerShare" name="PreferredStockStatedValuePerShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_PlacementAgentFeePercentage" name="PlacementAgentFeePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_PreferredStockDiscount" name="PreferredStockDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_FairValueEmbeddedDerivative" name="FairValueEmbeddedDerivative" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_WarrantLiabilityFairValue" name="WarrantLiabilityFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_DeemedDividend" name="DeemedDividend" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_ChangeInFairValueDerivativeLiability" name="ChangeInFairValueDerivativeLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_WarrantExercises" name="WarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="PMCB_IssuanceOfSeriesCConvertiblePreferredStock" name="IssuanceOfSeriesCConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>pmcb-20260131_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#Cover" roleURI="http://pharmacyte.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity" roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#NatureOfBusiness" roleURI="http://pharmacyte.com/role/NatureOfBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#LiquidityAndOtherUncertainties" roleURI="http://pharmacyte.com/role/LiquidityAndOtherUncertainties" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://pharmacyte.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecurities" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecurities" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#AccruedExpenses" roleURI="http://pharmacyte.com/role/AccruedExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#StockOptionsAndWarrants" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrants" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#OtherRelatedPartyTransactions" roleURI="http://pharmacyte.com/role/OtherRelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CommitmentsAndContingencies" roleURI="http://pharmacyte.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#EarningsPerShare" roleURI="http://pharmacyte.com/role/EarningsPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#PreferredStock" roleURI="http://pharmacyte.com/role/PreferredStock" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#TreasuryStock" roleURI="http://pharmacyte.com/role/TreasuryStock" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#FairValueMeasurements" roleURI="http://pharmacyte.com/role/FairValueMeasurements" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecuritiesTables" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#AccruedExpensesTables" roleURI="http://pharmacyte.com/role/AccruedExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#StockOptionsAndWarrantsTables" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#EarningsPerShareTables" roleURI="http://pharmacyte.com/role/EarningsPerShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#FairValueMeasurementsTables" roleURI="http://pharmacyte.com/role/FairValueMeasurementsTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#LiquidityAndOtherUncertaintiesDetailsNarrative" roleURI="http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecuritiesDetailsNarrative" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#AccruedExpensesDetails" roleURI="http://pharmacyte.com/role/AccruedExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#StockOptionsAndWarrantsDetails-OptionActivity" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#StockOptionsAndWarrantsDetails-WarrantActivity" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#StockOptionsAndWarrantsDetailsNarrative" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#OtherRelatedPartyTransactionsDetailsNarrative" roleURI="http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#EarningsPerShareDetails-PerShareCalculation" roleURI="http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#EarningsPerShareDetails-DilutedShares" roleURI="http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#PreferredStockDetailsNarrative" roleURI="http://pharmacyte.com/role/PreferredStockDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#TreasuryStockDetailsNarrative" roleURI="http://pharmacyte.com/role/TreasuryStockDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#FairValueMeasurementsDetails-FairValue" roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability" roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability" roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#FairValueMeasurementsDetails-FairValuesOfFinancialInstruments" roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetCurrent" xlink:label="loc_PMCBWarrantAssetCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_PMCBWarrantAssetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ConvertibleNoteReceivableCurrent" xlink:label="loc_PMCBConvertibleNoteReceivableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_PMCBConvertibleNoteReceivableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:label="loc_us-gaapInvestmentsAndOtherNoncurrentAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapInvestmentsAndOtherNoncurrentAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetNoncurrent" xlink:label="loc_PMCBWarrantAssetNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_PMCBWarrantAssetNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetFemasys" xlink:label="loc_PMCBWarrantAssetFemasys" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_PMCBWarrantAssetFemasys" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaapDividendsPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDividendsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilities" xlink:to="loc_us-gaapOtherAccruedLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantLiabilitiesNoncurrent" xlink:label="loc_PMCBWarrantLiabilitiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilities" xlink:to="loc_PMCBWarrantLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilities" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_TotalTemporaryEquity" xlink:label="loc_PMCBTotalTemporaryEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PMCBTotalTemporaryEquity" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ContingentlyRedeemableWarrants" xlink:label="loc_PMCBContingentlyRedeemableWarrants" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PMCBTotalTemporaryEquity" xlink:to="loc_PMCBContingentlyRedeemableWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="loc_us-gaapTreasuryStockCommonValue" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockCommonValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_PMCBTotalTemporaryEquity" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantLiability" xlink:label="loc_PMCBChangeInFairValueOfWarrantLiability" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_PMCBChangeInFairValueOfWarrantLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_PMCBChangeInFairValueOfDerivativeLiability" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_PMCBChangeInFairValueOfDerivativeLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfConvertibleNoteReceivable" xlink:label="loc_PMCBChangeInFairValueOfConvertibleNoteReceivable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_PMCBChangeInFairValueOfConvertibleNoteReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantAssetFemasys" xlink:label="loc_PMCBChangeInFairValueOfWarrantAssetFemasys" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_PMCBChangeInFairValueOfWarrantAssetFemasys" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfInvestment" xlink:label="loc_PMCBChangeInFairValueOfInvestment" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_PMCBChangeInFairValueOfInvestment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantAsset" xlink:label="loc_PMCBChangeInFairValueOfWarrantAsset" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_PMCBChangeInFairValueOfWarrantAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_GainOnFairValueOfWarrantsWainwright" xlink:label="loc_PMCBGainOnFairValueOfWarrantsWainwright" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_PMCBGainOnFairValueOfWarrantsWainwright" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_GainOnRelatedPartyInvestmentQcls" xlink:label="loc_PMCBGainOnRelatedPartyInvestmentQcls" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_PMCBGainOnRelatedPartyInvestmentQcls" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants" xlink:label="loc_PMCBIssuanceCostsSeriesCConvertiblePreferredStockAndWarrants" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_PMCBIssuanceCostsSeriesCConvertiblePreferredStockAndWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LossOnIssuanceOfSeriesCConvertiblePreferredStock" xlink:label="loc_PMCBLossOnIssuanceOfSeriesCConvertiblePreferredStock" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_PMCBLossOnIssuanceOfSeriesCConvertiblePreferredStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="loc_us-gaapPreferredStockAccretionOfRedemptionDiscount" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapPreferredStockAccretionOfRedemptionDiscount" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity" xlink:title="00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS&apos; EQUITY (UNAUDITED)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_GainOnRelatedPartyInvestmentQcls" xlink:label="loc_PMCBGainOnRelatedPartyInvestmentQcls" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBGainOnRelatedPartyInvestmentQcls" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_IssuanceCostsSeriesCPreferredStockAndWarrants" xlink:label="loc_PMCBIssuanceCostsSeriesCPreferredStockAndWarrants" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBIssuanceCostsSeriesCPreferredStockAndWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LossOnIssuanceOfSeriesCPreferredStock" xlink:label="loc_PMCBLossOnIssuanceOfSeriesCPreferredStock" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBLossOnIssuanceOfSeriesCPreferredStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_GainOnFairValueOfWarrants" xlink:label="loc_PMCBGainOnFairValueOfWarrants" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBGainOnFairValueOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_NoncashInterestIncome" xlink:label="loc_PMCBNoncashInterestIncome" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBNoncashInterestIncome" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_StockbasedCompensationOptions" xlink:label="loc_PMCBStockbasedCompensationOptions" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBStockbasedCompensationOptions" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantLiability" xlink:label="loc_PMCBChangeInFairValueOfWarrantLiability" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBChangeInFairValueOfWarrantLiability" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_PMCBChangeInFairValueOfDerivativeLiability" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBChangeInFairValueOfDerivativeLiability" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfConvertibleNotesReceivable" xlink:label="loc_PMCBChangeInFairValueOfConvertibleNotesReceivable" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBChangeInFairValueOfConvertibleNotesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantAssetFemasys" xlink:label="loc_PMCBChangeInFairValueOfWarrantAssetFemasys" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBChangeInFairValueOfWarrantAssetFemasys" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfInvestmentQcls" xlink:label="loc_PMCBChangeInFairValueOfInvestmentQcls" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBChangeInFairValueOfInvestmentQcls" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantsQcls" xlink:label="loc_PMCBChangeInFairValueOfWarrantsQcls" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PMCBChangeInFairValueOfWarrantsQcls" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ProceedsFromInvestmentNoteReceivable" xlink:label="loc_PMCBProceedsFromInvestmentNoteReceivable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PMCBProceedsFromInvestmentNoteReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_InvestmentInPreferredStockAndWarrantsInQcls" xlink:label="loc_PMCBInvestmentInPreferredStockAndWarrantsInQcls" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PMCBInvestmentInPreferredStockAndWarrantsInQcls" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_RedemptionOfPreferredStock" xlink:label="loc_PMCBRedemptionOfPreferredStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_PMCBRedemptionOfPreferredStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PaymentOfSeriesCConvertiblePreferredStockDividends" xlink:label="loc_PMCBPaymentOfSeriesCConvertiblePreferredStockDividends" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_PMCBPaymentOfSeriesCConvertiblePreferredStockDividends" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/NatureOfBusiness" xlink:title="999013 - Disclosure - NATURE OF BUSINESS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/LiquidityAndOtherUncertainties" xlink:title="999014 - Disclosure - LIQUIDITY AND OTHER UNCERTAINTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecurities" xlink:title="999016 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/AccruedExpenses" xlink:title="999017 - Disclosure - ACCRUED EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrants" xlink:title="999018 - Disclosure - STOCK OPTIONS AND WARRANTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/OtherRelatedPartyTransactions" xlink:title="999019 - Disclosure - OTHER RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CommitmentsAndContingencies" xlink:title="999020 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/EarningsPerShare" xlink:title="999021 - Disclosure - EARNINGS PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/PreferredStock" xlink:title="999022 - Disclosure - PREFERRED STOCK" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/TreasuryStock" xlink:title="999023 - Disclosure - TREASURY STOCK" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurements" xlink:title="999024 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables" xlink:title="999026 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/AccruedExpensesTables" xlink:title="999027 - Disclosure - ACCRUED EXPENSES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrantsTables" xlink:title="999028 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/EarningsPerShareTables" xlink:title="999029 - Disclosure - EARNINGS PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsTables" xlink:title="999030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative" xlink:title="999031 - Disclosure - LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants" xlink:title="999033 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Femasys Note and warrants)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities" xlink:title="999034 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Marketable securities)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants" xlink:title="999035 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series G Preferred Stock and Preferred Stock Warrants)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants" xlink:title="999036 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series H Preferred Stock and Preferred Stock Warrants)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative" xlink:title="999037 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/AccruedExpensesDetails" xlink:title="999038 - Disclosure - ACCRUED EXPENSES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity" xlink:title="999039 - Disclosure - STOCK OPTIONS AND WARRANTS (Details - Option activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity" xlink:title="999040 - Disclosure - STOCK OPTIONS AND WARRANTS (Details - Warrant activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative" xlink:title="999041 - Disclosure - STOCK OPTIONS AND WARRANTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative" xlink:title="999042 - Disclosure - OTHER RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation" xlink:title="999044 - Disclosure - EARNINGS PER SHARE (Details - Per share calculation)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares" xlink:title="999045 - Disclosure - EARNINGS PER SHARE (Details - Diluted shares)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/PreferredStockDetailsNarrative" xlink:title="999046 - Disclosure - PREFERRED STOCK (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/TreasuryStockDetailsNarrative" xlink:title="999047 - Disclosure - TREASURY STOCK (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue" xlink:title="999048 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair value)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability" xlink:title="999049 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of warrant liability)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability" xlink:title="999050 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of derivative liability)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments" xlink:title="999051 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair values of financial instruments)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>pmcb-20260131_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#Cover" roleURI="http://pharmacyte.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity" roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#NatureOfBusiness" roleURI="http://pharmacyte.com/role/NatureOfBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#LiquidityAndOtherUncertainties" roleURI="http://pharmacyte.com/role/LiquidityAndOtherUncertainties" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://pharmacyte.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecurities" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecurities" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#AccruedExpenses" roleURI="http://pharmacyte.com/role/AccruedExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#StockOptionsAndWarrants" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrants" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#OtherRelatedPartyTransactions" roleURI="http://pharmacyte.com/role/OtherRelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CommitmentsAndContingencies" roleURI="http://pharmacyte.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#EarningsPerShare" roleURI="http://pharmacyte.com/role/EarningsPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#PreferredStock" roleURI="http://pharmacyte.com/role/PreferredStock" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#TreasuryStock" roleURI="http://pharmacyte.com/role/TreasuryStock" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#FairValueMeasurements" roleURI="http://pharmacyte.com/role/FairValueMeasurements" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecuritiesTables" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#AccruedExpensesTables" roleURI="http://pharmacyte.com/role/AccruedExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#StockOptionsAndWarrantsTables" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#EarningsPerShareTables" roleURI="http://pharmacyte.com/role/EarningsPerShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#FairValueMeasurementsTables" roleURI="http://pharmacyte.com/role/FairValueMeasurementsTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#LiquidityAndOtherUncertaintiesDetailsNarrative" roleURI="http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecuritiesDetailsNarrative" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#AccruedExpensesDetails" roleURI="http://pharmacyte.com/role/AccruedExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#AccruedExpensesDetailsDefOnly" roleURI="http://pharmacyte.com/role/AccruedExpensesDetailsDefOnly" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#StockOptionsAndWarrantsDetails-OptionActivity" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#StockOptionsAndWarrantsDetails-WarrantActivity" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#StockOptionsAndWarrantsDetailsNarrative" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#OtherRelatedPartyTransactionsDetailsNarrative" roleURI="http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#EarningsPerShareDetails-PerShareCalculation" roleURI="http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#EarningsPerShareDetails-DilutedShares" roleURI="http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#PreferredStockDetailsNarrative" roleURI="http://pharmacyte.com/role/PreferredStockDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#TreasuryStockDetailsNarrative" roleURI="http://pharmacyte.com/role/TreasuryStockDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#FairValueMeasurementsDetails-FairValue" roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability" roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability" roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#FairValueMeasurementsDetails-FairValuesOfFinancialInstruments" roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#PvpExecutiveCategoriesOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#IndividualsOnly" roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#AwardTypeOnly" roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#TradingArrangmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_90" xlink:to="loc_us-gaapAssetsCurrentAbstract_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_90" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_90" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetCurrent" xlink:label="loc_PMCBWarrantAssetCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_90" xlink:to="loc_PMCBWarrantAssetCurrent_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ConvertibleNoteReceivableCurrent" xlink:label="loc_PMCBConvertibleNoteReceivableCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_90" xlink:to="loc_PMCBConvertibleNoteReceivableCurrent_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_90" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_90" xlink:to="loc_us-gaapAssetsCurrent_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_90" xlink:to="loc_us-gaapOtherAssetsAbstract_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherAssetsAbstract_90" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:label="loc_us-gaapInvestmentsAndOtherNoncurrentAssets_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherAssetsAbstract_90" xlink:to="loc_us-gaapInvestmentsAndOtherNoncurrentAssets_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetNoncurrent" xlink:label="loc_PMCBWarrantAssetNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherAssetsAbstract_90" xlink:to="loc_PMCBWarrantAssetNoncurrent_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetFemasys" xlink:label="loc_PMCBWarrantAssetFemasys_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherAssetsAbstract_90" xlink:to="loc_PMCBWarrantAssetFemasys_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_90" xlink:to="loc_us-gaapOtherAssets_90" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_90" xlink:to="loc_us-gaapAssetsNoncurrent_90" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets_90" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_90" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:to="loc_us-gaapAccountsPayableCurrent_90" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_90" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaapDividendsPayableCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:to="loc_us-gaapDividendsPayableCurrent_90" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_90" xlink:to="loc_us-gaapLiabilitiesCurrent_90" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesAbstract" xlink:label="loc_us-gaapOtherLiabilitiesAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherLiabilitiesAbstract_90" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAccruedLiabilitiesNoncurrent_90" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantLiabilitiesNoncurrent" xlink:label="loc_PMCBWarrantLiabilitiesNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBWarrantLiabilitiesNoncurrent_90" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent_90" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherLiabilities_90" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities_90" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommitmentsAndContingencies_90" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaapTemporaryEquityAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityAbstract_90" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent_90" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ContingentlyRedeemableWarrants" xlink:label="loc_PMCBContingentlyRedeemableWarrants_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBContingentlyRedeemableWarrants_90" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_TotalTemporaryEquity" xlink:label="loc_PMCBTotalTemporaryEquity_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBTotalTemporaryEquity_90" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract_90" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_90" xlink:to="loc_us-gaapPreferredStockValue_90" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_90" xlink:to="loc_us-gaapCommonStockValue_90" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_90" xlink:to="loc_us-gaapAdditionalPaidInCapital_90" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_90" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_90" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="loc_us-gaapTreasuryStockCommonValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_90" xlink:to="loc_us-gaapTreasuryStockCommonValue_90" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_90" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_90" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_90" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_90" xlink:type="arc" order="41" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockCommonMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="loc_us-gaapTemporaryEquityValueExcludingAdditionalPaidInCapital_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityValueExcludingAdditionalPaidInCapital_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaapTemporaryEquityLiquidationPreference_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityLiquidationPreference_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTreasuryStockCommonShares_110" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity" xlink:title="00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS&apos; EQUITY (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredStockSeriesBMember" xlink:label="loc_PMCBPreferredStockSeriesBMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_PMCBPreferredStockSeriesBMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredStockSeriesCMember" xlink:label="loc_PMCBPreferredStockSeriesCMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_PMCBPreferredStockSeriesCMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ContingentlyRedeemableWarrantsMember" xlink:label="loc_PMCBContingentlyRedeemableWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_PMCBContingentlyRedeemableWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockCommonMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTreasuryStockCommonShares_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FractionalSharesAdjustmentValue" xlink:label="loc_PMCBFractionalSharesAdjustmentValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBFractionalSharesAdjustmentValue_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FractionalSharesAdjustmentShares" xlink:label="loc_PMCBFractionalSharesAdjustmentShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBFractionalSharesAdjustmentShares_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_StockIssuedUponVestingOfRestrictedStockUnits" xlink:label="loc_PMCBStockIssuedUponVestingOfRestrictedStockUnits_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBStockIssuedUponVestingOfRestrictedStockUnits_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_StockIssuedUponVestingOfRestrictedStockUnitsShares" xlink:label="loc_PMCBStockIssuedUponVestingOfRestrictedStockUnitsShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBStockIssuedUponVestingOfRestrictedStockUnitsShares_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_IssuanceOfSeriesCPreferredStockAndWarrants" xlink:label="loc_PMCBIssuanceOfSeriesCPreferredStockAndWarrants_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBIssuanceOfSeriesCPreferredStockAndWarrants_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_IssuanceOfSeriesCPreferredStockAndWarrantsShares" xlink:label="loc_PMCBIssuanceOfSeriesCPreferredStockAndWarrantsShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBIssuanceOfSeriesCPreferredStockAndWarrantsShares_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredStockAccretion" xlink:label="loc_PMCBSeriesCPreferredStockAccretion_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesCPreferredStockAccretion_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredStockDividendSubjectToSettlement" xlink:label="loc_PMCBSeriesCPreferredStockDividendSubjectToSettlement_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesCPreferredStockDividendSubjectToSettlement_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredStockDividendsAccrual" xlink:label="loc_PMCBSeriesCPreferredStockDividendsAccrual_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesCPreferredStockDividendsAccrual_100" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredStockAccretion" xlink:label="loc_PMCBPreferredStockAccretion_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBPreferredStockAccretion_100" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredStockRedeemed" xlink:label="loc_PMCBSeriesCPreferredStockRedeemed_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesCPreferredStockRedeemed_100" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredStockRedeemedShares" xlink:label="loc_PMCBSeriesCPreferredStockRedeemedShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesCPreferredStockRedeemedShares_100" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredStockSubjectToSettlement" xlink:label="loc_PMCBSeriesCPreferredStockSubjectToSettlement_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesCPreferredStockSubjectToSettlement_100" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBPreferredStockSubjectToRedemption" xlink:label="loc_PMCBSeriesBPreferredStockSubjectToRedemption_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesBPreferredStockSubjectToRedemption_100" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBPreferredStockRedeemedShares" xlink:label="loc_PMCBSeriesBPreferredStockRedeemedShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesBPreferredStockRedeemedShares_100" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBPreferredStockRedemption" xlink:label="loc_PMCBSeriesBPreferredStockRedemption_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesBPreferredStockRedemption_100" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBPreferredStockSubjectToRedemptionShares" xlink:label="loc_PMCBSeriesBPreferredStockSubjectToRedemptionShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesBPreferredStockSubjectToRedemptionShares_100" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_100" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_100" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_100" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue_100" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_100" xlink:type="arc" order="28" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/NatureOfBusiness" xlink:title="999013 - Disclosure - NATURE OF BUSINESS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/LiquidityAndOtherUncertainties" xlink:title="999014 - Disclosure - LIQUIDITY AND OTHER UNCERTAINTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecurities" xlink:title="999016 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/AccruedExpenses" xlink:title="999017 - Disclosure - ACCRUED EXPENSES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrants" xlink:title="999018 - Disclosure - STOCK OPTIONS AND WARRANTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/OtherRelatedPartyTransactions" xlink:title="999019 - Disclosure - OTHER RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CommitmentsAndContingencies" xlink:title="999020 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/EarningsPerShare" xlink:title="999021 - Disclosure - EARNINGS PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/PreferredStock" xlink:title="999022 - Disclosure - PREFERRED STOCK" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/TreasuryStock" xlink:title="999023 - Disclosure - TREASURY STOCK" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurements" xlink:title="999024 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables" xlink:title="999026 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="loc_us-gaapSeriesHPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesHPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock" xlink:label="loc_us-gaapScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentTableTextBlock" xlink:label="loc_us-gaapInvestmentTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentTableTextBlock_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/AccruedExpensesTables" xlink:title="999027 - Disclosure - ACCRUED EXPENSES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrantsTables" xlink:title="999028 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/EarningsPerShareTables" xlink:title="999029 - Disclosure - EARNINGS PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsTables" xlink:title="999030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative" xlink:title="999031 - Disclosure - LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantsMember" xlink:label="loc_PMCBWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBWarrantsMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesHConvertiblePreferredStockMember" xlink:label="loc_PMCBQCLSSeriesHConvertiblePreferredStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBQCLSSeriesHConvertiblePreferredStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPaymentsToAcquireInvestments_80" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants" xlink:title="999033 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Femasys Note and warrants)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" xlink:label="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralTable" xlink:label="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" xlink:to="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralTable" xlink:to="loc_us-gaapInvestmentTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysNotesMember" xlink:label="loc_PMCBFemasysNotesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_PMCBFemasysNotesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysWarrantsMember" xlink:label="loc_PMCBFemasysWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_PMCBFemasysWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ConvertibleNoteReceivableCurrent" xlink:label="loc_PMCBConvertibleNoteReceivableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" xlink:to="loc_PMCBConvertibleNoteReceivableCurrent_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfConvertibleNotesReceivable" xlink:label="loc_PMCBChangeInFairValueOfConvertibleNotesReceivable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" xlink:to="loc_PMCBChangeInFairValueOfConvertibleNotesReceivable_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ProceedsFromInvestmentNoteReceivable" xlink:label="loc_PMCBProceedsFromInvestmentNoteReceivable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" xlink:to="loc_PMCBProceedsFromInvestmentNoteReceivable_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetFemasys" xlink:label="loc_PMCBWarrantAssetFemasys_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" xlink:to="loc_PMCBWarrantAssetFemasys_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantAssetFemasys" xlink:label="loc_PMCBChangeInFairValueOfWarrantAssetFemasys_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" xlink:to="loc_PMCBChangeInFairValueOfWarrantAssetFemasys_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities" xlink:title="999034 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Marketable securities)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems" xlink:label="loc_us-gaapQualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementTable" xlink:label="loc_us-gaapQualitativeAndQuantitativeInformationTransferorsContinuingInvolvementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapQualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems" xlink:to="loc_us-gaapQualitativeAndQuantitativeInformationTransferorsContinuingInvolvementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapQualitativeAndQuantitativeInformationTransferorsContinuingInvolvementTable" xlink:to="loc_us-gaapTransactionTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysPurchaseAgreementMember" xlink:label="loc_PMCBFemasysPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_PMCBFemasysPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapQualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesCurrent_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaapInvestmentOwnedAtCost_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapQualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtCost_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapQualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants" xlink:title="999035 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series G Preferred Stock and Preferred Stock Warrants)">
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DisclosureLineElements" xlink:label="loc_PMCBDisclosureLineElements" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DisclosureTable" xlink:label="loc_PMCBDisclosureTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_PMCBDisclosureTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PMCBDisclosureTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesGPreferredStockMember" xlink:label="loc_PMCBQCLSSeriesGPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBQCLSSeriesGPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesGWarrantsMember" xlink:label="loc_PMCBQCLSSeriesGWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBQCLSSeriesGWarrantsMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PMCBDisclosureTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSMember" xlink:label="loc_PMCBQCLSMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_PMCBQCLSMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:label="loc_us-gaapInvestmentsAndOtherNoncurrentAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_us-gaapInvestmentsAndOtherNoncurrentAssets_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfInvestment" xlink:label="loc_PMCBChangeInFairValueOfInvestment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_PMCBChangeInFairValueOfInvestment_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants" xlink:title="999036 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series H Preferred Stock and Preferred Stock Warrants)">
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DisclosureLineElements" xlink:label="loc_PMCBDisclosureLineElements" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DisclosureTable" xlink:label="loc_PMCBDisclosureTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_PMCBDisclosureTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PMCBDisclosureTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesHPreferredStockMember" xlink:label="loc_PMCBQCLSSeriesHPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBQCLSSeriesHPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PMCBDisclosureTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesHWarrantsMember" xlink:label="loc_PMCBQCLSSeriesHWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBQCLSSeriesHWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:label="loc_us-gaapInvestmentsAndOtherNoncurrentAssets_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_us-gaapInvestmentsAndOtherNoncurrentAssets_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaapInvestmentOwnedAtFairValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_us-gaapInvestmentOwnedAtFairValue_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfInvestmentQcls" xlink:label="loc_PMCBChangeInFairValueOfInvestmentQcls_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_PMCBChangeInFairValueOfInvestmentQcls_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative" xlink:title="999037 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTransactionTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysPurchaseAgreementMember" xlink:label="loc_PMCBFemasysPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_PMCBFemasysPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysNoteMember" xlink:label="loc_PMCBFemasysNoteMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_PMCBFemasysNoteMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysCommonStockMember" xlink:label="loc_PMCBFemasysCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_PMCBFemasysCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysWarrantsMember" xlink:label="loc_PMCBFemasysWarrantsMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_PMCBFemasysWarrantsMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysMember" xlink:label="loc_PMCBFemasysMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_PMCBFemasysMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSMember" xlink:label="loc_PMCBQCLSMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_PMCBQCLSMember_250" xlink:type="arc" order="252" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysSeriesAWarrantsMember" xlink:label="loc_PMCBFemasysSeriesAWarrantsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBFemasysSeriesAWarrantsMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysCommonStockMember" xlink:label="loc_PMCBFemasysCommonStockMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBFemasysCommonStockMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="loc_us-gaapSeriesGPreferredStockMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesGPreferredStockMember_250" xlink:type="arc" order="253" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSAccruedDividendReceivableMember" xlink:label="loc_PMCBQCLSAccruedDividendReceivableMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBQCLSAccruedDividendReceivableMember_350" xlink:type="arc" order="353" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesGPreferredStockMember" xlink:label="loc_PMCBQCLSSeriesGPreferredStockMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBQCLSSeriesGPreferredStockMember_370" xlink:type="arc" order="373" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesGWarrantsMember" xlink:label="loc_PMCBSeriesGWarrantsMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBSeriesGWarrantsMember_420" xlink:type="arc" order="422" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesHPreferredStockMember" xlink:label="loc_PMCBQCLSSeriesHPreferredStockMember_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBQCLSSeriesHPreferredStockMember_650" xlink:type="arc" order="652" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesHWarrantsMember" xlink:label="loc_PMCBQCLSSeriesHWarrantsMember_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBQCLSSeriesHWarrantsMember_750" xlink:type="arc" order="752" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SecuritiesPurchaseAgreementMember" xlink:label="loc_PMCBSecuritiesPurchaseAgreementMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PMCBSecuritiesPurchaseAgreementMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSecuritiesPurchaseAgreementMember" xlink:label="loc_PMCBQCLSSecuritiesPurchaseAgreementMember_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PMCBQCLSSecuritiesPurchaseAgreementMember_650" xlink:type="arc" order="651" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LongTermWarrantMember" xlink:label="loc_PMCBLongTermWarrantMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBLongTermWarrantMember_260" xlink:type="arc" order="263" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ShortTermWarrantMember" xlink:label="loc_PMCBShortTermWarrantMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBShortTermWarrantMember_270" xlink:type="arc" order="273" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesHWarrantMember" xlink:label="loc_PMCBQCLSSeriesHWarrantMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBQCLSSeriesHWarrantMember_460" xlink:type="arc" order="463" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSCommonStockMember" xlink:label="loc_PMCBQCLSCommonStockMember_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBQCLSCommonStockMember_490" xlink:type="arc" order="493" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesHPreferredStockMember" xlink:label="loc_PMCBQCLSSeriesHPreferredStockMember_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBQCLSSeriesHPreferredStockMember_500" xlink:type="arc" order="503" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_510" xlink:type="arc" order="514" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_520" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_520" xlink:type="arc" order="524" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputMaturityMember" xlink:label="loc_us-gaapMeasurementInputMaturityMember_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputMaturityMember_530" xlink:type="arc" order="534" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_MeasurementRedemptionPremiumMember" xlink:label="loc_PMCBMeasurementRedemptionPremiumMember_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_PMCBMeasurementRedemptionPremiumMember_540" xlink:type="arc" order="544" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_MeasurementInputMarketInterestRateMember" xlink:label="loc_PMCBMeasurementInputMarketInterestRateMember_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_PMCBMeasurementInputMarketInterestRateMember_550" xlink:type="arc" order="554" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_560" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_560" xlink:type="arc" order="564" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_570" xlink:type="arc" order="574" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember_590" xlink:type="arc" order="594" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_610" xlink:type="arc" order="614" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_MeasurementInputRedemptionPremiumMember" xlink:label="loc_PMCBMeasurementInputRedemptionPremiumMember_710" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_PMCBMeasurementInputRedemptionPremiumMember_710" xlink:type="arc" order="713" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsToAcquireInvestments_830" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ReceivableInstrumentConvertibleConversionPrice1" xlink:label="loc_PMCBReceivableInstrumentConvertibleConversionPrice1_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PMCBReceivableInstrumentConvertibleConversionPrice1_830" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares_830" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ProceedsFromInvestmentNoteReceivable" xlink:label="loc_PMCBProceedsFromInvestmentNoteReceivable_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PMCBProceedsFromInvestmentNoteReceivable_830" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_InvestmentSharesAddition" xlink:label="loc_PMCBInvestmentSharesAddition_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PMCBInvestmentSharesAddition_830" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SettlementOfAccruedInterest" xlink:label="loc_PMCBSettlementOfAccruedInterest_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PMCBSettlementOfAccruedInterest_830" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaapInterestAndOtherIncome_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInterestAndOtherIncome_830" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaapInterestReceivable_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInterestReceivable_830" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaapInvestmentOwnedAtFairValue_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtFairValue_830" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ConvertibleNoteReceivableCurrent" xlink:label="loc_PMCBConvertibleNoteReceivableCurrent_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PMCBConvertibleNoteReceivableCurrent_830" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetFemasys" xlink:label="loc_PMCBWarrantAssetFemasys_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PMCBWarrantAssetFemasys_830" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfConvertibleNotesReceivable" xlink:label="loc_PMCBChangeInFairValueOfConvertibleNotesReceivable_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PMCBChangeInFairValueOfConvertibleNotesReceivable_830" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantAssetFemasys" xlink:label="loc_PMCBChangeInFairValueOfWarrantAssetFemasys_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PMCBChangeInFairValueOfWarrantAssetFemasys_830" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaapPaymentsToAcquireEquityMethodInvestments_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsToAcquireEquityMethodInvestments_830" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss_830" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_830" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_830" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaapRealizedInvestmentGainsLosses_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRealizedInvestmentGainsLosses_830" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_830" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue" xlink:label="loc_us-gaapDerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_830" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaapInvestmentOwnedAtCost_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtCost_830" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_GainOnRelatedPartyInvestmentQcls" xlink:label="loc_PMCBGainOnRelatedPartyInvestmentQcls_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PMCBGainOnRelatedPartyInvestmentQcls_830" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesRealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesRealizedGainLoss_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtSecuritiesRealizedGainLoss_830" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_830" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_830" xlink:type="arc" order="24" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/AccruedExpensesDetails" xlink:title="999038 - Disclosure - ACCRUED EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DisclosureLineElements" xlink:label="loc_PMCBDisclosureLineElements" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DisclosureTable" xlink:label="loc_PMCBDisclosureTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_PMCBDisclosureTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionLocationBalanceAxis" xlink:label="loc_us-gaapStatementOfFinancialPositionLocationBalanceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PMCBDisclosureTable" xlink:to="loc_us-gaapStatementOfFinancialPositionLocationBalanceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaapNatureOfExpenseAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PMCBDisclosureTable" xlink:to="loc_us-gaapNatureOfExpenseAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PayrollRelatedCostsMember" xlink:label="loc_PMCBPayrollRelatedCostsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_PMCBPayrollRelatedCostsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DirectorFeesMember" xlink:label="loc_PMCBDirectorFeesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_PMCBDirectorFeesMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_RAndDCostsMember" xlink:label="loc_PMCBRAndDCostsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_PMCBRAndDCostsMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LegalSettlementMember" xlink:label="loc_PMCBLegalSettlementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_PMCBLegalSettlementMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ExciseTaxOnStockRepurchasesMember" xlink:label="loc_PMCBExciseTaxOnStockRepurchasesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_PMCBExciseTaxOnStockRepurchasesMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LongTermPortionOfLegalSettlementMember" xlink:label="loc_PMCBLongTermPortionOfLegalSettlementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_PMCBLongTermPortionOfLegalSettlementMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_150" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/AccruedExpensesDetailsDefOnly" xlink:title="999038 - Disclosure - ACCRUED EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DisclosureLineElements" xlink:label="loc_PMCBDisclosureLineElements" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DisclosureTable" xlink:label="loc_PMCBDisclosureTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_PMCBDisclosureTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaapNatureOfExpenseAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_PMCBDisclosureTable" xlink:to="loc_us-gaapNatureOfExpenseAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PayrollRelatedCostsMember" xlink:label="loc_PMCBPayrollRelatedCostsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_PMCBPayrollRelatedCostsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DirectorFeesMember" xlink:label="loc_PMCBDirectorFeesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_PMCBDirectorFeesMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_RAndDCostsMember" xlink:label="loc_PMCBRAndDCostsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_PMCBRAndDCostsMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LegalSettlementMember" xlink:label="loc_PMCBLegalSettlementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_PMCBLegalSettlementMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ExciseTaxOnStockRepurchasesMember" xlink:label="loc_PMCBExciseTaxOnStockRepurchasesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_PMCBExciseTaxOnStockRepurchasesMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LongTermPortionOfLegalSettlementMember" xlink:label="loc_PMCBLongTermPortionOfLegalSettlementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_PMCBLongTermPortionOfLegalSettlementMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_150" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity" xlink:title="999039 - Disclosure - STOCK OPTIONS AND WARRANTS (Details - Option activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity" xlink:title="999040 - Disclosure - STOCK OPTIONS AND WARRANTS (Details - Warrant activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBWarrantsAndSettlementWarrantsAdjustedMember" xlink:label="loc_PMCBSeriesBWarrantsAndSettlementWarrantsAdjustedMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PMCBSeriesBWarrantsAndSettlementWarrantsAdjustedMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantsIssuedShares" xlink:label="loc_PMCBWarrantsIssuedShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBWarrantsIssuedShares_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantExercised" xlink:label="loc_PMCBWarrantExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBWarrantExercised_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WeightedAverageExercisePriceWarrantsExercised" xlink:label="loc_PMCBWeightedAverageExercisePriceWarrantsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBWeightedAverageExercisePriceWarrantsExercised_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantsExpired" xlink:label="loc_PMCBWarrantsExpired_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBWarrantsExpired_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WeightedAverageExercisePriceWarrantsExpired" xlink:label="loc_PMCBWeightedAverageExercisePriceWarrantsExpired_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBWeightedAverageExercisePriceWarrantsExpired_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantsExercisable" xlink:label="loc_PMCBWarrantsExercisable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBWarrantsExercisable_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WeightedAverageExercisePriceWarrantsExercisable" xlink:label="loc_PMCBWeightedAverageExercisePriceWarrantsExercisable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBWeightedAverageExercisePriceWarrantsExercisable_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_60" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative" xlink:title="999041 - Disclosure - STOCK OPTIONS AND WARRANTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_EquityPlan2021Member" xlink:label="loc_PMCBEquityPlan2021Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_PMCBEquityPlan2021Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_EquityPlan2022Member" xlink:label="loc_PMCBEquityPlan2022Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_PMCBEquityPlan2022Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_EmployeesMember" xlink:label="loc_PMCBEmployeesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_PMCBEmployeesMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_AdditionalWarrantsMember" xlink:label="loc_PMCBAdditionalWarrantsMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PMCBAdditionalWarrantsMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPrivatePlacementAgreementMember" xlink:label="loc_PMCBSeriesCPrivatePlacementAgreementMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PMCBSeriesCPrivatePlacementAgreementMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBWarrantsMember" xlink:label="loc_PMCBSeriesBWarrantsMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBSeriesBWarrantsMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBPreferredWarrantsMember" xlink:label="loc_PMCBSeriesBPreferredWarrantsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBSeriesBPreferredWarrantsMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTransactionTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SettlementAgreementMember" xlink:label="loc_PMCBSettlementAgreementMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_PMCBSettlementAgreementMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FirstWarrantIssuanceMember" xlink:label="loc_PMCBFirstWarrantIssuanceMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBFirstWarrantIssuanceMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SettlementWarrantsMember" xlink:label="loc_PMCBSettlementWarrantsMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBSettlementWarrantsMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredWarrantsMember" xlink:label="loc_PMCBSeriesCPreferredWarrantsMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBSeriesCPreferredWarrantsMember_340" xlink:type="arc" order="342" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPlacementAgentWarrantsMember" xlink:label="loc_PMCBSeriesCPlacementAgentWarrantsMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBSeriesCPlacementAgentWarrantsMember_360" xlink:type="arc" order="362" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_390" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_390" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_390" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_390" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_390" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_390" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_390" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_390" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_390" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_390" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_390" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_390" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantLiability" xlink:label="loc_PMCBChangeInFairValueOfWarrantLiability_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBChangeInFairValueOfWarrantLiability_390" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_390" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_390" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementGain" xlink:label="loc_us-gaapLitigationSettlementGain_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLitigationSettlementGain_390" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_IssuanceFairValues" xlink:label="loc_PMCBIssuanceFairValues_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBIssuanceFairValues_390" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantAsset" xlink:label="loc_PMCBChangeInFairValueOfWarrantAsset_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBChangeInFairValueOfWarrantAsset_390" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative" xlink:title="999042 - Disclosure - OTHER RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SGAustraliaMember" xlink:label="loc_PMCBSGAustraliaMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_PMCBSGAustraliaMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_VinDeBonaMember" xlink:label="loc_PMCBVinDeBonaMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_PMCBVinDeBonaMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaapProfessionalAndContractServicesExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProfessionalAndContractServicesExpense_60" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SGAustriaAndSubsidiariesMember" xlink:label="loc_PMCBSGAustriaAndSubsidiariesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_PMCBSGAustriaAndSubsidiariesMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_LitigationCaseAxis" xlink:label="loc_srtLitigationCaseAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtLitigationCaseAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_HCWainwrightMember" xlink:label="loc_PMCBHCWainwrightMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtLitigationCaseTypeDomain" xlink:to="loc_PMCBHCWainwrightMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FirstWarrantIssuanceMember" xlink:label="loc_PMCBFirstWarrantIssuanceMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBFirstWarrantIssuanceMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_AdditionalWarrantsMember" xlink:label="loc_PMCBAdditionalWarrantsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBAdditionalWarrantsMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapContractualObligation_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaapPaymentsForLegalSettlements_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForLegalSettlements_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantsIssuedShares" xlink:label="loc_PMCBWarrantsIssuedShares_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_PMCBWarrantsIssuedShares_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation" xlink:title="999044 - Disclosure - EARNINGS PER SHARE (Details - Per share calculation)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaapEarningsPerShareBasicLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLoss_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="loc_us-gaapPreferredStockAccretionOfRedemptionDiscount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapPreferredStockAccretionOfRedemptionDiscount_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ConvertiblePreferredStockDividends" xlink:label="loc_PMCBConvertiblePreferredStockDividends_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_PMCBConvertiblePreferredStockDividends_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaapUndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapUndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LessAllocationOfUndistributedIncome" xlink:label="loc_PMCBLessAllocationOfUndistributedIncome_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_PMCBLessAllocationOfUndistributedIncome_90" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares" xlink:title="999045 - Disclosure - EARNINGS PER SHARE (Details - Diluted shares)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_OptionsMember" xlink:label="loc_PMCBOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_PMCBOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredSharesMember" xlink:label="loc_PMCBPreferredSharesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_PMCBPreferredSharesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantsMember" xlink:label="loc_PMCBWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_PMCBWarrantsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_170" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/PreferredStockDetailsNarrative" xlink:title="999046 - Disclosure - PREFERRED STOCK (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPurchaseAgreementMember" xlink:label="loc_PMCBSeriesCPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PMCBSeriesCPurchaseAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCWarrantsMember" xlink:label="loc_PMCBSeriesCWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBSeriesCWarrantsMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_MeasurementInputRedemptionPremiumMember" xlink:label="loc_PMCBMeasurementInputRedemptionPremiumMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_PMCBMeasurementInputRedemptionPremiumMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_MeasurementInputMarketInterestRateMember" xlink:label="loc_PMCBMeasurementInputMarketInterestRateMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_PMCBMeasurementInputMarketInterestRateMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DerivativeLiabilityMember" xlink:label="loc_PMCBDerivativeLiabilityMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBDerivativeLiabilityMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_240" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredStockParValuePerShare" xlink:label="loc_PMCBPreferredStockParValuePerShare_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_PMCBPreferredStockParValuePerShare_240" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredStockStatedValuePerShare" xlink:label="loc_PMCBPreferredStockStatedValuePerShare_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_PMCBPreferredStockStatedValuePerShare_240" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_240" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_240" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_240" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_240" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_240" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaapSaleOfStockDescriptionOfTransaction_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockDescriptionOfTransaction_240" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PlacementAgentFeePercentage" xlink:label="loc_PMCBPlacementAgentFeePercentage_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_PMCBPlacementAgentFeePercentage_240" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_240" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent_240" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:label="loc_us-gaapDerivativeAssetsLiabilitiesAtFairValueNet_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDerivativeAssetsLiabilitiesAtFairValueNet_240" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeAssetLiabilityNetMeasurementInput" xlink:label="loc_us-gaapDerivativeAssetLiabilityNetMeasurementInput_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDerivativeAssetLiabilityNetMeasurementInput_240" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredStockDiscount" xlink:label="loc_PMCBPreferredStockDiscount_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_PMCBPreferredStockDiscount_240" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FairValueEmbeddedDerivative" xlink:label="loc_PMCBFairValueEmbeddedDerivative_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_PMCBFairValueEmbeddedDerivative_240" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantLiabilityFairValue" xlink:label="loc_PMCBWarrantLiabilityFairValue_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_PMCBWarrantLiabilityFairValue_240" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock_240" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DeemedDividend" xlink:label="loc_PMCBDeemedDividend_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_PMCBDeemedDividend_240" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueDerivativeLiability" xlink:label="loc_PMCBChangeInFairValueDerivativeLiability_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_PMCBChangeInFairValueDerivativeLiability_240" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="loc_us-gaapDividendsPreferredStockStock_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDividendsPreferredStockStock_240" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaapDividendsPreferredStockCash_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDividendsPreferredStockCash_240" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendsPreferredStockPaidinkind" xlink:label="loc_us-gaapDividendsPreferredStockPaidinkind_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDividendsPreferredStockPaidinkind_240" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_240" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_240" xlink:type="arc" order="24" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/TreasuryStockDetailsNarrative" xlink:title="999047 - Disclosure - TREASURY STOCK (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapTreasuryStockCommonMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapTreasuryStockCommonShares_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="loc_us-gaapTreasuryStockCommonValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapTreasuryStockCommonValue_40" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue" xlink:title="999048 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair value)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantLiabilityMember" xlink:label="loc_PMCBWarrantLiabilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBWarrantLiabilityMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DerivativeLiabilityMember" xlink:label="loc_PMCBDerivativeLiabilityMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBDerivativeLiabilityMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability" xlink:title="999049 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of warrant liability)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantLiabilityMember" xlink:label="loc_PMCBWarrantLiabilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBWarrantLiabilityMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantExercises" xlink:label="loc_PMCBWarrantExercises_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_PMCBWarrantExercises_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantLiability" xlink:label="loc_PMCBChangeInFairValueOfWarrantLiability_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_PMCBChangeInFairValueOfWarrantLiability_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability" xlink:title="999050 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of derivative liability)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DerivativeLiabilityMember" xlink:label="loc_PMCBDerivativeLiabilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBDerivativeLiabilityMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_IssuanceOfSeriesCConvertiblePreferredStock" xlink:label="loc_PMCBIssuanceOfSeriesCConvertiblePreferredStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_PMCBIssuanceOfSeriesCConvertiblePreferredStock_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantLiability" xlink:label="loc_PMCBChangeInFairValueOfWarrantLiability_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_PMCBChangeInFairValueOfWarrantLiability_60" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments" xlink:title="999051 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair values of financial instruments)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_MarketableEquitySecuritiesMember" xlink:label="loc_PMCBMarketableEquitySecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBMarketableEquitySecuritiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_MoneyMarketAccountMember" xlink:label="loc_PMCBMoneyMarketAccountMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBMoneyMarketAccountMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ConvertibleNoteReceivableMember" xlink:label="loc_PMCBConvertibleNoteReceivableMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBConvertibleNoteReceivableMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetFemasysMember" xlink:label="loc_PMCBWarrantAssetFemasysMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBWarrantAssetFemasysMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_InvestmentInPreferredStockQCLSMember" xlink:label="loc_PMCBInvestmentInPreferredStockQCLSMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBInvestmentInPreferredStockQCLSMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetQCLSMember" xlink:label="loc_PMCBWarrantAssetQCLSMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBWarrantAssetQCLSMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:label="loc_us-gaapFinancialInstrumentsOwnedAtFairValue_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFinancialInstrumentsOwnedAtFairValue_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_AdditionalWarrantsMember" xlink:label="loc_PMCBAdditionalWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PMCBAdditionalWarrantsMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBWarrantsAndSettlementWarrantsAdjustedMember" xlink:label="loc_PMCBSeriesBWarrantsAndSettlementWarrantsAdjustedMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PMCBSeriesBWarrantsAndSettlementWarrantsAdjustedMember" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>pmcb-20260131_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredStockSeriesBMember" xlink:label="PMCB_PreferredStockSeriesBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_PreferredStockSeriesBMember" xlink:to="PMCB_PreferredStockSeriesBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_PreferredStockSeriesBMember_lbl" xml:lang="en-US">Preferred Stock Series B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredStockSeriesCMember" xlink:label="PMCB_PreferredStockSeriesCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_PreferredStockSeriesCMember" xlink:to="PMCB_PreferredStockSeriesCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_PreferredStockSeriesCMember_lbl" xml:lang="en-US">Preferred Stock Series C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ContingentlyRedeemableWarrantsMember" xlink:label="PMCB_ContingentlyRedeemableWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ContingentlyRedeemableWarrantsMember" xlink:to="PMCB_ContingentlyRedeemableWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ContingentlyRedeemableWarrantsMember_lbl" xml:lang="en-US">Contingently Redeemable Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantsMember" xlink:label="PMCB_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantsMember" xlink:to="PMCB_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesHConvertiblePreferredStockMember" xlink:label="PMCB_QCLSSeriesHConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_QCLSSeriesHConvertiblePreferredStockMember" xlink:to="PMCB_QCLSSeriesHConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_QCLSSeriesHConvertiblePreferredStockMember_lbl" xml:lang="en-US">QCLS Series H Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransactionTypeAxis" xlink:label="us-gaap_TransactionTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransactionTypeAxis_lbl" xml:lang="en-US">Transaction Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysPurchaseAgreementMember" xlink:label="PMCB_FemasysPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_FemasysPurchaseAgreementMember" xlink:to="PMCB_FemasysPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_FemasysPurchaseAgreementMember_lbl" xml:lang="en-US">Femasys Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysNoteMember" xlink:label="PMCB_FemasysNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_FemasysNoteMember" xlink:to="PMCB_FemasysNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_FemasysNoteMember_lbl" xml:lang="en-US">Femasys Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysMember" xlink:label="PMCB_FemasysMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_FemasysMember" xlink:to="PMCB_FemasysMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_FemasysMember_lbl" xml:lang="en-US">Femasys [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysCommonStockMember" xlink:label="PMCB_FemasysCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_FemasysCommonStockMember" xlink:to="PMCB_FemasysCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_FemasysCommonStockMember_lbl" xml:lang="en-US">Femasys Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysSeriesAWarrantsMember" xlink:label="PMCB_FemasysSeriesAWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_FemasysSeriesAWarrantsMember" xlink:to="PMCB_FemasysSeriesAWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_FemasysSeriesAWarrantsMember_lbl" xml:lang="en-US">Femasys Series A Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysWarrantsMember" xlink:label="PMCB_FemasysWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_FemasysWarrantsMember" xlink:to="PMCB_FemasysWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_FemasysWarrantsMember_lbl" xml:lang="en-US">Femasys Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SecuritiesPurchaseAgreementMember" xlink:label="PMCB_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SecuritiesPurchaseAgreementMember" xlink:to="PMCB_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSMember" xlink:label="PMCB_QCLSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_QCLSMember" xlink:to="PMCB_QCLSMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_QCLSMember_lbl" xml:lang="en-US">QCLS [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesGPreferredStockMember" xlink:to="us-gaap_SeriesGPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesGPreferredStockMember_lbl" xml:lang="en-US">Series G Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LongTermWarrantMember" xlink:label="PMCB_LongTermWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_LongTermWarrantMember" xlink:to="PMCB_LongTermWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_LongTermWarrantMember_lbl" xml:lang="en-US">Long Term Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ShortTermWarrantMember" xlink:label="PMCB_ShortTermWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ShortTermWarrantMember" xlink:to="PMCB_ShortTermWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ShortTermWarrantMember_lbl" xml:lang="en-US">Short Term Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSAccruedDividendReceivableMember" xlink:label="PMCB_QCLSAccruedDividendReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_QCLSAccruedDividendReceivableMember" xlink:to="PMCB_QCLSAccruedDividendReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_QCLSAccruedDividendReceivableMember_lbl" xml:lang="en-US">QCLS Accrued Dividend Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesGPreferredStockMember" xlink:label="PMCB_QCLSSeriesGPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_QCLSSeriesGPreferredStockMember" xlink:to="PMCB_QCLSSeriesGPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_QCLSSeriesGPreferredStockMember_lbl" xml:lang="en-US">QCLS Series G Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesGWarrantsMember" xlink:label="PMCB_SeriesGWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SeriesGWarrantsMember" xlink:to="PMCB_SeriesGWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SeriesGWarrantsMember_lbl" xml:lang="en-US">Series G Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesHWarrantMember" xlink:label="PMCB_QCLSSeriesHWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_QCLSSeriesHWarrantMember" xlink:to="PMCB_QCLSSeriesHWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_QCLSSeriesHWarrantMember_lbl" xml:lang="en-US">QCLS Series H Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSCommonStockMember" xlink:label="PMCB_QCLSCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_QCLSCommonStockMember" xlink:to="PMCB_QCLSCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_QCLSCommonStockMember_lbl" xml:lang="en-US">QCLS Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesHPreferredStockMember" xlink:label="PMCB_QCLSSeriesHPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_QCLSSeriesHPreferredStockMember" xlink:to="PMCB_QCLSSeriesHPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_QCLSSeriesHPreferredStockMember_lbl" xml:lang="en-US">QCLS Series H Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputMaturityMember" xlink:label="us-gaap_MeasurementInputMaturityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputMaturityMember" xlink:to="us-gaap_MeasurementInputMaturityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputMaturityMember_lbl" xml:lang="en-US">Measurement Input, Maturity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_MeasurementRedemptionPremiumMember" xlink:label="PMCB_MeasurementRedemptionPremiumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_MeasurementRedemptionPremiumMember" xlink:to="PMCB_MeasurementRedemptionPremiumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_MeasurementRedemptionPremiumMember_lbl" xml:lang="en-US">Measurement Redemption Premium [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_MeasurementInputMarketInterestRateMember" xlink:label="PMCB_MeasurementInputMarketInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_MeasurementInputMarketInterestRateMember" xlink:to="PMCB_MeasurementInputMarketInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_MeasurementInputMarketInterestRateMember_lbl" xml:lang="en-US">Measurement Input Market Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSecuritiesPurchaseAgreementMember" xlink:label="PMCB_QCLSSecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_QCLSSecuritiesPurchaseAgreementMember" xlink:to="PMCB_QCLSSecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_QCLSSecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">QCLS Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_MeasurementInputRedemptionPremiumMember" xlink:label="PMCB_MeasurementInputRedemptionPremiumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_MeasurementInputRedemptionPremiumMember" xlink:to="PMCB_MeasurementInputRedemptionPremiumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_MeasurementInputRedemptionPremiumMember_lbl" xml:lang="en-US">Measurement Input Redemption Premium [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesHWarrantsMember" xlink:label="PMCB_QCLSSeriesHWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_QCLSSeriesHWarrantsMember" xlink:to="PMCB_QCLSSeriesHWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_QCLSSeriesHWarrantsMember_lbl" xml:lang="en-US">QCLS Series H Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesHPreferredStockMember" xlink:to="us-gaap_SeriesHPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesHPreferredStockMember_lbl" xml:lang="en-US">Series H Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysNotesMember" xlink:label="PMCB_FemasysNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_FemasysNotesMember" xlink:to="PMCB_FemasysNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_FemasysNotesMember_lbl" xml:lang="en-US">Femasys Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesGWarrantsMember" xlink:label="PMCB_QCLSSeriesGWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_QCLSSeriesGWarrantsMember" xlink:to="PMCB_QCLSSeriesGWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_QCLSSeriesGWarrantsMember_lbl" xml:lang="en-US">QCLS Series G Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionLocationBalanceAxis" xlink:label="us-gaap_StatementOfFinancialPositionLocationBalanceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionLocationBalanceAxis" xlink:to="us-gaap_StatementOfFinancialPositionLocationBalanceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionLocationBalanceAxis_lbl" xml:lang="en-US">Location, Statement of Financial Position, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_NatureOfExpenseAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfExpenseAxis_lbl" xml:lang="en-US">Nature of Expense [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PayrollRelatedCostsMember" xlink:label="PMCB_PayrollRelatedCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_PayrollRelatedCostsMember" xlink:to="PMCB_PayrollRelatedCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_PayrollRelatedCostsMember_lbl" xml:lang="en-US">Payroll Related Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DirectorFeesMember" xlink:label="PMCB_DirectorFeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_DirectorFeesMember" xlink:to="PMCB_DirectorFeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_DirectorFeesMember_lbl" xml:lang="en-US">Director Fees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_RAndDCostsMember" xlink:label="PMCB_RAndDCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_RAndDCostsMember" xlink:to="PMCB_RAndDCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_RAndDCostsMember_lbl" xml:lang="en-US">R And D Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LegalSettlementMember" xlink:label="PMCB_LegalSettlementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_LegalSettlementMember" xlink:to="PMCB_LegalSettlementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_LegalSettlementMember_lbl" xml:lang="en-US">Legal Settlement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ExciseTaxOnStockRepurchasesMember" xlink:label="PMCB_ExciseTaxOnStockRepurchasesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ExciseTaxOnStockRepurchasesMember" xlink:to="PMCB_ExciseTaxOnStockRepurchasesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ExciseTaxOnStockRepurchasesMember_lbl" xml:lang="en-US">Excise Tax On Stock Repurchases [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LongTermPortionOfLegalSettlementMember" xlink:label="PMCB_LongTermPortionOfLegalSettlementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_LongTermPortionOfLegalSettlementMember" xlink:to="PMCB_LongTermPortionOfLegalSettlementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_LongTermPortionOfLegalSettlementMember_lbl" xml:lang="en-US">Long Term Portion Of Legal Settlement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_EquityPlan2021Member" xlink:label="PMCB_EquityPlan2021Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_EquityPlan2021Member" xlink:to="PMCB_EquityPlan2021Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_EquityPlan2021Member_lbl" xml:lang="en-US">Equity Plan 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_EquityPlan2022Member" xlink:label="PMCB_EquityPlan2022Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_EquityPlan2022Member" xlink:to="PMCB_EquityPlan2022Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_EquityPlan2022Member_lbl" xml:lang="en-US">Equity Plan 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_EmployeesMember" xlink:label="PMCB_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_EmployeesMember" xlink:to="PMCB_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBWarrantsMember" xlink:label="PMCB_SeriesBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SeriesBWarrantsMember" xlink:to="PMCB_SeriesBWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBPreferredWarrantsMember" xlink:label="PMCB_SeriesBPreferredWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SeriesBPreferredWarrantsMember" xlink:to="PMCB_SeriesBPreferredWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SeriesBPreferredWarrantsMember_lbl" xml:lang="en-US">Series B Preferred Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SettlementAgreementMember" xlink:label="PMCB_SettlementAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SettlementAgreementMember" xlink:to="PMCB_SettlementAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SettlementAgreementMember_lbl" xml:lang="en-US">Settlement Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FirstWarrantIssuanceMember" xlink:label="PMCB_FirstWarrantIssuanceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_FirstWarrantIssuanceMember" xlink:to="PMCB_FirstWarrantIssuanceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_FirstWarrantIssuanceMember_lbl" xml:lang="en-US">First Warrant Issuance [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SettlementWarrantsMember" xlink:label="PMCB_SettlementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SettlementWarrantsMember" xlink:to="PMCB_SettlementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SettlementWarrantsMember_lbl" xml:lang="en-US">Settlement Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_AdditionalWarrantsMember" xlink:label="PMCB_AdditionalWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_AdditionalWarrantsMember" xlink:to="PMCB_AdditionalWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_AdditionalWarrantsMember_lbl" xml:lang="en-US">Additional Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPrivatePlacementAgreementMember" xlink:label="PMCB_SeriesCPrivatePlacementAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SeriesCPrivatePlacementAgreementMember" xlink:to="PMCB_SeriesCPrivatePlacementAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SeriesCPrivatePlacementAgreementMember_lbl" xml:lang="en-US">Series C Private Placement Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredWarrantsMember" xlink:label="PMCB_SeriesCPreferredWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SeriesCPreferredWarrantsMember" xlink:to="PMCB_SeriesCPreferredWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SeriesCPreferredWarrantsMember_lbl" xml:lang="en-US">Series C Preferred Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPlacementAgentWarrantsMember" xlink:label="PMCB_SeriesCPlacementAgentWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SeriesCPlacementAgentWarrantsMember" xlink:to="PMCB_SeriesCPlacementAgentWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SeriesCPlacementAgentWarrantsMember_lbl" xml:lang="en-US">Series C Placement Agent Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBWarrantsAndSettlementWarrantsAdjustedMember" xlink:label="PMCB_SeriesBWarrantsAndSettlementWarrantsAdjustedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SeriesBWarrantsAndSettlementWarrantsAdjustedMember" xlink:to="PMCB_SeriesBWarrantsAndSettlementWarrantsAdjustedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SeriesBWarrantsAndSettlementWarrantsAdjustedMember_lbl" xml:lang="en-US">Series B Warrants And Settlement Warrants Adjusted [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SGAustraliaMember" xlink:label="PMCB_SGAustraliaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SGAustraliaMember" xlink:to="PMCB_SGAustraliaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SGAustraliaMember_lbl" xml:lang="en-US">SG Australia [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_VinDeBonaMember" xlink:label="PMCB_VinDeBonaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_VinDeBonaMember" xlink:to="PMCB_VinDeBonaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_VinDeBonaMember_lbl" xml:lang="en-US">Vin De Bona [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SGAustriaAndSubsidiariesMember" xlink:label="PMCB_SGAustriaAndSubsidiariesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SGAustriaAndSubsidiariesMember" xlink:to="PMCB_SGAustriaAndSubsidiariesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SGAustriaAndSubsidiariesMember_lbl" xml:lang="en-US">SG Austria And Subsidiaries [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseAxis_lbl" xml:lang="en-US">Litigation Case [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_HCWainwrightMember" xlink:label="PMCB_HCWainwrightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_HCWainwrightMember" xlink:to="PMCB_HCWainwrightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_HCWainwrightMember_lbl" xml:lang="en-US">H.C. Wainwright [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_OptionsMember" xlink:label="PMCB_OptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_OptionsMember" xlink:to="PMCB_OptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_OptionsMember_lbl" xml:lang="en-US">Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredSharesMember" xlink:label="PMCB_PreferredSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_PreferredSharesMember" xlink:to="PMCB_PreferredSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_PreferredSharesMember_lbl" xml:lang="en-US">Preferred Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPurchaseAgreementMember" xlink:label="PMCB_SeriesCPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SeriesCPurchaseAgreementMember" xlink:to="PMCB_SeriesCPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SeriesCPurchaseAgreementMember_lbl" xml:lang="en-US">Series C Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCWarrantsMember" xlink:label="PMCB_SeriesCWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SeriesCWarrantsMember" xlink:to="PMCB_SeriesCWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SeriesCWarrantsMember_lbl" xml:lang="en-US">Series C Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DerivativeLiabilityMember" xlink:label="PMCB_DerivativeLiabilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_DerivativeLiabilityMember" xlink:to="PMCB_DerivativeLiabilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_DerivativeLiabilityMember_lbl" xml:lang="en-US">Derivative Liability [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantLiabilityMember" xlink:label="PMCB_WarrantLiabilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantLiabilityMember" xlink:to="PMCB_WarrantLiabilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_WarrantLiabilityMember_lbl" xml:lang="en-US">Warrant Liability [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_MarketableEquitySecuritiesMember" xlink:label="PMCB_MarketableEquitySecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_MarketableEquitySecuritiesMember" xlink:to="PMCB_MarketableEquitySecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_MarketableEquitySecuritiesMember_lbl" xml:lang="en-US">Marketable Equity Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_MoneyMarketAccountMember" xlink:label="PMCB_MoneyMarketAccountMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_MoneyMarketAccountMember" xlink:to="PMCB_MoneyMarketAccountMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_MoneyMarketAccountMember_lbl" xml:lang="en-US">Money Market Account [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ConvertibleNoteReceivableMember" xlink:label="PMCB_ConvertibleNoteReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ConvertibleNoteReceivableMember" xlink:to="PMCB_ConvertibleNoteReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ConvertibleNoteReceivableMember_lbl" xml:lang="en-US">Convertible Note Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetFemasysMember" xlink:label="PMCB_WarrantAssetFemasysMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantAssetFemasysMember" xlink:to="PMCB_WarrantAssetFemasysMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_WarrantAssetFemasysMember_lbl" xml:lang="en-US">Warrant Asset Femasys [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_InvestmentInPreferredStockQCLSMember" xlink:label="PMCB_InvestmentInPreferredStockQCLSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_InvestmentInPreferredStockQCLSMember" xlink:to="PMCB_InvestmentInPreferredStockQCLSMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_InvestmentInPreferredStockQCLSMember_lbl" xml:lang="en-US">Investment In Preferred Stock QCLS [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetQCLSMember" xlink:label="PMCB_WarrantAssetQCLSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantAssetQCLSMember" xlink:to="PMCB_WarrantAssetQCLSMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_WarrantAssetQCLSMember_lbl" xml:lang="en-US">Warrant Asset QCLS [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetCurrent" xlink:label="PMCB_WarrantAssetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantAssetCurrent" xlink:to="PMCB_WarrantAssetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_WarrantAssetCurrent_lbl" xml:lang="en-US">Warrant asset &#8211; QCLS - current</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ConvertibleNoteReceivableCurrent" xlink:label="PMCB_ConvertibleNoteReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ConvertibleNoteReceivableCurrent" xlink:to="PMCB_ConvertibleNoteReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ConvertibleNoteReceivableCurrent_lbl" xml:lang="en-US">Convertible Note receivable &#8211; Femasys - current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:to="us-gaap_InvestmentsAndOtherNoncurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssets_lbl" xml:lang="en-US">Investment in preferred stock &#8211; QCLS</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetNoncurrent" xlink:label="PMCB_WarrantAssetNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantAssetNoncurrent" xlink:to="PMCB_WarrantAssetNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_WarrantAssetNoncurrent_lbl" xml:lang="en-US">Warrant asset &#8211; QCLS &#8211; non current</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetFemasys" xlink:label="PMCB_WarrantAssetFemasys" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantAssetFemasys" xlink:to="PMCB_WarrantAssetFemasys_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_WarrantAssetFemasys_lbl" xml:lang="en-US">Warrant asset &#8211; Femasys</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendsPayableCurrent" xlink:label="us-gaap_DividendsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrent" xlink:to="us-gaap_DividendsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableCurrent_lbl" xml:lang="en-US">Accrued Series C dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesAbstract" xlink:label="us-gaap_OtherLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesAbstract_lbl" xml:lang="en-US">Other liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Long-term portion of accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantLiabilitiesNoncurrent" xlink:label="PMCB_WarrantLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantLiabilitiesNoncurrent" xlink:to="PMCB_WarrantLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_WarrantLiabilitiesNoncurrent_lbl" xml:lang="en-US">Warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US">Derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Total other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 8)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US">Temporary Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Convertible preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ContingentlyRedeemableWarrants" xlink:label="PMCB_ContingentlyRedeemableWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ContingentlyRedeemableWarrants" xlink:to="PMCB_ContingentlyRedeemableWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ContingentlyRedeemableWarrants_lbl" xml:lang="en-US">Contingently redeemable warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_TotalTemporaryEquity" xlink:label="PMCB_TotalTemporaryEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_TotalTemporaryEquity" xlink:to="PMCB_TotalTemporaryEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="PMCB_TotalTemporaryEquity_lbl" xml:lang="en-US">Total temporary equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock: authorized 200,000,000 shares, $0.0001 par value; 26,005,715 and 21,672,095 shares issued and 10,735,649 and 6,795,779 shares outstanding as of January 31, 2026 and April 30, 2025, respectively.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="us-gaap_TreasuryStockCommonValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xml:lang="en-US">Treasury stock, at cost, 15,270,066 and 14,876,316 shares as of January 31, 2026, and April 30, 2025, respectively.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities, Temporary Equity and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Temporary equity, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Temporary equity, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl" xml:lang="en-US">Temporary equity, face value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Temporary equity, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Temporary equity, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US">Temporary equity liquidation preference</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Treasury stock, common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantLiability" xlink:label="PMCB_ChangeInFairValueOfWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfWarrantLiability" xlink:to="PMCB_ChangeInFairValueOfWarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ChangeInFairValueOfWarrantLiability_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfDerivativeLiability" xlink:label="PMCB_ChangeInFairValueOfDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfDerivativeLiability" xlink:to="PMCB_ChangeInFairValueOfDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ChangeInFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfConvertibleNoteReceivable" xlink:label="PMCB_ChangeInFairValueOfConvertibleNoteReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfConvertibleNoteReceivable" xlink:to="PMCB_ChangeInFairValueOfConvertibleNoteReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ChangeInFairValueOfConvertibleNoteReceivable_lbl" xml:lang="en-US">Change in fair value of convertible note receivable - Femasys</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantAssetFemasys" xlink:label="PMCB_ChangeInFairValueOfWarrantAssetFemasys" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfWarrantAssetFemasys" xlink:to="PMCB_ChangeInFairValueOfWarrantAssetFemasys_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ChangeInFairValueOfWarrantAssetFemasys_lbl" xml:lang="en-US">Change in fair value of warrant asset - Femasys</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfInvestment" xlink:label="PMCB_ChangeInFairValueOfInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfInvestment" xlink:to="PMCB_ChangeInFairValueOfInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ChangeInFairValueOfInvestment_lbl" xml:lang="en-US">Change in fair value of investment - QCLS</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantAsset" xlink:label="PMCB_ChangeInFairValueOfWarrantAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfWarrantAsset" xlink:to="PMCB_ChangeInFairValueOfWarrantAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ChangeInFairValueOfWarrantAsset_lbl" xml:lang="en-US">Change in fair value of warrants - QCLS</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_GainOnFairValueOfWarrantsWainwright" xlink:label="PMCB_GainOnFairValueOfWarrantsWainwright" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_GainOnFairValueOfWarrantsWainwright" xlink:to="PMCB_GainOnFairValueOfWarrantsWainwright_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_GainOnFairValueOfWarrantsWainwright_lbl" xml:lang="en-US">Gain on legal settlement &#8211; re-fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_GainOnRelatedPartyInvestmentQcls" xlink:label="PMCB_GainOnRelatedPartyInvestmentQcls" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_GainOnRelatedPartyInvestmentQcls" xlink:to="PMCB_GainOnRelatedPartyInvestmentQcls_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_GainOnRelatedPartyInvestmentQcls_lbl" xml:lang="en-US">Gain on related party investment - QCLS</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants" xlink:label="PMCB_IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants" xlink:to="PMCB_IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants_lbl" xml:lang="en-US">Issuance costs &#8211; Series C convertible preferred stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LossOnIssuanceOfSeriesCConvertiblePreferredStock" xlink:label="PMCB_LossOnIssuanceOfSeriesCConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_LossOnIssuanceOfSeriesCConvertiblePreferredStock" xlink:to="PMCB_LossOnIssuanceOfSeriesCConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_LossOnIssuanceOfSeriesCConvertiblePreferredStock_lbl" xml:lang="en-US">Loss on issuance of Series C convertible preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income and (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Preferred stock dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount_lbl" xml:lang="en-US">Preferred stock accretion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net income (loss) attributable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic income (loss) per share attributable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted income (loss) per share attributable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares outstanding basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares outstanding diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Foreign currency translation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Other comprehensive income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive income (loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_TreasuryStockCommonShares_2_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FractionalSharesAdjustmentValue" xlink:label="PMCB_FractionalSharesAdjustmentValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_FractionalSharesAdjustmentValue" xlink:to="PMCB_FractionalSharesAdjustmentValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_FractionalSharesAdjustmentValue_lbl" xml:lang="en-US">Fractional shares adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FractionalSharesAdjustmentShares" xlink:label="PMCB_FractionalSharesAdjustmentShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_FractionalSharesAdjustmentShares" xlink:to="PMCB_FractionalSharesAdjustmentShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_FractionalSharesAdjustmentShares_lbl" xml:lang="en-US">Fractional shares adjustment, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation options</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_StockIssuedUponVestingOfRestrictedStockUnits" xlink:label="PMCB_StockIssuedUponVestingOfRestrictedStockUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_StockIssuedUponVestingOfRestrictedStockUnits" xlink:to="PMCB_StockIssuedUponVestingOfRestrictedStockUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_StockIssuedUponVestingOfRestrictedStockUnits_lbl" xml:lang="en-US">Stock issued upon vesting of restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_StockIssuedUponVestingOfRestrictedStockUnitsShares" xlink:label="PMCB_StockIssuedUponVestingOfRestrictedStockUnitsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_StockIssuedUponVestingOfRestrictedStockUnitsShares" xlink:to="PMCB_StockIssuedUponVestingOfRestrictedStockUnitsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_StockIssuedUponVestingOfRestrictedStockUnitsShares_lbl" xml:lang="en-US">Stock issued upon vesting of restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock issued for warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock issued for warrant exercises, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_IssuanceOfSeriesCPreferredStockAndWarrants" xlink:label="PMCB_IssuanceOfSeriesCPreferredStockAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_IssuanceOfSeriesCPreferredStockAndWarrants" xlink:to="PMCB_IssuanceOfSeriesCPreferredStockAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_IssuanceOfSeriesCPreferredStockAndWarrants_lbl" xml:lang="en-US">Issuance of Series C preferred stock and warrants, net of transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_IssuanceOfSeriesCPreferredStockAndWarrantsShares" xlink:label="PMCB_IssuanceOfSeriesCPreferredStockAndWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_IssuanceOfSeriesCPreferredStockAndWarrantsShares" xlink:to="PMCB_IssuanceOfSeriesCPreferredStockAndWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_IssuanceOfSeriesCPreferredStockAndWarrantsShares_lbl" xml:lang="en-US">Issuance of Series C preferred stock and warrants, net of transaction costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredStockAccretion" xlink:label="PMCB_SeriesCPreferredStockAccretion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SeriesCPreferredStockAccretion" xlink:to="PMCB_SeriesCPreferredStockAccretion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SeriesCPreferredStockAccretion_lbl" xml:lang="en-US">Series C Preferred stock accretion</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredStockDividendSubjectToSettlement" xlink:label="PMCB_SeriesCPreferredStockDividendSubjectToSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SeriesCPreferredStockDividendSubjectToSettlement" xlink:to="PMCB_SeriesCPreferredStockDividendSubjectToSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SeriesCPreferredStockDividendSubjectToSettlement_lbl" xml:lang="en-US">Series C preferred stock dividend subject to settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredStockDividendsAccrual" xlink:label="PMCB_SeriesCPreferredStockDividendsAccrual" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SeriesCPreferredStockDividendsAccrual" xlink:to="PMCB_SeriesCPreferredStockDividendsAccrual_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SeriesCPreferredStockDividendsAccrual_lbl" xml:lang="en-US">Series C preferred stock dividends accrual</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredStockAccretion" xlink:label="PMCB_PreferredStockAccretion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_PreferredStockAccretion" xlink:to="PMCB_PreferredStockAccretion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_PreferredStockAccretion_lbl" xml:lang="en-US">Preferred stock accretion</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredStockRedeemed" xlink:label="PMCB_SeriesCPreferredStockRedeemed" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SeriesCPreferredStockRedeemed" xlink:to="PMCB_SeriesCPreferredStockRedeemed_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SeriesCPreferredStockRedeemed_lbl" xml:lang="en-US">Series C preferred stock redeemed</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredStockRedeemedShares" xlink:label="PMCB_SeriesCPreferredStockRedeemedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SeriesCPreferredStockRedeemedShares" xlink:to="PMCB_SeriesCPreferredStockRedeemedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SeriesCPreferredStockRedeemedShares_lbl" xml:lang="en-US">Series C preferred stock redeemed, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredStockSubjectToSettlement" xlink:label="PMCB_SeriesCPreferredStockSubjectToSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SeriesCPreferredStockSubjectToSettlement" xlink:to="PMCB_SeriesCPreferredStockSubjectToSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SeriesCPreferredStockSubjectToSettlement_lbl" xml:lang="en-US">Series C preferred stock subject to settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBPreferredStockSubjectToRedemption" xlink:label="PMCB_SeriesBPreferredStockSubjectToRedemption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SeriesBPreferredStockSubjectToRedemption" xlink:to="PMCB_SeriesBPreferredStockSubjectToRedemption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SeriesBPreferredStockSubjectToRedemption_lbl" xml:lang="en-US">Series B preferred stock redemption</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBPreferredStockRedeemedShares" xlink:label="PMCB_SeriesBPreferredStockRedeemedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SeriesBPreferredStockRedeemedShares" xlink:to="PMCB_SeriesBPreferredStockRedeemedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SeriesBPreferredStockRedeemedShares_lbl" xml:lang="en-US">Series B preferred stock redemption, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBPreferredStockRedemption" xlink:label="PMCB_SeriesBPreferredStockRedemption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SeriesBPreferredStockRedemption" xlink:to="PMCB_SeriesBPreferredStockRedemption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SeriesBPreferredStockRedemption_lbl" xml:lang="en-US">Series B preferred stock subject to redemption</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBPreferredStockSubjectToRedemptionShares" xlink:label="PMCB_SeriesBPreferredStockSubjectToRedemptionShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SeriesBPreferredStockSubjectToRedemptionShares" xlink:to="PMCB_SeriesBPreferredStockSubjectToRedemptionShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SeriesBPreferredStockSubjectToRedemptionShares_lbl" xml:lang="en-US">Series B preferred stock subject to redemption, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_lbl" xml:lang="en-US">Preferred stock dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Repurchase of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Repurchase of common stock, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_TreasuryStockCommonShares_3_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash used in operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_GainOnRelatedPartyInvestmentQcls" xlink:to="PMCB_GainOnRelatedPartyInvestmentQcls_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PMCB_GainOnRelatedPartyInvestmentQcls_2_lbl" xml:lang="en-US">Gain on related party investment &#8211; QCLS</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_IssuanceCostsSeriesCPreferredStockAndWarrants" xlink:label="PMCB_IssuanceCostsSeriesCPreferredStockAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_IssuanceCostsSeriesCPreferredStockAndWarrants" xlink:to="PMCB_IssuanceCostsSeriesCPreferredStockAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_IssuanceCostsSeriesCPreferredStockAndWarrants_lbl" xml:lang="en-US">Issuance costs &#8211; Series C preferred stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LossOnIssuanceOfSeriesCPreferredStock" xlink:label="PMCB_LossOnIssuanceOfSeriesCPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_LossOnIssuanceOfSeriesCPreferredStock" xlink:to="PMCB_LossOnIssuanceOfSeriesCPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_LossOnIssuanceOfSeriesCPreferredStock_lbl" xml:lang="en-US">Loss on issuance of Series C preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_GainOnFairValueOfWarrants" xlink:label="PMCB_GainOnFairValueOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_GainOnFairValueOfWarrants" xlink:to="PMCB_GainOnFairValueOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PMCB_GainOnFairValueOfWarrants_lbl" xml:lang="en-US">Gain on re-fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_NoncashInterestIncome" xlink:label="PMCB_NoncashInterestIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_NoncashInterestIncome" xlink:to="PMCB_NoncashInterestIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PMCB_NoncashInterestIncome_lbl" xml:lang="en-US">Non-cash interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock issued for compensation - RSUs</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_StockbasedCompensationOptions" xlink:label="PMCB_StockbasedCompensationOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_StockbasedCompensationOptions" xlink:to="PMCB_StockbasedCompensationOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_StockbasedCompensationOptions_lbl" xml:lang="en-US">Stock-based compensation - options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_2_lbl" xml:lang="en-US">Unrealized loss on marketable equity securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfWarrantLiability" xlink:to="PMCB_ChangeInFairValueOfWarrantLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PMCB_ChangeInFairValueOfWarrantLiability_2_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfDerivativeLiability" xlink:to="PMCB_ChangeInFairValueOfDerivativeLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PMCB_ChangeInFairValueOfDerivativeLiability_2_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfConvertibleNotesReceivable" xlink:label="PMCB_ChangeInFairValueOfConvertibleNotesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfConvertibleNotesReceivable" xlink:to="PMCB_ChangeInFairValueOfConvertibleNotesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PMCB_ChangeInFairValueOfConvertibleNotesReceivable_lbl" xml:lang="en-US">Change in fair value of convertible note receivable - Femasys</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfWarrantAssetFemasys" xlink:to="PMCB_ChangeInFairValueOfWarrantAssetFemasys_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PMCB_ChangeInFairValueOfWarrantAssetFemasys_2_lbl" xml:lang="en-US">Change in fair value of warrant asset &#8211; Femasys</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfInvestmentQcls" xlink:label="PMCB_ChangeInFairValueOfInvestmentQcls" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfInvestmentQcls" xlink:to="PMCB_ChangeInFairValueOfInvestmentQcls_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PMCB_ChangeInFairValueOfInvestmentQcls_lbl" xml:lang="en-US">Change in fair value of investment &#8211; QCLS</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantsQcls" xlink:label="PMCB_ChangeInFairValueOfWarrantsQcls" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfWarrantsQcls" xlink:to="PMCB_ChangeInFairValueOfWarrantsQcls_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PMCB_ChangeInFairValueOfWarrantsQcls_lbl" xml:lang="en-US">Change in fair value of warrants - QCLS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xml:lang="en-US">Change in assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Decrease in prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Increase in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xml:lang="en-US">Decrease in accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash and cash equivalents used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ProceedsFromInvestmentNoteReceivable" xlink:label="PMCB_ProceedsFromInvestmentNoteReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ProceedsFromInvestmentNoteReceivable" xlink:to="PMCB_ProceedsFromInvestmentNoteReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ProceedsFromInvestmentNoteReceivable_lbl" xml:lang="en-US">Proceeds from investment - note receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_InvestmentInPreferredStockAndWarrantsInQcls" xlink:label="PMCB_InvestmentInPreferredStockAndWarrantsInQcls" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_InvestmentInPreferredStockAndWarrantsInQcls" xlink:to="PMCB_InvestmentInPreferredStockAndWarrantsInQcls_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PMCB_InvestmentInPreferredStockAndWarrantsInQcls_lbl" xml:lang="en-US">Investment in preferred stock and warrants in QCLS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash and cash equivalents provided by (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Repurchase of common stock, net</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_RedemptionOfPreferredStock" xlink:label="PMCB_RedemptionOfPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_RedemptionOfPreferredStock" xlink:to="PMCB_RedemptionOfPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PMCB_RedemptionOfPreferredStock_lbl" xml:lang="en-US">Redemption of preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Net proceeds from issuance of Series C convertible preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Net proceeds from exercises of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PaymentOfSeriesCConvertiblePreferredStockDividends" xlink:label="PMCB_PaymentOfSeriesCConvertiblePreferredStockDividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_PaymentOfSeriesCConvertiblePreferredStockDividends" xlink:to="PMCB_PaymentOfSeriesCConvertiblePreferredStockDividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PMCB_PaymentOfSeriesCConvertiblePreferredStockDividends_lbl" xml:lang="en-US">Payment of Series C convertible preferred stock dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash and cash equivalents provided by (used in) financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of currency rate exchange on cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of the period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents at end of the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability" xlink:label="PMCB_ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability" xlink:to="PMCB_ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability_lbl" xml:lang="en-US">Reclassification of Series B Convertible Preferred Stock and dividends to current liability</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock" xlink:label="PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock" xlink:to="PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock_lbl" xml:lang="en-US">Accretion of discounts to redemption value of Series B Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_AccrualOfSeriesCConvertiblePreferredStockDividends" xlink:label="PMCB_AccrualOfSeriesCConvertiblePreferredStockDividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_AccrualOfSeriesCConvertiblePreferredStockDividends" xlink:to="PMCB_AccrualOfSeriesCConvertiblePreferredStockDividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_AccrualOfSeriesCConvertiblePreferredStockDividends_lbl" xml:lang="en-US">Accrual of Series C Convertible Preferred Stock dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts" xlink:label="PMCB_AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts" xlink:to="PMCB_AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts_lbl" xml:lang="en-US">Accrual of Series C Convertible Preferred Stock issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock" xlink:label="PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock" xlink:to="PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock_lbl" xml:lang="en-US">Accretion of discounts to redemption value of Series C Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_InitialFairValueOfInvestmentInQclsSeriesHPreferredShares" xlink:label="PMCB_InitialFairValueOfInvestmentInQclsSeriesHPreferredShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_InitialFairValueOfInvestmentInQclsSeriesHPreferredShares" xlink:to="PMCB_InitialFairValueOfInvestmentInQclsSeriesHPreferredShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_InitialFairValueOfInvestmentInQclsSeriesHPreferredShares_lbl" xml:lang="en-US">Initial fair value of investment in QCLS Series H preferred shares</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_InitialFairValueOfInvestmentInQclsSeriesHWarrants" xlink:label="PMCB_InitialFairValueOfInvestmentInQclsSeriesHWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_InitialFairValueOfInvestmentInQclsSeriesHWarrants" xlink:to="PMCB_InitialFairValueOfInvestmentInQclsSeriesHWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_InitialFairValueOfInvestmentInQclsSeriesHWarrants_lbl" xml:lang="en-US">Initial fair value of investment in QCLS Series H warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_NoncashDerivativeLiabilityAtInitialFairValue" xlink:label="PMCB_NoncashDerivativeLiabilityAtInitialFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_NoncashDerivativeLiabilityAtInitialFairValue" xlink:to="PMCB_NoncashDerivativeLiabilityAtInitialFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_NoncashDerivativeLiabilityAtInitialFairValue_lbl" xml:lang="en-US">Non-cash derivative liability at initial fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_NoncashWarrantLiabilityAtInitialFairValue" xlink:label="PMCB_NoncashWarrantLiabilityAtInitialFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_NoncashWarrantLiabilityAtInitialFairValue" xlink:to="PMCB_NoncashWarrantLiabilityAtInitialFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_NoncashWarrantLiabilityAtInitialFairValue_lbl" xml:lang="en-US">Non-cash warrant liability at initial fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_NoncashRedemptionOfSeriesCConvertiblePreferredStock" xlink:label="PMCB_NoncashRedemptionOfSeriesCConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_NoncashRedemptionOfSeriesCConvertiblePreferredStock" xlink:to="PMCB_NoncashRedemptionOfSeriesCConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_NoncashRedemptionOfSeriesCConvertiblePreferredStock_lbl" xml:lang="en-US">Non-cash redemption of Series C convertible preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueAssociatedWarrantExercises" xlink:label="PMCB_ChangeInFairValueAssociatedWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueAssociatedWarrantExercises" xlink:to="PMCB_ChangeInFairValueAssociatedWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ChangeInFairValueAssociatedWarrantExercises_lbl" xml:lang="en-US">Change in fair value associated warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FairValueOfContingentlyRedeemablePlacementAgentWarrants" xlink:label="PMCB_FairValueOfContingentlyRedeemablePlacementAgentWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_FairValueOfContingentlyRedeemablePlacementAgentWarrants" xlink:to="PMCB_FairValueOfContingentlyRedeemablePlacementAgentWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_FairValueOfContingentlyRedeemablePlacementAgentWarrants_lbl" xml:lang="en-US">Fair value of contingently redeemable placement agent warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ExciseTaxAccruedOnRepurchaseOfCommonStock" xlink:label="PMCB_ExciseTaxAccruedOnRepurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ExciseTaxAccruedOnRepurchaseOfCommonStock" xlink:to="PMCB_ExciseTaxAccruedOnRepurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ExciseTaxAccruedOnRepurchaseOfCommonStock_lbl" xml:lang="en-US">Excise tax accrued on repurchase of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EqtyAwrdsAdjFnTextBlock_lbl" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl" xml:lang="en-US">Aggregate Available</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">NATURE OF BUSINESS</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DisclosureLiquidityAndOtherUncertaintiesAbstract" xlink:label="PMCB_DisclosureLiquidityAndOtherUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_DisclosureLiquidityAndOtherUncertaintiesAbstract" xlink:to="PMCB_DisclosureLiquidityAndOtherUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_DisclosureLiquidityAndOtherUncertaintiesAbstract_lbl" xml:lang="en-US">Liquidity And Other Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LiquidityAndOtherUncertainitiesTextBlock" xlink:label="PMCB_LiquidityAndOtherUncertainitiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_LiquidityAndOtherUncertainitiesTextBlock" xlink:to="PMCB_LiquidityAndOtherUncertainitiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_LiquidityAndOtherUncertainitiesTextBlock_lbl" xml:lang="en-US">LIQUIDITY AND OTHER UNCERTAINTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:label="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:to="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock_lbl" xml:lang="en-US">INVESTMENT IN DEBT AND EQUITY SECURITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK OPTIONS AND WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">OTHER RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">EARNINGS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US">PREFERRED STOCK</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockTextBlock" xlink:label="us-gaap_TreasuryStockTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockTextBlock" xlink:to="us-gaap_TreasuryStockTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockTextBlock_lbl" xml:lang="en-US">TREASURY STOCK</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates in the Preparation of Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Reclassifications" xlink:label="us-gaap_Reclassifications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Reclassifications" xlink:to="us-gaap_Reclassifications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Reclassifications_lbl" xml:lang="en-US">Reclassification</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncement Effective in Future Periods</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock" xlink:label="us-gaap_ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock" xlink:to="us-gaap_ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock_lbl" xml:lang="en-US">Schedule of activity for the notes and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock" xlink:label="us-gaap_ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock" xlink:to="us-gaap_ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock_lbl" xml:lang="en-US">Schedule of marketable equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentTableTextBlock" xlink:label="us-gaap_InvestmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTableTextBlock" xlink:to="us-gaap_InvestmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTableTextBlock_lbl" xml:lang="en-US">Schedule of activity preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of warrant activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of basic and diluted earnings (loss) per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of potentially dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of fair value of financial liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of change in the fair value warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of change in the fair value derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of fair values of financial instruments by class</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock issued new, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from sale of equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="us-gaap_InvestmentOwnedBalanceShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalanceShares" xlink:to="us-gaap_InvestmentOwnedBalanceShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedBalanceShares_lbl" xml:lang="en-US">Investment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US">Payments to Acquire Investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, uninsured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of Reportable Segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralTable" xlink:label="us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralTable" xlink:to="us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralTable_lbl" xml:lang="en-US">Financial Instruments Owned and Pledged as Collateral [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" xlink:label="us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" xlink:to="us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralLineItems_lbl" xml:lang="en-US">Financial Instruments Owned and Pledged as Collateral [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ConvertibleNoteReceivableCurrent" xlink:to="PMCB_ConvertibleNoteReceivableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="PMCB_ConvertibleNoteReceivableCurrent_2_lbl" xml:lang="en-US">Investment, beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfConvertibleNotesReceivable" xlink:to="PMCB_ChangeInFairValueOfConvertibleNotesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ChangeInFairValueOfConvertibleNotesReceivable_2_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ProceedsFromInvestmentNoteReceivable" xlink:to="PMCB_ProceedsFromInvestmentNoteReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PMCB_ProceedsFromInvestmentNoteReceivable_2_lbl" xml:lang="en-US">Settlement of Femasys Note</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ConvertibleNoteReceivableCurrent" xlink:to="PMCB_ConvertibleNoteReceivableCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="PMCB_ConvertibleNoteReceivableCurrent_3_lbl" xml:lang="en-US">Investment, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantAssetFemasys" xlink:to="PMCB_WarrantAssetFemasys_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="PMCB_WarrantAssetFemasys_2_lbl" xml:lang="en-US">Investment, beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfWarrantAssetFemasys" xlink:to="PMCB_ChangeInFairValueOfWarrantAssetFemasys_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PMCB_ChangeInFairValueOfWarrantAssetFemasys_3_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantAssetFemasys" xlink:to="PMCB_WarrantAssetFemasys_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="PMCB_WarrantAssetFemasys_3_lbl" xml:lang="en-US">Investment, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementTable" xlink:label="us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementTable" xlink:to="us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementTable_lbl" xml:lang="en-US">Qualitative and Quantitative Information, Transferor's Continuing Involvement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems" xlink:label="us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems" xlink:to="us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems_lbl" xml:lang="en-US">Qualitative and Quantitative Information, Transferor's Continuing Involvement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_2_lbl" xml:lang="en-US">Carrying value at fair market value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="us-gaap_InvestmentOwnedAtCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtCost" xlink:to="us-gaap_InvestmentOwnedAtCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedAtCost_lbl" xml:lang="en-US">Adjusted cost basis</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_3_lbl" xml:lang="en-US">Unrealized loss</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DisclosureTable" xlink:label="PMCB_DisclosureTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_DisclosureTable" xlink:to="PMCB_DisclosureTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_DisclosureTable_lbl" xml:lang="en-US">DisclosureTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DisclosureLineElements" xlink:label="PMCB_DisclosureLineElements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_DisclosureLineElements" xlink:to="PMCB_DisclosureLineElements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_DisclosureLineElements_lbl" xml:lang="en-US">DisclosureLineElements [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:to="us-gaap_InvestmentsAndOtherNoncurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssets_2_lbl" xml:lang="en-US">Investment, beginnning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfInvestment" xlink:to="PMCB_ChangeInFairValueOfInvestment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PMCB_ChangeInFairValueOfInvestment_2_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:to="us-gaap_InvestmentsAndOtherNoncurrentAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_InvestmentsAndOtherNoncurrentAssets_3_lbl" xml:lang="en-US">Investment, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtFairValue" xlink:to="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xml:lang="en-US">Initial fair value of Investment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfInvestmentQcls" xlink:to="PMCB_ChangeInFairValueOfInvestmentQcls_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PMCB_ChangeInFairValueOfInvestmentQcls_2_lbl" xml:lang="en-US">Change in fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquireInvestments_2_lbl" xml:lang="en-US">Payments for investments</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ReceivableInstrumentConvertibleConversionPrice1" xlink:label="PMCB_ReceivableInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ReceivableInstrumentConvertibleConversionPrice1" xlink:to="PMCB_ReceivableInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ReceivableInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Receivable conversion price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedBalanceShares" xlink:to="us-gaap_InvestmentOwnedBalanceShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentOwnedBalanceShares_2_lbl" xml:lang="en-US">Investment shares owned</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_InvestmentSharesAddition" xlink:label="PMCB_InvestmentSharesAddition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_InvestmentSharesAddition" xlink:to="PMCB_InvestmentSharesAddition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_InvestmentSharesAddition_lbl" xml:lang="en-US">Investment shares additions</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SettlementOfAccruedInterest" xlink:label="PMCB_SettlementOfAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_SettlementOfAccruedInterest" xlink:to="PMCB_SettlementOfAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_SettlementOfAccruedInterest_lbl" xml:lang="en-US">Settlement of accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US">Interest and other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US">Interest receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtFairValue" xlink:to="us-gaap_InvestmentOwnedAtFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentOwnedAtFairValue_2_lbl" xml:lang="en-US">Investment, fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ConvertibleNoteReceivableCurrent" xlink:to="PMCB_ConvertibleNoteReceivableCurrent_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PMCB_ConvertibleNoteReceivableCurrent_4_lbl" xml:lang="en-US">Convertible note receivable, current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantAssetFemasys" xlink:to="PMCB_WarrantAssetFemasys_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PMCB_WarrantAssetFemasys_4_lbl" xml:lang="en-US">Warrant asset - Femasys</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfConvertibleNotesReceivable" xlink:to="PMCB_ChangeInFairValueOfConvertibleNotesReceivable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PMCB_ChangeInFairValueOfConvertibleNotesReceivable_3_lbl" xml:lang="en-US">Change in fair value of the convertible note receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfWarrantAssetFemasys" xlink:to="PMCB_ChangeInFairValueOfWarrantAssetFemasys_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="PMCB_ChangeInFairValueOfWarrantAssetFemasys_4_lbl" xml:lang="en-US">Change in fair value of the convertible note receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireEquityMethodInvestments_lbl" xml:lang="en-US">Investment interest payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_4_lbl" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrant shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Stockholders equity, reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="us-gaap_RealizedInvestmentGainsLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xml:lang="en-US">Recognized gain (loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RealizedInvestmentGainsLosses_2_lbl" xml:lang="en-US">Recognized gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue" xlink:label="us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue" xlink:to="us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_lbl" xml:lang="en-US">Fair value measurement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtCost" xlink:to="us-gaap_InvestmentOwnedAtCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentOwnedAtCost_2_lbl" xml:lang="en-US">Investment, cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_GainOnRelatedPartyInvestmentQcls" xlink:to="PMCB_GainOnRelatedPartyInvestmentQcls_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PMCB_GainOnRelatedPartyInvestmentQcls_3_lbl" xml:lang="en-US">Investment, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesRealizedGainLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesRealizedGainLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtSecuritiesRealizedGainLoss_lbl" xml:lang="en-US">Recognized gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of the warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Accrued liabilities, current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price per share, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of options, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price per share, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of options, expired and forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price per share, expired and forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options outstanding, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price per share, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price per share, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted-average remaining contractual term, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding, beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Weighted average exercise price warrants outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantsIssuedShares" xlink:label="PMCB_WarrantsIssuedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantsIssuedShares" xlink:to="PMCB_WarrantsIssuedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PMCB_WarrantsIssuedShares_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average exercise price warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantExercised" xlink:label="PMCB_WarrantExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantExercised" xlink:to="PMCB_WarrantExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PMCB_WarrantExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WeightedAverageExercisePriceWarrantsExercised" xlink:label="PMCB_WeightedAverageExercisePriceWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WeightedAverageExercisePriceWarrantsExercised" xlink:to="PMCB_WeightedAverageExercisePriceWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_WeightedAverageExercisePriceWarrantsExercised_lbl" xml:lang="en-US">Weighted average exercise price warrants Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantsExpired" xlink:label="PMCB_WarrantsExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantsExpired" xlink:to="PMCB_WarrantsExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PMCB_WarrantsExpired_lbl" xml:lang="en-US">Warrants expired</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WeightedAverageExercisePriceWarrantsExpired" xlink:label="PMCB_WeightedAverageExercisePriceWarrantsExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WeightedAverageExercisePriceWarrantsExpired" xlink:to="PMCB_WeightedAverageExercisePriceWarrantsExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_WeightedAverageExercisePriceWarrantsExpired_lbl" xml:lang="en-US">Weighted average exercise price warrants Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Warrants outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Weighted average exercise price warrants outstanding, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantsExercisable" xlink:label="PMCB_WarrantsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantsExercisable" xlink:to="PMCB_WarrantsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_WarrantsExercisable_lbl" xml:lang="en-US">Warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WeightedAverageExercisePriceWarrantsExercisable" xlink:label="PMCB_WeightedAverageExercisePriceWarrantsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WeightedAverageExercisePriceWarrantsExercisable" xlink:to="PMCB_WeightedAverageExercisePriceWarrantsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_WeightedAverageExercisePriceWarrantsExercisable_lbl" xml:lang="en-US">Weighted average exercise price warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Shares authorized for grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_lbl" xml:lang="en-US">Increase number of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Employee service unrecognized compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Warrants acquire</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Proceeds from warrant exercises</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfWarrantLiability" xlink:to="PMCB_ChangeInFairValueOfWarrantLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="PMCB_ChangeInFairValueOfWarrantLiability_3_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Fair value of the warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Fair value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementGain" xlink:label="us-gaap_LitigationSettlementGain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementGain" xlink:to="us-gaap_LitigationSettlementGain_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementGain_lbl" xml:lang="en-US">Gain on legal settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_IssuanceFairValues" xlink:label="PMCB_IssuanceFairValues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_IssuanceFairValues" xlink:to="PMCB_IssuanceFairValues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_IssuanceFairValues_lbl" xml:lang="en-US">Issuance fair values</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfWarrantAsset" xlink:to="PMCB_ChangeInFairValueOfWarrantAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PMCB_ChangeInFairValueOfWarrantAsset_2_lbl" xml:lang="en-US">Change in fair value warrant asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity interest owned</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">Consulting fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Contractual obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xml:lang="en-US">Initial payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLegalSettlements" xlink:to="us-gaap_PaymentsForLegalSettlements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl" xml:lang="en-US">Payment for legal settlements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Debt instrument periodic payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantsIssuedShares" xlink:to="PMCB_WarrantsIssuedShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_WarrantsIssuedShares_2_lbl" xml:lang="en-US">Warrants issued shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_4_lbl" xml:lang="en-US">Warrants issued per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount_2_lbl" xml:lang="en-US">Less: Accretion of discounts to redemption of convertible preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ConvertiblePreferredStockDividends" xlink:label="PMCB_ConvertiblePreferredStockDividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ConvertiblePreferredStockDividends" xlink:to="PMCB_ConvertiblePreferredStockDividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="PMCB_ConvertiblePreferredStockDividends_lbl" xml:lang="en-US">Less: Convertible preferred stock dividends</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_lbl" xml:lang="en-US">Undistributed income (loss) available to common stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average shares outstanding used in basic earnings per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted average shares outstanding used in diluted earnings per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Net income (loss) per share basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Net income (loss) per share diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LessAllocationOfUndistributedIncome" xlink:label="PMCB_LessAllocationOfUndistributedIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_LessAllocationOfUndistributedIncome" xlink:to="PMCB_LessAllocationOfUndistributedIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_LessAllocationOfUndistributedIncome_lbl" xml:lang="en-US">Less: Allocation of undistributed income to Series B convertible preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Aggregate shares</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredStockParValuePerShare" xlink:label="PMCB_PreferredStockParValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_PreferredStockParValuePerShare" xlink:to="PMCB_PreferredStockParValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PMCB_PreferredStockParValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredStockStatedValuePerShare" xlink:label="PMCB_PreferredStockStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_PreferredStockStatedValuePerShare" xlink:to="PMCB_PreferredStockStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_PreferredStockStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, stated value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Conversion shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Aggregate gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xml:lang="en-US">Engagement letter, description</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PlacementAgentFeePercentage" xlink:label="PMCB_PlacementAgentFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_PlacementAgentFeePercentage" xlink:to="PMCB_PlacementAgentFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_PlacementAgentFeePercentage_lbl" xml:lang="en-US">Placement agent, cash fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:to="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_lbl" xml:lang="en-US">Fair value of derivative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeAssetLiabilityNetMeasurementInput" xlink:label="us-gaap_DerivativeAssetLiabilityNetMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetLiabilityNetMeasurementInput" xlink:to="us-gaap_DerivativeAssetLiabilityNetMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeAssetLiabilityNetMeasurementInput_lbl" xml:lang="en-US">Derivative, measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredStockDiscount" xlink:label="PMCB_PreferredStockDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_PreferredStockDiscount" xlink:to="PMCB_PreferredStockDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_PreferredStockDiscount_lbl" xml:lang="en-US">Total discount on preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FairValueEmbeddedDerivative" xlink:label="PMCB_FairValueEmbeddedDerivative" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_FairValueEmbeddedDerivative" xlink:to="PMCB_FairValueEmbeddedDerivative_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_FairValueEmbeddedDerivative_lbl" xml:lang="en-US">Fair value of embedded derivative</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantLiabilityFairValue" xlink:label="PMCB_WarrantLiabilityFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantLiabilityFairValue" xlink:to="PMCB_WarrantLiabilityFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_WarrantLiabilityFairValue_lbl" xml:lang="en-US">Fair value of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Proceeds from issuance of preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DeemedDividend" xlink:label="PMCB_DeemedDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_DeemedDividend" xlink:to="PMCB_DeemedDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_DeemedDividend_lbl" xml:lang="en-US">Deemed dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueDerivativeLiability" xlink:label="PMCB_ChangeInFairValueDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueDerivativeLiability" xlink:to="PMCB_ChangeInFairValueDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ChangeInFairValueDerivativeLiability_lbl" xml:lang="en-US">Change in fair value derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockStock" xlink:to="us-gaap_DividendsPreferredStockStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US">Preferred dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="us-gaap_DividendsPreferredStockCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockCash" xlink:to="us-gaap_DividendsPreferredStockCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockCash_lbl" xml:lang="en-US">Dividend paid in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendsPreferredStockPaidinkind" xlink:label="us-gaap_DividendsPreferredStockPaidinkind" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockPaidinkind" xlink:to="us-gaap_DividendsPreferredStockPaidinkind_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockPaidinkind_lbl" xml:lang="en-US">Dividend accrued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Stock converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Restricted stock vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted units valued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_3_lbl" xml:lang="en-US">Stock issued for compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonValue_2_lbl" xml:lang="en-US">Treasury stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xml:lang="en-US">Fair Value, off-Balance-Sheet Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xml:lang="en-US">Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_2_lbl" xml:lang="en-US">Warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_3_lbl" xml:lang="en-US">Fair value, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_lbl" xml:lang="en-US">Issuance of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantExercises" xlink:label="PMCB_WarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantExercises" xlink:to="PMCB_WarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_WarrantExercises_lbl" xml:lang="en-US">Warrant exercises</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfWarrantLiability" xlink:to="PMCB_ChangeInFairValueOfWarrantLiability_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="PMCB_ChangeInFairValueOfWarrantLiability_4_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_4_lbl" xml:lang="en-US">Fair value, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_IssuanceOfSeriesCConvertiblePreferredStock" xlink:label="PMCB_IssuanceOfSeriesCConvertiblePreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_IssuanceOfSeriesCConvertiblePreferredStock" xlink:to="PMCB_IssuanceOfSeriesCConvertiblePreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_IssuanceOfSeriesCConvertiblePreferredStock_lbl" xml:lang="en-US">Issuance of Series C convertible preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:to="us-gaap_FinancialInstrumentsOwnedAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsOwnedAtFairValue_lbl" xml:lang="en-US">Fair value of financial assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_NoncashRedemptionOfSeriesCConvertiblePreferredStock" xlink:to="PMCB_NoncashRedemptionOfSeriesCConvertiblePreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="PMCB_NoncashRedemptionOfSeriesCConvertiblePreferredStock_doc" xml:lang="en-US">Noncash Redemption of Series C Convertible Preferred Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_2_lbl" xml:lang="en-US">Other Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_TotalTemporaryEquity" xlink:to="PMCB_TotalTemporaryEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_TotalTemporaryEquity_2_lbl" xml:lang="en-US">TotalTemporaryEquity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_2_lbl" xml:lang="en-US">Dividends, Preferred Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount_3_lbl" xml:lang="en-US">Preferred Stock, Accretion of Redemption Discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_2_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings_2_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_2_lbl" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_2_lbl" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_GainOnFairValueOfWarrants" xlink:to="PMCB_GainOnFairValueOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_GainOnFairValueOfWarrants_2_lbl" xml:lang="en-US">GainOnFairValueOfWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_NoncashInterestIncome" xlink:to="PMCB_NoncashInterestIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_NoncashInterestIncome_2_lbl" xml:lang="en-US">NoncashInterestIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfInvestmentQcls" xlink:to="PMCB_ChangeInFairValueOfInvestmentQcls_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ChangeInFairValueOfInvestmentQcls_3_lbl" xml:lang="en-US">ChangeInFairValueOfInvestmentQcls</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ChangeInFairValueOfWarrantsQcls" xlink:to="PMCB_ChangeInFairValueOfWarrantsQcls_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ChangeInFairValueOfWarrantsQcls_2_lbl" xml:lang="en-US">ChangeInFairValueOfWarrantsQcls</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_InvestmentInPreferredStockAndWarrantsInQcls" xlink:to="PMCB_InvestmentInPreferredStockAndWarrantsInQcls_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_InvestmentInPreferredStockAndWarrantsInQcls_2_lbl" xml:lang="en-US">InvestmentInPreferredStockAndWarrantsInQcls</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_2_lbl" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_RedemptionOfPreferredStock" xlink:to="PMCB_RedemptionOfPreferredStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_RedemptionOfPreferredStock_2_lbl" xml:lang="en-US">RedemptionOfPreferredStock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_PaymentOfSeriesCConvertiblePreferredStockDividends" xlink:to="PMCB_PaymentOfSeriesCConvertiblePreferredStockDividends_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_PaymentOfSeriesCConvertiblePreferredStockDividends_2_lbl" xml:lang="en-US">PaymentOfSeriesCConvertiblePreferredStockDividends</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesRealizedGainLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesRealizedGainLoss_2_lbl" xml:lang="en-US">Debt Securities, Realized Gain (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantExercised" xlink:to="PMCB_WarrantExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_WarrantExercised_2_lbl" xml:lang="en-US">WarrantExercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_WarrantsExpired" xlink:to="PMCB_WarrantsExpired_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_WarrantsExpired_2_lbl" xml:lang="en-US">WarrantsExpired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_5_lbl" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_ConvertiblePreferredStockDividends" xlink:to="PMCB_ConvertiblePreferredStockDividends_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_ConvertiblePreferredStockDividends_2_lbl" xml:lang="en-US">ConvertiblePreferredStockDividends</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PMCB_PreferredStockParValuePerShare" xlink:to="PMCB_PreferredStockParValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="PMCB_PreferredStockParValuePerShare_2_lbl" xml:lang="en-US">PreferredStockParValuePerShare</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Accounts Payable</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>pmcb-20260131_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.4b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#Cover" roleURI="http://pharmacyte.com/role/Cover" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity" roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#NatureOfBusiness" roleURI="http://pharmacyte.com/role/NatureOfBusiness" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#LiquidityAndOtherUncertainties" roleURI="http://pharmacyte.com/role/LiquidityAndOtherUncertainties" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://pharmacyte.com/role/SummaryOfSignificantAccountingPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecurities" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecurities" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#AccruedExpenses" roleURI="http://pharmacyte.com/role/AccruedExpenses" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#StockOptionsAndWarrants" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrants" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#OtherRelatedPartyTransactions" roleURI="http://pharmacyte.com/role/OtherRelatedPartyTransactions" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CommitmentsAndContingencies" roleURI="http://pharmacyte.com/role/CommitmentsAndContingencies" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#EarningsPerShare" roleURI="http://pharmacyte.com/role/EarningsPerShare" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#PreferredStock" roleURI="http://pharmacyte.com/role/PreferredStock" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#TreasuryStock" roleURI="http://pharmacyte.com/role/TreasuryStock" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#FairValueMeasurements" roleURI="http://pharmacyte.com/role/FairValueMeasurements" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecuritiesTables" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#AccruedExpensesTables" roleURI="http://pharmacyte.com/role/AccruedExpensesTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#StockOptionsAndWarrantsTables" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#EarningsPerShareTables" roleURI="http://pharmacyte.com/role/EarningsPerShareTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#FairValueMeasurementsTables" roleURI="http://pharmacyte.com/role/FairValueMeasurementsTables" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#LiquidityAndOtherUncertaintiesDetailsNarrative" roleURI="http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" roleURI="http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#InvestmentInDebtAndEquitySecuritiesDetailsNarrative" roleURI="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#AccruedExpensesDetails" roleURI="http://pharmacyte.com/role/AccruedExpensesDetails" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#StockOptionsAndWarrantsDetails-OptionActivity" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#StockOptionsAndWarrantsDetails-WarrantActivity" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#StockOptionsAndWarrantsDetailsNarrative" roleURI="http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#OtherRelatedPartyTransactionsDetailsNarrative" roleURI="http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#CommitmentsAndContingenciesDetailsNarrative" roleURI="http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#EarningsPerShareDetails-PerShareCalculation" roleURI="http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#EarningsPerShareDetails-DilutedShares" roleURI="http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#PreferredStockDetailsNarrative" roleURI="http://pharmacyte.com/role/PreferredStockDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#TreasuryStockDetailsNarrative" roleURI="http://pharmacyte.com/role/TreasuryStockDetailsNarrative" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#FairValueMeasurementsDetails-FairValue" roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability" roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability" roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability" />
    <link:roleRef xlink:type="simple" xlink:href="pmcb-20260131.xsd#FairValueMeasurementsDetails-FairValuesOfFinancialInstruments" roleURI="http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#PvpDisclosureWithAdditionalMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#PvpTable" roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#PvpAdjustmentsToCompensation" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#TabularListsByExecutiveCategory" roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#TabularListMeasures" roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#PvpMeasures" roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#PvpPensionBenefitsAdjustments" roleURI="http://xbrl.sec.gov/ecd/role/PvpPensionBenefitsAdjustments" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ErrCompDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ForgoneRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#OutstandingRecoveries" roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#AwardTimingDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#AwardsCloseToMnpiDisc" roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#InsiderTradingArrangemenstByInd" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" />
    <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#Defaults" roleURI="http://xbrl.sec.gov/ecd/role/Defaults" />
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetCurrent" xlink:label="loc_PMCBWarrantAssetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_PMCBWarrantAssetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ConvertibleNoteReceivableCurrent" xlink:label="loc_PMCBConvertibleNoteReceivableCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_PMCBConvertibleNoteReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:label="loc_us-gaapInvestmentsAndOtherNoncurrentAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapInvestmentsAndOtherNoncurrentAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetNoncurrent" xlink:label="loc_PMCBWarrantAssetNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_PMCBWarrantAssetNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetFemasys" xlink:label="loc_PMCBWarrantAssetFemasys" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_PMCBWarrantAssetFemasys" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaapDividendsPayableCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDividendsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilitiesAbstract" xlink:label="loc_us-gaapOtherLiabilitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAccruedLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantLiabilitiesNoncurrent" xlink:label="loc_PMCBWarrantLiabilitiesNoncurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBWarrantLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherLiabilities" xlink:label="loc_us-gaapOtherLiabilities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="loc_us-gaapTemporaryEquityAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ContingentlyRedeemableWarrants" xlink:label="loc_PMCBContingentlyRedeemableWarrants" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBContingentlyRedeemableWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_TotalTemporaryEquity" xlink:label="loc_PMCBTotalTemporaryEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBTotalTemporaryEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="loc_us-gaapTreasuryStockCommonValue" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapTreasuryStockCommonValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockCommonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaapTemporaryEquitySharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="loc_us-gaapTemporaryEquityValueExcludingAdditionalPaidInCapital" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaapTemporaryEquitySharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaapTemporaryEquityLiquidationPreference" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquityLiquidationPreference" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTreasuryStockCommonShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantLiability" xlink:label="loc_PMCBChangeInFairValueOfWarrantLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_PMCBChangeInFairValueOfWarrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_PMCBChangeInFairValueOfDerivativeLiability" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_PMCBChangeInFairValueOfDerivativeLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfConvertibleNoteReceivable" xlink:label="loc_PMCBChangeInFairValueOfConvertibleNoteReceivable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_PMCBChangeInFairValueOfConvertibleNoteReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantAssetFemasys" xlink:label="loc_PMCBChangeInFairValueOfWarrantAssetFemasys" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_PMCBChangeInFairValueOfWarrantAssetFemasys" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfInvestment" xlink:label="loc_PMCBChangeInFairValueOfInvestment" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_PMCBChangeInFairValueOfInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantAsset" xlink:label="loc_PMCBChangeInFairValueOfWarrantAsset" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_PMCBChangeInFairValueOfWarrantAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_GainOnFairValueOfWarrantsWainwright" xlink:label="loc_PMCBGainOnFairValueOfWarrantsWainwright" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_PMCBGainOnFairValueOfWarrantsWainwright" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_GainOnRelatedPartyInvestmentQcls" xlink:label="loc_PMCBGainOnRelatedPartyInvestmentQcls" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_PMCBGainOnRelatedPartyInvestmentQcls" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants" xlink:label="loc_PMCBIssuanceCostsSeriesCConvertiblePreferredStockAndWarrants" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_PMCBIssuanceCostsSeriesCConvertiblePreferredStockAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LossOnIssuanceOfSeriesCConvertiblePreferredStock" xlink:label="loc_PMCBLossOnIssuanceOfSeriesCConvertiblePreferredStock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_PMCBLossOnIssuanceOfSeriesCConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="loc_us-gaapPreferredStockAccretionOfRedemptionDiscount" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapPreferredStockAccretionOfRedemptionDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity" xlink:title="00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS&apos; EQUITY (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="90" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredStockSeriesBMember" xlink:label="loc_PMCBPreferredStockSeriesBMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_PMCBPreferredStockSeriesBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredStockSeriesCMember" xlink:label="loc_PMCBPreferredStockSeriesCMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_PMCBPreferredStockSeriesCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ContingentlyRedeemableWarrantsMember" xlink:label="loc_PMCBContingentlyRedeemableWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_PMCBContingentlyRedeemableWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapTreasuryStockCommonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTreasuryStockCommonShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FractionalSharesAdjustmentValue" xlink:label="loc_PMCBFractionalSharesAdjustmentValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBFractionalSharesAdjustmentValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FractionalSharesAdjustmentShares" xlink:label="loc_PMCBFractionalSharesAdjustmentShares" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBFractionalSharesAdjustmentShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_StockIssuedUponVestingOfRestrictedStockUnits" xlink:label="loc_PMCBStockIssuedUponVestingOfRestrictedStockUnits" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBStockIssuedUponVestingOfRestrictedStockUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_StockIssuedUponVestingOfRestrictedStockUnitsShares" xlink:label="loc_PMCBStockIssuedUponVestingOfRestrictedStockUnitsShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBStockIssuedUponVestingOfRestrictedStockUnitsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_IssuanceOfSeriesCPreferredStockAndWarrants" xlink:label="loc_PMCBIssuanceOfSeriesCPreferredStockAndWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBIssuanceOfSeriesCPreferredStockAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_IssuanceOfSeriesCPreferredStockAndWarrantsShares" xlink:label="loc_PMCBIssuanceOfSeriesCPreferredStockAndWarrantsShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBIssuanceOfSeriesCPreferredStockAndWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredStockAccretion" xlink:label="loc_PMCBSeriesCPreferredStockAccretion" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesCPreferredStockAccretion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredStockDividendSubjectToSettlement" xlink:label="loc_PMCBSeriesCPreferredStockDividendSubjectToSettlement" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesCPreferredStockDividendSubjectToSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredStockDividendsAccrual" xlink:label="loc_PMCBSeriesCPreferredStockDividendsAccrual" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesCPreferredStockDividendsAccrual" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredStockAccretion" xlink:label="loc_PMCBPreferredStockAccretion" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBPreferredStockAccretion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredStockRedeemed" xlink:label="loc_PMCBSeriesCPreferredStockRedeemed" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesCPreferredStockRedeemed" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredStockRedeemedShares" xlink:label="loc_PMCBSeriesCPreferredStockRedeemedShares" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesCPreferredStockRedeemedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredStockSubjectToSettlement" xlink:label="loc_PMCBSeriesCPreferredStockSubjectToSettlement" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesCPreferredStockSubjectToSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBPreferredStockSubjectToRedemption" xlink:label="loc_PMCBSeriesBPreferredStockSubjectToRedemption" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesBPreferredStockSubjectToRedemption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBPreferredStockRedeemedShares" xlink:label="loc_PMCBSeriesBPreferredStockRedeemedShares" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesBPreferredStockRedeemedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBPreferredStockRedemption" xlink:label="loc_PMCBSeriesBPreferredStockRedemption" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesBPreferredStockRedemption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBPreferredStockSubjectToRedemptionShares" xlink:label="loc_PMCBSeriesBPreferredStockSubjectToRedemptionShares" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_PMCBSeriesBPreferredStockSubjectToRedemptionShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTreasuryStockCommonShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_GainOnRelatedPartyInvestmentQcls" xlink:label="loc_PMCBGainOnRelatedPartyInvestmentQcls" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_PMCBGainOnRelatedPartyInvestmentQcls" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_IssuanceCostsSeriesCPreferredStockAndWarrants" xlink:label="loc_PMCBIssuanceCostsSeriesCPreferredStockAndWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_PMCBIssuanceCostsSeriesCPreferredStockAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LossOnIssuanceOfSeriesCPreferredStock" xlink:label="loc_PMCBLossOnIssuanceOfSeriesCPreferredStock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_PMCBLossOnIssuanceOfSeriesCPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_GainOnFairValueOfWarrants" xlink:label="loc_PMCBGainOnFairValueOfWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_PMCBGainOnFairValueOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_NoncashInterestIncome" xlink:label="loc_PMCBNoncashInterestIncome" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_PMCBNoncashInterestIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_StockbasedCompensationOptions" xlink:label="loc_PMCBStockbasedCompensationOptions" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_PMCBStockbasedCompensationOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantLiability" xlink:label="loc_PMCBChangeInFairValueOfWarrantLiability" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_PMCBChangeInFairValueOfWarrantLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_PMCBChangeInFairValueOfDerivativeLiability" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_PMCBChangeInFairValueOfDerivativeLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfConvertibleNotesReceivable" xlink:label="loc_PMCBChangeInFairValueOfConvertibleNotesReceivable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_PMCBChangeInFairValueOfConvertibleNotesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantAssetFemasys" xlink:label="loc_PMCBChangeInFairValueOfWarrantAssetFemasys" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_PMCBChangeInFairValueOfWarrantAssetFemasys" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfInvestmentQcls" xlink:label="loc_PMCBChangeInFairValueOfInvestmentQcls" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_PMCBChangeInFairValueOfInvestmentQcls" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantsQcls" xlink:label="loc_PMCBChangeInFairValueOfWarrantsQcls" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_PMCBChangeInFairValueOfWarrantsQcls" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ProceedsFromInvestmentNoteReceivable" xlink:label="loc_PMCBProceedsFromInvestmentNoteReceivable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_PMCBProceedsFromInvestmentNoteReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_InvestmentInPreferredStockAndWarrantsInQcls" xlink:label="loc_PMCBInvestmentInPreferredStockAndWarrantsInQcls" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_PMCBInvestmentInPreferredStockAndWarrantsInQcls" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_RedemptionOfPreferredStock" xlink:label="loc_PMCBRedemptionOfPreferredStock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_PMCBRedemptionOfPreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PaymentOfSeriesCConvertiblePreferredStockDividends" xlink:label="loc_PMCBPaymentOfSeriesCConvertiblePreferredStockDividends" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_PMCBPaymentOfSeriesCConvertiblePreferredStockDividends" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability" xlink:label="loc_PMCBReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_PMCBReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock" xlink:label="loc_PMCBAccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_PMCBAccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_AccrualOfSeriesCConvertiblePreferredStockDividends" xlink:label="loc_PMCBAccrualOfSeriesCConvertiblePreferredStockDividends" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_PMCBAccrualOfSeriesCConvertiblePreferredStockDividends" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts" xlink:label="loc_PMCBAccrualOfSeriesCConvertiblePreferredStockIssuanceCosts" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_PMCBAccrualOfSeriesCConvertiblePreferredStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock" xlink:label="loc_PMCBAccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_PMCBAccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_InitialFairValueOfInvestmentInQclsSeriesHPreferredShares" xlink:label="loc_PMCBInitialFairValueOfInvestmentInQclsSeriesHPreferredShares" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_PMCBInitialFairValueOfInvestmentInQclsSeriesHPreferredShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_InitialFairValueOfInvestmentInQclsSeriesHWarrants" xlink:label="loc_PMCBInitialFairValueOfInvestmentInQclsSeriesHWarrants" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_PMCBInitialFairValueOfInvestmentInQclsSeriesHWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_NoncashDerivativeLiabilityAtInitialFairValue" xlink:label="loc_PMCBNoncashDerivativeLiabilityAtInitialFairValue" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_PMCBNoncashDerivativeLiabilityAtInitialFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_NoncashWarrantLiabilityAtInitialFairValue" xlink:label="loc_PMCBNoncashWarrantLiabilityAtInitialFairValue" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_PMCBNoncashWarrantLiabilityAtInitialFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_NoncashRedemptionOfSeriesCConvertiblePreferredStock" xlink:label="loc_PMCBNoncashRedemptionOfSeriesCConvertiblePreferredStock" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_PMCBNoncashRedemptionOfSeriesCConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueAssociatedWarrantExercises" xlink:label="loc_PMCBChangeInFairValueAssociatedWarrantExercises" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_PMCBChangeInFairValueAssociatedWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FairValueOfContingentlyRedeemablePlacementAgentWarrants" xlink:label="loc_PMCBFairValueOfContingentlyRedeemablePlacementAgentWarrants" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_PMCBFairValueOfContingentlyRedeemablePlacementAgentWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ExciseTaxAccruedOnRepurchaseOfCommonStock" xlink:label="loc_PMCBExciseTaxAccruedOnRepurchaseOfCommonStock" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_PMCBExciseTaxAccruedOnRepurchaseOfCommonStock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_EqtyAwrdsAdjFnTextBlock" xlink:label="loc_ecdEqtyAwrdsAdjFnTextBlock" />
      <link:presentationArc order="2290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdEqtyAwrdsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="loc_ecdTrdArrSecuritiesAggAvailAmt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrSecuritiesAggAvailAmt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/NatureOfBusiness" xlink:title="999013 - Disclosure - NATURE OF BUSINESS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/LiquidityAndOtherUncertainties" xlink:title="999014 - Disclosure - LIQUIDITY AND OTHER UNCERTAINTIES">
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DisclosureLiquidityAndOtherUncertaintiesAbstract" xlink:label="loc_PMCBDisclosureLiquidityAndOtherUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LiquidityAndOtherUncertainitiesTextBlock" xlink:label="loc_PMCBLiquidityAndOtherUncertainitiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureLiquidityAndOtherUncertaintiesAbstract" xlink:to="loc_PMCBLiquidityAndOtherUncertainitiesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecurities" xlink:title="999016 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:label="loc_us-gaapTradingSecuritiesAndCertainTradingAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapTradingSecuritiesAndCertainTradingAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/AccruedExpenses" xlink:title="999017 - Disclosure - ACCRUED EXPENSES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrants" xlink:title="999018 - Disclosure - STOCK OPTIONS AND WARRANTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/OtherRelatedPartyTransactions" xlink:title="999019 - Disclosure - OTHER RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CommitmentsAndContingencies" xlink:title="999020 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/EarningsPerShare" xlink:title="999021 - Disclosure - EARNINGS PER SHARE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/PreferredStock" xlink:title="999022 - Disclosure - PREFERRED STOCK">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaapPreferredStockTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapPreferredStockTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/TreasuryStock" xlink:title="999023 - Disclosure - TREASURY STOCK">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockTextBlock" xlink:label="loc_us-gaapTreasuryStockTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapTreasuryStockTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurements" xlink:title="999024 - Disclosure - FAIR VALUE MEASUREMENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_Reclassifications" xlink:label="loc_us-gaapReclassifications" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReclassifications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables" xlink:title="999026 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="loc_us-gaapSeriesHPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesHPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock" xlink:label="loc_us-gaapScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentTableTextBlock" xlink:label="loc_us-gaapInvestmentTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInvestmentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/AccruedExpensesTables" xlink:title="999027 - Disclosure - ACCRUED EXPENSES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrantsTables" xlink:title="999028 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/EarningsPerShareTables" xlink:title="999029 - Disclosure - EARNINGS PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsTables" xlink:title="999030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative" xlink:title="999031 - Disclosure - LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DisclosureLiquidityAndOtherUncertaintiesAbstract" xlink:label="loc_PMCBDisclosureLiquidityAndOtherUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureLiquidityAndOtherUncertaintiesAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantsMember" xlink:label="loc_PMCBWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesHConvertiblePreferredStockMember" xlink:label="loc_PMCBQCLSSeriesHConvertiblePreferredStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBQCLSSeriesHConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaapCashUninsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashUninsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaapNumberOfReportableSegments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNumberOfReportableSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants" xlink:title="999033 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Femasys Note and warrants)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralTable" xlink:label="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" xlink:label="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralTable" xlink:to="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralTable" xlink:to="loc_us-gaapInvestmentTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysNotesMember" xlink:label="loc_PMCBFemasysNotesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_PMCBFemasysNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysWarrantsMember" xlink:label="loc_PMCBFemasysWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_PMCBFemasysWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ConvertibleNoteReceivableCurrent" xlink:label="loc_PMCBConvertibleNoteReceivableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" xlink:to="loc_PMCBConvertibleNoteReceivableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfConvertibleNotesReceivable" xlink:label="loc_PMCBChangeInFairValueOfConvertibleNotesReceivable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" xlink:to="loc_PMCBChangeInFairValueOfConvertibleNotesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ProceedsFromInvestmentNoteReceivable" xlink:label="loc_PMCBProceedsFromInvestmentNoteReceivable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" xlink:to="loc_PMCBProceedsFromInvestmentNoteReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ConvertibleNoteReceivableCurrent" xlink:label="loc_PMCBConvertibleNoteReceivableCurrent_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" xlink:to="loc_PMCBConvertibleNoteReceivableCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetFemasys" xlink:label="loc_PMCBWarrantAssetFemasys" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" xlink:to="loc_PMCBWarrantAssetFemasys" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantAssetFemasys" xlink:label="loc_PMCBChangeInFairValueOfWarrantAssetFemasys" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" xlink:to="loc_PMCBChangeInFairValueOfWarrantAssetFemasys" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetFemasys" xlink:label="loc_PMCBWarrantAssetFemasys_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentsOwnedAndPledgedAsCollateralLineItems" xlink:to="loc_PMCBWarrantAssetFemasys_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities" xlink:title="999034 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Marketable securities)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementTable" xlink:label="loc_us-gaapQualitativeAndQuantitativeInformationTransferorsContinuingInvolvementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapQualitativeAndQuantitativeInformationTransferorsContinuingInvolvementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems" xlink:label="loc_us-gaapQualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQualitativeAndQuantitativeInformationTransferorsContinuingInvolvementTable" xlink:to="loc_us-gaapQualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQualitativeAndQuantitativeInformationTransferorsContinuingInvolvementTable" xlink:to="loc_us-gaapTransactionTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysPurchaseAgreementMember" xlink:label="loc_PMCBFemasysPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_PMCBFemasysPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaapMarketableSecuritiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaapInvestmentOwnedAtCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants" xlink:title="999035 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series G Preferred Stock and Preferred Stock Warrants)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DisclosureTable" xlink:label="loc_PMCBDisclosureTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_PMCBDisclosureTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DisclosureLineElements" xlink:label="loc_PMCBDisclosureLineElements" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureTable" xlink:to="loc_PMCBDisclosureLineElements" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesGPreferredStockMember" xlink:label="loc_PMCBQCLSSeriesGPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBQCLSSeriesGPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesGWarrantsMember" xlink:label="loc_PMCBQCLSSeriesGWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBQCLSSeriesGWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureTable" xlink:to="loc_srtCounterpartyNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSMember" xlink:label="loc_PMCBQCLSMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_PMCBQCLSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:label="loc_us-gaapInvestmentsAndOtherNoncurrentAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_us-gaapInvestmentsAndOtherNoncurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfInvestment" xlink:label="loc_PMCBChangeInFairValueOfInvestment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_PMCBChangeInFairValueOfInvestment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:label="loc_us-gaapInvestmentsAndOtherNoncurrentAssets_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_us-gaapInvestmentsAndOtherNoncurrentAssets_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants" xlink:title="999036 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series H Preferred Stock and Preferred Stock Warrants)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DisclosureTable" xlink:label="loc_PMCBDisclosureTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_PMCBDisclosureTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DisclosureLineElements" xlink:label="loc_PMCBDisclosureLineElements" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureTable" xlink:to="loc_PMCBDisclosureLineElements" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesHPreferredStockMember" xlink:label="loc_PMCBQCLSSeriesHPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBQCLSSeriesHPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesHWarrantsMember" xlink:label="loc_PMCBQCLSSeriesHWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBQCLSSeriesHWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:label="loc_us-gaapInvestmentsAndOtherNoncurrentAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_us-gaapInvestmentsAndOtherNoncurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaapInvestmentOwnedAtFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_us-gaapInvestmentOwnedAtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfInvestmentQcls" xlink:label="loc_PMCBChangeInFairValueOfInvestmentQcls" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_PMCBChangeInFairValueOfInvestmentQcls" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssets" xlink:label="loc_us-gaapInvestmentsAndOtherNoncurrentAssets_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_us-gaapInvestmentsAndOtherNoncurrentAssets_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative" xlink:title="999037 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTransactionTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysPurchaseAgreementMember" xlink:label="loc_PMCBFemasysPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_PMCBFemasysPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysNoteMember" xlink:label="loc_PMCBFemasysNoteMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_PMCBFemasysNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysCommonStockMember" xlink:label="loc_PMCBFemasysCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_PMCBFemasysCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysWarrantsMember" xlink:label="loc_PMCBFemasysWarrantsMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_PMCBFemasysWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtCounterpartyNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysMember" xlink:label="loc_PMCBFemasysMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_PMCBFemasysMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSMember" xlink:label="loc_PMCBQCLSMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_PMCBQCLSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysSeriesAWarrantsMember" xlink:label="loc_PMCBFemasysSeriesAWarrantsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBFemasysSeriesAWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FemasysCommonStockMember" xlink:label="loc_PMCBFemasysCommonStockMember_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBFemasysCommonStockMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="loc_us-gaapSeriesGPreferredStockMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesGPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSAccruedDividendReceivableMember" xlink:label="loc_PMCBQCLSAccruedDividendReceivableMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBQCLSAccruedDividendReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesGPreferredStockMember" xlink:label="loc_PMCBQCLSSeriesGPreferredStockMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBQCLSSeriesGPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesGWarrantsMember" xlink:label="loc_PMCBSeriesGWarrantsMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBSeriesGWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesHPreferredStockMember" xlink:label="loc_PMCBQCLSSeriesHPreferredStockMember" />
      <link:presentationArc order="660" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBQCLSSeriesHPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesHWarrantsMember" xlink:label="loc_PMCBQCLSSeriesHWarrantsMember" />
      <link:presentationArc order="760" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBQCLSSeriesHWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SecuritiesPurchaseAgreementMember" xlink:label="loc_PMCBSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PMCBSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSecuritiesPurchaseAgreementMember" xlink:label="loc_PMCBQCLSSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="660" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PMCBQCLSSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LongTermWarrantMember" xlink:label="loc_PMCBLongTermWarrantMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBLongTermWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ShortTermWarrantMember" xlink:label="loc_PMCBShortTermWarrantMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBShortTermWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesHWarrantMember" xlink:label="loc_PMCBQCLSSeriesHWarrantMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBQCLSSeriesHWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSCommonStockMember" xlink:label="loc_PMCBQCLSCommonStockMember" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBQCLSCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_QCLSSeriesHPreferredStockMember" xlink:label="loc_PMCBQCLSSeriesHPreferredStockMember_2" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBQCLSSeriesHPreferredStockMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputMaturityMember" xlink:label="loc_us-gaapMeasurementInputMaturityMember" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputMaturityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_MeasurementRedemptionPremiumMember" xlink:label="loc_PMCBMeasurementRedemptionPremiumMember" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_PMCBMeasurementRedemptionPremiumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_MeasurementInputMarketInterestRateMember" xlink:label="loc_PMCBMeasurementInputMarketInterestRateMember" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_PMCBMeasurementInputMarketInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaapMeasurementInputExercisePriceMember" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExercisePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_MeasurementInputRedemptionPremiumMember" xlink:label="loc_PMCBMeasurementInputRedemptionPremiumMember" />
      <link:presentationArc order="720" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_PMCBMeasurementInputRedemptionPremiumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaapPaymentsToAcquireInvestments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsToAcquireInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ReceivableInstrumentConvertibleConversionPrice1" xlink:label="loc_PMCBReceivableInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PMCBReceivableInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaapInvestmentOwnedBalanceShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInvestmentOwnedBalanceShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ProceedsFromInvestmentNoteReceivable" xlink:label="loc_PMCBProceedsFromInvestmentNoteReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PMCBProceedsFromInvestmentNoteReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_InvestmentSharesAddition" xlink:label="loc_PMCBInvestmentSharesAddition" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PMCBInvestmentSharesAddition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SettlementOfAccruedInterest" xlink:label="loc_PMCBSettlementOfAccruedInterest" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PMCBSettlementOfAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaapInterestAndOtherIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInterestAndOtherIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaapInterestReceivable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInterestReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaapInvestmentOwnedAtFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ConvertibleNoteReceivableCurrent" xlink:label="loc_PMCBConvertibleNoteReceivableCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PMCBConvertibleNoteReceivableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetFemasys" xlink:label="loc_PMCBWarrantAssetFemasys" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PMCBWarrantAssetFemasys" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfConvertibleNotesReceivable" xlink:label="loc_PMCBChangeInFairValueOfConvertibleNotesReceivable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PMCBChangeInFairValueOfConvertibleNotesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantAssetFemasys" xlink:label="loc_PMCBChangeInFairValueOfWarrantAssetFemasys" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PMCBChangeInFairValueOfWarrantAssetFemasys" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaapPaymentsToAcquireEquityMethodInvestments" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsToAcquireEquityMethodInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapMarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaapRealizedInvestmentGainsLosses" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRealizedInvestmentGainsLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:label="loc_us-gaapRealizedInvestmentGainsLosses_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRealizedInvestmentGainsLosses_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue" xlink:label="loc_us-gaapDerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InvestmentOwnedAtCost" xlink:label="loc_us-gaapInvestmentOwnedAtCost" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_GainOnRelatedPartyInvestmentQcls" xlink:label="loc_PMCBGainOnRelatedPartyInvestmentQcls" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_PMCBGainOnRelatedPartyInvestmentQcls" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtSecuritiesRealizedGainLoss" xlink:label="loc_us-gaapDebtSecuritiesRealizedGainLoss" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapDebtSecuritiesRealizedGainLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/AccruedExpensesDetails" xlink:title="999038 - Disclosure - ACCRUED EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DisclosureTable" xlink:label="loc_PMCBDisclosureTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_PMCBDisclosureTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DisclosureLineElements" xlink:label="loc_PMCBDisclosureLineElements" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureTable" xlink:to="loc_PMCBDisclosureLineElements" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementOfFinancialPositionLocationBalanceAxis" xlink:label="loc_us-gaapStatementOfFinancialPositionLocationBalanceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureTable" xlink:to="loc_us-gaapStatementOfFinancialPositionLocationBalanceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaapNatureOfExpenseAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureTable" xlink:to="loc_us-gaapNatureOfExpenseAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PayrollRelatedCostsMember" xlink:label="loc_PMCBPayrollRelatedCostsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_PMCBPayrollRelatedCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DirectorFeesMember" xlink:label="loc_PMCBDirectorFeesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_PMCBDirectorFeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_RAndDCostsMember" xlink:label="loc_PMCBRAndDCostsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_PMCBRAndDCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LegalSettlementMember" xlink:label="loc_PMCBLegalSettlementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_PMCBLegalSettlementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ExciseTaxOnStockRepurchasesMember" xlink:label="loc_PMCBExciseTaxOnStockRepurchasesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_PMCBExciseTaxOnStockRepurchasesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LongTermPortionOfLegalSettlementMember" xlink:label="loc_PMCBLongTermPortionOfLegalSettlementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_PMCBLongTermPortionOfLegalSettlementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_us-gaapAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_PMCBDisclosureLineElements" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity" xlink:title="999039 - Disclosure - STOCK OPTIONS AND WARRANTS (Details - Option activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity" xlink:title="999040 - Disclosure - STOCK OPTIONS AND WARRANTS (Details - Warrant activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBWarrantsAndSettlementWarrantsAdjustedMember" xlink:label="loc_PMCBSeriesBWarrantsAndSettlementWarrantsAdjustedMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PMCBSeriesBWarrantsAndSettlementWarrantsAdjustedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantsIssuedShares" xlink:label="loc_PMCBWarrantsIssuedShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBWarrantsIssuedShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantExercised" xlink:label="loc_PMCBWarrantExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBWarrantExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WeightedAverageExercisePriceWarrantsExercised" xlink:label="loc_PMCBWeightedAverageExercisePriceWarrantsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBWeightedAverageExercisePriceWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantsExpired" xlink:label="loc_PMCBWarrantsExpired" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBWarrantsExpired" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WeightedAverageExercisePriceWarrantsExpired" xlink:label="loc_PMCBWeightedAverageExercisePriceWarrantsExpired" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBWeightedAverageExercisePriceWarrantsExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantsExercisable" xlink:label="loc_PMCBWarrantsExercisable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBWarrantsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WeightedAverageExercisePriceWarrantsExercisable" xlink:label="loc_PMCBWeightedAverageExercisePriceWarrantsExercisable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBWeightedAverageExercisePriceWarrantsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative" xlink:title="999041 - Disclosure - STOCK OPTIONS AND WARRANTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_EquityPlan2021Member" xlink:label="loc_PMCBEquityPlan2021Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_PMCBEquityPlan2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_EquityPlan2022Member" xlink:label="loc_PMCBEquityPlan2022Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_PMCBEquityPlan2022Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtCounterpartyNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_EmployeesMember" xlink:label="loc_PMCBEmployeesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_PMCBEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_AdditionalWarrantsMember" xlink:label="loc_PMCBAdditionalWarrantsMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_PMCBAdditionalWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPrivatePlacementAgreementMember" xlink:label="loc_PMCBSeriesCPrivatePlacementAgreementMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_PMCBSeriesCPrivatePlacementAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBWarrantsMember" xlink:label="loc_PMCBSeriesBWarrantsMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBSeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesBPreferredWarrantsMember" xlink:label="loc_PMCBSeriesBPreferredWarrantsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_PMCBSeriesBPreferredWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaapTransactionTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTransactionTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaapTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionTypeAxis" xlink:to="loc_us-gaapTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SettlementAgreementMember" xlink:label="loc_PMCBSettlementAgreementMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransactionDomain" xlink:to="loc_PMCBSettlementAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FirstWarrantIssuanceMember" xlink:label="loc_PMCBFirstWarrantIssuanceMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBFirstWarrantIssuanceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SettlementWarrantsMember" xlink:label="loc_PMCBSettlementWarrantsMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBSettlementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPreferredWarrantsMember" xlink:label="loc_PMCBSeriesCPreferredWarrantsMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBSeriesCPreferredWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPlacementAgentWarrantsMember" xlink:label="loc_PMCBSeriesCPlacementAgentWarrantsMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBSeriesCPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantLiability" xlink:label="loc_PMCBChangeInFairValueOfWarrantLiability" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBChangeInFairValueOfWarrantLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementGain" xlink:label="loc_us-gaapLitigationSettlementGain" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLitigationSettlementGain" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_IssuanceFairValues" xlink:label="loc_PMCBIssuanceFairValues" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBIssuanceFairValues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantAsset" xlink:label="loc_PMCBChangeInFairValueOfWarrantAsset" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_PMCBChangeInFairValueOfWarrantAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative" xlink:title="999042 - Disclosure - OTHER RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SGAustraliaMember" xlink:label="loc_PMCBSGAustraliaMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_PMCBSGAustraliaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_VinDeBonaMember" xlink:label="loc_PMCBVinDeBonaMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_PMCBVinDeBonaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaapProfessionalAndContractServicesExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProfessionalAndContractServicesExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SGAustriaAndSubsidiariesMember" xlink:label="loc_PMCBSGAustriaAndSubsidiariesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_PMCBSGAustriaAndSubsidiariesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_LitigationCaseAxis" xlink:label="loc_srtLitigationCaseAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtLitigationCaseAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_HCWainwrightMember" xlink:label="loc_PMCBHCWainwrightMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtLitigationCaseTypeDomain" xlink:to="loc_PMCBHCWainwrightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FirstWarrantIssuanceMember" xlink:label="loc_PMCBFirstWarrantIssuanceMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBFirstWarrantIssuanceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_AdditionalWarrantsMember" xlink:label="loc_PMCBAdditionalWarrantsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBAdditionalWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaapPaymentsForLegalSettlements" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForLegalSettlements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantsIssuedShares" xlink:label="loc_PMCBWarrantsIssuedShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_PMCBWarrantsIssuedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation" xlink:title="999044 - Disclosure - EARNINGS PER SHARE (Details - Per share calculation)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaapEarningsPerShareBasicLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapEarningsPerShareBasicLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="loc_us-gaapPreferredStockAccretionOfRedemptionDiscount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapPreferredStockAccretionOfRedemptionDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ConvertiblePreferredStockDividends" xlink:label="loc_PMCBConvertiblePreferredStockDividends" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_PMCBConvertiblePreferredStockDividends" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:label="loc_us-gaapUndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapUndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_LessAllocationOfUndistributedIncome" xlink:label="loc_PMCBLessAllocationOfUndistributedIncome" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicLineItems" xlink:to="loc_PMCBLessAllocationOfUndistributedIncome" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares" xlink:title="999045 - Disclosure - EARNINGS PER SHARE (Details - Diluted shares)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_OptionsMember" xlink:label="loc_PMCBOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_PMCBOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredSharesMember" xlink:label="loc_PMCBPreferredSharesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_PMCBPreferredSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantsMember" xlink:label="loc_PMCBWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_PMCBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/PreferredStockDetailsNarrative" xlink:title="999046 - Disclosure - PREFERRED STOCK (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCPurchaseAgreementMember" xlink:label="loc_PMCBSeriesCPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_PMCBSeriesCPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_SeriesCWarrantsMember" xlink:label="loc_PMCBSeriesCWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_PMCBSeriesCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_MeasurementInputRedemptionPremiumMember" xlink:label="loc_PMCBMeasurementInputRedemptionPremiumMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_PMCBMeasurementInputRedemptionPremiumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_MeasurementInputMarketInterestRateMember" xlink:label="loc_PMCBMeasurementInputMarketInterestRateMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_PMCBMeasurementInputMarketInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DerivativeLiabilityMember" xlink:label="loc_PMCBDerivativeLiabilityMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBDerivativeLiabilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredStockParValuePerShare" xlink:label="loc_PMCBPreferredStockParValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_PMCBPreferredStockParValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredStockStatedValuePerShare" xlink:label="loc_PMCBPreferredStockStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_PMCBPreferredStockStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaapSaleOfStockDescriptionOfTransaction" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockDescriptionOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PlacementAgentFeePercentage" xlink:label="loc_PMCBPlacementAgentFeePercentage" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_PMCBPlacementAgentFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:label="loc_us-gaapDerivativeAssetsLiabilitiesAtFairValueNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDerivativeAssetsLiabilitiesAtFairValueNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DerivativeAssetLiabilityNetMeasurementInput" xlink:label="loc_us-gaapDerivativeAssetLiabilityNetMeasurementInput" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDerivativeAssetLiabilityNetMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_PreferredStockDiscount" xlink:label="loc_PMCBPreferredStockDiscount" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_PMCBPreferredStockDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_FairValueEmbeddedDerivative" xlink:label="loc_PMCBFairValueEmbeddedDerivative" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_PMCBFairValueEmbeddedDerivative" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantLiabilityFairValue" xlink:label="loc_PMCBWarrantLiabilityFairValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_PMCBWarrantLiabilityFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DeemedDividend" xlink:label="loc_PMCBDeemedDividend" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_PMCBDeemedDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueDerivativeLiability" xlink:label="loc_PMCBChangeInFairValueDerivativeLiability" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_PMCBChangeInFairValueDerivativeLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="loc_us-gaapDividendsPreferredStockStock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDividendsPreferredStockStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaapDividendsPreferredStockCash" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDividendsPreferredStockCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_DividendsPreferredStockPaidinkind" xlink:label="loc_us-gaapDividendsPreferredStockPaidinkind" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDividendsPreferredStockPaidinkind" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/TreasuryStockDetailsNarrative" xlink:title="999047 - Disclosure - TREASURY STOCK (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="loc_us-gaapTreasuryStockCommonMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapTreasuryStockCommonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaapTreasuryStockCommonShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapTreasuryStockCommonShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TreasuryStockCommonValue" xlink:label="loc_us-gaapTreasuryStockCommonValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapTreasuryStockCommonValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue" xlink:title="999048 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair value)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantLiabilityMember" xlink:label="loc_PMCBWarrantLiabilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBWarrantLiabilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DerivativeLiabilityMember" xlink:label="loc_PMCBDerivativeLiabilityMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBDerivativeLiabilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability" xlink:title="999049 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of warrant liability)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantLiabilityMember" xlink:label="loc_PMCBWarrantLiabilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBWarrantLiabilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:label="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantExercises" xlink:label="loc_PMCBWarrantExercises" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_PMCBWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantLiability" xlink:label="loc_PMCBChangeInFairValueOfWarrantLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_PMCBChangeInFairValueOfWarrantLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability" xlink:title="999050 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of derivative liability)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_DerivativeLiabilityMember" xlink:label="loc_PMCBDerivativeLiabilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBDerivativeLiabilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_IssuanceOfSeriesCConvertiblePreferredStock" xlink:label="loc_PMCBIssuanceOfSeriesCConvertiblePreferredStock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_PMCBIssuanceOfSeriesCConvertiblePreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ChangeInFairValueOfWarrantLiability" xlink:label="loc_PMCBChangeInFairValueOfWarrantLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_PMCBChangeInFairValueOfWarrantLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFinancialLiabilitiesFairValueDisclosure_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments" xlink:title="999051 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair values of financial instruments)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_MarketableEquitySecuritiesMember" xlink:label="loc_PMCBMarketableEquitySecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBMarketableEquitySecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_MoneyMarketAccountMember" xlink:label="loc_PMCBMoneyMarketAccountMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBMoneyMarketAccountMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_ConvertibleNoteReceivableMember" xlink:label="loc_PMCBConvertibleNoteReceivableMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBConvertibleNoteReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetFemasysMember" xlink:label="loc_PMCBWarrantAssetFemasysMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBWarrantAssetFemasysMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_InvestmentInPreferredStockQCLSMember" xlink:label="loc_PMCBInvestmentInPreferredStockQCLSMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBInvestmentInPreferredStockQCLSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="pmcb-20260131.xsd#PMCB_WarrantAssetQCLSMember" xlink:label="loc_PMCBWarrantAssetQCLSMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_PMCBWarrantAssetQCLSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_FinancialInstrumentsOwnedAtFairValue" xlink:label="loc_us-gaapFinancialInstrumentsOwnedAtFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapFinancialInstrumentsOwnedAtFairValue" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Mar. 12, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--04-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PHARMACYTE BIOTECH, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001157075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1772151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3960 Howard Hughes Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Las Vegas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">89169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">595-2850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.0001 Per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PMCB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,735,649<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 20,165,535<span></span>
</td>
<td class="nump">$ 15,172,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable equity securities</a></td>
<td class="nump">372,251<span></span>
</td>
<td class="nump">366,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantAssetCurrent', window );">Warrant asset &#8211; QCLS - current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,917,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ConvertibleNoteReceivableCurrent', window );">Convertible Note receivable &#8211; Femasys - current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,696,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">158,664<span></span>
</td>
<td class="nump">223,759<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">20,696,450<span></span>
</td>
<td class="nump">22,375,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible asset</a></td>
<td class="nump">1,549,427<span></span>
</td>
<td class="nump">1,549,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssets', window );">Investment in preferred stock &#8211; QCLS</a></td>
<td class="nump">22,472,000<span></span>
</td>
<td class="nump">22,474,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantAssetNoncurrent', window );">Warrant asset &#8211; QCLS &#8211; non current</a></td>
<td class="nump">10,242,000<span></span>
</td>
<td class="nump">5,701,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantAssetFemasys', window );">Warrant asset &#8211; Femasys</a></td>
<td class="nump">906,000<span></span>
</td>
<td class="nump">3,061,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">7,688<span></span>
</td>
<td class="nump">7,688<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">35,177,115<span></span>
</td>
<td class="nump">32,793,115<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">55,873,565<span></span>
</td>
<td class="nump">55,168,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,200,082<span></span>
</td>
<td class="nump">399,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">445,656<span></span>
</td>
<td class="nump">2,515,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Accrued Series C dividends</a></td>
<td class="nump">32,491<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,678,229<span></span>
</td>
<td class="nump">2,914,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesAbstract', window );"><strong>Other liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Long-term portion of accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantLiabilitiesNoncurrent', window );">Warrant liabilities</a></td>
<td class="nump">13,657,000<span></span>
</td>
<td class="nump">338,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities</a></td>
<td class="nump">1,136,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Total other liabilities</a></td>
<td class="nump">14,793,000<span></span>
</td>
<td class="nump">363,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">16,471,229<span></span>
</td>
<td class="nump">3,277,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ContingentlyRedeemableWarrants', window );">Contingently redeemable warrants</a></td>
<td class="nump">417,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_TotalTemporaryEquity', window );">Total temporary equity</a></td>
<td class="nump">1,289,323<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock: authorized 200,000,000 shares, $0.0001 par value; 26,005,715 and 21,672,095 shares issued and 10,735,649 and 6,795,779 shares outstanding as of January 31, 2026 and April 30, 2025, respectively.</a></td>
<td class="nump">2,602<span></span>
</td>
<td class="nump">2,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">183,141,663<span></span>
</td>
<td class="nump">181,489,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(100,000,171)<span></span>
</td>
<td class="num">(84,968,960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost, 15,270,066 and 14,876,316 shares as of January 31, 2026, and April 30, 2025, respectively.</a></td>
<td class="num">(45,009,541)<span></span>
</td>
<td class="num">(44,607,916)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(21,540)<span></span>
</td>
<td class="num">(23,869)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">38,113,013<span></span>
</td>
<td class="nump">51,891,069<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities, Temporary Equity and Stockholders&#8217; Equity</a></td>
<td class="nump">55,873,565<span></span>
</td>
<td class="nump">55,168,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Temporary Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="nump">872,323<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ContingentlyRedeemableWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ContingentlyRedeemableWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ConvertibleNoteReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ConvertibleNoteReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_TotalTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_TotalTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_WarrantAssetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_WarrantAssetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_WarrantAssetFemasys">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_WarrantAssetFemasys</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_WarrantAssetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_WarrantAssetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_WarrantLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_WarrantLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of finite- and indefinite-lived intangible assets and capitalized cost for software to be sold, leased, or marketed. Excludes goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments, and noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479772/718-30-S55-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481108/505-30-30-6<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">26,005,715<span></span>
</td>
<td class="nump">21,672,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">10,735,649<span></span>
</td>
<td class="nump">6,795,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock, Common [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common shares</a></td>
<td class="nump">15,270,066<span></span>
</td>
<td class="nump">14,876,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital', window );">Temporary equity, face value</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary equity, shares authorized</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital', window );">Temporary equity, face value</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, shares issued</a></td>
<td class="nump">4,766<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares outstanding</a></td>
<td class="nump">4,766<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Temporary equity liquidation preference</a></td>
<td class="nump">$ 4,765,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-13<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-13<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-13<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-13<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-13<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-13<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481108/505-30-30-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">93,113<span></span>
</td>
<td class="nump">118,196<span></span>
</td>
<td class="nump">329,355<span></span>
</td>
<td class="nump">311,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,024,989<span></span>
</td>
<td class="nump">842,056<span></span>
</td>
<td class="nump">4,013,103<span></span>
</td>
<td class="nump">3,024,316<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,118,102<span></span>
</td>
<td class="nump">960,252<span></span>
</td>
<td class="nump">4,342,458<span></span>
</td>
<td class="nump">3,335,998<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,118,102)<span></span>
</td>
<td class="num">(960,252)<span></span>
</td>
<td class="num">(4,342,458)<span></span>
</td>
<td class="num">(3,335,998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">230,668<span></span>
</td>
<td class="nump">255,692<span></span>
</td>
<td class="nump">654,848<span></span>
</td>
<td class="nump">1,185,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
<td class="nump">1,895,865<span></span>
</td>
<td class="nump">4,487,000<span></span>
</td>
<td class="num">(8,335,135)<span></span>
</td>
<td class="nump">8,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfDerivativeLiability', window );">Change in fair value of derivative liability</a></td>
<td class="nump">557,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">859,000<span></span>
</td>
<td class="nump">2,184,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfConvertibleNoteReceivable', window );">Change in fair value of convertible note receivable - Femasys</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(79,000)<span></span>
</td>
<td class="nump">1,304,000<span></span>
</td>
<td class="nump">601,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfWarrantAssetFemasys', window );">Change in fair value of warrant asset - Femasys</a></td>
<td class="num">(214,000)<span></span>
</td>
<td class="num">(596,000)<span></span>
</td>
<td class="num">(2,155,000)<span></span>
</td>
<td class="num">(1,830,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfInvestment', window );">Change in fair value of investment - QCLS</a></td>
<td class="nump">1,725,000<span></span>
</td>
<td class="num">(3,031,000)<span></span>
</td>
<td class="num">(3,485,000)<span></span>
</td>
<td class="num">(1,642,050)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfWarrantAsset', window );">Change in fair value of warrants - QCLS</a></td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="num">(3,194,000)<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="num">(8,123,684)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_GainOnFairValueOfWarrantsWainwright', window );">Gain on legal settlement &#8211; re-fair value of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">106,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_GainOnRelatedPartyInvestmentQcls', window );">Gain on related party investment - QCLS</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,089,000<span></span>
</td>
<td class="nump">21,395,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants', window );">Issuance costs &#8211; Series C convertible preferred stock and warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,234,553)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_LossOnIssuanceOfSeriesCConvertiblePreferredStock', window );">Loss on issuance of Series C convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(215,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(128,939)<span></span>
</td>
<td class="nump">72,632<span></span>
</td>
<td class="num">(294,065)<span></span>
</td>
<td class="nump">72,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(632)<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="num">(848)<span></span>
</td>
<td class="num">(852)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income and (expense), net</a></td>
<td class="nump">2,864,962<span></span>
</td>
<td class="num">(2,085,076)<span></span>
</td>
<td class="num">(10,688,753)<span></span>
</td>
<td class="nump">22,242,466<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">746,860<span></span>
</td>
<td class="num">(3,045,328)<span></span>
</td>
<td class="num">(15,031,211)<span></span>
</td>
<td class="nump">18,906,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividends</a></td>
<td class="num">(98,458)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(195,097)<span></span>
</td>
<td class="num">(1,129,759)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Preferred stock accretion</a></td>
<td class="num">(2,204,657)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,106,653)<span></span>
</td>
<td class="num">(3,193,404)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common stockholders</a></td>
<td class="num">$ (1,556,255)<span></span>
</td>
<td class="num">$ (3,045,328)<span></span>
</td>
<td class="num">$ (18,332,961)<span></span>
</td>
<td class="nump">$ 14,583,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic income (loss) per share attributable to common stockholders</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (2.41)<span></span>
</td>
<td class="nump">$ 1.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted income (loss) per share attributable to common stockholders</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (2.41)<span></span>
</td>
<td class="nump">$ 1.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding basic</a></td>
<td class="nump">9,262,829<span></span>
</td>
<td class="nump">6,960,014<span></span>
</td>
<td class="nump">7,618,128<span></span>
</td>
<td class="nump">7,487,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding diluted</a></td>
<td class="nump">9,262,829<span></span>
</td>
<td class="nump">6,960,014<span></span>
</td>
<td class="nump">7,618,128<span></span>
</td>
<td class="nump">7,487,813<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfConvertibleNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfConvertibleNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfWarrantAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfWarrantAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfWarrantAssetFemasys">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfWarrantAssetFemasys</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_GainOnFairValueOfWarrantsWainwright">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_GainOnFairValueOfWarrantsWainwright</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_GainOnRelatedPartyInvestmentQcls">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_GainOnRelatedPartyInvestmentQcls</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_LossOnIssuanceOfSeriesCConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_LossOnIssuanceOfSeriesCConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 405<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accretion of the preferred stock redemption discount during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockAccretionOfRedemptionDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 746,860<span></span>
</td>
<td class="num">$ (3,045,328)<span></span>
</td>
<td class="num">$ (15,031,211)<span></span>
</td>
<td class="nump">$ 18,906,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="nump">2,587<span></span>
</td>
<td class="num">(1,219)<span></span>
</td>
<td class="nump">2,329<span></span>
</td>
<td class="num">(975)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">2,587<span></span>
</td>
<td class="num">(1,219)<span></span>
</td>
<td class="nump">2,329<span></span>
</td>
<td class="num">(975)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 749,447<span></span>
</td>
<td class="num">$ (3,046,547)<span></span>
</td>
<td class="num">$ (15,028,882)<span></span>
</td>
<td class="nump">$ 18,905,493<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock Series B [Member]</div></th>
<th class="th"><div>Preferred Stock Series C [Member]</div></th>
<th class="th"><div>Contingently Redeemable Warrants [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Treasury Stock, Common [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Apr. 30, 2024</a></td>
<td class="nump">$ 11,867,016<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,167<span></span>
</td>
<td class="nump">$ 185,334,173<span></span>
</td>
<td class="num">$ (42,040,216)<span></span>
</td>
<td class="num">$ (115,625,010)<span></span>
</td>
<td class="num">$ (23,511)<span></span>
</td>
<td class="nump">$ 27,647,603<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Apr. 30, 2024</a></td>
<td class="nump">14,646<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,672,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, shares at Apr. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,634,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">222,677<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">222,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_PreferredStockAccretion', window );">Preferred stock accretion</a></td>
<td class="nump">2,148,047<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,148,047)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,148,047)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_SeriesBPreferredStockSubjectToRedemption', window );">Series B preferred stock redemption</a></td>
<td class="num">$ (2,893,144)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_SeriesBPreferredStockRedeemedShares', window );">Series B preferred stock redemption, shares</a></td>
<td class="num">(2,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_SeriesBPreferredStockRedemption', window );">Series B preferred stock subject to redemption</a></td>
<td class="num">$ (5,788,805)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_SeriesBPreferredStockSubjectToRedemptionShares', window );">Series B preferred stock subject to redemption, shares</a></td>
<td class="num">(5,833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings', window );">Preferred stock dividends</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(685,801)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(685,801)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">23,421,355<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">23,421,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (749,600)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(749,600)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(320,346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jul. 31, 2024</a></td>
<td class="nump">$ 5,333,114<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,167<span></span>
</td>
<td class="nump">182,723,002<span></span>
</td>
<td class="num">$ (42,789,816)<span></span>
</td>
<td class="num">(92,203,655)<span></span>
</td>
<td class="num">(23,328)<span></span>
</td>
<td class="nump">47,708,370<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jul. 31, 2024</a></td>
<td class="nump">5,896<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,672,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, shares at Jul. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,954,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Apr. 30, 2024</a></td>
<td class="nump">$ 11,867,016<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,167<span></span>
</td>
<td class="nump">185,334,173<span></span>
</td>
<td class="num">$ (42,040,216)<span></span>
</td>
<td class="num">(115,625,010)<span></span>
</td>
<td class="num">(23,511)<span></span>
</td>
<td class="nump">27,647,603<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Apr. 30, 2024</a></td>
<td class="nump">14,646<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,672,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, shares at Apr. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,634,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,906,468<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jan. 31, 2025</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,167<span></span>
</td>
<td class="nump">181,425,703<span></span>
</td>
<td class="num">$ (44,434,656)<span></span>
</td>
<td class="num">(96,718,543)<span></span>
</td>
<td class="num">(24,486)<span></span>
</td>
<td class="nump">40,250,185<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jan. 31, 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,672,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, shares at Jan. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,767,201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jul. 31, 2024</a></td>
<td class="nump">$ 5,333,114<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,167<span></span>
</td>
<td class="nump">182,723,002<span></span>
</td>
<td class="num">$ (42,789,816)<span></span>
</td>
<td class="num">(92,203,655)<span></span>
</td>
<td class="num">(23,328)<span></span>
</td>
<td class="nump">47,708,370<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Jul. 31, 2024</a></td>
<td class="nump">5,896<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,672,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, shares at Jul. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,954,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_FractionalSharesAdjustmentValue', window );">Fractional shares adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_FractionalSharesAdjustmentShares', window );">Fractional shares adjustment, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">119,155<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">119,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_PreferredStockAccretion', window );">Preferred stock accretion</a></td>
<td class="nump">1,045,357<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,045,357)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,045,357)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_SeriesBPreferredStockSubjectToRedemption', window );">Series B preferred stock redemption</a></td>
<td class="num">$ (2,868,607)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_SeriesBPreferredStockRedeemedShares', window );">Series B preferred stock redemption, shares</a></td>
<td class="num">(2,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_SeriesBPreferredStockRedemption', window );">Series B preferred stock subject to redemption</a></td>
<td class="num">$ (3,509,864)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_SeriesBPreferredStockSubjectToRedemptionShares', window );">Series B preferred stock subject to redemption, shares</a></td>
<td class="num">(2,979)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings', window );">Preferred stock dividends</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(443,958)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(443,958)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,469,560)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,469,560)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (1,417,565)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,417,565)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(683,036)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Oct. 31, 2024</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,167<span></span>
</td>
<td class="nump">181,352,842<span></span>
</td>
<td class="num">$ (44,207,381)<span></span>
</td>
<td class="num">(93,673,215)<span></span>
</td>
<td class="num">(23,267)<span></span>
</td>
<td class="nump">43,451,146<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Oct. 31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,672,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, shares at Oct. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,637,836)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">72,861<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">72,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,219)<span></span>
</td>
<td class="num">(1,219)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,045,328)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,045,328)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (227,275)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(227,275)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(129,365)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jan. 31, 2025</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,167<span></span>
</td>
<td class="nump">181,425,703<span></span>
</td>
<td class="num">$ (44,434,656)<span></span>
</td>
<td class="num">(96,718,543)<span></span>
</td>
<td class="num">(24,486)<span></span>
</td>
<td class="nump">40,250,185<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jan. 31, 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,672,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, shares at Jan. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,767,201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Apr. 30, 2025</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,167<span></span>
</td>
<td class="nump">181,489,647<span></span>
</td>
<td class="num">$ (44,607,916)<span></span>
</td>
<td class="num">(84,968,960)<span></span>
</td>
<td class="num">(23,869)<span></span>
</td>
<td class="nump">51,891,069<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Apr. 30, 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,672,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, shares at Apr. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,876,316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">60,492<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">60,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,360,096)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,360,096)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jul. 31, 2025</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,167<span></span>
</td>
<td class="nump">181,550,139<span></span>
</td>
<td class="num">$ (44,607,916)<span></span>
</td>
<td class="num">(93,329,056)<span></span>
</td>
<td class="num">(23,746)<span></span>
</td>
<td class="nump">43,591,588<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jul. 31, 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,672,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, shares at Jul. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,876,316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Apr. 30, 2025</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,167<span></span>
</td>
<td class="nump">181,489,647<span></span>
</td>
<td class="num">$ (44,607,916)<span></span>
</td>
<td class="num">(84,968,960)<span></span>
</td>
<td class="num">(23,869)<span></span>
</td>
<td class="nump">51,891,069<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Apr. 30, 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,672,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, shares at Apr. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,876,316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,031,211)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jan. 31, 2026</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 872,323<span></span>
</td>
<td class="nump">417,000<span></span>
</td>
<td class="nump">$ 2,602<span></span>
</td>
<td class="nump">183,141,663<span></span>
</td>
<td class="num">$ (45,009,541)<span></span>
</td>
<td class="num">(100,000,171)<span></span>
</td>
<td class="num">(21,540)<span></span>
</td>
<td class="nump">38,113,013<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jan. 31, 2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,005,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, shares at Jan. 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,270,066)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jul. 31, 2025</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,167<span></span>
</td>
<td class="nump">181,550,139<span></span>
</td>
<td class="num">$ (44,607,916)<span></span>
</td>
<td class="num">(93,329,056)<span></span>
</td>
<td class="num">(23,746)<span></span>
</td>
<td class="nump">43,591,588<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Jul. 31, 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,672,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, shares at Jul. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,876,316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">60,492<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">60,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_IssuanceOfSeriesCPreferredStockAndWarrants', window );">Issuance of Series C preferred stock and warrants, net of transaction costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">417,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_IssuanceOfSeriesCPreferredStockAndWarrantsShares', window );">Issuance of Series C preferred stock and warrants, net of transaction costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_SeriesCPreferredStockAccretion', window );">Series C Preferred stock accretion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 901,996<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(901,996)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(901,996)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_SeriesCPreferredStockDividendSubjectToSettlement', window );">Series C preferred stock dividend subject to settlement</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(96,639)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_SeriesCPreferredStockDividendsAccrual', window );">Series C preferred stock dividends accrual</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">96,639<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(96,639)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(96,639)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(381)<span></span>
</td>
<td class="num">(381)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,417,975)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,417,975)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Oct. 31, 2025</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 901,996<span></span>
</td>
<td class="nump">417,000<span></span>
</td>
<td class="nump">$ 2,167<span></span>
</td>
<td class="nump">180,611,996<span></span>
</td>
<td class="num">$ (44,607,916)<span></span>
</td>
<td class="num">(100,747,031)<span></span>
</td>
<td class="num">(24,127)<span></span>
</td>
<td class="nump">35,235,089<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Oct. 31, 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,672,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, shares at Oct. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,876,316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">60,492<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">60,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_StockIssuedUponVestingOfRestrictedStockUnits', window );">Stock issued upon vesting of restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">892,411<span></span>
</td>
<td class="num">$ (401,625)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">490,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_StockIssuedUponVestingOfRestrictedStockUnitsShares', window );">Stock issued upon vesting of restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(393,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock issued for warrant exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">1,645,785<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,645,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issued for warrant exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_PreferredStockAccretion', window );">Preferred stock accretion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,204,657<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,204,657)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,204,657)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_SeriesCPreferredStockRedeemed', window );">Series C preferred stock redeemed</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (2,234,330)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
<td class="nump">2,234,094<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,234,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_SeriesCPreferredStockRedeemedShares', window );">Series C preferred stock redeemed, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,358,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_SeriesCPreferredStockSubjectToSettlement', window );">Series C preferred stock subject to settlement</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (98,458)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings', window );">Preferred stock dividends</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">98,458<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(98,458)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(98,458)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,587<span></span>
</td>
<td class="nump">2,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">746,860<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">746,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jan. 31, 2026</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 872,323<span></span>
</td>
<td class="nump">$ 417,000<span></span>
</td>
<td class="nump">$ 2,602<span></span>
</td>
<td class="nump">$ 183,141,663<span></span>
</td>
<td class="num">$ (45,009,541)<span></span>
</td>
<td class="num">$ (100,000,171)<span></span>
</td>
<td class="num">$ (21,540)<span></span>
</td>
<td class="nump">$ 38,113,013<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jan. 31, 2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,005,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, shares at Jan. 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,270,066)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_FractionalSharesAdjustmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_FractionalSharesAdjustmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_FractionalSharesAdjustmentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_FractionalSharesAdjustmentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_IssuanceOfSeriesCPreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_IssuanceOfSeriesCPreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_IssuanceOfSeriesCPreferredStockAndWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_IssuanceOfSeriesCPreferredStockAndWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_PreferredStockAccretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_PreferredStockAccretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_SeriesBPreferredStockRedeemedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_SeriesBPreferredStockRedeemedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_SeriesBPreferredStockRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_SeriesBPreferredStockRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_SeriesBPreferredStockSubjectToRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_SeriesBPreferredStockSubjectToRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_SeriesBPreferredStockSubjectToRedemptionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_SeriesBPreferredStockSubjectToRedemptionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_SeriesCPreferredStockAccretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_SeriesCPreferredStockAccretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_SeriesCPreferredStockDividendSubjectToSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_SeriesCPreferredStockDividendSubjectToSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_SeriesCPreferredStockDividendsAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_SeriesCPreferredStockDividendsAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_SeriesCPreferredStockRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_SeriesCPreferredStockRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_SeriesCPreferredStockRedeemedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_SeriesCPreferredStockRedeemedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_SeriesCPreferredStockSubjectToSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_SeriesCPreferredStockSubjectToSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_StockIssuedUponVestingOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_StockIssuedUponVestingOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_StockIssuedUponVestingOfRestrictedStockUnitsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_StockIssuedUponVestingOfRestrictedStockUnitsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481108/505-30-30-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (15,031,211)<span></span>
</td>
<td class="nump">$ 18,906,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_GainOnRelatedPartyInvestmentQcls', window );">Gain on related party investment &#8211; QCLS</a></td>
<td class="num">(2,089,000)<span></span>
</td>
<td class="num">(21,395,734)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_IssuanceCostsSeriesCPreferredStockAndWarrants', window );">Issuance costs &#8211; Series C preferred stock and warrants</a></td>
<td class="nump">1,234,553<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_LossOnIssuanceOfSeriesCPreferredStock', window );">Loss on issuance of Series C preferred stock</a></td>
<td class="nump">215,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_GainOnFairValueOfWarrants', window );">Gain on re-fair value of warrants</a></td>
<td class="num">(106,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_NoncashInterestIncome', window );">Non-cash interest income</a></td>
<td class="num">(300,000)<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock issued for compensation - RSUs</a></td>
<td class="nump">892,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_StockbasedCompensationOptions', window );">Stock-based compensation - options</a></td>
<td class="nump">181,476<span></span>
</td>
<td class="nump">414,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable equity securities</a></td>
<td class="nump">294,065<span></span>
</td>
<td class="num">(72,632)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">8,335,135<span></span>
</td>
<td class="num">(8,400,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfDerivativeLiability', window );">Change in fair value of derivative liability</a></td>
<td class="num">(859,000)<span></span>
</td>
<td class="num">(2,184,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfConvertibleNotesReceivable', window );">Change in fair value of convertible note receivable - Femasys</a></td>
<td class="num">(1,304,000)<span></span>
</td>
<td class="num">(601,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfWarrantAssetFemasys', window );">Change in fair value of warrant asset &#8211; Femasys</a></td>
<td class="nump">2,155,000<span></span>
</td>
<td class="nump">1,830,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfInvestmentQcls', window );">Change in fair value of investment &#8211; QCLS</a></td>
<td class="nump">3,485,000<span></span>
</td>
<td class="nump">1,642,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfWarrantsQcls', window );">Change in fair value of warrants - QCLS</a></td>
<td class="num">(18,000)<span></span>
</td>
<td class="nump">8,123,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Change in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease in prepaid expenses and other current assets</a></td>
<td class="nump">65,095<span></span>
</td>
<td class="nump">52,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Increase in accounts payable</a></td>
<td class="nump">714,459<span></span>
</td>
<td class="nump">95,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Decrease in accrued expenses</a></td>
<td class="num">(1,625,424)<span></span>
</td>
<td class="num">(49,470)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash and cash equivalents used in operating activities</a></td>
<td class="num">(3,760,352)<span></span>
</td>
<td class="num">(1,937,925)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ProceedsFromInvestmentNoteReceivable', window );">Proceeds from investment - note receivable</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_InvestmentInPreferredStockAndWarrantsInQcls', window );">Investment in preferred stock and warrants in QCLS</a></td>
<td class="num">(3,000,000)<span></span>
</td>
<td class="num">(7,000,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash and cash equivalents provided by (used in) investing activities</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="num">(7,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock, net</a></td>
<td class="num">(401,625)<span></span>
</td>
<td class="num">(2,370,733)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_RedemptionOfPreferredStock', window );">Redemption of preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(22,486,875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from issuance of Series C convertible preferred stock</a></td>
<td class="nump">6,268,866<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from exercises of warrants</a></td>
<td class="nump">1,046,760<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_PaymentOfSeriesCConvertiblePreferredStockDividends', window );">Payment of Series C convertible preferred stock dividends</a></td>
<td class="num">(162,606)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash and cash equivalents provided by (used in) financing activities</a></td>
<td class="nump">6,751,395<span></span>
</td>
<td class="num">(24,857,608)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of currency rate exchange on cash and cash equivalents</a></td>
<td class="nump">2,329<span></span>
</td>
<td class="num">(975)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">4,993,372<span></span>
</td>
<td class="num">(33,796,508)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">15,172,163<span></span>
</td>
<td class="nump">50,179,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">20,165,535<span></span>
</td>
<td class="nump">16,383,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability', window );">Reclassification of Series B Convertible Preferred Stock and dividends to current liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,190,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock', window );">Accretion of discounts to redemption value of Series B Preferred Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,193,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_AccrualOfSeriesCConvertiblePreferredStockDividends', window );">Accrual of Series C Convertible Preferred Stock dividends</a></td>
<td class="nump">195,097<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts', window );">Accrual of Series C Convertible Preferred Stock issuance costs</a></td>
<td class="nump">86,419<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock', window );">Accretion of discounts to redemption value of Series C Preferred Stock</a></td>
<td class="nump">3,106,653<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_InitialFairValueOfInvestmentInQclsSeriesHPreferredShares', window );">Initial fair value of investment in QCLS Series H preferred shares</a></td>
<td class="nump">3,483,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_InitialFairValueOfInvestmentInQclsSeriesHWarrants', window );">Initial fair value of investment in QCLS Series H warrants</a></td>
<td class="nump">1,606,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_NoncashDerivativeLiabilityAtInitialFairValue', window );">Non-cash derivative liability at initial fair value</a></td>
<td class="nump">1,995,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_NoncashWarrantLiabilityAtInitialFairValue', window );">Non-cash warrant liability at initial fair value</a></td>
<td class="nump">5,220,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_NoncashRedemptionOfSeriesCConvertiblePreferredStock', window );">Non-cash redemption of Series C convertible preferred stock</a></td>
<td class="nump">2,234,330<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueAssociatedWarrantExercises', window );">Change in fair value associated warrant exercises</a></td>
<td class="nump">599,135<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_FairValueOfContingentlyRedeemablePlacementAgentWarrants', window );">Fair value of contingently redeemable placement agent warrants</a></td>
<td class="nump">417,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ExciseTaxAccruedOnRepurchaseOfCommonStock', window );">Excise tax accrued on repurchase of common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23,707<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_AccrualOfSeriesCConvertiblePreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_AccrualOfSeriesCConvertiblePreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueAssociatedWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueAssociatedWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfConvertibleNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfConvertibleNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfInvestmentQcls">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfInvestmentQcls</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfWarrantAssetFemasys">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfWarrantAssetFemasys</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfWarrantsQcls">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfWarrantsQcls</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ExciseTaxAccruedOnRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ExciseTaxAccruedOnRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_FairValueOfContingentlyRedeemablePlacementAgentWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_FairValueOfContingentlyRedeemablePlacementAgentWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_GainOnFairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_GainOnFairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_GainOnRelatedPartyInvestmentQcls">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_GainOnRelatedPartyInvestmentQcls</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_InitialFairValueOfInvestmentInQclsSeriesHPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_InitialFairValueOfInvestmentInQclsSeriesHPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_InitialFairValueOfInvestmentInQclsSeriesHWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_InitialFairValueOfInvestmentInQclsSeriesHWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_InvestmentInPreferredStockAndWarrantsInQcls">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_InvestmentInPreferredStockAndWarrantsInQcls</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_IssuanceCostsSeriesCPreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_IssuanceCostsSeriesCPreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_LossOnIssuanceOfSeriesCPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_LossOnIssuanceOfSeriesCPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_NoncashDerivativeLiabilityAtInitialFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_NoncashDerivativeLiabilityAtInitialFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_NoncashInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_NoncashInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_NoncashRedemptionOfSeriesCConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Redemption of Series C Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_NoncashRedemptionOfSeriesCConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_NoncashWarrantLiabilityAtInitialFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_NoncashWarrantLiabilityAtInitialFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_PaymentOfSeriesCConvertiblePreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_PaymentOfSeriesCConvertiblePreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ProceedsFromInvestmentNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ProceedsFromInvestmentNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_RedemptionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_RedemptionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_StockbasedCompensationOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_StockbasedCompensationOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Jul. 31, 2025</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 746,860<span></span>
</td>
<td class="num">$ (7,417,975)<span></span>
</td>
<td class="num">$ (8,360,096)<span></span>
</td>
<td class="num">$ (3,045,328)<span></span>
</td>
<td class="num">$ (1,469,560)<span></span>
</td>
<td class="nump">$ 23,421,355<span></span>
</td>
<td class="num">$ (15,031,211)<span></span>
</td>
<td class="nump">$ 18,906,468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF BUSINESS</a></td>
<td class="text"><p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zOOTQMet2C56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 &#8211; <span id="xdx_82A_zNQYknODog77">NATURE OF BUSINESS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PharmaCyte Biotech, Inc. (the &#8220;Company&#8221;)
is a biotechnology company focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation
technology known as &#8220;Cell-in-a-Box<sup>&#174;</sup>.&#8221; The Cell-in-a-Box<sup>&#174;</sup> technology is intended to be used as
a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (&#8220;LAPC&#8221;)
will be developed. The current generation of the Company&#8217;s product candidate is referred to as &#8220;CypCaps&#8482;.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a Nevada corporation incorporated
in 1996. In 2013, the Company restructured its operations to focus on biotechnology. The Company acquired licenses from SG Austria Pte.
Ltd., a Singapore corporation (&#8220;SG Austria&#8221;) and its wholly owned subsidiary, Austrianova Singapore Pte. Ltd., a Singapore
corporation (&#8220;Austrianova Singapore&#8221;) using the Cell-in-the-Box technology to treat cancer. The restructuring resulted in
the Company focusing all its efforts upon the development of a novel, effective and safe way to treat cancer. In January 2015, the Company
changed its name from Nuvilex, Inc. to PharmaCyte Biotech, Inc. to reflect the nature of its current business. In October 2021, the Company
moved its headquarters from Laguna Hills, California to Las Vegas, Nevada.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 1, 2020, the Company submitted an
Investigational New Drug Application (&#8220;IND&#8221;) to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for a planned clinical
trial in locally advanced pancreatic cancer (&#8220;LAPC&#8221;). On October 1, 2020, the Company received notice from the FDA that it
had placed the IND on clinical hold. On October 30, 2020, the FDA sent a letter to the Company setting forth the reasons for the clinical
hold and specific guidance on what the Company must do to have the clinical hold lifted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To lift the clinical hold, the FDA informed the
Company that it needs to conduct several additional preclinical studies. The FDA also requested additional information regarding several
topics, including DNA sequencing data, manufacturing information and product release specifications. The Company has been in the process
of conducting these studies and gathering additional information to submit to the FDA. See &#8220;Investigational New Drug Application
and Clinical Hold&#8221; below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 15, 2022, the Company entered into a
Cooperation Agreement (&#8220;Cooperation Agreement&#8221;) with Iroquois Master Fund Ltd. and its affiliates, pursuant to which the Company
elected a reconstituted Board of Directors (the &#8220;Board&#8221;). The Board has formed a Business Review Committee to evaluate, investigate
and review the Company&#8217;s business, affairs, strategy, management and operations and in its sole discretion to make recommendations
to the Company&#8217;s management and Board with respect thereto. The Business Review Committee is also reviewing many of the risks relative
to the Company&#8217;s business. In addition, the Board is reviewing the Company&#8217;s development programs and its relationship with
SG Austria, including that all licensed patents have expired, that know-how relating to the Company&#8217;s Cell-in-a-Box&#174; technology
solely resides with SG Austria, and that the incentives of SG Austria and its management may not be currently aligned with those of the
Company. The Board has curtailed spending on the Company&#8217;s programs, including pre-clinical and clinical activities, until the review
by the Business Review Committee and the Board is complete and the Board has determined the actions and plans to be implemented. The Business
Review Committee&#8217;s recommendations will include potentially seeking a new framework for the Company&#8217;s relationship with SG
Austria and its subsidiaries. In the event the Company is unsuccessful in seeking an acceptable new framework, the Company will reevaluate
whether it should continue those programs which are dependent on SG Austria, including its development programs for LAPC. The issues involving
SG Austria have delayed the Company&#8217;s timeline for addressing the FDA clinical hold for its planned clinical trial in LAPC and could
result in other delays or termination of the development activities. In addition, the curtailment of spending on the Company&#8217;s programs
pending the review by the Business Review Committee and the Board may cause additional delays.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Cell-in-a-Box<sup>&#174;</sup> encapsulation
technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules.
The technology is intended to result in the formation of pinhead sized cellulose-based porous capsules in which genetically modified live
human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been
shown to create a micro-environment in which encapsulated cells survive and flourish. They are protected from environmental challenges,
such as the sheer forces associated with bioreactors and passage through catheters and needles, which the Company believes enables greater
cell growth and production of the active molecules. The capsules are largely composed of cellulose (cotton) and are bioinert.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has been developing therapies for
pancreatic solid cancerous tumors by using genetically engineered live human cells that it believes are capable of converting a cancer
prodrug into its cancer-killing form. The Company encapsulates those cells using the Cell-in-a-Box<sup>&#174;</sup> technology and places
those capsules in the body as close as possible to the tumor. In this way, the Company believes that when a cancer prodrug is administered
to a patient with a particular type of cancer that may be affected by the prodrug, the killing of the patient&#8217;s cancerous tumor
may be optimized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until the review by the Business Review Committee
and the Board is complete and the Board has determined the actions and plans to be implemented, spending on the Company&#8217;s programs
has been curtailed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Investigational New Drug Application and
Clinical Hold</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 1, 2020, the Company submitted an
IND to the FDA for a planned clinical trial in LAPC. On October 1, 2020, the Company received notice from the FDA that it had placed the
Company&#8217;s IND on clinical hold. On October 30, 2020, the FDA sent the Company a letter setting forth the reasons for the clinical
hold and providing specific guidance on what the Company must do to have the clinical hold lifted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to address the clinical hold, the FDA requested that the Company:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide additional sequencing data and genetic stability studies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct a stability study on &#8204;the Company&#8217;s final formulated product candidate as well as the cells from the Company&#8217;s Master Cell Bank;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluate the compatibility of the delivery devices (the prefilled syringe and the microcatheter used to implant the CypCaps<sup>&#8482;</sup>) with &#8204;the Company&#8217;s product candidate for pancreatic cancer;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide additional detailed description of the manufacturing process of &#8204;the Company&#8217;s product candidate for pancreatic cancer;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide additional product release specifications for the Company&#8217;s encapsulated cells;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Demonstrate comparability between the 1<sup>st</sup> and 2<sup>nd</sup> generation of &#8204;the Company&#8217;s product candidate for pancreatic cancer and ensure adequate and consistent product performance and safety between the two generations;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct a biocompatibility assessment using the Company&#8217;s capsules material;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address specified insufficiencies in the Chemistry, Manufacturing and Controls information in the cross-referenced Drug Master File;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct an additional nonclinical study in a large animal (such as a pig) to assess the safety, activity, and distribution of the product candidate for pancreatic cancer; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revise the Investigators Brochure to include any additional preclinical studies conducted in response to the clinical hold and remove any statements not supported by the data the Company generated.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA also requested that the Company address
the following issues as an amendment to the Company&#8217;s IND:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide a Certificate of Analysis for pc3/2B1 plasmid that includes tests for assessing purity, safety, and potency;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Perform qualification studies for the drug filling step to ensure that the Company&#8217;s product candidate for pancreatic cancer remains sterile and stable during the filling process;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submit an updated batch analysis for the Company&#8217;s product candidate for the specific lot that will be used for manufacturing all future product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide additional details for the methodology for the Resorufin (CYP2B1) potency and the PrestoBlue cell metabolic assays;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide a few examples of common microcatheters that fit the specifications in &#8204;the Company&#8217;s Angiography Procedure Manual;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clarify the language in the Company&#8217;s Pharmacy Manual regarding proper use of the syringe fill with the Company&#8217;s product candidate for pancreatic cancer; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provide a discussion with data for trial of the potential for cellular and humoral immune reactivity against the heterologous rat CYP2B1 protein and potential for induction of autoimmune-mediated toxicities in &#8204;the Company&#8217;s study population.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company assembled a scientific and regulatory
team of experts to address the FDA requests. Through January 31, 2026, the Company&#8217;s scientific consultants have been in active
dialog with the FDA. The Company received communications from the FDA and responded, including the submission of the updated drug master
file. The FDA accepted the updated master drug file and cleared many of the clinical hold items. The Company believes that the technology
upon which the LAPC treatment will be based, intra-arterial chemotherapy, has been used in five clinical trials in humans. The Company&#8217;s
position is that the data available from these human clinical trials supersedes large animal study data, making the study unnecessary.
The treatment may not be a treatment of pancreatic cancer, but a method of improving and possibly enabling complete surgical resection
of the tumor. The Company is waiting for the FDA&#8217;s responses and hopes the FDA will accept that the LAPC treatment now meets manufacturing
standard requirements, which have significantly improved since the clinical hold was first placed. The FDA may require additional preclinical
studies when the meeting takes place. The Company is in ongoing dialogue with SG Austria to prepare for the next steps, including the
preparation of the syringes filled with the latest generation of CypCaps&#8482; with the working cell material.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.4-03(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY AND OTHER UNCERTAINTIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_DisclosureLiquidityAndOtherUncertaintiesAbstract', window );"><strong>Liquidity And Other Uncertainties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_LiquidityAndOtherUncertainitiesTextBlock', window );">LIQUIDITY AND OTHER UNCERTAINTIES</a></td>
<td class="text"><p id="xdx_80F_ecustom--LiquidityAndOtherUncertainitiesTextBlock_zrHMuctJJlOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2 &#8211; <span id="xdx_82F_zI5bbh6y7x9d">LIQUIDITY AND OTHER UNCERTAINTIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of January 31, 2026, the Company had approximately
$<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_dxH_c20260131_ziflwvAgMvu4" title="Cash and cash equivalents::XDX::20165535">20.2</span> million in cash and cash equivalents as compared to approximately $<span id="xdx_90A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_dxH_c20250430_zJirND3gYRc7" title="Cash and cash equivalents::XDX::15172163">15.2</span> million at April 30, 2025. The Company expects that its
current cash and cash equivalents of approximately $19 million, as of the filing of this Quarterly Report on Form 10-Q, will be sufficient
to support its projected operating requirements and financial commitments for at least the next twelve months from the date of this Quarterly
Report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2025, the Company entered into a securities
purchase agreement pursuant to which it agreed to sell to investors in a private placement an aggregate of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250801__20250831__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_ztvrvToq2nzb" title="Stock issued new, shares">7,000</span> shares of the Company&#8217;s
newly designated Series C convertible preferred stock with a stated value of $1,000 per share and warrants to purchase up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pn6n6_c20250831__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--WarrantsMember_zyZAqNsg79zi" title="Warrants issued">7</span> million
shares of common stock, resulting in aggregate gross proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20250801__20250831__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zgbx1xXSz2" title="Proceeds from sale of equity">7</span> million. See Note 10 - Preferred stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2025, the Company entered into a
securities purchase agreement pursuant to which it agreed to purchase in a private placement QCLS Series H Preferred Stock (as defined
herein) initially convertible into <span id="xdx_909_eus-gaap--InvestmentOwnedBalanceShares_iI_c20250930__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHConvertiblePreferredStockMember_zG5udMArbW08" title="Investment shares">600,000</span> shares, subject to adjustment of QCLS (as defined herein) common stock and warrants for an
aggregate purchase price of $<span id="xdx_90C_eus-gaap--PaymentsToAcquireInvestments_pn6n6_c20250901__20250930__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHConvertiblePreferredStockMember_zyKoiN7aXDQd">3</span> million. See Note 4 - Investment in debt and equity securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expects to need additional capital
in order to complete a clinical trial for the treatment of pancreatic cancer. If any additional equity financing, if available, may not
be on favorable terms and would likely be significantly dilutive to the Company&#8217;s current stockholders and debt financing, if available,
may involve restrictive covenants. If the Company is able to access funds through collaborative or licensing arrangements, it may be required
to relinquish rights to some of its product candidates that the Company would otherwise seek to develop or commercialize on its own, on
terms that are not favorable to the Company. The Company&#8217;s ability to access capital is not assured and, if not achieved on a timely
basis, will likely have a material adverse effect on the Company&#8217;s business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates in an industry that is subject
to rapid technological change, competition and government regulation. The Company&#8217;s operations are subject to significant risk and
uncertainties including financial operational, technological, regulatory, and other risks. Such factors, include but not limited to, results
of clinical testing and trial activities, the ability to obtain regulatory approval, the supply of needed materials, the ability to obtain
manufacturing and the ability to raise capital to achieve strategic objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_DisclosureLiquidityAndOtherUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_DisclosureLiquidityAndOtherUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_LiquidityAndOtherUncertainitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_LiquidityAndOtherUncertainitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zk5BMDdRWtEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 3 &#8211; <span id="xdx_821_zAKl9Qnxushb">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zEn8a5sVwzBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86F_zF924hLUdH9g">Principles of Consolidation and Basis of Presentation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated
financial statements have been prepared in accordance with U.S. GAAP for interim financial information and the rules and regulation of
the United States Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by
U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of
normal recurring items) which are considered necessary for a fair statement of the unaudited condensed consolidated financial statements
of the Company as of January 31, 2026 and for the three and nine months then ended. The results of operations for the three and nine months
ended January 31, 2026 are not necessarily indicative of the operating results for the year or any other period. These unaudited condensed
consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures as of April
30, 2025 and for the year then ended which are included in the Company&#8217;s Annual Report on Form 10- K, filed with the SEC on August
11, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited condensed consolidated financial
statements include the accounts of the Company and its wholly owned subsidiaries. The Company operates independently and through three
wholly owned subsidiaries: (i) PharmaCyte Biotech Europe Limited; (ii) PharmaCyte Biotech Australia Pty. Ltd.; and (iii) Viridis Biotech,
Inc. and are prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and the Rules and Regulations
of the Commission. Upon consolidation, intercompany balances and transactions are eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84C_eus-gaap--UseOfEstimates_zdlBwwa553N9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86B_z5PEf66noUIc">Use of Estimates in the Preparation of Financial
Statements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of
contingent assets and liabilities known to exist as of the date the financial statements are published and the reported amounts of revenues
and expenses during the reporting period. Uncertainties with respect to such estimates and assumptions are inherent in the preparation
of the Company&#8217;s unaudited condensed consolidated financial statements; accordingly, it is possible that the actual results could
differ from these estimates and assumptions, which could have a material effect on the reported amounts of the Company&#8217;s condensed
consolidated financial position and results of operations. The Company&#8217;s most significant estimates and assumptions are the assessment
of the fair value of long-lived assets, fair value measurements of investments, the valuation of warrants and derivative liabilities,
and the measurement of stock-based compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p id="xdx_84D_eus-gaap--Reclassifications_z6JDFJSpFkTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_860_zjtxU3oKJfKe">Reclassification</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain balances in the unaudited condensed consolidated
financial statements for the three and nine months ended January 31, 2025 have been reclassified to conform to the presentation in the
condensed consolidated financial statements for the three and nine months ended January 31, 2026. In the prior year, the Company separately
disclosed compensation expense, director fees and legal and professional expenses and combined the QCLS change in fair value of the investment
and warrant assets and in the current year the Company has reclassified these costs on the consolidated statements of operations with
general and administrative expenses and the change in the fair value of the investment QCLS and the change in the fair value of the warrant
assets are presented separately. These reclassifications had no effect on the Company&#8217;s previously reported results of operations,
changes in convertible preferred stock and stockholders&#8217; equity, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zecu2pLZS4lb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_864_zPdv9rRu08qi">Cash and Cash Equivalents</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents include cash in banks
and short-term liquid investments purchased with maturities of three months or less. Additionally, the Company, as of January 31, 2026
and April 30, 2025 had $<span id="xdx_901_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20260131_zIsJD9ugzaQe" title="Cash, uninsured amount">2.1</span> million and $<span id="xdx_90B_eus-gaap--CashUninsuredAmount_iI_c20250430_zPY9BRgn84Fg" title="Cash, uninsured amount">76,287</span>, respectively, in a money market fund that is not insured by the Federal Deposit Insurance
Corporation (&#8220;FDIC&#8221;) and is classified as a cash equivalent. The Company has no significant off-balance-sheet concentrations
of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. The Company maintains most
of its cash balance at financial institutions located throughout the U.S. Accounts at these institutions are insured by the FDIC up to
$250,000. The Company has not experienced any losses in such accounts. Management believes it is not exposed to any significant credit
risk on cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_849_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_z5n34qUqwrFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86F_zOZQuZk62MQ5">Intangible Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s accounts for intangible assets
at cost. The intangible asset has an indefinite life; therefore, is not amortizable. The Company performs annual impairment analysis for
the intangible asset to ascertain the value at each year end and records a non-cash impairment expense should the value decrease below
book value. The asset is deemed to be an In-Process Research and Development (&#8220;IPR&amp;D&#8221;) as the asset is in the research
stage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Financial Accounting Standards Board (&#8220;FASB&#8221;)
standard on goodwill and other intangible assets prescribes a two-step process for impairment testing of goodwill and indefinite-lived
intangibles, which is performed annually, as well as when an event triggering impairment may have occurred. The first step tests for impairment,
while the second step, if necessary, measures the impairment. The Company has elected to perform its annual analysis at the end of its
reporting year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_znpaVd9AXJV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_862_zNSiRm1au4Fe">Fair Value of Financial Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting Standards Codification (&#8220;ASC&#8221;)
Topic 820, &#8220;Fair Value Measurements and Disclosures,&#8221; requires disclosure of the fair value of financial instruments held
by the Company. ASC Topic 825, &#8220;Financial Instruments,&#8221; defines fair value, and establishes a three-level valuation hierarchy
for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported
in the Consolidated Balance Sheets for current assets and liabilities qualify as financial instruments and are a reasonable estimate of
their fair values because of the short period between the origination of such instruments and their expected realization and their current
market rate of interest. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability
(an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use
of unobservable inputs. The three levels of valuation hierarchy are defined as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1. Observable inputs such as quoted prices in active markets</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2. Inputs, other than the quoted prices in active markets, which are observable either directly or indirectly; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These unobservable inputs are significant to the
fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p id="xdx_847_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zBHCex85zAM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Segment Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates in <span id="xdx_90F_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20250501__20260131_zASX9yMgXsV6" title="::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl1229">one</span></span> business
segment, which includes the business of research and development activities related to developing cellular cancer therapies. The determination
of a single business segment is consistent with the financial information regularly provided to the Company&#8217;s chief operating decision
maker (&#8220;CODM&#8221;). The Company&#8217;s CODM is its President and CEO, who reviews and evaluates consolidated net income as presented
in the accompanying consolidated statements of operations for purposes of assessing performance, making operating decisions, allocating
resources, and planning and forecasting for future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zRUkpy3lvvW" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86B_zo7ajKAyO8Wb">New Accounting Pronouncement Effective in Future
Periods</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2025, the FASB issued ASU 2025-11
&#8211; Interim Reporting (Topic 270): Narrow-Scope Improvements to improve the guidance in Topic 270, Interim Reporting, by improving
the navigability of the required interim disclosures and clarifying when that guidance is applicable. The amendments also provide additional
guidance on what disclosures should be provided in interim reporting periods. The guidance is effective for the Company&#8217;s interim
periods&#160;within annual reporting periods beginning after December 15, 2027. The Company is evaluating the impact of adoption of this
standard on its financial statements and disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN DEBT AND EQUITY SECURITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock', window );">INVESTMENT IN DEBT AND EQUITY SECURITIES</a></td>
<td class="text"><p id="xdx_801_eus-gaap--TradingSecuritiesAndCertainTradingAssetsTextBlock_z219I15BXJw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4 &#8211; <span id="xdx_82A_zVblqXKVwvdc">INVESTMENT IN DEBT AND EQUITY
SECURITIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>INVESTMENT IN FEMASYS SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 14, 2023, the Company entered into
a Securities Purchase Agreement (the &#8220;Femasys Purchase Agreement&#8221;) with Femasys Inc. (&#8220;Femasys&#8221;), pursuant to
which it agreed to purchase from Femasys for a sum of $<span id="xdx_904_eus-gaap--PaymentsToAcquireInvestments_c20231113__20231114__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zLcj5u7fnul2" title="Payment for investment">5,000,000</span>, (i)&#160;senior unsecured convertible note (the &#8220;Femasys Note&#8221;)
in an aggregate principal amount of $5,000,000, convertible into shares of Femasys common stock, par value $0.001 per share (the &#8220;Femasys
Shares&#8221;) at a conversion price of $<span id="xdx_90E_ecustom--ReceivableInstrumentConvertibleConversionPrice1_iI_c20231114__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zHVzT1Kdnz6g" title="Receivable conversion price">1.18</span> per share, (ii) Series A Warrants (the &#8220;Series A Warrants&#8221;) to purchase up to
an aggregate of <span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_c20231114__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_z9rFcisGttN6" title="Investment shares">4,237,288</span> Femasys Shares at an exercise price of $1.18 per share, and (iii) Series B Warrants (the &#8220;Series B Warrants&#8221;,
together with the Series A Warrants, the &#8220;Femasys Warrants,&#8221; and, together with the Notes, the &#8220;Femasys Securities&#8221;)
to purchase up to an aggregate of 4,237,288 Femasys Shares at an exercise price of $1.475 per share (collectively, the &#8220;Investment&#8221;).
The Femasys Note accrues interest at 6.0% per annum, payable annually, and mature two years after the date of issuance. The Series A Warrants
expire five years from the date of issuance. The Series B Warrants expired in November 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Femasys Purchase
Agreement, the Company&#8217;s Chief Executive Officer was appointed to the Femasys board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The convertible note receivable is not traded
in active markets and the fair value was historically determined using a Monte Carlo simulation. The convertible note receivable is accounted
for as available-for-sale debt securities based on &#8220;Level&#160;3&#8221; inputs, which consist of unobservable inputs and reflect
management&#8217;s estimates of assumptions that market participants would use in pricing the asset. The Company elected the fair value
option for the Femasys Note, therefore, holding gains and losses are included within change in fair value of the note in the unaudited
condensed consolidated statement of operations. The Femasys Warrants are accounted for as an equity security and are valued using a Monte
Carlo simulation based on &#8220;Level 3&#8221; inputs, which consist of unobservable inputs and reflect management&#8217;s estimates
of assumptions that market participants would use in pricing the asset, recorded at fair value with subsequent changes included within
change in fair value of the warrants in the unaudited condensed consolidated statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of January 31, 2026, the Company received $<span id="xdx_908_ecustom--ProceedsFromInvestmentNoteReceivable_pn6n6_c20260129__20260131__us-gaap--TransactionTypeAxis__custom--FemasysNoteMember_z3FcWOAhwI62" title="Proceeds from investment - note receivable">5</span>
million in full settlement of the Femasys Note. Additionally, the Company received <span id="xdx_90A_ecustom--InvestmentSharesAddition_c20260129__20260131__srt--CounterpartyNameAxis__custom--FemasysMember_z9fVH9nzhZl2" title="Investment shares additions">379,747</span> shares of Femasys common stock in full settlement
of the accrued interest of $<span id="xdx_905_ecustom--SettlementOfAccruedInterest_c20260129__20260131__us-gaap--TransactionTypeAxis__custom--FemasysNoteMember_zzHliDpcSK26" title="Settlement of accrued interest">300,000</span>. The Company holds <span id="xdx_90D_eus-gaap--InvestmentOwnedBalanceShares_iI_c20260131__us-gaap--TransactionTypeAxis__custom--FemasysCommonStockMember_zrPDxviwDO73" title="Investment shares owned">695,537</span> shares of Femasys common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended January 31, 2026
and 2025, the Company recognized interest income of $<span id="xdx_90E_eus-gaap--InterestAndOtherIncome_c20251101__20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_z19F0T74GJs4" title="Interest income">12,500</span> and $<span id="xdx_908_eus-gaap--InterestAndOtherIncome_c20241101__20250131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zQX2dnaYVmp1" title="Interest income">75,000</span>, respectively, and during the nine months ended January 31, 2026
and 2025 the Company recognized interest income of $<span id="xdx_904_eus-gaap--InterestAndOtherIncome_c20250501__20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zl78V5En0eT8" title="Interest income">162,500</span> and $<span id="xdx_90C_eus-gaap--InterestAndOtherIncome_c20240501__20250131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zb5ja9cB7XV9" title="Interest income">225,000</span>, respectively, from the Femasys Note. As of January 31, 2026
and April 30, 2025, the Company has accrued interest receivable of $<span id="xdx_905_eus-gaap--InterestReceivable_iI_c20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_z4muJVXWSDub" title="Interest receivable">0</span> and $<span id="xdx_90A_eus-gaap--InterestReceivable_iI_c20250430__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zMWRTJ76sYB4" title="Interest receivable">137,500</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of January 31, 2026, the fair value of the
Femasys Series A Warrants was approximately $<span id="xdx_90E_eus-gaap--InvestmentOwnedAtFairValue_iI_c20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--FemasysSeriesAWarrantsMember_zPFmkAJ9fBT2" title="Investment fair value">906,000</span> and was determined utilizing the following assumptions: Femasys stock price of $0.54,
exercise price of $1.18, risk free rate of 3.58%, equity volatility of 102.0% and remaining term of 2.79 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognized the Femasys Note and Femasys
Warrants based on their respective fair values as of April 30, 2025 of $<span id="xdx_90D_ecustom--ConvertibleNoteReceivableCurrent_iI_c20250430__us-gaap--TransactionTypeAxis__custom--FemasysNoteMember_zAx1e3l3CDhj" title="Convertible note receivable, current">3,696,000</span> and $<span id="xdx_90D_ecustom--WarrantAssetFemasys_iI_c20250430__us-gaap--TransactionTypeAxis__custom--FemasysWarrantsMember_zUCHdhdvSCf" title="Warrant asset - Femasys">3,061,000</span>, respectively. Subsequent changes in
the fair value of the Femasys Note and Femasys Warrants are recognized in earnings, at each reporting date. During the three and nine
months ended January 31, 2026, the Company recognized gains for change in fair value of the convertible note receivable of $<span id="xdx_907_ecustom--ChangeInFairValueOfConvertibleNotesReceivable_c20251101__20260131__us-gaap--TransactionTypeAxis__custom--FemasysNoteMember_zHxVS2TuGxNj" title="Change in fair value of the convertible note receivable">0</span> and $<span id="xdx_90F_ecustom--ChangeInFairValueOfConvertibleNotesReceivable_c20250501__20260131__us-gaap--TransactionTypeAxis__custom--FemasysNoteMember_zavfvQdqlWxb" title="Change in fair value of the convertible note receivable">1,304,000</span>,
respectively, and losses for change in fair value of the warrant asset of $<span id="xdx_90A_ecustom--ChangeInFairValueOfWarrantAssetFemasys_iN_di_c20251101__20260131__us-gaap--TransactionTypeAxis__custom--FemasysWarrantsMember_znfrkPMNAJBd" title="Change in fair value of the convertible note receivable">214,000</span> and $<span id="xdx_90F_ecustom--ChangeInFairValueOfWarrantAssetFemasys_iN_di_c20250501__20260131__us-gaap--TransactionTypeAxis__custom--FemasysWarrantsMember_zv0dD2FQ3mz8" title="Change in fair value of the convertible note receivable">2,155,000</span>, respectively. See Note 12 &#8211; Fair
value Measurements for further information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is a summary of activity for the Femasys
Note and Femasys Warrants as of January 31, 2026:</p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock_zIJZbr9fmyab" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Femasys Note and warrants)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B6_zPFx5JpVVhV8" style="display: none">Schedule of activity for the notes and warrants</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: justify">Balance of Femasys Note as of April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ConvertibleNoteReceivableCurrent_iS_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zcVqZmWeVxJf" style="width: 13%; text-align: right" title="Investment, beginning balance">3,696,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ChangeInFairValueOfConvertibleNotesReceivable_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zzRyXvMMS5y1" style="text-align: right" title="Change in fair value">1,304,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Settlement of Femasys Note</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ProceedsFromInvestmentNoteReceivable_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zxwa0yFTbJP6" style="border-bottom: Black 1pt solid; text-align: right" title="Settlement of Femasys Note">(5,000,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Balance of Femasys Note as of January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ConvertibleNoteReceivableCurrent_iE_d0_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zfJXwdRVpvTd" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: justify">Balance of Femasys Warrant Asset as of April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--WarrantAssetFemasys_iS_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysWarrantsMember_zXIWBF6vdp01" style="width: 13%; text-align: right" title="Investment, beginning balance">3,061,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--ChangeInFairValueOfWarrantAssetFemasys_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysWarrantsMember_zvxqJ0ydPnb" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(2,155,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Balance of Femasys Warrant Asset as of January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--WarrantAssetFemasys_iE_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysWarrantsMember_znNVChNbG69b" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance">906,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_z6Hmbxx60Oud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>MARKETABLE SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 21, 2025 and 2024, the Company
received from the Femasys Notes payments in Femasys common stock for interest income in the amount of $<span id="xdx_900_eus-gaap--InterestAndOtherIncome_c20251120__20251121__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--FemasysCommonStockMember_zmlXyrGr8mh3" title="Interest and other income">300,000</span>
and $<span id="xdx_907_eus-gaap--InterestAndOtherIncome_c20241120__20241121__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--FemasysCommonStockMember_zEbFh4PxG7Bi" title="Interest and other income">300,000</span>,
respectively. The interest income payments were based on the Femasys average stock price on those dates of $0.79 and $0.95,
respectively, therefore, the Company received <span id="xdx_909_ecustom--InvestmentSharesAddition_c20251120__20251121__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zvHWQVHUhxn1">379,747</span>
and <span id="xdx_909_ecustom--InvestmentSharesAddition_c20241120__20241121__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zJXHg6pF4oRl">315,790</span>
common stock shares, respectively. The Company elected the fair value option on this investment. The related unrealized loss
pertaining to this investment is recorded in other income and expense. The value of the initial interest payment was $<span id="xdx_90B_eus-gaap--PaymentsToAcquireEquityMethodInvestments_c20240501__20250430__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zSs2my83FyPb" title="Investment interest payment">366,316</span>
on April 30, 2025. The Company holds a total of <span id="xdx_900_eus-gaap--InvestmentOwnedBalanceShares_iI_c20260131__srt--CounterpartyNameAxis__custom--FemasysMember_zZ0APWx5Zh41">695,537</span>
common stock shares. As of January 31, 2026, the current market value of the Femasys common stock shares was $0.54 that generated an
unrealized loss of $<span id="xdx_906_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_iN_di_c20250501__20260131__srt--CounterpartyNameAxis__custom--FemasysMember_zuuZTwMa8Doc" title="Unrealized loss on marketable securities">294,065</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cost and fair value of marketable equity securities
at January 31, 2026 are as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock_zvFiqG8cQ8nd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Marketable securities)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B3_zvXzbb3lexK5" style="display: none">Schedule of marketable equity securities</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Carrying Value</td><td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">At Fair Market</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Adjusted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Unrealized</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 55%; text-align: justify; padding-bottom: 1pt">Marketable securities</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Basis</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Equity &#8211; stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--MarketableSecuritiesCurrent_iI_c20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_ztFDbwbPoEN8" title="Carrying value at fair market value">372,251</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--InvestmentOwnedAtCost_iI_c20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zczNH370gFRj" title="Adjusted cost basis">666,316</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20250501__20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zAt1iAJWMWD1" title="Unrealized loss">294,065</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zS5gpO4LWg9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of equity securities has been measured
on a recurring basis using Level 1 inputs, which are based on unadjusted quoted market prices within active markets. There have been no
changes in valuation approaches or techniques and related inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white"><b>INVESTMENT
IN Q/C TECHNOLOGIES, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Series G Preferred Shares and Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 20, 2024, the Company entered into a Securities
Purchase Agreement (the &#8220;Series G SPA&#8221;) with a public company operating in the medical industry, MyMD Pharmaceuticals, Inc.
which subsequently changed its name to TNF Pharmaceuticals, Inc. and then to Q/C Technologies, Inc., (&#8220;QCLS&#8221;). Pursuant to
the Series G SPA, the Company purchased (i) <span id="xdx_90D_eus-gaap--InvestmentOwnedBalanceShares_iI_c20240520__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_z1uNwUsqKdVl" title="Investment shares owned">7,000</span> shares of QCLS&#8217;s Series G Convertible Preferred Stock (the &#8220;Series G Preferred
Shares&#8221; or &#8220;Series G Preferred Stock&#8221;) with an original conversion price of $1.816 per Series G Preferred Share, which
were initially convertible into 3,854,626 shares of common stock of QCLS (&#8220;QCLS Common Stock&#8221;); (ii) warrants to purchase
up to <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240520__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--LongTermWarrantMember_z2joAwK5Kvtc" title="Warrants">3,854,626</span> shares of QCLS Common Stock with a five-year term (&#8220;QCLS Series G Long-Term Warrant&#8221;); and (iii) warrants
to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240520__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ShortTermWarrantMember_zKRQLTc7Jjr" title="Warrants">3,854,626</span> shares of QCLS Common Stock with a 18-month term (&#8220;QCLS Series G Short-Term Warrant&#8221;) (collectively,
the &#8220;QCLS Series G Warrants&#8221;), for an aggregate purchase price of $<span id="xdx_909_eus-gaap--PaymentsToAcquireInvestments_c20240519__20240520__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zRAHMfPVbLrf" title="Payments for investments">7,000,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2025, QCLS issued securities that caused
changes to the original terms of the Series G Preferred Stock. The conversion and exercises prices were adjusted to $0.1832 per Series
G Preferred Share, the number of QCLS Series G Long-Term Warrants were adjusted to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--LongTermWarrantMember_zaLsWtEZVwT4" title="Warrants">38,209,611</span> shares of QCLS Common Stock and
the number of QCLS Series G Short-Term Warrants were adjusted to purchase 38,209,611 shares of QCLS Common Stock. In September 2025, in
connection with the QCLS&#8217; <span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20250901__20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zrUnZqn72I88" title="Stockholders equity, reverse stock split">1-for-100 reverse stock split</span> and pursuant to the stock combination event adjustment provisions of the
Series G Preferred Shares and QCLS Series G Warrants, the conversion price and the exercise price was adjusted to $3.37 per share, the
7,000 Series G Preferred Shares were adjusted to be convertible into 2,076,351 shares of QCLS Common Stock, and the number of QCLS Series
G Long-Term Warrants were adjusted to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--LongTermWarrantMember_z8PhV2jf0gY5" title="Warrants">2,076,351</span> shares of QCLS Common Stock and the number of QCLS Series G Short-Term Warrants
were adjusted to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ShortTermWarrantMember_zy7W7OI7o566" title="Warrants">2,076,351</span> shares of QCLS Common Stock. On November 23, 2025, the QCLS Series G Short-Term Warrants expired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Series G SPA, the Company has
the right to participate in future sales of QCLS&#8217;s equity and equity-linked securities until the second anniversary of the Closing
or the date on which no Series G Preferred Shares remain outstanding, whichever is earlier. Additionally, the Company has the right to
nominate one individual to serve on QCLS&#8217;s board of directors until PharmaCyte no longer beneficially owns at least 20% of QCLS
Common Stock on an as-converted basis. The Company&#8217;s Chief Executive Officer serves on the board of directors of QCLS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company determined that QCLS is a VIE, since
QCLS does not have sufficient equity at risk to finance its own operations without additional subordinated financial support. However,
the Company has determined that it is not the primary beneficiary of QCLS. Furthermore, Series G Preferred Stock is not considered in
substance common stock, and as such, the equity method of accounting does not apply. The Company recorded its investment in Series G Preferred
Stock at its fair value as the Company did not elect the measurement alternative to account for the investment at cost less impairment.
Subsequent changes in fair value of the Series G Preferred Stock are recognized in earnings at each reporting period. The fair value of
the Series G Preferred Stock was estimated utilizing a Monte Carlo simulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The QCLS Series G Warrants were determined to
meet the definition of a derivative and were required to be recorded at fair value in accordance with ASC 815. Subsequent changes in the
fair value of the QCLS Series G Warrants are recognized in earnings, at each reporting date. The issuance date fair value of the QCLS
Series G Warrants was determined utilizing the Black Scholes Merton Method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series G Preferred Stock shares include a
10% dividend, which are payable in cash or shares of QCLS Series G Preferred Stock at the Company&#8217;s option, and the Company has
elected to receive shares of the QCLS Preferred Stock as Payment in Kind (&#8220;PIK&#8221;). As of January 31, 2026, and April 30, 2025
the Company owned <span id="xdx_90D_eus-gaap--InvestmentOwnedBalanceShares_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zcuWseDqodl3"><span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_c20250430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zKR3zSS6yyUk">8,577</span></span> shares including accrued dividend of <span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_c20250430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSAccruedDividendReceivableMember_zN1HwkIkgCYe"><span id="xdx_903_eus-gaap--InvestmentOwnedBalanceShares_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSAccruedDividendReceivableMember_zN6PDxdC1L34">1,577</span></span> shares, and <span id="xdx_902_eus-gaap--InvestmentOwnedBalanceShares_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_ziDWMlK366G"><span id="xdx_906_eus-gaap--InvestmentOwnedBalanceShares_iI_c20250430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zj8sh39WEck9">7,831</span></span> Series G Preferred Stock shares, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recognized a gain for the change in fair value of the Series G Preferred Stock of $<span id="xdx_907_eus-gaap--RealizedInvestmentGainsLosses_c20251101__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__srt--CounterpartyNameAxis__custom--QCLSMember_zNW87lik5PU9" title="Recognized gain (loss)">1,433,000</span> and a loss of $<span id="xdx_909_eus-gaap--RealizedInvestmentGainsLosses_iN_di_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__srt--CounterpartyNameAxis__custom--QCLSMember_z9xmBNKjZ4U7" title="Recognized gain (loss)">5,127,000</span>,
respectively. The $<span id="xdx_900_eus-gaap--InvestmentOwnedAtFairValue_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__srt--CounterpartyNameAxis__custom--QCLSMember_zm27p3EQQYGc" title="Investment at fair value">17,347,000</span> fair value of the Series G Preferred Stock was estimated utilizing a Monte Carlo simulation with the following
assumptions on January 31, 2026: QCLS stock price of $4.19, expected time to settlement of 5.00 years, dividend rate of 10%, discount
market interest rate of 10%, risk free rate of 3.79%, equity volatility of 135.0% and probability of default of 24.7%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recognized a loss of $<span id="xdx_906_eus-gaap--RealizedInvestmentGainsLosses_iN_di_c20251101__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGWarrantsMember__srt--CounterpartyNameAxis__custom--QCLSMember_zeFX0DJq8gyk" title="Recognized gain (loss)">1,461,000</span> and $<span id="xdx_907_eus-gaap--RealizedInvestmentGainsLosses_iN_di_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGWarrantsMember__srt--CounterpartyNameAxis__custom--QCLSMember_z9zpQ3wh8Zb9" title="Recognized gain (loss)">1,652,000</span>, respectively, related to the change in the QCLS Series
G Warrants fair value. The $<span id="xdx_904_eus-gaap--InvestmentOwnedAtFairValue_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGWarrantsMember__srt--CounterpartyNameAxis__custom--QCLSMember_z1qfsR1BQ7D1" title="Investment at fair value">6,966,000</span> fair value of the QCLS Series G Warrants was determined utilizing a Black Scholes Merton model with
the following assumptions on January 31, 2026: QCLS stock price of $4.19, exercise price of $3.37, risk free rate of 3.57%, equity volatility
of 130.0% and remaining term of 3.31 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is a summary of activity for the Series
G Preferred Stock as of January 31, 2026:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--InvestmentTableTextBlock_z2pMAY7NicW2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series G Preferred Stock and Preferred Stock Warrants)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_z9Ya0pjiqgBa" style="display: none">Schedule of activity preferred stock</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: justify">Balance of Series G Preferred Stock as of April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zJWApdCZnImc" style="width: 13%; text-align: right" title="Investment, beginnning balance">22,474,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ChangeInFairValueOfInvestment_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zVOsyYNARIR2" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(5,127,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Balance of Series G Preferred Stock as of January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zsTyPAX3lp3c" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance">17,347,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is a summary of activity for the QCLS Warrants
as of January 31, 2026:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: justify">Balance of QCLS Series G Warrant assets as of April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_c20250501__20260131__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGWarrantsMember_zWMuwb6FjXK5" style="width: 13%; text-align: right" title="Investment, beginnning balance">8,618,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ChangeInFairValueOfInvestment_c20250501__20260131__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGWarrantsMember_zX7yT8Eu3rD1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(1,652,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Balance of QCLS Series G Warrant assets as of January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGWarrantsMember_zPbgi1cCOVA6" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance">6,966,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zEZR9p8KbHkd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Series H Preferred Shares and Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 2, 2025, the Company entered into
a Securities Purchase Agreement (the &#8220;Series H SPA&#8221;) with QCLS. Pursuant to the Series H SPA, the Company purchased (i) <span id="xdx_901_eus-gaap--InvestmentOwnedBalanceShares_iI_c20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zYbCmXXR9Xcd" title="Investment shares owned">3,000</span>
shares of QCLS&#8217;s Series H Convertible Preferred Stock (the &#8220;Series H Preferred Shares&#8221; or &#8220;Series H Preferred
Stock&#8221;), at a stated value of $1,000 per Series G Preferred Share, with an initial conversion price of $5.00 which were initially
convertible into 600,000 shares of QCLS Common Stock ; (ii) warrants to purchase up to <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember_z0crNGR4mhY3" title="Warrants">600,000</span> shares of QCLS&#8217;s Common Stock with
a five-year term (&#8220;QCLS Series H Warrant&#8221;), for a total purchase price of $<span id="xdx_903_eus-gaap--PaymentsToAcquireInvestments_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zM8ruhAXtEDh" title="Payments for investments">3,000,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2025, in connection with the QCLS&#8217;
1-for-100 reverse stock split and pursuant to the stock combination event adjustment provisions of the Series H Preferred Shares and QCLS
Series H Warrants, the conversion price and the exercise price was adjusted to $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember_zLYWHTya9n2" title="Exercise price">3.37</span> per share, the 3,000 Series H Preferred Shares were
adjusted to be convertible into 889,864 shares of QCLS Common Stock and the number of QCLS Series H Warrants was adjusted to purchase
<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSCommonStockMember_z8l7ZXxa9Nlf" title="Warrant shares">889,864</span> shares of QCLS Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series H Preferred Stock is not considered
in substance common stock, and as such, the equity method of accounting does not apply. The Company recorded its investment in Series
H Preferred Stock at its fair value as the Company did not elect the measurement alternative to account for the investment at cost less
impairment. Subsequent changes in fair value of the Series H Preferred Stock are recognized in earnings at each reporting period. The
initial fair value of the Series H Preferred Stock of $<span id="xdx_905_eus-gaap--InvestmentOwnedAtFairValue_iI_c20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember_zT5Nspg14Dic">3,483,000</span> was estimated utilizing a probability-weighted scenario model, with the
following inputs: the fair value of QCLS Common Stock of <span id="xdx_90E_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zvCR4pKKU5M8" title="Fair value measurement">$3.61</span>, estimated equity volatility of <span id="xdx_904_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zCM1TNaXoj09" title="Fair value measurement">100.0%</span>, the time to maturity of <span id="xdx_901_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputMaturityMember_zBJyvJfZhHN8" title="Fair value measurement">1.49 years</span>,
the redemption premium of <span id="xdx_902_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementRedemptionPremiumMember_z3qEwrWcB3N2" title="Fair value measurement">106%</span>, the liquidation premium of 125%, the conversion price of $5.00 per share, a market interest rate of <span id="xdx_901_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketInterestRateMember_zu6O3Sd2Orj2" title="Fair value measurement">19.51%</span>,
a risk-free rate of <span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z9qLKV5VmfFg" title="Fair value measurement">3.61%</span>, and dividend rate of <span id="xdx_900_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zcatBCq9rW29" title="Fair value measurement">7.00%</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The QCLS Series H Warrants were determined to
meet the definition of a derivative and were required to be recorded at fair value in accordance with ASC 815. Subsequent changes in the
fair value of the QCLS Series H Warrants are recognized in earnings, at each reporting date. The issuance date fair value of the QCLS
Series H Warrants of $<span id="xdx_902_eus-gaap--InvestmentOwnedAtFairValue_iI_c20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember_zfEo4DWUmLf8">1,606,000</span> was determined utilizing the Black Scholes Merton Method using the following inputs: the fair value of
QCLS&#8217; s common stock of <span id="xdx_900_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zFETuWycUad8" title="Fair value measurement">$3.61</span>, exercise price of <span id="xdx_90A_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zKJuzoU25pF8" title="Fair value measurement">$5.00</span>; dividend yield of <span id="xdx_907_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zG2XAEvXHb01" title="Fair value measurement">0%</span>; remaining term of <span id="xdx_90B_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zq67PnSZnSGj" title="Fair value measurement">5.00 years</span>; equity volatility of
<span id="xdx_908_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zIOUYKeQVW4f" title="Fair value measurement">105.0%</span>; and a risk-free interest rate of <span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_ztxNOMAxxwg4" title="Fair value measurement">3.59%</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total aggregated fair value of the QCLS Series
H Preferred Stock and the QCLS Series H Warrants of $<span id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zDA9vEWXniZ8" title="Investment, fair value">5,089,000</span> exceeded the total purchase price of $<span id="xdx_908_eus-gaap--InvestmentOwnedAtCost_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zvjtqinXZTNh" title="Investment, cost">3,000,000</span> by $<span id="xdx_905_ecustom--GainOnRelatedPartyInvestmentQcls_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zelXRyGJYRN9" title="Investment, fair value">2,089,000</span>, which was
recognized as a gain on investment in QCLS on the condensed consolidated statement of operations for the nine months ended January
31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recognized a gain on the change in fair value of the Series H Preferred Stock of $<span id="xdx_905_eus-gaap--DebtSecuritiesRealizedGainLoss_c20251101__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zBxcpU3mFzYl">292,000</span> and $<span id="xdx_90A_eus-gaap--DebtSecuritiesRealizedGainLoss_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zVwgIsgTKMse">1,642,000</span>, respectively.
The $<span id="xdx_908_eus-gaap--InvestmentOwnedAtCost_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zwY2WLJPFFic">5,125,000</span> fair value of the Series H Preferred Stock was estimated utilizing a probability-weighted scenario model, with the following
inputs: the fair value of QCLS Common Stock of <span id="xdx_904_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z5geTJmuiFYa">$4.19</span>, estimated equity volatility of <span id="xdx_90D_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zy1ZVYCfLcXd">150.0%</span>, the time to maturity of <span id="xdx_902_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgfHluaohRk5">1.08 years</span>, the redemption
premium of <span id="xdx_90D_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRedemptionPremiumMember_z3YeQXgNHkX">106%</span>, the liquidation premium of 125%, the conversion price of $3.37 per share, a market interest rate of <span id="xdx_901_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketInterestRateMember_zaYKClbVAnO1">16.37%</span>, a risk-free
rate of <span id="xdx_904_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zRn1BGFNfNyl">3.42%</span>, and dividend rate of <span id="xdx_90B_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zT3iDeAmRzhi">7.00%</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recognized a gain of $<span id="xdx_901_eus-gaap--DebtSecuritiesRealizedGainLoss_c20251101__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember_zvAYRzWziQb1" title="Recognized gain (loss)">261,000</span> and $<span id="xdx_903_eus-gaap--DebtSecuritiesRealizedGainLoss_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember_zXzxIYLEYr2a" title="Recognized gain (loss)">1,670,000</span>, respectively, related to the change in the QCLS Series H Warrants
fair value. The $<span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember_zpj3mZjZRmF6" title="Fair value of the warrants">3,276,000</span> fair value of the QCLS Series H Warrants was determined utilizing a Black Scholes Merton model with the following
assumptions on January 31, 2026: the fair value of QCLS&#8217;s common stock of <span id="xdx_904_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zqfuKpJ7vnMf">$4.19</span>, exercise price of <span id="xdx_902_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zsMjjLd31e3l">$3.37</span>, risk free rate of <span id="xdx_90B_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zhRtF73UUEaf">3.68%</span>,
equity volatility of <span id="xdx_906_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z5apMLrDIqFj">135.0%</span>, and remaining term of <span id="xdx_90A_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zn045s94KhHf">4.59 years</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has determined that QCLS is a VIE,
as QCLS does not have sufficient equity at risk to finance its own operations without additional subordinated financial support. However,
the Company has determined that it is not the primary beneficiary of QCLS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is a summary of activity for the Series
H Preferred Stock as of January 31, 2026:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--InvestmentTableTextBlock_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zfEVQb40lg51" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series H Preferred Stock and Preferred Stock Warrants)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_z6IJ0Rx6rgya" style="display: none">Schedule of activity preferred stock</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: justify">Balance of Series H Preferred Stock as of April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_d0_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zkLGmajUPc4g" style="width: 13%; text-align: right" title="Investment, beginning balance">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Initial fair value of investment Series H Preferred Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--InvestmentOwnedAtFairValue_iI_c20250902__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zvMRwQxuSUNi" style="text-align: right" title="Initial fair value of Investment">3,483,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ChangeInFairValueOfInvestmentQcls_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zW4yEHlezcM6" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">1,642,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Balance of Series H Preferred Stock as of January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zR9XFRjFULte" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance">5,125,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is a summary of activity for the QCLS Series
H Warrants as of January 31, 2026:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: justify">Balance of QCLS Series H Warrant assets as of April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_d0_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zN1LwFG8Jbyc" style="width: 13%; text-align: right" title="Investment, beginning balance">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Initial fair value of investment in of QCLS Series H Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--InvestmentOwnedAtFairValue_iI_c20250902__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zacjDXECZvh8" style="text-align: right" title="Initial fair value of Investment">1,606,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--ChangeInFairValueOfInvestmentQcls_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zp8eUhbkLUM4" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">1,670,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Balance of QCLS Series H Warrant assets as of January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zwUz1V3pxHM6" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance">3,276,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zNLlMm3N3Wka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zZXGy1qjxGyb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5 &#8211; <span id="xdx_824_zTSYEmpOKWf4">ACCRUED EXPENSES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accrued expenses at January 31, 2026 and April
30, 2025, are summarized below:</p>

<table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z6sz1XjptWR6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCRUED EXPENSES (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B6_zz4ZxbsiawG7" style="display: none">Schedule of accrued expenses</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">January 31, 2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify">Payroll related costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--PayrollRelatedCostsMember_z5Z6s3hvwP47" style="width: 13%; text-align: right" title="Accrued liabilities">185,846</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--PayrollRelatedCostsMember_zEzO2lwRUUXd" style="width: 13%; text-align: right" title="Accrued liabilities">335,846</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Director fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--DirectorFeesMember_zTFrCxa1TXk9" style="text-align: right" title="Accrued liabilities">67,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--DirectorFeesMember_z97Wn1e0mxEd" style="text-align: right" title="Accrued liabilities">67,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">R&amp;D costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--RAndDCostsMember_zCC1dAi5A4ve" style="text-align: right" title="Accrued liabilities">92,310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--RAndDCostsMember_z79qi1A8c18k" style="text-align: right" title="Accrued liabilities">92,310</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Legal settlement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LegalSettlementMember_zGzALkLR9NTd" style="text-align: right" title="Accrued liabilities">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LegalSettlementMember_zcTYAJpGCEue" style="text-align: right" title="Accrued liabilities">2,019,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Excise tax on stock repurchases</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_d0_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--ExciseTaxOnStockRepurchasesMember_z2VTRJAFL8kj" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_d0_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--ExciseTaxOnStockRepurchasesMember_z0hYN3MSnks8" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities">25,424</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131_z0YQ0hNQSJUk" style="text-align: right" title="Accrued liabilities">445,656</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430_zQjA8i06jb6l" style="text-align: right" title="Accrued liabilities">2,540,080</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Less: Long-term portion of legal settlement</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LongTermPortionOfLegalSettlementMember_z6dZocZKBjgc" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1489">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LongTermPortionOfLegalSettlementMember_zpnXjBA3TZma" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities">(25,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AccruedLiabilitiesCurrent_iI_c20260131_zptDgpGu0iTj" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued liabilities, current">445,656</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrent_iI_c20250430_zW3pBe71mdtg" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued liabilities, current">2,515,080</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS AND WARRANTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK OPTIONS AND WARRANTS</a></td>
<td class="text"><p id="xdx_805_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zmtZvJpme0j4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6 &#8211; <span id="xdx_823_z53GYDCltHP4">STOCK OPTIONS AND WARRANTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2021 Equity Incentive Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective June 30, 2021, the Company implemented
the 2021 Equity Incentive Plan (&#8220;2021 Equity Plan&#8221;) as approved by the Company&#8217;s stockholders. The 2021 Equity Plan
is administered by the Compensation Committee of the Board and has <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210630__us-gaap--PlanNameAxis__custom--EquityPlan2021Member_zSQ8ZapKCF9">166,667</span> shares authorized under this plan. The 2021 Equity Plan can
issue various types of awards, as follows: stock options, stock appreciation rights, restricted stock, restricted stock units, and cash
or other stock-based awards. The 2021 Equity Plan is available to be issued to employees, directors, consultants, and other individuals
who provide services to the Company. An incentive stock options (&#8220;ISOs&#8221;) can only be granted to employees and shall not exceed
10-years (5-years in the case of ISOs granted to any 10% shareholder). As of January 31, 2026, there are <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20260131__us-gaap--PlanNameAxis__custom--EquityPlan2021Member_z1SD9GF3Ad9l" title="Shares available for grant">154,596</span> shares remaining available
under the 2021 Equity Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2022 Equity Incentive Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective December 28, 2022, the Company implemented
the 2022 Equity Incentive Plan (&#8220;2022 Equity Plan&#8221;) as approved by the Company&#8217;s stockholders. In October 2025, the
Company held a special meeting of stockholders (the &#8220;2025 Special Meeting&#8221;). At the 2025 Special Meeting, the stockholders
of the Company approved an amendment to the 2022 Equity Plan which, among other things, increased the number of shares of common stock
available for grant under the 2022 Equity Plan by <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_c20251001__20251031_zz9x0wnDi2ta" title="Increase number of shares">2,250,000</span>. The 2022 Equity Plan is administered by the Compensation Committee of the
Board and has <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20221228__us-gaap--PlanNameAxis__custom--EquityPlan2022Member_z3Mo5siVCexg" title="Shares authorized for grant">5,000,000</span> shares available under this plan, as amended. The 2022 Equity Plan can issue various types of awards, as follows:
stock options, stock appreciation rights, restricted stock, restricted stock units, and cash or other stock-based awards. The 2022 Equity
Plan is available to be issued to employees, directors, consultants, and other individuals who provide services to the Company. An incentive
stock options (&#8220;ISOs&#8221;) can only be granted to employees and shall not exceed 10-years (5-years in the case of ISOs granted
to any 10% shareholder). As of January 31, 2026, there are <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20260131__us-gaap--PlanNameAxis__custom--EquityPlan2022Member_zTWtMDzaGuW5">2,970,040</span> shares remaining available under the 2022 Equity Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock Options</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the Company&#8217;s stock option
activity and related information for the nine months ended January 31, 2026, are shown below:</p>

<table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zhN8BJ7Hr51l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details - Option activity)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B3_zEN5pPGVLvof" style="display: none">Schedule of stock option activity</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Options</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Options</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Exercise <br/> Price per<br/> Share</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average <br/> Remaining<br/> Contractual <br/> Term in Years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 55%; text-align: justify">Outstanding, April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zU18bZQ2oYrb" style="width: 11%; text-align: right" title="Number of options outstanding, beginning">1,169,961</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqjjd7wljfJc" style="width: 11%; text-align: right" title="Weighted average exercise price per share, beginning">2.21</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240501__20250430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_ztAHF3gpWixi" title="Weighted average remaining contractual term">8.62</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zH3YEuCSe837" style="text-align: right" title="Number of options, issued">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z6b1fkdt5B86" style="text-align: right" title="Weighted average exercise price per share, issued">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Expired and forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNIYCM2ch8l7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, expired and forfeited">(9,334</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zB4tdiEYEEkc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price per share, expired and forfeited">10.78</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding, January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zgZNfkXpwA41" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending">1,160,627</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zR7Opdz4xT3i" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, ending">2.14</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zw5CCEnpK5re" title="Weighted average remaining contractual term">7.92</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Exercisable, January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZh3fse2DOo2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, exercisable">907,695</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zvqSvYplALk3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, exercisable">2.39</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zb2OQOjkaBPk" title="Weighted-average remaining contractual term, exercisable">7.56</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zDIvHMFEL1qd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20251101__20260131__srt--CounterpartyNameAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMYR0u7BUigf" title="Stock-based compensation">60,492</span> and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20250501__20260131__srt--CounterpartyNameAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z5yPYeMbXKn8" title="Stock-based compensation">181,476</span> of
stock-based compensation expense related to the issuance of Employee Options to certain officers and directors in exchange for
services during the three and nine months ended January 31, 2026, respectively, and $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20241101__20250131__srt--CounterpartyNameAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zRNNQhIsbc6h" title="Stock-based compensation">72,859</span> and $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20240501__20250131__srt--CounterpartyNameAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPedYnLT1CFb" title="Stock-based compensation">414,692</span> for the three and nine
months ended January 31, 2025, respectively. As of January 31, 2026, there remained $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20260131__srt--CounterpartyNameAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9ie6UBeTFc5" title="Employee service unrecognized compensation expense">54,579</span> of unrecognized compensation expense
related to unvested Employee Options granted to officers and directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value of vested outstanding
options as of January 31, 2026 was $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_pp0p0_c20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zB2elHkZAJG2" title="Aggregate intrinsic value">0</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Series B Warrant</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 10, 2023, the Company entered into a Securities
Purchase Agreement (the &#8220;Private Placement Agreement&#8221;) with certain accredited investors (the &#8220;Investors&#8221;), pursuant
to which it agreed to sell to the Investors warrants to acquire up to an aggregate of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230510__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zpnxX9KXAk88" title="Warrants acquire">8,750,000</span> shares of Common Stock, collectively,
the (&#8220;Series B Warrants&#8221;), with an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230510__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z2ElVcvjisbj" title="Warrant exercise price">4.00</span> per share (subject to adjustment), for a period of five years from
the date of issuance. In connection with the Series C Private Placement (as defined herein), in August 2025, the exercise price of the
Series B Preferred Warrants was adjusted to $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260131__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zlS32ZhOy5Ya" title="Exercise price">0.95</span> per share and the number of shares of Common Stock issuable upon exercise of the Series
B Warrants was adjusted proportionally to 36,780,161 pursuant to the full ratchet anti-dilution provisions contained therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series B Warrants were determined to be subject
to liability classification as they are considered to be indexed to the Company&#8217;s own stock but fail to meet the requirements for
equity classification in accordance with ASC 815. As such, the Company recorded the Series B Warrants as a liability at fair value with
subsequent changes in fair value recognized in earnings. The Company utilized the Black-Scholes-Merton Model to calculate the value of
the Series B Warrants issued on May 10, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company received Series B exercise notices totaling <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20251101__20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zRB2rWhqigLb" title="Warrants exercised"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zHTNkSXlKcRf" title="Warrants exercised">1,100,000</span></span> shares. The exercises resulted in the Company received cash
in the amount of $<span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_z8LLi4MetkEh" title="Proceeds from warrant exercises">1,046,740</span> and a reduction in the warrant liability of $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_z3YTIv1hI1s6" title="Reduction in warrant liability">599,135</span>. Following the exercises the Company has <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zOLYbcSmE6d" title="Warrants outstanding">35,680,160</span> Series
B warrant shares remaining.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recorded a gain of approximately $<span id="xdx_90D_ecustom--ChangeInFairValueOfWarrantLiability_iN_di_c20251101__20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBPreferredWarrantsMember_zgnbDfHEHlr4" title="Change in fair value of warrant liability">874,000</span> and a loss of $<span id="xdx_90D_ecustom--ChangeInFairValueOfWarrantLiability_iN_di_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBPreferredWarrantsMember_zWe5COUedCdg" title="Change in fair value of warrant liability">9,182,000</span>, respectively, related to the change in fair
value of the warrant liability which is recorded in other income on the unaudited condensed consolidated statements of operations. The
fair value of the Series B Warrants of $<span id="xdx_90B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBPreferredWarrantsMember_z5iwPDQWekjk" title="Fair value of the warrants">9,520,000</span> was estimated at January 31, 2026, utilizing the Black-Scholes-Merton Model using the
fair value of the Company&#8217;s common stock of $0.82 and the following weighted average assumptions: dividend yield 0%; remaining term
of 2.27 years; equity volatility of 60.0%; and a risk-free interest rate of 3.48%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2025, the Company recorded a gain of approximately $<span id="xdx_907_ecustom--ChangeInFairValueOfWarrantLiability_iN_di_c20241101__20250131__us-gaap--StatementClassOfStockAxis__custom--SeriesBPreferredWarrantsMember_zS4DTrJhIFS9" title="Change in fair value of warrant liability">4,487,000</span> and $<span id="xdx_905_ecustom--ChangeInFairValueOfWarrantLiability_iN_di_c20240501__20250131__us-gaap--StatementClassOfStockAxis__custom--SeriesBPreferredWarrantsMember_zGtQmNSkvveg" title="Change in fair value of warrant liability">8,400,000</span>, respectively, related to the change in fair value of
the warrant liability which is recorded in other income (expense) on the Condensed Consolidated Statements of Operations. The fair value
of the Series B Warrants of $<span id="xdx_90F_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20250131__us-gaap--StatementClassOfStockAxis__custom--SeriesBPreferredWarrantsMember_zEIgkL9ceNS4" title="Fair value of the warrants">2,384,000</span> was estimated at January 31, 2025, utilizing the Black-Scholes-Merton Model using the fair value
of the Company&#8217;s common stock of $1.60 and the following weighted average assumptions: dividend yield 0%; remaining term of 3.27
years; equity volatility of 55.0%; and a risk-free interest rate of 4.19%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Settlement Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Settlement Agreement, as
defined on Note 8 &#8211; Commitments and Contingencies, on May 16, 2025, the Company issued warrants (&#8220;First Warrant Issuance&#8221;)
to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250516__us-gaap--TransactionTypeAxis__custom--SettlementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FirstWarrantIssuanceMember_zJOKpIArpksc">343,183</span> shares of Common Stock with an exercise price of $4.00 per share and a term of five years from the issuance date.
On October 29, 2025, the Company issued additional warrants (&#8220;Additional Warrants&#8221;, and collectively with the First Warrant
Issuance, the &#8220;Settlement Warrants&#8221;) to purchase <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251029__us-gaap--TransactionTypeAxis__custom--SettlementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SettlementWarrantsMember_zRVKgkuu28Ck">313,067</span> shares of the Company&#8217;s common stock with an exercise price
of $4.00 per share and a term of five years from the issuance date. In connection with the Series C Private Placement (as defined herein),
in August 2025, the exercise price of the Settlement Warrants was adjusted to $0.95 per share and the number of shares of Common Stock
issuable upon exercise Settlement Warrants was adjusted proportionally to 2,758,511 pursuant to the full ratchet anti-dilution provisions
contained in their respective agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Settlement Warrants were determined to be
subject to liability classification. As such, the Company recorded the Settlement Warrants as a liability upon issuance at their fair
value with subsequent changes in fair value recognized in earnings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company utilized the Black-Scholes-Merton
Model to calculate the value of the Settlement Warrants issued during the three and nine months ended January 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the First Warrant Issuance of
approximately $<span id="xdx_907_eus-gaap--FairValueAdjustmentOfWarrants_c20250515__20250516__us-gaap--ClassOfWarrantOrRightAxis__custom--FirstWarrantIssuanceMember_zLBIRjlEG6P5" title="Fair value of the warrants">199,000</span> was estimated at May 16, 2025 (the date of issuance) using the fair value of the Company&#8217;s common stock of
$1.06 on the issuance date as well as the following input assumptions: expected dividend yield of 0%; expected term of 5.0 years; equity
volatility of 97.0%; and a risk-free interest rate of 4.1%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the Additional Warrants of approximately
$<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20250728__20250729__us-gaap--AwardTypeAxis__custom--AdditionalWarrantsMember_z8HpMF7JSCfd" title="Fair value of the warrants">164,000</span> was estimated at July 29, 2025 (the date of issuance) using the fair value of the Company&#8217;s common stock of $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20250729__us-gaap--AwardTypeAxis__custom--AdditionalWarrantsMember_zD7BwdQZIDo9" title="Fair value per share">1.02</span> on the
issuance date as well as the following input assumptions: expected dividend yield of 0%; expected term of 5.0 years; equity volatility
of 94.0%; and a risk-free interest rate of 3.9%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recorded a gain on legal settlement of $<span id="xdx_900_eus-gaap--LitigationSettlementGain_c20251101__20260131_z1Zl42Eh5DGi" title="Gain on legal settlement">0</span> and $<span id="xdx_909_eus-gaap--LitigationSettlementGain_c20250501__20260131_zADkI1LIrW6l" title="Gain on legal settlement">106,000</span>, respectively, which represents the difference between the
estimated fair value of the Settlement Warrants recognized during the year ended April 30, 2025 totaling $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20240501__20250430_zfR4OThLqtxa" title="Fair value of the warrants">469,000</span> and their issuance date
fair values totaling $<span id="xdx_90B_ecustom--IssuanceFairValues_c20240501__20250430_zciLjZyjQ825" title="Issuance fair values">363,000</span>. See Note 8 &#8211; Commitment and Contingencies &#8211; Legal Proceedings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recorded a gain of $<span id="xdx_902_ecustom--ChangeInFairValueOfWarrantLiability_iN_di_c20251101__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--SettlementWarrantsMember_zkSXgMslh5X6">545,000</span> and a loss of $<span id="xdx_908_ecustom--ChangeInFairValueOfWarrantLiability_iN_di_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--SettlementWarrantsMember_zWqsgjBVStSd">694,000</span>, respectively, related to the change in fair value of the warrant
liability associated with the Settlement Warrants which is recorded in other income (expense) on the unaudited condensed consolidated
statements of operations. The fair value of the Settlement Warrants of $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--SettlementWarrantsMember_z18hBVmQBbZ5" title="Fair value of the warrants">1,057,000</span> was estimated at January 31, 2026 utilizing the Black-Scholes-Merton
Model using the fair value of the Company&#8217;s common stock of $0.82 and was based on the following weighted average assumptions: expected
dividend yield of 0%; expected term of 4.39 years; equity volatility of 60.0%; and a risk-free interest rate of 3.7%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Series C Warrant</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 17, 2025, the Company entered into a
Securities Purchase Agreement (the &#8220;Series C Private Placement Agreement&#8221;) with certain accredited investors (the &#8220;Investors&#8221;),
pursuant to which it agreed to sell in a private placement to the Investors warrants to acquire up to an aggregate of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250819__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember_zlTAJSYuGJvj">7,000,000</span> shares
of Common Stock, collectively, the (&#8220;Series C Preferred Warrant&#8221;), with an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250819__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember_zRAB3pyO0Pv2">1.00</span> per share (subject to adjustment),
for a period of five years from the date of issuance. The Series C Private Placement Agreement closed on August 19, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series C Warrants were determined to be subject
to liability classification as they are considered to be indexed to the Company&#8217;s own stock but fail to meet the requirements for
equity classification in accordance with ASC 815. As such, the Company recorded the Series C Warrants as a liability at fair value with
subsequent changes in fair value recognized in earnings. The fair value of the Series C Warrants of $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20250801__20250819__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember_zilEi7MTIc8k" title="Fair value of the warrants">5,220,000</span> was estimated at August
19, 2025, utilizing the Black-Scholes-Merton Model using the fair value of the Company&#8217;s common stock of $1.01 and the following
weighted average assumptions: dividend yield of 0%; remaining term of 5.00 years; equity volatility of 95.0%; and a risk-free interest
rate of 3.75%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recorded a gain of approximately $<span id="xdx_908_ecustom--ChangeInFairValueOfWarrantAsset_c20251101__20260131__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCPreferredWarrantsMember_zscCxlc2zlCf" title="Change in fair value warrant asset">1,076,000</span> and $<span id="xdx_903_ecustom--ChangeInFairValueOfWarrantAsset_c20250501__20260131__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCPreferredWarrantsMember_zCwbgfEcOeBd">2,140,000</span>, respectively, related to the change in fair value of
the warrant liability associated with the Series C Warrants which is recorded in other income on the unaudited condensed consolidated
statements of operations. The fair value of the Series C Warrants of $<span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20250501__20260131__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCPreferredWarrantsMember_zxMEFhIwzPC9">3,080,000</span> was estimated at January 31, 2026, utilizing the Black-Scholes-Merton
Model using the fair value of the Company&#8217;s common stock of $0.82 and the following weighted average assumptions: dividend yield
0%; remaining term of 4.55 years; equity volatility of 70.0%; and a risk-free interest rate of 3.68%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Placement Agent Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Series C Private Placement
Agreement, the Company also issued warrants to purchase up to an aggregate of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250819__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCPlacementAgentWarrantsMember_zM34x6wuNf3b">560,000</span> shares of the Common Stock as compensation to placement
agents for services rendered (the &#8220;Series C Placement Agent Warrants&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series C Placement Agent Warrants are classified
as a contingently redeemable warrant in accordance with ASC 718, as it was determined that the warrants were not precluded from equity
classification under that guidance, but could be settled in cash or other assets in the event that another person or entity becomes the
beneficial owner of&#160;50% of the outstanding shares of the Common Stock. The Series C Placement Agent Warrants were thus classified
in temporary equity on the Company&#8217;s condensed consolidated balance sheets as of January 31, 2026 pursuant to ASC 480-10-S99-3A.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the Series C Placement Agent
Warrants of $<span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20250801__20250819__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCPlacementAgentWarrantsMember_z8JZymXNJhKj">417,000</span> was estimated at August 19, 2025, utilizing the Black-Scholes-Merton Model using the fair value of the Company&#8217;s
common stock of $1.01 and the following weighted average assumptions: dividend yield of 0%; remaining term of 5.00 years; equity volatility
of 95.0%; and a risk-free interest rate of 3.75%. The fair value of the Series C Placement Agent Warrants was expensed as incurred and
was recorded in Series C convertible preferred stock and warrants issuance costs on the condensed consolidated statement of operations
for the nine months ended January 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the Company&#8217;s warrant activity
and related information for the nine months ended January 31, 2026, are shown below:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zlKnRnxcRI3g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details - Warrant activity)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B3_zcALJrtgtFwa" style="display: none">Schedule of warrant activity</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise Price Per Share</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining Contractual Term In Years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 55%">Outstanding, April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJBlos8fFIj7" style="width: 11%; text-align: right" title="Warrants outstanding, beginning balance">18,570,847</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zP1ahsgBRuK2" style="width: 11%; text-align: right" title="Weighted average exercise price warrants outstanding, beginning balance">4.54</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240501__20250430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zvI9x1qfoP4b" title="Weighted average remaining contractual term">2.12</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--WarrantsIssuedShares_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQ3ewShGzi9" style="text-align: right" title="Warrants issued">8,216,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zStQwJ09LwF5" style="text-align: right" title="Weighted average exercise price warrants issued">1.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Issued - Series B Warrants and Settlement Warrants adjusted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--WarrantsIssuedShares_d0_c20250501__20260131__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsAndSettlementWarrantsAdjustedMember_zrk6zl7qbTK5" style="text-align: right" title="Warrants issued">30,132,422</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20250501__20260131__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsAndSettlementWarrantsAdjustedMember_zHd0FGdR57v5" style="text-align: right" title="Weighted average exercise price warrants issued">0.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--WarrantExercised_iN_di_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxLNNtOa0Hnl" style="text-align: right" title="Warrants exercised">(1,100,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--WeightedAverageExercisePriceWarrantsExercised_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmu9SNWDPLke" style="text-align: right" title="Weighted average exercise price warrants Exercised">0.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--WarrantsExpired_iN_di0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zF2aD6730o6h" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--WeightedAverageExercisePriceWarrantsExpired_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3x0aTXrP1ub" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price warrants Expired">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Outstanding, January 31, 2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOgTvl4NlbE7" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, ending balance">55,819,519</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zN6gAdwQkCbj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price warrants outstanding, ending balance">1.68</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxZRaHOKg9F5" title="Weighted average remaining contractual term">2.61</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Exercisable, January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_ecustom--WarrantsExercisable_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zMZVcf06fIZf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable">55,819,519</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWWMcdN6Pmk1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price warrants exercisable">1.68</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zl6tMlzLhwF3" title="Weighted-average remaining contractual term, exercisable">2.61</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zTCo32KlALc2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">OTHER RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zABU17sipgMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7 &#8211; <span id="xdx_82E_zTsBTjEMBru5">OTHER RELATED PARTY TRANSACTIONS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had the following related party transactions
during the three and nine months ended January 31, 2026 and 2025, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company owns <span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20260131__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SGAustraliaMember_zDLW0fWYJNs9" title="Equity interest owned">13.8</span>% of the equity in SG Austria
which is presented using the measurement alternative allowed under <i>ASC 321 - Investments Equity Securities</i> with no readily determinable
fair values. SG Austria has two subsidiaries: (i) Austrianova; and (ii) Austrianova Thailand. The Company purchased products and services
from these entities in the approximate amounts of $0 in the three and nine months ended January 31, 2026, and 2025, respectively. The
investment in SG Austria was fully impaired as of April 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2014, the Company entered into the
Vin-de-Bona Consulting Agreement pursuant to which it agreed to provide professional consulting services to the Company. Vin-de-Bona
is owned by Prof. G&#252;nzburg and Dr. Salmons, both of whom are involved in numerous aspects of the Company&#8217;s scientific
endeavors relating to cancer (Prof. G&#252;nzburg is the Chairman of Austrianova, and Dr. Salmons is the Chief Executive Officer and
President of Austrianova). The term of the agreement is for 12 months and is automatically renewable for successive 12-month terms.
After the initial term, either party can terminate the agreement by giving the other party 30 days&#8217; written notice before the
effective date of termination. To date, the agreement has been automatically renewed annually. The amounts incurred for the three
and nine months ended January 31, 2026 were approximately $<span id="xdx_908_eus-gaap--ProfessionalAndContractServicesExpense_pp0p0_c20251101__20260131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VinDeBonaMember_zbrGFfWuYBJb" title="Consulting fees">10,500</span> and $<span id="xdx_903_eus-gaap--ProfessionalAndContractServicesExpense_pp0p0_c20250501__20260131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VinDeBonaMember_zxGo0YYc5c27" title="Consulting fees">10,500</span>, respectively and approximately $<span id="xdx_90C_eus-gaap--ProfessionalAndContractServicesExpense_pp0p0_c20241101__20250131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VinDeBonaMember_zgGeGAKibqs6" title="Consulting fees">10,390</span> and $<span id="xdx_900_eus-gaap--ProfessionalAndContractServicesExpense_pp0p0_c20240501__20250131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VinDeBonaMember_zxKEQMVmOsO" title="Consulting fees">15,670</span>
for the three and nine months ended January 31, 2025, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&#8217;s Chief Executive Officer was appointed to the Femasys
board of directors, see Note 4 &#8211; Investment in Debt and Equity Securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&#8217;s Chief Executive Officer serves on the board of
directors as the executive chairman of QCLS, see Note 4 &#8211; Investment in Debt and Equity Securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(e)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z8nQFBbELu77" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8 &#8211; <span id="xdx_824_ztpgKhsbGKc8">COMMITMENTS AND CONTINGENCIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acquires assets still in development
and enters R&amp;D arrangements with third parties that often require milestone and royalty payments to the third-party contingent upon
the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required, contingent
upon the successful achievement of an important point in the development lifecycle of the pharmaceutical product (e.g., approval of the
product for marketing by a regulatory agency). If required by the license agreements, the Company may have to make royalty payments based
upon a percentage of the sales of the pharmaceutical products if regulatory approval for marketing is obtained. For the three and nine
months ended January 31, 2026 the Company expensed $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20251101__20260131_z3h7DA7ZsCzg" title="Research and development expenses">93,113</span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20250501__20260131_zh6SbZoLG0Kg" title="Research and development expenses">329,355</span>, respectively, and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20241101__20250131_z8KlzLcEmOig" title="Research and development expenses">118,196</span> and $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20240501__20250131_zpzK5mdi34wh" title="Research and development expenses">311,682</span> for the three and nine
months ended January 31, 2025, respectively in research and development expenses within the accompanying unaudited condensed consolidated
statements of operations. There have been no recognized costs related to royalty payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are future royalty payments as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Four percent royalty on all gross sales received by us or the Company&#8217;s affiliates;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Twenty percent royalty on gross revenues received by the Company or the Company&#8217;s affiliates from a sublicense or right to use the patents or the licenses granted by the Company or the Company&#8217;s affiliates; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fifty percent of any other financial and non-financial consideration received from sublicensees of the Cell-in-a-Box&#174;&#160;technology; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The removal of all milestone payments.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Office Lease</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2023, the Company entered into a month-to-month
agreement of the Las Vegas office space, commencing on May 1, 2023. Additionally, the Company rents storage space pursuant to a month-to-month
agreement in Laguna Hills, California.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rent expenses for these offices for the three
and nine months ended January 31, 2026 were $<span id="xdx_90F_eus-gaap--OperatingLeaseExpense_pp0p0_c20251101__20260131_zAEhXsDu3oai" title="Operating lease expense">7,196</span> and $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_pp0p0_c20250501__20260131_zG5q7T7XhKoe" title="Operating lease expense">21,404</span>, respectively, and for the three and nine month ended January 31, 2025
were $<span id="xdx_904_eus-gaap--OperatingLeaseExpense_pp0p0_c20241101__20250131_ziMfUhKkfADa">7,071</span> and $<span id="xdx_90A_eus-gaap--OperatingLeaseExpense_pp0p0_c20240501__20250131_zbA6XCANbO7f">21,298</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the month-to-month office rental agreements
there are no aggregate future minimum lease payments required to be made.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Service Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has entered into several service agreements
with independent and related parties pursuant to which services will be provided over a specified period-of-time related to the IND which
the FDA has placed on clinical hold. The services include regulatory affairs strategy, advice and follow-up work on the IND and services
related to having the clinical hold lifted. The total remaining cost is estimated to be approximately $<span id="xdx_900_eus-gaap--ContractualObligation_iI_c20260131_zWYTFtmsRoTg" title="Contractual obligation">543,000</span>, of which the related party
(SG Austria and its subsidiaries) portion will be approximately $<span id="xdx_90E_eus-gaap--ContractualObligation_iI_c20260131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SGAustriaAndSubsidiariesMember_zpH8HZkuAMO9" title="Contractual obligation">157,000</span>. These amounts take into account some of the cost associated
with the work and preclinical studies required to lift the clinical hold.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company is subject to legal
proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims
cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect
on the Company&#8217;s financial condition or operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 16, 2025, the Company entered into a settlement
and release agreement (&#8220;Settlement Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC relating to a complaint filed on December
4, 2023, alleging a breach of contract. The Settlement Agreement resolved fully all differences, disputes or claims without admitting
any liability, fault or wrongdoing on the part of all parties. The Settlement Agreement required the Company to pay $<span id="xdx_906_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn4n6_c20250515__20250516__srt--LitigationCaseAxis__custom--HCWainwrightMember_zOZdX55ygBdb" title="Initial payment">1.55</span> million, comprised
of an initial payment of $<span id="xdx_901_eus-gaap--PaymentsForLegalSettlements_pn4n6_c20250519__20250520__srt--LitigationCaseAxis__custom--HCWainwrightMember_zqy5goazwaH" title="Payment for legal settlements">1.25</span> million paid on May 20, 2025, and twelve equal payments of $<span id="xdx_909_eus-gaap--DebtInstrumentPeriodicPayment_c20250515__20250516__srt--LitigationCaseAxis__custom--HCWainwrightMember_z52G52wMZ11h" title="Debt instrument periodic payment">25,000</span> beginning on the one-month anniversary
of the initial payment. On May 16, 2025, as part of the settlement, the Company also issued warrants &#8220;(First Warrant Issuance&#8221;)
to purchase <span id="xdx_90F_ecustom--WarrantsIssuedShares_c20250515__20250516__srt--LitigationCaseAxis__custom--HCWainwrightMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FirstWarrantIssuanceMember_zSHdHlZooiuc" title="Warrants issued shares">343,183</span> shares of Common Stock with an exercise price of $4.00 per share and a term of five years from the issuance date.
On July 29, 2025, as part of the settlement, the Company issued additional warrants (&#8220;Additional Warrants&#8221;) to purchase <span id="xdx_906_ecustom--WarrantsIssuedShares_c20250515__20250516__srt--LitigationCaseAxis__custom--HCWainwrightMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AdditionalWarrantsMember_zQ8xm8VFALCl">313,067</span>
shares of Common Stock with an exercise price of $4.00 per share and a term of five years. See Note 6 &#8211; Stock Options and Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 19, 2025, pursuant to the warrant terms,
the exercise price of the First Warrant Issuance and the Additional Warrants was adjusted to $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250819__us-gaap--ClassOfWarrantOrRightAxis__custom--AdditionalWarrantsMember_z1lH3U3Ltx5f" title="Warrants issued per share">0.95</span> per share. The price adjustment resulted
in the number of shares underlying the First Warrant Issuance to increase to <span id="xdx_903_ecustom--WarrantsIssuedShares_c20250818__20250819__us-gaap--ClassOfWarrantOrRightAxis__custom--FirstWarrantIssuanceMember_zTDXQpGlA5Lg">1,442,551</span> shares and the number of shares underlying the
Additional Warrants to increase to <span id="xdx_903_ecustom--WarrantsIssuedShares_c20250818__20250819__us-gaap--ClassOfWarrantOrRightAxis__custom--AdditionalWarrantsMember_zNBdnXVHI7Aj">1,315,960</span> shares. See Note 6 &#8211; Stock Options and Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Company&#8217;s knowledge there are no
other legal proceedings pending to which any property of the Company is subject.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS PER SHARE</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--EarningsPerShareTextBlock_z7lEbo5zFc1e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9 &#8211; <span id="xdx_829_zAWu52m9fDh2">EARNINGS PER SHARE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company computes basic earnings per share
using the two-class method. The two-class method of computing earnings per share is an earnings allocation formula that determines earnings
per share for common stock and any participating securities according to dividends declared (whether paid or unpaid) and participation
rights in undistributed earnings. The Series B Preferred Shares and Series C Preferred Shares are considered participating securities
as preferred shareholders are entitled to participate with common stockholders on an as-converted basis in any distributions of assets
by the Company under the terms of their respective Certificates of Designations. Diluted earnings per share for the nine months ended
January 31, 2025 was computed using the two-class method. Under the two-class method, there is no change in the weighted average shares
outstanding used between the basic and diluted earnings per share calculations as the Series B Preferred Shares represent the only dilutive
share equivalents during the nine months ended January 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three and nine months ended January 31, 2026 and the three
months ended January 31, 2025 the Company incurred losses attributable to common shareholders. Accordingly, the effects of any common
stock equivalent would be anti-dilutive during the period and thus are not included in the calculation of diluted weighted average number
of shares outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table illustrates the computation
of basic and diluted earnings (loss) per share:</p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zWXykV1ecHvf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EARNINGS PER SHARE (Details - Per share calculation)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B0_zxLqDWzUcPOj" style="display: none">Schedule of  basic and diluted earnings (loss) per share</span></td><td>&#160;</td>
    <td colspan="3" id="xdx_496_20251101_20260131" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_494_20241101_20250131" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended January 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Earnings per share</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">746,860</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(3,045,328</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--PreferredStockAccretionOfRedemptionDiscount_iN_pp0p0_di0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKLTnQEC55Ll" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Less: Accretion of discounts to redemption of convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,204,657</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ConvertiblePreferredStockDividends_iN_pp0p0_di0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zO2jMDPdpqzj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Less: Convertible preferred stock dividends</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(98,458</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_z1YZW2LKWxLi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,556,255</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,045,328</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Weighted average shares outstanding used in basic and diluted earnings per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20251101__20260131_pdd" title="Weighted average shares outstanding used in basic earnings per share"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20251101__20260131_pdd" title="Weighted average shares outstanding used in diluted earnings per share">9,262,829</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20241101__20250131_pdd" title="Weighted average shares outstanding used in basic earnings per share"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20241101__20250131_pdd" title="Weighted average shares outstanding used in diluted earnings per share">6,960,014</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per share basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20251101__20260131_pdd" title="Net income (loss) per share basic"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20251101__20260131_pdd" title="Net income (loss) per share diluted">(0.17</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20241101__20250131_pdd" title="Net income (loss) per share basic"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20241101__20250131_pdd" title="Net income (loss) per share diluted">(0.44</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_49E_20250501__20260131_znWz4okqdtPb" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_496_20240501__20250131_zBaFV8T3dyNe" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended January 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Earnings per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_z8o8ZmHolDi4" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: justify">Net income (loss)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(15,031,211</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">18,906,468</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PreferredStockAccretionOfRedemptionDiscount_iN_pp0p0_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zNJIKfNLSUe4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify">Less: Accretion of discounts to redemption of convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,106,653</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,193,404</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--ConvertiblePreferredStockDividends_iN_pp0p0_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zF4x150XcIpf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Less: Convertible preferred stock dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(195,097</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,129,759</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--LessAllocationOfUndistributedIncome_d0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzgjUJNVZCY6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Less: Allocation of undistributed income to Series B convertible preferred stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,067,733</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_iP3us-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zV9P8rWTMqui" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Undistributed income (loss) available to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,332,961</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,515,572</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Weighted average shares outstanding used in basic earnings per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250501__20260131_pdd" title="Weighted average shares outstanding used in basic earnings per share"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250501__20260131_pdd" title="Weighted average shares outstanding used in diluted earnings per share">7,618,128</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240501__20250131_pdd" title="Weighted average shares outstanding used in basic earnings per share"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240501__20250131_pdd" title="Weighted average shares outstanding used in diluted earnings per share">7,487,813</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) per share basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_c20250501__20260131_pdd" title="Net income (loss) per share basic"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250501__20260131_pdd" title="Net income (loss) per share diluted">(2.41</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20240501__20250131_pdd" title="Net income (loss) per share basic"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20240501__20250131_pdd" title="Net income (loss) per share diluted">1.67</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zMEpQRkfKw2a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below sets forth the potentially dilutive
securities excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive:</p>

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zIMlQuiVdZ7e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EARNINGS PER SHARE (Details - Diluted shares)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BD_zxhk3UkMI4uk" style="display: none">Schedule of potentially dilutive securities</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three and Nine Months Ended <br/> January 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify">Excluded options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares">1,160,627</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares">917,697</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Excluded preferred shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_pdd" title="Antidilutive shares"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_pdd" title="Antidilutive shares">5,008,061</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_z5pGw8qxByt6" title="Antidilutive shares"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240501__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_zpkZStzTy9Td" title="Antidilutive shares">&#8211;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Excluded warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares">55,819,519</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares">18,570,847</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total excluded options, preferred shares and warrants</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131_pdd" title="Antidilutive shares"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131_pdd" title="Antidilutive shares">61,988,207</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131_pdd" title="Antidilutive shares"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250131_pdd" title="Antidilutive shares">19,488,544</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zOOcYe0NJb45" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diluted earnings per share were calculated under
both the if-converted and the two-class methods to determine the most dilutive amount for the common stock. The Company applied the treasury
stock two-class method which assumes the securities remain in their current non-exercised or converted form and therefore, deemed anti-dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481468/505-20-05-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREFERRED STOCK<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">PREFERRED STOCK</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--PreferredStockTextBlock_zbVNKkYoPyEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10 &#8211; <span id="xdx_825_zaDnPOk3UUr3">PREFERRED STOCK</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Series C Private Placement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 17, 2025, the Company entered into the
Series C Private Placement Agreement with the Investors, pursuant to which it agreed to sell to the Investors in a private placement (the
&#8220;Series C Private Placement&#8221;) (i) an aggregate of <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_z4Qq5BaFh1o2" title="Aggregate shares">7,000</span> shares of the Company&#8217;s newly designated Series C convertible
preferred stock, par value $<span id="xdx_90A_ecustom--PreferredStockParValuePerShare_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_z5hy8M3ko5F5" title="Preferred stock, par value">0.0001</span>, with a stated value of $<span id="xdx_900_ecustom--PreferredStockStatedValuePerShare_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zf9mQBr3OYPj" title="Preferred stock, stated value">1,000</span> per share (the &#8220;Series C Preferred Stock&#8221;), initially convertible
into up to <span id="xdx_902_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zkyi08q8NQkk" title="Conversion shares">7,000,000</span> shares of the Company&#8217;s common stock, par value $<span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zhwHsggJkYgi" title="Common stock, par value">0.0001</span> per share at an initial conversion price of $<span id="xdx_90E_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zkEhX6F0fsP3" title="Conversion price">1.00</span> and
(ii) the Series C Preferred Warrants to purchase up to an aggregate of <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zhwp0RVdxIqi" title="Warrants to purchase shares">7,000,000</span> shares of Common Stock. The closing of the Private Placement
occurred on August 19, 2025. The aggregate gross proceeds from the Private Placement totaled $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zuYInITqCogl" title="Aggregate gross proceeds">7,000,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Series C Private Placement,
pursuant to an Engagement Letter (the &#8220;Engagement Letter&#8221;) between the Company and the Placement Agent, the Company has agreed
to pay the Placement Agent <span id="xdx_908_eus-gaap--SaleOfStockDescriptionOfTransaction_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zL7VWD19NPzh" title="Engagement letter, description">(i) a cash fee equal to 8.0% of the gross proceeds from the Series C Private Placement, and (ii) warrants to
purchase shares of Common Stock equal to 8.0% of the number of shares of common stock that the Preferred Stock are initially convertible
into, with an exercise price of $1.00 per share and a five-year term.</span> Further, pursuant to the Engagement Letter, the Placement Agent
is entitled to compensation with respect to any financing of the Company occurring during the term of the Engagement Letter or within
twelve months thereafter when such financing is provided by investors whom the Placement Agent introduced to the Company. In addition,
for any warrants of the Company that are issued to investors who are introduced to the Company by the Placement Agent in the Private Placement
or were previously issued in connection with the Company&#8217;s May 2023 private placement, and are exercised during the term of the
Engagement Letter, the Company shall pay the Placement Agent a cash fee equal to <span id="xdx_90E_ecustom--PlacementAgentFeePercentage_dp_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zH5pOu8SJJd4" title="Placement agent, cash fee percentage">8.0</span>% of the net proceeds received by the Company from
such warrant exercises.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Transaction costs totaling $<span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250501__20260131__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zjLFYX6Oppe8" title="Transaction costs">1,234,553</span>&#160;were
incurred related to the Series C Private Placement consisting of cash expenses for placement agent fees, legal fees, and accounting costs
related to the financing, as well as the fair value of the warrants issued to the Placement Agent, of which $<span id="xdx_900_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20260131__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zz2TAyAthFQb" title="Accounts payable">86,419</span> was included in accounts
payable on the condensed consolidated balance sheet as of January 31, 2026. These costs were proportionately allocated to the Series C
Preferred Stock and the Series C Warrants based on the allocated gross proceeds of the instruments. Accordingly, none of the transaction
costs were allocated against the carrying value of the Preferred Stock and the total of $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_ziJNsPo1Usad" title="Transaction costs">1,234,553</span>&#160;of transaction costs were immediately
expensed related to the Series C Warrants which are accounted for as liabilities in accordance with ASC 815, and the bifurcated derivative
related to the Series C Preferred Stock, which is included as a Series C preferred stock and warrants issuance costs on the condensed
consolidated statement of operations for the three and nine months ended January 31, 2026. Net proceeds from the Series C Private Placement
totaled $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250501__20260131__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_z3dkfiszPdq5" title="Aggregate gross proceeds">6,182,447</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Series C Preferred Stock</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The terms of the Series C Preferred Stock are
as set forth in the form of Certificate of Designations (the &#8220;Certificate of Designations&#8221;). The Series C Preferred Stock
are convertible into shares of Common Stock (the &#8220;Conversion Shares&#8221;) at the election of the holder at any time at an initial
conversion price of $<span id="xdx_90B_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20260131_z4SYctm2OJ9k" title="Conversion price">1.00</span> (the &#8220;Conversion Price&#8221;). The Conversion Price is subject to customary adjustments for stock dividends,
stock splits, reclassifications and the like, and subject to price-based adjustment in the event of any issuances of Common Stock, or
securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable Conversion Price (subject to
certain exceptions). The conversion price was reduced to $0.95 after issuance pursuant to the full ratchet anti-dilution provisions contained
in the Certificate of Designations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of the Series C Preferred Stock will
be entitled to dividends of 7% per annum, compounded quarterly, which will be payable in cash. Upon the occurrence and during the continuance
of a Triggering Event (as defined in the Certificate of Designations), the Series C Preferred Stock will accrue dividends at the rate
of 15% per annum. The holders of Series C Preferred Stock are entitled to vote with holders of the Common Stock as a single class on all
matters that holders of Common Stock are entitled to vote upon, with the number of votes per Series C Preferred Share equal to the stated
value of such Series C Preferred Share divided by the then applicable Conversion Price; provided, however that in no event shall the then
applicable Conversion Price be less than the &#8220;Minimum Price&#8221; (as defined in Nasdaq Listing Rule 5635) on the date immediately
prior to the date of the Purchase Agreement.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2025, the Company held a special meeting
of stockholders (the &#8220;2025 Special Meeting&#8221;). At the 2025 Special Meeting, the stockholders of the Company approved, for purposes
of complying with Nasdaq Listing Rule 5635(d), (the &#8220;Exchange Cap&#8221;) the issuance of shares of Common Stock underlying the
Series C Preferred Stock and Series C Warrants, which allows the Company to settle all Series C Preferred Stock conversions into shares
of Common Stock. The Series C Certificate of Designations contains a certain beneficial ownership limitation after giving effect to the
issuance of shares of Common Stock issuable upon conversion of the Series C Preferred Stock or Series C Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company obtained stockholder approval to remove
the Exchange Cap on October 30, 2025, upon which event the conversion floor price was adjusted to $0.19.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series C Certificate of Designations includes
certain Triggering Events (as defined in the Series C Certificate of Designations), including, among other things, the Company&#8217;s
failure to pay any amounts due to the holders of the Series C Preferred Stock when due. In connection with a Triggering Event, each holder
of Series C Preferred Stock will be able to require the Company to redeem in cash any or all of the holder&#8217;s Series C Preferred
Stock at a premium set forth in the Series C Certificate of Designations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Series C Preferred Shares were determined
to be more akin to a debt-like host than an equity-like host. The Company identified certain embedded features that were deemed not to
be clearly and closely related to the debt host instrument and were therefore bifurcated as a derivative under ASC 815. These features
were bundled together, assigned probabilities of being affected and measured at fair value. Subsequent changes in fair value of these
features are recognized in the condensed consolidated statement of operations. The Company estimated the $<span id="xdx_900_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20260131_z1ivcrYtcXng" title="Fair value of derivative">1,995,000</span>&#160;fair value of
the compound bifurcated embedded derivative at issuance using a probability-weighted scenario model, with the following inputs: the fair
value of the Company&#8217;s common stock of $<span id="xdx_907_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_uUSDPShares_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zO3z69qDxM7d" title="Derivative, measurement input">1.01</span>&#160;on the issuance date, estimated equity volatility of&#160;<span id="xdx_902_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_znT6Z7A9jO8d" title="Derivative, measurement input">60.0</span>%, the time to maturity
of&#160;<span id="xdx_906_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_uYear_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zAupil9Jk1f9" title="Derivative, measurement input">1.50</span>&#160;years, the maturity redemption premium of&#160;<span id="xdx_908_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRedemptionPremiumMember_zOh7F0nRoTxk" title="Derivative, measurement input">106</span>%, the liquidation premium of 125%, a market interest rate of&#160;<span id="xdx_900_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketInterestRateMember_z4WAycjbueH5" title="Derivative, measurement input">16.92</span>%,
a risk-free rate of&#160;<span id="xdx_908_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zjhWbjYK1XG9" title="Derivative, measurement input">3.76</span>%, and dividend rate of <span id="xdx_90F_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zkFicZjjdzll" title="Derivative, measurement input">7.00</span>%. The fair value of the bifurcated derivative liability was estimated utilizing
the with and without method which uses the probability weighted difference between the scenarios with the derivative and the plain vanilla
scenario without a derivative.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The discount to the fair value is included as
a reduction to the carrying value of the Series C Preferred Stock. During the nine months ended January 31, 2026, the Company recorded
a total discount of $<span id="xdx_906_ecustom--PreferredStockDiscount_pp0p0_c20251101__20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zzhCB6Yvr4f2" title="Total discount on preferred stock">7,000,000</span> upon issuance of the Series C Preferred Stock, which was comprised of the issuance date fair value of the
associated embedded derivative of $<span id="xdx_90E_ecustom--FairValueEmbeddedDerivative_pp0p0_c20251101__20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zqEiRdlAbQE6" title="Fair value of embedded derivative">1,995,000</span> and the difference between the remaining gross proceeds after allocation to the derivative
liability and the residual fair value of the Series C Preferred Shares of $<span id="xdx_90B_ecustom--WarrantLiabilityFairValue_pp0p0_c20251101__20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zjcSY14lUBr1" title="Fair value of warrant">5,005,000</span>, which represents the portion of the total of the
Series C Warrant liability of $5,220,000 allocated to the discount. As the fair value of the liabilities required to be subsequently measured
at fair value exceeded the net proceeds received, the Company recognized the excess of the fair value over the net proceeds received as
a loss upon issuance of preferred stock of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20251101__20260131_ziNmSMxlwx6k" title="Proceeds from issuance of preferred stock"><span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20250501__20260131_zy1woTaUUX68" title="Proceeds from issuance of preferred stock">215,000</span></span>&#160;which is included in other income (expense) in the condensed consolidated statement
of operations for the nine months ended January 31, 2026. As of January 31, 2026, it is probable that the Series C Preferred Stock will
be redeemed. In accordance with ASC 480-10-S99-3A, the Company is accreting the discount using the effective interest method and $<span id="xdx_906_ecustom--DeemedDividend_pp0p0_c20251101__20260131_zEdRFFwGvm22" title="Deemed dividend">2,204,657</span>
and $<span id="xdx_90E_ecustom--DeemedDividend_c20250501__20260131_pp0p0" title="Deemed dividend">3,106,653</span>, respectively,&#160;was recorded as a deemed dividend during the three and nine months ended January 31, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recorded a gain of $<span id="xdx_90D_ecustom--ChangeInFairValueDerivativeLiability_pp0p0_c20251101__20260131_z3RELHctJgQ5" title="Change in fair value derivative liability">557,000</span> and $<span id="xdx_90E_ecustom--ChangeInFairValueDerivativeLiability_pp0p0_c20250501__20260131_z1gSVLCj3joj" title="Change in fair value derivative liability">859,000</span>, respectively, related to the change in fair value of the derivative liability
which is recorded in other income (expense) on the condensed consolidated statements of operations. The Company estimated the $<span id="xdx_907_ecustom--WarrantLiabilityFairValue_pp0p0_c20251101__20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zaFOys2XDHzl" title="Fair value of warrant">1,136,000</span>&#160;fair
value of the bifurcated embedded derivative at January 31, 2026 using a probability-weighted scenario model, with the following inputs:
the fair value of the Company&#8217;s common stock of $<span id="xdx_902_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_uUSDPShares_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_z5zy8cncjno1">0.82</span>&#160;on the measurement date, estimated equity volatility of&#160;<span id="xdx_90A_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zeupaYbnmpf8">85.0</span>%, the
time to maturity of&#160;<span id="xdx_90B_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_uYear_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zVruSaU2mKQ9">1.05</span>&#160;years, the maturity redemption premium of&#160;<span id="xdx_90C_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRedemptionPremiumMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zNurQC2Tb4T1">106</span>%, the liquidation premium of 125% a market interest
rate of&#160;<span id="xdx_900_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketInterestRateMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_z8GBw3rkvEXg">20.10</span>%, a risk-free rate of&#160;<span id="xdx_908_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zwdUG4pfSOR">3.42</span>%, and dividend rate of <span id="xdx_901_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zYEG0KEkT8ni">7.00</span>%. The fair value of the bifurcated derivative liability
was estimated utilizing the with and without method which uses the probability weighted difference between the scenarios with the derivative
and the plain vanilla scenarios without a derivative.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three and nine months ended January
31, 2026, the Company recognized a total of $<span id="xdx_900_eus-gaap--DividendsPreferredStockStock_c20251101__20260131_zYuGn86aADfe" title="Preferred dividends">98,458</span> and $<span id="xdx_900_eus-gaap--DividendsPreferredStockStock_c20250501__20260131_z218shCEqrP4" title="Preferred dividends">195,097</span>, respectively, of preferred dividends at the stated dividend rate, of
which $<span id="xdx_90D_eus-gaap--DividendsPreferredStockCash_c20251101__20260131_zea7dqRyAyLf" title="Dividend paid in cash">101,356</span> and $<span id="xdx_903_eus-gaap--DividendsPreferredStockCash_c20250501__20260131_zF5HkZlw1hk3" title="Dividend paid in cash">162,606</span>, respectively, were paid in cash and $<span id="xdx_904_eus-gaap--DividendsPreferredStockPaidinkind_c20251101__20260131_zislt7KY9Ha6" title="Dividend accrued">32,491</span> are accrued in accrued Series C Preferred Stock and dividends
on the condensed consolidated balance sheet as of January 31, 2026. During the three months ended January 31, 2026, there were <span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_c20251101__20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zy7Xhk4h7nz6" title="Stock converted">2,234</span> Series
C preferred stock converted that resulted in <span id="xdx_90E_eus-gaap--ConversionOfStockSharesIssued1_c20251101__20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zGHAfHjmimx8" title="Shares issued">2,358,620</span> shares of common stock being issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-13<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TREASURY STOCK<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">TREASURY STOCK</a></td>
<td class="text"><p id="xdx_801_eus-gaap--TreasuryStockTextBlock_z05biwOFw9D9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11 &#8211; <span id="xdx_826_z0QudCCnAqA9">TREASURY STOCK</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2022, the Board authorized a share repurchase
program to acquire its outstanding common stock for up to $10 million. In January 2023, the Board authorized an additional share repurchase
program to acquire up to an additional $10 million of the Company&#8217;s outstanding common stock. In conjunction with the share repurchase
programs, the Company selected a broker to repurchase shares on behalf of the Company. The amount of common stock repurchased on any given
trading day is determined by a formula, which is based on the market price of the common stock and average daily volumes. Shares repurchased
are held in treasury for general corporate purposes. The shares are treated as Treasury Stock using the cost method. As of April 2025,
the Company has paused the repurchase program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 11, 2025, the Company granted the
directors of the Company <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20251210__20251211__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSCY3nNp30bd" title="Restricted stock">875,000</span> shares of common stock in a restricted stock unit (&#8220;RSU&#8221;) transaction. The RSUs vested immediately
and the Company withheld <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20251210__20251211__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNKiFu3YEpSg" title="Restricted stock vested">393,750</span> shares valued at $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20251210__20251211__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7MAV44xa0N4" title="Restricted units valued">401,625</span> to cover the expected income tax effect of the grants. The Company recorded
stock based compensation expense to general and administrative expenses of $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20251210__20251211__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzDtIa02IHR9" title="Stock issued for compensation">892,500</span> related to the RSU grants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of January 31, 2026 and April 30, 2025, the
total number of shares held in Treasury Stock was <span id="xdx_90D_eus-gaap--TreasuryStockCommonShares_iI_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--TreasuryStockCommonMember_zeharu2husK8" title="Treasury stock, common shares">15,270,066</span> and <span id="xdx_905_eus-gaap--TreasuryStockCommonShares_iI_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--TreasuryStockCommonMember_zJhKLAewAxmg" title="Treasury stock, common shares">14,876,316</span>, respectively, shares at total costs of $<span id="xdx_90A_eus-gaap--TreasuryStockCommonValue_iI_pp0p0_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--TreasuryStockCommonMember_z5eQUeKLUwfa" title="Treasury stock, value">45,009,541</span> and $<span id="xdx_906_eus-gaap--TreasuryStockCommonValue_iI_pp0p0_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--TreasuryStockCommonMember_zGUTxHAJD8A1" title="Treasury stock, value">44,607,916</span>,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--FairValueDisclosuresTextBlock_zQasBjGXWRnl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12 &#8211; <span id="xdx_829_z6jXmNqYPeQ5">FAIR VALUE MEASUREMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fair value measurements discussed herein are based
upon certain market assumptions and pertinent information available to management as of and during the three and nine months ended January
31, 2026. The carrying amounts of cash equivalents, other current assets, accounts payable and accrued expenses approximate their face
values at January 31, 2026 due to their short-term nature. The fair value of the bifurcated embedded derivative related to the convertible
preferred stock was estimated using a probability-weighted scenario model, which uses as inputs the fair value of the Company&#8217;s
common stock and estimates for the equity volatility and of the Company&#8217;s common stock, the time to maturity of the convertible
preferred stock, the risk-free interest rate for a period of time that approximates the time to maturity, the maturity redemption premium
rate, the liquidation premium rate, the market discount rate, and the dividend rate. The fair value of the warrant liability was estimated
using the Black Scholes Merton Model which uses as inputs the following weighted average assumptions, as noted above: dividend yield,
expected terms in years, equity volatility and risk-free rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Fair Value on a Recurring Basis</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the guidance in ASC 820 for
its financial assets and liabilities that are re-measured and reported at fair at each reporting period, and non-financial assets and
liabilities that are re-measured and reported at fair value at least annually. The estimated fair value of the warrant liability and bifurcated
embedded derivative represent Level 3 measurements. The following table presents information about the Company&#8217;s liabilities that
are measured at fair value on a recurring basis at January 31, 2026 and April 30, 2025, and indicates the fair value hierarchy of the
valuation inputs the Company utilized to determine such fair value:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zF9lBkc5Vir9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair value)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B6_zCx3vSGvWar2" style="display: none">Schedule of fair value of financial liabilities</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: justify">Description</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Level</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">January 31, 2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">April 30, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Liabilities:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; text-align: justify">Warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 11%; text-align: center">3</td><td style="width: 1%; text-align: center">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20260131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_ztEgxCLFA8Yg" style="width: 11%; text-align: right" title="Warrant liabilities">13,657,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FinancialLiabilitiesFairValueDisclosure_pp0p0_c20250430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zpRAlvZ7ydcl" style="width: 11%; text-align: right" title="Warrant liabilities">338,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Derivative liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20260131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zELHs1Gy564k" style="text-align: right" title="Warrant liabilities">1,136,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_d0_c20250430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zTB27IoUPQug" style="text-align: right" title="Warrant liabilities">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zl9Ml1eQruZh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth a summary of the
change in the fair value of the warrant liability that is measured at fair value on a recurring basis:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zjATpYIMOsv" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of warrant liability)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_zK9pFyzu0yq4" style="display: none">Schedule of change in the fair value warrant liability</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended January 31, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%">Balance on October 31, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zPinaFMb2qVl" style="width: 13%; text-align: right" title="Fair value of the warrant liability at beginning">16,152,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pp0p0_d0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zRj80Tmfx8Pb" style="text-align: right" title="Issuance of warrants">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Warrant exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--WarrantExercises_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zGzvOXGHFIOg" style="text-align: right" title="Warrant exercises">(599,135</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ChangeInFairValueOfWarrantLiability_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability">(1,895,865</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Balance on January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zgCPiGJi7Emc" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of the warrant liability at ending">13,657,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt; width: 83%">&#160;</td><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 1%">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center; width: 13%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine Months Ended January 31, 2026</span></td><td style="padding-bottom: 1pt; text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Balance on April 30, 2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zid8xXInSDa1" style="text-align: right" title="Fair value, beginning">338,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_z3f6fB8kM2Jf" style="text-align: right" title="Issuance of warrants">5,583,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Warrant exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--WarrantExercises_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zGwMiBjNtHwk" style="text-align: right" title="Warrant exercises">(599,135</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiability_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability">8,335,135</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Balance on January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_z8ZefvQM88B" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value, ending">13,657,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_z03HtV5aCvE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth a summary of the
change in the fair value of the derivative liability that is measured at fair value on a recurring basis:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zB3WdxHNSH4b" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of derivative liability)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BE_zBPBqzsLGbJ6" style="display: none">Schedule of change in the fair value derivative liability</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three Months Ended January 31, 2026</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance on October 31, 2025</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zz6jtwY1f8ia" style="text-align: right" title="Fair value of the warrant liability at beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,693,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 84%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of Series C convertible preferred stock</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_985_ecustom--IssuanceOfSeriesCConvertiblePreferredStock_pp0p0_d0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zmI71ikrL7jd" style="width: 13%; text-align: right" title="Issuance of Series C convertible preferred stock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in fair value of derivative liability</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_ecustom--ChangeInFairValueOfWarrantLiability_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zuPImSdAN83l" style="border-bottom: black 1pt solid; text-align: right" title="Change in fair value of derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(557,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance on January 31, 2026</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zJtanI2USiFf" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value of the warrant liability at ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,136,000</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine Months Ended January 31, 2026</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance on April 30, 2025</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_980_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_d0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zqDxowByTRS8" style="text-align: right" title="Fair value, beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 84%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of Series C convertible preferred stock</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_986_ecustom--IssuanceOfSeriesCConvertiblePreferredStock_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_pp0p0" style="width: 13%; text-align: right" title="Issuance of Series C convertible preferred stock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,995,000</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in fair value of derivative liability</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiability_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_pp0p0" style="border-bottom: black 1pt solid; text-align: right" title="Change in fair value of derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(859,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance on January 31, 2026</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zV8ZJWF4fvzj" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value, ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,136,000</span></td>
    <td>&#160;</td></tr>
  </table>
<p id="xdx_8AF_zDmWku3XIn9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the convertible note receivable
was historically estimated using the income approach, which uses as inputs the fair value of debtor&#8217;s common stock and estimates
for the equity volatility and volume volatility of debtor&#8217;s common stock, the time to expiration of the convertible note, the discount
rate, the stated interest rate compared to the current market rate, the risk-free interest rate for a period that approximates the time
to expiration, and probability of default. Therefore, the estimate of expected future volatility is based on the actual volatility of
debtor&#8217;s common stock and historical volatility of debtor&#8217;s common stock utilizing a lookback period consistent with the time
to expiration. The time to expiration is based on the contractual maturity date. The risk-free interest rate is determined by reference
to the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration.
Probability of default is estimated using the S&amp;P Global default rate for companies with a similar credit rating to debtor&#8217;s.
At January 31, 2026, the fair value of the convertible note receivable was estimated to be equal to its principal value the note was near
its maturity and was expected to be fully settled in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair values of financial instruments by class
as of January 31, 2026 and April 30, 2025 are as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zGaBW8wYEk61" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair values of financial instruments)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B3_zLyMlzDJddi8" style="display: none">Schedule of fair values of financial instruments by class</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Level</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">January 31, 2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">April 30, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: justify">Financial Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; text-align: left">Marketable equity securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 11%; text-align: center">1</td><td style="width: 1%; text-align: center">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20260131__us-gaap--FinancialInstrumentAxis__custom--MarketableEquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 11%; text-align: right" title="Fair value of financial assets">372,251</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--MarketableEquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 11%; text-align: right" title="Fair value of financial assets">366,316</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Money market account</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20260131__us-gaap--FinancialInstrumentAxis__custom--MoneyMarketAccountMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Fair value of financial assets">2,081,636</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--MoneyMarketAccountMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Fair value of financial assets">76,287</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible note receivable &#8211; investment in debt security - Femasys</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_d0_c20260131__us-gaap--FinancialInstrumentAxis__custom--ConvertibleNoteReceivableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zC0yzOpRIE41" style="text-align: right" title="Fair value of financial assets">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--ConvertibleNoteReceivableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets">3,696,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Warrant asset - Femasys</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20260131__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetFemasysMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets">906,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetFemasysMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets">3,061,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment in preferred stock - QCLS</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_c20260131__us-gaap--FinancialInstrumentAxis__custom--InvestmentInPreferredStockQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaBdqNmylt05" style="text-align: right" title="Fair value of financial assets">22,472,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--InvestmentInPreferredStockQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets">22,474,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Warrant assets - QCLS</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_c20260131__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z8xXTGJ8HWue" style="text-align: right" title="Fair value of financial assets">10,242,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets">8,618,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_z3I6Soh50QTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assumptions used in the valuation of the Level
3 assets include time to expiration, discount rate, risk-free rate, volatility and probability of default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation and Basis of Presentation</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zEn8a5sVwzBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86F_zF924hLUdH9g">Principles of Consolidation and Basis of Presentation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated
financial statements have been prepared in accordance with U.S. GAAP for interim financial information and the rules and regulation of
the United States Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by
U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of
normal recurring items) which are considered necessary for a fair statement of the unaudited condensed consolidated financial statements
of the Company as of January 31, 2026 and for the three and nine months then ended. The results of operations for the three and nine months
ended January 31, 2026 are not necessarily indicative of the operating results for the year or any other period. These unaudited condensed
consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures as of April
30, 2025 and for the year then ended which are included in the Company&#8217;s Annual Report on Form 10- K, filed with the SEC on August
11, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The unaudited condensed consolidated financial
statements include the accounts of the Company and its wholly owned subsidiaries. The Company operates independently and through three
wholly owned subsidiaries: (i) PharmaCyte Biotech Europe Limited; (ii) PharmaCyte Biotech Australia Pty. Ltd.; and (iii) Viridis Biotech,
Inc. and are prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and the Rules and Regulations
of the Commission. Upon consolidation, intercompany balances and transactions are eliminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates in the Preparation of Financial Statements</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--UseOfEstimates_zdlBwwa553N9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86B_z5PEf66noUIc">Use of Estimates in the Preparation of Financial
Statements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in accordance
with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of
contingent assets and liabilities known to exist as of the date the financial statements are published and the reported amounts of revenues
and expenses during the reporting period. Uncertainties with respect to such estimates and assumptions are inherent in the preparation
of the Company&#8217;s unaudited condensed consolidated financial statements; accordingly, it is possible that the actual results could
differ from these estimates and assumptions, which could have a material effect on the reported amounts of the Company&#8217;s condensed
consolidated financial position and results of operations. The Company&#8217;s most significant estimates and assumptions are the assessment
of the fair value of long-lived assets, fair value measurements of investments, the valuation of warrants and derivative liabilities,
and the measurement of stock-based compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>













<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Reclassifications', window );">Reclassification</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--Reclassifications_z6JDFJSpFkTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_860_zjtxU3oKJfKe">Reclassification</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain balances in the unaudited condensed consolidated
financial statements for the three and nine months ended January 31, 2025 have been reclassified to conform to the presentation in the
condensed consolidated financial statements for the three and nine months ended January 31, 2026. In the prior year, the Company separately
disclosed compensation expense, director fees and legal and professional expenses and combined the QCLS change in fair value of the investment
and warrant assets and in the current year the Company has reclassified these costs on the consolidated statements of operations with
general and administrative expenses and the change in the fair value of the investment QCLS and the change in the fair value of the warrant
assets are presented separately. These reclassifications had no effect on the Company&#8217;s previously reported results of operations,
changes in convertible preferred stock and stockholders&#8217; equity, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zecu2pLZS4lb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_864_zPdv9rRu08qi">Cash and Cash Equivalents</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents include cash in banks
and short-term liquid investments purchased with maturities of three months or less. Additionally, the Company, as of January 31, 2026
and April 30, 2025 had $<span id="xdx_901_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20260131_zIsJD9ugzaQe" title="Cash, uninsured amount">2.1</span> million and $<span id="xdx_90B_eus-gaap--CashUninsuredAmount_iI_c20250430_zPY9BRgn84Fg" title="Cash, uninsured amount">76,287</span>, respectively, in a money market fund that is not insured by the Federal Deposit Insurance
Corporation (&#8220;FDIC&#8221;) and is classified as a cash equivalent. The Company has no significant off-balance-sheet concentrations
of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. The Company maintains most
of its cash balance at financial institutions located throughout the U.S. Accounts at these institutions are insured by the FDIC up to
$250,000. The Company has not experienced any losses in such accounts. Management believes it is not exposed to any significant credit
risk on cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_849_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_z5n34qUqwrFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86F_zOZQuZk62MQ5">Intangible Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s accounts for intangible assets
at cost. The intangible asset has an indefinite life; therefore, is not amortizable. The Company performs annual impairment analysis for
the intangible asset to ascertain the value at each year end and records a non-cash impairment expense should the value decrease below
book value. The asset is deemed to be an In-Process Research and Development (&#8220;IPR&amp;D&#8221;) as the asset is in the research
stage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Financial Accounting Standards Board (&#8220;FASB&#8221;)
standard on goodwill and other intangible assets prescribes a two-step process for impairment testing of goodwill and indefinite-lived
intangibles, which is performed annually, as well as when an event triggering impairment may have occurred. The first step tests for impairment,
while the second step, if necessary, measures the impairment. The Company has elected to perform its annual analysis at the end of its
reporting year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_znpaVd9AXJV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_862_zNSiRm1au4Fe">Fair Value of Financial Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting Standards Codification (&#8220;ASC&#8221;)
Topic 820, &#8220;Fair Value Measurements and Disclosures,&#8221; requires disclosure of the fair value of financial instruments held
by the Company. ASC Topic 825, &#8220;Financial Instruments,&#8221; defines fair value, and establishes a three-level valuation hierarchy
for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported
in the Consolidated Balance Sheets for current assets and liabilities qualify as financial instruments and are a reasonable estimate of
their fair values because of the short period between the origination of such instruments and their expected realization and their current
market rate of interest. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability
(an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use
of unobservable inputs. The three levels of valuation hierarchy are defined as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1. Observable inputs such as quoted prices in active markets</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2. Inputs, other than the quoted prices in active markets, which are observable either directly or indirectly; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These unobservable inputs are significant to the
fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_847_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zBHCex85zAM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Segment Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company operates in <span id="xdx_90F_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20250501__20260131_zASX9yMgXsV6" title="::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl1229">one</span></span> business
segment, which includes the business of research and development activities related to developing cellular cancer therapies. The determination
of a single business segment is consistent with the financial information regularly provided to the Company&#8217;s chief operating decision
maker (&#8220;CODM&#8221;). The Company&#8217;s CODM is its President and CEO, who reviews and evaluates consolidated net income as presented
in the accompanying consolidated statements of operations for purposes of assessing performance, making operating decisions, allocating
resources, and planning and forecasting for future periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncement Effective in Future Periods</a></td>
<td class="text"><p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zRUkpy3lvvW" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86B_zo7ajKAyO8Wb">New Accounting Pronouncement Effective in Future
Periods</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2025, the FASB issued ASU 2025-11
&#8211; Interim Reporting (Topic 270): Narrow-Scope Improvements to improve the guidance in Topic 270, Interim Reporting, by improving
the navigability of the required interim disclosures and clarifying when that guidance is applicable. The amendments also provide additional
guidance on what disclosures should be provided in interim reporting periods. The guidance is effective for the Company&#8217;s interim
periods&#160;within annual reporting periods beginning after December 15, 2027. The Company is evaluating the impact of adoption of this
standard on its financial statements and disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Reclassifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Reclassifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN DEBT AND EQUITY SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock', window );">Schedule of activity for the notes and warrants</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock_zIJZbr9fmyab" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Femasys Note and warrants)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B6_zPFx5JpVVhV8" style="display: none">Schedule of activity for the notes and warrants</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: justify">Balance of Femasys Note as of April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ConvertibleNoteReceivableCurrent_iS_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zcVqZmWeVxJf" style="width: 13%; text-align: right" title="Investment, beginning balance">3,696,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Change in fair value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ChangeInFairValueOfConvertibleNotesReceivable_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zzRyXvMMS5y1" style="text-align: right" title="Change in fair value">1,304,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Settlement of Femasys Note</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ProceedsFromInvestmentNoteReceivable_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zxwa0yFTbJP6" style="border-bottom: Black 1pt solid; text-align: right" title="Settlement of Femasys Note">(5,000,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Balance of Femasys Note as of January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ConvertibleNoteReceivableCurrent_iE_d0_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zfJXwdRVpvTd" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance">&#8211;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: justify">Balance of Femasys Warrant Asset as of April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--WarrantAssetFemasys_iS_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysWarrantsMember_zXIWBF6vdp01" style="width: 13%; text-align: right" title="Investment, beginning balance">3,061,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_ecustom--ChangeInFairValueOfWarrantAssetFemasys_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysWarrantsMember_zvxqJ0ydPnb" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(2,155,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Balance of Femasys Warrant Asset as of January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_ecustom--WarrantAssetFemasys_iE_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysWarrantsMember_znNVChNbG69b" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance">906,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock', window );">Schedule of marketable equity securities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock_zvFiqG8cQ8nd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Marketable securities)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B3_zvXzbb3lexK5" style="display: none">Schedule of marketable equity securities</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Carrying Value</td><td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">At Fair Market</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Adjusted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">Unrealized</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 55%; text-align: justify; padding-bottom: 1pt">Marketable securities</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Value</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Basis</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Equity &#8211; stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--MarketableSecuritiesCurrent_iI_c20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_ztFDbwbPoEN8" title="Carrying value at fair market value">372,251</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--InvestmentOwnedAtCost_iI_c20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zczNH370gFRj" title="Adjusted cost basis">666,316</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20250501__20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zAt1iAJWMWD1" title="Unrealized loss">294,065</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTableTextBlock', window );">Schedule of activity preferred stock</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--InvestmentTableTextBlock_z2pMAY7NicW2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series G Preferred Stock and Preferred Stock Warrants)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_z9Ya0pjiqgBa" style="display: none">Schedule of activity preferred stock</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: justify">Balance of Series G Preferred Stock as of April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zJWApdCZnImc" style="width: 13%; text-align: right" title="Investment, beginnning balance">22,474,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ChangeInFairValueOfInvestment_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zVOsyYNARIR2" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(5,127,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Balance of Series G Preferred Stock as of January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zsTyPAX3lp3c" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance">17,347,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is a summary of activity for the QCLS Warrants
as of January 31, 2026:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: justify">Balance of QCLS Series G Warrant assets as of April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_c20250501__20260131__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGWarrantsMember_zWMuwb6FjXK5" style="width: 13%; text-align: right" title="Investment, beginnning balance">8,618,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--ChangeInFairValueOfInvestment_c20250501__20260131__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGWarrantsMember_zX7yT8Eu3rD1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">(1,652,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Balance of QCLS Series G Warrant assets as of January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGWarrantsMember_zPbgi1cCOVA6" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance">6,966,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember', window );">Series H Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTableTextBlock', window );">Schedule of activity preferred stock</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--InvestmentTableTextBlock_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zfEVQb40lg51" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series H Preferred Stock and Preferred Stock Warrants)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_z6IJ0Rx6rgya" style="display: none">Schedule of activity preferred stock</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: justify">Balance of Series H Preferred Stock as of April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_d0_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zkLGmajUPc4g" style="width: 13%; text-align: right" title="Investment, beginning balance">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Initial fair value of investment Series H Preferred Shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--InvestmentOwnedAtFairValue_iI_c20250902__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zvMRwQxuSUNi" style="text-align: right" title="Initial fair value of Investment">3,483,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ChangeInFairValueOfInvestmentQcls_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zW4yEHlezcM6" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">1,642,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Balance of Series H Preferred Stock as of January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zR9XFRjFULte" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance">5,125,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is a summary of activity for the QCLS Series
H Warrants as of January 31, 2026:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: justify">Balance of QCLS Series H Warrant assets as of April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_d0_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zN1LwFG8Jbyc" style="width: 13%; text-align: right" title="Investment, beginning balance">&#8211;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Initial fair value of investment in of QCLS Series H Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--InvestmentOwnedAtFairValue_iI_c20250902__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zacjDXECZvh8" style="text-align: right" title="Initial fair value of Investment">1,606,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Change in fair value</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--ChangeInFairValueOfInvestmentQcls_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zp8eUhbkLUM4" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value">1,670,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Balance of QCLS Series H Warrant assets as of January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zwUz1V3pxHM6" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance">3,276,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org/325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other investments not readily marketable, including, but not limited to, description of investment, fair value and value as measured by quoted price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of not readily marketable securities and investments including, but not limited to, description of security or investment, fair value and value as measured by quoted price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesHPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z6sz1XjptWR6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCRUED EXPENSES (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B6_zz4ZxbsiawG7" style="display: none">Schedule of accrued expenses</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">January 31, 2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">April 30, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify">Payroll related costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--PayrollRelatedCostsMember_z5Z6s3hvwP47" style="width: 13%; text-align: right" title="Accrued liabilities">185,846</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--PayrollRelatedCostsMember_zEzO2lwRUUXd" style="width: 13%; text-align: right" title="Accrued liabilities">335,846</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Director fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--DirectorFeesMember_zTFrCxa1TXk9" style="text-align: right" title="Accrued liabilities">67,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--DirectorFeesMember_z97Wn1e0mxEd" style="text-align: right" title="Accrued liabilities">67,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">R&amp;D costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--RAndDCostsMember_zCC1dAi5A4ve" style="text-align: right" title="Accrued liabilities">92,310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--RAndDCostsMember_z79qi1A8c18k" style="text-align: right" title="Accrued liabilities">92,310</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Legal settlement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LegalSettlementMember_zGzALkLR9NTd" style="text-align: right" title="Accrued liabilities">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LegalSettlementMember_zcTYAJpGCEue" style="text-align: right" title="Accrued liabilities">2,019,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Excise tax on stock repurchases</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_d0_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--ExciseTaxOnStockRepurchasesMember_z2VTRJAFL8kj" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_d0_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--ExciseTaxOnStockRepurchasesMember_z0hYN3MSnks8" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities">25,424</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131_z0YQ0hNQSJUk" style="text-align: right" title="Accrued liabilities">445,656</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430_zQjA8i06jb6l" style="text-align: right" title="Accrued liabilities">2,540,080</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Less: Long-term portion of legal settlement</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LongTermPortionOfLegalSettlementMember_z6dZocZKBjgc" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1489">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LongTermPortionOfLegalSettlementMember_zpnXjBA3TZma" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities">(25,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AccruedLiabilitiesCurrent_iI_c20260131_zptDgpGu0iTj" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued liabilities, current">445,656</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrent_iI_c20250430_zW3pBe71mdtg" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued liabilities, current">2,515,080</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS AND WARRANTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zhN8BJ7Hr51l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details - Option activity)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B3_zEN5pPGVLvof" style="display: none">Schedule of stock option activity</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Options</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Options</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> Exercise <br/> Price per<br/> Share</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average <br/> Remaining<br/> Contractual <br/> Term in Years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 55%; text-align: justify">Outstanding, April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zU18bZQ2oYrb" style="width: 11%; text-align: right" title="Number of options outstanding, beginning">1,169,961</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqjjd7wljfJc" style="width: 11%; text-align: right" title="Weighted average exercise price per share, beginning">2.21</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240501__20250430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_ztAHF3gpWixi" title="Weighted average remaining contractual term">8.62</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zH3YEuCSe837" style="text-align: right" title="Number of options, issued">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z6b1fkdt5B86" style="text-align: right" title="Weighted average exercise price per share, issued">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Expired and forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNIYCM2ch8l7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, expired and forfeited">(9,334</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zB4tdiEYEEkc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price per share, expired and forfeited">10.78</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Outstanding, January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zgZNfkXpwA41" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending">1,160,627</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zR7Opdz4xT3i" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, ending">2.14</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zw5CCEnpK5re" title="Weighted average remaining contractual term">7.92</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Exercisable, January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZh3fse2DOo2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, exercisable">907,695</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zvqSvYplALk3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, exercisable">2.39</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zb2OQOjkaBPk" title="Weighted-average remaining contractual term, exercisable">7.56</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrant activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zlKnRnxcRI3g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details - Warrant activity)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B3_zcALJrtgtFwa" style="display: none">Schedule of warrant activity</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Exercise Price Per Share</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted<br/> Average<br/> Remaining Contractual Term In Years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 55%">Outstanding, April 30, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJBlos8fFIj7" style="width: 11%; text-align: right" title="Warrants outstanding, beginning balance">18,570,847</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zP1ahsgBRuK2" style="width: 11%; text-align: right" title="Weighted average exercise price warrants outstanding, beginning balance">4.54</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240501__20250430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zvI9x1qfoP4b" title="Weighted average remaining contractual term">2.12</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--WarrantsIssuedShares_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQ3ewShGzi9" style="text-align: right" title="Warrants issued">8,216,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zStQwJ09LwF5" style="text-align: right" title="Weighted average exercise price warrants issued">1.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Issued - Series B Warrants and Settlement Warrants adjusted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--WarrantsIssuedShares_d0_c20250501__20260131__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsAndSettlementWarrantsAdjustedMember_zrk6zl7qbTK5" style="text-align: right" title="Warrants issued">30,132,422</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20250501__20260131__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsAndSettlementWarrantsAdjustedMember_zHd0FGdR57v5" style="text-align: right" title="Weighted average exercise price warrants issued">0.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--WarrantExercised_iN_di_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxLNNtOa0Hnl" style="text-align: right" title="Warrants exercised">(1,100,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--WeightedAverageExercisePriceWarrantsExercised_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmu9SNWDPLke" style="text-align: right" title="Weighted average exercise price warrants Exercised">0.95</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--WarrantsExpired_iN_di0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zF2aD6730o6h" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--WeightedAverageExercisePriceWarrantsExpired_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3x0aTXrP1ub" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price warrants Expired">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Outstanding, January 31, 2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOgTvl4NlbE7" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, ending balance">55,819,519</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zN6gAdwQkCbj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price warrants outstanding, ending balance">1.68</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxZRaHOKg9F5" title="Weighted average remaining contractual term">2.61</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Exercisable, January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_ecustom--WarrantsExercisable_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zMZVcf06fIZf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable">55,819,519</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWWMcdN6Pmk1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price warrants exercisable">1.68</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zl6tMlzLhwF3" title="Weighted-average remaining contractual term, exercisable">2.61</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted earnings (loss) per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zWXykV1ecHvf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EARNINGS PER SHARE (Details - Per share calculation)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B0_zxLqDWzUcPOj" style="display: none">Schedule of  basic and diluted earnings (loss) per share</span></td><td>&#160;</td>
    <td colspan="3" id="xdx_496_20251101_20260131" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_494_20241101_20250131" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended January 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Earnings per share</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">746,860</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(3,045,328</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--PreferredStockAccretionOfRedemptionDiscount_iN_pp0p0_di0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKLTnQEC55Ll" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Less: Accretion of discounts to redemption of convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,204,657</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ConvertiblePreferredStockDividends_iN_pp0p0_di0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zO2jMDPdpqzj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Less: Convertible preferred stock dividends</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(98,458</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_z1YZW2LKWxLi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,556,255</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,045,328</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Weighted average shares outstanding used in basic and diluted earnings per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20251101__20260131_pdd" title="Weighted average shares outstanding used in basic earnings per share"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20251101__20260131_pdd" title="Weighted average shares outstanding used in diluted earnings per share">9,262,829</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20241101__20250131_pdd" title="Weighted average shares outstanding used in basic earnings per share"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20241101__20250131_pdd" title="Weighted average shares outstanding used in diluted earnings per share">6,960,014</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per share basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20251101__20260131_pdd" title="Net income (loss) per share basic"><span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20251101__20260131_pdd" title="Net income (loss) per share diluted">(0.17</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20241101__20250131_pdd" title="Net income (loss) per share basic"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20241101__20250131_pdd" title="Net income (loss) per share diluted">(0.44</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_49E_20250501__20260131_znWz4okqdtPb" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_496_20240501__20250131_zBaFV8T3dyNe" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended January 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Earnings per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_z8o8ZmHolDi4" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: justify">Net income (loss)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(15,031,211</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">18,906,468</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PreferredStockAccretionOfRedemptionDiscount_iN_pp0p0_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zNJIKfNLSUe4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify">Less: Accretion of discounts to redemption of convertible preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,106,653</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,193,404</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_ecustom--ConvertiblePreferredStockDividends_iN_pp0p0_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zF4x150XcIpf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Less: Convertible preferred stock dividends</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(195,097</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,129,759</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--LessAllocationOfUndistributedIncome_d0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzgjUJNVZCY6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Less: Allocation of undistributed income to Series B convertible preferred stock</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,067,733</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_iP3us-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zV9P8rWTMqui" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Undistributed income (loss) available to common stockholders</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,332,961</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,515,572</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Weighted average shares outstanding used in basic earnings per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250501__20260131_pdd" title="Weighted average shares outstanding used in basic earnings per share"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250501__20260131_pdd" title="Weighted average shares outstanding used in diluted earnings per share">7,618,128</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240501__20250131_pdd" title="Weighted average shares outstanding used in basic earnings per share"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240501__20250131_pdd" title="Weighted average shares outstanding used in diluted earnings per share">7,487,813</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net income (loss) per share basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_c20250501__20260131_pdd" title="Net income (loss) per share basic"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250501__20260131_pdd" title="Net income (loss) per share diluted">(2.41</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20240501__20250131_pdd" title="Net income (loss) per share basic"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20240501__20250131_pdd" title="Net income (loss) per share diluted">1.67</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zIMlQuiVdZ7e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EARNINGS PER SHARE (Details - Diluted shares)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BD_zxhk3UkMI4uk" style="display: none">Schedule of potentially dilutive securities</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three and Nine Months Ended <br/> January 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify">Excluded options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares">1,160,627</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares">917,697</span></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Excluded preferred shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_pdd" title="Antidilutive shares"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_pdd" title="Antidilutive shares">5,008,061</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_z5pGw8qxByt6" title="Antidilutive shares"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240501__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_zpkZStzTy9Td" title="Antidilutive shares">&#8211;</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Excluded warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares">55,819,519</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares">18,570,847</span></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Total excluded options, preferred shares and warrants</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131_pdd" title="Antidilutive shares"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131_pdd" title="Antidilutive shares">61,988,207</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131_pdd" title="Antidilutive shares"><span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250131_pdd" title="Antidilutive shares">19,488,544</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of fair value of financial liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zF9lBkc5Vir9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair value)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B6_zCx3vSGvWar2" style="display: none">Schedule of fair value of financial liabilities</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; text-align: justify">Description</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Level</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">January 31, 2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">April 30, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Liabilities:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; text-align: justify">Warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 11%; text-align: center">3</td><td style="width: 1%; text-align: center">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20260131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_ztEgxCLFA8Yg" style="width: 11%; text-align: right" title="Warrant liabilities">13,657,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FinancialLiabilitiesFairValueDisclosure_pp0p0_c20250430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zpRAlvZ7ydcl" style="width: 11%; text-align: right" title="Warrant liabilities">338,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Derivative liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20260131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zELHs1Gy564k" style="text-align: right" title="Warrant liabilities">1,136,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_d0_c20250430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zTB27IoUPQug" style="text-align: right" title="Warrant liabilities">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of change in the fair value warrant liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zjATpYIMOsv" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of warrant liability)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_zK9pFyzu0yq4" style="display: none">Schedule of change in the fair value warrant liability</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended January 31, 2026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%">Balance on October 31, 2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zPinaFMb2qVl" style="width: 13%; text-align: right" title="Fair value of the warrant liability at beginning">16,152,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pp0p0_d0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zRj80Tmfx8Pb" style="text-align: right" title="Issuance of warrants">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Warrant exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--WarrantExercises_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zGzvOXGHFIOg" style="text-align: right" title="Warrant exercises">(599,135</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ChangeInFairValueOfWarrantLiability_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability">(1,895,865</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Balance on January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zgCPiGJi7Emc" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of the warrant liability at ending">13,657,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt; width: 83%">&#160;</td><td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; width: 1%">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center; width: 13%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine Months Ended January 31, 2026</span></td><td style="padding-bottom: 1pt; text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Balance on April 30, 2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zid8xXInSDa1" style="text-align: right" title="Fair value, beginning">338,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuance of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_z3f6fB8kM2Jf" style="text-align: right" title="Issuance of warrants">5,583,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Warrant exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--WarrantExercises_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zGwMiBjNtHwk" style="text-align: right" title="Warrant exercises">(599,135</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiability_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability">8,335,135</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Balance on January 31, 2026</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_z8ZefvQM88B" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value, ending">13,657,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of change in the fair value derivative liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zB3WdxHNSH4b" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of derivative liability)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BE_zBPBqzsLGbJ6" style="display: none">Schedule of change in the fair value derivative liability</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three Months Ended January 31, 2026</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance on October 31, 2025</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zz6jtwY1f8ia" style="text-align: right" title="Fair value of the warrant liability at beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,693,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 84%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of Series C convertible preferred stock</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_985_ecustom--IssuanceOfSeriesCConvertiblePreferredStock_pp0p0_d0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zmI71ikrL7jd" style="width: 13%; text-align: right" title="Issuance of Series C convertible preferred stock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in fair value of derivative liability</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98D_ecustom--ChangeInFairValueOfWarrantLiability_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zuPImSdAN83l" style="border-bottom: black 1pt solid; text-align: right" title="Change in fair value of derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(557,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance on January 31, 2026</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_98A_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zJtanI2USiFf" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value of the warrant liability at ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,136,000</span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine Months Ended January 31, 2026</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance on April 30, 2025</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_980_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_d0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zqDxowByTRS8" style="text-align: right" title="Fair value, beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211;</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 84%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of Series C convertible preferred stock</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td id="xdx_986_ecustom--IssuanceOfSeriesCConvertiblePreferredStock_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_pp0p0" style="width: 13%; text-align: right" title="Issuance of Series C convertible preferred stock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,995,000</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in fair value of derivative liability</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiability_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_pp0p0" style="border-bottom: black 1pt solid; text-align: right" title="Change in fair value of derivative liability"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(859,000</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance on January 31, 2026</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 2.25pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td id="xdx_988_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zV8ZJWF4fvzj" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value, ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,136,000</span></td>
    <td>&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair values of financial instruments by class</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zGaBW8wYEk61" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair values of financial instruments)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B3_zLyMlzDJddi8" style="display: none">Schedule of fair values of financial instruments by class</span></td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: right">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">Level</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">January 31, 2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center">April 30, 2025</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: justify">Financial Assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; text-align: left">Marketable equity securities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 11%; text-align: center">1</td><td style="width: 1%; text-align: center">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20260131__us-gaap--FinancialInstrumentAxis__custom--MarketableEquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 11%; text-align: right" title="Fair value of financial assets">372,251</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--MarketableEquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 11%; text-align: right" title="Fair value of financial assets">366,316</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Money market account</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20260131__us-gaap--FinancialInstrumentAxis__custom--MoneyMarketAccountMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Fair value of financial assets">2,081,636</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--MoneyMarketAccountMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Fair value of financial assets">76,287</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible note receivable &#8211; investment in debt security - Femasys</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_d0_c20260131__us-gaap--FinancialInstrumentAxis__custom--ConvertibleNoteReceivableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zC0yzOpRIE41" style="text-align: right" title="Fair value of financial assets">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--ConvertibleNoteReceivableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets">3,696,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Warrant asset - Femasys</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20260131__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetFemasysMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets">906,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetFemasysMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets">3,061,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investment in preferred stock - QCLS</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_c20260131__us-gaap--FinancialInstrumentAxis__custom--InvestmentInPreferredStockQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaBdqNmylt05" style="text-align: right" title="Fair value of financial assets">22,472,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--InvestmentInPreferredStockQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets">22,474,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Warrant assets - QCLS</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_c20260131__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z8xXTGJ8HWue" style="text-align: right" title="Fair value of financial assets">10,242,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets">8,618,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Aug. 31, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>May 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,165,535<span></span>
</td>
<td class="nump">$ 15,172,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHConvertiblePreferredStockMember', window );">QCLS Series H Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment shares</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to Acquire Investments</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued new, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PMCB_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PMCB_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2026 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, uninsured amount | $</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 76,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments | Integer</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Femasys Note and warrants) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralLineItems', window );"><strong>Financial Instruments Owned and Pledged as Collateral [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ConvertibleNoteReceivableCurrent', window );">Investment, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfConvertibleNotesReceivable', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,304,000<span></span>
</td>
<td class="nump">$ 601,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ProceedsFromInvestmentNoteReceivable', window );">Settlement of Femasys Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ConvertibleNoteReceivableCurrent', window );">Investment, ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantAssetFemasys', window );">Investment, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,061,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfWarrantAssetFemasys', window );">Change in fair value</a></td>
<td class="num">(214,000)<span></span>
</td>
<td class="num">$ (596,000)<span></span>
</td>
<td class="num">(2,155,000)<span></span>
</td>
<td class="num">$ (1,830,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantAssetFemasys', window );">Investment, ending balance</a></td>
<td class="nump">906,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">906,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=PMCB_FemasysNotesMember', window );">Femasys Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralLineItems', window );"><strong>Financial Instruments Owned and Pledged as Collateral [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ConvertibleNoteReceivableCurrent', window );">Investment, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfConvertibleNotesReceivable', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,304,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ProceedsFromInvestmentNoteReceivable', window );">Settlement of Femasys Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ConvertibleNoteReceivableCurrent', window );">Investment, ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=PMCB_FemasysWarrantsMember', window );">Femasys Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralLineItems', window );"><strong>Financial Instruments Owned and Pledged as Collateral [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantAssetFemasys', window );">Investment, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,061,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfWarrantAssetFemasys', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,155,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantAssetFemasys', window );">Investment, ending balance</a></td>
<td class="nump">$ 906,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 906,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfConvertibleNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfConvertibleNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfWarrantAssetFemasys">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfWarrantAssetFemasys</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ConvertibleNoteReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ConvertibleNoteReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ProceedsFromInvestmentNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ProceedsFromInvestmentNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_WarrantAssetFemasys">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_WarrantAssetFemasys</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480031/860-30-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481444/860-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=PMCB_FemasysNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=PMCB_FemasysNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=PMCB_FemasysWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=PMCB_FemasysWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Marketable securities) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems', window );"><strong>Qualitative and Quantitative Information, Transferor's Continuing Involvement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Carrying value at fair market value</a></td>
<td class="nump">$ 372,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss</a></td>
<td class="num">(128,939)<span></span>
</td>
<td class="nump">$ 72,632<span></span>
</td>
<td class="num">(294,065)<span></span>
</td>
<td class="nump">$ 72,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=PMCB_FemasysPurchaseAgreementMember', window );">Femasys Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems', window );"><strong>Qualitative and Quantitative Information, Transferor's Continuing Involvement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Carrying value at fair market value</a></td>
<td class="nump">372,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Adjusted cost basis</a></td>
<td class="nump">$ 666,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(5)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(4)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=PMCB_FemasysPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=PMCB_FemasysPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series G Preferred Stock and Preferred Stock Warrants) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_DisclosureLineElements', window );"><strong>DisclosureLineElements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssets', window );">Investment, beginnning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,474,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfInvestment', window );">Change in fair value</a></td>
<td class="nump">$ 1,725,000<span></span>
</td>
<td class="num">$ (3,031,000)<span></span>
</td>
<td class="num">(3,485,000)<span></span>
</td>
<td class="num">$ (1,642,050)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssets', window );">Investment, ending balance</a></td>
<td class="nump">22,472,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,472,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesGPreferredStockMember', window );">QCLS Series G Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_DisclosureLineElements', window );"><strong>DisclosureLineElements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssets', window );">Investment, beginnning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,474,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfInvestment', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,127,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssets', window );">Investment, ending balance</a></td>
<td class="nump">17,347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesGWarrantsMember', window );">QCLS Series G Warrants [Member] | QCLS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_DisclosureLineElements', window );"><strong>DisclosureLineElements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssets', window );">Investment, beginnning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,618,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfInvestment', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,652,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssets', window );">Investment, ending balance</a></td>
<td class="nump">$ 6,966,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,966,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_DisclosureLineElements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_DisclosureLineElements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments, and noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesGWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesGWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=PMCB_QCLSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=PMCB_QCLSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series H Preferred Stock and Preferred Stock Warrants) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Sep. 02, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_DisclosureLineElements', window );"><strong>DisclosureLineElements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssets', window );">Investment, beginnning balance</a></td>
<td class="nump">$ 22,474,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfInvestmentQcls', window );">Change in fair value</a></td>
<td class="num">(3,485,000)<span></span>
</td>
<td class="num">$ (1,642,050)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssets', window );">Investment, ending balance</a></td>
<td class="nump">22,472,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=PMCB_QCLSSeriesHWarrantsMember', window );">QCLS Series H Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_DisclosureLineElements', window );"><strong>DisclosureLineElements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssets', window );">Investment, beginnning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Initial fair value of Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,606,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfInvestmentQcls', window );">Change in fair value</a></td>
<td class="nump">1,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssets', window );">Investment, ending balance</a></td>
<td class="nump">3,276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHPreferredStockMember', window );">QCLS Series H Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_DisclosureLineElements', window );"><strong>DisclosureLineElements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssets', window );">Investment, beginnning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Initial fair value of Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,483,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfInvestmentQcls', window );">Change in fair value</a></td>
<td class="nump">1,642,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssets', window );">Investment, ending balance</a></td>
<td class="nump">$ 5,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfInvestmentQcls">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfInvestmentQcls</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_DisclosureLineElements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_DisclosureLineElements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in security owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments, and noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PMCB_QCLSSeriesHWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PMCB_QCLSSeriesHWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT IN DEBT AND EQUITY SECURITIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Nov. 21, 2025</div></th>
<th class="th"><div>Sep. 02, 2025</div></th>
<th class="th"><div>Nov. 21, 2024</div></th>
<th class="th"><div>May 20, 2024</div></th>
<th class="th"><div>Nov. 14, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ProceedsFromInvestmentNoteReceivable', window );">Proceeds from investment - note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ConvertibleNoteReceivableCurrent', window );">Convertible note receivable, current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,696,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantAssetFemasys', window );">Warrant asset - Femasys</a></td>
<td class="nump">906,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">906,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">906,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,061,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfConvertibleNotesReceivable', window );">Change in fair value of the convertible note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,304,000<span></span>
</td>
<td class="nump">601,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfWarrantAssetFemasys', window );">Change in fair value of the convertible note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,000<span></span>
</td>
<td class="nump">$ 596,000<span></span>
</td>
<td class="nump">2,155,000<span></span>
</td>
<td class="nump">1,830,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,939<span></span>
</td>
<td class="num">(72,632)<span></span>
</td>
<td class="nump">294,065<span></span>
</td>
<td class="num">(72,632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_GainOnRelatedPartyInvestmentQcls', window );">Investment, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,089,000<span></span>
</td>
<td class="nump">21,395,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHPreferredStockMember', window );">QCLS Series H Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHPreferredStockMember', window );">QCLS Series H Preferred Stock [Member] | QCLS Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Investment, cost</a></td>
<td class="nump">$ 5,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesRealizedGainLoss', window );">Recognized gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,642,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHPreferredStockMember', window );">QCLS Series H Preferred Stock [Member] | QCLS Securities Purchase Agreement [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$4.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHPreferredStockMember', window );">QCLS Series H Preferred Stock [Member] | QCLS Securities Purchase Agreement [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">150.0%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHPreferredStockMember', window );">QCLS Series H Preferred Stock [Member] | QCLS Securities Purchase Agreement [Member] | Measurement Input Market Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHPreferredStockMember', window );">QCLS Series H Preferred Stock [Member] | QCLS Securities Purchase Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHPreferredStockMember', window );">QCLS Series H Preferred Stock [Member] | QCLS Securities Purchase Agreement [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHPreferredStockMember', window );">QCLS Series H Preferred Stock [Member] | QCLS Securities Purchase Agreement [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1.08 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHPreferredStockMember', window );">QCLS Series H Preferred Stock [Member] | QCLS Securities Purchase Agreement [Member] | Measurement Input Redemption Premium [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">106%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHWarrantsMember', window );">QCLS Series H Warrants [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesRealizedGainLoss', window );">Recognized gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHWarrantsMember', window );">QCLS Series H Warrants [Member] | QCLS Securities Purchase Agreement [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$4.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHWarrantsMember', window );">QCLS Series H Warrants [Member] | QCLS Securities Purchase Agreement [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">135.0%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHWarrantsMember', window );">QCLS Series H Warrants [Member] | QCLS Securities Purchase Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHWarrantsMember', window );">QCLS Series H Warrants [Member] | QCLS Securities Purchase Agreement [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$3.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHWarrantsMember', window );">QCLS Series H Warrants [Member] | QCLS Securities Purchase Agreement [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4.59 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_FemasysMember', window );">Femasys [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment shares owned</a></td>
<td class="nump">695,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">695,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">695,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_InvestmentSharesAddition', window );">Investment shares additions</a></td>
<td class="nump">379,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments for investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment shares owned</a></td>
<td class="nump">8,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment, fair value</a></td>
<td class="nump">$ 5,089,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,089,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,089,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders equity, reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-100 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Investment, cost</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_GainOnRelatedPartyInvestmentQcls', window );">Investment, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,089,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Securities Purchase Agreement [Member] | Long Term Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,854,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,076,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,209,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Securities Purchase Agreement [Member] | Short Term Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,854,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,076,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Securities Purchase Agreement [Member] | QCLS Series H Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,606,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Securities Purchase Agreement [Member] | QCLS Series H Warrant [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$3.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Securities Purchase Agreement [Member] | QCLS Series H Warrant [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">105.0%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Securities Purchase Agreement [Member] | QCLS Series H Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Securities Purchase Agreement [Member] | QCLS Series H Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Securities Purchase Agreement [Member] | QCLS Series H Warrant [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Securities Purchase Agreement [Member] | QCLS Series H Warrant [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5.00 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Securities Purchase Agreement [Member] | QCLS Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">889,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Securities Purchase Agreement [Member] | QCLS Series H Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Securities Purchase Agreement [Member] | QCLS Series H Preferred Stock [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$3.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Securities Purchase Agreement [Member] | QCLS Series H Preferred Stock [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">100.0%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Securities Purchase Agreement [Member] | QCLS Series H Preferred Stock [Member] | Measurement Input, Maturity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1.49 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Securities Purchase Agreement [Member] | QCLS Series H Preferred Stock [Member] | Measurement Redemption Premium [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">106%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Securities Purchase Agreement [Member] | QCLS Series H Preferred Stock [Member] | Measurement Input Market Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">19.51%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Securities Purchase Agreement [Member] | QCLS Series H Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Securities Purchase Agreement [Member] | QCLS Series H Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue', window );">Fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Series G Preferred Stock [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment shares owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment, fair value</a></td>
<td class="nump">$ 17,347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Recognized gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,433,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,127,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Recognized gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,433,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,127,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | QCLS Accrued Dividend Receivable [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment shares owned</a></td>
<td class="nump">1,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,577<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | QCLS Series G Preferred Stock [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment shares owned</a></td>
<td class="nump">7,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_QCLSMember', window );">QCLS [Member] | Series G Warrants [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment, fair value</a></td>
<td class="nump">$ 6,966,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,966,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,966,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Recognized gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,461,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,652,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Recognized gain (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,461,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,652,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=PMCB_FemasysPurchaseAgreementMember', window );">Femasys Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments for investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ReceivableInstrumentConvertibleConversionPrice1', window );">Receivable conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment shares owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,237,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_InvestmentSharesAddition', window );">Investment shares additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">379,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">162,500<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Investment interest payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(294,065)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Investment, cost</a></td>
<td class="nump">666,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=PMCB_FemasysPurchaseAgreementMember', window );">Femasys Purchase Agreement [Member] | Femasys Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment, fair value</a></td>
<td class="nump">906,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">906,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">906,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=PMCB_FemasysPurchaseAgreementMember', window );">Femasys Purchase Agreement [Member] | Femasys Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=PMCB_FemasysNoteMember', window );">Femasys Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ProceedsFromInvestmentNoteReceivable', window );">Proceeds from investment - note receivable</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_SettlementOfAccruedInterest', window );">Settlement of accrued interest</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ConvertibleNoteReceivableCurrent', window );">Convertible note receivable, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,696,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfConvertibleNotesReceivable', window );">Change in fair value of the convertible note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,304,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=PMCB_FemasysCommonStockMember', window );">Femasys Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment shares owned</a></td>
<td class="nump">695,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">695,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">695,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=PMCB_FemasysWarrantsMember', window );">Femasys Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantAssetFemasys', window );">Warrant asset - Femasys</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,061,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfWarrantAssetFemasys', window );">Change in fair value of the convertible note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfConvertibleNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfConvertibleNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfWarrantAssetFemasys">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfWarrantAssetFemasys</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ConvertibleNoteReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ConvertibleNoteReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_GainOnRelatedPartyInvestmentQcls">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_GainOnRelatedPartyInvestmentQcls</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_InvestmentSharesAddition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_InvestmentSharesAddition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ProceedsFromInvestmentNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ProceedsFromInvestmentNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ReceivableInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ReceivableInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_SettlementOfAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_SettlementOfAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_WarrantAssetFemasys">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_WarrantAssetFemasys</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes how an entity determines the fair values of its derivatives, including its valuation methodology and significant assumptions used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in security owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479951/505-20-S50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479982/505-20-S25-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PMCB_QCLSSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PMCB_QCLSSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=PMCB_MeasurementInputMarketInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=PMCB_MeasurementInputMarketInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=PMCB_MeasurementInputRedemptionPremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=PMCB_MeasurementInputRedemptionPremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesHWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PMCB_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PMCB_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=PMCB_FemasysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=PMCB_FemasysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=PMCB_QCLSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=PMCB_QCLSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PMCB_LongTermWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PMCB_LongTermWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PMCB_ShortTermWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PMCB_ShortTermWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PMCB_QCLSSeriesHWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PMCB_QCLSSeriesHWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PMCB_QCLSCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PMCB_QCLSCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PMCB_QCLSSeriesHPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PMCB_QCLSSeriesHPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputMaturityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputMaturityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=PMCB_MeasurementRedemptionPremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=PMCB_MeasurementRedemptionPremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSAccruedDividendReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PMCB_QCLSAccruedDividendReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PMCB_QCLSSeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PMCB_SeriesGWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PMCB_SeriesGWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=PMCB_FemasysPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=PMCB_FemasysPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PMCB_FemasysSeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PMCB_FemasysSeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PMCB_FemasysCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PMCB_FemasysCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=PMCB_FemasysNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=PMCB_FemasysNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=PMCB_FemasysCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=PMCB_FemasysCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=PMCB_FemasysWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=PMCB_FemasysWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_DisclosureLineElements', window );"><strong>DisclosureLineElements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 445,656<span></span>
</td>
<td class="nump">$ 2,540,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities, current</a></td>
<td class="nump">445,656<span></span>
</td>
<td class="nump">2,515,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionLocationBalanceAxis=us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Location, Statement of Financial Position, Balance [Axis]: us-gaap:AccruedLiabilitiesCurrentAndNoncurrent | Payroll Related Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_DisclosureLineElements', window );"><strong>DisclosureLineElements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="nump">185,846<span></span>
</td>
<td class="nump">335,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionLocationBalanceAxis=us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Location, Statement of Financial Position, Balance [Axis]: us-gaap:AccruedLiabilitiesCurrentAndNoncurrent | Director Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_DisclosureLineElements', window );"><strong>DisclosureLineElements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="nump">67,500<span></span>
</td>
<td class="nump">67,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionLocationBalanceAxis=us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Location, Statement of Financial Position, Balance [Axis]: us-gaap:AccruedLiabilitiesCurrentAndNoncurrent | R And D Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_DisclosureLineElements', window );"><strong>DisclosureLineElements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="nump">92,310<span></span>
</td>
<td class="nump">92,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionLocationBalanceAxis=us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Location, Statement of Financial Position, Balance [Axis]: us-gaap:AccruedLiabilitiesCurrentAndNoncurrent | Legal Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_DisclosureLineElements', window );"><strong>DisclosureLineElements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">2,019,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionLocationBalanceAxis=us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Location, Statement of Financial Position, Balance [Axis]: us-gaap:AccruedLiabilitiesCurrentAndNoncurrent | Excise Tax On Stock Repurchases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_DisclosureLineElements', window );"><strong>DisclosureLineElements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionLocationBalanceAxis=us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Location, Statement of Financial Position, Balance [Axis]: us-gaap:AccruedLiabilitiesCurrentAndNoncurrent | Long Term Portion Of Legal Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_DisclosureLineElements', window );"><strong>DisclosureLineElements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (25,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_DisclosureLineElements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_DisclosureLineElements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionLocationBalanceAxis=us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionLocationBalanceAxis=us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=PMCB_PayrollRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=PMCB_PayrollRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=PMCB_DirectorFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=PMCB_DirectorFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=PMCB_RAndDCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=PMCB_RAndDCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=PMCB_LegalSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=PMCB_LegalSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=PMCB_ExciseTaxOnStockRepurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=PMCB_ExciseTaxOnStockRepurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=PMCB_LongTermPortionOfLegalSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=PMCB_LongTermPortionOfLegalSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS AND WARRANTS (Details - Option activity) - Equity Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, beginning</a></td>
<td class="nump">1,169,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price per share, beginning</a></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term</a></td>
<td class="text">7 years 11 months 1 day<span></span>
</td>
<td class="text">8 years 7 months 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of options, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price per share, issued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of options, expired and forfeited</a></td>
<td class="num">(9,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price per share, expired and forfeited</a></td>
<td class="nump">$ 10.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, ending</a></td>
<td class="nump">1,160,627<span></span>
</td>
<td class="nump">1,169,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price per share, ending</a></td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, exercisable</a></td>
<td class="nump">907,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price per share, exercisable</a></td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term, exercisable</a></td>
<td class="text">7 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average contractual term remaining for exercisable stock option, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS AND WARRANTS (Details - Warrant activity) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance</a></td>
<td class="nump">18,570,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price warrants outstanding, beginning balance</a></td>
<td class="nump">$ 4.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term</a></td>
<td class="text">2 years 7 months 9 days<span></span>
</td>
<td class="text">2 years 1 month 13 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantsIssuedShares', window );">Warrants issued</a></td>
<td class="nump">8,216,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average exercise price warrants issued</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantExercised', window );">Warrants exercised</a></td>
<td class="num">(1,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WeightedAverageExercisePriceWarrantsExercised', window );">Weighted average exercise price warrants Exercised</a></td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantsExpired', window );">Warrants expired</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WeightedAverageExercisePriceWarrantsExpired', window );">Weighted average exercise price warrants Expired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance</a></td>
<td class="nump">55,819,519<span></span>
</td>
<td class="nump">18,570,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price warrants outstanding, ending balance</a></td>
<td class="nump">$ 1.68<span></span>
</td>
<td class="nump">$ 4.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantsExercisable', window );">Warrants exercisable</a></td>
<td class="nump">55,819,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WeightedAverageExercisePriceWarrantsExercisable', window );">Weighted average exercise price warrants exercisable</a></td>
<td class="nump">$ 1.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term, exercisable</a></td>
<td class="text">2 years 7 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=PMCB_SeriesBWarrantsAndSettlementWarrantsAdjustedMember', window );">Series B Warrants And Settlement Warrants Adjusted [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantsIssuedShares', window );">Warrants issued</a></td>
<td class="nump">30,132,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average exercise price warrants issued</a></td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_WarrantExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_WarrantExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_WarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_WarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_WarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_WarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_WarrantsIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_WarrantsIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_WeightedAverageExercisePriceWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_WeightedAverageExercisePriceWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_WeightedAverageExercisePriceWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_WeightedAverageExercisePriceWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_WeightedAverageExercisePriceWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_WeightedAverageExercisePriceWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average contractual term remaining for exercisable stock option, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PMCB_SeriesBWarrantsAndSettlementWarrantsAdjustedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PMCB_SeriesBWarrantsAndSettlementWarrantsAdjustedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 29, 2025</div></th>
<th class="th"><div>May 16, 2025</div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Aug. 19, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Oct. 29, 2025</div></th>
<th class="th"><div>May 10, 2023</div></th>
<th class="th"><div>Dec. 28, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod', window );">Increase number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 892,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,046,760<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,895,865)<span></span>
</td>
<td class="num">$ (4,487,000)<span></span>
</td>
<td class="nump">8,335,135<span></span>
</td>
<td class="num">(8,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementGain', window );">Gain on legal settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_IssuanceFairValues', window );">Issuance fair values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 363,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfWarrantAsset', window );">Change in fair value warrant asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="num">(3,194,000)<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="num">(8,123,684)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=PMCB_FirstWarrantIssuanceMember', window );">First Warrant Issuance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=PMCB_SettlementWarrantsMember', window );">Settlement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,057,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 694,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=PMCB_SettlementAgreementMember', window );">Settlement Agreement [Member] | First Warrant Issuance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants acquire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TransactionTypeAxis=PMCB_SettlementAgreementMember', window );">Settlement Agreement [Member] | Settlement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants acquire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,046,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 599,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,680,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,680,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=PMCB_SeriesBPreferredWarrantsMember', window );">Series B Preferred Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 874,000<span></span>
</td>
<td class="nump">4,487,000<span></span>
</td>
<td class="nump">$ 9,182,000<span></span>
</td>
<td class="nump">8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,520,000<span></span>
</td>
<td class="nump">2,384,000<span></span>
</td>
<td class="nump">$ 9,520,000<span></span>
</td>
<td class="nump">2,384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants acquire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=PMCB_SeriesCPrivatePlacementAgreementMember', window );">Series C Private Placement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants acquire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=PMCB_SeriesCPrivatePlacementAgreementMember', window );">Series C Private Placement Agreement [Member] | Series C Preferred Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,080,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfWarrantAsset', window );">Change in fair value warrant asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,076,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=PMCB_SeriesCPrivatePlacementAgreementMember', window );">Series C Private Placement Agreement [Member] | Series C Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants acquire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 417,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=PMCB_AdditionalWarrantsMember', window );">Additional Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of the warrants</a></td>
<td class="nump">$ 164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Fair value per share</a></td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=PMCB_EmployeesMember', window );">Employees [Member] | Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,492<span></span>
</td>
<td class="nump">$ 72,859<span></span>
</td>
<td class="nump">181,476<span></span>
</td>
<td class="nump">$ 414,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee service unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=PMCB_EquityPlan2021Member', window );">Equity Plan 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=PMCB_EquityPlan2022Member', window );">Equity Plan 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,970,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,970,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfWarrantAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfWarrantAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_IssuanceFairValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_IssuanceFairValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain from litigation settlement for amount awarded from other party. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PMCB_FirstWarrantIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PMCB_FirstWarrantIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PMCB_SettlementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PMCB_SettlementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=PMCB_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=PMCB_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PMCB_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PMCB_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=PMCB_SeriesBPreferredWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=PMCB_SeriesBPreferredWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=PMCB_SeriesCPrivatePlacementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=PMCB_SeriesCPrivatePlacementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PMCB_SeriesCPreferredWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PMCB_SeriesCPreferredWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PMCB_SeriesCPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PMCB_SeriesCPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=PMCB_AdditionalWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=PMCB_AdditionalWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=PMCB_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=PMCB_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=PMCB_EquityPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=PMCB_EquityPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=PMCB_EquityPlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=PMCB_EquityPlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PMCB_VinDeBonaMember', window );">Vin De Bona [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Consulting fees</a></td>
<td class="nump">$ 10,500<span></span>
</td>
<td class="nump">$ 10,390<span></span>
</td>
<td class="nump">$ 10,500<span></span>
</td>
<td class="nump">$ 15,670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=PMCB_SGAustraliaMember', window );">SG Australia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest owned</a></td>
<td class="nump">13.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for professional and contracted services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7)(e)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 970<br> -SubTopic 810<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477383/970-810-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PMCB_VinDeBonaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PMCB_VinDeBonaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=PMCB_SGAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=PMCB_SGAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 19, 2025</div></th>
<th class="th"><div>May 20, 2025</div></th>
<th class="th"><div>May 16, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,113<span></span>
</td>
<td class="nump">$ 118,196<span></span>
</td>
<td class="nump">$ 329,355<span></span>
</td>
<td class="nump">$ 311,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,196<span></span>
</td>
<td class="nump">$ 7,071<span></span>
</td>
<td class="nump">21,404<span></span>
</td>
<td class="nump">$ 21,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=PMCB_FirstWarrantIssuanceMember', window );">First Warrant Issuance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantsIssuedShares', window );">Warrants issued shares</a></td>
<td class="nump">1,442,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=PMCB_AdditionalWarrantsMember', window );">Additional Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantsIssuedShares', window );">Warrants issued shares</a></td>
<td class="nump">1,315,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants issued per share</a></td>
<td class="nump">$ 0.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=PMCB_HCWainwrightMember', window );">H.C. Wainwright [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Initial payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payment for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt instrument periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=PMCB_HCWainwrightMember', window );">H.C. Wainwright [Member] | First Warrant Issuance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantsIssuedShares', window );">Warrants issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=PMCB_HCWainwrightMember', window );">H.C. Wainwright [Member] | Additional Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantsIssuedShares', window );">Warrants issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PMCB_SGAustriaAndSubsidiariesMember', window );">SG Austria And Subsidiaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_WarrantsIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_WarrantsIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.9-06)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482645/405-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.W.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479583/944-40-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PMCB_FirstWarrantIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PMCB_FirstWarrantIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PMCB_AdditionalWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PMCB_AdditionalWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=PMCB_HCWainwrightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=PMCB_HCWainwrightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PMCB_SGAustriaAndSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PMCB_SGAustriaAndSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE (Details - Per share calculation) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Jul. 31, 2025</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 746,860<span></span>
</td>
<td class="num">$ (7,417,975)<span></span>
</td>
<td class="num">$ (8,360,096)<span></span>
</td>
<td class="num">$ (3,045,328)<span></span>
</td>
<td class="num">$ (1,469,560)<span></span>
</td>
<td class="nump">$ 23,421,355<span></span>
</td>
<td class="num">$ (15,031,211)<span></span>
</td>
<td class="nump">$ 18,906,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Less: Accretion of discounts to redemption of convertible preferred stock</a></td>
<td class="num">(2,204,657)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,106,653)<span></span>
</td>
<td class="num">(3,193,404)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (1,556,255)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,045,328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,332,961)<span></span>
</td>
<td class="nump">14,583,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Undistributed income (loss) available to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18,332,961)<span></span>
</td>
<td class="nump">$ 12,515,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding used in basic earnings per share</a></td>
<td class="nump">9,262,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,960,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,618,128<span></span>
</td>
<td class="nump">7,487,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding used in diluted earnings per share</a></td>
<td class="nump">9,262,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,960,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,618,128<span></span>
</td>
<td class="nump">7,487,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share basic</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.41)<span></span>
</td>
<td class="nump">$ 1.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share diluted</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.41)<span></span>
</td>
<td class="nump">$ 1.67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Less: Accretion of discounts to redemption of convertible preferred stock</a></td>
<td class="num">$ (2,204,657)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,106,653)<span></span>
</td>
<td class="num">$ (3,193,404)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ConvertiblePreferredStockDividends', window );">Less: Convertible preferred stock dividends</a></td>
<td class="num">$ (98,458)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(195,097)<span></span>
</td>
<td class="num">(1,129,759)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_LessAllocationOfUndistributedIncome', window );">Less: Allocation of undistributed income to Series B convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (2,067,733)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ConvertiblePreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ConvertiblePreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_LessAllocationOfUndistributedIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_LessAllocationOfUndistributedIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482705/350-40-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479719/606-10-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accretion of the preferred stock redemption discount during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockAccretionOfRedemptionDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481679/480-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 65<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-65<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER SHARE (Details - Diluted shares) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="nump">61,988,207<span></span>
</td>
<td class="nump">19,488,544<span></span>
</td>
<td class="nump">61,988,207<span></span>
</td>
<td class="nump">19,488,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PMCB_OptionsMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="nump">1,160,627<span></span>
</td>
<td class="nump">917,697<span></span>
</td>
<td class="nump">1,160,627<span></span>
</td>
<td class="nump">917,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PMCB_PreferredSharesMember', window );">Preferred Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="nump">5,008,061<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,008,061<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PMCB_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="nump">55,819,519<span></span>
</td>
<td class="nump">18,570,847<span></span>
</td>
<td class="nump">55,819,519<span></span>
</td>
<td class="nump">18,570,847<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PMCB_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PMCB_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PMCB_PreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PMCB_PreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PMCB_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=PMCB_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREFERRED STOCK (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 17, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2026 </div>
<div>USD ($) </div>
<div>Year </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2026 </div>
<div>USD ($) </div>
<div>Year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 30, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 10, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Fair value of derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,995,000<span></span>
</td>
<td class="nump">$ 1,995,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_DeemedDividend', window );">Deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,204,657<span></span>
</td>
<td class="nump">3,106,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueDerivativeLiability', window );">Change in fair value derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">557,000<span></span>
</td>
<td class="nump">859,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Preferred dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,458<span></span>
</td>
<td class="nump">195,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Dividend paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,356<span></span>
</td>
<td class="nump">$ 162,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockPaidinkind', window );">Dividend accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_PreferredStockDiscount', window );">Total discount on preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_FairValueEmbeddedDerivative', window );">Fair value of embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,995,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Stock converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,358,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantLiabilityFairValue', window );">Fair value of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,005,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Derivative Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantLiabilityFairValue', window );">Fair value of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Derivative, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50<span></span>
</td>
<td class="nump">1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Derivative Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Derivative, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.05<span></span>
</td>
<td class="nump">1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Derivative, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.600<span></span>
</td>
<td class="nump">0.600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Derivative Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Derivative, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.850<span></span>
</td>
<td class="nump">0.850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=PMCB_MeasurementInputRedemptionPremiumMember', window );">Measurement Input Redemption Premium [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Derivative, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.06<span></span>
</td>
<td class="nump">1.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=PMCB_MeasurementInputRedemptionPremiumMember', window );">Measurement Input Redemption Premium [Member] | Derivative Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Derivative, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.06<span></span>
</td>
<td class="nump">1.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=PMCB_MeasurementInputMarketInterestRateMember', window );">Measurement Input Market Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Derivative, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1692<span></span>
</td>
<td class="nump">0.1692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=PMCB_MeasurementInputMarketInterestRateMember', window );">Measurement Input Market Interest Rate [Member] | Derivative Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Derivative, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2010<span></span>
</td>
<td class="nump">0.2010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Derivative, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0376<span></span>
</td>
<td class="nump">0.0376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Derivative Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Derivative, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0342<span></span>
</td>
<td class="nump">0.0342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Derivative, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0700<span></span>
</td>
<td class="nump">0.0700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member] | Derivative Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Derivative, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0700<span></span>
</td>
<td class="nump">0.0700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Series C Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Aggregate shares | shares</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_PreferredStockParValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_PreferredStockStatedValuePerShare', window );">Preferred stock, stated value | $ / shares</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion shares | shares</a></td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate gross proceeds</a></td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,182,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Engagement letter, description</a></td>
<td class="text">(i) a cash fee equal to 8.0% of the gross proceeds from the Series C Private Placement, and (ii) warrants to
purchase shares of Common Stock equal to 8.0% of the number of shares of common stock that the Preferred Stock are initially convertible
into, with an exercise price of $1.00 per share and a five-year term.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_PlacementAgentFeePercentage', window );">Placement agent, cash fee percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Transaction costs</a></td>
<td class="nump">$ 1,234,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,234,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,419<span></span>
</td>
<td class="nump">$ 86,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Series C Purchase Agreement [Member] | Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued | shares</a></td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_FairValueEmbeddedDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_FairValueEmbeddedDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_PlacementAgentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_PlacementAgentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_PreferredStockDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_PreferredStockDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_PreferredStockParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_PreferredStockParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_PreferredStockStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_PreferredStockStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_WarrantLiabilityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_WarrantLiabilityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure net derivative asset (liability).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetLiabilityNetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 405<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockPaidinkind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 405<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockPaidinkind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 405<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-23<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=PMCB_DerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=PMCB_DerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=PMCB_MeasurementInputRedemptionPremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=PMCB_MeasurementInputRedemptionPremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=PMCB_MeasurementInputMarketInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=PMCB_MeasurementInputMarketInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=PMCB_SeriesCPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=PMCB_SeriesCPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=PMCB_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=PMCB_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TREASURY STOCK (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 11, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock issued for compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 892,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,009,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,607,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock, Common [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,270,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,876,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,009,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,607,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock</a></td>
<td class="nump">875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock vested</a></td>
<td class="nump">393,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted units valued</a></td>
<td class="nump">$ 401,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock issued for compensation</a></td>
<td class="nump">$ 892,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-13<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481108/505-30-30-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481108/505-30-30-6<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details - Fair value) - Fair Value, Recurring [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Warrant liabilities</a></td>
<td class="nump">$ 13,657,000<span></span>
</td>
<td class="nump">$ 16,152,000<span></span>
</td>
<td class="nump">$ 338,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Derivative Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Warrant liabilities</a></td>
<td class="nump">1,136,000<span></span>
</td>
<td class="nump">$ 1,693,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Warrant liabilities</a></td>
<td class="nump">13,657,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Derivative Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Warrant liabilities</a></td>
<td class="nump">$ 1,136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=PMCB_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=PMCB_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=PMCB_DerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=PMCB_DerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details - Changes in fair value of warrant liability) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of derivative liability</a></td>
<td class="nump">$ 1,895,865<span></span>
</td>
<td class="nump">$ 4,487,000<span></span>
</td>
<td class="num">$ (8,335,135)<span></span>
</td>
<td class="nump">$ 8,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value, beginning</a></td>
<td class="nump">16,152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues', window );">Issuance of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,583,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_WarrantExercises', window );">Warrant exercises</a></td>
<td class="num">(599,135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(599,135)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of derivative liability</a></td>
<td class="num">(1,895,865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,335,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value, ending</a></td>
<td class="nump">$ 13,657,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,657,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_WarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_WarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 45<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480865/815-45-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=PMCB_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=PMCB_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details - Changes in fair value of derivative liability) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of derivative liability</a></td>
<td class="nump">$ 1,895,865<span></span>
</td>
<td class="nump">$ 4,487,000<span></span>
</td>
<td class="num">$ (8,335,135)<span></span>
</td>
<td class="nump">$ 8,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Derivative Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value, beginning</a></td>
<td class="nump">1,693,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_IssuanceOfSeriesCConvertiblePreferredStock', window );">Issuance of Series C convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,995,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_PMCB_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of derivative liability</a></td>
<td class="num">(557,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(859,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value, ending</a></td>
<td class="nump">$ 1,136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_PMCB_IssuanceOfSeriesCConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">PMCB_IssuanceOfSeriesCConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>PMCB_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 45<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480865/815-45-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=PMCB_DerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=PMCB_DerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details - Fair values of financial instruments) - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=PMCB_MarketableEquitySecuritiesMember', window );">Marketable Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAtFairValue', window );">Fair value of financial assets</a></td>
<td class="nump">$ 372,251<span></span>
</td>
<td class="nump">$ 366,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=PMCB_MoneyMarketAccountMember', window );">Money Market Account [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAtFairValue', window );">Fair value of financial assets</a></td>
<td class="nump">2,081,636<span></span>
</td>
<td class="nump">76,287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=PMCB_ConvertibleNoteReceivableMember', window );">Convertible Note Receivable [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAtFairValue', window );">Fair value of financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,696,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=PMCB_WarrantAssetFemasysMember', window );">Warrant Asset Femasys [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAtFairValue', window );">Fair value of financial assets</a></td>
<td class="nump">906,000<span></span>
</td>
<td class="nump">3,061,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=PMCB_InvestmentInPreferredStockQCLSMember', window );">Investment In Preferred Stock QCLS [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAtFairValue', window );">Fair value of financial assets</a></td>
<td class="nump">22,472,000<span></span>
</td>
<td class="nump">22,474,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=PMCB_WarrantAssetQCLSMember', window );">Warrant Asset QCLS [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedAtFairValue', window );">Fair value of financial assets</a></td>
<td class="nump">$ 10,242,000<span></span>
</td>
<td class="nump">$ 8,618,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 825<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value as of the balance sheet date of financial instruments and other positions owned by the entity including: (1) mortgages, mortgage-backed and asset backed securities; (2) US government and agency obligations; (3) state and municipal government obligations; (4) other sovereign government debt; (5) corporate obligations; (6) corporate equities; (7) principal investments; (8) derivative contracts; and (9) physical commodities. Includes both pledged and unpledged holdings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479035/940-320-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=PMCB_MarketableEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=PMCB_MarketableEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=PMCB_MoneyMarketAccountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=PMCB_MoneyMarketAccountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=PMCB_ConvertibleNoteReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=PMCB_ConvertibleNoteReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=PMCB_WarrantAssetFemasysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=PMCB_WarrantAssetFemasysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=PMCB_InvestmentInPreferredStockQCLSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=PMCB_InvestmentInPreferredStockQCLSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=PMCB_WarrantAssetQCLSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=PMCB_WarrantAssetQCLSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>377</ContextCount>
  <ElementCount>300</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>95</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS' EQUITY (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS' EQUITY (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999013 - Disclosure - NATURE OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/NatureOfBusiness</Role>
      <ShortName>NATURE OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999014 - Disclosure - LIQUIDITY AND OTHER UNCERTAINTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/LiquidityAndOtherUncertainties</Role>
      <ShortName>LIQUIDITY AND OTHER UNCERTAINTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999016 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/InvestmentInDebtAndEquitySecurities</Role>
      <ShortName>INVESTMENT IN DEBT AND EQUITY SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999017 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/AccruedExpenses</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999018 - Disclosure - STOCK OPTIONS AND WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/StockOptionsAndWarrants</Role>
      <ShortName>STOCK OPTIONS AND WARRANTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999019 - Disclosure - OTHER RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/OtherRelatedPartyTransactions</Role>
      <ShortName>OTHER RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999020 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999021 - Disclosure - EARNINGS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/EarningsPerShare</Role>
      <ShortName>EARNINGS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999022 - Disclosure - PREFERRED STOCK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/PreferredStock</Role>
      <ShortName>PREFERRED STOCK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999023 - Disclosure - TREASURY STOCK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/TreasuryStock</Role>
      <ShortName>TREASURY STOCK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999024 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/FairValueMeasurements</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999026 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables</Role>
      <ShortName>INVESTMENT IN DEBT AND EQUITY SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/InvestmentInDebtAndEquitySecurities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999027 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/AccruedExpensesTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/AccruedExpenses</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999028 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/StockOptionsAndWarrantsTables</Role>
      <ShortName>STOCK OPTIONS AND WARRANTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/StockOptionsAndWarrants</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999029 - Disclosure - EARNINGS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/EarningsPerShareTables</Role>
      <ShortName>EARNINGS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/EarningsPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/FairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999031 - Disclosure - LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative</Role>
      <ShortName>LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/LiquidityAndOtherUncertainties</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999033 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Femasys Note and warrants)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants</Role>
      <ShortName>INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Femasys Note and warrants)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999034 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Marketable securities)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities</Role>
      <ShortName>INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Marketable securities)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999035 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series G Preferred Stock and Preferred Stock Warrants)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants</Role>
      <ShortName>INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series G Preferred Stock and Preferred Stock Warrants)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999036 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series H Preferred Stock and Preferred Stock Warrants)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants</Role>
      <ShortName>INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series H Preferred Stock and Preferred Stock Warrants)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999037 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative</Role>
      <ShortName>INVESTMENT IN DEBT AND EQUITY SECURITIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999038 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/AccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/AccruedExpensesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999039 - Disclosure - STOCK OPTIONS AND WARRANTS (Details - Option activity)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity</Role>
      <ShortName>STOCK OPTIONS AND WARRANTS (Details - Option activity)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/StockOptionsAndWarrantsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999040 - Disclosure - STOCK OPTIONS AND WARRANTS (Details - Warrant activity)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity</Role>
      <ShortName>STOCK OPTIONS AND WARRANTS (Details - Warrant activity)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/StockOptionsAndWarrantsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999041 - Disclosure - STOCK OPTIONS AND WARRANTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative</Role>
      <ShortName>STOCK OPTIONS AND WARRANTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/StockOptionsAndWarrantsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999042 - Disclosure - OTHER RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>OTHER RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/OtherRelatedPartyTransactions</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999044 - Disclosure - EARNINGS PER SHARE (Details - Per share calculation)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation</Role>
      <ShortName>EARNINGS PER SHARE (Details - Per share calculation)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/EarningsPerShareTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999045 - Disclosure - EARNINGS PER SHARE (Details - Diluted shares)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares</Role>
      <ShortName>EARNINGS PER SHARE (Details - Diluted shares)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/EarningsPerShareTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999046 - Disclosure - PREFERRED STOCK (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/PreferredStockDetailsNarrative</Role>
      <ShortName>PREFERRED STOCK (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/PreferredStock</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999047 - Disclosure - TREASURY STOCK (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/TreasuryStockDetailsNarrative</Role>
      <ShortName>TREASURY STOCK (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/TreasuryStock</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999048 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair value)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details - Fair value)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999049 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of warrant liability)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details - Changes in fair value of warrant liability)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999050 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of derivative liability)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details - Changes in fair value of derivative liability)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="pharmacyte_i10q-013126.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999051 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair values of financial instruments)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details - Fair values of financial instruments)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://pharmacyte.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="pharmacyte_i10q-013126.htm">pharmacyte_i10q-013126.htm</File>
    <File>pmcb-20260131.xsd</File>
    <File>pmcb-20260131_cal.xml</File>
    <File>pmcb-20260131_def.xml</File>
    <File>pmcb-20260131_lab.xml</File>
    <File>pmcb-20260131_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="891">http://fasb.org/us-gaap/2026</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pharmacyte_i10q-013126.htm": {
   "nsprefix": "PMCB",
   "nsuri": "http://pharmacyte.com/20260131",
   "dts": {
    "inline": {
     "local": [
      "pharmacyte_i10q-013126.htm"
     ]
    },
    "schema": {
     "local": [
      "pmcb-20260131.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
      "https://xbrl.sec.gov/country/2026/country-2026.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd",
      "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "pmcb-20260131_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pmcb-20260131_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pmcb-20260131_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pmcb-20260131_pre.xml"
     ]
    }
   },
   "keyStandard": 217,
   "keyCustom": 83,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 25,
   "memberCustom": 63,
   "hidden": {
    "total": 296,
    "http://pharmacyte.com/20260131": 104,
    "http://fasb.org/us-gaap/2026": 187,
    "http://xbrl.sec.gov/dei/2026": 5
   },
   "contextCount": 377,
   "entityCount": 1,
   "segmentCount": 95,
   "elementCount": 596,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2026": 891,
    "http://xbrl.sec.gov/dei/2026": 30,
    "http://xbrl.sec.gov/ecd/2026": 4
   },
   "report": {
    "R1": {
     "role": "http://pharmacyte.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2026-01-31",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-01-31",
      "name": "PMCB:WarrantAssetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2026-01-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-01-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations",
     "longName": "00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2025-11-012026-01-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-11-012026-01-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss",
     "longName": "00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2025-11-012026-01-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-11-012026-01-31",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity",
     "longName": "00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS' EQUITY (UNAUDITED)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS' EQUITY (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "AsOf2024-04-30_custom_PreferredStockSeriesBMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-05-012024-07-31_us-gaap_AdditionalPaidInCapitalMember",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "longName": "00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "PMCB:IssuanceCostsSeriesCPreferredStockAndWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2025-11-012026-01-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2025-11-012026-01-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-11-012026-01-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://pharmacyte.com/role/NatureOfBusiness",
     "longName": "999013 - Disclosure - NATURE OF BUSINESS",
     "shortName": "NATURE OF BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://pharmacyte.com/role/LiquidityAndOtherUncertainties",
     "longName": "999014 - Disclosure - LIQUIDITY AND OTHER UNCERTAINTIES",
     "shortName": "LIQUIDITY AND OTHER UNCERTAINTIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "PMCB:LiquidityAndOtherUncertainitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "PMCB:LiquidityAndOtherUncertainitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://pharmacyte.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecurities",
     "longName": "999016 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES",
     "shortName": "INVESTMENT IN DEBT AND EQUITY SECURITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://pharmacyte.com/role/AccruedExpenses",
     "longName": "999017 - Disclosure - ACCRUED EXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://pharmacyte.com/role/StockOptionsAndWarrants",
     "longName": "999018 - Disclosure - STOCK OPTIONS AND WARRANTS",
     "shortName": "STOCK OPTIONS AND WARRANTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://pharmacyte.com/role/OtherRelatedPartyTransactions",
     "longName": "999019 - Disclosure - OTHER RELATED PARTY TRANSACTIONS",
     "shortName": "OTHER RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://pharmacyte.com/role/CommitmentsAndContingencies",
     "longName": "999020 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://pharmacyte.com/role/EarningsPerShare",
     "longName": "999021 - Disclosure - EARNINGS PER SHARE",
     "shortName": "EARNINGS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://pharmacyte.com/role/PreferredStock",
     "longName": "999022 - Disclosure - PREFERRED STOCK",
     "shortName": "PREFERRED STOCK",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://pharmacyte.com/role/TreasuryStock",
     "longName": "999023 - Disclosure - TREASURY STOCK",
     "shortName": "TREASURY STOCK",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:TreasuryStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:TreasuryStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://pharmacyte.com/role/FairValueMeasurements",
     "longName": "999024 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables",
     "longName": "999026 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Tables)",
     "shortName": "INVESTMENT IN DEBT AND EQUITY SECURITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://pharmacyte.com/role/AccruedExpensesTables",
     "longName": "999027 - Disclosure - ACCRUED EXPENSES (Tables)",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://pharmacyte.com/role/StockOptionsAndWarrantsTables",
     "longName": "999028 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables)",
     "shortName": "STOCK OPTIONS AND WARRANTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://pharmacyte.com/role/EarningsPerShareTables",
     "longName": "999029 - Disclosure - EARNINGS PER SHARE (Tables)",
     "shortName": "EARNINGS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://pharmacyte.com/role/FairValueMeasurementsTables",
     "longName": "999030 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative",
     "longName": "999031 - Disclosure - LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)",
     "shortName": "LIQUIDITY AND OTHER UNCERTAINTIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-30_custom_QCLSSeriesHConvertiblePreferredStockMember",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "PMCB:LiquidityAndOtherUncertainitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-30_custom_QCLSSeriesHConvertiblePreferredStockMember",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "PMCB:LiquidityAndOtherUncertainitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2026-01-31",
      "name": "us-gaap:CashUninsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-01-31",
      "name": "us-gaap:CashUninsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants",
     "longName": "999033 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Femasys Note and warrants)",
     "shortName": "INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Femasys Note and warrants)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2025-04-30",
      "name": "PMCB:ConvertibleNoteReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-04-30_custom_FemasysNotesMember",
      "name": "PMCB:ConvertibleNoteReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock",
       "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities",
     "longName": "999034 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Marketable securities)",
     "shortName": "INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Marketable securities)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2026-01-31",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R32": {
     "role": "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants",
     "longName": "999035 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series G Preferred Stock and Preferred Stock Warrants)",
     "shortName": "INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series G Preferred Stock and Preferred Stock Warrants)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2025-04-30",
      "name": "us-gaap:InvestmentsAndOtherNoncurrentAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-04-30_custom_QCLSSeriesGPreferredStockMember",
      "name": "us-gaap:InvestmentsAndOtherNoncurrentAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentTableTextBlock",
       "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants",
     "longName": "999036 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series H Preferred Stock and Preferred Stock Warrants)",
     "shortName": "INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series H Preferred Stock and Preferred Stock Warrants)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "AsOf2025-04-30",
      "name": "us-gaap:InvestmentsAndOtherNoncurrentAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-04-30_custom_QCLSSeriesHWarrantsMember",
      "name": "us-gaap:InvestmentsAndOtherNoncurrentAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentTableTextBlock",
       "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
     "longName": "999037 - Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details Narrative)",
     "shortName": "INVESTMENT IN DEBT AND EQUITY SECURITIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "PMCB:ProceedsFromInvestmentNoteReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-11-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember",
      "name": "us-gaap:DebtSecuritiesRealizedGainLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://pharmacyte.com/role/AccruedExpensesDetails",
     "longName": "999038 - Disclosure - ACCRUED EXPENSES (Details)",
     "shortName": "ACCRUED EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2026-01-31",
      "name": "us-gaap:AccruedLiabilitiesCurrentAndNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-01-31",
      "name": "us-gaap:AccruedLiabilitiesCurrentAndNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity",
     "longName": "999039 - Disclosure - STOCK OPTIONS AND WARRANTS (Details - Option activity)",
     "shortName": "STOCK OPTIONS AND WARRANTS (Details - Option activity)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2025-04-30_us-gaap_StockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-012026-01-31_us-gaap_StockOptionMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity",
     "longName": "999040 - Disclosure - STOCK OPTIONS AND WARRANTS (Details - Warrant activity)",
     "shortName": "STOCK OPTIONS AND WARRANTS (Details - Warrant activity)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2025-04-30_us-gaap_WarrantMember",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-012026-01-31_us-gaap_WarrantMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative",
     "longName": "999041 - Disclosure - STOCK OPTIONS AND WARRANTS (Details Narrative)",
     "shortName": "STOCK OPTIONS AND WARRANTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2025-10-012025-10-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-10-012025-10-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative",
     "longName": "999042 - Disclosure - OTHER RELATED PARTY TRANSACTIONS (Details Narrative)",
     "shortName": "OTHER RELATED PARTY TRANSACTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2025-11-012026-01-31_custom_VinDeBonaMember",
      "name": "us-gaap:ProfessionalAndContractServicesExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-11-012026-01-31_custom_VinDeBonaMember",
      "name": "us-gaap:ProfessionalAndContractServicesExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999043 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2025-11-012026-01-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-11-012026-01-31",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation",
     "longName": "999044 - Disclosure - EARNINGS PER SHARE (Details - Per share calculation)",
     "shortName": "EARNINGS PER SHARE (Details - Per share calculation)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2025-11-012026-01-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares",
     "longName": "999045 - Disclosure - EARNINGS PER SHARE (Details - Diluted shares)",
     "shortName": "EARNINGS PER SHARE (Details - Diluted shares)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2025-11-012026-01-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-11-012026-01-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://pharmacyte.com/role/PreferredStockDetailsNarrative",
     "longName": "999046 - Disclosure - PREFERRED STOCK (Details Narrative)",
     "shortName": "PREFERRED STOCK (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2026-01-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-11-012026-01-31",
      "name": "us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://pharmacyte.com/role/TreasuryStockDetailsNarrative",
     "longName": "999047 - Disclosure - TREASURY STOCK (Details Narrative)",
     "shortName": "TREASURY STOCK (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2025-05-01to2026-01-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-01-31_us-gaap_TreasuryStockCommonMember266868390",
      "name": "us-gaap:TreasuryStockCommonShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:TreasuryStockTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue",
     "longName": "999048 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair value)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details - Fair value)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-01-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability",
     "longName": "999049 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of warrant liability)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details - Changes in fair value of warrant liability)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2025-11-012026-01-31",
      "name": "PMCB:ChangeInFairValueOfWarrantLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-11-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability",
     "longName": "999050 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of derivative liability)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details - Changes in fair value of derivative liability)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2025-11-012026-01-31",
      "name": "PMCB:ChangeInFairValueOfWarrantLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-11-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember",
      "name": "PMCB:IssuanceOfSeriesCConvertiblePreferredStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments",
     "longName": "999051 - Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair values of financial instruments)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details - Fair values of financial instruments)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2026-01-31_custom_MarketableEquitySecuritiesMember_us-gaap_FairValueInputsLevel1Member",
      "name": "us-gaap:FinancialInstrumentsOwnedAtFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-01-31_custom_MarketableEquitySecuritiesMember_us-gaap_FairValueInputsLevel1Member",
      "name": "us-gaap:FinancialInstrumentsOwnedAtFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pharmacyte_i10q-013126.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r739",
      "r865",
      "r867"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r1033",
      "r1034",
      "r1035",
      "r1041"
     ]
    },
    "PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion of discounts to redemption value of Series B Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion of discounts to redemption value of Series C Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_AccrualOfSeriesCConvertiblePreferredStockDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "AccrualOfSeriesCConvertiblePreferredStockDividends",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual of Series C Convertible Preferred Stock dividends"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual of Series C Convertible Preferred Stock issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/AccruedExpensesDetails",
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "verboseLabel": "Accrued liabilities, current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r22",
      "r82",
      "r289",
      "r493",
      "r494",
      "r506",
      "r546",
      "r562",
      "r563",
      "r1002"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7",
      "r14",
      "r389",
      "r392",
      "r395",
      "r440",
      "r558",
      "r559",
      "r890",
      "r891",
      "r892",
      "r904",
      "r905",
      "r906",
      "r907",
      "r945",
      "r947"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r289",
      "r493",
      "r494",
      "r506",
      "r739",
      "r1048"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r576",
      "r904",
      "r905",
      "r906",
      "r907",
      "r1003",
      "r1050"
     ]
    },
    "PMCB_AdditionalWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "AdditionalWarrantsMember",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Preferred stock dividends",
        "label": "Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from dividends legally declared (or paid) in excess of retained earnings balance."
       }
      }
     },
     "auth_ref": [
      "r939",
      "r945",
      "r947"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net income (loss) to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r773",
      "r784",
      "r794",
      "r820"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r787",
      "r797",
      "r823"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r777",
      "r788",
      "r798",
      "r816",
      "r824",
      "r828",
      "r836"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive shares",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r66",
      "r107",
      "r109",
      "r110",
      "r152",
      "r160",
      "r171",
      "r172",
      "r211",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r292",
      "r371",
      "r373",
      "r429",
      "r493",
      "r494",
      "r497",
      "r514",
      "r515",
      "r539",
      "r619",
      "r706",
      "r707",
      "r714",
      "r739",
      "r742",
      "r743",
      "r754",
      "r936",
      "r937",
      "r1020"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r85",
      "r107",
      "r109",
      "r110",
      "r211",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r292",
      "r371",
      "r373",
      "r429",
      "r739",
      "r860",
      "r936",
      "r937",
      "r1020"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r107",
      "r109",
      "r110",
      "r211",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r292",
      "r371",
      "r373",
      "r429",
      "r936",
      "r937",
      "r1020"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative",
      "http://pharmacyte.com/role/TreasuryStockDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets",
      "http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r102",
      "r104",
      "r689",
      "r1026"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of the period",
        "periodEndLabel": "Cash and cash equivalents at end of the period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r102",
      "r104"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r30"
     ]
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, uninsured amount",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_ChangeInFairValueAssociatedWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ChangeInFairValueAssociatedWarrantExercises",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value associated warrant exercises"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_ChangeInFairValueDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ChangeInFairValueDerivativeLiability",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value derivative liability"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_ChangeInFairValueOfConvertibleNoteReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ChangeInFairValueOfConvertibleNoteReceivable",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of convertible note receivable - Femasys"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_ChangeInFairValueOfConvertibleNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ChangeInFairValueOfConvertibleNotesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of convertible note receivable - Femasys",
        "label": "Change in fair value",
        "verboseLabel": "Change in fair value of the convertible note receivable"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_ChangeInFairValueOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ChangeInFairValueOfDerivativeLiability",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of derivative liability",
        "negatedLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_ChangeInFairValueOfInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ChangeInFairValueOfInvestment",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of investment - QCLS",
        "verboseLabel": "Change in fair value"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_ChangeInFairValueOfInvestmentQcls": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ChangeInFairValueOfInvestmentQcls",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of investment \u2013 QCLS",
        "verboseLabel": "Change in fair value",
        "label": "ChangeInFairValueOfInvestmentQcls"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_ChangeInFairValueOfWarrantAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ChangeInFairValueOfWarrantAsset",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrants - QCLS",
        "verboseLabel": "Change in fair value warrant asset"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_ChangeInFairValueOfWarrantAssetFemasys": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ChangeInFairValueOfWarrantAssetFemasys",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      },
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant asset - Femasys",
        "negatedLabel": "Change in fair value of warrant asset \u2013 Femasys",
        "verboseLabel": "Change in fair value",
        "negatedTerseLabel": "Change in fair value of the convertible note receivable"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_ChangeInFairValueOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ChangeInFairValueOfWarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liability",
        "negatedLabel": "Change in fair value of warrant liabilities",
        "negatedTerseLabel": "Change in fair value of warrant liability",
        "verboseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_ChangeInFairValueOfWarrantsQcls": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ChangeInFairValueOfWarrantsQcls",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of warrants - QCLS",
        "label": "ChangeInFairValueOfWarrantsQcls"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CityAreaCode",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets",
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables",
      "http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative",
      "http://pharmacyte.com/role/TreasuryStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r59",
      "r60",
      "r73",
      "r74",
      "r75",
      "r77",
      "r78",
      "r79",
      "r107",
      "r110",
      "r137",
      "r138",
      "r142",
      "r146",
      "r154",
      "r155",
      "r211",
      "r242",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r257",
      "r258",
      "r260",
      "r261",
      "r263",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r429",
      "r493",
      "r494",
      "r503",
      "r504",
      "r505",
      "r535",
      "r568",
      "r569",
      "r570",
      "r571",
      "r576",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r607",
      "r627",
      "r649",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r845",
      "r900",
      "r901",
      "r908",
      "r946",
      "r948"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://pharmacyte.com/role/TreasuryStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r73",
      "r78",
      "r79",
      "r154",
      "r260",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r281",
      "r282",
      "r284",
      "r285",
      "r287",
      "r288",
      "r291",
      "r293",
      "r387",
      "r493",
      "r494",
      "r504",
      "r505",
      "r568",
      "r569",
      "r570",
      "r571",
      "r845",
      "r898",
      "r900",
      "r946"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "periodStartLabel": "Weighted average exercise price warrants outstanding, beginning balance",
        "periodEndLabel": "Weighted average exercise price warrants outstanding, ending balance",
        "verboseLabel": "Warrants issued per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r111",
      "r282"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued",
        "verboseLabel": "Warrant shares",
        "terseLabel": "Warrants acquire",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants outstanding, beginning balance",
        "periodEndLabel": "Warrants outstanding, ending balance",
        "label": "Warrants outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Note 8)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r493",
      "r494",
      "r502",
      "r542",
      "r606"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r687",
      "r927",
      "r928",
      "r929"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockMember",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r288",
      "r493",
      "r494",
      "r505",
      "r744",
      "r745",
      "r746",
      "r748",
      "r749",
      "r750",
      "r751",
      "r904",
      "r905",
      "r907",
      "r1003",
      "r1045",
      "r1050"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r877",
      "r944",
      "r1033",
      "r1034",
      "r1038"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r288",
      "r493",
      "r494",
      "r505",
      "r607"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r288",
      "r493",
      "r494",
      "r505"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r288",
      "r493",
      "r494",
      "r505",
      "r607",
      "r625",
      "r939",
      "r1050",
      "r1051"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock: authorized 200,000,000 shares, $0.0001 par value; 26,005,715 and 21,672,095 shares issued and 10,735,649 and 6,795,779 shares outstanding as of January 31, 2026 and April 30, 2025, respectively.",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r258",
      "r266",
      "r288",
      "r493",
      "r494",
      "r505",
      "r544",
      "r739"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income (loss)",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r90",
      "r92",
      "r98",
      "r512",
      "r553",
      "r554"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation and Basis of Presentation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r698"
     ]
    },
    "PMCB_ContingentlyRedeemableWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ContingentlyRedeemableWarrants",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "PMCB_TotalTemporaryEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingently redeemable warrants"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_ContingentlyRedeemableWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ContingentlyRedeemableWarrantsMember",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingently Redeemable Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual obligation",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r903",
      "r1039"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "PMCB_ConvertibleNoteReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ConvertibleNoteReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note receivable \u2013 Femasys - current",
        "periodStartLabel": "Investment, beginning balance",
        "periodEndLabel": "Investment, ending balance",
        "verboseLabel": "Convertible note receivable, current"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_ConvertibleNoteReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ConvertibleNoteReceivableMember",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Note Receivable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_ConvertiblePreferredStockDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ConvertiblePreferredStockDividends",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Convertible preferred stock dividends",
        "label": "ConvertiblePreferredStockDividends"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion shares",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r279",
      "r282"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r107",
      "r114",
      "r115",
      "r251",
      "r275",
      "r446",
      "r448",
      "r473",
      "r537",
      "r691",
      "r692",
      "r693",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1027",
      "r1028"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CountryRegion",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument periodic payment",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r866",
      "r870"
     ]
    },
    "us-gaap_DebtSecuritiesRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DebtSecuritiesRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Recognized gain (loss)",
        "label": "Debt Securities, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r894",
      "r895"
     ]
    },
    "PMCB_DeemedDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "DeemedDividend",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed dividend"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeAssetLiabilityNetMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DerivativeAssetLiabilityNetMeasurementInput",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, measurement input",
        "documentation": "Value of input used to measure net derivative asset (liability)."
       }
      }
     },
     "auth_ref": [
      "r1007",
      "r1008",
      "r1009"
     ]
    },
    "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DerivativeAssetsLiabilitiesAtFairValueNet",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of derivative",
        "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments."
       }
      }
     },
     "auth_ref": [
      "r1007",
      "r1008",
      "r1009"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liabilities",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "PMCB_DerivativeLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "DerivativeLiabilityMember",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value measurement",
        "documentation": "Describes how an entity determines the fair values of its derivatives, including its valuation methodology and significant assumptions used."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "PMCB_DirectorFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "DirectorFeesMember",
     "presentation": [
      "http://pharmacyte.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director Fees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_DisclosureLineElements": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "DisclosureLineElements",
     "presentation": [
      "http://pharmacyte.com/role/AccruedExpensesDetails",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureLineElements [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_DisclosureLiquidityAndOtherUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "DisclosureLiquidityAndOtherUncertaintiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity And Other Uncertainties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK OPTIONS AND WARRANTS",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r323",
      "r351",
      "r352",
      "r353",
      "r720"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_DisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "DisclosureTable",
     "presentation": [
      "http://pharmacyte.com/role/AccruedExpensesDetails",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DisclosureTable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DividendsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Series C dividends",
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_DividendsPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DividendsPreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Preferred stock dividends",
        "label": "Dividends, Preferred Stock",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r293",
      "r535"
     ]
    },
    "us-gaap_DividendsPreferredStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DividendsPreferredStockCash",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend paid in cash",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r947",
      "r1040"
     ]
    },
    "us-gaap_DividendsPreferredStockPaidinkind": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DividendsPreferredStockPaidinkind",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend accrued",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r947",
      "r1040"
     ]
    },
    "us-gaap_DividendsPreferredStockStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "DividendsPreferredStockStock",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred dividends",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r876",
      "r943",
      "r945",
      "r947",
      "r1040"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r768",
      "r780"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentType",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic income (loss) per share attributable to common stockholders",
        "verboseLabel": "Net income (loss) per share basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r99",
      "r119",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r134",
      "r137",
      "r142",
      "r145",
      "r146",
      "r151",
      "r232",
      "r255",
      "r306",
      "r354",
      "r366",
      "r369",
      "r402",
      "r403",
      "r513",
      "r555",
      "r699"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r142",
      "r146"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted income (loss) per share attributable to common stockholders",
        "verboseLabel": "Net income (loss) per share diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r99",
      "r119",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r137",
      "r142",
      "r145",
      "r146",
      "r151",
      "r232",
      "r255",
      "r306",
      "r354",
      "r366",
      "r369",
      "r402",
      "r403",
      "r513",
      "r555",
      "r699"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "EARNINGS PER SHARE",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r147",
      "r148",
      "r149",
      "r150",
      "r297"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of currency rate exchange on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee service unrecognized compensation expense",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "PMCB_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "EmployeesMember",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r59",
      "r78",
      "r79",
      "r93",
      "r94",
      "r95",
      "r116",
      "r117",
      "r118",
      "r120",
      "r127",
      "r129",
      "r131",
      "r153",
      "r212",
      "r213",
      "r231",
      "r232",
      "r233",
      "r254",
      "r281",
      "r286",
      "r287",
      "r288",
      "r291",
      "r293",
      "r296",
      "r304",
      "r305",
      "r307",
      "r308",
      "r354",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r432",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r490",
      "r493",
      "r494",
      "r504",
      "r505",
      "r535",
      "r551",
      "r558",
      "r559",
      "r560",
      "r576",
      "r649",
      "r948"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r362",
      "r429",
      "r846",
      "r847",
      "r848",
      "r977",
      "r978",
      "r979",
      "r980"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity interest owned",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r429"
     ]
    },
    "PMCB_EquityPlan2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "EquityPlan2021Member",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Plan 2021 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_EquityPlan2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "EquityPlan2022Member",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Plan 2022 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r773",
      "r784",
      "r794",
      "r820"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r770",
      "r781",
      "r791",
      "r817"
     ]
    },
    "PMCB_ExciseTaxAccruedOnRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ExciseTaxAccruedOnRepurchaseOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excise tax accrued on repurchase of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_ExciseTaxOnStockRepurchasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ExciseTaxOnStockRepurchasesMember",
     "presentation": [
      "http://pharmacyte.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excise Tax On Stock Repurchases [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Extension",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of the warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r406",
      "r407",
      "r418",
      "r728"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r406",
      "r407",
      "r418",
      "r728"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair values of financial instruments by class",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r417",
      "r418",
      "r420",
      "r426",
      "r452",
      "r453",
      "r454",
      "r458",
      "r712",
      "r713",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r728",
      "r730",
      "r737",
      "r738"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r410",
      "r728",
      "r1008",
      "r1011"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENTS",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r413",
      "r415",
      "r416",
      "r417",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r492",
      "r728",
      "r731"
     ]
    },
    "PMCB_FairValueEmbeddedDerivative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "FairValueEmbeddedDerivative",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of embedded derivative"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r309",
      "r314",
      "r316",
      "r407",
      "r418",
      "r426",
      "r452",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r728",
      "r737",
      "r738"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r407",
      "r408",
      "r409",
      "r410",
      "r418",
      "r426",
      "r454",
      "r712",
      "r713",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r728",
      "r730",
      "r737",
      "r738"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of change in the fair value warrant liability",
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset."
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value of financial liabilities",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r414",
      "r419"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r410",
      "r728",
      "r1008",
      "r1011"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r410",
      "r417",
      "r418",
      "r420",
      "r426",
      "r452",
      "r453",
      "r454",
      "r458",
      "r712",
      "r713",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r728",
      "r730",
      "r737",
      "r738"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1011"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants",
        "documentation": "Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r419"
     ]
    },
    "PMCB_FairValueOfContingentlyRedeemablePlacementAgentWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "FairValueOfContingentlyRedeemablePlacementAgentWarrants",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of contingently redeemable placement agent warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r536"
     ]
    },
    "PMCB_FemasysCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "FemasysCommonStockMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Femasys Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_FemasysMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "FemasysMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Femasys [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_FemasysNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "FemasysNoteMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Femasys Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_FemasysNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "FemasysNotesMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Femasys Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_FemasysPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "FemasysPurchaseAgreementMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Femasys Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_FemasysSeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "FemasysSeriesAWarrantsMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Femasys Series A Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_FemasysWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "FemasysWarrantsMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Femasys Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r253",
      "r280",
      "r387",
      "r425",
      "r428",
      "r430",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r471",
      "r472",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r536",
      "r552",
      "r710",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r918",
      "r919",
      "r920",
      "r921",
      "r1004",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1013",
      "r1014"
     ]
    },
    "us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinancialInstrumentsOwnedAndPledgedAsCollateralLineItems",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments Owned and Pledged as Collateral [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r470",
      "r474",
      "r599"
     ]
    },
    "us-gaap_FinancialInstrumentsOwnedAndPledgedAsCollateralTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinancialInstrumentsOwnedAndPledgedAsCollateralTable",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments Owned and Pledged as Collateral [Table]",
        "documentation": "Disclosure of information about financial instrument held by broker-dealer for its own account for trading or investment purposes and pledged to counterparty as collateral for financing transaction."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r470",
      "r474",
      "r599"
     ]
    },
    "us-gaap_FinancialInstrumentsOwnedAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinancialInstrumentsOwnedAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of financial assets",
        "documentation": "The aggregate fair value as of the balance sheet date of financial instruments and other positions owned by the entity including: (1) mortgages, mortgage-backed and asset backed securities; (2) US government and agency obligations; (3) state and municipal government obligations; (4) other sovereign government debt; (5) corporate obligations; (6) corporate equities; (7) principal investments; (8) derivative contracts; and (9) physical commodities. Includes both pledged and unpledged holdings."
       }
      }
     },
     "auth_ref": [
      "r1026",
      "r1031"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value of the warrants",
        "terseLabel": "Warrant liabilities",
        "periodStartLabel": "Fair value, beginning",
        "periodEndLabel": "Fair value, ending",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1006",
      "r1010",
      "r1013",
      "r1014",
      "r1015",
      "r1016"
     ]
    },
    "PMCB_FirstWarrantIssuanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "FirstWarrantIssuanceMember",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Warrant Issuance [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r788",
      "r798",
      "r824"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r788",
      "r798",
      "r824"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r788",
      "r798",
      "r824"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r788",
      "r798",
      "r824"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r788",
      "r798",
      "r824"
     ]
    },
    "PMCB_FractionalSharesAdjustmentShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "FractionalSharesAdjustmentShares",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fractional shares adjustment, shares"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_FractionalSharesAdjustmentValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "FractionalSharesAdjustmentValue",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fractional shares adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_GainOnFairValueOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "GainOnFairValueOfWarrants",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on re-fair value of warrants",
        "label": "GainOnFairValueOfWarrants"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_GainOnFairValueOfWarrantsWainwright": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "GainOnFairValueOfWarrantsWainwright",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on legal settlement \u2013 re-fair value of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_GainOnRelatedPartyInvestmentQcls": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "GainOnRelatedPartyInvestmentQcls",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on related party investment - QCLS",
        "negatedLabel": "Gain on related party investment \u2013 QCLS",
        "verboseLabel": "Investment, fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r629"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r923",
      "r924"
     ]
    },
    "PMCB_HCWainwrightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "HCWainwrightMember",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "H.C. Wainwright [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in accounts payable",
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease in accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r777",
      "r788",
      "r798",
      "r816",
      "r824",
      "r828",
      "r836"
     ]
    },
    "PMCB_InitialFairValueOfInvestmentInQclsSeriesHPreferredShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "InitialFairValueOfInvestmentInQclsSeriesHPreferredShares",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial fair value of investment in QCLS Series H preferred shares"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_InitialFairValueOfInvestmentInQclsSeriesHWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "InitialFairValueOfInvestmentInQclsSeriesHWarrants",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial fair value of investment in QCLS Series H warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r840"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r840"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r769",
      "r840"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible asset",
        "documentation": "Amount, after accumulated amortization, of finite- and indefinite-lived intangible assets and capitalized cost for software to be sold, leased, or marketed. Excludes goodwill."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r493",
      "r494",
      "r495",
      "r925",
      "r926"
     ]
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest and other income",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest receivable",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r864",
      "r878",
      "r1052"
     ]
    },
    "us-gaap_InterimPeriodCostsNotAllocableDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InterimPeriodCostsNotAllocableDomain",
     "presentation": [
      "http://pharmacyte.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "PMCB_InvestmentInPreferredStockAndWarrantsInQcls": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "InvestmentInPreferredStockAndWarrantsInQcls",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Investment in preferred stock and warrants in QCLS",
        "label": "InvestmentInPreferredStockAndWarrantsInQcls"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_InvestmentInPreferredStockQCLSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "InvestmentInPreferredStockQCLSMember",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment In Preferred Stock QCLS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentOwnedAtCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InvestmentOwnedAtCost",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjusted cost basis",
        "verboseLabel": "Investment, cost",
        "documentation": "Cost of the investment."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r595",
      "r596",
      "r659",
      "r661",
      "r666",
      "r675",
      "r746",
      "r754",
      "r1046"
     ]
    },
    "us-gaap_InvestmentOwnedAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InvestmentOwnedAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial fair value of Investment",
        "verboseLabel": "Investment, fair value",
        "documentation": "Fair value of investment in security owned."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r589",
      "r590",
      "r591",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r610",
      "r611",
      "r655",
      "r657",
      "r658",
      "r660",
      "r663",
      "r664",
      "r667",
      "r668",
      "r669",
      "r671",
      "r672",
      "r674",
      "r676",
      "r677",
      "r746",
      "r754",
      "r1046"
     ]
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment shares",
        "verboseLabel": "Investment shares owned",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r597",
      "r656",
      "r665",
      "r673",
      "r746"
     ]
    },
    "PMCB_InvestmentSharesAddition": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "InvestmentSharesAddition",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment shares additions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InvestmentTableTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of activity preferred stock",
        "documentation": "Tabular disclosure of investment."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r850",
      "r917"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r592",
      "r593",
      "r595",
      "r597",
      "r655",
      "r657",
      "r662",
      "r664",
      "r667",
      "r670",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r746"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r592",
      "r593",
      "r595",
      "r597",
      "r655",
      "r657",
      "r662",
      "r664",
      "r667",
      "r670",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r746"
     ]
    },
    "us-gaap_InvestmentsAndOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InvestmentsAndOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in preferred stock \u2013 QCLS",
        "periodStartLabel": "Investment, beginnning balance",
        "periodEndLabel": "Investment, ending balance",
        "documentation": "Amount of investments, and noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance costs \u2013 Series C convertible preferred stock and warrants"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_IssuanceCostsSeriesCPreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "IssuanceCostsSeriesCPreferredStockAndWarrants",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance costs \u2013 Series C preferred stock and warrants"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_IssuanceFairValues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "IssuanceFairValues",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance fair values"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_IssuanceOfSeriesCConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "IssuanceOfSeriesCConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series C convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_IssuanceOfSeriesCPreferredStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "IssuanceOfSeriesCPreferredStockAndWarrants",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series C preferred stock and warrants, net of transaction costs"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_IssuanceOfSeriesCPreferredStockAndWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "IssuanceOfSeriesCPreferredStockAndWarrantsShares",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Series C preferred stock and warrants, net of transaction costs, shares"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_LegalSettlementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "LegalSettlementMember",
     "presentation": [
      "http://pharmacyte.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Settlement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_LessAllocationOfUndistributedIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "LessAllocationOfUndistributedIncome",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: Allocation of undistributed income to Series B convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r107",
      "r109",
      "r110",
      "r211",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r292",
      "r372",
      "r373",
      "r374",
      "r429",
      "r605",
      "r701",
      "r714",
      "r754",
      "r880",
      "r936",
      "r1020",
      "r1021"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities, Temporary Equity and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r493",
      "r494",
      "r508",
      "r548",
      "r739",
      "r742",
      "r743",
      "r898",
      "r902",
      "r922",
      "r1017"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58",
      "r68",
      "r107",
      "r109",
      "r110",
      "r211",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r292",
      "r372",
      "r373",
      "r374",
      "r429",
      "r739",
      "r936",
      "r1020",
      "r1021"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_LiquidityAndOtherUncertainitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "LiquidityAndOtherUncertainitiesTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/LiquidityAndOtherUncertainties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIQUIDITY AND OTHER UNCERTAINTIES"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": [
      "r932",
      "r934"
     ]
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "auth_ref": [
      "r932",
      "r934"
     ]
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial payment",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_LitigationSettlementGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LitigationSettlementGain",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on legal settlement",
        "documentation": "Amount of gain from litigation settlement for amount awarded from other party. Excludes claims within an insurance entity's normal claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_LongTermPortionOfLegalSettlementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "LongTermPortionOfLegalSettlementMember",
     "presentation": [
      "http://pharmacyte.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Portion Of Legal Settlement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_LongTermWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "LongTermWarrantMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r234",
      "r238",
      "r239",
      "r240",
      "r241",
      "r357",
      "r564",
      "r711",
      "r931",
      "r933"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r234",
      "r238",
      "r239",
      "r240",
      "r241",
      "r357",
      "r564",
      "r711",
      "r931",
      "r933"
     ]
    },
    "PMCB_LossOnIssuanceOfSeriesCConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "LossOnIssuanceOfSeriesCConvertiblePreferredStock",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on issuance of Series C convertible preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_LossOnIssuanceOfSeriesCPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "LossOnIssuanceOfSeriesCPreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on issuance of Series C preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_MarketableEquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "MarketableEquitySecuritiesMember",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Equity Securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable equity securities",
        "verboseLabel": "Carrying value at fair market value",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r868"
     ]
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      },
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized loss on marketable securities",
        "negatedLabel": "Unrealized loss on marketable equity securities",
        "verboseLabel": "Unrealized loss",
        "negatedTerseLabel": "Unrealized loss on marketable securities",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r970",
      "r1007",
      "r1008",
      "r1009"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r1007",
      "r1008",
      "r1009"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r1007",
      "r1008",
      "r1009"
     ]
    },
    "PMCB_MeasurementInputMarketInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "MeasurementInputMarketInterestRateMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Market Interest Rate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputMaturityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputMaturityMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Maturity [Member]",
        "documentation": "Measurement input using due date of last payment of principal and interest for financial instrument. Excludes expected term."
       }
      }
     },
     "auth_ref": [
      "r1007",
      "r1008",
      "r1009"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r730",
      "r1007",
      "r1008",
      "r1009"
     ]
    },
    "PMCB_MeasurementInputRedemptionPremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "MeasurementInputRedemptionPremiumMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Redemption Premium [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r1007",
      "r1008",
      "r1009"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1007",
      "r1008",
      "r1009"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r408",
      "r409",
      "r410",
      "r722",
      "r723",
      "r724",
      "r730",
      "r1029"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r722",
      "r723",
      "r724",
      "r730",
      "r1029"
     ]
    },
    "PMCB_MeasurementRedemptionPremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "MeasurementRedemptionPremiumMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Redemption Premium [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "PMCB_MoneyMarketAccountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "MoneyMarketAccountMember",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Account [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_NatureOfExpenseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NatureOfExpenseAxis",
     "presentation": [
      "http://pharmacyte.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Expense [Axis]",
        "documentation": "Information by type of cost or expense."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash and cash equivalents provided by (used in) financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash and cash equivalents provided by (used in) investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash and cash equivalents used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity",
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "label": "Net income (loss)",
        "verboseLabel": "Net income",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r32",
      "r40",
      "r50",
      "r56",
      "r57",
      "r88",
      "r91",
      "r95",
      "r107",
      "r109",
      "r110",
      "r113",
      "r119",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r130",
      "r131",
      "r139",
      "r211",
      "r232",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r255",
      "r259",
      "r262",
      "r268",
      "r292",
      "r306",
      "r354",
      "r366",
      "r369",
      "r403",
      "r429",
      "r550",
      "r626",
      "r647",
      "r648",
      "r694",
      "r696",
      "r697",
      "r752",
      "r936"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) attributable to common stockholders",
        "label": "Net loss attributable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r100",
      "r123",
      "r124",
      "r125",
      "r126",
      "r134",
      "r135",
      "r141",
      "r146",
      "r259",
      "r262",
      "r268",
      "r369"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncement Effective in Future Periods",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "PMCB_NoncashDerivativeLiabilityAtInitialFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "NoncashDerivativeLiabilityAtInitialFairValue",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash derivative liability at initial fair value"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_NoncashInterestIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "NoncashInterestIncome",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-cash interest income",
        "label": "NoncashInterestIncome"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_NoncashRedemptionOfSeriesCConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "NoncashRedemptionOfSeriesCConvertiblePreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash redemption of Series C convertible preferred stock",
        "documentation": "Noncash Redemption of Series C Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_NoncashWarrantLiabilityAtInitialFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "NoncashWarrantLiabilityAtInitialFairValue",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash warrant liability at initial fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income and (expense), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r858",
      "r859",
      "r922"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expenses):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r703",
      "r709",
      "r912"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r858",
      "r859",
      "r922"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r697",
      "r702",
      "r858",
      "r859",
      "r911",
      "r913",
      "r914",
      "r915",
      "r916",
      "r922"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "PMCB_OptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "OptionsMember",
     "presentation": [
      "http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/NatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF BUSINESS",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r51",
      "r53",
      "r54",
      "r565",
      "r566"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAccruedLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term portion of accrued expenses",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r65",
      "r493",
      "r494",
      "r496",
      "r538",
      "r707",
      "r742",
      "r743",
      "r754"
     ]
    },
    "us-gaap_OtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherAssetsAbstract",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment",
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r7",
      "r38"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r7",
      "r38"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r87",
      "r89",
      "r92",
      "r97",
      "r127",
      "r432",
      "r433",
      "r438",
      "r511",
      "r551",
      "r890",
      "r891",
      "r939"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other liabilities",
        "label": "Other Liabilities",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r67",
      "r71",
      "r493",
      "r494",
      "r498",
      "r499",
      "r500",
      "r540",
      "r601",
      "r602",
      "r714",
      "r742",
      "r743",
      "r754",
      "r871",
      "r1042",
      "r1047"
     ]
    },
    "us-gaap_OtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherLiabilitiesAbstract",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other expense",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r725"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r775",
      "r786",
      "r796",
      "r822"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r789",
      "r799",
      "r825"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r789",
      "r799",
      "r825"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_PaymentOfSeriesCConvertiblePreferredStockDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "PaymentOfSeriesCConvertiblePreferredStockDividends",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of Series C convertible preferred stock dividends",
        "label": "PaymentOfSeriesCConvertiblePreferredStockDividends"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for legal settlements",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of common stock, net",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment interest payment",
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Investments",
        "verboseLabel": "Payments for investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "PMCB_PayrollRelatedCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "PayrollRelatedCostsMember",
     "presentation": [
      "http://pharmacyte.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payroll Related Costs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "PMCB_PlacementAgentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "PlacementAgentFeePercentage",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement agent, cash fee percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "PMCB_PreferredSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "PreferredSharesMember",
     "presentation": [
      "http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_PreferredStockAccretion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "PreferredStockAccretion",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock accretion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockAccretionOfRedemptionDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockAccretionOfRedemptionDiscount",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Preferred stock accretion",
        "negatedTerseLabel": "Less: Accretion of discounts to redemption of convertible preferred stock",
        "label": "Preferred Stock, Accretion of Redemption Discount",
        "documentation": "The amount of accretion of the preferred stock redemption discount during the period."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r876",
      "r943"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "PMCB_PreferredStockDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "PreferredStockDiscount",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total discount on preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r862",
      "r876",
      "r943",
      "r1033",
      "r1034",
      "r1037"
     ]
    },
    "PMCB_PreferredStockParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "PreferredStockParValuePerShare",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value",
        "label": "PreferredStockParValuePerShare"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_PreferredStockSeriesBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "PreferredStockSeriesBMember",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Series B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_PreferredStockSeriesCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "PreferredStockSeriesCMember",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Series C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r78",
      "r287",
      "r493",
      "r494",
      "r504",
      "r607"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r78",
      "r271",
      "r287",
      "r493",
      "r494",
      "r504"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r78",
      "r287",
      "r493",
      "r494",
      "r504",
      "r607",
      "r625",
      "r939",
      "r1050",
      "r1051"
     ]
    },
    "PMCB_PreferredStockStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "PreferredStockStatedValuePerShare",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, stated value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PREFERRED STOCK",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r73",
      "r76",
      "r260",
      "r493",
      "r494",
      "r507"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock value",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r78",
      "r258",
      "r265",
      "r287",
      "r493",
      "r494",
      "r504",
      "r543",
      "r739"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_ProceedsFromInvestmentNoteReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ProceedsFromInvestmentNoteReceivable",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from investment - note receivable",
        "verboseLabel": "Settlement of Femasys Note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from issuance of Series C convertible preferred stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of preferred stock",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate gross proceeds",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r568"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from exercises of warrants",
        "verboseLabel": "Proceeds from warrant exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ProfessionalAndContractServicesExpense",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting fees",
        "documentation": "Amount of expense for professional and contracted services."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "PMCB_QCLSAccruedDividendReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "QCLSAccruedDividendReceivableMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "QCLS Accrued Dividend Receivable [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_QCLSCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "QCLSCommonStockMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "QCLS Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_QCLSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "QCLSMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "QCLS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_QCLSSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "QCLSSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "QCLS Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_QCLSSeriesGPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "QCLSSeriesGPreferredStockMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "QCLS Series G Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_QCLSSeriesGWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "QCLSSeriesGWarrantsMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "QCLS Series G Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_QCLSSeriesHConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "QCLSSeriesHConvertiblePreferredStockMember",
     "presentation": [
      "http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "QCLS Series H Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_QCLSSeriesHPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "QCLSSeriesHPreferredStockMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "QCLS Series H Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_QCLSSeriesHWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "QCLSSeriesHWarrantMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "QCLS Series H Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_QCLSSeriesHWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "QCLSSeriesHWarrantsMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "QCLS Series H Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementLineItems",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Qualitative and Quantitative Information, Transferor's Continuing Involvement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "QualitativeAndQuantitativeInformationTransferorsContinuingInvolvementTable",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Qualitative and Quantitative Information, Transferor's Continuing Involvement [Table]",
        "documentation": "Disclosure of information about transferor's continuing involvement with transferred financial asset in securitization, asset-backed financing arrangement, and similar transfer."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "PMCB_RAndDCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "RAndDCostsMember",
     "presentation": [
      "http://pharmacyte.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R And D Costs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RealizedInvestmentGainsLosses",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recognized gain (loss)",
        "negatedLabel": "Recognized gain (loss)",
        "documentation": "Amount of realized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "PMCB_ReceivableInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ReceivableInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable conversion price"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of Series B Convertible Preferred Stock and dividends to current liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Reclassifications": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Reclassifications",
     "presentation": [
      "http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification",
        "documentation": "The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r770",
      "r781",
      "r791",
      "r817"
     ]
    },
    "PMCB_RedemptionOfPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "RedemptionOfPreferredStock",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Redemption of preferred stock",
        "label": "RedemptionOfPreferredStock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r67",
      "r69",
      "r70",
      "r107",
      "r112",
      "r113",
      "r177",
      "r315",
      "r318",
      "r444",
      "r445",
      "r493",
      "r494",
      "r498",
      "r499",
      "r501",
      "r509",
      "r541",
      "r549",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r624",
      "r654",
      "r690",
      "r1049",
      "r1053"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r112",
      "r113",
      "r177",
      "r444",
      "r445",
      "r446",
      "r493",
      "r494",
      "r498",
      "r499",
      "r501",
      "r509",
      "r630",
      "r631",
      "r634",
      "r1053"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r67",
      "r69",
      "r70",
      "r107",
      "r112",
      "r113",
      "r177",
      "r315",
      "r318",
      "r444",
      "r445",
      "r493",
      "r494",
      "r498",
      "r499",
      "r501",
      "r509",
      "r541",
      "r549",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r624",
      "r654",
      "r690",
      "r1019",
      "r1049",
      "r1053"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/OtherRelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442",
      "r443",
      "r445",
      "r447",
      "r493",
      "r494",
      "r510",
      "r573",
      "r574",
      "r575",
      "r632",
      "r633",
      "r634",
      "r652",
      "r653"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "auth_ref": [
      "r107",
      "r114",
      "r115",
      "r251",
      "r275",
      "r446",
      "r448",
      "r473",
      "r537",
      "r691",
      "r692",
      "r693",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1027",
      "r1028"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development costs",
        "verboseLabel": "Research and development expenses",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r688",
      "r694",
      "r695",
      "r706",
      "r1030"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r771",
      "r782",
      "r792",
      "r818"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r772",
      "r783",
      "r793",
      "r819"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r779",
      "r790",
      "r800",
      "r826"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://pharmacyte.com/role/TreasuryStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r83",
      "r289",
      "r493",
      "r494",
      "r506",
      "r547",
      "r561",
      "r563",
      "r572",
      "r608",
      "r739"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r116",
      "r117",
      "r118",
      "r120",
      "r127",
      "r129",
      "r131",
      "r212",
      "r213",
      "r231",
      "r232",
      "r233",
      "r254",
      "r286",
      "r296",
      "r304",
      "r305",
      "r307",
      "r308",
      "r354",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r396",
      "r401",
      "r439",
      "r490",
      "r535",
      "r558",
      "r560",
      "r576",
      "r945",
      "r947",
      "r1050"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r107",
      "r109",
      "r110",
      "r152",
      "r161",
      "r162",
      "r170",
      "r172",
      "r174",
      "r175",
      "r176",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r292",
      "r429",
      "r514",
      "r516",
      "r706",
      "r725",
      "r742",
      "r743",
      "r858",
      "r859",
      "r922",
      "r936"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "PMCB_SGAustraliaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SGAustraliaMember",
     "presentation": [
      "http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SG Australia [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_SGAustriaAndSubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SGAustriaAndSubsidiariesMember",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SG Austria And Subsidiaries [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction costs",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockDescriptionOfTransaction": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockDescriptionOfTransaction",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Engagement letter, description",
        "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r20",
      "r39"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate shares",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of accrued expenses",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/EarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of potentially dilutive securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/EarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of basic and diluted earnings (loss) per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r142",
      "r146"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2026",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r362",
      "r429",
      "r846",
      "r847",
      "r848",
      "r977",
      "r978",
      "r979",
      "r980"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of change in the fair value derivative liability",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, off-Balance-Sheet Risk [Table]",
        "documentation": "Disclosure of information about fair value of financial asset and liability not recognized in financial statement because of failure to meet criterion for recognition."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r536",
      "r1013"
     ]
    },
    "us-gaap_ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of activity for the notes and warrants",
        "documentation": "Tabular disclosure of other investments not readily marketable, including, but not limited to, description of investment, fair value and value as measured by quoted price."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r112",
      "r113",
      "r444",
      "r445",
      "r446",
      "r493",
      "r494",
      "r498",
      "r499",
      "r501",
      "r509",
      "r630",
      "r631",
      "r634",
      "r1053"
     ]
    },
    "us-gaap_ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of marketable equity securities",
        "documentation": "Tabular disclosure of not readily marketable securities and investments including, but not limited to, description of security or investment, fair value and value as measured by quoted price."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r353"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r34"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://pharmacyte.com/role/TreasuryStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r44",
      "r45",
      "r59",
      "r78",
      "r79",
      "r154",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r281",
      "r282",
      "r284",
      "r285",
      "r287",
      "r288",
      "r291",
      "r293",
      "r387",
      "r493",
      "r494",
      "r504",
      "r505",
      "r568",
      "r569",
      "r570",
      "r571",
      "r845",
      "r898",
      "r900",
      "r946"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of warrant activity",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "PMCB_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12bTitle",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12gTitle",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r173",
      "r175",
      "r704",
      "r705",
      "r708"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets",
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r863",
      "r873",
      "r875",
      "r876",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r1033",
      "r1034",
      "r1036",
      "r1037"
     ]
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets",
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r863",
      "r873",
      "r875",
      "r876",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r1033",
      "r1034",
      "r1036",
      "r1037"
     ]
    },
    "PMCB_SeriesBPreferredStockRedeemedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SeriesBPreferredStockRedeemedShares",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B preferred stock redemption, shares"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_SeriesBPreferredStockRedemption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SeriesBPreferredStockRedemption",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B preferred stock subject to redemption"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_SeriesBPreferredStockSubjectToRedemption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SeriesBPreferredStockSubjectToRedemption",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B preferred stock redemption"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_SeriesBPreferredStockSubjectToRedemptionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SeriesBPreferredStockSubjectToRedemptionShares",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B preferred stock subject to redemption, shares"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_SeriesBPreferredWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SeriesBPreferredWarrantsMember",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_SeriesBWarrantsAndSettlementWarrantsAdjustedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SeriesBWarrantsAndSettlementWarrantsAdjustedMember",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants And Settlement Warrants Adjusted [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_SeriesCPlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SeriesCPlacementAgentWarrantsMember",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_SeriesCPreferredStockAccretion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SeriesCPreferredStockAccretion",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred stock accretion"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_SeriesCPreferredStockDividendSubjectToSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SeriesCPreferredStockDividendSubjectToSettlement",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C preferred stock dividend subject to settlement"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_SeriesCPreferredStockDividendsAccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SeriesCPreferredStockDividendsAccrual",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C preferred stock dividends accrual"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets",
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r863",
      "r873",
      "r875",
      "r876",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r1033",
      "r1034",
      "r1036",
      "r1037"
     ]
    },
    "PMCB_SeriesCPreferredStockRedeemed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SeriesCPreferredStockRedeemed",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C preferred stock redeemed"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_SeriesCPreferredStockRedeemedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SeriesCPreferredStockRedeemedShares",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C preferred stock redeemed, shares"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_SeriesCPreferredStockSubjectToSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SeriesCPreferredStockSubjectToSettlement",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C preferred stock subject to settlement"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_SeriesCPreferredWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SeriesCPreferredWarrantsMember",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_SeriesCPrivatePlacementAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SeriesCPrivatePlacementAgreementMember",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Private Placement Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_SeriesCPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SeriesCPurchaseAgreementMember",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_SeriesCWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SeriesCWarrantsMember",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesGPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SeriesGPreferredStockMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series G Preferred Stock [Member]",
        "documentation": "Series G preferred stock."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r863",
      "r873",
      "r875",
      "r876",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r1033",
      "r1034",
      "r1036",
      "r1037"
     ]
    },
    "PMCB_SeriesGWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SeriesGWarrantsMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series G Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesHPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SeriesHPreferredStockMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series H Preferred Stock [Member]",
        "documentation": "Series H preferred stock."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r863",
      "r873",
      "r875",
      "r876",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r1033",
      "r1034",
      "r1036",
      "r1037"
     ]
    },
    "PMCB_SettlementAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SettlementAgreementMember",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_SettlementOfAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SettlementOfAccruedInterest",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement of accrued interest"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_SettlementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "SettlementWarrantsMember",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative",
      "http://pharmacyte.com/role/TreasuryStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued for compensation - RSUs",
        "verboseLabel": "Stock-based compensation",
        "terseLabel": "Stock issued for compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price warrants issued",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://pharmacyte.com/role/TreasuryStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value per share",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r353"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares authorized for grant",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price per share, exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options, expired and forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price per share, expired and forfeited",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, issued",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r876",
      "r877",
      "r943",
      "r944",
      "r956"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase number of shares",
        "documentation": "The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options outstanding, beginning",
        "periodEndLabel": "Number of options outstanding, ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price per share, beginning",
        "periodEndLabel": "Weighted average exercise price per share, ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative",
      "http://pharmacyte.com/role/TreasuryStockDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price per share, issued",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual term",
        "documentation": "Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average remaining contractual term, exercisable",
        "documentation": "Weighted-average contractual term remaining for exercisable stock option, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r939",
      "r945",
      "r947"
     ]
    },
    "PMCB_ShortTermWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "ShortTermWarrantMember",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short Term Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets",
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesGPreferredStockAndPreferredStockWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-SeriesHPreferredStockAndPreferredStockWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables",
      "http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative",
      "http://pharmacyte.com/role/TreasuryStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r59",
      "r60",
      "r73",
      "r74",
      "r75",
      "r77",
      "r78",
      "r79",
      "r107",
      "r110",
      "r137",
      "r138",
      "r142",
      "r146",
      "r154",
      "r155",
      "r211",
      "r242",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r257",
      "r258",
      "r260",
      "r261",
      "r263",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r429",
      "r493",
      "r494",
      "r503",
      "r504",
      "r505",
      "r535",
      "r568",
      "r569",
      "r570",
      "r571",
      "r576",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r607",
      "r627",
      "r649",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r845",
      "r900",
      "r901",
      "r908",
      "r946",
      "r948"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r59",
      "r78",
      "r79",
      "r93",
      "r94",
      "r95",
      "r116",
      "r117",
      "r118",
      "r120",
      "r127",
      "r129",
      "r131",
      "r153",
      "r212",
      "r213",
      "r231",
      "r232",
      "r233",
      "r254",
      "r281",
      "r286",
      "r287",
      "r288",
      "r291",
      "r293",
      "r296",
      "r304",
      "r305",
      "r307",
      "r308",
      "r354",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r432",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r490",
      "r493",
      "r494",
      "r504",
      "r505",
      "r535",
      "r551",
      "r558",
      "r559",
      "r560",
      "r576",
      "r649",
      "r948"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementLineItems",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets",
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r62",
      "r63",
      "r67",
      "r69",
      "r70",
      "r73",
      "r77",
      "r78",
      "r79",
      "r83",
      "r116",
      "r117",
      "r118",
      "r153",
      "r257",
      "r258",
      "r260",
      "r263",
      "r269",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r295",
      "r296",
      "r303",
      "r439",
      "r491",
      "r493",
      "r494",
      "r503",
      "r504",
      "r505",
      "r567",
      "r577",
      "r588",
      "r598",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r607",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r628",
      "r629",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r649",
      "r690",
      "r696",
      "r697",
      "r747",
      "r1049"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionLocationBalanceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfFinancialPositionLocationBalanceAxis",
     "presentation": [
      "http://pharmacyte.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Location, Statement of Financial Position, Balance [Axis]",
        "documentation": "Information by location in statement of financial position line item where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r428",
      "r726",
      "r727",
      "r1043",
      "r1044"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementTable",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets",
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r59",
      "r60",
      "r62",
      "r63",
      "r67",
      "r69",
      "r70",
      "r73",
      "r77",
      "r78",
      "r79",
      "r83",
      "r116",
      "r117",
      "r118",
      "r153",
      "r177",
      "r257",
      "r258",
      "r260",
      "r263",
      "r269",
      "r281",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r295",
      "r296",
      "r303",
      "r439",
      "r491",
      "r493",
      "r494",
      "r503",
      "r504",
      "r505",
      "r535",
      "r567",
      "r577",
      "r588",
      "r598",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r607",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r628",
      "r629",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r649",
      "r690",
      "r696",
      "r697",
      "r747",
      "r1049"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r774",
      "r785",
      "r795",
      "r821"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued new, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r649",
      "r683",
      "r862",
      "r876",
      "r877",
      "r939",
      "r943",
      "r944",
      "r945",
      "r947",
      "r1033",
      "r1034",
      "r1037",
      "r1038"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://pharmacyte.com/role/TreasuryStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r876",
      "r877",
      "r939",
      "r943",
      "r944",
      "r945",
      "r947"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued for warrant exercises, shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r862",
      "r876",
      "r877",
      "r939",
      "r943",
      "r944",
      "r945",
      "r947",
      "r1033",
      "r1034",
      "r1037",
      "r1038"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/TreasuryStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted units valued",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r876",
      "r877",
      "r939",
      "r943",
      "r944",
      "r945",
      "r947",
      "r1033",
      "r1034",
      "r1037",
      "r1038"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued for warrant exercises",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r876",
      "r877",
      "r939",
      "r943",
      "r944",
      "r945",
      "r947",
      "r1033",
      "r1034",
      "r1037",
      "r1038"
     ]
    },
    "PMCB_StockIssuedUponVestingOfRestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "StockIssuedUponVestingOfRestrictedStockUnits",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued upon vesting of restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_StockIssuedUponVestingOfRestrictedStockUnitsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "StockIssuedUponVestingOfRestrictedStockUnitsShares",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued upon vesting of restricted stock units, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockOptionMember",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-OptionActivity",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of common stock, shares",
        "label": "Stock Repurchased During Period, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r649",
      "r685",
      "r862",
      "r876",
      "r877",
      "r939",
      "r943",
      "r944",
      "r945",
      "r947",
      "r1033",
      "r1034",
      "r1037",
      "r1038"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of common stock",
        "label": "Stock Repurchased During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r649",
      "r685",
      "r753",
      "r862",
      "r876",
      "r877",
      "r939",
      "r943",
      "r944",
      "r945",
      "r947",
      "r1033",
      "r1034",
      "r1037",
      "r1038"
     ]
    },
    "PMCB_StockbasedCompensationOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "StockbasedCompensationOptions",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation - options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets",
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r609",
      "r625",
      "r650",
      "r651",
      "r739",
      "r754",
      "r880",
      "r898",
      "r901",
      "r902",
      "r922",
      "r1017",
      "r1050"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders equity, reverse stock split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r298",
      "r299"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_TemporaryEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TemporaryEquityAbstract",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "PMCB_TotalTemporaryEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible preferred stock",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r73",
      "r77",
      "r242",
      "r244",
      "r245",
      "r246",
      "r249",
      "r250",
      "r257",
      "r258",
      "r260",
      "r264",
      "r292",
      "r355",
      "r356",
      "r493",
      "r494",
      "r503",
      "r545"
     ]
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity liquidation preference",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r503",
      "r863",
      "r874"
     ]
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, par value",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r874",
      "r1033",
      "r1034",
      "r1036"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, shares authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r73",
      "r260",
      "r493",
      "r494",
      "r503"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, shares issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r73",
      "r260",
      "r493",
      "r494",
      "r503"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, shares outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r73",
      "r260",
      "r493",
      "r494",
      "r503"
     ]
    },
    "us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TemporaryEquityValueExcludingAdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary equity, face value",
        "documentation": "Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r874",
      "r1033",
      "r1034",
      "r1036"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "PMCB_TotalTemporaryEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "TotalTemporaryEquity",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total temporary equity",
        "label": "TotalTemporaryEquity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TradingSecuritiesAndCertainTradingAssetsTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVESTMENT IN DEBT AND EQUITY SECURITIES",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "TradingSymbol",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TransactionDomain",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r466",
      "r467",
      "r468",
      "r469",
      "r740",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_TransactionTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TransactionTypeAxis",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-MarketableSecurities",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Type [Axis]",
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r459",
      "r466",
      "r467",
      "r468",
      "r469",
      "r740",
      "r1022",
      "r1023",
      "r1024",
      "r1025"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfDerivativeLiability",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r253",
      "r280",
      "r387",
      "r425",
      "r428",
      "r430",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r471",
      "r472",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r536",
      "r552",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r741",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r918",
      "r919",
      "r920",
      "r921",
      "r1004",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1013",
      "r1014"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity",
      "http://pharmacyte.com/role/TreasuryStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r505",
      "r948"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfChangesInTemporaryEquityAndStockholdersEquity",
      "http://pharmacyte.com/role/TreasuryStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury stock, common shares",
        "negatedPeriodStartLabel": "Beginning balance, shares",
        "negatedPeriodEndLabel": "Ending balance, shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r1033",
      "r1034",
      "r1038"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets",
      "http://pharmacyte.com/role/TreasuryStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, at cost, 15,270,066 and 14,876,316 shares as of January 31, 2026, and April 30, 2025, respectively.",
        "label": "Treasury stock, value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r877",
      "r944",
      "r1033",
      "r1034",
      "r1038"
     ]
    },
    "us-gaap_TreasuryStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TreasuryStockTextBlock",
     "presentation": [
      "http://pharmacyte.com/role/TreasuryStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "TREASURY STOCK",
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative",
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Undistributed income (loss) available to common stockholders",
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r143",
      "r144",
      "r256"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2026",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://pharmacyte.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates in the Preparation of Financial Statements",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r156",
      "r157",
      "r158",
      "r159",
      "r514",
      "r516",
      "r700"
     ]
    },
    "PMCB_VinDeBonaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "VinDeBonaMember",
     "presentation": [
      "http://pharmacyte.com/role/OtherRelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vin De Bona [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_WarrantAssetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "WarrantAssetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant asset \u2013 QCLS - current"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_WarrantAssetFemasys": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "WarrantAssetFemasys",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetails-FemasysNoteAndWarrants",
      "http://pharmacyte.com/role/InvestmentInDebtAndEquitySecuritiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant asset \u2013 Femasys",
        "periodStartLabel": "Investment, beginning balance",
        "periodEndLabel": "Investment, ending balance",
        "verboseLabel": "Warrant asset - Femasys"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_WarrantAssetFemasysMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "WarrantAssetFemasysMember",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Asset Femasys [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_WarrantAssetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "WarrantAssetNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant asset \u2013 QCLS \u2013 non current"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_WarrantAssetQCLSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "WarrantAssetQCLSMember",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValuesOfFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Asset QCLS [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_WarrantExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "WarrantExercised",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrants exercised",
        "label": "WarrantExercised"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_WarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "WarrantExercises",
     "crdr": "credit",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercises"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_WarrantLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "WarrantLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_OtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_WarrantLiabilityFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "WarrantLiabilityFairValue",
     "crdr": "debit",
     "presentation": [
      "http://pharmacyte.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrant"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_WarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "WarrantLiabilityMember",
     "presentation": [
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-ChangesInFairValueOfWarrantLiability",
      "http://pharmacyte.com/role/FairValueMeasurementsDetails-FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WarrantMember",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r744",
      "r745",
      "r748",
      "r749",
      "r750",
      "r751"
     ]
    },
    "PMCB_WarrantsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "WarrantsExercisable",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_WarrantsExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "WarrantsExpired",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrants expired",
        "label": "WarrantsExpired"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_WarrantsIssuedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "WarrantsIssuedShares",
     "presentation": [
      "http://pharmacyte.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants issued",
        "label": "Warrants issued shares"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "WarrantsMember",
     "presentation": [
      "http://pharmacyte.com/role/EarningsPerShareDetails-DilutedShares",
      "http://pharmacyte.com/role/LiquidityAndOtherUncertaintiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_WeightedAverageExercisePriceWarrantsExercisable": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "WeightedAverageExercisePriceWarrantsExercisable",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price warrants exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_WeightedAverageExercisePriceWarrantsExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "WeightedAverageExercisePriceWarrantsExercised",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "PMCB_WeightedAverageExercisePriceWarrantsExpired": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://pharmacyte.com/20260131",
     "localname": "WeightedAverageExercisePriceWarrantsExpired",
     "presentation": [
      "http://pharmacyte.com/role/StockOptionsAndWarrantsDetails-WarrantActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price warrants Expired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding diluted",
        "verboseLabel": "Weighted average shares outstanding used in diluted earnings per share",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r146"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://pharmacyte.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://pharmacyte.com/role/EarningsPerShareDetails-PerShareCalculation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding basic",
        "verboseLabel": "Weighted average shares outstanding used in basic earnings per share",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r146"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://pharmacyte.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-8"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.4-03(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-13"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-7"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "65",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-65"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "66",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-66"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-12"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-20"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482645/405-30-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481679/480-10-45-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480125/505-10-S35-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-8"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-6"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 5.Q.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-7"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481468/505-20-05-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505-30/tableOfContent"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481108/505-30-30-6"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479772/718-30-S55-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "45",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480865/815-45-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480088/860-10-S50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(cc)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480031/860-30-S50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-5"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7)(e)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7)(e)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(ff)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(fff)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "108",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481296/860-20-55-108"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/321/tableOfContent"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "325",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/325/tableOfContent"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-13"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483049/450-30-50-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-8"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-8"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479035/940-320-45-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.9-06)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "810",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477383/970-810-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001683168-26-001917-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-26-001917-xbrl.zip
M4$L#!!0    ( #=^<5QL$]B-F0<  -$C   5    <&AA<FUA8WET95]E>#,Q
M,#$N:'1M[5KO;^*X%OV.Q/]@(>VHE6@I[?2M7LM6"I#9LF(I"^G3S$>3.,5O
MDIBQ$QC>7__.M<./G=(=.J_,CM37#Y0XU[['OL?G7B>T;H/?^S?52NO6][KX
MS^BO%?2"OG_3:KC_N-LH;[?:=]T/;!Q\Z/N_U&*5Y5>L>3;+62!38=A +-A(
MI3RKNX8Z&PLMXQHZHNOPN?VN6<KU@\RN&)F>U6Y:[1O__6VOW0O81?.TV6JT
M@7'X,J-?LUQ\SD]X(A_0]._"Y#)>6I=OLHF971_062BR7&CKJ^./@MZ[7L<+
M>G<#=O>.#4>]0:<W]/K,?^]W[H/>OWPTP\(??1]$P_O1^-X;!"RX8Z/[OC]F
MS0OOI/GVR#MFWJ#+FI?=D^8E7=T/NOZH6@EN?38&U%$OZ,':?]^Y]0:_^LSK
M!#2AYC\OWGX?Y-Z8>=V[8>!WV?8D@,TN[L79.>&Q<+U1VQOXXY.[]WW_0[52
M0CT_.SO_/E /3K$UGWMU]ILRTX*SP2D;RV0NM!TI%)H,6#[E^=6A0:RF>T@O
M9:/,(D&#GIU>RJQVTSQUOO?Y[%4K4SX73(NY% L186T$^Z/@&E%+EFPD9DKG
M3&7LG=(I4)_\P53,AE..%>TL<\':4N4BG-99+PM/V=&;)/I4J&O7[XVV%\>,
M9Q&3N6&FF!@92:XEYATK;;W-,%L552L"LXC8;SR#]R6TKPYNGO_C;UG!OR]V
MY\^(79L;@75#<-(E^YBI12*B!U''HDJSBERD@#)3.0L!G<L,H5BR(LMU(9C)
M>2Y2>*>0<D!&S"5/6,Q#-&FF4IFS7#F[1P:9"(4Q%"J8I/RCJ%8HFNM!#1HC
MH(%/S'MJG9!!*'58I##+T!]0(J'98BK#*=A!'YO^"Z%%.0C-()4F$3R2V0-;
MR'P*RIJ9""W"#8TP3^QV6I;)<GLA7AF-+EZ$1H+%,D.<*.:;N-3M=E:XK;?N
MRPS[&0R1&$=F85+09D;LMV)0!W$DJ<H,H2/:$1V39,.K,J+&,6DS-K@;21JY
M3B9% FZ 3 H1M_Z,!11R,V5QHA9FQ30M'J3)-8<G3HT..&#6MPAC5F@>P7UE
ME'G[#,H$4^SVS?*^T89TWI2D*-,L;505QQ*7=N%[C&MA8XR0R4DB; 80(-8D
MD69*YF260J5(J>@ZDB9,E"G0C_1+J\3%>J95*"(T@RI'B&TD0!870/]S..79
M@V >I&%4),(XR,T+3B6<.':7-$KS,G)-98*B2B5S="-7C)1DBX7:LH)@/>$2
M-=5.G_%CGS%\KO+?-DUA0>GXP,7)CT:](WZ\/_>ZPF!$4BR;+[Y.D3KELI 7
M4#FV9Q?**1.!&#M79992A<8 D(VY-%:,8"4R&H<$B^<;(=L60RT2;EE3YJE-
MN.NE4-)-JHX QJA$1CRW2#>E$@Q=-K7RG-%(A6%(<':_&9L.K78I(ZB.RB&6
MU&N&,DZ&1<))=#$QBV*3*M'%)=[M@@'?)H(,(8OH+Z)7)H-'DV_GXMX*\HB2
M^VO/7LP$'Q71>2XC(APW*N,DN-R K51X$0NYCE:$ $<EG\A$YDM*GKO\T@:Q
MW+&T<-3^D^E6X69U_;.;4;4R*_0,Q#0VW8>ATI%%8&NX!Y$AB2>@)^Z(&1&?
M3%"@.@IB@\@9]/2UD3!\!@G].4\*T@Q7-HDX1@TEYUA9LZ,46N?J/5307>ZN
MCBSGT!$"9EP--E%%3LZ@0+L@["/4?&TMJ,2,=Q3V[,]U/9M0]4H'5+N/A%L+
M +JN5C#Z*Z--]!SM<O$@VGP163HBED64O;.3/L]0+$J-*@P+3>';2D./1ZU6
M4F5RW*#'1AC,A!CIDWL:P8Z>0!*#B9"2+ZQ+Y#@5"'N\I9-O5JR!'3M84V[6
M69M$R!)71!!02!A69*V=2QQB/XJD/.Q^T:'^/R_2-7MU9+T\_'G#/MF*5CRO
M;[2"M&N;:1O9(*Y\)6J$9)W''Q5U:VP<A5VNM%EG3MN ,=-4YKD0?R'-;87<
M3/>[$@#M($?@(X30D-+B/Y67\%\J_J="8@)VRQ19:(_$Q_\_0CS]Z24((A50
M$FRA<Q<=YD(I$-XRZZTK^87@'RF+N?+%YC%;>MGG8ZL'$'N09DL/7<WMSL(K
M=:E6-O+"(_0T8JTN3Q*L+-C0!2Q!655WN=1@-4V18B7E?X2=C?.]^V'-*U2>
M9Y7X7H;@Q!J;MX[("2LXB+U](%F2I.YRB<SF*ID+2B@9?R@?K.I2HT0Z2]12
MX.YBJIPP<;9-05!FGW1;K7R-7Z<_0# #K]WW6<?O]\=#K],;_/I+[:QFKX=>
MM[NZ?C:ZA8SR*9F>_73-)F"\T">A2A(^,^**K;[5[!O>5C!:.9A3?D!ML)I)
MKF:U\BUP*^BNK,K!+W_^Z:FWI._N!L$VZ).8IS)97GT-MK4UV(QNEK6;+E7K
M5^QWKB$$S9_=BXY6@\:G]]'=)\&='QY;>WFU#Y*WS<-#:=W?-$QCUZN\_;?O
MMWVV&O<WVZN C]&WL>HO7PWN6M^7Z?!R01CP%-]WQ.!'7Y_5MP.]W@UDGF!A
M.E,I8N9_%F%!!UYVYPI0IX2']'\T= ]'(/V/O!^3^R\"T[":?/-2/U$YP,O\
M)\:U8S?H)SGN-SKT4Y[_ E!+ P04    "  W?G%<QZBZQI\'  #+(P  %0
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MZOJCH'_5[WI!_W; ;J_8<-0?=/M#[X9=]0<>3G%V>X46_NC[(!K>C^[NO4'
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M]]:O3$H$AP3AB^ TK"JW]_?%>S\_'WG"KK7=H!_CN%_GT(]X_@)02P,$%
M  @ -WYQ7*27"F&#!   3Q$  !4   !P:&%R;6%C>71E7V5X,S(P,2YH=&W=
M6%UOVD@4?4?B/UPA-2*2^0I-VH*+9,#94%&@V$C-XV"/X]DU,\[,.(3]]7O'
MQFR:-+O;58BVFP>PN5_GGKGC.;%]Y7^>#JH5^\IUQO@-YL_V)_[4'=BMXANM
MK;W9'L['U^#YUU/W8RT27/>@TTXU^&Q#%<SH%I9B0[A5_&"!1R6+:AB(H8L?
MC>O#AL@;QGM@7-M]T/1>-TC";O"G7S.E6;2K#>SAP/UZ-1E.?.B>-3MV:XC
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M%?S&Q3:FP9H:?$1W3[TLQ0"<MHJ']'Q.B<2UB7>PH$B<AE#(; UN<P-07(L
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M,/C.YL@$8R*Z,_B.^8@3@L5@4O$?S(!YX$$6#U_1"(:!)S)(^"I%-J$@NKW
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MW+4T*(ONK>#+-$N3CEB[PV5\J6%ITA1=6^/+[$J3GHB*&U\F5JJ 2ZS#=],
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M&7_]!&Y:(CJN^ L@L(,LL='!5\& F;:ED7(LB[W2NRJ;?;A,0O_4_H[5%WF
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MVXJ?!DHR%"C9#C@R&BA)F3D2+;TA-E"2>B%VA,FG@9(#F7P:*"$Z4+(U.-!
MR>X#)5N?;!HH(2]0LG40T+4R"6OE[<L^72MG9JV\#7#0 @-REX/I)DU$F'RZ
M'#R0R:?+0=*7@]N! UT.$K$<W.YDT^4@D<O![8* [IN3LV^^]<FGL0!"8@%;
M5OPT%I"E6,!6P)')??,M,(<6&) ;*$D]:8(6&) ;*-GNY-- ">&!DBW!@09*
M2 B4;'FR::"$Q$#)ED%  R4D!4JV//DT4$)&H&3;BI\&2C(4*-D..#(:*$F+
M.2L'I]#FE82%3,Q-#X99:N.1YJD[M/DE82&7#(.'AFS("]ED$4XTY+.CD$^6
MP4)#1H2$C+(,(AIRVG'(*<O@H2&KG86LL@P;&O(B/.2507!E)V26">:6ILRE
MN4E$!]I*\<&S$*7=,7AHH(V")Q)X:*"-_$!;%N!$ VV$!-JR!!8::",TT)8E
M$-% &V&!MBR!AP;:B FT90DV--"6L4!;!L"5W4 ;B<SE.(>Y* A( VWD!MKL
M>8H%'G=&"0$/#;11\$0"#PVT$1]HRP2<:*"-C$!;IL!" VUD!MHR!2(::",K
MT)8I\-! &RF!MDS!A@;:LA5H(Q!<TBRCC7;.)CD6)"7(V)/2SMB+!1X:"Z+@
MB00>&@LB/!:4$3C16! )L:",@87&@DB,!64,1#061%(L*&/@H;$@,F)!&8,-
MC05E*1:4#7!E-.F*5.:6ILREU8U$!]IB9^Q):6?LQ0(/#;11\$0"#PVTD1]H
MRP*<:*"-D$!;EL!" VV$!MJR!"(::",LT)8E\-! &S&!MBS!A@;:,A9HRP"X
MLAMH(Y&YTW3) JUN)#K0%C\=LI!^.F0,\-! &P5/)/#00!OQ@;9,P(D&VL@(
MM&4*+#301F:@+5,@HH$VL@)MF0(/#;21$FC+%&QHH"U;@3:2P#4[V))&@(B*
M "T<W+DP^6F<:DHC.$1%<'8X^30"0UX$9A=PH!&4'450=CG9- )"2 1DER"@
M$8P=1S!V.?DT K&S",1.%3^-() =0=@!.+*3:K--YM!4&7(#)04")I\&2@YD
M\FF@A.A R=;@0 ,ENP^4;'VR::"$O$#)UD% U\HDK)6W+_MTK9R9M7)ZX/ I
M4(&?/#"Y,=07R)>;@=RS&>D0//O9=9D7_>@]P,VX:ZJ**AN3MCP S4>;K$7,
M^#,F%"")T%L=R*;I.XHU_-]A9DB2*B$;=JEFAD3!M;LJVJ/U#^E(ME=@1*RU
MEC"X>RU+<4?55IXMYP5VJI=^5*_:CLJ_K.K:"S LM3L >V=]0[1%="[L3I.@
M64M5DY1GFH0")!L 6=8VY03:Q@LK_+G9 LKIY839)W$*JW,PE,V)>3,V>GW9
M!)4G ^R)G>I O\.4>R@*U)F,@ =$ZVG>&7#<.8H%''<VTS-3%"X$P<5CB)8F
M'K\ALB,3?'EU7\EE1T.W]B",%#KK<S)WIA?<F8BE%U(O]@F#1W:A81K6<54?
M0XJ-$>3TI"$/?7!!,1&Z >UR:J_V'4/UQ?[O.(:UR* N C$>)5F5?&$GQU/@
M$ ,<P@^XI!J'5. D.;!A"QK'<QH&!0Z1P!&3G?2Q"X>6PF77P8_44VH@LD1/
M[)U./"$3[\Y+>A,?2^*7KG+V)2K[DV&0&CCB#")L1V@=\P]+/=&([)XH(?_I
M/2"]0H04IS?-$2-H5)X/.DX6%NZ@\#CHH$:8]J#F@FJ1"%J$PH1JDREVX;_3
M3\E6P(>UU4O0ZI>PENH\&PO=+N12WG*TT2U2=%-T;[@O&A/=8MKH3JB[*7JI
M6DRD%BEP#EWC+&RHTXTR0H&3:$-=3*<,9>WV6G;106JN\)8[#*R-,-#9357.
MR0HGN')N*Q]^9A;:H#<V5$L%82LM5-[G?K/8A^)BWPH=D1%I/E901.K)9H0'
M6*'LPK(("T'W?"JVM>1;['SA.^,[TJ$NG-/;\<4@+^XW5[KVU '&T UV4D')
MJJ"X\N'.8]-HJ4]]+^V^$TWE(TP^VGW=L*B '(" ^,_TWDF(=TG.E;'("I4&
M,J0AU=  %Z]X= G J?3#\4:2J NTGYC>5Q=H"]F" 8V!J(+/K#"D&!,BJ 61
M?\,SJN#W$]-[K.!3ZOR&73[H&O=0!(2H-6[J$K*TOT0=G\S*0-:V.K&M42D
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MJ]EZYGZ+(K%B&//\1IK70G%.<;YW^ARS7[9T0B_- "#8#TOA %^Z][]?<GI
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M :4#C&'V4;A,W6IKRW#Z#Q4)4#Q[X$X?R)8ZL!M$'AX8?%FP[WAP3=,R+UI
M 4,[K>T&?JN.]UH[V 8B(@<.% _7LO$,X$<+&,"T6M"0'QP@@EBP[X@(LA@M
MU7P^AU[4H8 BZ(I@/APJ,J9>U9GZ@J9).51D!/-A[Y 1L;U ]6#K-'TII^E
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M/\\/4$<?G7100)71'YDJDF7-@OB03[Y^1L^ _XQ., SI"X.41%X>J$_PJQY
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M)WX)3S_&L@'Y.IBTP$@W+']HW3?UB7G:N7ZT'A-CZU$WAK+U[Y'Z9AUW=7T
MH'=CC,$2Z(I^H%L:(Y+'<E$L? F$H/N/I<1B^A16P;>52^E.UH_;2JM3:UW=
M,ZW:3;/586YN6^W;2J/#=)H,U)$=J @93F":+8:3_E$^,LUSIG-98SSJ<Z8Z
M*]4.^IDK"Z*7(?#_&8XEM(7F!(>MPZH>CT[.=8.Q^H#Y.YUVQO%Z&: I0%G1
MD+4E1-_8%]><'%Y_/#>+E;^66?IS_X?#@F<%]<:%]_45>3*!W@[0EF!=\H/U
MPD"/3K[)&B1XP@A<CD$O"D1WFLK5"V7[ @7T=.CXPL76,3.&_(?>E 8'JQO;
M&,X"L+*MY-/4Z<L2T(&K;5-%<[9.J?>NQM90X9Z_U8LXE?JC/#"7M7K9UY58
M&J6KUL6-U'I$+8YS-CJM2J-=MU5SAK2V*W"JAB)"\+M/DJJEILFMV51/5?DC
M!!7S,/L?8^F>O[+NRZ/>YZJ) E3,HPIUEC:VPU:1E>NR?$NN?-?LR-(Y?&1C
M[%1%^<GUY*)1^_U=Z6F@BV4AP+->Z5T> XHR<GF1+93+87*[JTGE<:T[@O2N
MPY,6>%)-A'2K ;D5X$C7?[P]2;?%N\X S]QPJW.S.(ZCDYO+2NNZ4KWOU)C3
M>K-3JU[FF'JC^FE7"[A_:F]P]/:P4<3#F V7D4W&'($>BD\KC HY;9E,KV\[
M@1^IGV&/V-)'@4Z&A)X<ZM5MYGFL"D%Y00CJ&M1H(U>IV6=&5%&&MC&IZDJ
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MZK5VCNG4KF^:K4KKGJG]N*UW[IE*XXQI=YK5[Y?-J[-:JVUO9!6_V -Q+J&
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M1LUA7IU',5=@B[ERL%"F[S1X*RX]/E33Z@,#:5<#](%F0NFN:U I@BO=-!O
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M8^9&?H+"TH:K8G3@TS$C,/F\*]B*^C)]K_.TO*6/CID"@I#[Q118!5N";#!
MO@X&+O!L$*._(71ZT[\CKCG<WZ$I'\@C$XYL^ND+\ZHJ5A^Q@?WO%\:#5L07
M-(Q QQJ.WQ?]<XEQ'RT(_YUC;U&FIE>(__6'DY>Y4[9^83J3$1Q@Q8!:I/>%
M:4#=XK"^H2-^"]Z;/D_O0K\$O5WXKZ^&\PX9R>A40+]^AI.Y.JU= \C/^2Z
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M@_&UYMX&N<T1,&1T1F/M;80"U^;"<4GRZ/+[MQ>S\JW^E%YSL87!S\;# '=
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MK-Y"NNA_5,>W\H^;+$C1-NNBT,(9%:^<!CEEUO2$/KE)$:"#9"M%@'(F*$6
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MK?3"EM'F9JZNX>M5MLXE#BEIM=:NZSSRE*MU!G^;F$U!Q1Y9[RM'G&P&2K?
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M=_!9>-G(U@X1XP] S.\,O)?5+?I,4/&X&<+$BDLBA\>,KBC.^ 9#Q[&!&\L
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M#""1V1B9TL3RI(B\'A%CK$[Q'BM^$!XT;]CB0HSJQ/G@S&T\]!/[*.5E"ED
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M#!)T0P^5U<^!JQ(IAT ?A18=S%]NL8?$3-71W^2.GN5B7,2&LVYYUYS4<PY
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M-49^ <\RQG,3E1<4606J90=N@^YHAPOV:M;75&OLC'B,6Z@)<VEGBH5'V@#
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M+,\3>SG:Q=GQ'[!OTA\)%F.-D5H=08D62GZA$T(P<_;N CBG&"B!=\\8L1T
MH^_8>BA-0];V'=/VJOBT\#!J-N8T#"\C?!D<6X>UU_;O=15W^QRT,<A!+A_6
MG/L&S@7],^MSMS4;+:2O2NCF.@LU]+I3-8:_OO8*X.H;(V^2>+H8TK[$=?ZU
M^#K_ZCM^7:4_YOX*X8[7$RYPV?_Z9^OX9J0WQ=/1EDB&[)AX)'!+)&LF)!FW
M<G>MSE:;L1?86!=%1/X2PW50'HB$6)F#CCTJ-J[ ]$K8R.DXV;4S:>%4&6#_
MVU4P.H;"&?1GC/=V#'/J3(_V3E].NV>=T,$+C/'V0P$\-V1)7\,'6A ]Z.%Z
M-F,X/'+"RR-KK* U(ZI"9FOZ1S@R6K'JE+ZY$TH@2T2/06&"X]^!&4 ?9&<,
M!X[S?@4J3<YWW:^-E<%HN?(TO%9HFFOCQKD  %:<(E.\/6>]C&2'2AZ0Z;)G
MY,T:='!4O&,Z8T9P4XR?M]W#00*FXJMR@:\2N#?,)41W<N.Y\C\DVG"O*HJN
M-NDNII+9//![%&]:)) @9'/>_ X:##K%"GYW+-43$O08PYDXB8/8 +L(*RJ8
M%0;I[W%(H4656PXM/AK& &IL47APAN1!'T$LUL:AXNOQ1? N8O*']!8U71!_
MW_]^-D^+ CVC2ZRN?GV=_7JL5R^^UN#"J+M*ABSSH(*+R,)L5RN=@B9W^R0K
MJ$@VSG&(VBW_&>L?*1J&NXHH,8;9YLH'4%X3XUFL5]X]@:.A!2!D815V!N;!
M<W 9AHI^K9I.]PZ_$W3%CGH_GM/D'#%Y)P38/BD2TGN<Q2FZ.X<'#GC 5"/-
M.2)1E/\N)^MR:UC\9R$G9>+ADLA>&,^5OF$\DK^0;9!UJ'!;$YD5;#J@6YR.
M/ JY"V]9T*<8+40F<5V75-SCE[K^Y>SZYO^3)M,/7=_)6-YYBNTT+R-G0N1)
M4'\Q4@HU0+L]I_4.J!F_KA:JY' 3.HLY-J 7G>>>V[?'+N7\3G7(2H\<\Q.H
M]%Z1<)SSRJ;:AXP;9C,>X3[T[@!9K!6^F+@UWL@KAA[N:P YWJKX[_$._>!$
MD0@[]E(@[1J)J-U9U[B?'9(=.&BUH89\-%)(*9R_ K@A@K$A0\9@A5-<1GKI
MD1;ZWDP$_VML!:U!(X=TE@+P$/XLN6GAUM*Q[C$9$3[_VZM.5]%(OR2X^.YT
M^E=M3X<]Q76.34$%21Q1\<^(03D/RH6NP+RGB'RX*=?5T)/G,QAP.IOX:?8K
MWC/1]WL+?2I]&[3:/SY_VWB@57+'6>TM+F_5FPDOS<13Y8__8*W,-Q=>\M4W
ML-Z#<J619JEC#/Q9%ZYU:M]ZN4/ESI@B66M648[LVBZ?;A?!XV_L*OSZ1]9Y
MA%]_$BH/B4#XP@&ZPP(4_FN#BA-=>_>UT H9=V4U?V51//3609H36(&7DOLT
M"IZP <4DV)P"O'"D@<L+'-Z/591[(2\VKX"1"E9YPKHCZP%(+J?H8P+'!S8?
MZM,&SUM]@)/@R$Z?/*^@PL4C*UYA: "_=?I-,+=CW X5ET8[X'!, 0X9=8(+
MAJ.)[Y8'2E ?:QDZ/L-UBRJ<BG UN 'HJRM+P>;G@/0XU36AF<(&\A50G>?4
M1N"L9_G5Y.GD9B@&8>&F7ZA47?7V6''R:--IG(8+!16( T]]\JI^CPHG7O&2
M4M)W@HS@\(N"G1[+I%V%$]S@MNPJ]B2XYA!*:22/KO/*7^ /7U2;//)OOQ (
MUTC";2^35*I(@R>4J*&P")I]NS" <[;AO<I[KG/=#9]\:_-@N:-'5^<94PE.
MMM&K<&VXVV_6ETP0EW=8A0DM\84S%5I:DX;(:&/.QT.B"5WR)M*+.H';EH%B
M,J-O*>:31%J]3&<.[^"$(/A)2,MG^LIGB: 34 ]K'5:I",W#<AA@'IGX9>4U
MO2N)8=[*R*Y=3^:*<ZA[V+W_'%MQ_AUSM2*A+C;U>V: 9<&::OGMUQU-LO(>
MM)!QXV4G<15.5X&NK).S(#-*S,X:^K*!2P\!TZ"H^"GDG!6JY?&8 ^>G0B9@
M'"AC!"AH7;7/:J"/OHF](G(PMH:O^NN&ZT9(]WGR0;>]>;AH%H89D)NZ[JU\
MYP9^L-1R.X. _:F+KX("1Y&S&(N#!?#-I @':89Z0SB%$97H2+(,)9[=WH)[
M[EQ]_&++#W<;WPC.K992["UFG/*]^8T_^;08E699B%K#,:>;G[_>J?TREG@*
M<26>[=["_/[IL_DL7YVT>5KBN:423V&G+9%./IGWVL^Q^F!(>U3B>=);?.M^
MY+7VYY?1=5%5'O&Z7S@XUUSI_:",P!W<N.Z7H&FO'VTU@JT?DGR_MSC^U%%>
MFK5%^Z) <,Y9"^,MYC PMK@V-<NU$<$V#FY#9T(*T%:'.%9O\'+>FYTA21I!
M2V9<+%%S^EDZE2;MVQ^M^<7HA_6M[I5-N*,0EL+)(TN1C]27H[$Z0+'0>P:M
MI*J^]$T-R5KKC_\,7?$"-5+=X78;JEAD/=ZI@#?*>*QX'R+7K0*G1H/ J9'?
M5<:[*>W'C.[<&#PIS1F$:^-)3=XMVP%,19LX:!$ "1),Z1EI@=<[:\1U#N2F
M/AD*Y=R"CNYW0+H; )HR)8/>!K&MN<:J,@Q<3X="$"CRK$RD1[1>%SGM7'4O
M7.@T^HH2? (?CZ$H$)I>J -R;CA@.B=70&%HG_6D*L\$15$($J)8X5)-7<'=
M$Z"EEF3Y-9 N+!AJ+I&LQA,/&YR94$W@W?%SAE.3TQ)@C#>+:I402$\D#==2
MP/ EM"!C9LJ@/;@H5I-TW>WQ QY%EBQO()0[S19#A =5_0A_#9MPM/9 UQW3
MT WH#14X&WG=F@=KT=(^JK>XN7^<S@7MZ>G[5F_[&@WIX4M[?M7\WO_C/WA^
MX" BM&[F!)?E CR Y/@4BT6%S&XXK).8,_W_9^\[>Q-'U[_?\RFL>7;_FI%(
M#FZ4V7-&HB:D0 *DOD$&&W!B; :;$/CTSUW<&[:Q"<F.=%8GDX!]EZN7WT4T
MA+$;XAOFA(UI%]7^'?K+"4GF#,BDM@[=8JI,XCM.@5"EPH^?P*9<+I7U27\,
MP0+:>)@99G0X=@3_&[UGNA)Q<S\X9/,!>>_C\["FR1P)AZH99.Y-G!KA:#W
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M:Z\;W2NZ;;]1[FWR=LO_EA[>1T=_H^'!\, ;31[_SM,%)E2:Y;P9$;T$<)<
M<(RA\F7Y:BB!^.JHSI 74^!XM\*2)\O7F^M.]:+&'YI&=BJYB.P>INY*,0+P
M$&KL?]]./)%X,I1.DDB '1>\EP!P7_!;@6]0K5MZOBT?[P6'<W_H!<>P)8,N
M.$^R,9(MP+ 1<&L'' )K=!'#;>?>O'C/&+MCJ6/4FZ J7R!*7(-S$U"M.6PI
MG4,#"I57(1";C;O".A=BV?F&FW]: ;%4>]Y+%0]BU'@F\"L)$*R>$S0;1<&:
M>P+'B]+F&M4B0R:P=[Y'"]>8K>45>W=\PK<.M^V+Y]&R,IEO. CGA4\>O>"G
M#5@<^!FA?>NV!F[B>P.\0Y14RS>QS'"CZ/E'@NA M/C3+L1>'!JQX9*Z^O5K
M11B ?V<O%O?W,QM2/B^J"XG;_(1308#D,H[;ET:AG%,=^W6@<0: H8+MP _]
M[YL5BHP03XJR6W!VW/AUNE16,@_/3UF"QTU'WRFZG-?_^Q$(8UQV![8LCM6A
MSVTE9OBB?6(< 5$SZN\H",GDWWY!PK_,9YIZLER($S7I[U"/%@^%FL>F:AS?
M_WZ>/PCW[Q<3G[Q-W@9%H@_(^N;>9T ,\7#A%5^=6$[LYX3%5WSIP?^FTZ+Y
MAYFH"5Y"]Q^PZ&/3A+*OS\.\JW<0*YV-6Q>7;+>]S>/;]76?W9"A%EV85/IP
M;\Z?<#-QYYR$FQVU[I;0OLC+NNE@Y@!(&.QWUJS;I;5[/[Y?#Z'W75FC&/S0
MC-G(DRX;O*^YPJ8U&%W<!)7ZVX\M<M;,AUF^9]'MDYQ)]G=IP\!&=E*7'XG\
M.*2L][(,=<I"J@^W;]P.QJZMZ@^-RTKH:P2OK,#%1[6"R#A64'/(%U)FI<G%
MXYKOW2_>!KRO(23(O)\5%'/_&1E'<=G'%3#8"DN%Y]19J'K1O?S8[((.(ZJ%
M9(#]'WI,2X12@X]Q^@[G!ADY.A2J^DA_J+4C4YF""^0.$#ZV'VJMXAN_*) '
M\X+2S&]2Q6*YR"*GQ\'GF20ZC]H)"K EPSRC([ BP].??ER0.@N\O?^^*&SX
M&SD\3Y:5#7FPT'D JU1BQ L2Q- _RJ),R1\+-B[]M,816YF%';JEF3YCR9W[
M^JPS.BM61A]J6$;5-_'S3Y7$(8O@(NE,;$HWEK -M;?:&&Z+Y_/1^WNQT%WQ
MF0\)R10J]KK:NVP.JK6KYK\!I)8B]9)$O?V2<=0NY:S1G'[]82H$:\-I2@@E
M[X<!H0^/=W1N&N,3+*!0=_:[$+GKFBK@/D'PTT<V=OC $\REQ\WR;%F>SVAO
M7Y-][G@67=S@_XV?DK5W[( RJ&2%-Y'SK88H16[SUNF!.3YZ:(Y:,^;F_:Q4
M$P]*#XQ)#TR&])"\(G<':G'.63H!*[;=\L040FLX9M%>EFW*) Y8?;"XW='X
M S^BJ!C]4=7[@$H57(]3.*VP[@HN&[I;)%2B2D14HFS$V/;M_.'V_OQN]BZ3
MZ:$0)90N+FHI9PE+A$1(TKO(1H1L+Q[/I\5%BU%Z4GIWD9"S77>Q'SHO3;+Y
M4B58G#N, 8Q0XZZ&V@VZ2!AC.&0TAL,&K8:_;4R[6LEX=KF *RWAW!#-Z+]3
MW%^%E4<FVA\P2>SB%P^%>E] 4#[\"D>)&WBDAH=<Z8)(ET"H)]&CO&IAN/A-
MU$%X+0!)Q+LQ\NTP""DV7/=5:KXITZW-C9]/Y=E4;*#\@"WM!DE(V)A-%Y*7
M*Q2+>9HL!E(OV*PSBNL'A\4!XM+@O'DO4'@A&3)6?%2ZYT+UYN&=?9XQ@;(^
M9:PKWXN@L@2X\I,E00@56$/K[4H&$*AOPXC/0S$;PYY@?8J2(*,9@SP0"SF7
MC/%U7XJV:[=*\"S([COS&6= /%V!QX15[\:GAM7J>;"^YLH-96QR^)U[W;)^
M+"B-8Z'X[B*?:/M)%&OT)2EF_]!BA<D7BH'XE!E7TA[0KZ\KNB?A+,JV7;,3
MV!?<7 Z0MYMW,"RPJO?0JQG5T=*%8G =K45:2$:E749;\BVCC?-28%VWQ-]G
MY?%M6>93KZ*]]F/,(ZZ@I<%Q/&Y'(UH2WB_9*!6T83290NFLT0GNS!DE>9(G
M^ICRHZ+F)R(6,>Z_2N/HZMQRB:8)WN\LA/QSA/Y'6-505X?.SJD\D8?+%/@T
MGF4I[7V/41<E+.M?,!&05?85<H%5$@$/V2/#'#GW'O^1[F>:P!3V0=$(-6/"
MS8&"^;E+CGL0-G2F= A*GZ*"B+G24)B-/V?O.GMD9M4X571KJC\7<)@+@ Y&
M)D=_>$T2M8<@6GM0] ?^6<S1EN_K!1TXBF:VAZ+XQ(?7@NQ77A$S2N("NTD5
M^5-K-4;KT8W2[-B:F@V+%WO.Q@ 8>_ H27 D?NEQM*!GU!R*-^A9HO(42P;%
M0U(I'_F*-.H!5X2&0";4.=YVSNE28=KJ64@JAND/R B8'R-H?L1&@X0+3IL.
MR4)2.BR&!]__T&% #BEB1#E#H/.J1HK5BX?KAP89%%_^P#!R-+*-FJKP FN'
MAY,_H/J.&F[[['319:X>IA7I$U??#3S07I[@(((6'PF"3,PQ2@8/DW0<S.0"
M/8MK08%HU&?4X=%SI&OF'&>O$EG)G"%9?Z\4^'_&V#A8)*(:$_HXQT!&E 8$
M3YEQX'=H-;*2LS#*T/KQ,#P$7\R-9[# 9 EV/9[)XN^58$RVPWEKO+P/2$2$
M@,66E.YY[TSDSZ?94U14O,G*<+OBWK<5MG)[L3Z:53'#[?6Z,BHT9]O"9I31
MLO:!FF6#H&8;P^TS^3YXJ&T>;BQ WC](L]DBS;(?AS1;'6X'_/KRDBK<MIXK
MGPAIEAQNF8G68J_/)L]O6?'8P>%G'2$Q;T!AC1NW@."VDHBY=H>X_4^=&#3K
MYYWN5?>LW>SGB7:G?HK%NFZ#?)&,]G_%7_I4@#/B9BE,A"6<OFT,+0<:],&$
MVQ$S7LHA[)^N3%QS&X+"Q4;.4GP"B1P\3T4!!H]E-N<,@Y<P+5Z_\?5G1/^F
M:LQFQP-M.6(!/!"4S<?OT(?, LM)K]&?"SR4J>"?/%CD<I,GKC?7#>(&W,"<
M&PLK)''!)MOR^#2'K2MK2JZTT5$.P:(U%3D L YOT&GY/\ 8<RW#3R$BA^82
MX(6I*.@?R1/?]5W=UJ_ZYJ1YPC:W' '$VO?L/,:%?E@\\5W\L?<H0Z; 4H["
M/"#ZNY,J)$H\JMCI6%F7%EAL'J':!VX]3FVZ]1ET*F<F)SGJT\E59WVG_K[D
M[Z6#CU-$98"46?RW^YCT#]I.0G_W,&2/+@]POR+D4BBFHS6+T:!3-*_:)$L[
MRK9-L*$B-%_>-3^4PPLPIFD#IR+PH_AY+I:7P5=$((D 4V.D1A7>GWWB19DL
M$D .$$&25W>C<JC:7B^%A:QNVQ*2472^S#+Y(E6TG8:CVDX_'0=+$[C1P+GT
M?P"O F8U!VB#AQMLG%LMX#_=?$S9^%AG"%U5=)<]:#T!1QI0A+WHIPYV 6AU
M8Z@4_8-'R.J^&W)^[TJ1IP-A.=<_8_ X]:)4UY?LY9LV=L.+[XS8['F,6?&]
M_AO?#3L9GHH:J0RH=#?(.2+3.RC9T+<3\4TX@>-?\$ 8!^6;_ ;W<@(W8Y@W
M%A] #0EXP<8,.1LS$/[,4/^7,T-_IBPU'VZX[-U>#<:EBY?E%V,&_PV[N&&_
M6NU4N($LGR <_3!F0'OQY0;B.XP2F.U9.9O:=#[".'WCBWG4E0I8A)N"$YW"
MD4XF!UF*T*>#*+B-PZ=U@\0#R3^:4[:]ZOGUY.9^=+6T0"J-]>OMN5:/1MQ>
MCTC]'60E%>IVT6^,PG#7(-L0\+)#5(0?PI-L&XTK>#8GX@=15>$\3ELL'74W
MC+D5\(;,Z#5JE!(L(Q&RIFHT3039F+@MQF9/XOXI/$Y--4/IT& TH^W@17\5
M3LDR3=FLS9R/M8D =I%H-85)L*KT>8O)VV$31U/2BYY&K6/6BP%&(G>E/FC-
MY_OU@#D*O>CJ#,O82"SNIQ;+>:I0R1?)P/**4+T(V"871NY>91A&[]9BPEYZ
M2@!AT1<6F@X(@02&*.? 3<@"OF.DKN&Z;,ZLAYOLH]C1@V%W'! 'N)"I)T#1
M(* _]!>2J.GL4C$['"L?RCC;Y9W\_%LN4>VR51%DWX:>BH3-JV@G1L<8W(O)
M%>'=,16ST[&R'SV[2+;L::39??S??I$G@,Y/R$+!;T>>?+-M5L7"BK4AHL!?
M Y[]""@,1"_@>7!Z":))%#Q:+)4W$2H&0Y/DPL.Z_O9;WC9?PA:UT*.&A&M\
M)QH>:U<V]"E=0JI&-?5*#MD"@9$.'^8:"=Y !Y4OE(IYF@UEL[RY3E_FSNVI
MRZI9Z+*/9<DT=%GY9G9/O4P*TR?V6'39GKP?0Y?1^P4\3+).JLI"+3<?59:+
M3N[E?SFY!X4T-J6'4K==4MAB\8O1>Y28!KU?3&,O@C\E'+!:=%ZWI RS*=R(
M$]X7P)OFOX#G>>.R#H(S<>#ZD;&+JAD0MW.P@D-<P( ,Q,U<:;"%5N4DGTR*
M7AB&_$STXXDDRJ].]Q8P'O" D8DB -J$[?NR"&T'?=006HRDP$JQG#[(A4?S
MO66]4$Q60DP#/-N;4%::JG$(AE!/C$!K"H*+"-Q2$H7E*6& N, TB><("/L1
MY&1E#HTHN 9X!KSX)O(KZ(4K8 _+-[0VQSF,%&[)P\WP@'[&FK(TMHTSK/6-
M!J?3$!+0%F!5(T$6)N"(4<)&60-SC-,(2>!4#5#KW\8AYQR"''GS!*>>Z'8/
M. %48N> PC#74Y^)PH1HOH-;0 5SW0EX'[2YX.I5 Y;)9]7ZN[\ !]@10FP#
MZE&P10_$$!QQWV[F"4!Z8R&'?LDKX+VRHN&:0G4%STV$MK-!Z1H>0P\H80)(
M!%8,P:0ZN$0C:P^M:^BI 8HD.)/D8#Y>6?*(JGC]JR+Z]0+..CTESI4UI%@<
M/[43IGOM(H+,@4N$GP1&-AK999(4YBETAT0+#RR;(ZRLH*"1\31 5ZK(Z[4-
M.5@^H*'MV7.%V'H&BU)7XQGF(?U<Y@AG!D]E&D-=BZ:W&H?)+19NB"$+\T=S
MP@')/BO-Z<:,ACYMJTW5&=>\9Y%'[T/X17KEA#G$C> D<)+0-WI#!1#Z0LWI
M4;9%P'@<K.\'(@\L#CQ;7"*8HYSO+%R?Z7N!AQT\_M9G^BT@*%'A\;DYWI$+
M?0=TN<!. &$@-"8@AL0M?!Q'7$/3@*@#B0@$F3A?25]EB-W H]Z=SIN=B93<
M7! P=?" 9V01@UH!R@7_7HIOF$#0%#$!W18*L1MNITFW1F,2OA-4FPS_@G@&
M16JJ_3I1)MF  <K([_423L FDDQ-1AA]*K0"QKI&]7]=SN?,G'+'(B'X'5PV
MVA_/%&@17 -=!(X/XTQ]$4H*Y"S=\ 3J I8D$ER.!.H:60>"S-OKVA?<AL.!
M"6+,J3-8'^(R6H,EA&87::9&Q]AK5OC";KZ9<&V*@8)H>YM)59X7J82>2(++
MO!1A3EM/W-VT+ZVBKB!H)[@2)RR70W>A$J6]*[L\#3.'#DB.5P^JT/BM\!+M
M[0=JQ=S-1^<EMI<]>MOO%S>;N]>L <KV#JC242&Y_=W(E'>W?_K#M;NHB5/_
MW97S;,D/HBVH&\KA.&/YA4R"\7@)LY&&#/-#SV,^&9'' @J&WZOB0VCH9V"-
M*S*XID.>KU_;K]/ZD^"5 ?0GDV@9'$_QIO'.U\DK0-/'QW;VW^S8BHM#HX)K
M'T3^["]=DQ_$?LE8<@]1A:V,L++2+\ERH17B8N/A6KJDB\6S6(WR7T-6AY[,
M2UF=T96'YOBU<N3\%[D\GHZ*Z/Y)C*!DA[!OCT"9]DLFA N@'4Z@"S[[@(YO
M2%MNY_[I;J[<GJ\>A6/JRSV[ONP*5Q+7JU2.9EDL$!=*^VU]43RG:UF=UC[M
MPL6@=F%JN#V_FZK%2D&LG97^] L?J%^X^'']PH!6)Z6WY>@W_2"KXB?J%VX-
MMV_WVQJWZCPTY<,#&&0DC1NKI1$+U69 WR$;519E@4!E]"H<AP:TA1XQRSG!
MT.WY#SV:RQ%3F,(T\A!CGY&%._,*?J7R=GSEG@[I8JE\".ZB0G07037&GP2!
MU.QM%*;6'ADWWM5Y*)<D\96]N:N8A1@]Z^31N7^'0#D_=ME*H0<8/*/%#R!G
M]X%%Z*+<%5]B$A?FDWF&ID/;*E$2,!AWOQ*9[D+@]K\"]57>Y[7.Y<LS<U?Z
M .H+@&<Z#/5%#1F$#;<GJ=#N7K^95#M&V+F V,Q!K=D%"CZ,]N94:4$W;V^?
MSL9^?>2.[&5L!#OSX-)QE=,@N,0XC&0I3S/A;>0Q]'#<W+M5U(_G/, B*$ ?
MJ_D"5Y* 3[@S;S]Q.D^USU #4I@Y)2MY-"T)YP)%#/.@"AJX>W3GX%/L::%
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MK.D-G 8#,!JJU#$K)/Y"=66[!A?I(Y#TJ47^$Y!0J2I&U'&..,IYD'^+>)!
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M'HHO3Y!_>")[GKC6+\!@AMK%YNUB\CP[[WPU#>'<J8L+V RXX)2IX([?($[
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M3HFKF'3]X>27M*PS*DU248L(@LLWF5.6.5**#'UPX"V%5 ^C/8]V8P.-W-A
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MS+98GU68QRON$\W# *0J=2JUF?*@/0^X+#G:+4[3;O!F/0W>/=R9?L,MM<T
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M]8-+D5]9ZHREUM?/)&F5W:)^+M%\N>[:BN.H#!RZ]I09-G$]+KB>$(,<6!Q
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M*0.6X_W+7[L?#K9;WZ/T@11D_&T>J@AZRP]J%KR>0F'I/*#//),'1-$N(AU
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M.''%2&FA&PE^Z/;']"VC"Y_^K]H@LV(>9<VH3)AVYWL,SH%C<VVF3=Y<LS-
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M/J2F@5SFDBVPLT$GQ0R& 7FGY63#+D?JI1EB1#<"1A(6@8VE9D/1' $URHL
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MXR)+Q&O4'%54_,8#!>%UL1>Y]U/,F:W7ZZ57]NM7E=>F?FZ%% 8^%9T?6QC
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M9E3"MGA.AODI>ZCPP,=* 5WAEU=?34_.A/.KP.&PIX?:ANBXYV 64$I:DFI
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M$I?S4\"$W[,X+#1);!3WKHNS":4Q Q9%M[R9I6?WI;C(1Z)[18C@_GCN%+=
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M'JDW,M G'I'(0P>E51MS@BNQ_KQV#P\[I&;-J2["&/9D^NOT*,@SNG]-</A
MI1CGUUIL"Q&NST6,IBHFQV2IXO'\IEXT("#>RAN9_UBS?+DGL^SP;.F#DWTL
M#KOQ RZ=<X*AZ U#+;@'[C6*L4YRCG#/'? L -F\3(A&K=E(*+H/=L;YVP!N
M2#/=92LD6!6P\<;Q2"TWN?LY\22A9]H\= N'H&*G<1XR3@ZZCB\R#@!N \ M
MCYIA$R)>RM'([ECVN-?GGP4XU@M^!'E.SBQD>D8H*@==]B?$1YZ%4=MI@A35
MI]UB'R(YK%X$:DR:2C,<.@$*7YS&A8H+*@NW@%]H&!',:34Y34=="&YC(@9P
M1Y-A)0@4-HEQ(=@1FP98]+B'//ZN>X63O&CVC,WSRZ8XC<8-A6(A;ICF8-C1
M #:[QSVZU>@40Y]"8L6T":\7#34+HD;14;.AYT'5?![FNJAZ]G!(]90OS@UU
M!AG O?0,-;J=*)JCB-QDVAE' +O$WDR>J*R68UGYPO5N3?'F^1HQTC@WKD3Q
MQ#@\SJ:0[=B-Z*K4@O; ,F/;L[39MWK#"YH5MV6>87M^,0).=GIW:(QQ<H2Q
M=O\1,^-<#T,-W]6R/I)#C^7L5WT4KV@!SX^BWCN@2ASDK?!5B;*92\4GIJ/>
MGGA.M \3Q$3D141CBD:,P&E] CVPEG7C\K-M];QY7:7;+]&F1X@VM5^B34^4
MK,ZXM5\4UG@F_J>O">LL=*A;HBE:&49V6<C!#0/'P:+\=[!+LVR=,#.?=M:(
MD[T1E4='!:E0!\CROLB%93JDD*I&<N0Y3;+G&EY6J5':15-VU<>E]!;J*4V
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M2$3Q98R1=)HNZ (3LOP-,11B.$'O@I;7-U1V3U)?S,)^Q$!M!"TY];&[EXR
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M A(=W[Z+*&X2'8_GD?"3A&. )-IO,^._!5-LIFN*A#B+$J.WB[MK  1HZ-1
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MX.><@-$Y;T)TS/8TU(,<NT?.S+L3=D'-L 7-20?6D=TN%?.DAB]UI))^H)9
MW\*OA?KIJO =PF]9T" BX$3$E7@R^;LC51]\_?@V +T-<'E0+D_,$Y<C@0M=
M7RY A+93SG"PX?WR"J(1K2MR-, L3%3:',T+52A=OBRZ%<, ''@Z\&6 <W0'
MS"B0V4&)SG5HER.Y.T"VCK55(B!F3"-]=4%L)Q+8I9CA/4QV+!NPQ*3@)?12
M($^?<6 1H\$C&*9IF=\OW3HO.0&>E/,', X?Y1DO2 P2GXG!/Y 8)#X3@^]J
M(]&+^%R6K2ANFH0TD.5V3]S5U&F,#)SZ4;SS88A,B>)C,.)[RA;Z($,#;Z9(
M3=R3ZMK7"C9>B/&XLT]W\N5._^5'GFWD1S?\EZB=^X.>Y-'7J:*]/]/\!Y]3
M-4_Y#F8>CFI:.T<(S<!5VQ"-2%#V_B5=G*#M60B&I@?A9@\,T=*O&*1P9D7R
MKZ27]S/-U5_PI&>D^F "0D+U&I'0H"AKJ)R1]['QK;CV!NCGI4-Q-O>D/_O)
M@KR.\#^,O,/;N2_!NWCLOWU*]36T^.(Z>O7F"T)[<<S75DS@O)]TI(KSB^!Z
M'/FH:=&QU@ %'%OE*,]PVG *I19@$@I$7<"E R050IL-*@,2A@3;<EU-A"6+
ML,4ZC&\GR@!X&V$<)'I.1*8<Q&D[%*< >('X$]'NC)7G>(I\JLZ_-H!)<W%3
MV44!+\B]YR$4./2 PG_]%/ O[TW0W0!4&IXD\6#%Z&D Y;RKE!-3?9]\(NDY
M$&\+= &]O[H@D7/[KEW)!S"4_#D,A;A/CTQ'68(8 FRE)>BHDJF.>D4<D1$P
M5S!"0*.X\]P' :VPEOG6=*MOC2XJ/"!WJRFP4ME-CT!-[D Q-<LY6<X;!MF]
M[H*\O>R+#PC4NJ!D=" LE' ''6F@;ESD,.&@AZ=(:/1N5OBW/=P+(F#D9P3L
M#T3 R,\(V"ULCTO+63JWG+G[= ^B+DYXEF_8:+[$PQ;#7;=TPEN!#'::Y?Q(
M0__]RS^U)(6<\E3 TOL,PX!I)8ULH6L;%4:?<X*EC^+=R_N?)8SXJ2B2_/T[
M ,7@F)C#RXY3EBT[O*PT=&'Y4Q8;/R6 Z\)Q#/_Y$SP*PTG\YX&D9T5MRC5*
MH\47@.EV732DK9K>3[ZI'V;$?BN1XV ^*'MT7?<E0E_/I_1RW&JK\Z;NSX-*
M13+;JFC(NC@9^W*K6_[RS^7\J&A^X8'_RU,L\U:GME2VFY+TJE/4]C],RV1]
M(UQR"=$C[SU>6?S]!<#\P4R^X_AW# <S"7]\)_$O::2N?W_1]MX/T;)T13 7
M@NXJ7^"[ H@WAA& @C=MAJ;I[R_A2_]XY(7?=@;$Z0P>EWIXYT*__&_V;#+_
M//P]NCC!'T S+Y>X=D4%AXYA>L\L;[\QZ.O%R523WU(!Z]<5\"43G$^'_4Z_
M5)J9KSO#-UQ]\C'].[[OVTZ >D+]3N<01^)^60&3Z!QBA0B'_HX?8V+'GG\Q
MY:N5\,2"'/0S7TK:(0BAG1:N$\6B*P!6!%04H"%YTKTM/?C>.<89;O$\>WA
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M52OONC:;KY']%3Y>S<3U;A3J[2+PZ_APE5MERYUUHZ,VE4[H :[E(I?WC95
MY$1LHC3<<G5'Z0XV/W2[Q+)D,_DJ6>,K^<";4V72R#?;?=/HKQ>[76>WXT8Z
M-BOLRCFFU]6'JE/E=KV6WF<+K4/?%BR.F3.2L<E65BV7,'*.:='<=,,%7=X+
M!]$LK\2O]<$R%)_#5_3>>$:+PV5[5V%W#8.B]IN]N&L-^< :%IUJ>V&P-E?)
MF06)WXZTA4\N&S-.50E>]@(Z4YANIG./;RT,VQL45E6Q5,/M>6U<P ]B3W1=
M@LU*6[N7=PYJ8S<:L+W0T!R<>B/?W%&&UMN18G.J%["AN_4<AJ\M2*ZB]!2I
M;UO]+KDHT-9P*SEV=K0JU;/Y(EL4,-^A"6XP,M=<OU/S'&V\8]N!VZQPZX!M
M4IMJ19+Y2I^@B2HOU5>M(HYI&+96S4+6Z&CA9-I<T#JLQ7F/]]=]@>JYKM_&
MNKG6P*(-4C4P):.PMN/M^*'4;NSS3H/,9DR\R>4[([ZI=H?Y@ZROA19#T8+1
MX^U9,8\O_1E)=%UF1[&+K:YMZHJI!DZIFA/T9FO?]8MN9U;:^ZW!:A'45T1[
MULVZJC7)#R=5;TKADK9O=0X:VUB6*;MI$!-);PY[!%7!UY(;A,<U4YALNKO%
MB-'U(E8O281EV.&1I6_;4]_OYL<X.=*E43 @ZLTZH[!!=;@G&AF&:CH":>=(
MIS_WYG1X?,R;A6J^(LR[>\$NL(7< 9_LQ]XF*/0&6\/C]!ZY+6';C=#QQX5@
MNCQ,)PM'8X)Q:1 8G$I.FN-UAK+GTXPP'P6TR@VM<<?=BGFVL''M$L>SV?%L
M3QG+0:ZS#G";Q&=Y<MNCZ!+GYVS-JVUS!ZF[JXS"DXDX6*3%YB8%QQVV-NYA
M9SI=*]A2O&4[)6<J4&U^5PU$+6^L;"Z44\TZ=/J%LL'TE>IHOLF.PS-D627E
M9OAL[* /VNP\=ZAGY&QN+M@-[N^_D4>2%2TY #]5S]#_^3]02P,$%     @
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MF7 X2"&$U,5!DL(E&I?>.\<QG$/##GS[G V3@WSV0>>>I67V' Y5B&5U<:C
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MB; 2:NX5]MTJ7U-AP5$6R-$+N13N/89,[!UVV)[P>61\E(%+7*8^3Q4CL7+
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M:M''JL%E]5@9=TZ':T@*KJ>5I ZVE*X]KRIU,*P T9=%K(,BK6^O=J .@DP
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M!C9CG4@>:I:$9.E37I!OVLSKH=F]!,U::B97&E/Z]^D2^UY]%<6^-I+FCC<
M)&B&$] $-V>=4*:9<(#\([4!3X9#%OLE]EQ]VPR11;[ _NKQ@TS+!2;=LXK;
M9]/96=%MO&84-ET:(5(V&V0RJLJ&QH.W:\:'[\7\\;J1$S&+@01F)FO#*.2K
M2$1F)LLV"^3QQ*1IFRRYFMN*L73+V<M@O/TK(92P1S&*56 X-\*=C[<55[O
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MY$376$7;RI1AJA7>\S-\VD;A*R@.:!CI3V]($C0N+8]PSKM?RJ)J%&Q<02#
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M"S<$,R,W^ IPK7VKY^XOFC:44I,A %D'56K C8EH4P!X'/AVZO1-$F6$[KJ
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M F4%#^^*_324QXP*PR;BGO*D^F@ME"6T ()<_4M=XM-1C/C/!*O\I-56@^/
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M6K>M:S>,-J4?23DFR[<1<]^"";1M7"+3(A"7 -[#% ?A#VMO"EH,Q5BT7D^
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MY!C>+/%.&H6?K%RJ;0BH!A5Y2R2,76SG['-XY;ZX#C[^0;X4/F$SX)&0Q;B
MP-Z:L'W];!&D%FPBP5/@81ZC1 >"RR*_HV8@>X1LQ@4&[GS')<G8]^L8.1LU
M) )YR0=)=(,$-ES;?4X"C;MW+3C0']MSH\:"$F&-BT3\@8A7$#E]O(A9CVC_
M4<1<[6G.2)#JIE&PRTNF.G91%<97KD>&\H$DTBA#';4!9Z9LQH5/J))+>I ;
MA1HL@4" 0R\VV<@21R<C:#0^>1D@A,J^+@.<4F[0=HM.SDQ[^WAJW0''% '*
M9H A(PR$RH5I@<&]E9D6$OP@%Q+,^DO#@I&F6&#?CUV',.*^H)W]./QI>VNL
M,_*D#RF0O(XS$(NZ.1@!AZN*NB_HCB\>*8EP\%'-=XR)3*H>8F ,4R4^Q@<X
MCQ3V\I7> 3M$6NE'#0BR*AU!07VJ,RZ&2V>669^6J2>-!89KQ$]DQ&BH1&P$
M[B;'DLT;&[5>\\L>O69>,=MK4W?Y8MD)%3#XKBG4M0OM)*<#IFZI;9>:<DK+
M*!D6 '1?*U:WT#7)PNU"33=2RRB8PCGH##',9A!>1=/K,Y79KFGWR]-/)J&N
M[!"E4#D"F1[U^G,*47*!.IP?BXZ<Z6QX/9S-AE>]^6(R^+LYE3>WM:Y>YQ8Y
MP"0B"CAE>'2:7"U;KB8A[;V!'*^7KX>--\UXCA:E7S'&S2(V%(K.DPHT;KSK
MA*HI3FXX3*+/;5$%=M#P #1ED,LAQR$QAB8/N<*-O,.G"*VFM'(N H&T).:Y
M#:K%SF37@7I\#4U+GX;NBQ6CJ6?9B6IX&>GT]IH\!Q*SJIA("TEAW/I)RNM-
M'G)/H+)W1*!YFW=#IH8,RK3-<4B>(1@'OK7[3;Z<,6\.2G>D9X]DXQ(<)Y)Y
MFZ4N>$W>1BL< O46[D[N,@VFZ]!^(K5D'T/$WBV3XM=,(EW.]I(3+9"1R[BE
MMR7%76O83+N2L/5OE%U)V*XDK.:2L-F:+A1OH[;5?!U9M"8IS#LX;[0M;[?(
M(G$.,MY&_O,Z)L84>\^"*=J\9?'T9- M*QJKO)601:-GO^(JG(^/N;N56HA,
MWJN4P6BH:[/(,"F9:Y/KF2A<\<[@?%I=SW<*S"8V;H H$'[Z7N0H,IX4LOL6
MD!IM7K*/R$%()5]JRALY&D58&@C(3XISLXH<[6I03/%OW34\QPBY(+6N;"YQ
M?&2%@> IG> E",^M%7XG50QB%&*+:F;%["<?1,EU77P[#B"F-!!"%\:LA#,W
M^GX=(B2$)J PN ^\G9N.:4F9P.#>.V.@W>S.FZHQ9:"%^UB>JK='Z[5:()E
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M@/K!]@U2/D<&.$AKFLMC[V5?WTE_@? ?D]_(NT#8_34$804R@B.@K(\$S*?
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M\9=D$;[#"$6S^1WO.CJ33->#)56N#X&<^.9M32VIER-M,Y0H?Z.[DGY7_L:
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MY1%3O0&UC0;3DT!SCXZ<EGE_Y=2XE$\5[Z^<FISK0>'WJ*=S-!U J\+N7.2
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MK<-%:#DD!3:GH)WUE#%#_N\>JPO_YO\#4$L#!!0    ( #=^<5Q1AEA$;6P
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MSE#,+0/D(/LLZ,L 8H(4F((-K2S+9N^%$7-BF7*:MR3"+_^)]\IZ"7)N.:&
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MRQ:G!2:3,SL4[KF&"D-KI>ER,AM1E>ZD9J'FG9?CL4K2U5!-A+EJP5RIC 4
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M)&Y,+W9YG#[RMS>X ;W%-&-.6-:[M_1)H1]IS+=J:!U8F%.+=E2%>\;NH)+
M,/@H^)(G%RMY*!F3JKQP.*+7_G%:L.C+&3TDXZ'CY_M6I'IGAM62/X'=OD53
ML/>SUD]!>L/"RXM?2%7I;6S>7*K&=?9YIV/'<:/V1INC;\,9GVXK;!K1Z)EI
M^1_8<K/%3@DFFJ],90&8KNRJ:S%;Z0N",QB.0*]A]BZ-RX*?$6F9[=RFVEO
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MX\86ID4?=?4\^0)D(-/T./@"\_]=IJL<TT3]%]6V3K5+.DLCMCN@#K0YK"0
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M*F/'?0#6$4@2>XB)MU2!U\22<B.J J7'V$&_"3UR^=$9NO9??(^$'GCN""N
M+RJM84<A.SHW.M.FQ7PQ\%I'4T9 $^7<]H79V:^\",-,T=P:4$J-V1C ^SZ5
MU.BS*S^2UQ0TY#P,J HERIA90H\H" YFK6Y0"DH6K);0&[--J*%7"V'))+DF
ML?_BL)0MFE-$61'*$KZ! H@!.E=5C0M?7^!LX-L31%*>\08!Q%DCNHS9%)J8
M?]X 4RP.V#_< HZB+"D'"5TI<])*4":-F1S 3 )D1U>!*[)A(<#Q#FIQ%5:
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MC0.AM"U[XJ];#Q  9L9R!D4N(5YR0X4['C&9,4AI+X-5M2<6&WANTT'$5+;
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MM56]9H/8OO-Z,5,M<;-(70_#U/=87_T7<CS:CU_=8$NG]0W%B2FP[3X59H-
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ME-C M^PXQ+0.'#8!#7X <0>RW*K#A[O]BAT#RMRTK!ZG.P4/WZ+^5D*(>QL
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M'E#H1\?&"T]Q*)EMTR1U0L\/UWDPEX'=@/A3R E&N]L[=;4=4+'2^$#\G)G
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MU%89 TB&O>K-8__%20G5*:[\F>Z]14)0'M_O 3P$JP8^*0)& [Q'U6\?CD^
MH&YU96CTDKDK?6U.=,2S92VC@.9'WMR;#;*6B:M8HNE,KV5B $JQ)ZANGUF7
M5&L7KZPE#*I&)=\5\T02,_:M2MH%G?05NHN-,;N\>(Q($DSTF3EDOO>'U8%9
M6 F*M[$8%2V\%;*C+QBE15!M7N06MD3%&%XDN**7["CH[*E6!VL/,I(1*.;
M]*JP3[T#W0,+RT/-/,:VO<!=KD)@=#W%C<Z0:RM)%3M&OFF=)0&@%,=I$9_
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M9; O^J##KWR<X(IIR!'Z>-V4[=&ET K*8IM7FT L%=NPS[D4XX8AH<8.PTW
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M>#,Q,#$N:'1M4$L! A0#%     @ -WYQ7,>HNL:?!P  RR,  !4
M     ( !S <  '!H87)M86-Y=&5?97@S,3 R+FAT;5!+ 0(4 Q0    ( #=^
M<5RDEPIA@P0  $\1   5              "  9X/  !P:&%R;6%C>71E7V5X
M,S(P,2YH=&U02P$"% ,4    "  W?G%<89/9GX<$  ""$0  %0
M    @ %4%   <&AA<FUA8WET95]E>#,R,#(N:'1M4$L! A0#%     @ -WYQ
M7/-NZ'22Q@$ .U85 !H              ( !#AD  '!H87)M86-Y=&5?:3$P
M<2TP,3,Q,C8N:'1M4$L! A0#%     @ -WYQ7!5"L=!!$@  >^   !$
M         ( !V-\! '!M8V(M,C R-C Q,S$N>'-D4$L! A0#%     @ -WYQ
M7#EX\"H%$@  PN$  !4              ( !2/(! '!M8V(M,C R-C Q,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( #=^<5P(K2>NR#L  -!)!  5
M  "  8 $ @!P;6-B+3(P,C8P,3,Q7V1E9BYX;6Q02P$"% ,4    "  W?G%<
M48981&UL   F2P8 %0              @ %[0 ( <&UC8BTR,#(V,#$S,5]L
M86(N>&UL4$L! A0#%     @ -WYQ7*P^#<B 5@  [>4% !4
M ( !&ZT" '!M8V(M,C R-C Q,S%?<')E+GAM;%!+!08     "@ * )\"  #.
% P,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>pharmacyte_i10q-013126_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:PMCB="http://pharmacyte.com/20260131"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pmcb-20260131.xsd" xlink:type="simple"/>
    <context id="From2025-05-01to2026-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
        </entity>
        <period>
            <instant>2026-03-12</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="From2025-11-012026-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012025-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012025-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-04-30_custom_PreferredStockSeriesBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_custom_PreferredStockSeriesCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_custom_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="AsOf2024-07-31_custom_PreferredStockSeriesBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-07-31_custom_PreferredStockSeriesCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-07-31_custom_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-07-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-07-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-07-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-07-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_PreferredStockSeriesBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_PreferredStockSeriesCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_custom_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2024-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_PreferredStockSeriesBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_PreferredStockSeriesCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2025-07-31_custom_PreferredStockSeriesBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="AsOf2025-07-31_custom_PreferredStockSeriesCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="AsOf2025-07-31_custom_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="AsOf2025-07-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="AsOf2025-07-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="AsOf2025-07-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="AsOf2025-07-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="AsOf2025-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="AsOf2025-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="AsOf2025-10-31_custom_PreferredStockSeriesBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="AsOf2025-10-31_custom_PreferredStockSeriesCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="AsOf2025-10-31_custom_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="AsOf2025-10-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="AsOf2025-10-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="AsOf2025-10-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="AsOf2025-10-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="AsOf2025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="AsOf2025-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-07-31_custom_PreferredStockSeriesCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-07-31_custom_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-07-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-07-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-07-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012024-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-10-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-08-012024-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
        </entity>
        <period>
            <startDate>2024-08-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012025-01-31_custom_PreferredStockSeriesBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012025-01-31_custom_PreferredStockSeriesCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012025-01-31_custom_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012025-01-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012025-01-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012025-01-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012025-01-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012025-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012025-07-31_custom_PreferredStockSeriesBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012025-07-31_custom_PreferredStockSeriesCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012025-07-31_custom_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012025-07-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012025-07-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012025-07-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012025-07-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012025-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012025-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="From2025-08-012025-10-31_custom_PreferredStockSeriesBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="From2025-08-012025-10-31_custom_PreferredStockSeriesCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="From2025-08-012025-10-31_custom_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="From2025-08-012025-10-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="From2025-08-012025-10-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="From2025-08-012025-10-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="From2025-08-012025-10-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="From2025-08-012025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="From2025-08-012025-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-31_custom_PreferredStockSeriesBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-01-31_custom_PreferredStockSeriesCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-01-31_custom_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-01-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-01-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-01-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-01-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_PreferredStockSeriesBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_PreferredStockSeriesCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:PreferredStockSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_ContingentlyRedeemableWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">PMCB:ContingentlyRedeemableWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="From2025-08-012025-08-31_us-gaap_PrivatePlacementMember_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-31_us-gaap_PrivatePlacementMember_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-31</instant>
        </period>
    </context>
    <context id="From2025-08-012025-08-31_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_QCLSSeriesHConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-09-012025-09-30_custom_QCLSSeriesHConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2023-11-132023-11-14_custom_FemasysPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-13</startDate>
            <endDate>2023-11-14</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-14_custom_FemasysPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-14</instant>
        </period>
    </context>
    <context id="From2026-01-292026-01-31_custom_FemasysNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-29</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2026-01-292026-01-31_custom_FemasysMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:FemasysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-29</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_FemasysCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_custom_FemasysPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012025-01-31_custom_FemasysPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_FemasysPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012025-01-31_custom_FemasysPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_FemasysPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_FemasysPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_FemasysPurchaseAgreementMember_custom_FemasysSeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:FemasysSeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_FemasysNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_FemasysWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_custom_FemasysNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_FemasysNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_custom_FemasysWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_FemasysWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-11-202025-11-21_custom_FemasysPurchaseAgreementMember_custom_FemasysCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:FemasysCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-20</startDate>
            <endDate>2025-11-21</endDate>
        </period>
    </context>
    <context id="From2024-11-202024-11-21_custom_FemasysPurchaseAgreementMember_custom_FemasysCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:FemasysCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-20</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="From2025-11-202025-11-21_custom_FemasysPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-20</startDate>
            <endDate>2025-11-21</endDate>
        </period>
    </context>
    <context id="From2024-11-202024-11-21_custom_FemasysPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-20</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="From2024-05-012025-04-30_custom_FemasysPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:FemasysPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_FemasysMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:FemasysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_FemasysMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:FemasysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-20_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_us-gaap_SeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-20</instant>
        </period>
    </context>
    <context id="AsOf2024-05-20_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_LongTermWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:LongTermWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-20</instant>
        </period>
    </context>
    <context id="AsOf2024-05-20_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_ShortTermWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:ShortTermWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-20</instant>
        </period>
    </context>
    <context id="From2024-05-192024-05-20_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-19</startDate>
            <endDate>2024-05-20</endDate>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_LongTermWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:LongTermWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="From2025-09-012025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_LongTermWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:LongTermWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_ShortTermWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:ShortTermWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSAccruedDividendReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSAccruedDividendReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSAccruedDividendReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSAccruedDividendReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesGPreferredStockMember_custom_QCLSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesGPreferredStockMember_custom_QCLSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesGPreferredStockMember_custom_QCLSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_SeriesGWarrantsMember_custom_QCLSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesGWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_SeriesGWarrantsMember_custom_QCLSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesGWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_SeriesGWarrantsMember_custom_QCLSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesGWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-02</instant>
        </period>
    </context>
    <context id="AsOf2025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-02</instant>
        </period>
    </context>
    <context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-02</instant>
        </period>
    </context>
    <context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputMaturityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputMaturityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_custom_MeasurementRedemptionPremiumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">PMCB:MeasurementRedemptionPremiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_custom_MeasurementInputMarketInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">PMCB:MeasurementInputMarketInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-02</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_custom_MeasurementInputRedemptionPremiumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">PMCB:MeasurementInputRedemptionPremiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_custom_MeasurementInputMarketInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">PMCB:MeasurementInputMarketInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:QCLSSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_FemasysNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">PMCB:FemasysNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_FemasysNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">PMCB:FemasysNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_FemasysNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">PMCB:FemasysNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_FemasysWarrantsMember266865281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">PMCB:FemasysWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_FemasysWarrantsMember266865281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">PMCB:FemasysWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_FemasysWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">PMCB:FemasysWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_QCLSSeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_QCLSSeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_QCLSSeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_QCLSMember_custom_QCLSSeriesGWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesGWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_QCLSMember_custom_QCLSSeriesGWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesGWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_QCLSMember_custom_QCLSSeriesGWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:QCLSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesGWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_QCLSSeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-02_custom_QCLSSeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-02</instant>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_QCLSSeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_QCLSSeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:QCLSSeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_QCLSSeriesHWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-02_custom_QCLSSeriesHWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-02</instant>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_QCLSSeriesHWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_QCLSSeriesHWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:QCLSSeriesHWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_PayrollRelatedCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:PayrollRelatedCostsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_PayrollRelatedCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:PayrollRelatedCostsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_DirectorFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:DirectorFeesMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_DirectorFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:DirectorFeesMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_RAndDCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:RAndDCostsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_RAndDCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:RAndDCostsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_LegalSettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:LegalSettlementMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_LegalSettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:LegalSettlementMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_ExciseTaxOnStockRepurchasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:ExciseTaxOnStockRepurchasesMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_ExciseTaxOnStockRepurchasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:ExciseTaxOnStockRepurchasesMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_LongTermPortionOfLegalSettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:LongTermPortionOfLegalSettlementMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_LongTermPortionOfLegalSettlementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">PMCB:LongTermPortionOfLegalSettlementMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:StatementOfFinancialPositionLocationBalanceAxis">
                    <us-gaap:QName.domain>us-gaap:AccruedLiabilitiesCurrentAndNoncurrent</us-gaap:QName.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_EquityPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PMCB:EquityPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_EquityPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PMCB:EquityPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="From2025-10-012025-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-28_custom_EquityPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PMCB:EquityPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-28</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_EquityPlan2022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">PMCB:EquityPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_custom_EmployeesMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_EmployeesMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012025-01-31_custom_EmployeesMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012025-01-31_custom_EmployeesMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_EmployeesMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">PMCB:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-10_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_custom_SeriesBPreferredWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesBPreferredWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_SeriesBPreferredWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesBPreferredWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_SeriesBPreferredWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesBPreferredWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="From2024-11-012025-01-31_custom_SeriesBPreferredWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesBPreferredWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012025-01-31_custom_SeriesBPreferredWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesBPreferredWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-31_custom_SeriesBPreferredWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">PMCB:SeriesBPreferredWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-05-16_custom_SettlementAgreementMember_custom_FirstWarrantIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:FirstWarrantIssuanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-16</instant>
        </period>
    </context>
    <context id="AsOf2025-10-29_custom_SettlementAgreementMember_custom_SettlementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:SettlementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">PMCB:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-29</instant>
        </period>
    </context>
    <context id="From2025-05-152025-05-16_custom_FirstWarrantIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:FirstWarrantIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-15</startDate>
            <endDate>2025-05-16</endDate>
        </period>
    </context>
    <context id="From2025-07-282025-07-29_custom_AdditionalWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PMCB:AdditionalWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-28</startDate>
            <endDate>2025-07-29</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-29_custom_AdditionalWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PMCB:AdditionalWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-29</instant>
        </period>
    </context>
    <context id="From2024-05-012025-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_custom_SettlementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:SettlementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_SettlementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:SettlementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-19_custom_SeriesCPrivatePlacementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PMCB:SeriesCPrivatePlacementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-19</instant>
        </period>
    </context>
    <context id="From2025-08-012025-08-19_custom_SeriesCPrivatePlacementAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PMCB:SeriesCPrivatePlacementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-19</endDate>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_custom_SeriesCPrivatePlacementAgreementMember_custom_SeriesCPreferredWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:SeriesCPreferredWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PMCB:SeriesCPrivatePlacementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_SeriesCPrivatePlacementAgreementMember_custom_SeriesCPreferredWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:SeriesCPreferredWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PMCB:SeriesCPrivatePlacementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-19_custom_SeriesCPrivatePlacementAgreementMember_custom_SeriesCPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:SeriesCPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PMCB:SeriesCPrivatePlacementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-19</instant>
        </period>
    </context>
    <context id="From2025-08-012025-08-19_custom_SeriesCPrivatePlacementAgreementMember_custom_SeriesCPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:SeriesCPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">PMCB:SeriesCPrivatePlacementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-19</endDate>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="From2024-05-012025-04-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="From2024-05-012025-04-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_SeriesBWarrantsAndSettlementWarrantsAdjustedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">PMCB:SeriesBWarrantsAndSettlementWarrantsAdjustedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_SGAustraliaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">PMCB:SGAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_custom_VinDeBonaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PMCB:VinDeBonaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_VinDeBonaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PMCB:VinDeBonaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012025-01-31_custom_VinDeBonaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PMCB:VinDeBonaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012025-01-31_custom_VinDeBonaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PMCB:VinDeBonaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_SGAustriaAndSubsidiariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">PMCB:SGAustriaAndSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="From2025-05-152025-05-16_custom_HCWainwrightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">PMCB:HCWainwrightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-15</startDate>
            <endDate>2025-05-16</endDate>
        </period>
    </context>
    <context id="From2025-05-192025-05-20_custom_HCWainwrightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">PMCB:HCWainwrightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-19</startDate>
            <endDate>2025-05-20</endDate>
        </period>
    </context>
    <context id="From2025-05-152025-05-16_custom_HCWainwrightMember_custom_FirstWarrantIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">PMCB:HCWainwrightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:FirstWarrantIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-15</startDate>
            <endDate>2025-05-16</endDate>
        </period>
    </context>
    <context id="From2025-05-152025-05-16_custom_HCWainwrightMember_custom_AdditionalWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">PMCB:HCWainwrightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:AdditionalWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-15</startDate>
            <endDate>2025-05-16</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-19_custom_AdditionalWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:AdditionalWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-19</instant>
        </period>
    </context>
    <context id="From2025-08-182025-08-19_custom_FirstWarrantIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:FirstWarrantIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-18</startDate>
            <endDate>2025-08-19</endDate>
        </period>
    </context>
    <context id="From2025-08-182025-08-19_custom_AdditionalWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:AdditionalWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-18</startDate>
            <endDate>2025-08-19</endDate>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012025-01-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012025-01-31_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_custom_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012025-01-31_custom_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012025-01-31_custom_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_custom_PreferredSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:PreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_PreferredSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:PreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012025-01-31_custom_PreferredSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:PreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012025-01-31_custom_PreferredSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:PreferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012025-01-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2024-05-012025-01-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">PMCB:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="From2025-08-162025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SeriesCPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-16</startDate>
            <endDate>2025-08-17</endDate>
        </period>
    </context>
    <context id="AsOf2025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SeriesCPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-17</instant>
        </period>
    </context>
    <context id="AsOf2025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">PMCB:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SeriesCPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-17</instant>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SeriesCPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">PMCB:SeriesCPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_MeasurementInputRedemptionPremiumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">PMCB:MeasurementInputRedemptionPremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_MeasurementInputMarketInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">PMCB:MeasurementInputMarketInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_us-gaap_SeriesAPreferredStockMember_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_MeasurementInputExpectedTermMember_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_MeasurementInputRedemptionPremiumMember_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">PMCB:MeasurementInputRedemptionPremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_MeasurementInputMarketInterestRateMember_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">PMCB:MeasurementInputMarketInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="From2025-12-102025-12-11_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-10</startDate>
            <endDate>2025-12-11</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_TreasuryStockCommonMember266868390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_TreasuryStockCommonMember266868390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2025-10-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-10-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="From2025-11-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="From2025-05-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:DerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_MarketableEquitySecuritiesMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_MarketableEquitySecuritiesMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:MarketableEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_MoneyMarketAccountMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:MoneyMarketAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_MoneyMarketAccountMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:MoneyMarketAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_ConvertibleNoteReceivableMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:ConvertibleNoteReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_ConvertibleNoteReceivableMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:ConvertibleNoteReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_WarrantAssetFemasysMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantAssetFemasysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_WarrantAssetFemasysMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantAssetFemasysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_InvestmentInPreferredStockQCLSMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:InvestmentInPreferredStockQCLSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_InvestmentInPreferredStockQCLSMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:InvestmentInPreferredStockQCLSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="AsOf2026-01-31_custom_WarrantAssetQCLSMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantAssetQCLSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-01-31</instant>
        </period>
    </context>
    <context id="AsOf2025-04-30_custom_WarrantAssetQCLSMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001157075</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">PMCB:WarrantAssetQCLSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Year">
        <measure>PMCB:Year</measure>
    </unit>
    <unit id="Integer">
        <measure>PMCB:Integer</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-05-01to2026-01-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-05-01to2026-01-31" id="Fact000004">--04-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2025-05-01to2026-01-31" id="Fact000005">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-05-01to2026-01-31" id="Fact000006">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-05-01to2026-01-31" id="Fact000007">0001157075</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2026-01-31"
      id="xdx2ixbrl0126"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-05-012024-07-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-05-012024-07-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-05-012024-07-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-05-012024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:PreferredStockAccretion
      contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:PreferredStockAccretion
      contextRef="From2024-05-012024-07-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:PreferredStockAccretion
      contextRef="From2024-05-012024-07-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:PreferredStockAccretion
      contextRef="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:PreferredStockAccretion
      contextRef="From2024-05-012024-07-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:PreferredStockAccretion
      contextRef="From2024-05-012024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockSubjectToRedemption
      contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0477"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockSubjectToRedemption
      contextRef="From2024-05-012024-07-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockSubjectToRedemption
      contextRef="From2024-05-012024-07-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockSubjectToRedemption
      contextRef="From2024-05-012024-07-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockSubjectToRedemption
      contextRef="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockSubjectToRedemption
      contextRef="From2024-05-012024-07-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockSubjectToRedemption
      contextRef="From2024-05-012024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0483"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockSubjectToRedemption
      contextRef="From2024-05-012024-07-31"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockRedemption
      contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockRedemption
      contextRef="From2024-05-012024-07-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockRedemption
      contextRef="From2024-05-012024-07-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockRedemption
      contextRef="From2024-05-012024-07-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockRedemption
      contextRef="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockRedemption
      contextRef="From2024-05-012024-07-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0494"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockRedemption
      contextRef="From2024-05-012024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockRedemption
      contextRef="From2024-05-012024-07-31"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0501"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2024-05-012024-07-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2024-05-012024-07-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0505"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2024-05-012024-07-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2024-05-012024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-05-012024-07-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0512"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-05-012024-07-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0513"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-05-012024-07-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0514"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-05-012024-07-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0516"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0520"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0521"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-012024-07-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0522"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-012024-07-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-012024-07-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0524"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0525"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-012024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0527"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0530"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-05-012024-07-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-05-012024-07-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0533"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-05-012024-07-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-05-012024-07-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0536"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-05-012024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:FractionalSharesAdjustmentValue
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0560"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:FractionalSharesAdjustmentValue
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0561"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:FractionalSharesAdjustmentValue
      contextRef="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0562"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:FractionalSharesAdjustmentValue
      contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0563"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:FractionalSharesAdjustmentValue
      contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0564"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:FractionalSharesAdjustmentValue
      contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:FractionalSharesAdjustmentValue
      contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:FractionalSharesAdjustmentValue
      contextRef="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0567"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:FractionalSharesAdjustmentValue
      contextRef="From2024-08-012024-10-31"
      id="xdx2ixbrl0568"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0572"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0573"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0574"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0575"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0577"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0578"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0579"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:PreferredStockAccretion
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0583"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:PreferredStockAccretion
      contextRef="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0584"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:PreferredStockAccretion
      contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0585"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:PreferredStockAccretion
      contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0587"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:PreferredStockAccretion
      contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0588"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:PreferredStockAccretion
      contextRef="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0589"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockSubjectToRedemption
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0593"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockSubjectToRedemption
      contextRef="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0594"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockSubjectToRedemption
      contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0595"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockSubjectToRedemption
      contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0596"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockSubjectToRedemption
      contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0597"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockSubjectToRedemption
      contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0598"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockSubjectToRedemption
      contextRef="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockSubjectToRedemption
      contextRef="From2024-08-012024-10-31"
      id="xdx2ixbrl0600"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockRedemption
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0605"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockRedemption
      contextRef="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0606"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockRedemption
      contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0607"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockRedemption
      contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0608"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockRedemption
      contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0609"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockRedemption
      contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0610"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockRedemption
      contextRef="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0611"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesBPreferredStockRedemption
      contextRef="From2024-08-012024-10-31"
      id="xdx2ixbrl0612"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0616"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0617"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0618"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0619"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0621"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0622"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0623"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0626"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0627"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0628"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0629"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0630"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0631"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0632"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0636"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0637"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0638"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0639"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0640"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0641"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0643"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0646"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0647"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-08-012024-10-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0648"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0649"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0650"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0652"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0653"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-11-012025-01-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0676"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-11-012025-01-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0677"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-11-012025-01-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0678"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-11-012025-01-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0679"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-11-012025-01-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0681"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-11-012025-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0682"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-11-012025-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0683"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-11-012025-01-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0686"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-11-012025-01-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0687"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-11-012025-01-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0688"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-11-012025-01-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0689"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-11-012025-01-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0690"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-11-012025-01-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0691"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-11-012025-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0692"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-11-012025-01-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0696"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-11-012025-01-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0697"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-11-012025-01-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0698"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-11-012025-01-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0699"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-11-012025-01-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0700"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-11-012025-01-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0701"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-11-012025-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0703"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-11-012025-01-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0706"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-11-012025-01-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0707"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-11-012025-01-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0708"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-11-012025-01-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0709"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-11-012025-01-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0710"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-11-012025-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0712"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-11-012025-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0713"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-05-012025-07-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0754"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-05-012025-07-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0755"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-05-012025-07-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0756"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-05-012025-07-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0757"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-05-012025-07-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0759"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-05-012025-07-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0760"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-05-012025-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0761"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-05-012025-07-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0764"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-05-012025-07-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0765"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-05-012025-07-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0766"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-05-012025-07-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0767"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-05-012025-07-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0768"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-05-012025-07-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0769"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-05-012025-07-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0770"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-05-012025-07-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0774"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-05-012025-07-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0775"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-05-012025-07-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0776"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-05-012025-07-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0777"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-05-012025-07-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0778"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-05-012025-07-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0779"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-05-012025-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0781"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0802"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0803"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-08-012025-10-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0804"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-08-012025-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0805"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-08-012025-10-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0807"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-08-012025-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0808"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-08-012025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0809"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:IssuanceOfSeriesCPreferredStockAndWarrants
      contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0812"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:IssuanceOfSeriesCPreferredStockAndWarrants
      contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0813"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:IssuanceOfSeriesCPreferredStockAndWarrants
      contextRef="From2025-08-012025-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0815"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:IssuanceOfSeriesCPreferredStockAndWarrants
      contextRef="From2025-08-012025-10-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0816"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:IssuanceOfSeriesCPreferredStockAndWarrants
      contextRef="From2025-08-012025-10-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0817"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:IssuanceOfSeriesCPreferredStockAndWarrants
      contextRef="From2025-08-012025-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0818"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:IssuanceOfSeriesCPreferredStockAndWarrants
      contextRef="From2025-08-012025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0819"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:IssuanceOfSeriesCPreferredStockAndWarrants
      contextRef="From2025-08-012025-10-31"
      id="xdx2ixbrl0820"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockAccretion
      contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0824"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockAccretion
      contextRef="From2025-08-012025-10-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0826"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockAccretion
      contextRef="From2025-08-012025-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0827"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockAccretion
      contextRef="From2025-08-012025-10-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0829"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockAccretion
      contextRef="From2025-08-012025-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0830"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockAccretion
      contextRef="From2025-08-012025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0831"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockDividendSubjectToSettlement
      contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0834"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockDividendSubjectToSettlement
      contextRef="From2025-08-012025-10-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0836"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockDividendSubjectToSettlement
      contextRef="From2025-08-012025-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0837"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockDividendSubjectToSettlement
      contextRef="From2025-08-012025-10-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0838"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockDividendSubjectToSettlement
      contextRef="From2025-08-012025-10-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0839"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockDividendSubjectToSettlement
      contextRef="From2025-08-012025-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0840"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockDividendSubjectToSettlement
      contextRef="From2025-08-012025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0841"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockDividendSubjectToSettlement
      contextRef="From2025-08-012025-10-31"
      id="xdx2ixbrl0842"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockDividendsAccrual
      contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0844"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockDividendsAccrual
      contextRef="From2025-08-012025-10-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0846"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockDividendsAccrual
      contextRef="From2025-08-012025-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0847"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockDividendsAccrual
      contextRef="From2025-08-012025-10-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0849"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockDividendsAccrual
      contextRef="From2025-08-012025-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0850"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockDividendsAccrual
      contextRef="From2025-08-012025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0851"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0854"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0855"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-08-012025-10-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0856"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-08-012025-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0857"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-08-012025-10-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0858"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-08-012025-10-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0859"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-08-012025-10-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0860"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0864"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0865"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-08-012025-10-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0866"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-08-012025-10-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0867"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-08-012025-10-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0868"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-08-012025-10-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0869"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-08-012025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0871"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0892"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0893"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0894"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0895"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0897"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0898"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0899"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:StockIssuedUponVestingOfRestrictedStockUnits
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0902"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:StockIssuedUponVestingOfRestrictedStockUnits
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0903"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:StockIssuedUponVestingOfRestrictedStockUnits
      contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0904"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:StockIssuedUponVestingOfRestrictedStockUnits
      contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0908"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:StockIssuedUponVestingOfRestrictedStockUnits
      contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0909"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0916"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0917"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0918"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0921"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0922"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0923"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:PreferredStockAccretion
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0928"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:PreferredStockAccretion
      contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0930"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:PreferredStockAccretion
      contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0931"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:PreferredStockAccretion
      contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0933"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:PreferredStockAccretion
      contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0934"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:PreferredStockAccretion
      contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0935"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockRedeemed
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0938"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockRedeemed
      contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0940"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockRedeemed
      contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0943"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockRedeemed
      contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0944"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockRedeemed
      contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0945"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockSubjectToSettlement
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0952"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockSubjectToSettlement
      contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0954"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockSubjectToSettlement
      contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0955"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockSubjectToSettlement
      contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0956"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockSubjectToSettlement
      contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0957"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockSubjectToSettlement
      contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0958"
      unitRef="USD"
      xsi:nil="true"/>
    <PMCB:SeriesCPreferredStockSubjectToSettlement
      contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0959"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0962"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0964"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0965"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0967"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0968"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0969"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0972"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0973"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0974"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0975"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0976"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0977"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0978"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0982"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0983"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0984"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0985"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0986"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0987"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0989"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesBMember"
      id="xdx2ixbrl0992"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember"
      id="xdx2ixbrl0993"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-11-012026-01-31_custom_ContingentlyRedeemableWarrantsMember"
      id="xdx2ixbrl0994"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0995"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0996"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0997"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0998"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0999"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-11-012026-01-31"
      id="xdx2ixbrl1000"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="xdx2ixbrl1185"
      unitRef="USD">20165535</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="xdx2ixbrl1187"
      unitRef="USD">15172163</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2025-05-01to2026-01-31"
      decimals="INF"
      id="xdx2ixbrl1229"
      unitRef="Integer">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_LongTermPortionOfLegalSettlementMember"
      id="xdx2ixbrl1489"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-05-01to2026-01-31" id="Fact000016">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2025-05-01to2026-01-31" id="Fact000017">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-05-01to2026-01-31" id="Fact000018">2026-01-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2025-05-01to2026-01-31" id="Fact000019">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-05-01to2026-01-31" id="Fact000020">001-40699</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-05-01to2026-01-31" id="Fact000021">PHARMACYTE BIOTECH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-05-01to2026-01-31" id="Fact000022">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-05-01to2026-01-31" id="Fact000023">62-1772151</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-05-01to2026-01-31" id="Fact000024">3960 Howard Hughes Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-05-01to2026-01-31" id="Fact000025">Suite 500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-05-01to2026-01-31" id="Fact000026">Las Vegas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-05-01to2026-01-31" id="Fact000027">NV</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-05-01to2026-01-31" id="Fact000028">89169</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-05-01to2026-01-31" id="Fact000029">917</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-05-01to2026-01-31" id="Fact000030">595-2850</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2025-05-01to2026-01-31" id="Fact000031">Common Stock, Par Value $0.0001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2025-05-01to2026-01-31" id="Fact000032">PMCB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2025-05-01to2026-01-31" id="Fact000033">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2025-05-01to2026-01-31" id="Fact000034">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-05-01to2026-01-31" id="Fact000035">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-05-01to2026-01-31" id="Fact000036">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-05-01to2026-01-31" id="Fact000037">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-05-01to2026-01-31" id="Fact000038">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2025-05-01to2026-01-31" id="Fact000039">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-03-12"
      decimals="INF"
      id="Fact000040"
      unitRef="Shares">10735649</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000048"
      unitRef="USD">20165535</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000049"
      unitRef="USD">15172163</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000051"
      unitRef="USD">372251</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000052"
      unitRef="USD">366316</us-gaap:MarketableSecuritiesCurrent>
    <PMCB:WarrantAssetCurrent
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000054"
      unitRef="USD">0</PMCB:WarrantAssetCurrent>
    <PMCB:WarrantAssetCurrent
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000055"
      unitRef="USD">2917000</PMCB:WarrantAssetCurrent>
    <PMCB:ConvertibleNoteReceivableCurrent
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000057"
      unitRef="USD">0</PMCB:ConvertibleNoteReceivableCurrent>
    <PMCB:ConvertibleNoteReceivableCurrent
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000058"
      unitRef="USD">3696000</PMCB:ConvertibleNoteReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000060"
      unitRef="USD">158664</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000061"
      unitRef="USD">223759</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000063"
      unitRef="USD">20696450</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000064"
      unitRef="USD">22375238</us-gaap:AssetsCurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000069"
      unitRef="USD">1549427</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000070"
      unitRef="USD">1549427</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:InvestmentsAndOtherNoncurrentAssets
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000072"
      unitRef="USD">22472000</us-gaap:InvestmentsAndOtherNoncurrentAssets>
    <us-gaap:InvestmentsAndOtherNoncurrentAssets
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000073"
      unitRef="USD">22474000</us-gaap:InvestmentsAndOtherNoncurrentAssets>
    <PMCB:WarrantAssetNoncurrent
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000075"
      unitRef="USD">10242000</PMCB:WarrantAssetNoncurrent>
    <PMCB:WarrantAssetNoncurrent
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000076"
      unitRef="USD">5701000</PMCB:WarrantAssetNoncurrent>
    <PMCB:WarrantAssetFemasys
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000078"
      unitRef="USD">906000</PMCB:WarrantAssetFemasys>
    <PMCB:WarrantAssetFemasys
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000079"
      unitRef="USD">3061000</PMCB:WarrantAssetFemasys>
    <us-gaap:OtherAssets
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000081"
      unitRef="USD">7688</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000082"
      unitRef="USD">7688</us-gaap:OtherAssets>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000084"
      unitRef="USD">35177115</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000085"
      unitRef="USD">32793115</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000087"
      unitRef="USD">55873565</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000088"
      unitRef="USD">55168353</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000096"
      unitRef="USD">1200082</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000097"
      unitRef="USD">399204</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000099"
      unitRef="USD">445656</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000100"
      unitRef="USD">2515080</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000102"
      unitRef="USD">32491</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000103"
      unitRef="USD">0</us-gaap:DividendsPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000105"
      unitRef="USD">1678229</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000106"
      unitRef="USD">2914284</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000111"
      unitRef="USD">0</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000112"
      unitRef="USD">25000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <PMCB:WarrantLiabilitiesNoncurrent
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000114"
      unitRef="USD">13657000</PMCB:WarrantLiabilitiesNoncurrent>
    <PMCB:WarrantLiabilitiesNoncurrent
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000115"
      unitRef="USD">338000</PMCB:WarrantLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000117"
      unitRef="USD">1136000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000118"
      unitRef="USD">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000120"
      unitRef="USD">14793000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000121"
      unitRef="USD">363000</us-gaap:OtherLiabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000123"
      unitRef="USD">16471229</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000124"
      unitRef="USD">3277284</us-gaap:Liabilities>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2026-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000132"
      unitRef="Shares">35000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2025-04-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000134"
      unitRef="Shares">35000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2026-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000136"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2025-04-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000138"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital
      contextRef="AsOf2026-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact000140"
      unitRef="USD">1000</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital
      contextRef="AsOf2025-04-30_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact000142"
      unitRef="USD">1000</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2026-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000144"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2026-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000146"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2025-04-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000148"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2025-04-30_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact000150"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2026-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact000152"
      unitRef="USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2025-04-30_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact000154"
      unitRef="USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2026-01-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000156"
      unitRef="Shares">7000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2025-04-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000158"
      unitRef="Shares">7000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2026-01-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000160"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="AsOf2025-04-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000162"
      unitRef="USDPShares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital
      contextRef="AsOf2026-01-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000164"
      unitRef="USD">1000</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital
      contextRef="AsOf2025-04-30_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000166"
      unitRef="USD">1000</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2026-01-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000168"
      unitRef="Shares">4766</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2026-01-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000170"
      unitRef="Shares">4766</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2025-04-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000172"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="AsOf2025-04-30_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact000174"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="AsOf2026-01-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000176"
      unitRef="USD">4765671</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2026-01-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000178"
      unitRef="USD">872323</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2025-04-30_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact000180"
      unitRef="USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <PMCB:ContingentlyRedeemableWarrants
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000182"
      unitRef="USD">417000</PMCB:ContingentlyRedeemableWarrants>
    <PMCB:ContingentlyRedeemableWarrants
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000183"
      unitRef="USD">0</PMCB:ContingentlyRedeemableWarrants>
    <PMCB:TotalTemporaryEquity
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000185"
      unitRef="USD">1289323</PMCB:TotalTemporaryEquity>
    <PMCB:TotalTemporaryEquity
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000186"
      unitRef="USD">0</PMCB:TotalTemporaryEquity>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-01-31"
      decimals="INF"
      id="Fact000191"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-04-30"
      decimals="INF"
      id="Fact000193"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-01-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000195"
      unitRef="Shares">1</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-04-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000197"
      unitRef="Shares">1</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-01-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000199"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-04-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000201"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-01-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000203"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-01-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000205"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-04-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000207"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-04-30_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000209"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2026-01-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000211"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-04-30_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact000213"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-01-31"
      decimals="INF"
      id="Fact000218"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-04-30"
      decimals="INF"
      id="Fact000220"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-01-31"
      decimals="INF"
      id="Fact000222"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-04-30"
      decimals="INF"
      id="Fact000224"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-01-31"
      decimals="INF"
      id="Fact000226"
      unitRef="Shares">26005715</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-04-30"
      decimals="INF"
      id="Fact000228"
      unitRef="Shares">21672095</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-01-31"
      decimals="INF"
      id="Fact000230"
      unitRef="Shares">10735649</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-04-30"
      decimals="INF"
      id="Fact000232"
      unitRef="Shares">6795779</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000215"
      unitRef="USD">2602</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000216"
      unitRef="USD">2167</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000234"
      unitRef="USD">183141663</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000235"
      unitRef="USD">181489647</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000237"
      unitRef="USD">-100000171</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000238"
      unitRef="USD">-84968960</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2026-01-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000243"
      unitRef="Shares">15270066</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2025-04-30_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000245"
      unitRef="Shares">14876316</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000240"
      unitRef="USD">45009541</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000241"
      unitRef="USD">44607916</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000247"
      unitRef="USD">-21540</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000248"
      unitRef="USD">-23869</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000250"
      unitRef="USD">38113013</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000251"
      unitRef="USD">51891069</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact000253"
      unitRef="USD">55873565</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000254"
      unitRef="USD">55168353</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000256"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000257"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000258"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000259"
      unitRef="USD">0</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000266"
      unitRef="USD">93113</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000267"
      unitRef="USD">118196</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000268"
      unitRef="USD">329355</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000269"
      unitRef="USD">311682</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000271"
      unitRef="USD">2024989</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000272"
      unitRef="USD">842056</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000273"
      unitRef="USD">4013103</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000274"
      unitRef="USD">3024316</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000276"
      unitRef="USD">2118102</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000277"
      unitRef="USD">960252</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000278"
      unitRef="USD">4342458</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000279"
      unitRef="USD">3335998</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000281"
      unitRef="USD">-2118102</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000282"
      unitRef="USD">-960252</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000283"
      unitRef="USD">-4342458</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000284"
      unitRef="USD">-3335998</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000291"
      unitRef="USD">230668</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000292"
      unitRef="USD">255692</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000293"
      unitRef="USD">654848</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000294"
      unitRef="USD">1185686</us-gaap:InterestIncomeOther>
    <PMCB:ChangeInFairValueOfWarrantLiability
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000296"
      unitRef="USD">1895865</PMCB:ChangeInFairValueOfWarrantLiability>
    <PMCB:ChangeInFairValueOfWarrantLiability
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000297"
      unitRef="USD">4487000</PMCB:ChangeInFairValueOfWarrantLiability>
    <PMCB:ChangeInFairValueOfWarrantLiability
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000298"
      unitRef="USD">-8335135</PMCB:ChangeInFairValueOfWarrantLiability>
    <PMCB:ChangeInFairValueOfWarrantLiability
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000299"
      unitRef="USD">8400000</PMCB:ChangeInFairValueOfWarrantLiability>
    <PMCB:ChangeInFairValueOfDerivativeLiability
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000301"
      unitRef="USD">557000</PMCB:ChangeInFairValueOfDerivativeLiability>
    <PMCB:ChangeInFairValueOfDerivativeLiability
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000302"
      unitRef="USD">0</PMCB:ChangeInFairValueOfDerivativeLiability>
    <PMCB:ChangeInFairValueOfDerivativeLiability
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000303"
      unitRef="USD">859000</PMCB:ChangeInFairValueOfDerivativeLiability>
    <PMCB:ChangeInFairValueOfDerivativeLiability
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000304"
      unitRef="USD">2184000</PMCB:ChangeInFairValueOfDerivativeLiability>
    <PMCB:ChangeInFairValueOfConvertibleNoteReceivable
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000306"
      unitRef="USD">0</PMCB:ChangeInFairValueOfConvertibleNoteReceivable>
    <PMCB:ChangeInFairValueOfConvertibleNoteReceivable
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000307"
      unitRef="USD">-79000</PMCB:ChangeInFairValueOfConvertibleNoteReceivable>
    <PMCB:ChangeInFairValueOfConvertibleNoteReceivable
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000308"
      unitRef="USD">1304000</PMCB:ChangeInFairValueOfConvertibleNoteReceivable>
    <PMCB:ChangeInFairValueOfConvertibleNoteReceivable
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000309"
      unitRef="USD">601000</PMCB:ChangeInFairValueOfConvertibleNoteReceivable>
    <PMCB:ChangeInFairValueOfWarrantAssetFemasys
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000311"
      unitRef="USD">-214000</PMCB:ChangeInFairValueOfWarrantAssetFemasys>
    <PMCB:ChangeInFairValueOfWarrantAssetFemasys
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000312"
      unitRef="USD">-596000</PMCB:ChangeInFairValueOfWarrantAssetFemasys>
    <PMCB:ChangeInFairValueOfWarrantAssetFemasys
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000313"
      unitRef="USD">-2155000</PMCB:ChangeInFairValueOfWarrantAssetFemasys>
    <PMCB:ChangeInFairValueOfWarrantAssetFemasys
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000314"
      unitRef="USD">-1830000</PMCB:ChangeInFairValueOfWarrantAssetFemasys>
    <PMCB:ChangeInFairValueOfInvestment
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000316"
      unitRef="USD">1725000</PMCB:ChangeInFairValueOfInvestment>
    <PMCB:ChangeInFairValueOfInvestment
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000317"
      unitRef="USD">-3031000</PMCB:ChangeInFairValueOfInvestment>
    <PMCB:ChangeInFairValueOfInvestment
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000318"
      unitRef="USD">-3485000</PMCB:ChangeInFairValueOfInvestment>
    <PMCB:ChangeInFairValueOfInvestment
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000319"
      unitRef="USD">-1642050</PMCB:ChangeInFairValueOfInvestment>
    <PMCB:ChangeInFairValueOfWarrantAsset
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000321"
      unitRef="USD">-1200000</PMCB:ChangeInFairValueOfWarrantAsset>
    <PMCB:ChangeInFairValueOfWarrantAsset
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000322"
      unitRef="USD">-3194000</PMCB:ChangeInFairValueOfWarrantAsset>
    <PMCB:ChangeInFairValueOfWarrantAsset
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000323"
      unitRef="USD">18000</PMCB:ChangeInFairValueOfWarrantAsset>
    <PMCB:ChangeInFairValueOfWarrantAsset
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000324"
      unitRef="USD">-8123684</PMCB:ChangeInFairValueOfWarrantAsset>
    <PMCB:GainOnFairValueOfWarrantsWainwright
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000326"
      unitRef="USD">0</PMCB:GainOnFairValueOfWarrantsWainwright>
    <PMCB:GainOnFairValueOfWarrantsWainwright
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000327"
      unitRef="USD">0</PMCB:GainOnFairValueOfWarrantsWainwright>
    <PMCB:GainOnFairValueOfWarrantsWainwright
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000328"
      unitRef="USD">106000</PMCB:GainOnFairValueOfWarrantsWainwright>
    <PMCB:GainOnFairValueOfWarrantsWainwright
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000329"
      unitRef="USD">0</PMCB:GainOnFairValueOfWarrantsWainwright>
    <PMCB:GainOnRelatedPartyInvestmentQcls
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000331"
      unitRef="USD">0</PMCB:GainOnRelatedPartyInvestmentQcls>
    <PMCB:GainOnRelatedPartyInvestmentQcls
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000332"
      unitRef="USD">0</PMCB:GainOnRelatedPartyInvestmentQcls>
    <PMCB:GainOnRelatedPartyInvestmentQcls
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000333"
      unitRef="USD">2089000</PMCB:GainOnRelatedPartyInvestmentQcls>
    <PMCB:GainOnRelatedPartyInvestmentQcls
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000334"
      unitRef="USD">21395734</PMCB:GainOnRelatedPartyInvestmentQcls>
    <PMCB:IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000336"
      unitRef="USD">0</PMCB:IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants>
    <PMCB:IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000337"
      unitRef="USD">0</PMCB:IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants>
    <PMCB:IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000338"
      unitRef="USD">-1234553</PMCB:IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants>
    <PMCB:IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000339"
      unitRef="USD">0</PMCB:IssuanceCostsSeriesCConvertiblePreferredStockAndWarrants>
    <PMCB:LossOnIssuanceOfSeriesCConvertiblePreferredStock
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000341"
      unitRef="USD">0</PMCB:LossOnIssuanceOfSeriesCConvertiblePreferredStock>
    <PMCB:LossOnIssuanceOfSeriesCConvertiblePreferredStock
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000342"
      unitRef="USD">0</PMCB:LossOnIssuanceOfSeriesCConvertiblePreferredStock>
    <PMCB:LossOnIssuanceOfSeriesCConvertiblePreferredStock
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000343"
      unitRef="USD">-215000</PMCB:LossOnIssuanceOfSeriesCConvertiblePreferredStock>
    <PMCB:LossOnIssuanceOfSeriesCConvertiblePreferredStock
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000344"
      unitRef="USD">0</PMCB:LossOnIssuanceOfSeriesCConvertiblePreferredStock>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000346"
      unitRef="USD">-128939</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000347"
      unitRef="USD">72632</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000348"
      unitRef="USD">-294065</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000349"
      unitRef="USD">72632</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000351"
      unitRef="USD">-632</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000352"
      unitRef="USD">-400</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000353"
      unitRef="USD">-848</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000354"
      unitRef="USD">-852</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000356"
      unitRef="USD">2864962</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000357"
      unitRef="USD">-2085076</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000358"
      unitRef="USD">-10688753</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000359"
      unitRef="USD">22242466</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000361"
      unitRef="USD">746860</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000362"
      unitRef="USD">-3045328</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000363"
      unitRef="USD">-15031211</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000364"
      unitRef="USD">18906468</us-gaap:NetIncomeLoss>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000366"
      unitRef="USD">98458</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000367"
      unitRef="USD">-0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000368"
      unitRef="USD">195097</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000369"
      unitRef="USD">1129759</us-gaap:DividendsPreferredStock>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000371"
      unitRef="USD">2204657</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000372"
      unitRef="USD">-0</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000373"
      unitRef="USD">3106653</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000374"
      unitRef="USD">3193404</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000376"
      unitRef="USD">-1556255</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000377"
      unitRef="USD">-3045328</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000378"
      unitRef="USD">-18332961</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000379"
      unitRef="USD">14583305</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-11-012026-01-31"
      decimals="INF"
      id="Fact000381"
      unitRef="USDPShares">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-11-012026-01-31"
      decimals="INF"
      id="Fact000383"
      unitRef="USDPShares">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-11-012025-01-31"
      decimals="INF"
      id="Fact000385"
      unitRef="USDPShares">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-11-012025-01-31"
      decimals="INF"
      id="Fact000387"
      unitRef="USDPShares">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-05-01to2026-01-31"
      decimals="INF"
      id="Fact000389"
      unitRef="USDPShares">-2.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-05-01to2026-01-31"
      decimals="INF"
      id="Fact000391"
      unitRef="USDPShares">-2.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-05-012025-01-31"
      decimals="INF"
      id="Fact000393"
      unitRef="USDPShares">1.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-05-012025-01-31"
      decimals="INF"
      id="Fact000395"
      unitRef="USDPShares">1.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-11-012026-01-31"
      decimals="INF"
      id="Fact000397"
      unitRef="Shares">9262829</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-11-012026-01-31"
      decimals="INF"
      id="Fact000399"
      unitRef="Shares">9262829</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-11-012025-01-31"
      decimals="INF"
      id="Fact000401"
      unitRef="Shares">6960014</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-11-012025-01-31"
      decimals="INF"
      id="Fact000403"
      unitRef="Shares">6960014</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-05-01to2026-01-31"
      decimals="INF"
      id="Fact000405"
      unitRef="Shares">7618128</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-05-01to2026-01-31"
      decimals="INF"
      id="Fact000407"
      unitRef="Shares">7618128</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-05-012025-01-31"
      decimals="INF"
      id="Fact000409"
      unitRef="Shares">7487813</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-05-012025-01-31"
      decimals="INF"
      id="Fact000411"
      unitRef="Shares">7487813</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000413"
      unitRef="USD">746860</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000414"
      unitRef="USD">-3045328</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000415"
      unitRef="USD">-15031211</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000416"
      unitRef="USD">18906468</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000423"
      unitRef="USD">2587</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000424"
      unitRef="USD">-1219</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000425"
      unitRef="USD">2329</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000426"
      unitRef="USD">-975</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000428"
      unitRef="USD">2587</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000429"
      unitRef="USD">-1219</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000430"
      unitRef="USD">2329</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000431"
      unitRef="USD">-975</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000433"
      unitRef="USD">749447</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000434"
      unitRef="USD">-3046547</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact000435"
      unitRef="USD">-15028882</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact000436"
      unitRef="USD">18905493</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-04-30_custom_PreferredStockSeriesBMember"
      decimals="INF"
      id="Fact000448"
      unitRef="Shares">14646</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-04-30_custom_PreferredStockSeriesBMember"
      decimals="0"
      id="Fact000438"
      unitRef="USD">11867016</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-04-30_custom_PreferredStockSeriesCMember"
      decimals="INF"
      id="Fact000450"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-04-30_custom_PreferredStockSeriesCMember"
      decimals="0"
      id="Fact000439"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-04-30_custom_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="Fact000440"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-04-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000452"
      unitRef="Shares">21672078</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-04-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000441"
      unitRef="USD">2167</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-04-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000442"
      unitRef="USD">185334173</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2024-04-30_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000454"
      unitRef="Shares">13634454</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-04-30_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000443"
      unitRef="USD">-42040216</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-04-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000444"
      unitRef="USD">-115625010</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-04-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000445"
      unitRef="USD">-23511</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact000446"
      unitRef="USD">27647603</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-05-012024-07-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000460"
      unitRef="USD">222677</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-05-012024-07-31"
      decimals="0"
      id="Fact000464"
      unitRef="USD">222677</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <PMCB:PreferredStockAccretion
      contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember"
      decimals="0"
      id="Fact000466"
      unitRef="USD">2148047</PMCB:PreferredStockAccretion>
    <PMCB:PreferredStockAccretion
      contextRef="From2024-05-012024-07-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000470"
      unitRef="USD">-2148047</PMCB:PreferredStockAccretion>
    <PMCB:PreferredStockAccretion
      contextRef="From2024-05-012024-07-31"
      decimals="0"
      id="Fact000474"
      unitRef="USD">-2148047</PMCB:PreferredStockAccretion>
    <PMCB:SeriesBPreferredStockRedeemedShares
      contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember"
      decimals="INF"
      id="Fact000486"
      unitRef="Shares">-2917</PMCB:SeriesBPreferredStockRedeemedShares>
    <PMCB:SeriesBPreferredStockSubjectToRedemption
      contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember"
      decimals="0"
      id="Fact000476"
      unitRef="USD">-2893144</PMCB:SeriesBPreferredStockSubjectToRedemption>
    <PMCB:SeriesBPreferredStockSubjectToRedemptionShares
      contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember"
      decimals="INF"
      id="Fact000498"
      unitRef="Shares">-5833</PMCB:SeriesBPreferredStockSubjectToRedemptionShares>
    <PMCB:SeriesBPreferredStockRedemption
      contextRef="From2024-05-012024-07-31_custom_PreferredStockSeriesBMember"
      decimals="0"
      id="Fact000488"
      unitRef="USD">-5788805</PMCB:SeriesBPreferredStockRedemption>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2024-05-012024-07-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000504"
      unitRef="USD">685801</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2024-05-012024-07-31"
      decimals="0"
      id="Fact000508"
      unitRef="USD">685801</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-05-012024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000517"
      unitRef="USD">183</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-05-012024-07-31"
      decimals="0"
      id="Fact000518"
      unitRef="USD">183</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-012024-07-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000526"
      unitRef="USD">23421355</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-012024-07-31"
      decimals="0"
      id="Fact000528"
      unitRef="USD">23421355</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000540"
      unitRef="Shares">320346</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-05-012024-07-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000535"
      unitRef="USD">749600</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-05-012024-07-31"
      decimals="0"
      id="Fact000538"
      unitRef="USD">749600</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-07-31_custom_PreferredStockSeriesBMember"
      decimals="INF"
      id="Fact000552"
      unitRef="Shares">5896</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-07-31_custom_PreferredStockSeriesBMember"
      decimals="0"
      id="Fact000542"
      unitRef="USD">5333114</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-07-31_custom_PreferredStockSeriesCMember"
      decimals="INF"
      id="Fact000554"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-07-31_custom_PreferredStockSeriesCMember"
      decimals="0"
      id="Fact000543"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-07-31_custom_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="Fact000544"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-07-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000556"
      unitRef="Shares">21672078</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-07-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000545"
      unitRef="USD">2167</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-07-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000546"
      unitRef="USD">182723002</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2024-07-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000558"
      unitRef="Shares">13954800</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-07-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000547"
      unitRef="USD">-42789816</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-07-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000548"
      unitRef="USD">-92203655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000549"
      unitRef="USD">-23328</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-07-31"
      decimals="0"
      id="Fact000550"
      unitRef="USD">47708370</us-gaap:StockholdersEquity>
    <PMCB:FractionalSharesAdjustmentShares
      contextRef="From2024-08-012024-10-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000570"
      unitRef="Shares">17</PMCB:FractionalSharesAdjustmentShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000576"
      unitRef="USD">119155</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000580"
      unitRef="USD">119155</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <PMCB:PreferredStockAccretion
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember"
      decimals="0"
      id="Fact000582"
      unitRef="USD">1045357</PMCB:PreferredStockAccretion>
    <PMCB:PreferredStockAccretion
      contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000586"
      unitRef="USD">-1045357</PMCB:PreferredStockAccretion>
    <PMCB:PreferredStockAccretion
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000590"
      unitRef="USD">-1045357</PMCB:PreferredStockAccretion>
    <PMCB:SeriesBPreferredStockRedeemedShares
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember"
      decimals="INF"
      id="Fact000602"
      unitRef="Shares">-2917</PMCB:SeriesBPreferredStockRedeemedShares>
    <PMCB:SeriesBPreferredStockSubjectToRedemption
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember"
      decimals="0"
      id="Fact000592"
      unitRef="USD">-2868607</PMCB:SeriesBPreferredStockSubjectToRedemption>
    <PMCB:SeriesBPreferredStockSubjectToRedemptionShares
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember"
      decimals="INF"
      id="Fact000614"
      unitRef="Shares">-2979</PMCB:SeriesBPreferredStockSubjectToRedemptionShares>
    <PMCB:SeriesBPreferredStockRedemption
      contextRef="From2024-08-012024-10-31_custom_PreferredStockSeriesBMember"
      decimals="0"
      id="Fact000604"
      unitRef="USD">-3509864</PMCB:SeriesBPreferredStockRedemption>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2024-08-012024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000620"
      unitRef="USD">443958</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000624"
      unitRef="USD">443958</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-08-012024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000633"
      unitRef="USD">61</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000634"
      unitRef="USD">61</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-08-012024-10-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000642"
      unitRef="USD">-1469560</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000644"
      unitRef="USD">-1469560</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000656"
      unitRef="Shares">683036</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-08-012024-10-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000651"
      unitRef="USD">1417565</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-08-012024-10-31"
      decimals="0"
      id="Fact000654"
      unitRef="USD">1417565</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-10-31_custom_PreferredStockSeriesBMember"
      decimals="INF"
      id="Fact000668"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-10-31_custom_PreferredStockSeriesBMember"
      decimals="0"
      id="Fact000658"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-10-31_custom_PreferredStockSeriesCMember"
      decimals="INF"
      id="Fact000670"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-10-31_custom_PreferredStockSeriesCMember"
      decimals="0"
      id="Fact000659"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-10-31_custom_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="Fact000660"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-10-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000672"
      unitRef="Shares">21672095</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-10-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000661"
      unitRef="USD">2167</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000662"
      unitRef="USD">181352842</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2024-10-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000674"
      unitRef="Shares">14637836</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-10-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000663"
      unitRef="USD">-44207381</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-10-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000664"
      unitRef="USD">-93673215</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000665"
      unitRef="USD">-23267</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-10-31"
      decimals="0"
      id="Fact000666"
      unitRef="USD">43451146</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-11-012025-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000680"
      unitRef="USD">72861</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000684"
      unitRef="USD">72861</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-11-012025-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000693"
      unitRef="USD">-1219</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000694"
      unitRef="USD">-1219</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-11-012025-01-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000702"
      unitRef="USD">-3045328</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000704"
      unitRef="USD">-3045328</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2024-11-012025-01-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000716"
      unitRef="Shares">129365</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-11-012025-01-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000711"
      unitRef="USD">227275</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact000714"
      unitRef="USD">227275</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-01-31_custom_PreferredStockSeriesBMember"
      decimals="INF"
      id="Fact000728"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-01-31_custom_PreferredStockSeriesBMember"
      decimals="0"
      id="Fact000718"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-01-31_custom_PreferredStockSeriesCMember"
      decimals="INF"
      id="Fact000730"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-01-31_custom_PreferredStockSeriesCMember"
      decimals="0"
      id="Fact000719"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-01-31_custom_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="Fact000720"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000732"
      unitRef="Shares">21672095</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-01-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000721"
      unitRef="USD">2167</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000722"
      unitRef="USD">181425703</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2025-01-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000734"
      unitRef="Shares">14767201</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-01-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000723"
      unitRef="USD">-44434656</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-01-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000724"
      unitRef="USD">-96718543</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000725"
      unitRef="USD">-24486</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-01-31"
      decimals="0"
      id="Fact000726"
      unitRef="USD">40250185</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-04-30_custom_PreferredStockSeriesBMember"
      decimals="INF"
      id="Fact000746"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-04-30_custom_PreferredStockSeriesBMember"
      decimals="0"
      id="Fact000736"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-04-30_custom_PreferredStockSeriesCMember"
      decimals="INF"
      id="Fact000748"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-04-30_custom_PreferredStockSeriesCMember"
      decimals="0"
      id="Fact000737"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-04-30_custom_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="Fact000738"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-04-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000750"
      unitRef="Shares">21672095</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-04-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000739"
      unitRef="USD">2167</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-04-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000740"
      unitRef="USD">181489647</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2025-04-30_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000752"
      unitRef="Shares">14876316</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-04-30_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000741"
      unitRef="USD">-44607916</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-04-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000742"
      unitRef="USD">-84968960</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-04-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000743"
      unitRef="USD">-23869</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact000744"
      unitRef="USD">51891069</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-05-012025-07-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000758"
      unitRef="USD">60492</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-05-012025-07-31"
      decimals="0"
      id="Fact000762"
      unitRef="USD">60492</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-05-012025-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000771"
      unitRef="USD">123</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-05-012025-07-31"
      decimals="0"
      id="Fact000772"
      unitRef="USD">123</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-05-012025-07-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000780"
      unitRef="USD">-8360096</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-05-012025-07-31"
      decimals="0"
      id="Fact000782"
      unitRef="USD">-8360096</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-07-31_custom_PreferredStockSeriesBMember"
      decimals="INF"
      id="Fact000794"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-07-31_custom_PreferredStockSeriesBMember"
      decimals="0"
      id="Fact000784"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-07-31_custom_PreferredStockSeriesCMember"
      decimals="INF"
      id="Fact000796"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-07-31_custom_PreferredStockSeriesCMember"
      decimals="0"
      id="Fact000785"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-07-31_custom_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="Fact000786"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-07-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000798"
      unitRef="Shares">21672095</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-07-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000787"
      unitRef="USD">2167</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-07-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000788"
      unitRef="USD">181550139</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2025-07-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000800"
      unitRef="Shares">14876316</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-07-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000789"
      unitRef="USD">-44607916</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-07-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000790"
      unitRef="USD">-93329056</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-07-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000791"
      unitRef="USD">-23746</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-07-31"
      decimals="0"
      id="Fact000792"
      unitRef="USD">43591588</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-08-012025-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000806"
      unitRef="USD">60492</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-08-012025-10-31"
      decimals="0"
      id="Fact000810"
      unitRef="USD">60492</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <PMCB:IssuanceOfSeriesCPreferredStockAndWarrantsShares
      contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesCMember"
      decimals="INF"
      id="Fact000822"
      unitRef="Shares">7000</PMCB:IssuanceOfSeriesCPreferredStockAndWarrantsShares>
    <PMCB:IssuanceOfSeriesCPreferredStockAndWarrants
      contextRef="From2025-08-012025-10-31_custom_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="Fact000814"
      unitRef="USD">417000</PMCB:IssuanceOfSeriesCPreferredStockAndWarrants>
    <PMCB:SeriesCPreferredStockAccretion
      contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesCMember"
      decimals="0"
      id="Fact000825"
      unitRef="USD">901996</PMCB:SeriesCPreferredStockAccretion>
    <PMCB:SeriesCPreferredStockAccretion
      contextRef="From2025-08-012025-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000828"
      unitRef="USD">-901996</PMCB:SeriesCPreferredStockAccretion>
    <PMCB:SeriesCPreferredStockAccretion
      contextRef="From2025-08-012025-10-31"
      decimals="0"
      id="Fact000832"
      unitRef="USD">-901996</PMCB:SeriesCPreferredStockAccretion>
    <PMCB:SeriesCPreferredStockDividendSubjectToSettlement
      contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesCMember"
      decimals="0"
      id="Fact000835"
      unitRef="USD">-96639</PMCB:SeriesCPreferredStockDividendSubjectToSettlement>
    <PMCB:SeriesCPreferredStockDividendsAccrual
      contextRef="From2025-08-012025-10-31_custom_PreferredStockSeriesCMember"
      decimals="0"
      id="Fact000845"
      unitRef="USD">96639</PMCB:SeriesCPreferredStockDividendsAccrual>
    <PMCB:SeriesCPreferredStockDividendsAccrual
      contextRef="From2025-08-012025-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000848"
      unitRef="USD">-96639</PMCB:SeriesCPreferredStockDividendsAccrual>
    <PMCB:SeriesCPreferredStockDividendsAccrual
      contextRef="From2025-08-012025-10-31"
      decimals="0"
      id="Fact000852"
      unitRef="USD">-96639</PMCB:SeriesCPreferredStockDividendsAccrual>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-08-012025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000861"
      unitRef="USD">-381</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-08-012025-10-31"
      decimals="0"
      id="Fact000862"
      unitRef="USD">-381</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-08-012025-10-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000870"
      unitRef="USD">-7417975</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-08-012025-10-31"
      decimals="0"
      id="Fact000872"
      unitRef="USD">-7417975</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-10-31_custom_PreferredStockSeriesBMember"
      decimals="INF"
      id="Fact000884"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-10-31_custom_PreferredStockSeriesBMember"
      decimals="0"
      id="Fact000874"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-10-31_custom_PreferredStockSeriesCMember"
      decimals="INF"
      id="Fact000886"
      unitRef="Shares">7000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-10-31_custom_PreferredStockSeriesCMember"
      decimals="0"
      id="Fact000875"
      unitRef="USD">901996</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-10-31_custom_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="Fact000876"
      unitRef="USD">417000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-10-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000888"
      unitRef="Shares">21672095</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-10-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000877"
      unitRef="USD">2167</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-10-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000878"
      unitRef="USD">180611996</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2025-10-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000890"
      unitRef="Shares">14876316</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-10-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000879"
      unitRef="USD">-44607916</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-10-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000880"
      unitRef="USD">-100747031</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-10-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000881"
      unitRef="USD">-24127</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-10-31"
      decimals="0"
      id="Fact000882"
      unitRef="USD">35235089</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000896"
      unitRef="USD">60492</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000900"
      unitRef="USD">60492</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <PMCB:StockIssuedUponVestingOfRestrictedStockUnitsShares
      contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000912"
      unitRef="Shares">875000</PMCB:StockIssuedUponVestingOfRestrictedStockUnitsShares>
    <PMCB:StockIssuedUponVestingOfRestrictedStockUnits
      contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000905"
      unitRef="USD">89</PMCB:StockIssuedUponVestingOfRestrictedStockUnits>
    <PMCB:StockIssuedUponVestingOfRestrictedStockUnits
      contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000906"
      unitRef="USD">892411</PMCB:StockIssuedUponVestingOfRestrictedStockUnits>
    <PMCB:StockIssuedUponVestingOfRestrictedStockUnitsShares
      contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact000914"
      unitRef="Shares">-393750</PMCB:StockIssuedUponVestingOfRestrictedStockUnitsShares>
    <PMCB:StockIssuedUponVestingOfRestrictedStockUnits
      contextRef="From2025-11-012026-01-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact000907"
      unitRef="USD">-401625</PMCB:StockIssuedUponVestingOfRestrictedStockUnits>
    <PMCB:StockIssuedUponVestingOfRestrictedStockUnits
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000910"
      unitRef="USD">490875</PMCB:StockIssuedUponVestingOfRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000926"
      unitRef="Shares">1100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000919"
      unitRef="USD">110</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000920"
      unitRef="USD">1645785</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000924"
      unitRef="USD">1645895</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <PMCB:PreferredStockAccretion
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember"
      decimals="0"
      id="Fact000929"
      unitRef="USD">2204657</PMCB:PreferredStockAccretion>
    <PMCB:PreferredStockAccretion
      contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000932"
      unitRef="USD">-2204657</PMCB:PreferredStockAccretion>
    <PMCB:PreferredStockAccretion
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000936"
      unitRef="USD">-2204657</PMCB:PreferredStockAccretion>
    <PMCB:SeriesCPreferredStockRedeemedShares
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember"
      decimals="INF"
      id="Fact000948"
      unitRef="Shares">-2234</PMCB:SeriesCPreferredStockRedeemedShares>
    <PMCB:SeriesCPreferredStockRedeemed
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember"
      decimals="0"
      id="Fact000939"
      unitRef="USD">-2234330</PMCB:SeriesCPreferredStockRedeemed>
    <PMCB:SeriesCPreferredStockRedeemedShares
      contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000950"
      unitRef="Shares">2358620</PMCB:SeriesCPreferredStockRedeemedShares>
    <PMCB:SeriesCPreferredStockRedeemed
      contextRef="From2025-11-012026-01-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000941"
      unitRef="USD">236</PMCB:SeriesCPreferredStockRedeemed>
    <PMCB:SeriesCPreferredStockRedeemed
      contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000942"
      unitRef="USD">2234094</PMCB:SeriesCPreferredStockRedeemed>
    <PMCB:SeriesCPreferredStockRedeemed
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000946"
      unitRef="USD">2234330</PMCB:SeriesCPreferredStockRedeemed>
    <PMCB:SeriesCPreferredStockSubjectToSettlement
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember"
      decimals="0"
      id="Fact000953"
      unitRef="USD">-98458</PMCB:SeriesCPreferredStockSubjectToSettlement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-11-012026-01-31_custom_PreferredStockSeriesCMember"
      decimals="0"
      id="Fact000963"
      unitRef="USD">-98458</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-11-012026-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000966"
      unitRef="USD">98458</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000970"
      unitRef="USD">98458</us-gaap:AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-11-012026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000979"
      unitRef="USD">2587</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000980"
      unitRef="USD">2587</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-11-012026-01-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000988"
      unitRef="USD">746860</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact000990"
      unitRef="USD">746860</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-01-31_custom_PreferredStockSeriesBMember"
      decimals="INF"
      id="Fact001012"
      unitRef="Shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-01-31_custom_PreferredStockSeriesBMember"
      decimals="0"
      id="Fact001002"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-01-31_custom_PreferredStockSeriesCMember"
      decimals="INF"
      id="Fact001014"
      unitRef="Shares">4766</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-01-31_custom_PreferredStockSeriesCMember"
      decimals="0"
      id="Fact001003"
      unitRef="USD">872323</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-01-31_custom_ContingentlyRedeemableWarrantsMember"
      decimals="0"
      id="Fact001004"
      unitRef="USD">417000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-01-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001016"
      unitRef="Shares">26005715</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-01-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001005"
      unitRef="USD">2602</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-01-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact001006"
      unitRef="USD">183141663</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2026-01-31_us-gaap_TreasuryStockCommonMember"
      decimals="INF"
      id="Fact001018"
      unitRef="Shares">15270066</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-01-31_us-gaap_TreasuryStockCommonMember"
      decimals="0"
      id="Fact001007"
      unitRef="USD">-45009541</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-01-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact001008"
      unitRef="USD">-100000171</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-01-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact001009"
      unitRef="USD">-21540</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact001010"
      unitRef="USD">38113013</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001023"
      unitRef="USD">-15031211</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001024"
      unitRef="USD">18906468</us-gaap:NetIncomeLoss>
    <PMCB:GainOnRelatedPartyInvestmentQcls
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001029"
      unitRef="USD">2089000</PMCB:GainOnRelatedPartyInvestmentQcls>
    <PMCB:GainOnRelatedPartyInvestmentQcls
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001030"
      unitRef="USD">21395734</PMCB:GainOnRelatedPartyInvestmentQcls>
    <PMCB:IssuanceCostsSeriesCPreferredStockAndWarrants
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001032"
      unitRef="USD">1234553</PMCB:IssuanceCostsSeriesCPreferredStockAndWarrants>
    <PMCB:IssuanceCostsSeriesCPreferredStockAndWarrants
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001033"
      unitRef="USD">0</PMCB:IssuanceCostsSeriesCPreferredStockAndWarrants>
    <PMCB:LossOnIssuanceOfSeriesCPreferredStock
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001035"
      unitRef="USD">215000</PMCB:LossOnIssuanceOfSeriesCPreferredStock>
    <PMCB:LossOnIssuanceOfSeriesCPreferredStock
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001036"
      unitRef="USD">0</PMCB:LossOnIssuanceOfSeriesCPreferredStock>
    <PMCB:GainOnFairValueOfWarrants
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001038"
      unitRef="USD">106000</PMCB:GainOnFairValueOfWarrants>
    <PMCB:GainOnFairValueOfWarrants
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001039"
      unitRef="USD">-0</PMCB:GainOnFairValueOfWarrants>
    <PMCB:NoncashInterestIncome
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001041"
      unitRef="USD">300000</PMCB:NoncashInterestIncome>
    <PMCB:NoncashInterestIncome
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001042"
      unitRef="USD">300000</PMCB:NoncashInterestIncome>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001044"
      unitRef="USD">892500</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001045"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <PMCB:StockbasedCompensationOptions
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001047"
      unitRef="USD">181476</PMCB:StockbasedCompensationOptions>
    <PMCB:StockbasedCompensationOptions
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001048"
      unitRef="USD">414693</PMCB:StockbasedCompensationOptions>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001050"
      unitRef="USD">-294065</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001051"
      unitRef="USD">72632</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <PMCB:ChangeInFairValueOfWarrantLiability
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001053"
      unitRef="USD">-8335135</PMCB:ChangeInFairValueOfWarrantLiability>
    <PMCB:ChangeInFairValueOfWarrantLiability
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001054"
      unitRef="USD">8400000</PMCB:ChangeInFairValueOfWarrantLiability>
    <PMCB:ChangeInFairValueOfDerivativeLiability
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001056"
      unitRef="USD">859000</PMCB:ChangeInFairValueOfDerivativeLiability>
    <PMCB:ChangeInFairValueOfDerivativeLiability
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001057"
      unitRef="USD">2184000</PMCB:ChangeInFairValueOfDerivativeLiability>
    <PMCB:ChangeInFairValueOfConvertibleNotesReceivable
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001059"
      unitRef="USD">1304000</PMCB:ChangeInFairValueOfConvertibleNotesReceivable>
    <PMCB:ChangeInFairValueOfConvertibleNotesReceivable
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001060"
      unitRef="USD">601000</PMCB:ChangeInFairValueOfConvertibleNotesReceivable>
    <PMCB:ChangeInFairValueOfWarrantAssetFemasys
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001062"
      unitRef="USD">-2155000</PMCB:ChangeInFairValueOfWarrantAssetFemasys>
    <PMCB:ChangeInFairValueOfWarrantAssetFemasys
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001063"
      unitRef="USD">-1830000</PMCB:ChangeInFairValueOfWarrantAssetFemasys>
    <PMCB:ChangeInFairValueOfInvestmentQcls
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001065"
      unitRef="USD">-3485000</PMCB:ChangeInFairValueOfInvestmentQcls>
    <PMCB:ChangeInFairValueOfInvestmentQcls
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001066"
      unitRef="USD">-1642050</PMCB:ChangeInFairValueOfInvestmentQcls>
    <PMCB:ChangeInFairValueOfWarrantsQcls
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001068"
      unitRef="USD">18000</PMCB:ChangeInFairValueOfWarrantsQcls>
    <PMCB:ChangeInFairValueOfWarrantsQcls
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001069"
      unitRef="USD">-8123684</PMCB:ChangeInFairValueOfWarrantsQcls>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001074"
      unitRef="USD">-65095</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001075"
      unitRef="USD">-52438</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001077"
      unitRef="USD">714459</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001078"
      unitRef="USD">95578</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001080"
      unitRef="USD">-1625424</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001081"
      unitRef="USD">-49470</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001083"
      unitRef="USD">-3760352</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001084"
      unitRef="USD">-1937925</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <PMCB:ProceedsFromInvestmentNoteReceivable
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001089"
      unitRef="USD">5000000</PMCB:ProceedsFromInvestmentNoteReceivable>
    <PMCB:ProceedsFromInvestmentNoteReceivable
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001090"
      unitRef="USD">0</PMCB:ProceedsFromInvestmentNoteReceivable>
    <PMCB:InvestmentInPreferredStockAndWarrantsInQcls
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001092"
      unitRef="USD">3000000</PMCB:InvestmentInPreferredStockAndWarrantsInQcls>
    <PMCB:InvestmentInPreferredStockAndWarrantsInQcls
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001093"
      unitRef="USD">7000000</PMCB:InvestmentInPreferredStockAndWarrantsInQcls>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001095"
      unitRef="USD">2000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001096"
      unitRef="USD">-7000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001101"
      unitRef="USD">401625</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001102"
      unitRef="USD">2370733</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <PMCB:RedemptionOfPreferredStock
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001104"
      unitRef="USD">-0</PMCB:RedemptionOfPreferredStock>
    <PMCB:RedemptionOfPreferredStock
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001105"
      unitRef="USD">22486875</PMCB:RedemptionOfPreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001107"
      unitRef="USD">6268866</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001108"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001110"
      unitRef="USD">1046760</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001111"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <PMCB:PaymentOfSeriesCConvertiblePreferredStockDividends
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001113"
      unitRef="USD">162606</PMCB:PaymentOfSeriesCConvertiblePreferredStockDividends>
    <PMCB:PaymentOfSeriesCConvertiblePreferredStockDividends
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001114"
      unitRef="USD">-0</PMCB:PaymentOfSeriesCConvertiblePreferredStockDividends>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001116"
      unitRef="USD">6751395</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001117"
      unitRef="USD">-24857608</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001119"
      unitRef="USD">2329</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001120"
      unitRef="USD">-975</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001122"
      unitRef="USD">4993372</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001123"
      unitRef="USD">-33796508</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact001125"
      unitRef="USD">15172163</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-04-30"
      decimals="0"
      id="Fact001126"
      unitRef="USD">50179968</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact001128"
      unitRef="USD">20165535</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-01-31"
      decimals="0"
      id="Fact001129"
      unitRef="USD">16383460</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <PMCB:ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001134"
      unitRef="USD">0</PMCB:ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability>
    <PMCB:ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001135"
      unitRef="USD">16190179</PMCB:ReclassificationOfSeriesBConvertiblePreferredStockAndDividendsToCurrentLiability>
    <PMCB:AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001137"
      unitRef="USD">0</PMCB:AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock>
    <PMCB:AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001138"
      unitRef="USD">3193404</PMCB:AccretionOfDiscountsToRedemptionValueOfSeriesBPreferredStock>
    <PMCB:AccrualOfSeriesCConvertiblePreferredStockDividends
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001140"
      unitRef="USD">195097</PMCB:AccrualOfSeriesCConvertiblePreferredStockDividends>
    <PMCB:AccrualOfSeriesCConvertiblePreferredStockDividends
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001141"
      unitRef="USD">0</PMCB:AccrualOfSeriesCConvertiblePreferredStockDividends>
    <PMCB:AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001143"
      unitRef="USD">86419</PMCB:AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts>
    <PMCB:AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001144"
      unitRef="USD">0</PMCB:AccrualOfSeriesCConvertiblePreferredStockIssuanceCosts>
    <PMCB:AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001146"
      unitRef="USD">3106653</PMCB:AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock>
    <PMCB:AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001147"
      unitRef="USD">0</PMCB:AccretionOfDiscountsToRedemptionValueOfSeriesCPreferredStock>
    <PMCB:InitialFairValueOfInvestmentInQclsSeriesHPreferredShares
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001149"
      unitRef="USD">3483000</PMCB:InitialFairValueOfInvestmentInQclsSeriesHPreferredShares>
    <PMCB:InitialFairValueOfInvestmentInQclsSeriesHPreferredShares
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001150"
      unitRef="USD">0</PMCB:InitialFairValueOfInvestmentInQclsSeriesHPreferredShares>
    <PMCB:InitialFairValueOfInvestmentInQclsSeriesHWarrants
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001152"
      unitRef="USD">1606000</PMCB:InitialFairValueOfInvestmentInQclsSeriesHWarrants>
    <PMCB:InitialFairValueOfInvestmentInQclsSeriesHWarrants
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001153"
      unitRef="USD">0</PMCB:InitialFairValueOfInvestmentInQclsSeriesHWarrants>
    <PMCB:NoncashDerivativeLiabilityAtInitialFairValue
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001155"
      unitRef="USD">1995000</PMCB:NoncashDerivativeLiabilityAtInitialFairValue>
    <PMCB:NoncashDerivativeLiabilityAtInitialFairValue
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001156"
      unitRef="USD">0</PMCB:NoncashDerivativeLiabilityAtInitialFairValue>
    <PMCB:NoncashWarrantLiabilityAtInitialFairValue
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001158"
      unitRef="USD">5220000</PMCB:NoncashWarrantLiabilityAtInitialFairValue>
    <PMCB:NoncashWarrantLiabilityAtInitialFairValue
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001159"
      unitRef="USD">0</PMCB:NoncashWarrantLiabilityAtInitialFairValue>
    <PMCB:NoncashRedemptionOfSeriesCConvertiblePreferredStock
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001161"
      unitRef="USD">2234330</PMCB:NoncashRedemptionOfSeriesCConvertiblePreferredStock>
    <PMCB:NoncashRedemptionOfSeriesCConvertiblePreferredStock
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001162"
      unitRef="USD">0</PMCB:NoncashRedemptionOfSeriesCConvertiblePreferredStock>
    <PMCB:ChangeInFairValueAssociatedWarrantExercises
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001164"
      unitRef="USD">599135</PMCB:ChangeInFairValueAssociatedWarrantExercises>
    <PMCB:ChangeInFairValueAssociatedWarrantExercises
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001165"
      unitRef="USD">0</PMCB:ChangeInFairValueAssociatedWarrantExercises>
    <PMCB:FairValueOfContingentlyRedeemablePlacementAgentWarrants
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001167"
      unitRef="USD">417000</PMCB:FairValueOfContingentlyRedeemablePlacementAgentWarrants>
    <PMCB:FairValueOfContingentlyRedeemablePlacementAgentWarrants
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001168"
      unitRef="USD">0</PMCB:FairValueOfContingentlyRedeemablePlacementAgentWarrants>
    <PMCB:ExciseTaxAccruedOnRepurchaseOfCommonStock
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001170"
      unitRef="USD">0</PMCB:ExciseTaxAccruedOnRepurchaseOfCommonStock>
    <PMCB:ExciseTaxAccruedOnRepurchaseOfCommonStock
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001171"
      unitRef="USD">23707</PMCB:ExciseTaxAccruedOnRepurchaseOfCommonStock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001173">&lt;p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zOOTQMet2C56" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 1 &#x2013; &lt;span id="xdx_82A_zNQYknODog77"&gt;NATURE OF BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;PharmaCyte Biotech, Inc. (the &#x201c;Company&#x201d;)
is a biotechnology company focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation
technology known as &#x201c;Cell-in-a-Box&lt;sup&gt;&#xae;&lt;/sup&gt;.&#x201d; The Cell-in-a-Box&lt;sup&gt;&#xae;&lt;/sup&gt; technology is intended to be used as
a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (&#x201c;LAPC&#x201d;)
will be developed. The current generation of the Company&#x2019;s product candidate is referred to as &#x201c;CypCaps&#x2122;.&#x201d;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is a Nevada corporation incorporated
in 1996. In 2013, the Company restructured its operations to focus on biotechnology. The Company acquired licenses from SG Austria Pte.
Ltd., a Singapore corporation (&#x201c;SG Austria&#x201d;) and its wholly owned subsidiary, Austrianova Singapore Pte. Ltd., a Singapore
corporation (&#x201c;Austrianova Singapore&#x201d;) using the Cell-in-the-Box technology to treat cancer. The restructuring resulted in
the Company focusing all its efforts upon the development of a novel, effective and safe way to treat cancer. In January 2015, the Company
changed its name from Nuvilex, Inc. to PharmaCyte Biotech, Inc. to reflect the nature of its current business. In October 2021, the Company
moved its headquarters from Laguna Hills, California to Las Vegas, Nevada.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 1, 2020, the Company submitted an
Investigational New Drug Application (&#x201c;IND&#x201d;) to the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) for a planned clinical
trial in locally advanced pancreatic cancer (&#x201c;LAPC&#x201d;). On October 1, 2020, the Company received notice from the FDA that it
had placed the IND on clinical hold. On October 30, 2020, the FDA sent a letter to the Company setting forth the reasons for the clinical
hold and specific guidance on what the Company must do to have the clinical hold lifted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;To lift the clinical hold, the FDA informed the
Company that it needs to conduct several additional preclinical studies. The FDA also requested additional information regarding several
topics, including DNA sequencing data, manufacturing information and product release specifications. The Company has been in the process
of conducting these studies and gathering additional information to submit to the FDA. See &#x201c;Investigational New Drug Application
and Clinical Hold&#x201d; below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 15, 2022, the Company entered into a
Cooperation Agreement (&#x201c;Cooperation Agreement&#x201d;) with Iroquois Master Fund Ltd. and its affiliates, pursuant to which the Company
elected a reconstituted Board of Directors (the &#x201c;Board&#x201d;). The Board has formed a Business Review Committee to evaluate, investigate
and review the Company&#x2019;s business, affairs, strategy, management and operations and in its sole discretion to make recommendations
to the Company&#x2019;s management and Board with respect thereto. The Business Review Committee is also reviewing many of the risks relative
to the Company&#x2019;s business. In addition, the Board is reviewing the Company&#x2019;s development programs and its relationship with
SG Austria, including that all licensed patents have expired, that know-how relating to the Company&#x2019;s Cell-in-a-Box&#xae; technology
solely resides with SG Austria, and that the incentives of SG Austria and its management may not be currently aligned with those of the
Company. The Board has curtailed spending on the Company&#x2019;s programs, including pre-clinical and clinical activities, until the review
by the Business Review Committee and the Board is complete and the Board has determined the actions and plans to be implemented. The Business
Review Committee&#x2019;s recommendations will include potentially seeking a new framework for the Company&#x2019;s relationship with SG
Austria and its subsidiaries. In the event the Company is unsuccessful in seeking an acceptable new framework, the Company will reevaluate
whether it should continue those programs which are dependent on SG Austria, including its development programs for LAPC. The issues involving
SG Austria have delayed the Company&#x2019;s timeline for addressing the FDA clinical hold for its planned clinical trial in LAPC and could
result in other delays or termination of the development activities. In addition, the curtailment of spending on the Company&#x2019;s programs
pending the review by the Business Review Committee and the Board may cause additional delays.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Cell-in-a-Box&lt;sup&gt;&#xae;&lt;/sup&gt; encapsulation
technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules.
The technology is intended to result in the formation of pinhead sized cellulose-based porous capsules in which genetically modified live
human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been
shown to create a micro-environment in which encapsulated cells survive and flourish. They are protected from environmental challenges,
such as the sheer forces associated with bioreactors and passage through catheters and needles, which the Company believes enables greater
cell growth and production of the active molecules. The capsules are largely composed of cellulose (cotton) and are bioinert.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has been developing therapies for
pancreatic solid cancerous tumors by using genetically engineered live human cells that it believes are capable of converting a cancer
prodrug into its cancer-killing form. The Company encapsulates those cells using the Cell-in-a-Box&lt;sup&gt;&#xae;&lt;/sup&gt; technology and places
those capsules in the body as close as possible to the tumor. In this way, the Company believes that when a cancer prodrug is administered
to a patient with a particular type of cancer that may be affected by the prodrug, the killing of the patient&#x2019;s cancerous tumor
may be optimized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Until the review by the Business Review Committee
and the Board is complete and the Board has determined the actions and plans to be implemented, spending on the Company&#x2019;s programs
has been curtailed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Investigational New Drug Application and
Clinical Hold&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 1, 2020, the Company submitted an
IND to the FDA for a planned clinical trial in LAPC. On October 1, 2020, the Company received notice from the FDA that it had placed the
Company&#x2019;s IND on clinical hold. On October 30, 2020, the FDA sent the Company a letter setting forth the reasons for the clinical
hold and providing specific guidance on what the Company must do to have the clinical hold lifted.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;In order to address the clinical hold, the FDA requested that the Company:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provide additional sequencing data and genetic stability studies;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Conduct a stability study on &#x200c;the Company&#x2019;s final formulated product candidate as well as the cells from the Company&#x2019;s Master Cell Bank;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Evaluate the compatibility of the delivery devices (the prefilled syringe and the microcatheter used to implant the CypCaps&lt;sup&gt;&#x2122;&lt;/sup&gt;) with &#x200c;the Company&#x2019;s product candidate for pancreatic cancer;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provide additional detailed description of the manufacturing process of &#x200c;the Company&#x2019;s product candidate for pancreatic cancer;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provide additional product release specifications for the Company&#x2019;s encapsulated cells;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Demonstrate comparability between the 1&lt;sup&gt;st&lt;/sup&gt; and 2&lt;sup&gt;nd&lt;/sup&gt; generation of &#x200c;the Company&#x2019;s product candidate for pancreatic cancer and ensure adequate and consistent product performance and safety between the two generations;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Conduct a biocompatibility assessment using the Company&#x2019;s capsules material;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Address specified insufficiencies in the Chemistry, Manufacturing and Controls information in the cross-referenced Drug Master File;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Conduct an additional nonclinical study in a large animal (such as a pig) to assess the safety, activity, and distribution of the product candidate for pancreatic cancer; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revise the Investigators Brochure to include any additional preclinical studies conducted in response to the clinical hold and remove any statements not supported by the data the Company generated.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The FDA also requested that the Company address
the following issues as an amendment to the Company&#x2019;s IND:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provide a Certificate of Analysis for pc3/2B1 plasmid that includes tests for assessing purity, safety, and potency;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Perform qualification studies for the drug filling step to ensure that the Company&#x2019;s product candidate for pancreatic cancer remains sterile and stable during the filling process;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Submit an updated batch analysis for the Company&#x2019;s product candidate for the specific lot that will be used for manufacturing all future product candidates;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provide additional details for the methodology for the Resorufin (CYP2B1) potency and the PrestoBlue cell metabolic assays;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provide a few examples of common microcatheters that fit the specifications in &#x200c;the Company&#x2019;s Angiography Procedure Manual;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Clarify the language in the Company&#x2019;s Pharmacy Manual regarding proper use of the syringe fill with the Company&#x2019;s product candidate for pancreatic cancer; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Provide a discussion with data for trial of the potential for cellular and humoral immune reactivity against the heterologous rat CYP2B1 protein and potential for induction of autoimmune-mediated toxicities in &#x200c;the Company&#x2019;s study population.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company assembled a scientific and regulatory
team of experts to address the FDA requests. Through January 31, 2026, the Company&#x2019;s scientific consultants have been in active
dialog with the FDA. The Company received communications from the FDA and responded, including the submission of the updated drug master
file. The FDA accepted the updated master drug file and cleared many of the clinical hold items. The Company believes that the technology
upon which the LAPC treatment will be based, intra-arterial chemotherapy, has been used in five clinical trials in humans. The Company&#x2019;s
position is that the data available from these human clinical trials supersedes large animal study data, making the study unnecessary.
The treatment may not be a treatment of pancreatic cancer, but a method of improving and possibly enabling complete surgical resection
of the tumor. The Company is waiting for the FDA&#x2019;s responses and hopes the FDA will accept that the LAPC treatment now meets manufacturing
standard requirements, which have significantly improved since the clinical hold was first placed. The FDA may require additional preclinical
studies when the meeting takes place. The Company is in ongoing dialogue with SG Austria to prepare for the next steps, including the
preparation of the syringes filled with the latest generation of CypCaps&#x2122; with the working cell material.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <PMCB:LiquidityAndOtherUncertainitiesTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001183">&lt;p id="xdx_80F_ecustom--LiquidityAndOtherUncertainitiesTextBlock_zrHMuctJJlOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 2 &#x2013; &lt;span id="xdx_82F_zI5bbh6y7x9d"&gt;LIQUIDITY AND OTHER UNCERTAINTIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of January 31, 2026, the Company had approximately
$&lt;span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_dxH_c20260131_ziflwvAgMvu4" title="Cash and cash equivalents::XDX::20165535"&gt;20.2&lt;/span&gt; million in cash and cash equivalents as compared to approximately $&lt;span id="xdx_90A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_dxH_c20250430_zJirND3gYRc7" title="Cash and cash equivalents::XDX::15172163"&gt;15.2&lt;/span&gt; million at April 30, 2025. The Company expects that its
current cash and cash equivalents of approximately $19 million, as of the filing of this Quarterly Report on Form 10-Q, will be sufficient
to support its projected operating requirements and financial commitments for at least the next twelve months from the date of this Quarterly
Report.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In August 2025, the Company entered into a securities
purchase agreement pursuant to which it agreed to sell to investors in a private placement an aggregate of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250801__20250831__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_ztvrvToq2nzb" title="Stock issued new, shares"&gt;7,000&lt;/span&gt; shares of the Company&#x2019;s
newly designated Series C convertible preferred stock with a stated value of $1,000 per share and warrants to purchase up to &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pn6n6_c20250831__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--WarrantsMember_zyZAqNsg79zi" title="Warrants issued"&gt;7&lt;/span&gt; million
shares of common stock, resulting in aggregate gross proceeds of $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20250801__20250831__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zgbx1xXSz2" title="Proceeds from sale of equity"&gt;7&lt;/span&gt; million. See Note 10 - Preferred stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In September 2025, the Company entered into a
securities purchase agreement pursuant to which it agreed to purchase in a private placement QCLS Series H Preferred Stock (as defined
herein) initially convertible into &lt;span id="xdx_909_eus-gaap--InvestmentOwnedBalanceShares_iI_c20250930__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHConvertiblePreferredStockMember_zG5udMArbW08" title="Investment shares"&gt;600,000&lt;/span&gt; shares, subject to adjustment of QCLS (as defined herein) common stock and warrants for an
aggregate purchase price of $&lt;span id="xdx_90C_eus-gaap--PaymentsToAcquireInvestments_pn6n6_c20250901__20250930__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHConvertiblePreferredStockMember_zyKoiN7aXDQd"&gt;3&lt;/span&gt; million. See Note 4 - Investment in debt and equity securities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company expects to need additional capital
in order to complete a clinical trial for the treatment of pancreatic cancer. If any additional equity financing, if available, may not
be on favorable terms and would likely be significantly dilutive to the Company&#x2019;s current stockholders and debt financing, if available,
may involve restrictive covenants. If the Company is able to access funds through collaborative or licensing arrangements, it may be required
to relinquish rights to some of its product candidates that the Company would otherwise seek to develop or commercialize on its own, on
terms that are not favorable to the Company. The Company&#x2019;s ability to access capital is not assured and, if not achieved on a timely
basis, will likely have a material adverse effect on the Company&#x2019;s business, financial condition and results of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company operates in an industry that is subject
to rapid technological change, competition and government regulation. The Company&#x2019;s operations are subject to significant risk and
uncertainties including financial operational, technological, regulatory, and other risks. Such factors, include but not limited to, results
of clinical testing and trial activities, the ability to obtain regulatory approval, the supply of needed materials, the ability to obtain
manufacturing and the ability to raise capital to achieve strategic objectives.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</PMCB:LiquidityAndOtherUncertainitiesTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-08-012025-08-31_us-gaap_PrivatePlacementMember_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001189"
      unitRef="Shares">7000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-08-31_us-gaap_PrivatePlacementMember_custom_WarrantsMember"
      decimals="-6"
      id="Fact001191"
      unitRef="Shares">7000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-08-012025-08-31_us-gaap_PrivatePlacementMember"
      decimals="-6"
      id="Fact001193"
      unitRef="USD">7000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2025-09-30_custom_QCLSSeriesHConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact001195"
      unitRef="Shares">600000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2025-09-012025-09-30_custom_QCLSSeriesHConvertiblePreferredStockMember"
      decimals="-6"
      id="Fact001196"
      unitRef="USD">3000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001202">&lt;p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zk5BMDdRWtEj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 3 &#x2013; &lt;span id="xdx_821_zAKl9Qnxushb"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zEn8a5sVwzBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86F_zF924hLUdH9g"&gt;Principles of Consolidation and Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying unaudited condensed consolidated
financial statements have been prepared in accordance with U.S. GAAP for interim financial information and the rules and regulation of
the United States Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by
U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of
normal recurring items) which are considered necessary for a fair statement of the unaudited condensed consolidated financial statements
of the Company as of January 31, 2026 and for the three and nine months then ended. The results of operations for the three and nine months
ended January 31, 2026 are not necessarily indicative of the operating results for the year or any other period. These unaudited condensed
consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures as of April
30, 2025 and for the year then ended which are included in the Company&#x2019;s Annual Report on Form 10- K, filed with the SEC on August
11, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The unaudited condensed consolidated financial
statements include the accounts of the Company and its wholly owned subsidiaries. The Company operates independently and through three
wholly owned subsidiaries: (i) PharmaCyte Biotech Europe Limited; (ii) PharmaCyte Biotech Australia Pty. Ltd.; and (iii) Viridis Biotech,
Inc. and are prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and the Rules and Regulations
of the Commission. Upon consolidation, intercompany balances and transactions are eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zdlBwwa553N9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86B_z5PEf66noUIc"&gt;Use of Estimates in the Preparation of Financial
Statements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in accordance
with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of
contingent assets and liabilities known to exist as of the date the financial statements are published and the reported amounts of revenues
and expenses during the reporting period. Uncertainties with respect to such estimates and assumptions are inherent in the preparation
of the Company&#x2019;s unaudited condensed consolidated financial statements; accordingly, it is possible that the actual results could
differ from these estimates and assumptions, which could have a material effect on the reported amounts of the Company&#x2019;s condensed
consolidated financial position and results of operations. The Company&#x2019;s most significant estimates and assumptions are the assessment
of the fair value of long-lived assets, fair value measurements of investments, the valuation of warrants and derivative liabilities,
and the measurement of stock-based compensation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--Reclassifications_z6JDFJSpFkTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_860_zjtxU3oKJfKe"&gt;Reclassification&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain balances in the unaudited condensed consolidated
financial statements for the three and nine months ended January 31, 2025 have been reclassified to conform to the presentation in the
condensed consolidated financial statements for the three and nine months ended January 31, 2026. In the prior year, the Company separately
disclosed compensation expense, director fees and legal and professional expenses and combined the QCLS change in fair value of the investment
and warrant assets and in the current year the Company has reclassified these costs on the consolidated statements of operations with
general and administrative expenses and the change in the fair value of the investment QCLS and the change in the fair value of the warrant
assets are presented separately. These reclassifications had no effect on the Company&#x2019;s previously reported results of operations,
changes in convertible preferred stock and stockholders&#x2019; equity, or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zecu2pLZS4lb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_864_zPdv9rRu08qi"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash and cash equivalents include cash in banks
and short-term liquid investments purchased with maturities of three months or less. Additionally, the Company, as of January 31, 2026
and April 30, 2025 had $&lt;span id="xdx_901_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20260131_zIsJD9ugzaQe" title="Cash, uninsured amount"&gt;2.1&lt;/span&gt; million and $&lt;span id="xdx_90B_eus-gaap--CashUninsuredAmount_iI_c20250430_zPY9BRgn84Fg" title="Cash, uninsured amount"&gt;76,287&lt;/span&gt;, respectively, in a money market fund that is not insured by the Federal Deposit Insurance
Corporation (&#x201c;FDIC&#x201d;) and is classified as a cash equivalent. The Company has no significant off-balance-sheet concentrations
of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. The Company maintains most
of its cash balance at financial institutions located throughout the U.S. Accounts at these institutions are insured by the FDIC up to
$250,000. The Company has not experienced any losses in such accounts. Management believes it is not exposed to any significant credit
risk on cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_z5n34qUqwrFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86F_zOZQuZk62MQ5"&gt;Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s accounts for intangible assets
at cost. The intangible asset has an indefinite life; therefore, is not amortizable. The Company performs annual impairment analysis for
the intangible asset to ascertain the value at each year end and records a non-cash impairment expense should the value decrease below
book value. The asset is deemed to be an In-Process Research and Development (&#x201c;IPR&amp;amp;D&#x201d;) as the asset is in the research
stage.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
standard on goodwill and other intangible assets prescribes a two-step process for impairment testing of goodwill and indefinite-lived
intangibles, which is performed annually, as well as when an event triggering impairment may have occurred. The first step tests for impairment,
while the second step, if necessary, measures the impairment. The Company has elected to perform its annual analysis at the end of its
reporting year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_znpaVd9AXJV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_862_zNSiRm1au4Fe"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounting Standards Codification (&#x201c;ASC&#x201d;)
Topic 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; requires disclosure of the fair value of financial instruments held
by the Company. ASC Topic 825, &#x201c;Financial Instruments,&#x201d; defines fair value, and establishes a three-level valuation hierarchy
for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported
in the Consolidated Balance Sheets for current assets and liabilities qualify as financial instruments and are a reasonable estimate of
their fair values because of the short period between the origination of such instruments and their expected realization and their current
market rate of interest. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability
(an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use
of unobservable inputs. The three levels of valuation hierarchy are defined as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1. Observable inputs such as quoted prices in active markets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2. Inputs, other than the quoted prices in active markets, which are observable either directly or indirectly; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;These unobservable inputs are significant to the
fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p id="xdx_847_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zBHCex85zAM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Segment Reporting&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company operates in &lt;span id="xdx_90F_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20250501__20260131_zASX9yMgXsV6" title="::XDX::1"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1229"&gt;one&lt;/span&gt;&lt;/span&gt; business
segment, which includes the business of research and development activities related to developing cellular cancer therapies. The determination
of a single business segment is consistent with the financial information regularly provided to the Company&#x2019;s chief operating decision
maker (&#x201c;CODM&#x201d;). The Company&#x2019;s CODM is its President and CEO, who reviews and evaluates consolidated net income as presented
in the accompanying consolidated statements of operations for purposes of assessing performance, making operating decisions, allocating
resources, and planning and forecasting for future periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zRUkpy3lvvW" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86B_zo7ajKAyO8Wb"&gt;New Accounting Pronouncement Effective in Future
Periods&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2025, the FASB issued ASU 2025-11
&#x2013; Interim Reporting (Topic 270): Narrow-Scope Improvements to improve the guidance in Topic 270, Interim Reporting, by improving
the navigability of the required interim disclosures and clarifying when that guidance is applicable. The amendments also provide additional
guidance on what disclosures should be provided in interim reporting periods. The guidance is effective for the Company&#x2019;s interim
periods&#160;within annual reporting periods beginning after December 15, 2027. The Company is evaluating the impact of adoption of this
standard on its financial statements and disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001204">&lt;p id="xdx_84F_eus-gaap--ConsolidationPolicyTextBlock_zEn8a5sVwzBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86F_zF924hLUdH9g"&gt;Principles of Consolidation and Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying unaudited condensed consolidated
financial statements have been prepared in accordance with U.S. GAAP for interim financial information and the rules and regulation of
the United States Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by
U.S. GAAP for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of
normal recurring items) which are considered necessary for a fair statement of the unaudited condensed consolidated financial statements
of the Company as of January 31, 2026 and for the three and nine months then ended. The results of operations for the three and nine months
ended January 31, 2026 are not necessarily indicative of the operating results for the year or any other period. These unaudited condensed
consolidated financial statements should be read in conjunction with the audited financial statements and related disclosures as of April
30, 2025 and for the year then ended which are included in the Company&#x2019;s Annual Report on Form 10- K, filed with the SEC on August
11, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The unaudited condensed consolidated financial
statements include the accounts of the Company and its wholly owned subsidiaries. The Company operates independently and through three
wholly owned subsidiaries: (i) PharmaCyte Biotech Europe Limited; (ii) PharmaCyte Biotech Australia Pty. Ltd.; and (iii) Viridis Biotech,
Inc. and are prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and the Rules and Regulations
of the Commission. Upon consolidation, intercompany balances and transactions are eliminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2025-05-01to2026-01-31" id="Fact001206">&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zdlBwwa553N9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86B_z5PEf66noUIc"&gt;Use of Estimates in the Preparation of Financial
Statements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in accordance
with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of
contingent assets and liabilities known to exist as of the date the financial statements are published and the reported amounts of revenues
and expenses during the reporting period. Uncertainties with respect to such estimates and assumptions are inherent in the preparation
of the Company&#x2019;s unaudited condensed consolidated financial statements; accordingly, it is possible that the actual results could
differ from these estimates and assumptions, which could have a material effect on the reported amounts of the Company&#x2019;s condensed
consolidated financial position and results of operations. The Company&#x2019;s most significant estimates and assumptions are the assessment
of the fair value of long-lived assets, fair value measurements of investments, the valuation of warrants and derivative liabilities,
and the measurement of stock-based compensation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:Reclassifications contextRef="From2025-05-01to2026-01-31" id="Fact001212">&lt;p id="xdx_84D_eus-gaap--Reclassifications_z6JDFJSpFkTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_860_zjtxU3oKJfKe"&gt;Reclassification&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Certain balances in the unaudited condensed consolidated
financial statements for the three and nine months ended January 31, 2025 have been reclassified to conform to the presentation in the
condensed consolidated financial statements for the three and nine months ended January 31, 2026. In the prior year, the Company separately
disclosed compensation expense, director fees and legal and professional expenses and combined the QCLS change in fair value of the investment
and warrant assets and in the current year the Company has reclassified these costs on the consolidated statements of operations with
general and administrative expenses and the change in the fair value of the investment QCLS and the change in the fair value of the warrant
assets are presented separately. These reclassifications had no effect on the Company&#x2019;s previously reported results of operations,
changes in convertible preferred stock and stockholders&#x2019; equity, or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:Reclassifications>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001214">&lt;p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zecu2pLZS4lb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_864_zPdv9rRu08qi"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cash and cash equivalents include cash in banks
and short-term liquid investments purchased with maturities of three months or less. Additionally, the Company, as of January 31, 2026
and April 30, 2025 had $&lt;span id="xdx_901_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20260131_zIsJD9ugzaQe" title="Cash, uninsured amount"&gt;2.1&lt;/span&gt; million and $&lt;span id="xdx_90B_eus-gaap--CashUninsuredAmount_iI_c20250430_zPY9BRgn84Fg" title="Cash, uninsured amount"&gt;76,287&lt;/span&gt;, respectively, in a money market fund that is not insured by the Federal Deposit Insurance
Corporation (&#x201c;FDIC&#x201d;) and is classified as a cash equivalent. The Company has no significant off-balance-sheet concentrations
of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. The Company maintains most
of its cash balance at financial institutions located throughout the U.S. Accounts at these institutions are insured by the FDIC up to
$250,000. The Company has not experienced any losses in such accounts. Management believes it is not exposed to any significant credit
risk on cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2026-01-31"
      decimals="-5"
      id="Fact001216"
      unitRef="USD">2100000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact001218"
      unitRef="USD">76287</us-gaap:CashUninsuredAmount>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001220">&lt;p id="xdx_849_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_z5n34qUqwrFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86F_zOZQuZk62MQ5"&gt;Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s accounts for intangible assets
at cost. The intangible asset has an indefinite life; therefore, is not amortizable. The Company performs annual impairment analysis for
the intangible asset to ascertain the value at each year end and records a non-cash impairment expense should the value decrease below
book value. The asset is deemed to be an In-Process Research and Development (&#x201c;IPR&amp;amp;D&#x201d;) as the asset is in the research
stage.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Financial Accounting Standards Board (&#x201c;FASB&#x201d;)
standard on goodwill and other intangible assets prescribes a two-step process for impairment testing of goodwill and indefinite-lived
intangibles, which is performed annually, as well as when an event triggering impairment may have occurred. The first step tests for impairment,
while the second step, if necessary, measures the impairment. The Company has elected to perform its annual analysis at the end of its
reporting year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2025-05-01to2026-01-31" id="Fact001222">&lt;p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_znpaVd9AXJV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_862_zNSiRm1au4Fe"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounting Standards Codification (&#x201c;ASC&#x201d;)
Topic 820, &#x201c;Fair Value Measurements and Disclosures,&#x201d; requires disclosure of the fair value of financial instruments held
by the Company. ASC Topic 825, &#x201c;Financial Instruments,&#x201d; defines fair value, and establishes a three-level valuation hierarchy
for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported
in the Consolidated Balance Sheets for current assets and liabilities qualify as financial instruments and are a reasonable estimate of
their fair values because of the short period between the origination of such instruments and their expected realization and their current
market rate of interest. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability
(an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants
on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use
of unobservable inputs. The three levels of valuation hierarchy are defined as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1. Observable inputs such as quoted prices in active markets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2. Inputs, other than the quoted prices in active markets, which are observable either directly or indirectly; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;These unobservable inputs are significant to the
fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001228">&lt;p id="xdx_847_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zBHCex85zAM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Segment Reporting&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company operates in &lt;span id="xdx_90F_eus-gaap--NumberOfReportableSegments_dxL_uInteger_c20250501__20260131_zASX9yMgXsV6" title="::XDX::1"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1229"&gt;one&lt;/span&gt;&lt;/span&gt; business
segment, which includes the business of research and development activities related to developing cellular cancer therapies. The determination
of a single business segment is consistent with the financial information regularly provided to the Company&#x2019;s chief operating decision
maker (&#x201c;CODM&#x201d;). The Company&#x2019;s CODM is its President and CEO, who reviews and evaluates consolidated net income as presented
in the accompanying consolidated statements of operations for purposes of assessing performance, making operating decisions, allocating
resources, and planning and forecasting for future periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001231">&lt;p id="xdx_841_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zRUkpy3lvvW" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86B_zo7ajKAyO8Wb"&gt;New Accounting Pronouncement Effective in Future
Periods&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2025, the FASB issued ASU 2025-11
&#x2013; Interim Reporting (Topic 270): Narrow-Scope Improvements to improve the guidance in Topic 270, Interim Reporting, by improving
the navigability of the required interim disclosures and clarifying when that guidance is applicable. The amendments also provide additional
guidance on what disclosures should be provided in interim reporting periods. The guidance is effective for the Company&#x2019;s interim
periods&#160;within annual reporting periods beginning after December 15, 2027. The Company is evaluating the impact of adoption of this
standard on its financial statements and disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001233">&lt;p id="xdx_801_eus-gaap--TradingSecuritiesAndCertainTradingAssetsTextBlock_z219I15BXJw5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 4 &#x2013; &lt;span id="xdx_82A_zVblqXKVwvdc"&gt;INVESTMENT IN DEBT AND EQUITY
SECURITIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;INVESTMENT IN FEMASYS SECURITIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 14, 2023, the Company entered into
a Securities Purchase Agreement (the &#x201c;Femasys Purchase Agreement&#x201d;) with Femasys Inc. (&#x201c;Femasys&#x201d;), pursuant to
which it agreed to purchase from Femasys for a sum of $&lt;span id="xdx_904_eus-gaap--PaymentsToAcquireInvestments_c20231113__20231114__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zLcj5u7fnul2" title="Payment for investment"&gt;5,000,000&lt;/span&gt;, (i)&#160;senior unsecured convertible note (the &#x201c;Femasys Note&#x201d;)
in an aggregate principal amount of $5,000,000, convertible into shares of Femasys common stock, par value $0.001 per share (the &#x201c;Femasys
Shares&#x201d;) at a conversion price of $&lt;span id="xdx_90E_ecustom--ReceivableInstrumentConvertibleConversionPrice1_iI_c20231114__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zHVzT1Kdnz6g" title="Receivable conversion price"&gt;1.18&lt;/span&gt; per share, (ii) Series A Warrants (the &#x201c;Series A Warrants&#x201d;) to purchase up to
an aggregate of &lt;span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_c20231114__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_z9rFcisGttN6" title="Investment shares"&gt;4,237,288&lt;/span&gt; Femasys Shares at an exercise price of $1.18 per share, and (iii) Series B Warrants (the &#x201c;Series B Warrants&#x201d;,
together with the Series A Warrants, the &#x201c;Femasys Warrants,&#x201d; and, together with the Notes, the &#x201c;Femasys Securities&#x201d;)
to purchase up to an aggregate of 4,237,288 Femasys Shares at an exercise price of $1.475 per share (collectively, the &#x201c;Investment&#x201d;).
The Femasys Note accrues interest at 6.0% per annum, payable annually, and mature two years after the date of issuance. The Series A Warrants
expire five years from the date of issuance. The Series B Warrants expired in November 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the terms of the Femasys Purchase
Agreement, the Company&#x2019;s Chief Executive Officer was appointed to the Femasys board of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The convertible note receivable is not traded
in active markets and the fair value was historically determined using a Monte Carlo simulation. The convertible note receivable is accounted
for as available-for-sale debt securities based on &#x201c;Level&#160;3&#x201d; inputs, which consist of unobservable inputs and reflect
management&#x2019;s estimates of assumptions that market participants would use in pricing the asset. The Company elected the fair value
option for the Femasys Note, therefore, holding gains and losses are included within change in fair value of the note in the unaudited
condensed consolidated statement of operations. The Femasys Warrants are accounted for as an equity security and are valued using a Monte
Carlo simulation based on &#x201c;Level 3&#x201d; inputs, which consist of unobservable inputs and reflect management&#x2019;s estimates
of assumptions that market participants would use in pricing the asset, recorded at fair value with subsequent changes included within
change in fair value of the warrants in the unaudited condensed consolidated statement of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of January 31, 2026, the Company received $&lt;span id="xdx_908_ecustom--ProceedsFromInvestmentNoteReceivable_pn6n6_c20260129__20260131__us-gaap--TransactionTypeAxis__custom--FemasysNoteMember_z3FcWOAhwI62" title="Proceeds from investment - note receivable"&gt;5&lt;/span&gt;
million in full settlement of the Femasys Note. Additionally, the Company received &lt;span id="xdx_90A_ecustom--InvestmentSharesAddition_c20260129__20260131__srt--CounterpartyNameAxis__custom--FemasysMember_z9fVH9nzhZl2" title="Investment shares additions"&gt;379,747&lt;/span&gt; shares of Femasys common stock in full settlement
of the accrued interest of $&lt;span id="xdx_905_ecustom--SettlementOfAccruedInterest_c20260129__20260131__us-gaap--TransactionTypeAxis__custom--FemasysNoteMember_zzHliDpcSK26" title="Settlement of accrued interest"&gt;300,000&lt;/span&gt;. The Company holds &lt;span id="xdx_90D_eus-gaap--InvestmentOwnedBalanceShares_iI_c20260131__us-gaap--TransactionTypeAxis__custom--FemasysCommonStockMember_zrPDxviwDO73" title="Investment shares owned"&gt;695,537&lt;/span&gt; shares of Femasys common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three months ended January 31, 2026
and 2025, the Company recognized interest income of $&lt;span id="xdx_90E_eus-gaap--InterestAndOtherIncome_c20251101__20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_z19F0T74GJs4" title="Interest income"&gt;12,500&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--InterestAndOtherIncome_c20241101__20250131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zQX2dnaYVmp1" title="Interest income"&gt;75,000&lt;/span&gt;, respectively, and during the nine months ended January 31, 2026
and 2025 the Company recognized interest income of $&lt;span id="xdx_904_eus-gaap--InterestAndOtherIncome_c20250501__20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zl78V5En0eT8" title="Interest income"&gt;162,500&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--InterestAndOtherIncome_c20240501__20250131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zb5ja9cB7XV9" title="Interest income"&gt;225,000&lt;/span&gt;, respectively, from the Femasys Note. As of January 31, 2026
and April 30, 2025, the Company has accrued interest receivable of $&lt;span id="xdx_905_eus-gaap--InterestReceivable_iI_c20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_z4muJVXWSDub" title="Interest receivable"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--InterestReceivable_iI_c20250430__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zMWRTJ76sYB4" title="Interest receivable"&gt;137,500&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of January 31, 2026, the fair value of the
Femasys Series A Warrants was approximately $&lt;span id="xdx_90E_eus-gaap--InvestmentOwnedAtFairValue_iI_c20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--FemasysSeriesAWarrantsMember_zPFmkAJ9fBT2" title="Investment fair value"&gt;906,000&lt;/span&gt; and was determined utilizing the following assumptions: Femasys stock price of $0.54,
exercise price of $1.18, risk free rate of 3.58%, equity volatility of 102.0% and remaining term of 2.79 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognized the Femasys Note and Femasys
Warrants based on their respective fair values as of April 30, 2025 of $&lt;span id="xdx_90D_ecustom--ConvertibleNoteReceivableCurrent_iI_c20250430__us-gaap--TransactionTypeAxis__custom--FemasysNoteMember_zAx1e3l3CDhj" title="Convertible note receivable, current"&gt;3,696,000&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--WarrantAssetFemasys_iI_c20250430__us-gaap--TransactionTypeAxis__custom--FemasysWarrantsMember_zUCHdhdvSCf" title="Warrant asset - Femasys"&gt;3,061,000&lt;/span&gt;, respectively. Subsequent changes in
the fair value of the Femasys Note and Femasys Warrants are recognized in earnings, at each reporting date. During the three and nine
months ended January 31, 2026, the Company recognized gains for change in fair value of the convertible note receivable of $&lt;span id="xdx_907_ecustom--ChangeInFairValueOfConvertibleNotesReceivable_c20251101__20260131__us-gaap--TransactionTypeAxis__custom--FemasysNoteMember_zHxVS2TuGxNj" title="Change in fair value of the convertible note receivable"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90F_ecustom--ChangeInFairValueOfConvertibleNotesReceivable_c20250501__20260131__us-gaap--TransactionTypeAxis__custom--FemasysNoteMember_zavfvQdqlWxb" title="Change in fair value of the convertible note receivable"&gt;1,304,000&lt;/span&gt;,
respectively, and losses for change in fair value of the warrant asset of $&lt;span id="xdx_90A_ecustom--ChangeInFairValueOfWarrantAssetFemasys_iN_di_c20251101__20260131__us-gaap--TransactionTypeAxis__custom--FemasysWarrantsMember_znfrkPMNAJBd" title="Change in fair value of the convertible note receivable"&gt;214,000&lt;/span&gt; and $&lt;span id="xdx_90F_ecustom--ChangeInFairValueOfWarrantAssetFemasys_iN_di_c20250501__20260131__us-gaap--TransactionTypeAxis__custom--FemasysWarrantsMember_zv0dD2FQ3mz8" title="Change in fair value of the convertible note receivable"&gt;2,155,000&lt;/span&gt;, respectively. See Note 12 &#x2013; Fair
value Measurements for further information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Below is a summary of activity for the Femasys
Note and Femasys Warrants as of January 31, 2026:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock_zIJZbr9fmyab" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Femasys Note and warrants)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B6_zPFx5JpVVhV8" style="display: none"&gt;Schedule of activity for the notes and warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;Balance of Femasys Note as of April 30, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ConvertibleNoteReceivableCurrent_iS_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zcVqZmWeVxJf" style="width: 13%; text-align: right" title="Investment, beginning balance"&gt;3,696,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ChangeInFairValueOfConvertibleNotesReceivable_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zzRyXvMMS5y1" style="text-align: right" title="Change in fair value"&gt;1,304,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Settlement of Femasys Note&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ProceedsFromInvestmentNoteReceivable_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zxwa0yFTbJP6" style="border-bottom: Black 1pt solid; text-align: right" title="Settlement of Femasys Note"&gt;(5,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance of Femasys Note as of January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ConvertibleNoteReceivableCurrent_iE_d0_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zfJXwdRVpvTd" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;Balance of Femasys Warrant Asset as of April 30, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WarrantAssetFemasys_iS_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysWarrantsMember_zXIWBF6vdp01" style="width: 13%; text-align: right" title="Investment, beginning balance"&gt;3,061,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ChangeInFairValueOfWarrantAssetFemasys_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysWarrantsMember_zvxqJ0ydPnb" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(2,155,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance of Femasys Warrant Asset as of January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--WarrantAssetFemasys_iE_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysWarrantsMember_znNVChNbG69b" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance"&gt;906,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z6Hmbxx60Oud" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;MARKETABLE SECURITIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On November 21, 2025 and 2024, the Company
received from the Femasys Notes payments in Femasys common stock for interest income in the amount of $&lt;span id="xdx_900_eus-gaap--InterestAndOtherIncome_c20251120__20251121__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--FemasysCommonStockMember_zmlXyrGr8mh3" title="Interest and other income"&gt;300,000&lt;/span&gt;
and $&lt;span id="xdx_907_eus-gaap--InterestAndOtherIncome_c20241120__20241121__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--FemasysCommonStockMember_zEbFh4PxG7Bi" title="Interest and other income"&gt;300,000&lt;/span&gt;,
respectively. The interest income payments were based on the Femasys average stock price on those dates of $0.79 and $0.95,
respectively, therefore, the Company received &lt;span id="xdx_909_ecustom--InvestmentSharesAddition_c20251120__20251121__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zvHWQVHUhxn1"&gt;379,747&lt;/span&gt;
and &lt;span id="xdx_909_ecustom--InvestmentSharesAddition_c20241120__20241121__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zJXHg6pF4oRl"&gt;315,790&lt;/span&gt;
common stock shares, respectively. The Company elected the fair value option on this investment. The related unrealized loss
pertaining to this investment is recorded in other income and expense. The value of the initial interest payment was $&lt;span id="xdx_90B_eus-gaap--PaymentsToAcquireEquityMethodInvestments_c20240501__20250430__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zSs2my83FyPb" title="Investment interest payment"&gt;366,316&lt;/span&gt;
on April 30, 2025. The Company holds a total of &lt;span id="xdx_900_eus-gaap--InvestmentOwnedBalanceShares_iI_c20260131__srt--CounterpartyNameAxis__custom--FemasysMember_zZ0APWx5Zh41"&gt;695,537&lt;/span&gt;
common stock shares. As of January 31, 2026, the current market value of the Femasys common stock shares was $0.54 that generated an
unrealized loss of $&lt;span id="xdx_906_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_iN_di_c20250501__20260131__srt--CounterpartyNameAxis__custom--FemasysMember_zuuZTwMa8Doc" title="Unrealized loss on marketable securities"&gt;294,065&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Cost and fair value of marketable equity securities
at January 31, 2026 are as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock_zvFiqG8cQ8nd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Marketable securities)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_zvXzbb3lexK5" style="display: none"&gt;Schedule of marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Carrying Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;At Fair Market&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Adjusted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Unrealized&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 55%; text-align: justify; padding-bottom: 1pt"&gt;Marketable securities&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Equity &#x2013; stock&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--MarketableSecuritiesCurrent_iI_c20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_ztFDbwbPoEN8" title="Carrying value at fair market value"&gt;372,251&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--InvestmentOwnedAtCost_iI_c20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zczNH370gFRj" title="Adjusted cost basis"&gt;666,316&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20250501__20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zAt1iAJWMWD1" title="Unrealized loss"&gt;294,065&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zS5gpO4LWg9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of equity securities has been measured
on a recurring basis using Level 1 inputs, which are based on unadjusted quoted market prices within active markets. There have been no
changes in valuation approaches or techniques and related inputs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;INVESTMENT
IN Q/C TECHNOLOGIES, INC.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Series G Preferred Shares and Warrants&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 20, 2024, the Company entered into a Securities
Purchase Agreement (the &#x201c;Series G SPA&#x201d;) with a public company operating in the medical industry, MyMD Pharmaceuticals, Inc.
which subsequently changed its name to TNF Pharmaceuticals, Inc. and then to Q/C Technologies, Inc., (&#x201c;QCLS&#x201d;). Pursuant to
the Series G SPA, the Company purchased (i) &lt;span id="xdx_90D_eus-gaap--InvestmentOwnedBalanceShares_iI_c20240520__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_z1uNwUsqKdVl" title="Investment shares owned"&gt;7,000&lt;/span&gt; shares of QCLS&#x2019;s Series G Convertible Preferred Stock (the &#x201c;Series G Preferred
Shares&#x201d; or &#x201c;Series G Preferred Stock&#x201d;) with an original conversion price of $1.816 per Series G Preferred Share, which
were initially convertible into 3,854,626 shares of common stock of QCLS (&#x201c;QCLS Common Stock&#x201d;); (ii) warrants to purchase
up to &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240520__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--LongTermWarrantMember_z2joAwK5Kvtc" title="Warrants"&gt;3,854,626&lt;/span&gt; shares of QCLS Common Stock with a five-year term (&#x201c;QCLS Series G Long-Term Warrant&#x201d;); and (iii) warrants
to purchase up to &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20240520__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ShortTermWarrantMember_zKRQLTc7Jjr" title="Warrants"&gt;3,854,626&lt;/span&gt; shares of QCLS Common Stock with a 18-month term (&#x201c;QCLS Series G Short-Term Warrant&#x201d;) (collectively,
the &#x201c;QCLS Series G Warrants&#x201d;), for an aggregate purchase price of $&lt;span id="xdx_909_eus-gaap--PaymentsToAcquireInvestments_c20240519__20240520__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zRAHMfPVbLrf" title="Payments for investments"&gt;7,000,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In April 2025, QCLS issued securities that caused
changes to the original terms of the Series G Preferred Stock. The conversion and exercises prices were adjusted to $0.1832 per Series
G Preferred Share, the number of QCLS Series G Long-Term Warrants were adjusted to purchase &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--LongTermWarrantMember_zaLsWtEZVwT4" title="Warrants"&gt;38,209,611&lt;/span&gt; shares of QCLS Common Stock and
the number of QCLS Series G Short-Term Warrants were adjusted to purchase 38,209,611 shares of QCLS Common Stock. In September 2025, in
connection with the QCLS&#x2019; &lt;span id="xdx_908_eus-gaap--StockholdersEquityReverseStockSplit_c20250901__20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zrUnZqn72I88" title="Stockholders equity, reverse stock split"&gt;1-for-100 reverse stock split&lt;/span&gt; and pursuant to the stock combination event adjustment provisions of the
Series G Preferred Shares and QCLS Series G Warrants, the conversion price and the exercise price was adjusted to $3.37 per share, the
7,000 Series G Preferred Shares were adjusted to be convertible into 2,076,351 shares of QCLS Common Stock, and the number of QCLS Series
G Long-Term Warrants were adjusted to purchase &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--LongTermWarrantMember_z8PhV2jf0gY5" title="Warrants"&gt;2,076,351&lt;/span&gt; shares of QCLS Common Stock and the number of QCLS Series G Short-Term Warrants
were adjusted to purchase &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--ShortTermWarrantMember_zy7W7OI7o566" title="Warrants"&gt;2,076,351&lt;/span&gt; shares of QCLS Common Stock. On November 23, 2025, the QCLS Series G Short-Term Warrants expired.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the Series G SPA, the Company has
the right to participate in future sales of QCLS&#x2019;s equity and equity-linked securities until the second anniversary of the Closing
or the date on which no Series G Preferred Shares remain outstanding, whichever is earlier. Additionally, the Company has the right to
nominate one individual to serve on QCLS&#x2019;s board of directors until PharmaCyte no longer beneficially owns at least 20% of QCLS
Common Stock on an as-converted basis. The Company&#x2019;s Chief Executive Officer serves on the board of directors of QCLS.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company determined that QCLS is a VIE, since
QCLS does not have sufficient equity at risk to finance its own operations without additional subordinated financial support. However,
the Company has determined that it is not the primary beneficiary of QCLS. Furthermore, Series G Preferred Stock is not considered in
substance common stock, and as such, the equity method of accounting does not apply. The Company recorded its investment in Series G Preferred
Stock at its fair value as the Company did not elect the measurement alternative to account for the investment at cost less impairment.
Subsequent changes in fair value of the Series G Preferred Stock are recognized in earnings at each reporting period. The fair value of
the Series G Preferred Stock was estimated utilizing a Monte Carlo simulation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The QCLS Series G Warrants were determined to
meet the definition of a derivative and were required to be recorded at fair value in accordance with ASC 815. Subsequent changes in the
fair value of the QCLS Series G Warrants are recognized in earnings, at each reporting date. The issuance date fair value of the QCLS
Series G Warrants was determined utilizing the Black Scholes Merton Method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Series G Preferred Stock shares include a
10% dividend, which are payable in cash or shares of QCLS Series G Preferred Stock at the Company&#x2019;s option, and the Company has
elected to receive shares of the QCLS Preferred Stock as Payment in Kind (&#x201c;PIK&#x201d;). As of January 31, 2026, and April 30, 2025
the Company owned &lt;span id="xdx_90D_eus-gaap--InvestmentOwnedBalanceShares_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zcuWseDqodl3"&gt;&lt;span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_c20250430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zKR3zSS6yyUk"&gt;8,577&lt;/span&gt;&lt;/span&gt; shares including accrued dividend of &lt;span id="xdx_904_eus-gaap--InvestmentOwnedBalanceShares_iI_c20250430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSAccruedDividendReceivableMember_zN1HwkIkgCYe"&gt;&lt;span id="xdx_903_eus-gaap--InvestmentOwnedBalanceShares_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSAccruedDividendReceivableMember_zN6PDxdC1L34"&gt;1,577&lt;/span&gt;&lt;/span&gt; shares, and &lt;span id="xdx_902_eus-gaap--InvestmentOwnedBalanceShares_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_ziDWMlK366G"&gt;&lt;span id="xdx_906_eus-gaap--InvestmentOwnedBalanceShares_iI_c20250430__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zj8sh39WEck9"&gt;7,831&lt;/span&gt;&lt;/span&gt; Series G Preferred Stock shares, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three and nine months ended January
31, 2026, the Company recognized a gain for the change in fair value of the Series G Preferred Stock of $&lt;span id="xdx_907_eus-gaap--RealizedInvestmentGainsLosses_c20251101__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__srt--CounterpartyNameAxis__custom--QCLSMember_zNW87lik5PU9" title="Recognized gain (loss)"&gt;1,433,000&lt;/span&gt; and a loss of $&lt;span id="xdx_909_eus-gaap--RealizedInvestmentGainsLosses_iN_di_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__srt--CounterpartyNameAxis__custom--QCLSMember_z9xmBNKjZ4U7" title="Recognized gain (loss)"&gt;5,127,000&lt;/span&gt;,
respectively. The $&lt;span id="xdx_900_eus-gaap--InvestmentOwnedAtFairValue_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__srt--CounterpartyNameAxis__custom--QCLSMember_zm27p3EQQYGc" title="Investment at fair value"&gt;17,347,000&lt;/span&gt; fair value of the Series G Preferred Stock was estimated utilizing a Monte Carlo simulation with the following
assumptions on January 31, 2026: QCLS stock price of $4.19, expected time to settlement of 5.00 years, dividend rate of 10%, discount
market interest rate of 10%, risk free rate of 3.79%, equity volatility of 135.0% and probability of default of 24.7%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three and nine months ended January
31, 2026, the Company recognized a loss of $&lt;span id="xdx_906_eus-gaap--RealizedInvestmentGainsLosses_iN_di_c20251101__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGWarrantsMember__srt--CounterpartyNameAxis__custom--QCLSMember_zeFX0DJq8gyk" title="Recognized gain (loss)"&gt;1,461,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--RealizedInvestmentGainsLosses_iN_di_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGWarrantsMember__srt--CounterpartyNameAxis__custom--QCLSMember_z9zpQ3wh8Zb9" title="Recognized gain (loss)"&gt;1,652,000&lt;/span&gt;, respectively, related to the change in the QCLS Series
G Warrants fair value. The $&lt;span id="xdx_904_eus-gaap--InvestmentOwnedAtFairValue_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesGWarrantsMember__srt--CounterpartyNameAxis__custom--QCLSMember_z1qfsR1BQ7D1" title="Investment at fair value"&gt;6,966,000&lt;/span&gt; fair value of the QCLS Series G Warrants was determined utilizing a Black Scholes Merton model with
the following assumptions on January 31, 2026: QCLS stock price of $4.19, exercise price of $3.37, risk free rate of 3.57%, equity volatility
of 130.0% and remaining term of 3.31 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Below is a summary of activity for the Series
G Preferred Stock as of January 31, 2026:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--InvestmentTableTextBlock_z2pMAY7NicW2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series G Preferred Stock and Preferred Stock Warrants)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B4_z9Ya0pjiqgBa" style="display: none"&gt;Schedule of activity preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;Balance of Series G Preferred Stock as of April 30, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zJWApdCZnImc" style="width: 13%; text-align: right" title="Investment, beginnning balance"&gt;22,474,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ChangeInFairValueOfInvestment_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zVOsyYNARIR2" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(5,127,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance of Series G Preferred Stock as of January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zsTyPAX3lp3c" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance"&gt;17,347,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Below is a summary of activity for the QCLS Warrants
as of January 31, 2026:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;Balance of QCLS Series G Warrant assets as of April 30, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_c20250501__20260131__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGWarrantsMember_zWMuwb6FjXK5" style="width: 13%; text-align: right" title="Investment, beginnning balance"&gt;8,618,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ChangeInFairValueOfInvestment_c20250501__20260131__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGWarrantsMember_zX7yT8Eu3rD1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(1,652,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance of QCLS Series G Warrant assets as of January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGWarrantsMember_zPbgi1cCOVA6" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance"&gt;6,966,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zEZR9p8KbHkd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Series H Preferred Shares and Warrants&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 2, 2025, the Company entered into
a Securities Purchase Agreement (the &#x201c;Series H SPA&#x201d;) with QCLS. Pursuant to the Series H SPA, the Company purchased (i) &lt;span id="xdx_901_eus-gaap--InvestmentOwnedBalanceShares_iI_c20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zYbCmXXR9Xcd" title="Investment shares owned"&gt;3,000&lt;/span&gt;
shares of QCLS&#x2019;s Series H Convertible Preferred Stock (the &#x201c;Series H Preferred Shares&#x201d; or &#x201c;Series H Preferred
Stock&#x201d;), at a stated value of $1,000 per Series G Preferred Share, with an initial conversion price of $5.00 which were initially
convertible into 600,000 shares of QCLS Common Stock ; (ii) warrants to purchase up to &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember_z0crNGR4mhY3" title="Warrants"&gt;600,000&lt;/span&gt; shares of QCLS&#x2019;s Common Stock with
a five-year term (&#x201c;QCLS Series H Warrant&#x201d;), for a total purchase price of $&lt;span id="xdx_903_eus-gaap--PaymentsToAcquireInvestments_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zM8ruhAXtEDh" title="Payments for investments"&gt;3,000,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In September 2025, in connection with the QCLS&#x2019;
1-for-100 reverse stock split and pursuant to the stock combination event adjustment provisions of the Series H Preferred Shares and QCLS
Series H Warrants, the conversion price and the exercise price was adjusted to $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember_zLYWHTya9n2" title="Exercise price"&gt;3.37&lt;/span&gt; per share, the 3,000 Series H Preferred Shares were
adjusted to be convertible into 889,864 shares of QCLS Common Stock and the number of QCLS Series H Warrants was adjusted to purchase
&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250930__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSCommonStockMember_z8l7ZXxa9Nlf" title="Warrant shares"&gt;889,864&lt;/span&gt; shares of QCLS Common Stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Series H Preferred Stock is not considered
in substance common stock, and as such, the equity method of accounting does not apply. The Company recorded its investment in Series
H Preferred Stock at its fair value as the Company did not elect the measurement alternative to account for the investment at cost less
impairment. Subsequent changes in fair value of the Series H Preferred Stock are recognized in earnings at each reporting period. The
initial fair value of the Series H Preferred Stock of $&lt;span id="xdx_905_eus-gaap--InvestmentOwnedAtFairValue_iI_c20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember_zT5Nspg14Dic"&gt;3,483,000&lt;/span&gt; was estimated utilizing a probability-weighted scenario model, with the
following inputs: the fair value of QCLS Common Stock of &lt;span id="xdx_90E_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zvCR4pKKU5M8" title="Fair value measurement"&gt;$3.61&lt;/span&gt;, estimated equity volatility of &lt;span id="xdx_904_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zCM1TNaXoj09" title="Fair value measurement"&gt;100.0%&lt;/span&gt;, the time to maturity of &lt;span id="xdx_901_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputMaturityMember_zBJyvJfZhHN8" title="Fair value measurement"&gt;1.49 years&lt;/span&gt;,
the redemption premium of &lt;span id="xdx_902_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementRedemptionPremiumMember_z3qEwrWcB3N2" title="Fair value measurement"&gt;106%&lt;/span&gt;, the liquidation premium of 125%, the conversion price of $5.00 per share, a market interest rate of &lt;span id="xdx_901_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketInterestRateMember_zu6O3Sd2Orj2" title="Fair value measurement"&gt;19.51%&lt;/span&gt;,
a risk-free rate of &lt;span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z9qLKV5VmfFg" title="Fair value measurement"&gt;3.61%&lt;/span&gt;, and dividend rate of &lt;span id="xdx_900_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zcatBCq9rW29" title="Fair value measurement"&gt;7.00%&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The QCLS Series H Warrants were determined to
meet the definition of a derivative and were required to be recorded at fair value in accordance with ASC 815. Subsequent changes in the
fair value of the QCLS Series H Warrants are recognized in earnings, at each reporting date. The issuance date fair value of the QCLS
Series H Warrants of $&lt;span id="xdx_902_eus-gaap--InvestmentOwnedAtFairValue_iI_c20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember_zfEo4DWUmLf8"&gt;1,606,000&lt;/span&gt; was determined utilizing the Black Scholes Merton Method using the following inputs: the fair value of
QCLS&#x2019; s common stock of &lt;span id="xdx_900_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zFETuWycUad8" title="Fair value measurement"&gt;$3.61&lt;/span&gt;, exercise price of &lt;span id="xdx_90A_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zKJuzoU25pF8" title="Fair value measurement"&gt;$5.00&lt;/span&gt;; dividend yield of &lt;span id="xdx_907_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zG2XAEvXHb01" title="Fair value measurement"&gt;0%&lt;/span&gt;; remaining term of &lt;span id="xdx_90B_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zq67PnSZnSGj" title="Fair value measurement"&gt;5.00 years&lt;/span&gt;; equity volatility of
&lt;span id="xdx_908_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zIOUYKeQVW4f" title="Fair value measurement"&gt;105.0%&lt;/span&gt;; and a risk-free interest rate of &lt;span id="xdx_909_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250901__20250902__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_ztxNOMAxxwg4" title="Fair value measurement"&gt;3.59%&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The total aggregated fair value of the QCLS Series
H Preferred Stock and the QCLS Series H Warrants of $&lt;span id="xdx_909_eus-gaap--InvestmentOwnedAtFairValue_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zDA9vEWXniZ8" title="Investment, fair value"&gt;5,089,000&lt;/span&gt; exceeded the total purchase price of $&lt;span id="xdx_908_eus-gaap--InvestmentOwnedAtCost_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zvjtqinXZTNh" title="Investment, cost"&gt;3,000,000&lt;/span&gt; by $&lt;span id="xdx_905_ecustom--GainOnRelatedPartyInvestmentQcls_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--CounterpartyNameAxis__custom--QCLSMember_zelXRyGJYRN9" title="Investment, fair value"&gt;2,089,000&lt;/span&gt;, which was
recognized as a gain on investment in QCLS on the condensed consolidated statement of operations for the nine months ended January
31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three and nine months ended January
31, 2026, the Company recognized a gain on the change in fair value of the Series H Preferred Stock of $&lt;span id="xdx_905_eus-gaap--DebtSecuritiesRealizedGainLoss_c20251101__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zBxcpU3mFzYl"&gt;292,000&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--DebtSecuritiesRealizedGainLoss_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zVwgIsgTKMse"&gt;1,642,000&lt;/span&gt;, respectively.
The $&lt;span id="xdx_908_eus-gaap--InvestmentOwnedAtCost_iI_c20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zwY2WLJPFFic"&gt;5,125,000&lt;/span&gt; fair value of the Series H Preferred Stock was estimated utilizing a probability-weighted scenario model, with the following
inputs: the fair value of QCLS Common Stock of &lt;span id="xdx_904_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z5geTJmuiFYa"&gt;$4.19&lt;/span&gt;, estimated equity volatility of &lt;span id="xdx_90D_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zy1ZVYCfLcXd"&gt;150.0%&lt;/span&gt;, the time to maturity of &lt;span id="xdx_902_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgfHluaohRk5"&gt;1.08 years&lt;/span&gt;, the redemption
premium of &lt;span id="xdx_90D_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRedemptionPremiumMember_z3YeQXgNHkX"&gt;106%&lt;/span&gt;, the liquidation premium of 125%, the conversion price of $3.37 per share, a market interest rate of &lt;span id="xdx_901_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketInterestRateMember_zaYKClbVAnO1"&gt;16.37%&lt;/span&gt;, a risk-free
rate of &lt;span id="xdx_904_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zRn1BGFNfNyl"&gt;3.42%&lt;/span&gt;, and dividend rate of &lt;span id="xdx_90B_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zT3iDeAmRzhi"&gt;7.00%&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three and nine months ended January
31, 2026, the Company recognized a gain of $&lt;span id="xdx_901_eus-gaap--DebtSecuritiesRealizedGainLoss_c20251101__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember_zvAYRzWziQb1" title="Recognized gain (loss)"&gt;261,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--DebtSecuritiesRealizedGainLoss_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember_zXzxIYLEYr2a" title="Recognized gain (loss)"&gt;1,670,000&lt;/span&gt;, respectively, related to the change in the QCLS Series H Warrants
fair value. The $&lt;span id="xdx_90A_eus-gaap--FairValueAdjustmentOfWarrants_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember_zpj3mZjZRmF6" title="Fair value of the warrants"&gt;3,276,000&lt;/span&gt; fair value of the QCLS Series H Warrants was determined utilizing a Black Scholes Merton model with the following
assumptions on January 31, 2026: the fair value of QCLS&#x2019;s common stock of &lt;span id="xdx_904_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zqfuKpJ7vnMf"&gt;$4.19&lt;/span&gt;, exercise price of &lt;span id="xdx_902_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_zsMjjLd31e3l"&gt;$3.37&lt;/span&gt;, risk free rate of &lt;span id="xdx_90B_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zhRtF73UUEaf"&gt;3.68%&lt;/span&gt;,
equity volatility of &lt;span id="xdx_906_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z5apMLrDIqFj"&gt;135.0%&lt;/span&gt;, and remaining term of &lt;span id="xdx_90A_eus-gaap--DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue_c20250501__20260131__us-gaap--TypeOfArrangementAxis__custom--QCLSSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zn045s94KhHf"&gt;4.59 years&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has determined that QCLS is a VIE,
as QCLS does not have sufficient equity at risk to finance its own operations without additional subordinated financial support. However,
the Company has determined that it is not the primary beneficiary of QCLS.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Below is a summary of activity for the Series
H Preferred Stock as of January 31, 2026:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--InvestmentTableTextBlock_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zfEVQb40lg51" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series H Preferred Stock and Preferred Stock Warrants)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B4_z6IJ0Rx6rgya" style="display: none"&gt;Schedule of activity preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;Balance of Series H Preferred Stock as of April 30, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_d0_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zkLGmajUPc4g" style="width: 13%; text-align: right" title="Investment, beginning balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Initial fair value of investment Series H Preferred Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--InvestmentOwnedAtFairValue_iI_c20250902__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zvMRwQxuSUNi" style="text-align: right" title="Initial fair value of Investment"&gt;3,483,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ChangeInFairValueOfInvestmentQcls_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zW4yEHlezcM6" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;1,642,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance of Series H Preferred Stock as of January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zR9XFRjFULte" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance"&gt;5,125,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Below is a summary of activity for the QCLS Series
H Warrants as of January 31, 2026:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;Balance of QCLS Series H Warrant assets as of April 30, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_d0_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zN1LwFG8Jbyc" style="width: 13%; text-align: right" title="Investment, beginning balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Initial fair value of investment in of QCLS Series H Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--InvestmentOwnedAtFairValue_iI_c20250902__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zacjDXECZvh8" style="text-align: right" title="Initial fair value of Investment"&gt;1,606,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ChangeInFairValueOfInvestmentQcls_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zp8eUhbkLUM4" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;1,670,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance of QCLS Series H Warrant assets as of January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zwUz1V3pxHM6" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance"&gt;3,276,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zNLlMm3N3Wka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;











</us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2023-11-132023-11-14_custom_FemasysPurchaseAgreementMember"
      decimals="0"
      id="Fact001235"
      unitRef="USD">5000000</us-gaap:PaymentsToAcquireInvestments>
    <PMCB:ReceivableInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-11-14_custom_FemasysPurchaseAgreementMember"
      decimals="INF"
      id="Fact001237"
      unitRef="USDPShares">1.18</PMCB:ReceivableInstrumentConvertibleConversionPrice1>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2023-11-14_custom_FemasysPurchaseAgreementMember"
      decimals="INF"
      id="Fact001239"
      unitRef="Shares">4237288</us-gaap:InvestmentOwnedBalanceShares>
    <PMCB:ProceedsFromInvestmentNoteReceivable
      contextRef="From2026-01-292026-01-31_custom_FemasysNoteMember"
      decimals="-6"
      id="Fact001241"
      unitRef="USD">5000000</PMCB:ProceedsFromInvestmentNoteReceivable>
    <PMCB:InvestmentSharesAddition
      contextRef="From2026-01-292026-01-31_custom_FemasysMember"
      decimals="INF"
      id="Fact001243"
      unitRef="Shares">379747</PMCB:InvestmentSharesAddition>
    <PMCB:SettlementOfAccruedInterest
      contextRef="From2026-01-292026-01-31_custom_FemasysNoteMember"
      decimals="0"
      id="Fact001245"
      unitRef="USD">300000</PMCB:SettlementOfAccruedInterest>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2026-01-31_custom_FemasysCommonStockMember"
      decimals="INF"
      id="Fact001247"
      unitRef="Shares">695537</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InterestAndOtherIncome
      contextRef="From2025-11-012026-01-31_custom_FemasysPurchaseAgreementMember"
      decimals="0"
      id="Fact001249"
      unitRef="USD">12500</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="From2024-11-012025-01-31_custom_FemasysPurchaseAgreementMember"
      decimals="0"
      id="Fact001251"
      unitRef="USD">75000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="From2025-05-012026-01-31_custom_FemasysPurchaseAgreementMember"
      decimals="0"
      id="Fact001253"
      unitRef="USD">162500</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="From2024-05-012025-01-31_custom_FemasysPurchaseAgreementMember"
      decimals="0"
      id="Fact001255"
      unitRef="USD">225000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestReceivable
      contextRef="AsOf2026-01-31_custom_FemasysPurchaseAgreementMember"
      decimals="0"
      id="Fact001257"
      unitRef="USD">0</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="AsOf2025-04-30_custom_FemasysPurchaseAgreementMember"
      decimals="0"
      id="Fact001259"
      unitRef="USD">137500</us-gaap:InterestReceivable>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2026-01-31_custom_FemasysPurchaseAgreementMember_custom_FemasysSeriesAWarrantsMember"
      decimals="0"
      id="Fact001261"
      unitRef="USD">906000</us-gaap:InvestmentOwnedAtFairValue>
    <PMCB:ConvertibleNoteReceivableCurrent
      contextRef="AsOf2025-04-30_custom_FemasysNoteMember"
      decimals="0"
      id="Fact001267"
      unitRef="USD">3696000</PMCB:ConvertibleNoteReceivableCurrent>
    <PMCB:WarrantAssetFemasys
      contextRef="AsOf2025-04-30_custom_FemasysWarrantsMember"
      decimals="0"
      id="Fact001269"
      unitRef="USD">3061000</PMCB:WarrantAssetFemasys>
    <PMCB:ChangeInFairValueOfConvertibleNotesReceivable
      contextRef="From2025-11-012026-01-31_custom_FemasysNoteMember"
      decimals="0"
      id="Fact001271"
      unitRef="USD">0</PMCB:ChangeInFairValueOfConvertibleNotesReceivable>
    <PMCB:ChangeInFairValueOfConvertibleNotesReceivable
      contextRef="From2025-05-012026-01-31_custom_FemasysNoteMember"
      decimals="0"
      id="Fact001273"
      unitRef="USD">1304000</PMCB:ChangeInFairValueOfConvertibleNotesReceivable>
    <PMCB:ChangeInFairValueOfWarrantAssetFemasys
      contextRef="From2025-11-012026-01-31_custom_FemasysWarrantsMember"
      decimals="0"
      id="Fact001275"
      unitRef="USD">-214000</PMCB:ChangeInFairValueOfWarrantAssetFemasys>
    <PMCB:ChangeInFairValueOfWarrantAssetFemasys
      contextRef="From2025-05-012026-01-31_custom_FemasysWarrantsMember"
      decimals="0"
      id="Fact001277"
      unitRef="USD">-2155000</PMCB:ChangeInFairValueOfWarrantAssetFemasys>
    <us-gaap:ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001279">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock_zIJZbr9fmyab" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Femasys Note and warrants)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B6_zPFx5JpVVhV8" style="display: none"&gt;Schedule of activity for the notes and warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;Balance of Femasys Note as of April 30, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ConvertibleNoteReceivableCurrent_iS_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zcVqZmWeVxJf" style="width: 13%; text-align: right" title="Investment, beginning balance"&gt;3,696,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Change in fair value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ChangeInFairValueOfConvertibleNotesReceivable_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zzRyXvMMS5y1" style="text-align: right" title="Change in fair value"&gt;1,304,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Settlement of Femasys Note&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ProceedsFromInvestmentNoteReceivable_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zxwa0yFTbJP6" style="border-bottom: Black 1pt solid; text-align: right" title="Settlement of Femasys Note"&gt;(5,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance of Femasys Note as of January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--ConvertibleNoteReceivableCurrent_iE_d0_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysNotesMember_zfJXwdRVpvTd" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;Balance of Femasys Warrant Asset as of April 30, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--WarrantAssetFemasys_iS_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysWarrantsMember_zXIWBF6vdp01" style="width: 13%; text-align: right" title="Investment, beginning balance"&gt;3,061,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ChangeInFairValueOfWarrantAssetFemasys_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysWarrantsMember_zvxqJ0ydPnb" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(2,155,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance of Femasys Warrant Asset as of January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--WarrantAssetFemasys_iE_c20250501__20260131__us-gaap--InvestmentTypeAxis__custom--FemasysWarrantsMember_znNVChNbG69b" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance"&gt;906,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock>
    <PMCB:ConvertibleNoteReceivableCurrent
      contextRef="AsOf2025-04-30_custom_FemasysNotesMember"
      decimals="0"
      id="Fact001281"
      unitRef="USD">3696000</PMCB:ConvertibleNoteReceivableCurrent>
    <PMCB:ChangeInFairValueOfConvertibleNotesReceivable
      contextRef="From2025-05-012026-01-31_custom_FemasysNotesMember"
      decimals="0"
      id="Fact001283"
      unitRef="USD">1304000</PMCB:ChangeInFairValueOfConvertibleNotesReceivable>
    <PMCB:ProceedsFromInvestmentNoteReceivable
      contextRef="From2025-05-012026-01-31_custom_FemasysNotesMember"
      decimals="0"
      id="Fact001285"
      unitRef="USD">-5000000</PMCB:ProceedsFromInvestmentNoteReceivable>
    <PMCB:ConvertibleNoteReceivableCurrent
      contextRef="AsOf2026-01-31_custom_FemasysNotesMember"
      decimals="0"
      id="Fact001287"
      unitRef="USD">0</PMCB:ConvertibleNoteReceivableCurrent>
    <PMCB:WarrantAssetFemasys
      contextRef="AsOf2025-04-30_custom_FemasysWarrantsMember266865281"
      decimals="0"
      id="Fact001289"
      unitRef="USD">3061000</PMCB:WarrantAssetFemasys>
    <PMCB:ChangeInFairValueOfWarrantAssetFemasys
      contextRef="From2025-05-012026-01-31_custom_FemasysWarrantsMember266865281"
      decimals="0"
      id="Fact001291"
      unitRef="USD">-2155000</PMCB:ChangeInFairValueOfWarrantAssetFemasys>
    <PMCB:WarrantAssetFemasys
      contextRef="AsOf2026-01-31_custom_FemasysWarrantsMember"
      decimals="0"
      id="Fact001293"
      unitRef="USD">906000</PMCB:WarrantAssetFemasys>
    <us-gaap:InterestAndOtherIncome
      contextRef="From2025-11-202025-11-21_custom_FemasysPurchaseAgreementMember_custom_FemasysCommonStockMember"
      decimals="0"
      id="Fact001295"
      unitRef="USD">300000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="From2024-11-202024-11-21_custom_FemasysPurchaseAgreementMember_custom_FemasysCommonStockMember"
      decimals="0"
      id="Fact001297"
      unitRef="USD">300000</us-gaap:InterestAndOtherIncome>
    <PMCB:InvestmentSharesAddition
      contextRef="From2025-11-202025-11-21_custom_FemasysPurchaseAgreementMember"
      decimals="INF"
      id="Fact001298"
      unitRef="Shares">379747</PMCB:InvestmentSharesAddition>
    <PMCB:InvestmentSharesAddition
      contextRef="From2024-11-202024-11-21_custom_FemasysPurchaseAgreementMember"
      decimals="INF"
      id="Fact001299"
      unitRef="Shares">315790</PMCB:InvestmentSharesAddition>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="From2024-05-012025-04-30_custom_FemasysPurchaseAgreementMember"
      decimals="0"
      id="Fact001301"
      unitRef="USD">366316</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2026-01-31_custom_FemasysMember"
      decimals="INF"
      id="Fact001302"
      unitRef="Shares">695537</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2025-05-012026-01-31_custom_FemasysMember"
      decimals="0"
      id="Fact001304"
      unitRef="USD">-294065</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001306">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock_zvFiqG8cQ8nd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Marketable securities)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_zvXzbb3lexK5" style="display: none"&gt;Schedule of marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Carrying Value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;At Fair Market&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Adjusted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Unrealized&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="width: 55%; text-align: justify; padding-bottom: 1pt"&gt;Marketable securities&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 11%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Equity &#x2013; stock&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--MarketableSecuritiesCurrent_iI_c20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_ztFDbwbPoEN8" title="Carrying value at fair market value"&gt;372,251&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--InvestmentOwnedAtCost_iI_c20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zczNH370gFRj" title="Adjusted cost basis"&gt;666,316&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--MarketableSecuritiesUnrealizedGainLoss_c20250501__20260131__us-gaap--TransactionTypeAxis__custom--FemasysPurchaseAgreementMember_zAt1iAJWMWD1" title="Unrealized loss"&gt;294,065&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="AsOf2026-01-31_custom_FemasysPurchaseAgreementMember"
      decimals="0"
      id="Fact001308"
      unitRef="USD">372251</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2026-01-31_custom_FemasysPurchaseAgreementMember"
      decimals="0"
      id="Fact001310"
      unitRef="USD">666316</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="From2025-05-012026-01-31_custom_FemasysPurchaseAgreementMember"
      decimals="0"
      id="Fact001312"
      unitRef="USD">294065</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2024-05-20_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact001318"
      unitRef="Shares">7000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-05-20_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_LongTermWarrantMember"
      decimals="INF"
      id="Fact001320"
      unitRef="Shares">3854626</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-05-20_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_ShortTermWarrantMember"
      decimals="INF"
      id="Fact001322"
      unitRef="Shares">3854626</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2024-05-192024-05-20_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember"
      decimals="0"
      id="Fact001324"
      unitRef="USD">7000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-04-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_LongTermWarrantMember"
      decimals="INF"
      id="Fact001326"
      unitRef="Shares">38209611</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2025-09-012025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember"
      id="Fact001328">1-for-100 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_LongTermWarrantMember"
      decimals="INF"
      id="Fact001330"
      unitRef="Shares">2076351</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_ShortTermWarrantMember"
      decimals="INF"
      id="Fact001332"
      unitRef="Shares">2076351</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember"
      decimals="INF"
      id="Fact001333"
      unitRef="Shares">8577</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2025-04-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember"
      decimals="INF"
      id="Fact001334"
      unitRef="Shares">8577</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2025-04-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSAccruedDividendReceivableMember"
      decimals="INF"
      id="Fact001335"
      unitRef="Shares">1577</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSAccruedDividendReceivableMember"
      decimals="INF"
      id="Fact001336"
      unitRef="Shares">1577</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesGPreferredStockMember"
      decimals="INF"
      id="Fact001337"
      unitRef="Shares">7831</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2025-04-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesGPreferredStockMember"
      decimals="INF"
      id="Fact001338"
      unitRef="Shares">7831</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="From2025-11-012026-01-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesGPreferredStockMember_custom_QCLSMember"
      decimals="0"
      id="Fact001344"
      unitRef="USD">1433000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="From2025-05-012026-01-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesGPreferredStockMember_custom_QCLSMember"
      decimals="0"
      id="Fact001346"
      unitRef="USD">-5127000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_SeriesGPreferredStockMember_custom_QCLSMember"
      decimals="0"
      id="Fact001348"
      unitRef="USD">17347000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="From2025-11-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_SeriesGWarrantsMember_custom_QCLSMember"
      decimals="0"
      id="Fact001350"
      unitRef="USD">-1461000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="From2025-05-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_SeriesGWarrantsMember_custom_QCLSMember"
      decimals="0"
      id="Fact001352"
      unitRef="USD">-1652000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_SeriesGWarrantsMember_custom_QCLSMember"
      decimals="0"
      id="Fact001354"
      unitRef="USD">6966000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentTableTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001356">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--InvestmentTableTextBlock_z2pMAY7NicW2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series G Preferred Stock and Preferred Stock Warrants)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B4_z9Ya0pjiqgBa" style="display: none"&gt;Schedule of activity preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;Balance of Series G Preferred Stock as of April 30, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zJWApdCZnImc" style="width: 13%; text-align: right" title="Investment, beginnning balance"&gt;22,474,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ChangeInFairValueOfInvestment_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zVOsyYNARIR2" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(5,127,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance of Series G Preferred Stock as of January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGPreferredStockMember_zsTyPAX3lp3c" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance"&gt;17,347,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Below is a summary of activity for the QCLS Warrants
as of January 31, 2026:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;Balance of QCLS Series G Warrant assets as of April 30, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_c20250501__20260131__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGWarrantsMember_zWMuwb6FjXK5" style="width: 13%; text-align: right" title="Investment, beginnning balance"&gt;8,618,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ChangeInFairValueOfInvestment_c20250501__20260131__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGWarrantsMember_zX7yT8Eu3rD1" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(1,652,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance of QCLS Series G Warrant assets as of January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__srt--CounterpartyNameAxis__custom--QCLSMember__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesGWarrantsMember_zPbgi1cCOVA6" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance"&gt;6,966,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:InvestmentTableTextBlock>
    <us-gaap:InvestmentsAndOtherNoncurrentAssets
      contextRef="AsOf2025-04-30_custom_QCLSSeriesGPreferredStockMember"
      decimals="0"
      id="Fact001358"
      unitRef="USD">22474000</us-gaap:InvestmentsAndOtherNoncurrentAssets>
    <PMCB:ChangeInFairValueOfInvestment
      contextRef="From2025-05-012026-01-31_custom_QCLSSeriesGPreferredStockMember"
      decimals="0"
      id="Fact001360"
      unitRef="USD">-5127000</PMCB:ChangeInFairValueOfInvestment>
    <us-gaap:InvestmentsAndOtherNoncurrentAssets
      contextRef="AsOf2026-01-31_custom_QCLSSeriesGPreferredStockMember"
      decimals="0"
      id="Fact001362"
      unitRef="USD">17347000</us-gaap:InvestmentsAndOtherNoncurrentAssets>
    <us-gaap:InvestmentsAndOtherNoncurrentAssets
      contextRef="AsOf2025-04-30_custom_QCLSMember_custom_QCLSSeriesGWarrantsMember"
      decimals="0"
      id="Fact001364"
      unitRef="USD">8618000</us-gaap:InvestmentsAndOtherNoncurrentAssets>
    <PMCB:ChangeInFairValueOfInvestment
      contextRef="From2025-05-012026-01-31_custom_QCLSMember_custom_QCLSSeriesGWarrantsMember"
      decimals="0"
      id="Fact001366"
      unitRef="USD">-1652000</PMCB:ChangeInFairValueOfInvestment>
    <us-gaap:InvestmentsAndOtherNoncurrentAssets
      contextRef="AsOf2026-01-31_custom_QCLSMember_custom_QCLSSeriesGWarrantsMember"
      decimals="0"
      id="Fact001368"
      unitRef="USD">6966000</us-gaap:InvestmentsAndOtherNoncurrentAssets>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="AsOf2025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesGPreferredStockMember"
      decimals="INF"
      id="Fact001370"
      unitRef="Shares">3000</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember"
      decimals="INF"
      id="Fact001372"
      unitRef="Shares">600000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember"
      decimals="0"
      id="Fact001374"
      unitRef="USD">3000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember"
      decimals="INF"
      id="Fact001376"
      unitRef="USDPShares">3.37</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-09-30_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSCommonStockMember"
      decimals="INF"
      id="Fact001378"
      unitRef="Shares">889864</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember"
      decimals="0"
      id="Fact001379"
      unitRef="USD">3483000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputSharePriceMember"
      id="Fact001381">$3.61</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember"
      id="Fact001383">100.0%</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputMaturityMember"
      id="Fact001385">1.49 years</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_custom_MeasurementRedemptionPremiumMember"
      id="Fact001387">106%</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_custom_MeasurementInputMarketInterestRateMember"
      id="Fact001389">19.51%</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      id="Fact001391">3.61%</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="Fact001393">7.00%</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember"
      decimals="0"
      id="Fact001398"
      unitRef="USD">1606000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputSharePriceMember"
      id="Fact001400">$3.61</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputExercisePriceMember"
      id="Fact001402">$5.00</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="Fact001404">0%</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact001406">5.00 years</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputPriceVolatilityMember"
      id="Fact001408">105.0%</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-09-012025-09-02_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember_custom_QCLSSeriesHWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      id="Fact001410">3.59%</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember"
      decimals="0"
      id="Fact001412"
      unitRef="USD">5089000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember"
      decimals="0"
      id="Fact001414"
      unitRef="USD">3000000</us-gaap:InvestmentOwnedAtCost>
    <PMCB:GainOnRelatedPartyInvestmentQcls
      contextRef="From2025-05-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSMember"
      decimals="0"
      id="Fact001416"
      unitRef="USD">2089000</PMCB:GainOnRelatedPartyInvestmentQcls>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="From2025-11-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember"
      decimals="0"
      id="Fact001417"
      unitRef="USD">292000</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember"
      decimals="0"
      id="Fact001418"
      unitRef="USD">1642000</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:InvestmentOwnedAtCost
      contextRef="AsOf2026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember"
      decimals="0"
      id="Fact001419"
      unitRef="USD">5125000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputSharePriceMember"
      id="Fact001420">$4.19</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputPriceVolatilityMember"
      id="Fact001421">150.0%</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact001422">1.08 years</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_custom_MeasurementInputRedemptionPremiumMember"
      id="Fact001423">106%</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_custom_MeasurementInputMarketInterestRateMember"
      id="Fact001424">16.37%</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      id="Fact001425">3.42%</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHPreferredStockMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      id="Fact001426">7.00%</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="From2025-11-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember"
      decimals="0"
      id="Fact001428"
      unitRef="USD">261000</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="From2025-05-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember"
      decimals="0"
      id="Fact001430"
      unitRef="USD">1670000</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-05-012026-01-31_custom_SecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember"
      decimals="0"
      id="Fact001432"
      unitRef="USD">3276000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputSharePriceMember"
      id="Fact001433">$4.19</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputExercisePriceMember"
      id="Fact001434">$3.37</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      id="Fact001435">3.68%</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember"
      id="Fact001436">135.0%</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue
      contextRef="From2025-05-012026-01-31_custom_QCLSSecuritiesPurchaseAgreementMember_custom_QCLSSeriesHWarrantsMember_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact001437">4.59 years</us-gaap:DerivativesBasisAndUseOfDerivativesBasisDeterminationOfFairValue>
    <us-gaap:InvestmentTableTextBlock
      contextRef="From2025-05-012026-01-31_us-gaap_SeriesHPreferredStockMember"
      id="Fact001439">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--InvestmentTableTextBlock_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zfEVQb40lg51" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Series H Preferred Stock and Preferred Stock Warrants)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B4_z6IJ0Rx6rgya" style="display: none"&gt;Schedule of activity preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;Balance of Series H Preferred Stock as of April 30, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_d0_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zkLGmajUPc4g" style="width: 13%; text-align: right" title="Investment, beginning balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Initial fair value of investment Series H Preferred Shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--InvestmentOwnedAtFairValue_iI_c20250902__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zvMRwQxuSUNi" style="text-align: right" title="Initial fair value of Investment"&gt;3,483,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ChangeInFairValueOfInvestmentQcls_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zW4yEHlezcM6" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;1,642,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance of Series H Preferred Stock as of January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--QCLSSeriesHPreferredStockMember_zR9XFRjFULte" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance"&gt;5,125,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Below is a summary of activity for the QCLS Series
H Warrants as of January 31, 2026:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: justify"&gt;Balance of QCLS Series H Warrant assets as of April 30, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iS_d0_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zN1LwFG8Jbyc" style="width: 13%; text-align: right" title="Investment, beginning balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Initial fair value of investment in of QCLS Series H Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--InvestmentOwnedAtFairValue_iI_c20250902__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zacjDXECZvh8" style="text-align: right" title="Initial fair value of Investment"&gt;1,606,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ChangeInFairValueOfInvestmentQcls_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zp8eUhbkLUM4" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;1,670,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance of QCLS Series H Warrant assets as of January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InvestmentsAndOtherNoncurrentAssets_iE_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--QCLSSeriesHWarrantsMember_zwUz1V3pxHM6" style="border-bottom: Black 2.5pt double; text-align: right" title="Investment, ending balance"&gt;3,276,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:InvestmentTableTextBlock>
    <us-gaap:InvestmentsAndOtherNoncurrentAssets
      contextRef="AsOf2025-04-30_custom_QCLSSeriesHPreferredStockMember"
      decimals="0"
      id="Fact001441"
      unitRef="USD">0</us-gaap:InvestmentsAndOtherNoncurrentAssets>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2025-09-02_custom_QCLSSeriesHPreferredStockMember"
      decimals="0"
      id="Fact001443"
      unitRef="USD">3483000</us-gaap:InvestmentOwnedAtFairValue>
    <PMCB:ChangeInFairValueOfInvestmentQcls
      contextRef="From2025-05-012026-01-31_custom_QCLSSeriesHPreferredStockMember"
      decimals="0"
      id="Fact001445"
      unitRef="USD">1642000</PMCB:ChangeInFairValueOfInvestmentQcls>
    <us-gaap:InvestmentsAndOtherNoncurrentAssets
      contextRef="AsOf2026-01-31_custom_QCLSSeriesHPreferredStockMember"
      decimals="0"
      id="Fact001447"
      unitRef="USD">5125000</us-gaap:InvestmentsAndOtherNoncurrentAssets>
    <us-gaap:InvestmentsAndOtherNoncurrentAssets
      contextRef="AsOf2025-04-30_custom_QCLSSeriesHWarrantsMember"
      decimals="0"
      id="Fact001449"
      unitRef="USD">0</us-gaap:InvestmentsAndOtherNoncurrentAssets>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2025-09-02_custom_QCLSSeriesHWarrantsMember"
      decimals="0"
      id="Fact001451"
      unitRef="USD">1606000</us-gaap:InvestmentOwnedAtFairValue>
    <PMCB:ChangeInFairValueOfInvestmentQcls
      contextRef="From2025-05-012026-01-31_custom_QCLSSeriesHWarrantsMember"
      decimals="0"
      id="Fact001453"
      unitRef="USD">1670000</PMCB:ChangeInFairValueOfInvestmentQcls>
    <us-gaap:InvestmentsAndOtherNoncurrentAssets
      contextRef="AsOf2026-01-31_custom_QCLSSeriesHWarrantsMember"
      decimals="0"
      id="Fact001455"
      unitRef="USD">3276000</us-gaap:InvestmentsAndOtherNoncurrentAssets>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001461">&lt;p id="xdx_806_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zZXGy1qjxGyb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 5 &#x2013; &lt;span id="xdx_824_zTSYEmpOKWf4"&gt;ACCRUED EXPENSES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accrued expenses at January 31, 2026 and April
30, 2025, are summarized below:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z6sz1XjptWR6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCRUED EXPENSES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B6_zz4ZxbsiawG7" style="display: none"&gt;Schedule of accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;January 31, 2026&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;April 30, 2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Payroll related costs&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--PayrollRelatedCostsMember_z5Z6s3hvwP47" style="width: 13%; text-align: right" title="Accrued liabilities"&gt;185,846&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--PayrollRelatedCostsMember_zEzO2lwRUUXd" style="width: 13%; text-align: right" title="Accrued liabilities"&gt;335,846&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Director fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--DirectorFeesMember_zTFrCxa1TXk9" style="text-align: right" title="Accrued liabilities"&gt;67,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--DirectorFeesMember_z97Wn1e0mxEd" style="text-align: right" title="Accrued liabilities"&gt;67,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;R&amp;amp;D costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--RAndDCostsMember_zCC1dAi5A4ve" style="text-align: right" title="Accrued liabilities"&gt;92,310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--RAndDCostsMember_z79qi1A8c18k" style="text-align: right" title="Accrued liabilities"&gt;92,310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Legal settlement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LegalSettlementMember_zGzALkLR9NTd" style="text-align: right" title="Accrued liabilities"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LegalSettlementMember_zcTYAJpGCEue" style="text-align: right" title="Accrued liabilities"&gt;2,019,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Excise tax on stock repurchases&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_d0_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--ExciseTaxOnStockRepurchasesMember_z2VTRJAFL8kj" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_d0_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--ExciseTaxOnStockRepurchasesMember_z0hYN3MSnks8" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities"&gt;25,424&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131_z0YQ0hNQSJUk" style="text-align: right" title="Accrued liabilities"&gt;445,656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430_zQjA8i06jb6l" style="text-align: right" title="Accrued liabilities"&gt;2,540,080&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less: Long-term portion of legal settlement&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LongTermPortionOfLegalSettlementMember_z6dZocZKBjgc" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1489"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LongTermPortionOfLegalSettlementMember_zpnXjBA3TZma" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities"&gt;(25,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccruedLiabilitiesCurrent_iI_c20260131_zptDgpGu0iTj" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued liabilities, current"&gt;445,656&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrent_iI_c20250430_zW3pBe71mdtg" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued liabilities, current"&gt;2,515,080&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001463">&lt;table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z6sz1XjptWR6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCRUED EXPENSES (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B6_zz4ZxbsiawG7" style="display: none"&gt;Schedule of accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;January 31, 2026&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;April 30, 2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Payroll related costs&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--PayrollRelatedCostsMember_z5Z6s3hvwP47" style="width: 13%; text-align: right" title="Accrued liabilities"&gt;185,846&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--PayrollRelatedCostsMember_zEzO2lwRUUXd" style="width: 13%; text-align: right" title="Accrued liabilities"&gt;335,846&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Director fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--DirectorFeesMember_zTFrCxa1TXk9" style="text-align: right" title="Accrued liabilities"&gt;67,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--DirectorFeesMember_z97Wn1e0mxEd" style="text-align: right" title="Accrued liabilities"&gt;67,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;R&amp;amp;D costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--RAndDCostsMember_zCC1dAi5A4ve" style="text-align: right" title="Accrued liabilities"&gt;92,310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--RAndDCostsMember_z79qi1A8c18k" style="text-align: right" title="Accrued liabilities"&gt;92,310&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Legal settlement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LegalSettlementMember_zGzALkLR9NTd" style="text-align: right" title="Accrued liabilities"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LegalSettlementMember_zcTYAJpGCEue" style="text-align: right" title="Accrued liabilities"&gt;2,019,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Excise tax on stock repurchases&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_d0_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--ExciseTaxOnStockRepurchasesMember_z2VTRJAFL8kj" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_d0_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--ExciseTaxOnStockRepurchasesMember_z0hYN3MSnks8" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities"&gt;25,424&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131_z0YQ0hNQSJUk" style="text-align: right" title="Accrued liabilities"&gt;445,656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430_zQjA8i06jb6l" style="text-align: right" title="Accrued liabilities"&gt;2,540,080&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Less: Long-term portion of legal settlement&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20260131__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LongTermPortionOfLegalSettlementMember_z6dZocZKBjgc" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1489"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_c20250430__us-gaap--StatementOfFinancialPositionLocationBalanceAxis__us-gaap--AccruedLiabilitiesCurrentAndNoncurrent__us-gaap--NatureOfExpenseAxis__custom--LongTermPortionOfLegalSettlementMember_zpnXjBA3TZma" style="border-bottom: Black 1pt solid; text-align: right" title="Accrued liabilities"&gt;(25,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AccruedLiabilitiesCurrent_iI_c20260131_zptDgpGu0iTj" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued liabilities, current"&gt;445,656&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccruedLiabilitiesCurrent_iI_c20250430_zW3pBe71mdtg" style="border-bottom: Black 2.5pt double; text-align: right" title="Accrued liabilities, current"&gt;2,515,080&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_PayrollRelatedCostsMember"
      decimals="0"
      id="Fact001465"
      unitRef="USD">185846</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_PayrollRelatedCostsMember"
      decimals="0"
      id="Fact001467"
      unitRef="USD">335846</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_DirectorFeesMember"
      decimals="0"
      id="Fact001469"
      unitRef="USD">67500</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_DirectorFeesMember"
      decimals="0"
      id="Fact001471"
      unitRef="USD">67500</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_RAndDCostsMember"
      decimals="0"
      id="Fact001473"
      unitRef="USD">92310</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_RAndDCostsMember"
      decimals="0"
      id="Fact001475"
      unitRef="USD">92310</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_LegalSettlementMember"
      decimals="0"
      id="Fact001477"
      unitRef="USD">100000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_LegalSettlementMember"
      decimals="0"
      id="Fact001479"
      unitRef="USD">2019000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2026-01-31_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_ExciseTaxOnStockRepurchasesMember"
      decimals="0"
      id="Fact001481"
      unitRef="USD">0</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_ExciseTaxOnStockRepurchasesMember"
      decimals="0"
      id="Fact001483"
      unitRef="USD">25424</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact001485"
      unitRef="USD">445656</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact001487"
      unitRef="USD">2540080</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2025-04-30_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_custom_LongTermPortionOfLegalSettlementMember"
      decimals="0"
      id="Fact001491"
      unitRef="USD">-25000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact001493"
      unitRef="USD">445656</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2025-04-30"
      decimals="0"
      id="Fact001495"
      unitRef="USD">2515080</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001497">&lt;p id="xdx_805_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zmtZvJpme0j4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 6 &#x2013; &lt;span id="xdx_823_z53GYDCltHP4"&gt;STOCK OPTIONS AND WARRANTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;2021 Equity Incentive Plan&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective June 30, 2021, the Company implemented
the 2021 Equity Incentive Plan (&#x201c;2021 Equity Plan&#x201d;) as approved by the Company&#x2019;s stockholders. The 2021 Equity Plan
is administered by the Compensation Committee of the Board and has &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20210630__us-gaap--PlanNameAxis__custom--EquityPlan2021Member_zSQ8ZapKCF9"&gt;166,667&lt;/span&gt; shares authorized under this plan. The 2021 Equity Plan can
issue various types of awards, as follows: stock options, stock appreciation rights, restricted stock, restricted stock units, and cash
or other stock-based awards. The 2021 Equity Plan is available to be issued to employees, directors, consultants, and other individuals
who provide services to the Company. An incentive stock options (&#x201c;ISOs&#x201d;) can only be granted to employees and shall not exceed
10-years (5-years in the case of ISOs granted to any 10% shareholder). As of January 31, 2026, there are &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20260131__us-gaap--PlanNameAxis__custom--EquityPlan2021Member_z1SD9GF3Ad9l" title="Shares available for grant"&gt;154,596&lt;/span&gt; shares remaining available
under the 2021 Equity Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;2022 Equity Incentive Plan&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Effective December 28, 2022, the Company implemented
the 2022 Equity Incentive Plan (&#x201c;2022 Equity Plan&#x201d;) as approved by the Company&#x2019;s stockholders. In October 2025, the
Company held a special meeting of stockholders (the &#x201c;2025 Special Meeting&#x201d;). At the 2025 Special Meeting, the stockholders
of the Company approved an amendment to the 2022 Equity Plan which, among other things, increased the number of shares of common stock
available for grant under the 2022 Equity Plan by &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_c20251001__20251031_zz9x0wnDi2ta" title="Increase number of shares"&gt;2,250,000&lt;/span&gt;. The 2022 Equity Plan is administered by the Compensation Committee of the
Board and has &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20221228__us-gaap--PlanNameAxis__custom--EquityPlan2022Member_z3Mo5siVCexg" title="Shares authorized for grant"&gt;5,000,000&lt;/span&gt; shares available under this plan, as amended. The 2022 Equity Plan can issue various types of awards, as follows:
stock options, stock appreciation rights, restricted stock, restricted stock units, and cash or other stock-based awards. The 2022 Equity
Plan is available to be issued to employees, directors, consultants, and other individuals who provide services to the Company. An incentive
stock options (&#x201c;ISOs&#x201d;) can only be granted to employees and shall not exceed 10-years (5-years in the case of ISOs granted
to any 10% shareholder). As of January 31, 2026, there are &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20260131__us-gaap--PlanNameAxis__custom--EquityPlan2022Member_zTWtMDzaGuW5"&gt;2,970,040&lt;/span&gt; shares remaining available under the 2022 Equity Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Stock Options&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of the Company&#x2019;s stock option
activity and related information for the nine months ended January 31, 2026, are shown below:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zhN8BJ7Hr51l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details - Option activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_zEN5pPGVLvof" style="display: none"&gt;Schedule of stock option activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price per&lt;br/&gt; Share&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average &lt;br/&gt; Remaining&lt;br/&gt; Contractual &lt;br/&gt; Term in Years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 55%; text-align: justify"&gt;Outstanding, April 30, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zU18bZQ2oYrb" style="width: 11%; text-align: right" title="Number of options outstanding, beginning"&gt;1,169,961&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqjjd7wljfJc" style="width: 11%; text-align: right" title="Weighted average exercise price per share, beginning"&gt;2.21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240501__20250430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_ztAHF3gpWixi" title="Weighted average remaining contractual term"&gt;8.62&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zH3YEuCSe837" style="text-align: right" title="Number of options, issued"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z6b1fkdt5B86" style="text-align: right" title="Weighted average exercise price per share, issued"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Expired and forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNIYCM2ch8l7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, expired and forfeited"&gt;(9,334&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zB4tdiEYEEkc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price per share, expired and forfeited"&gt;10.78&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Outstanding, January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zgZNfkXpwA41" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending"&gt;1,160,627&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zR7Opdz4xT3i" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, ending"&gt;2.14&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zw5CCEnpK5re" title="Weighted average remaining contractual term"&gt;7.92&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Exercisable, January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZh3fse2DOo2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, exercisable"&gt;907,695&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zvqSvYplALk3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, exercisable"&gt;2.39&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zb2OQOjkaBPk" title="Weighted-average remaining contractual term, exercisable"&gt;7.56&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zDIvHMFEL1qd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recorded $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20251101__20260131__srt--CounterpartyNameAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMYR0u7BUigf" title="Stock-based compensation"&gt;60,492&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20250501__20260131__srt--CounterpartyNameAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z5yPYeMbXKn8" title="Stock-based compensation"&gt;181,476&lt;/span&gt; of
stock-based compensation expense related to the issuance of Employee Options to certain officers and directors in exchange for
services during the three and nine months ended January 31, 2026, respectively, and $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20241101__20250131__srt--CounterpartyNameAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zRNNQhIsbc6h" title="Stock-based compensation"&gt;72,859&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20240501__20250131__srt--CounterpartyNameAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPedYnLT1CFb" title="Stock-based compensation"&gt;414,692&lt;/span&gt; for the three and nine
months ended January 31, 2025, respectively. As of January 31, 2026, there remained $&lt;span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20260131__srt--CounterpartyNameAxis__custom--EmployeesMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9ie6UBeTFc5" title="Employee service unrecognized compensation expense"&gt;54,579&lt;/span&gt; of unrecognized compensation expense
related to unvested Employee Options granted to officers and directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The aggregate intrinsic value of vested outstanding
options as of January 31, 2026 was $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_pp0p0_c20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zB2elHkZAJG2" title="Aggregate intrinsic value"&gt;0&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Series B Warrant&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 10, 2023, the Company entered into a Securities
Purchase Agreement (the &#x201c;Private Placement Agreement&#x201d;) with certain accredited investors (the &#x201c;Investors&#x201d;), pursuant
to which it agreed to sell to the Investors warrants to acquire up to an aggregate of &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230510__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zpnxX9KXAk88" title="Warrants acquire"&gt;8,750,000&lt;/span&gt; shares of Common Stock, collectively,
the (&#x201c;Series B Warrants&#x201d;), with an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230510__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z2ElVcvjisbj" title="Warrant exercise price"&gt;4.00&lt;/span&gt; per share (subject to adjustment), for a period of five years from
the date of issuance. In connection with the Series C Private Placement (as defined herein), in August 2025, the exercise price of the
Series B Preferred Warrants was adjusted to $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260131__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zlS32ZhOy5Ya" title="Exercise price"&gt;0.95&lt;/span&gt; per share and the number of shares of Common Stock issuable upon exercise of the Series
B Warrants was adjusted proportionally to 36,780,161 pursuant to the full ratchet anti-dilution provisions contained therein.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Series B Warrants were determined to be subject
to liability classification as they are considered to be indexed to the Company&#x2019;s own stock but fail to meet the requirements for
equity classification in accordance with ASC 815. As such, the Company recorded the Series B Warrants as a liability at fair value with
subsequent changes in fair value recognized in earnings. The Company utilized the Black-Scholes-Merton Model to calculate the value of
the Series B Warrants issued on May 10, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three and nine months ended January
31, 2026, the Company received Series B exercise notices totaling &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20251101__20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zRB2rWhqigLb" title="Warrants exercised"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zHTNkSXlKcRf" title="Warrants exercised"&gt;1,100,000&lt;/span&gt;&lt;/span&gt; shares. The exercises resulted in the Company received cash
in the amount of $&lt;span id="xdx_909_eus-gaap--ProceedsFromWarrantExercises_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_z8LLi4MetkEh" title="Proceeds from warrant exercises"&gt;1,046,740&lt;/span&gt; and a reduction in the warrant liability of $&lt;span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_z3YTIv1hI1s6" title="Reduction in warrant liability"&gt;599,135&lt;/span&gt;. Following the exercises the Company has &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBWarrantsMember_zOLYbcSmE6d" title="Warrants outstanding"&gt;35,680,160&lt;/span&gt; Series
B warrant shares remaining.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three and nine months ended January
31, 2026, the Company recorded a gain of approximately $&lt;span id="xdx_90D_ecustom--ChangeInFairValueOfWarrantLiability_iN_di_c20251101__20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBPreferredWarrantsMember_zgnbDfHEHlr4" title="Change in fair value of warrant liability"&gt;874,000&lt;/span&gt; and a loss of $&lt;span id="xdx_90D_ecustom--ChangeInFairValueOfWarrantLiability_iN_di_c20250501__20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBPreferredWarrantsMember_zWe5COUedCdg" title="Change in fair value of warrant liability"&gt;9,182,000&lt;/span&gt;, respectively, related to the change in fair
value of the warrant liability which is recorded in other income on the unaudited condensed consolidated statements of operations. The
fair value of the Series B Warrants of $&lt;span id="xdx_90B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20260131__us-gaap--StatementClassOfStockAxis__custom--SeriesBPreferredWarrantsMember_z5iwPDQWekjk" title="Fair value of the warrants"&gt;9,520,000&lt;/span&gt; was estimated at January 31, 2026, utilizing the Black-Scholes-Merton Model using the
fair value of the Company&#x2019;s common stock of $0.82 and the following weighted average assumptions: dividend yield 0%; remaining term
of 2.27 years; equity volatility of 60.0%; and a risk-free interest rate of 3.48%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three and nine months ended January
31, 2025, the Company recorded a gain of approximately $&lt;span id="xdx_907_ecustom--ChangeInFairValueOfWarrantLiability_iN_di_c20241101__20250131__us-gaap--StatementClassOfStockAxis__custom--SeriesBPreferredWarrantsMember_zS4DTrJhIFS9" title="Change in fair value of warrant liability"&gt;4,487,000&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--ChangeInFairValueOfWarrantLiability_iN_di_c20240501__20250131__us-gaap--StatementClassOfStockAxis__custom--SeriesBPreferredWarrantsMember_zGtQmNSkvveg" title="Change in fair value of warrant liability"&gt;8,400,000&lt;/span&gt;, respectively, related to the change in fair value of
the warrant liability which is recorded in other income (expense) on the Condensed Consolidated Statements of Operations. The fair value
of the Series B Warrants of $&lt;span id="xdx_90F_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_c20250131__us-gaap--StatementClassOfStockAxis__custom--SeriesBPreferredWarrantsMember_zEIgkL9ceNS4" title="Fair value of the warrants"&gt;2,384,000&lt;/span&gt; was estimated at January 31, 2025, utilizing the Black-Scholes-Merton Model using the fair value
of the Company&#x2019;s common stock of $1.60 and the following weighted average assumptions: dividend yield 0%; remaining term of 3.27
years; equity volatility of 55.0%; and a risk-free interest rate of 4.19%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Settlement Warrants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the Settlement Agreement, as
defined on Note 8 &#x2013; Commitments and Contingencies, on May 16, 2025, the Company issued warrants (&#x201c;First Warrant Issuance&#x201d;)
to purchase &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250516__us-gaap--TransactionTypeAxis__custom--SettlementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FirstWarrantIssuanceMember_zJOKpIArpksc"&gt;343,183&lt;/span&gt; shares of Common Stock with an exercise price of $4.00 per share and a term of five years from the issuance date.
On October 29, 2025, the Company issued additional warrants (&#x201c;Additional Warrants&#x201d;, and collectively with the First Warrant
Issuance, the &#x201c;Settlement Warrants&#x201d;) to purchase &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251029__us-gaap--TransactionTypeAxis__custom--SettlementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SettlementWarrantsMember_zRVKgkuu28Ck"&gt;313,067&lt;/span&gt; shares of the Company&#x2019;s common stock with an exercise price
of $4.00 per share and a term of five years from the issuance date. In connection with the Series C Private Placement (as defined herein),
in August 2025, the exercise price of the Settlement Warrants was adjusted to $0.95 per share and the number of shares of Common Stock
issuable upon exercise Settlement Warrants was adjusted proportionally to 2,758,511 pursuant to the full ratchet anti-dilution provisions
contained in their respective agreements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Settlement Warrants were determined to be
subject to liability classification. As such, the Company recorded the Settlement Warrants as a liability upon issuance at their fair
value with subsequent changes in fair value recognized in earnings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company utilized the Black-Scholes-Merton
Model to calculate the value of the Settlement Warrants issued during the three and nine months ended January 31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of the First Warrant Issuance of
approximately $&lt;span id="xdx_907_eus-gaap--FairValueAdjustmentOfWarrants_c20250515__20250516__us-gaap--ClassOfWarrantOrRightAxis__custom--FirstWarrantIssuanceMember_zLBIRjlEG6P5" title="Fair value of the warrants"&gt;199,000&lt;/span&gt; was estimated at May 16, 2025 (the date of issuance) using the fair value of the Company&#x2019;s common stock of
$1.06 on the issuance date as well as the following input assumptions: expected dividend yield of 0%; expected term of 5.0 years; equity
volatility of 97.0%; and a risk-free interest rate of 4.1%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of the Additional Warrants of approximately
$&lt;span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20250728__20250729__us-gaap--AwardTypeAxis__custom--AdditionalWarrantsMember_z8HpMF7JSCfd" title="Fair value of the warrants"&gt;164,000&lt;/span&gt; was estimated at July 29, 2025 (the date of issuance) using the fair value of the Company&#x2019;s common stock of $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20250729__us-gaap--AwardTypeAxis__custom--AdditionalWarrantsMember_zD7BwdQZIDo9" title="Fair value per share"&gt;1.02&lt;/span&gt; on the
issuance date as well as the following input assumptions: expected dividend yield of 0%; expected term of 5.0 years; equity volatility
of 94.0%; and a risk-free interest rate of 3.9%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three and nine months ended January
31, 2026, the Company recorded a gain on legal settlement of $&lt;span id="xdx_900_eus-gaap--LitigationSettlementGain_c20251101__20260131_z1Zl42Eh5DGi" title="Gain on legal settlement"&gt;0&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--LitigationSettlementGain_c20250501__20260131_zADkI1LIrW6l" title="Gain on legal settlement"&gt;106,000&lt;/span&gt;, respectively, which represents the difference between the
estimated fair value of the Settlement Warrants recognized during the year ended April 30, 2025 totaling $&lt;span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20240501__20250430_zfR4OThLqtxa" title="Fair value of the warrants"&gt;469,000&lt;/span&gt; and their issuance date
fair values totaling $&lt;span id="xdx_90B_ecustom--IssuanceFairValues_c20240501__20250430_zciLjZyjQ825" title="Issuance fair values"&gt;363,000&lt;/span&gt;. See Note 8 &#x2013; Commitment and Contingencies &#x2013; Legal Proceedings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three and nine months ended January
31, 2026, the Company recorded a gain of $&lt;span id="xdx_902_ecustom--ChangeInFairValueOfWarrantLiability_iN_di_c20251101__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--SettlementWarrantsMember_zkSXgMslh5X6"&gt;545,000&lt;/span&gt; and a loss of $&lt;span id="xdx_908_ecustom--ChangeInFairValueOfWarrantLiability_iN_di_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--SettlementWarrantsMember_zWqsgjBVStSd"&gt;694,000&lt;/span&gt;, respectively, related to the change in fair value of the warrant
liability associated with the Settlement Warrants which is recorded in other income (expense) on the unaudited condensed consolidated
statements of operations. The fair value of the Settlement Warrants of $&lt;span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_c20250501__20260131__us-gaap--ClassOfWarrantOrRightAxis__custom--SettlementWarrantsMember_z18hBVmQBbZ5" title="Fair value of the warrants"&gt;1,057,000&lt;/span&gt; was estimated at January 31, 2026 utilizing the Black-Scholes-Merton
Model using the fair value of the Company&#x2019;s common stock of $0.82 and was based on the following weighted average assumptions: expected
dividend yield of 0%; expected term of 4.39 years; equity volatility of 60.0%; and a risk-free interest rate of 3.7%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Series C Warrant&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 17, 2025, the Company entered into a
Securities Purchase Agreement (the &#x201c;Series C Private Placement Agreement&#x201d;) with certain accredited investors (the &#x201c;Investors&#x201d;),
pursuant to which it agreed to sell in a private placement to the Investors warrants to acquire up to an aggregate of &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250819__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember_zlTAJSYuGJvj"&gt;7,000,000&lt;/span&gt; shares
of Common Stock, collectively, the (&#x201c;Series C Preferred Warrant&#x201d;), with an exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250819__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember_zRAB3pyO0Pv2"&gt;1.00&lt;/span&gt; per share (subject to adjustment),
for a period of five years from the date of issuance. The Series C Private Placement Agreement closed on August 19, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Series C Warrants were determined to be subject
to liability classification as they are considered to be indexed to the Company&#x2019;s own stock but fail to meet the requirements for
equity classification in accordance with ASC 815. As such, the Company recorded the Series C Warrants as a liability at fair value with
subsequent changes in fair value recognized in earnings. The fair value of the Series C Warrants of $&lt;span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_c20250801__20250819__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember_zilEi7MTIc8k" title="Fair value of the warrants"&gt;5,220,000&lt;/span&gt; was estimated at August
19, 2025, utilizing the Black-Scholes-Merton Model using the fair value of the Company&#x2019;s common stock of $1.01 and the following
weighted average assumptions: dividend yield of 0%; remaining term of 5.00 years; equity volatility of 95.0%; and a risk-free interest
rate of 3.75%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three and nine months ended January
31, 2026, the Company recorded a gain of approximately $&lt;span id="xdx_908_ecustom--ChangeInFairValueOfWarrantAsset_c20251101__20260131__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCPreferredWarrantsMember_zscCxlc2zlCf" title="Change in fair value warrant asset"&gt;1,076,000&lt;/span&gt; and $&lt;span id="xdx_903_ecustom--ChangeInFairValueOfWarrantAsset_c20250501__20260131__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCPreferredWarrantsMember_zCwbgfEcOeBd"&gt;2,140,000&lt;/span&gt;, respectively, related to the change in fair value of
the warrant liability associated with the Series C Warrants which is recorded in other income on the unaudited condensed consolidated
statements of operations. The fair value of the Series C Warrants of $&lt;span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20250501__20260131__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCPreferredWarrantsMember_zxMEFhIwzPC9"&gt;3,080,000&lt;/span&gt; was estimated at January 31, 2026, utilizing the Black-Scholes-Merton
Model using the fair value of the Company&#x2019;s common stock of $0.82 and the following weighted average assumptions: dividend yield
0%; remaining term of 4.55 years; equity volatility of 70.0%; and a risk-free interest rate of 3.68%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Placement Agent Warrants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the Series C Private Placement
Agreement, the Company also issued warrants to purchase up to an aggregate of &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250819__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCPlacementAgentWarrantsMember_zM34x6wuNf3b"&gt;560,000&lt;/span&gt; shares of the Common Stock as compensation to placement
agents for services rendered (the &#x201c;Series C Placement Agent Warrants&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Series C Placement Agent Warrants are classified
as a contingently redeemable warrant in accordance with ASC 718, as it was determined that the warrants were not precluded from equity
classification under that guidance, but could be settled in cash or other assets in the event that another person or entity becomes the
beneficial owner of&#160;50% of the outstanding shares of the Common Stock. The Series C Placement Agent Warrants were thus classified
in temporary equity on the Company&#x2019;s condensed consolidated balance sheets as of January 31, 2026 pursuant to ASC 480-10-S99-3A.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of the Series C Placement Agent
Warrants of $&lt;span id="xdx_90D_eus-gaap--FairValueAdjustmentOfWarrants_c20250801__20250819__us-gaap--SubsidiarySaleOfStockAxis__custom--SeriesCPrivatePlacementAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCPlacementAgentWarrantsMember_z8JZymXNJhKj"&gt;417,000&lt;/span&gt; was estimated at August 19, 2025, utilizing the Black-Scholes-Merton Model using the fair value of the Company&#x2019;s
common stock of $1.01 and the following weighted average assumptions: dividend yield of 0%; remaining term of 5.00 years; equity volatility
of 95.0%; and a risk-free interest rate of 3.75%. The fair value of the Series C Placement Agent Warrants was expensed as incurred and
was recorded in Series C convertible preferred stock and warrants issuance costs on the condensed consolidated statement of operations
for the nine months ended January 31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A summary of the Company&#x2019;s warrant activity
and related information for the nine months ended January 31, 2026, are shown below:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zlKnRnxcRI3g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details - Warrant activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_zcALJrtgtFwa" style="display: none"&gt;Schedule of warrant activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise Price Per Share&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining Contractual Term In Years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 55%"&gt;Outstanding, April 30, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJBlos8fFIj7" style="width: 11%; text-align: right" title="Warrants outstanding, beginning balance"&gt;18,570,847&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zP1ahsgBRuK2" style="width: 11%; text-align: right" title="Weighted average exercise price warrants outstanding, beginning balance"&gt;4.54&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240501__20250430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zvI9x1qfoP4b" title="Weighted average remaining contractual term"&gt;2.12&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--WarrantsIssuedShares_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQ3ewShGzi9" style="text-align: right" title="Warrants issued"&gt;8,216,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zStQwJ09LwF5" style="text-align: right" title="Weighted average exercise price warrants issued"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Issued - Series B Warrants and Settlement Warrants adjusted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--WarrantsIssuedShares_d0_c20250501__20260131__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsAndSettlementWarrantsAdjustedMember_zrk6zl7qbTK5" style="text-align: right" title="Warrants issued"&gt;30,132,422&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20250501__20260131__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsAndSettlementWarrantsAdjustedMember_zHd0FGdR57v5" style="text-align: right" title="Weighted average exercise price warrants issued"&gt;0.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantExercised_iN_di_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxLNNtOa0Hnl" style="text-align: right" title="Warrants exercised"&gt;(1,100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--WeightedAverageExercisePriceWarrantsExercised_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmu9SNWDPLke" style="text-align: right" title="Weighted average exercise price warrants Exercised"&gt;0.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--WarrantsExpired_iN_di0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zF2aD6730o6h" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--WeightedAverageExercisePriceWarrantsExpired_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3x0aTXrP1ub" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price warrants Expired"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Outstanding, January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOgTvl4NlbE7" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, ending balance"&gt;55,819,519&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zN6gAdwQkCbj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price warrants outstanding, ending balance"&gt;1.68&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxZRaHOKg9F5" title="Weighted average remaining contractual term"&gt;2.61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--WarrantsExercisable_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zMZVcf06fIZf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable"&gt;55,819,519&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWWMcdN6Pmk1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price warrants exercisable"&gt;1.68&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zl6tMlzLhwF3" title="Weighted-average remaining contractual term, exercisable"&gt;2.61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zTCo32KlALc2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;











</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-06-30_custom_EquityPlan2021Member"
      decimals="INF"
      id="Fact001498"
      unitRef="Shares">166667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2026-01-31_custom_EquityPlan2021Member"
      decimals="INF"
      id="Fact001500"
      unitRef="Shares">154596</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="From2025-10-012025-10-31"
      decimals="INF"
      id="Fact001502"
      unitRef="Shares">2250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2022-12-28_custom_EquityPlan2022Member"
      decimals="INF"
      id="Fact001504"
      unitRef="Shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2026-01-31_custom_EquityPlan2022Member"
      decimals="INF"
      id="Fact001505"
      unitRef="Shares">2970040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001511">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zhN8BJ7Hr51l" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details - Option activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_zEN5pPGVLvof" style="display: none"&gt;Schedule of stock option activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;Options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; Exercise &lt;br/&gt; Price per&lt;br/&gt; Share&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average &lt;br/&gt; Remaining&lt;br/&gt; Contractual &lt;br/&gt; Term in Years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 55%; text-align: justify"&gt;Outstanding, April 30, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zU18bZQ2oYrb" style="width: 11%; text-align: right" title="Number of options outstanding, beginning"&gt;1,169,961&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zqjjd7wljfJc" style="width: 11%; text-align: right" title="Weighted average exercise price per share, beginning"&gt;2.21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240501__20250430__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_ztAHF3gpWixi" title="Weighted average remaining contractual term"&gt;8.62&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zH3YEuCSe837" style="text-align: right" title="Number of options, issued"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z6b1fkdt5B86" style="text-align: right" title="Weighted average exercise price per share, issued"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Expired and forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zNIYCM2ch8l7" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options, expired and forfeited"&gt;(9,334&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zB4tdiEYEEkc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price per share, expired and forfeited"&gt;10.78&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Outstanding, January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zgZNfkXpwA41" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending"&gt;1,160,627&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zR7Opdz4xT3i" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, ending"&gt;2.14&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zw5CCEnpK5re" title="Weighted average remaining contractual term"&gt;7.92&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Exercisable, January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZh3fse2DOo2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, exercisable"&gt;907,695&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zvqSvYplALk3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price per share, exercisable"&gt;2.39&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zb2OQOjkaBPk" title="Weighted-average remaining contractual term, exercisable"&gt;7.56&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-04-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001513"
      unitRef="Shares">1169961</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-04-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001515"
      unitRef="USDPShares">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-05-012025-04-30_us-gaap_StockOptionMember"
      id="Fact001517">P8Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-05-012026-01-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001519"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-05-012026-01-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001521"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2025-05-012026-01-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001523"
      unitRef="Shares">9334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-05-012026-01-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001525"
      unitRef="USDPShares">10.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2026-01-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001527"
      unitRef="Shares">1160627</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2026-01-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001529"
      unitRef="USDPShares">2.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-05-012026-01-31_us-gaap_StockOptionMember"
      id="Fact001531">P7Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2026-01-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001533"
      unitRef="Shares">907695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2026-01-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001535"
      unitRef="USDPShares">2.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-05-012026-01-31_us-gaap_StockOptionMember"
      id="Fact001537">P7Y6M21D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-11-012026-01-31_custom_EmployeesMember_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact001539"
      unitRef="USD">60492</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-05-012026-01-31_custom_EmployeesMember_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact001541"
      unitRef="USD">181476</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-11-012025-01-31_custom_EmployeesMember_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact001543"
      unitRef="USD">72859</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-05-012025-01-31_custom_EmployeesMember_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact001545"
      unitRef="USD">414692</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2026-01-31_custom_EmployeesMember_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact001547"
      unitRef="USD">54579</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="AsOf2026-01-31_us-gaap_StockOptionMember"
      decimals="0"
      id="Fact001549"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-05-10_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001551"
      unitRef="Shares">8750000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-05-10_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001553"
      unitRef="USDPShares">4.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-01-31_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact001555"
      unitRef="USDPShares">0.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-11-012026-01-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact001557"
      unitRef="Shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2025-05-012026-01-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact001559"
      unitRef="Shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-05-012026-01-31_custom_SeriesBWarrantsMember"
      decimals="0"
      id="Fact001561"
      unitRef="USD">1046740</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-05-012026-01-31_custom_SeriesBWarrantsMember"
      decimals="0"
      id="Fact001563"
      unitRef="USD">599135</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-01-31_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact001565"
      unitRef="Shares">35680160</us-gaap:ClassOfWarrantOrRightOutstanding>
    <PMCB:ChangeInFairValueOfWarrantLiability
      contextRef="From2025-11-012026-01-31_custom_SeriesBPreferredWarrantsMember"
      decimals="0"
      id="Fact001571"
      unitRef="USD">-874000</PMCB:ChangeInFairValueOfWarrantLiability>
    <PMCB:ChangeInFairValueOfWarrantLiability
      contextRef="From2025-05-012026-01-31_custom_SeriesBPreferredWarrantsMember"
      decimals="0"
      id="Fact001573"
      unitRef="USD">-9182000</PMCB:ChangeInFairValueOfWarrantLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2026-01-31_custom_SeriesBPreferredWarrantsMember"
      decimals="0"
      id="Fact001575"
      unitRef="USD">9520000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <PMCB:ChangeInFairValueOfWarrantLiability
      contextRef="From2024-11-012025-01-31_custom_SeriesBPreferredWarrantsMember"
      decimals="0"
      id="Fact001577"
      unitRef="USD">-4487000</PMCB:ChangeInFairValueOfWarrantLiability>
    <PMCB:ChangeInFairValueOfWarrantLiability
      contextRef="From2024-05-012025-01-31_custom_SeriesBPreferredWarrantsMember"
      decimals="0"
      id="Fact001579"
      unitRef="USD">-8400000</PMCB:ChangeInFairValueOfWarrantLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2025-01-31_custom_SeriesBPreferredWarrantsMember"
      decimals="0"
      id="Fact001581"
      unitRef="USD">2384000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-05-16_custom_SettlementAgreementMember_custom_FirstWarrantIssuanceMember"
      decimals="INF"
      id="Fact001582"
      unitRef="Shares">343183</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-10-29_custom_SettlementAgreementMember_custom_SettlementWarrantsMember"
      decimals="INF"
      id="Fact001583"
      unitRef="Shares">313067</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-05-152025-05-16_custom_FirstWarrantIssuanceMember"
      decimals="0"
      id="Fact001585"
      unitRef="USD">199000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-07-282025-07-29_custom_AdditionalWarrantsMember"
      decimals="0"
      id="Fact001587"
      unitRef="USD">164000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2025-07-29_custom_AdditionalWarrantsMember"
      decimals="INF"
      id="Fact001589"
      unitRef="USDPShares">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:LitigationSettlementGain
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact001591"
      unitRef="USD">0</us-gaap:LitigationSettlementGain>
    <us-gaap:LitigationSettlementGain
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001593"
      unitRef="USD">106000</us-gaap:LitigationSettlementGain>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-05-012025-04-30"
      decimals="0"
      id="Fact001595"
      unitRef="USD">469000</us-gaap:FairValueAdjustmentOfWarrants>
    <PMCB:IssuanceFairValues
      contextRef="From2024-05-012025-04-30"
      decimals="0"
      id="Fact001597"
      unitRef="USD">363000</PMCB:IssuanceFairValues>
    <PMCB:ChangeInFairValueOfWarrantLiability
      contextRef="From2025-11-012026-01-31_custom_SettlementWarrantsMember"
      decimals="0"
      id="Fact001598"
      unitRef="USD">-545000</PMCB:ChangeInFairValueOfWarrantLiability>
    <PMCB:ChangeInFairValueOfWarrantLiability
      contextRef="From2025-05-012026-01-31_custom_SettlementWarrantsMember"
      decimals="0"
      id="Fact001599"
      unitRef="USD">-694000</PMCB:ChangeInFairValueOfWarrantLiability>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-05-012026-01-31_custom_SettlementWarrantsMember"
      decimals="0"
      id="Fact001601"
      unitRef="USD">1057000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-08-19_custom_SeriesCPrivatePlacementAgreementMember"
      decimals="INF"
      id="Fact001606"
      unitRef="Shares">7000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-08-19_custom_SeriesCPrivatePlacementAgreementMember"
      decimals="INF"
      id="Fact001607"
      unitRef="USDPShares">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-08-012025-08-19_custom_SeriesCPrivatePlacementAgreementMember"
      decimals="0"
      id="Fact001609"
      unitRef="USD">5220000</us-gaap:FairValueAdjustmentOfWarrants>
    <PMCB:ChangeInFairValueOfWarrantAsset
      contextRef="From2025-11-012026-01-31_custom_SeriesCPrivatePlacementAgreementMember_custom_SeriesCPreferredWarrantsMember"
      decimals="0"
      id="Fact001611"
      unitRef="USD">1076000</PMCB:ChangeInFairValueOfWarrantAsset>
    <PMCB:ChangeInFairValueOfWarrantAsset
      contextRef="From2025-05-012026-01-31_custom_SeriesCPrivatePlacementAgreementMember_custom_SeriesCPreferredWarrantsMember"
      decimals="0"
      id="Fact001612"
      unitRef="USD">2140000</PMCB:ChangeInFairValueOfWarrantAsset>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-05-012026-01-31_custom_SeriesCPrivatePlacementAgreementMember_custom_SeriesCPreferredWarrantsMember"
      decimals="0"
      id="Fact001613"
      unitRef="USD">3080000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-08-19_custom_SeriesCPrivatePlacementAgreementMember_custom_SeriesCPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001614"
      unitRef="Shares">560000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-08-012025-08-19_custom_SeriesCPrivatePlacementAgreementMember_custom_SeriesCPlacementAgentWarrantsMember"
      decimals="0"
      id="Fact001615"
      unitRef="USD">417000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001617">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zlKnRnxcRI3g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTIONS AND WARRANTS (Details - Warrant activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_zcALJrtgtFwa" style="display: none"&gt;Schedule of warrant activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise Price Per Share&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining Contractual Term In Years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 55%"&gt;Outstanding, April 30, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJBlos8fFIj7" style="width: 11%; text-align: right" title="Warrants outstanding, beginning balance"&gt;18,570,847&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zP1ahsgBRuK2" style="width: 11%; text-align: right" title="Weighted average exercise price warrants outstanding, beginning balance"&gt;4.54&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240501__20250430__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zvI9x1qfoP4b" title="Weighted average remaining contractual term"&gt;2.12&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--WarrantsIssuedShares_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zQ3ewShGzi9" style="text-align: right" title="Warrants issued"&gt;8,216,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zStQwJ09LwF5" style="text-align: right" title="Weighted average exercise price warrants issued"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Issued - Series B Warrants and Settlement Warrants adjusted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--WarrantsIssuedShares_d0_c20250501__20260131__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsAndSettlementWarrantsAdjustedMember_zrk6zl7qbTK5" style="text-align: right" title="Warrants issued"&gt;30,132,422&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0_c20250501__20260131__us-gaap--AwardTypeAxis__custom--SeriesBWarrantsAndSettlementWarrantsAdjustedMember_zHd0FGdR57v5" style="text-align: right" title="Weighted average exercise price warrants issued"&gt;0.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantExercised_iN_di_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxLNNtOa0Hnl" style="text-align: right" title="Warrants exercised"&gt;(1,100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--WeightedAverageExercisePriceWarrantsExercised_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zmu9SNWDPLke" style="text-align: right" title="Weighted average exercise price warrants Exercised"&gt;0.95&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--WarrantsExpired_iN_di0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zF2aD6730o6h" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--WeightedAverageExercisePriceWarrantsExpired_d0_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3x0aTXrP1ub" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price warrants Expired"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Outstanding, January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zOgTvl4NlbE7" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants outstanding, ending balance"&gt;55,819,519&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zN6gAdwQkCbj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price warrants outstanding, ending balance"&gt;1.68&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxZRaHOKg9F5" title="Weighted average remaining contractual term"&gt;2.61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable, January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--WarrantsExercisable_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zMZVcf06fIZf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable"&gt;55,819,519&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--WeightedAverageExercisePriceWarrantsExercisable_iI_c20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWWMcdN6Pmk1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price warrants exercisable"&gt;1.68&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20250501__20260131__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zl6tMlzLhwF3" title="Weighted-average remaining contractual term, exercisable"&gt;2.61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-04-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001619"
      unitRef="Shares">18570847</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-04-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001621"
      unitRef="USDPShares">4.54</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-05-012025-04-30_us-gaap_WarrantMember"
      id="Fact001623">P2Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <PMCB:WarrantsIssuedShares
      contextRef="From2025-05-012026-01-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001625"
      unitRef="Shares">8216250</PMCB:WarrantsIssuedShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-05-012026-01-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001627"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <PMCB:WarrantsIssuedShares
      contextRef="From2025-05-012026-01-31_custom_SeriesBWarrantsAndSettlementWarrantsAdjustedMember"
      decimals="INF"
      id="Fact001629"
      unitRef="Shares">30132422</PMCB:WarrantsIssuedShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2025-05-012026-01-31_custom_SeriesBWarrantsAndSettlementWarrantsAdjustedMember"
      decimals="INF"
      id="Fact001631"
      unitRef="USDPShares">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <PMCB:WarrantExercised
      contextRef="From2025-05-012026-01-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001633"
      unitRef="Shares">1100000</PMCB:WarrantExercised>
    <PMCB:WeightedAverageExercisePriceWarrantsExercised
      contextRef="From2025-05-012026-01-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001635"
      unitRef="USDPShares">0.95</PMCB:WeightedAverageExercisePriceWarrantsExercised>
    <PMCB:WarrantsExpired
      contextRef="From2025-05-012026-01-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001637"
      unitRef="Shares">-0</PMCB:WarrantsExpired>
    <PMCB:WeightedAverageExercisePriceWarrantsExpired
      contextRef="From2025-05-012026-01-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001639"
      unitRef="USDPShares">0</PMCB:WeightedAverageExercisePriceWarrantsExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2026-01-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001641"
      unitRef="Shares">55819519</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2026-01-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001643"
      unitRef="USDPShares">1.68</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-05-012026-01-31_us-gaap_WarrantMember"
      id="Fact001645">P2Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <PMCB:WarrantsExercisable
      contextRef="AsOf2026-01-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001647"
      unitRef="Shares">55819519</PMCB:WarrantsExercisable>
    <PMCB:WeightedAverageExercisePriceWarrantsExercisable
      contextRef="AsOf2026-01-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001649"
      unitRef="USDPShares">1.68</PMCB:WeightedAverageExercisePriceWarrantsExercisable>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="From2025-05-012026-01-31_us-gaap_WarrantMember"
      id="Fact001651">P2Y7M9D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001657">&lt;p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zABU17sipgMh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 7 &#x2013; &lt;span id="xdx_82E_zTsBTjEMBru5"&gt;OTHER RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company had the following related party transactions
during the three and nine months ended January 31, 2026 and 2025, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company owns &lt;span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_c20260131__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--SGAustraliaMember_zDLW0fWYJNs9" title="Equity interest owned"&gt;13.8&lt;/span&gt;% of the equity in SG Austria
which is presented using the measurement alternative allowed under &lt;i&gt;ASC 321 - Investments Equity Securities&lt;/i&gt; with no readily determinable
fair values. SG Austria has two subsidiaries: (i) Austrianova; and (ii) Austrianova Thailand. The Company purchased products and services
from these entities in the approximate amounts of $0 in the three and nine months ended January 31, 2026, and 2025, respectively. The
investment in SG Austria was fully impaired as of April 30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In April 2014, the Company entered into the
Vin-de-Bona Consulting Agreement pursuant to which it agreed to provide professional consulting services to the Company. Vin-de-Bona
is owned by Prof. G&#xfc;nzburg and Dr. Salmons, both of whom are involved in numerous aspects of the Company&#x2019;s scientific
endeavors relating to cancer (Prof. G&#xfc;nzburg is the Chairman of Austrianova, and Dr. Salmons is the Chief Executive Officer and
President of Austrianova). The term of the agreement is for 12 months and is automatically renewable for successive 12-month terms.
After the initial term, either party can terminate the agreement by giving the other party 30 days&#x2019; written notice before the
effective date of termination. To date, the agreement has been automatically renewed annually. The amounts incurred for the three
and nine months ended January 31, 2026 were approximately $&lt;span id="xdx_908_eus-gaap--ProfessionalAndContractServicesExpense_pp0p0_c20251101__20260131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VinDeBonaMember_zbrGFfWuYBJb" title="Consulting fees"&gt;10,500&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ProfessionalAndContractServicesExpense_pp0p0_c20250501__20260131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VinDeBonaMember_zxGo0YYc5c27" title="Consulting fees"&gt;10,500&lt;/span&gt;, respectively and approximately $&lt;span id="xdx_90C_eus-gaap--ProfessionalAndContractServicesExpense_pp0p0_c20241101__20250131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VinDeBonaMember_zgGeGAKibqs6" title="Consulting fees"&gt;10,390&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--ProfessionalAndContractServicesExpense_pp0p0_c20240501__20250131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VinDeBonaMember_zxKEQMVmOsO" title="Consulting fees"&gt;15,670&lt;/span&gt;
for the three and nine months ended January 31, 2025, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company&#x2019;s Chief Executive Officer was appointed to the Femasys
board of directors, see Note 4 &#x2013; Investment in Debt and Equity Securities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company&#x2019;s Chief Executive Officer serves on the board of
directors as the executive chairman of QCLS, see Note 4 &#x2013; Investment in Debt and Equity Securities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2026-01-31_custom_SGAustraliaMember"
      decimals="INF"
      id="Fact001659"
      unitRef="Pure">0.138</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2025-11-012026-01-31_custom_VinDeBonaMember"
      decimals="0"
      id="Fact001661"
      unitRef="USD">10500</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2025-05-012026-01-31_custom_VinDeBonaMember"
      decimals="0"
      id="Fact001663"
      unitRef="USD">10500</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2024-11-012025-01-31_custom_VinDeBonaMember"
      decimals="0"
      id="Fact001665"
      unitRef="USD">10390</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="From2024-05-012025-01-31_custom_VinDeBonaMember"
      decimals="0"
      id="Fact001667"
      unitRef="USD">15670</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001669">&lt;p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z8nQFBbELu77" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 8 &#x2013; &lt;span id="xdx_824_ztpgKhsbGKc8"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company acquires assets still in development
and enters R&amp;amp;D arrangements with third parties that often require milestone and royalty payments to the third-party contingent upon
the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required, contingent
upon the successful achievement of an important point in the development lifecycle of the pharmaceutical product (e.g., approval of the
product for marketing by a regulatory agency). If required by the license agreements, the Company may have to make royalty payments based
upon a percentage of the sales of the pharmaceutical products if regulatory approval for marketing is obtained. For the three and nine
months ended January 31, 2026 the Company expensed $&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_c20251101__20260131_z3h7DA7ZsCzg" title="Research and development expenses"&gt;93,113&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20250501__20260131_zh6SbZoLG0Kg" title="Research and development expenses"&gt;329,355&lt;/span&gt;, respectively, and $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_c20241101__20250131_z8KlzLcEmOig" title="Research and development expenses"&gt;118,196&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20240501__20250131_zpzK5mdi34wh" title="Research and development expenses"&gt;311,682&lt;/span&gt; for the three and nine
months ended January 31, 2025, respectively in research and development expenses within the accompanying unaudited condensed consolidated
statements of operations. There have been no recognized costs related to royalty payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;There are future royalty payments as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Four percent royalty on all gross sales received by us or the Company&#x2019;s affiliates;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Twenty percent royalty on gross revenues received by the Company or the Company&#x2019;s affiliates from a sublicense or right to use the patents or the licenses granted by the Company or the Company&#x2019;s affiliates; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fifty percent of any other financial and non-financial consideration received from sublicensees of the Cell-in-a-Box&#xae;&#160;technology; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The removal of all milestone payments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Office Lease&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In January 2023, the Company entered into a month-to-month
agreement of the Las Vegas office space, commencing on May 1, 2023. Additionally, the Company rents storage space pursuant to a month-to-month
agreement in Laguna Hills, California.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Rent expenses for these offices for the three
and nine months ended January 31, 2026 were $&lt;span id="xdx_90F_eus-gaap--OperatingLeaseExpense_pp0p0_c20251101__20260131_zAEhXsDu3oai" title="Operating lease expense"&gt;7,196&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--OperatingLeaseExpense_pp0p0_c20250501__20260131_zG5q7T7XhKoe" title="Operating lease expense"&gt;21,404&lt;/span&gt;, respectively, and for the three and nine month ended January 31, 2025
were $&lt;span id="xdx_904_eus-gaap--OperatingLeaseExpense_pp0p0_c20241101__20250131_ziMfUhKkfADa"&gt;7,071&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--OperatingLeaseExpense_pp0p0_c20240501__20250131_zbA6XCANbO7f"&gt;21,298&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;With the month-to-month office rental agreements
there are no aggregate future minimum lease payments required to be made.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Service Agreements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has entered into several service agreements
with independent and related parties pursuant to which services will be provided over a specified period-of-time related to the IND which
the FDA has placed on clinical hold. The services include regulatory affairs strategy, advice and follow-up work on the IND and services
related to having the clinical hold lifted. The total remaining cost is estimated to be approximately $&lt;span id="xdx_900_eus-gaap--ContractualObligation_iI_c20260131_zWYTFtmsRoTg" title="Contractual obligation"&gt;543,000&lt;/span&gt;, of which the related party
(SG Austria and its subsidiaries) portion will be approximately $&lt;span id="xdx_90E_eus-gaap--ContractualObligation_iI_c20260131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SGAustriaAndSubsidiariesMember_zpH8HZkuAMO9" title="Contractual obligation"&gt;157,000&lt;/span&gt;. These amounts take into account some of the cost associated
with the work and preclinical studies required to lift the clinical hold.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Legal Proceedings&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From time to time, the Company is subject to legal
proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims
cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect
on the Company&#x2019;s financial condition or operating results.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 16, 2025, the Company entered into a settlement
and release agreement (&#x201c;Settlement Agreement&#x201d;) with H.C. Wainwright &amp;amp; Co., LLC relating to a complaint filed on December
4, 2023, alleging a breach of contract. The Settlement Agreement resolved fully all differences, disputes or claims without admitting
any liability, fault or wrongdoing on the part of all parties. The Settlement Agreement required the Company to pay $&lt;span id="xdx_906_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn4n6_c20250515__20250516__srt--LitigationCaseAxis__custom--HCWainwrightMember_zOZdX55ygBdb" title="Initial payment"&gt;1.55&lt;/span&gt; million, comprised
of an initial payment of $&lt;span id="xdx_901_eus-gaap--PaymentsForLegalSettlements_pn4n6_c20250519__20250520__srt--LitigationCaseAxis__custom--HCWainwrightMember_zqy5goazwaH" title="Payment for legal settlements"&gt;1.25&lt;/span&gt; million paid on May 20, 2025, and twelve equal payments of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentPeriodicPayment_c20250515__20250516__srt--LitigationCaseAxis__custom--HCWainwrightMember_z52G52wMZ11h" title="Debt instrument periodic payment"&gt;25,000&lt;/span&gt; beginning on the one-month anniversary
of the initial payment. On May 16, 2025, as part of the settlement, the Company also issued warrants &#x201c;(First Warrant Issuance&#x201d;)
to purchase &lt;span id="xdx_90F_ecustom--WarrantsIssuedShares_c20250515__20250516__srt--LitigationCaseAxis__custom--HCWainwrightMember__us-gaap--ClassOfWarrantOrRightAxis__custom--FirstWarrantIssuanceMember_zSHdHlZooiuc" title="Warrants issued shares"&gt;343,183&lt;/span&gt; shares of Common Stock with an exercise price of $4.00 per share and a term of five years from the issuance date.
On July 29, 2025, as part of the settlement, the Company issued additional warrants (&#x201c;Additional Warrants&#x201d;) to purchase &lt;span id="xdx_906_ecustom--WarrantsIssuedShares_c20250515__20250516__srt--LitigationCaseAxis__custom--HCWainwrightMember__us-gaap--ClassOfWarrantOrRightAxis__custom--AdditionalWarrantsMember_zQ8xm8VFALCl"&gt;313,067&lt;/span&gt;
shares of Common Stock with an exercise price of $4.00 per share and a term of five years. See Note 6 &#x2013; Stock Options and Warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 19, 2025, pursuant to the warrant terms,
the exercise price of the First Warrant Issuance and the Additional Warrants was adjusted to $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250819__us-gaap--ClassOfWarrantOrRightAxis__custom--AdditionalWarrantsMember_z1lH3U3Ltx5f" title="Warrants issued per share"&gt;0.95&lt;/span&gt; per share. The price adjustment resulted
in the number of shares underlying the First Warrant Issuance to increase to &lt;span id="xdx_903_ecustom--WarrantsIssuedShares_c20250818__20250819__us-gaap--ClassOfWarrantOrRightAxis__custom--FirstWarrantIssuanceMember_zTDXQpGlA5Lg"&gt;1,442,551&lt;/span&gt; shares and the number of shares underlying the
Additional Warrants to increase to &lt;span id="xdx_903_ecustom--WarrantsIssuedShares_c20250818__20250819__us-gaap--ClassOfWarrantOrRightAxis__custom--AdditionalWarrantsMember_zNBdnXVHI7Aj"&gt;1,315,960&lt;/span&gt; shares. See Note 6 &#x2013; Stock Options and Warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;To the Company&#x2019;s knowledge there are no
other legal proceedings pending to which any property of the Company is subject.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact001671"
      unitRef="USD">93113</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001673"
      unitRef="USD">329355</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact001675"
      unitRef="USD">118196</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001677"
      unitRef="USD">311682</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact001683"
      unitRef="USD">7196</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001685"
      unitRef="USD">21404</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact001686"
      unitRef="USD">7071</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001687"
      unitRef="USD">21298</us-gaap:OperatingLeaseExpense>
    <us-gaap:ContractualObligation
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact001689"
      unitRef="USD">543000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="AsOf2026-01-31_custom_SGAustriaAndSubsidiariesMember"
      decimals="0"
      id="Fact001691"
      unitRef="USD">157000</us-gaap:ContractualObligation>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="From2025-05-152025-05-16_custom_HCWainwrightMember"
      decimals="-4"
      id="Fact001693"
      unitRef="USD">1550000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="From2025-05-192025-05-20_custom_HCWainwrightMember"
      decimals="-4"
      id="Fact001695"
      unitRef="USD">1250000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2025-05-152025-05-16_custom_HCWainwrightMember"
      decimals="0"
      id="Fact001697"
      unitRef="USD">25000</us-gaap:DebtInstrumentPeriodicPayment>
    <PMCB:WarrantsIssuedShares
      contextRef="From2025-05-152025-05-16_custom_HCWainwrightMember_custom_FirstWarrantIssuanceMember"
      decimals="INF"
      id="Fact001699"
      unitRef="Shares">343183</PMCB:WarrantsIssuedShares>
    <PMCB:WarrantsIssuedShares
      contextRef="From2025-05-152025-05-16_custom_HCWainwrightMember_custom_AdditionalWarrantsMember"
      decimals="INF"
      id="Fact001700"
      unitRef="Shares">313067</PMCB:WarrantsIssuedShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-08-19_custom_AdditionalWarrantsMember"
      decimals="INF"
      id="Fact001702"
      unitRef="USDPShares">0.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <PMCB:WarrantsIssuedShares
      contextRef="From2025-08-182025-08-19_custom_FirstWarrantIssuanceMember"
      decimals="INF"
      id="Fact001703"
      unitRef="Shares">1442551</PMCB:WarrantsIssuedShares>
    <PMCB:WarrantsIssuedShares
      contextRef="From2025-08-182025-08-19_custom_AdditionalWarrantsMember"
      decimals="INF"
      id="Fact001704"
      unitRef="Shares">1315960</PMCB:WarrantsIssuedShares>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001710">&lt;p id="xdx_80F_eus-gaap--EarningsPerShareTextBlock_z7lEbo5zFc1e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 9 &#x2013; &lt;span id="xdx_829_zAWu52m9fDh2"&gt;EARNINGS PER SHARE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company computes basic earnings per share
using the two-class method. The two-class method of computing earnings per share is an earnings allocation formula that determines earnings
per share for common stock and any participating securities according to dividends declared (whether paid or unpaid) and participation
rights in undistributed earnings. The Series B Preferred Shares and Series C Preferred Shares are considered participating securities
as preferred shareholders are entitled to participate with common stockholders on an as-converted basis in any distributions of assets
by the Company under the terms of their respective Certificates of Designations. Diluted earnings per share for the nine months ended
January 31, 2025 was computed using the two-class method. Under the two-class method, there is no change in the weighted average shares
outstanding used between the basic and diluted earnings per share calculations as the Series B Preferred Shares represent the only dilutive
share equivalents during the nine months ended January 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;During the three and nine months ended January 31, 2026 and the three
months ended January 31, 2025 the Company incurred losses attributable to common shareholders. Accordingly, the effects of any common
stock equivalent would be anti-dilutive during the period and thus are not included in the calculation of diluted weighted average number
of shares outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table illustrates the computation
of basic and diluted earnings (loss) per share:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zWXykV1ecHvf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EARNINGS PER SHARE (Details - Per share calculation)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B0_zxLqDWzUcPOj" style="display: none"&gt;Schedule of  basic and diluted earnings (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20251101_20260131" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_494_20241101_20250131" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended January 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Earnings per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;746,860&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;(3,045,328&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PreferredStockAccretionOfRedemptionDiscount_iN_pp0p0_di0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKLTnQEC55Ll" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Less: Accretion of discounts to redemption of convertible preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,204,657&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ConvertiblePreferredStockDividends_iN_pp0p0_di0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zO2jMDPdpqzj" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Less: Convertible preferred stock dividends&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(98,458&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_z1YZW2LKWxLi" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1,556,255&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3,045,328&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Weighted average shares outstanding used in basic and diluted earnings per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20251101__20260131_pdd" title="Weighted average shares outstanding used in basic earnings per share"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20251101__20260131_pdd" title="Weighted average shares outstanding used in diluted earnings per share"&gt;9,262,829&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20241101__20250131_pdd" title="Weighted average shares outstanding used in basic earnings per share"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20241101__20250131_pdd" title="Weighted average shares outstanding used in diluted earnings per share"&gt;6,960,014&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss per share basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20251101__20260131_pdd" title="Net income (loss) per share basic"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20251101__20260131_pdd" title="Net income (loss) per share diluted"&gt;(0.17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20241101__20250131_pdd" title="Net income (loss) per share basic"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20241101__20250131_pdd" title="Net income (loss) per share diluted"&gt;(0.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49E_20250501__20260131_znWz4okqdtPb" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20240501__20250131_zBaFV8T3dyNe" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine Months Ended January 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;Earnings per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLoss_z8o8ZmHolDi4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Net income (loss)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;(15,031,211&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;18,906,468&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PreferredStockAccretionOfRedemptionDiscount_iN_pp0p0_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zNJIKfNLSUe4" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Less: Accretion of discounts to redemption of convertible preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,106,653&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,193,404&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ConvertiblePreferredStockDividends_iN_pp0p0_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zF4x150XcIpf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Less: Convertible preferred stock dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(195,097&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,129,759&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LessAllocationOfUndistributedIncome_d0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzgjUJNVZCY6" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Less: Allocation of undistributed income to Series B convertible preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,067,733&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_iP3us-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zV9P8rWTMqui" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Undistributed income (loss) available to common stockholders&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18,332,961&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12,515,572&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average shares outstanding used in basic earnings per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250501__20260131_pdd" title="Weighted average shares outstanding used in basic earnings per share"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250501__20260131_pdd" title="Weighted average shares outstanding used in diluted earnings per share"&gt;7,618,128&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240501__20250131_pdd" title="Weighted average shares outstanding used in basic earnings per share"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240501__20250131_pdd" title="Weighted average shares outstanding used in diluted earnings per share"&gt;7,487,813&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net income (loss) per share basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--EarningsPerShareBasic_c20250501__20260131_pdd" title="Net income (loss) per share basic"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250501__20260131_pdd" title="Net income (loss) per share diluted"&gt;(2.41&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20240501__20250131_pdd" title="Net income (loss) per share basic"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20240501__20250131_pdd" title="Net income (loss) per share diluted"&gt;1.67&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zMEpQRkfKw2a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The table below sets forth the potentially dilutive
securities excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zIMlQuiVdZ7e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EARNINGS PER SHARE (Details - Diluted shares)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BD_zxhk3UkMI4uk" style="display: none"&gt;Schedule of potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three and Nine Months Ended &lt;br/&gt; January 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Excluded options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares"&gt;1,160,627&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares"&gt;&lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares"&gt;917,697&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Excluded preferred shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_pdd" title="Antidilutive shares"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_pdd" title="Antidilutive shares"&gt;5,008,061&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_z5pGw8qxByt6" title="Antidilutive shares"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240501__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_zpkZStzTy9Td" title="Antidilutive shares"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Excluded warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares"&gt;55,819,519&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares"&gt;&lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares"&gt;18,570,847&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total excluded options, preferred shares and warrants&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131_pdd" title="Antidilutive shares"&gt;&lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131_pdd" title="Antidilutive shares"&gt;61,988,207&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131_pdd" title="Antidilutive shares"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250131_pdd" title="Antidilutive shares"&gt;19,488,544&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zOOcYe0NJb45" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Diluted earnings per share were calculated under
both the if-converted and the two-class methods to determine the most dilutive amount for the common stock. The Company applied the treasury
stock two-class method which assumes the securities remain in their current non-exercised or converted form and therefore, deemed anti-dilutive.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001712">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zWXykV1ecHvf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EARNINGS PER SHARE (Details - Per share calculation)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B0_zxLqDWzUcPOj" style="display: none"&gt;Schedule of  basic and diluted earnings (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20251101_20260131" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_494_20241101_20250131" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three Months Ended January 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Earnings per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;746,860&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;(3,045,328&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PreferredStockAccretionOfRedemptionDiscount_iN_pp0p0_di0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKLTnQEC55Ll" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Less: Accretion of discounts to redemption of convertible preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,204,657&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ConvertiblePreferredStockDividends_iN_pp0p0_di0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zO2jMDPdpqzj" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Less: Convertible preferred stock dividends&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(98,458&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_z1YZW2LKWxLi" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net loss attributable to common stockholders&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1,556,255&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3,045,328&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Weighted average shares outstanding used in basic and diluted earnings per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20251101__20260131_pdd" title="Weighted average shares outstanding used in basic earnings per share"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20251101__20260131_pdd" title="Weighted average shares outstanding used in diluted earnings per share"&gt;9,262,829&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20241101__20250131_pdd" title="Weighted average shares outstanding used in basic earnings per share"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20241101__20250131_pdd" title="Weighted average shares outstanding used in diluted earnings per share"&gt;6,960,014&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss per share basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20251101__20260131_pdd" title="Net income (loss) per share basic"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_c20251101__20260131_pdd" title="Net income (loss) per share diluted"&gt;(0.17&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20241101__20250131_pdd" title="Net income (loss) per share basic"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20241101__20250131_pdd" title="Net income (loss) per share diluted"&gt;(0.44&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49E_20250501__20260131_znWz4okqdtPb" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_496_20240501__20250131_zBaFV8T3dyNe" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine Months Ended January 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;Earnings per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetIncomeLoss_z8o8ZmHolDi4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Net income (loss)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;(15,031,211&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;18,906,468&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PreferredStockAccretionOfRedemptionDiscount_iN_pp0p0_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zNJIKfNLSUe4" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Less: Accretion of discounts to redemption of convertible preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,106,653&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,193,404&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ConvertiblePreferredStockDividends_iN_pp0p0_di_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zF4x150XcIpf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Less: Convertible preferred stock dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(195,097&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,129,759&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LessAllocationOfUndistributedIncome_d0_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzgjUJNVZCY6" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt"&gt;Less: Allocation of undistributed income to Series B convertible preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,067,733&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_iP3us-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zV9P8rWTMqui" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Undistributed income (loss) available to common stockholders&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18,332,961&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12,515,572&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Weighted average shares outstanding used in basic earnings per share&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20250501__20260131_pdd" title="Weighted average shares outstanding used in basic earnings per share"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20250501__20260131_pdd" title="Weighted average shares outstanding used in diluted earnings per share"&gt;7,618,128&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20240501__20250131_pdd" title="Weighted average shares outstanding used in basic earnings per share"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20240501__20250131_pdd" title="Weighted average shares outstanding used in diluted earnings per share"&gt;7,487,813&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net income (loss) per share basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--EarningsPerShareBasic_c20250501__20260131_pdd" title="Net income (loss) per share basic"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20250501__20260131_pdd" title="Net income (loss) per share diluted"&gt;(2.41&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20240501__20250131_pdd" title="Net income (loss) per share basic"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20240501__20250131_pdd" title="Net income (loss) per share diluted"&gt;1.67&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact001714"
      unitRef="USD">746860</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact001715"
      unitRef="USD">-3045328</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="From2025-11-012026-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001717"
      unitRef="USD">2204657</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="From2024-11-012025-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001718"
      unitRef="USD">-0</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <PMCB:ConvertiblePreferredStockDividends
      contextRef="From2025-11-012026-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001720"
      unitRef="USD">98458</PMCB:ConvertiblePreferredStockDividends>
    <PMCB:ConvertiblePreferredStockDividends
      contextRef="From2024-11-012025-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001721"
      unitRef="USD">-0</PMCB:ConvertiblePreferredStockDividends>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact001723"
      unitRef="USD">-1556255</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-11-012025-01-31"
      decimals="0"
      id="Fact001724"
      unitRef="USD">-3045328</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-11-012026-01-31"
      decimals="INF"
      id="Fact001726"
      unitRef="Shares">9262829</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-11-012026-01-31"
      decimals="INF"
      id="Fact001728"
      unitRef="Shares">9262829</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-11-012025-01-31"
      decimals="INF"
      id="Fact001730"
      unitRef="Shares">6960014</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-11-012025-01-31"
      decimals="INF"
      id="Fact001732"
      unitRef="Shares">6960014</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-11-012026-01-31"
      decimals="INF"
      id="Fact001734"
      unitRef="USDPShares">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-11-012026-01-31"
      decimals="INF"
      id="Fact001736"
      unitRef="USDPShares">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-11-012025-01-31"
      decimals="INF"
      id="Fact001738"
      unitRef="USDPShares">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-11-012025-01-31"
      decimals="INF"
      id="Fact001740"
      unitRef="USDPShares">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001742"
      unitRef="USD">-15031211</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001743"
      unitRef="USD">18906468</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="From2025-05-012026-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001745"
      unitRef="USD">3106653</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="From2024-05-012025-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001746"
      unitRef="USD">3193404</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <PMCB:ConvertiblePreferredStockDividends
      contextRef="From2025-05-012026-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001748"
      unitRef="USD">195097</PMCB:ConvertiblePreferredStockDividends>
    <PMCB:ConvertiblePreferredStockDividends
      contextRef="From2024-05-012025-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001749"
      unitRef="USD">1129759</PMCB:ConvertiblePreferredStockDividends>
    <PMCB:LessAllocationOfUndistributedIncome
      contextRef="From2025-05-012026-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001751"
      unitRef="USD">0</PMCB:LessAllocationOfUndistributedIncome>
    <PMCB:LessAllocationOfUndistributedIncome
      contextRef="From2024-05-012025-01-31_us-gaap_SeriesBPreferredStockMember"
      decimals="0"
      id="Fact001752"
      unitRef="USD">-2067733</PMCB:LessAllocationOfUndistributedIncome>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001754"
      unitRef="USD">-18332961</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="From2024-05-012025-01-31"
      decimals="0"
      id="Fact001755"
      unitRef="USD">12515572</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-05-01to2026-01-31"
      decimals="INF"
      id="Fact001757"
      unitRef="Shares">7618128</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-05-01to2026-01-31"
      decimals="INF"
      id="Fact001759"
      unitRef="Shares">7618128</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-05-012025-01-31"
      decimals="INF"
      id="Fact001761"
      unitRef="Shares">7487813</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-05-012025-01-31"
      decimals="INF"
      id="Fact001763"
      unitRef="Shares">7487813</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-05-01to2026-01-31"
      decimals="INF"
      id="Fact001765"
      unitRef="USDPShares">-2.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-05-01to2026-01-31"
      decimals="INF"
      id="Fact001767"
      unitRef="USDPShares">-2.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-05-012025-01-31"
      decimals="INF"
      id="Fact001769"
      unitRef="USDPShares">1.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-05-012025-01-31"
      decimals="INF"
      id="Fact001771"
      unitRef="USDPShares">1.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001777">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zIMlQuiVdZ7e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - EARNINGS PER SHARE (Details - Diluted shares)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BD_zxhk3UkMI4uk" style="display: none"&gt;Schedule of potentially dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Three and Nine Months Ended &lt;br/&gt; January 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Excluded options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares"&gt;1,160,627&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares"&gt;&lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_pdd" title="Antidilutive shares"&gt;917,697&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Excluded preferred shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_pdd" title="Antidilutive shares"&gt;&lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_pdd" title="Antidilutive shares"&gt;5,008,061&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_z5pGw8qxByt6" title="Antidilutive shares"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_c20240501__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PreferredSharesMember_zpkZStzTy9Td" title="Antidilutive shares"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Excluded warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares"&gt;55,819,519&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares"&gt;&lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250131__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_pdd" title="Antidilutive shares"&gt;18,570,847&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total excluded options, preferred shares and warrants&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20251101__20260131_pdd" title="Antidilutive shares"&gt;&lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20260131_pdd" title="Antidilutive shares"&gt;61,988,207&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20241101__20250131_pdd" title="Antidilutive shares"&gt;&lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240501__20250131_pdd" title="Antidilutive shares"&gt;19,488,544&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-11-012026-01-31_custom_OptionsMember"
      decimals="INF"
      id="Fact001779"
      unitRef="Shares">1160627</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-05-012026-01-31_custom_OptionsMember"
      decimals="INF"
      id="Fact001781"
      unitRef="Shares">1160627</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-11-012025-01-31_custom_OptionsMember"
      decimals="INF"
      id="Fact001783"
      unitRef="Shares">917697</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-05-012025-01-31_custom_OptionsMember"
      decimals="INF"
      id="Fact001785"
      unitRef="Shares">917697</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-11-012026-01-31_custom_PreferredSharesMember"
      decimals="INF"
      id="Fact001787"
      unitRef="Shares">5008061</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-05-012026-01-31_custom_PreferredSharesMember"
      decimals="INF"
      id="Fact001789"
      unitRef="Shares">5008061</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-11-012025-01-31_custom_PreferredSharesMember"
      decimals="INF"
      id="Fact001791"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-05-012025-01-31_custom_PreferredSharesMember"
      decimals="INF"
      id="Fact001793"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-11-012026-01-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact001795"
      unitRef="Shares">55819519</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-05-012026-01-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact001797"
      unitRef="Shares">55819519</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-11-012025-01-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact001799"
      unitRef="Shares">18570847</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-05-012025-01-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact001801"
      unitRef="Shares">18570847</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-11-012026-01-31"
      decimals="INF"
      id="Fact001803"
      unitRef="Shares">61988207</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-05-01to2026-01-31"
      decimals="INF"
      id="Fact001805"
      unitRef="Shares">61988207</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-11-012025-01-31"
      decimals="INF"
      id="Fact001807"
      unitRef="Shares">19488544</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-05-012025-01-31"
      decimals="INF"
      id="Fact001809"
      unitRef="Shares">19488544</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PreferredStockTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001811">&lt;p id="xdx_80B_eus-gaap--PreferredStockTextBlock_zbVNKkYoPyEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 10 &#x2013; &lt;span id="xdx_825_zaDnPOk3UUr3"&gt;PREFERRED STOCK&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Series C Private Placement&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 17, 2025, the Company entered into the
Series C Private Placement Agreement with the Investors, pursuant to which it agreed to sell to the Investors in a private placement (the
&#x201c;Series C Private Placement&#x201d;) (i) an aggregate of &lt;span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_z4Qq5BaFh1o2" title="Aggregate shares"&gt;7,000&lt;/span&gt; shares of the Company&#x2019;s newly designated Series C convertible
preferred stock, par value $&lt;span id="xdx_90A_ecustom--PreferredStockParValuePerShare_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_z5hy8M3ko5F5" title="Preferred stock, par value"&gt;0.0001&lt;/span&gt;, with a stated value of $&lt;span id="xdx_900_ecustom--PreferredStockStatedValuePerShare_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zf9mQBr3OYPj" title="Preferred stock, stated value"&gt;1,000&lt;/span&gt; per share (the &#x201c;Series C Preferred Stock&#x201d;), initially convertible
into up to &lt;span id="xdx_902_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zkyi08q8NQkk" title="Conversion shares"&gt;7,000,000&lt;/span&gt; shares of the Company&#x2019;s common stock, par value $&lt;span id="xdx_909_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zhwHsggJkYgi" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share at an initial conversion price of $&lt;span id="xdx_90E_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zkEhX6F0fsP3" title="Conversion price"&gt;1.00&lt;/span&gt; and
(ii) the Series C Preferred Warrants to purchase up to an aggregate of &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesCWarrantsMember_zhwp0RVdxIqi" title="Warrants to purchase shares"&gt;7,000,000&lt;/span&gt; shares of Common Stock. The closing of the Private Placement
occurred on August 19, 2025. The aggregate gross proceeds from the Private Placement totaled $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zuYInITqCogl" title="Aggregate gross proceeds"&gt;7,000,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the Series C Private Placement,
pursuant to an Engagement Letter (the &#x201c;Engagement Letter&#x201d;) between the Company and the Placement Agent, the Company has agreed
to pay the Placement Agent &lt;span id="xdx_908_eus-gaap--SaleOfStockDescriptionOfTransaction_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zL7VWD19NPzh" title="Engagement letter, description"&gt;(i) a cash fee equal to 8.0% of the gross proceeds from the Series C Private Placement, and (ii) warrants to
purchase shares of Common Stock equal to 8.0% of the number of shares of common stock that the Preferred Stock are initially convertible
into, with an exercise price of $1.00 per share and a five-year term.&lt;/span&gt; Further, pursuant to the Engagement Letter, the Placement Agent
is entitled to compensation with respect to any financing of the Company occurring during the term of the Engagement Letter or within
twelve months thereafter when such financing is provided by investors whom the Placement Agent introduced to the Company. In addition,
for any warrants of the Company that are issued to investors who are introduced to the Company by the Placement Agent in the Private Placement
or were previously issued in connection with the Company&#x2019;s May 2023 private placement, and are exercised during the term of the
Engagement Letter, the Company shall pay the Placement Agent a cash fee equal to &lt;span id="xdx_90E_ecustom--PlacementAgentFeePercentage_dp_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zH5pOu8SJJd4" title="Placement agent, cash fee percentage"&gt;8.0&lt;/span&gt;% of the net proceeds received by the Company from
such warrant exercises.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Transaction costs totaling $&lt;span id="xdx_907_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250501__20260131__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zjLFYX6Oppe8" title="Transaction costs"&gt;1,234,553&lt;/span&gt;&#160;were
incurred related to the Series C Private Placement consisting of cash expenses for placement agent fees, legal fees, and accounting costs
related to the financing, as well as the fair value of the warrants issued to the Placement Agent, of which $&lt;span id="xdx_900_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20260131__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_zz2TAyAthFQb" title="Accounts payable"&gt;86,419&lt;/span&gt; was included in accounts
payable on the condensed consolidated balance sheet as of January 31, 2026. These costs were proportionately allocated to the Series C
Preferred Stock and the Series C Warrants based on the allocated gross proceeds of the instruments. Accordingly, none of the transaction
costs were allocated against the carrying value of the Preferred Stock and the total of $&lt;span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20250816__20250817__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_ziJNsPo1Usad" title="Transaction costs"&gt;1,234,553&lt;/span&gt;&#160;of transaction costs were immediately
expensed related to the Series C Warrants which are accounted for as liabilities in accordance with ASC 815, and the bifurcated derivative
related to the Series C Preferred Stock, which is included as a Series C preferred stock and warrants issuance costs on the condensed
consolidated statement of operations for the three and nine months ended January 31, 2026. Net proceeds from the Series C Private Placement
totaled $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_c20250501__20260131__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SeriesCPurchaseAgreementMember_z3dkfiszPdq5" title="Aggregate gross proceeds"&gt;6,182,447&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Series C Preferred Stock&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The terms of the Series C Preferred Stock are
as set forth in the form of Certificate of Designations (the &#x201c;Certificate of Designations&#x201d;). The Series C Preferred Stock
are convertible into shares of Common Stock (the &#x201c;Conversion Shares&#x201d;) at the election of the holder at any time at an initial
conversion price of $&lt;span id="xdx_90B_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20260131_z4SYctm2OJ9k" title="Conversion price"&gt;1.00&lt;/span&gt; (the &#x201c;Conversion Price&#x201d;). The Conversion Price is subject to customary adjustments for stock dividends,
stock splits, reclassifications and the like, and subject to price-based adjustment in the event of any issuances of Common Stock, or
securities convertible, exercisable or exchangeable for Common Stock, at a price below the then-applicable Conversion Price (subject to
certain exceptions). The conversion price was reduced to $0.95 after issuance pursuant to the full ratchet anti-dilution provisions contained
in the Certificate of Designations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The holders of the Series C Preferred Stock will
be entitled to dividends of 7% per annum, compounded quarterly, which will be payable in cash. Upon the occurrence and during the continuance
of a Triggering Event (as defined in the Certificate of Designations), the Series C Preferred Stock will accrue dividends at the rate
of 15% per annum. The holders of Series C Preferred Stock are entitled to vote with holders of the Common Stock as a single class on all
matters that holders of Common Stock are entitled to vote upon, with the number of votes per Series C Preferred Share equal to the stated
value of such Series C Preferred Share divided by the then applicable Conversion Price; provided, however that in no event shall the then
applicable Conversion Price be less than the &#x201c;Minimum Price&#x201d; (as defined in Nasdaq Listing Rule 5635) on the date immediately
prior to the date of the Purchase Agreement.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In October 2025, the Company held a special meeting
of stockholders (the &#x201c;2025 Special Meeting&#x201d;). At the 2025 Special Meeting, the stockholders of the Company approved, for purposes
of complying with Nasdaq Listing Rule 5635(d), (the &#x201c;Exchange Cap&#x201d;) the issuance of shares of Common Stock underlying the
Series C Preferred Stock and Series C Warrants, which allows the Company to settle all Series C Preferred Stock conversions into shares
of Common Stock. The Series C Certificate of Designations contains a certain beneficial ownership limitation after giving effect to the
issuance of shares of Common Stock issuable upon conversion of the Series C Preferred Stock or Series C Warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company obtained stockholder approval to remove
the Exchange Cap on October 30, 2025, upon which event the conversion floor price was adjusted to $0.19.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Series C Certificate of Designations includes
certain Triggering Events (as defined in the Series C Certificate of Designations), including, among other things, the Company&#x2019;s
failure to pay any amounts due to the holders of the Series C Preferred Stock when due. In connection with a Triggering Event, each holder
of Series C Preferred Stock will be able to require the Company to redeem in cash any or all of the holder&#x2019;s Series C Preferred
Stock at a premium set forth in the Series C Certificate of Designations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Series C Preferred Shares were determined
to be more akin to a debt-like host than an equity-like host. The Company identified certain embedded features that were deemed not to
be clearly and closely related to the debt host instrument and were therefore bifurcated as a derivative under ASC 815. These features
were bundled together, assigned probabilities of being affected and measured at fair value. Subsequent changes in fair value of these
features are recognized in the condensed consolidated statement of operations. The Company estimated the $&lt;span id="xdx_900_eus-gaap--DerivativeAssetsLiabilitiesAtFairValueNet_iI_c20260131_z1ivcrYtcXng" title="Fair value of derivative"&gt;1,995,000&lt;/span&gt;&#160;fair value of
the compound bifurcated embedded derivative at issuance using a probability-weighted scenario model, with the following inputs: the fair
value of the Company&#x2019;s common stock of $&lt;span id="xdx_907_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_uUSDPShares_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zO3z69qDxM7d" title="Derivative, measurement input"&gt;1.01&lt;/span&gt;&#160;on the issuance date, estimated equity volatility of&#160;&lt;span id="xdx_902_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_znT6Z7A9jO8d" title="Derivative, measurement input"&gt;60.0&lt;/span&gt;%, the time to maturity
of&#160;&lt;span id="xdx_906_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_uYear_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zAupil9Jk1f9" title="Derivative, measurement input"&gt;1.50&lt;/span&gt;&#160;years, the maturity redemption premium of&#160;&lt;span id="xdx_908_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRedemptionPremiumMember_zOh7F0nRoTxk" title="Derivative, measurement input"&gt;106&lt;/span&gt;%, the liquidation premium of 125%, a market interest rate of&#160;&lt;span id="xdx_900_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketInterestRateMember_z4WAycjbueH5" title="Derivative, measurement input"&gt;16.92&lt;/span&gt;%,
a risk-free rate of&#160;&lt;span id="xdx_908_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zjhWbjYK1XG9" title="Derivative, measurement input"&gt;3.76&lt;/span&gt;%, and dividend rate of &lt;span id="xdx_90F_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zkFicZjjdzll" title="Derivative, measurement input"&gt;7.00&lt;/span&gt;%. The fair value of the bifurcated derivative liability was estimated utilizing
the with and without method which uses the probability weighted difference between the scenarios with the derivative and the plain vanilla
scenario without a derivative.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The discount to the fair value is included as
a reduction to the carrying value of the Series C Preferred Stock. During the nine months ended January 31, 2026, the Company recorded
a total discount of $&lt;span id="xdx_906_ecustom--PreferredStockDiscount_pp0p0_c20251101__20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zzhCB6Yvr4f2" title="Total discount on preferred stock"&gt;7,000,000&lt;/span&gt; upon issuance of the Series C Preferred Stock, which was comprised of the issuance date fair value of the
associated embedded derivative of $&lt;span id="xdx_90E_ecustom--FairValueEmbeddedDerivative_pp0p0_c20251101__20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zqEiRdlAbQE6" title="Fair value of embedded derivative"&gt;1,995,000&lt;/span&gt; and the difference between the remaining gross proceeds after allocation to the derivative
liability and the residual fair value of the Series C Preferred Shares of $&lt;span id="xdx_90B_ecustom--WarrantLiabilityFairValue_pp0p0_c20251101__20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zjcSY14lUBr1" title="Fair value of warrant"&gt;5,005,000&lt;/span&gt;, which represents the portion of the total of the
Series C Warrant liability of $5,220,000 allocated to the discount. As the fair value of the liabilities required to be subsequently measured
at fair value exceeded the net proceeds received, the Company recognized the excess of the fair value over the net proceeds received as
a loss upon issuance of preferred stock of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20251101__20260131_ziNmSMxlwx6k" title="Proceeds from issuance of preferred stock"&gt;&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20250501__20260131_zy1woTaUUX68" title="Proceeds from issuance of preferred stock"&gt;215,000&lt;/span&gt;&lt;/span&gt;&#160;which is included in other income (expense) in the condensed consolidated statement
of operations for the nine months ended January 31, 2026. As of January 31, 2026, it is probable that the Series C Preferred Stock will
be redeemed. In accordance with ASC 480-10-S99-3A, the Company is accreting the discount using the effective interest method and $&lt;span id="xdx_906_ecustom--DeemedDividend_pp0p0_c20251101__20260131_zEdRFFwGvm22" title="Deemed dividend"&gt;2,204,657&lt;/span&gt;
and $&lt;span id="xdx_90E_ecustom--DeemedDividend_c20250501__20260131_pp0p0" title="Deemed dividend"&gt;3,106,653&lt;/span&gt;, respectively,&#160;was recorded as a deemed dividend during the three and nine months ended January 31, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three and nine months ended January
31, 2026, the Company recorded a gain of $&lt;span id="xdx_90D_ecustom--ChangeInFairValueDerivativeLiability_pp0p0_c20251101__20260131_z3RELHctJgQ5" title="Change in fair value derivative liability"&gt;557,000&lt;/span&gt; and $&lt;span id="xdx_90E_ecustom--ChangeInFairValueDerivativeLiability_pp0p0_c20250501__20260131_z1gSVLCj3joj" title="Change in fair value derivative liability"&gt;859,000&lt;/span&gt;, respectively, related to the change in fair value of the derivative liability
which is recorded in other income (expense) on the condensed consolidated statements of operations. The Company estimated the $&lt;span id="xdx_907_ecustom--WarrantLiabilityFairValue_pp0p0_c20251101__20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zaFOys2XDHzl" title="Fair value of warrant"&gt;1,136,000&lt;/span&gt;&#160;fair
value of the bifurcated embedded derivative at January 31, 2026 using a probability-weighted scenario model, with the following inputs:
the fair value of the Company&#x2019;s common stock of $&lt;span id="xdx_902_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_uUSDPShares_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_z5zy8cncjno1"&gt;0.82&lt;/span&gt;&#160;on the measurement date, estimated equity volatility of&#160;&lt;span id="xdx_90A_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zeupaYbnmpf8"&gt;85.0&lt;/span&gt;%, the
time to maturity of&#160;&lt;span id="xdx_90B_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_uYear_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zVruSaU2mKQ9"&gt;1.05&lt;/span&gt;&#160;years, the maturity redemption premium of&#160;&lt;span id="xdx_90C_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRedemptionPremiumMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zNurQC2Tb4T1"&gt;106&lt;/span&gt;%, the liquidation premium of 125% a market interest
rate of&#160;&lt;span id="xdx_900_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketInterestRateMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_z8GBw3rkvEXg"&gt;20.10&lt;/span&gt;%, a risk-free rate of&#160;&lt;span id="xdx_908_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zwdUG4pfSOR"&gt;3.42&lt;/span&gt;%, and dividend rate of &lt;span id="xdx_901_eus-gaap--DerivativeAssetLiabilityNetMeasurementInput_iI_pip0_dp_uPure_c20260131__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zYEG0KEkT8ni"&gt;7.00&lt;/span&gt;%. The fair value of the bifurcated derivative liability
was estimated utilizing the with and without method which uses the probability weighted difference between the scenarios with the derivative
and the plain vanilla scenarios without a derivative.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the three and nine months ended January
31, 2026, the Company recognized a total of $&lt;span id="xdx_900_eus-gaap--DividendsPreferredStockStock_c20251101__20260131_zYuGn86aADfe" title="Preferred dividends"&gt;98,458&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--DividendsPreferredStockStock_c20250501__20260131_z218shCEqrP4" title="Preferred dividends"&gt;195,097&lt;/span&gt;, respectively, of preferred dividends at the stated dividend rate, of
which $&lt;span id="xdx_90D_eus-gaap--DividendsPreferredStockCash_c20251101__20260131_zea7dqRyAyLf" title="Dividend paid in cash"&gt;101,356&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--DividendsPreferredStockCash_c20250501__20260131_zF5HkZlw1hk3" title="Dividend paid in cash"&gt;162,606&lt;/span&gt;, respectively, were paid in cash and $&lt;span id="xdx_904_eus-gaap--DividendsPreferredStockPaidinkind_c20251101__20260131_zislt7KY9Ha6" title="Dividend accrued"&gt;32,491&lt;/span&gt; are accrued in accrued Series C Preferred Stock and dividends
on the condensed consolidated balance sheet as of January 31, 2026. During the three months ended January 31, 2026, there were &lt;span id="xdx_900_eus-gaap--ConversionOfStockSharesConverted1_c20251101__20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zy7Xhk4h7nz6" title="Stock converted"&gt;2,234&lt;/span&gt; Series
C preferred stock converted that resulted in &lt;span id="xdx_90E_eus-gaap--ConversionOfStockSharesIssued1_c20251101__20260131__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zGHAfHjmimx8" title="Shares issued"&gt;2,358,620&lt;/span&gt; shares of common stock being issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:PreferredStockTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-08-162025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember"
      decimals="INF"
      id="Fact001813"
      unitRef="Shares">7000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <PMCB:PreferredStockParValuePerShare
      contextRef="From2025-08-162025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember"
      decimals="INF"
      id="Fact001815"
      unitRef="USDPShares">0.0001</PMCB:PreferredStockParValuePerShare>
    <PMCB:PreferredStockStatedValuePerShare
      contextRef="From2025-08-162025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember"
      decimals="INF"
      id="Fact001817"
      unitRef="USDPShares">1000</PMCB:PreferredStockStatedValuePerShare>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember"
      decimals="INF"
      id="Fact001819"
      unitRef="Shares">7000000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember"
      decimals="INF"
      id="Fact001821"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember"
      decimals="INF"
      id="Fact001823"
      unitRef="USDPShares">1.00</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact001825"
      unitRef="Shares">7000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2025-08-162025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember"
      decimals="0"
      id="Fact001827"
      unitRef="USD">7000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SaleOfStockDescriptionOfTransaction
      contextRef="From2025-08-162025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember"
      id="Fact001829">(i) a cash fee equal to 8.0% of the gross proceeds from the Series C Private Placement, and (ii) warrants to
purchase shares of Common Stock equal to 8.0% of the number of shares of common stock that the Preferred Stock are initially convertible
into, with an exercise price of $1.00 per share and a five-year term.</us-gaap:SaleOfStockDescriptionOfTransaction>
    <PMCB:PlacementAgentFeePercentage
      contextRef="From2025-08-162025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember"
      decimals="INF"
      id="Fact001831"
      unitRef="Pure">0.080</PMCB:PlacementAgentFeePercentage>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-05-012026-01-31_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember"
      decimals="0"
      id="Fact001833"
      unitRef="USD">1234553</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2026-01-31_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember"
      decimals="0"
      id="Fact001835"
      unitRef="USD">86419</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2025-08-162025-08-17_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember"
      decimals="0"
      id="Fact001837"
      unitRef="USD">1234553</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2025-05-012026-01-31_us-gaap_PrivatePlacementMember_custom_SeriesCPurchaseAgreementMember"
      decimals="0"
      id="Fact001839"
      unitRef="USD">6182447</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2026-01-31"
      decimals="INF"
      id="Fact001845"
      unitRef="USDPShares">1.00</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="AsOf2026-01-31"
      decimals="0"
      id="Fact001847"
      unitRef="USD">1995000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput
      contextRef="AsOf2026-01-31_us-gaap_MeasurementInputExpectedTermMember"
      decimals="INF"
      id="Fact001849"
      unitRef="USDPShares">1.01</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput
      contextRef="AsOf2026-01-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001851"
      unitRef="Pure">0.600</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput
      contextRef="AsOf2026-01-31_us-gaap_MeasurementInputExpectedTermMember"
      decimals="INF"
      id="Fact001853"
      unitRef="Year">1.50</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput
      contextRef="AsOf2026-01-31_custom_MeasurementInputRedemptionPremiumMember"
      decimals="INF"
      id="Fact001855"
      unitRef="Pure">1.06</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput
      contextRef="AsOf2026-01-31_custom_MeasurementInputMarketInterestRateMember"
      decimals="INF"
      id="Fact001857"
      unitRef="Pure">0.1692</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput
      contextRef="AsOf2026-01-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001859"
      unitRef="Pure">0.0376</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput
      contextRef="AsOf2026-01-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001861"
      unitRef="Pure">0.0700</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <PMCB:PreferredStockDiscount
      contextRef="From2025-11-012026-01-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact001863"
      unitRef="USD">7000000</PMCB:PreferredStockDiscount>
    <PMCB:FairValueEmbeddedDerivative
      contextRef="From2025-11-012026-01-31_us-gaap_SeriesCPreferredStockMember"
      decimals="0"
      id="Fact001865"
      unitRef="USD">1995000</PMCB:FairValueEmbeddedDerivative>
    <PMCB:WarrantLiabilityFairValue
      contextRef="From2025-11-012026-01-31_us-gaap_SeriesAPreferredStockMember"
      decimals="0"
      id="Fact001867"
      unitRef="USD">5005000</PMCB:WarrantLiabilityFairValue>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact001869"
      unitRef="USD">215000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001871"
      unitRef="USD">215000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <PMCB:DeemedDividend
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact001873"
      unitRef="USD">2204657</PMCB:DeemedDividend>
    <PMCB:DeemedDividend
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001875"
      unitRef="USD">3106653</PMCB:DeemedDividend>
    <PMCB:ChangeInFairValueDerivativeLiability
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact001881"
      unitRef="USD">557000</PMCB:ChangeInFairValueDerivativeLiability>
    <PMCB:ChangeInFairValueDerivativeLiability
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001883"
      unitRef="USD">859000</PMCB:ChangeInFairValueDerivativeLiability>
    <PMCB:WarrantLiabilityFairValue
      contextRef="From2025-11-012026-01-31_us-gaap_SeriesAPreferredStockMember_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact001885"
      unitRef="USD">1136000</PMCB:WarrantLiabilityFairValue>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput
      contextRef="AsOf2026-01-31_us-gaap_MeasurementInputExpectedTermMember_custom_DerivativeLiabilityMember"
      decimals="INF"
      id="Fact001886"
      unitRef="USDPShares">0.82</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput
      contextRef="AsOf2026-01-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_DerivativeLiabilityMember"
      decimals="INF"
      id="Fact001887"
      unitRef="Pure">0.850</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput
      contextRef="AsOf2026-01-31_us-gaap_MeasurementInputExpectedTermMember_custom_DerivativeLiabilityMember"
      decimals="INF"
      id="Fact001888"
      unitRef="Year">1.05</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput
      contextRef="AsOf2026-01-31_custom_MeasurementInputRedemptionPremiumMember_custom_DerivativeLiabilityMember"
      decimals="INF"
      id="Fact001889"
      unitRef="Pure">1.06</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput
      contextRef="AsOf2026-01-31_custom_MeasurementInputMarketInterestRateMember_custom_DerivativeLiabilityMember"
      decimals="INF"
      id="Fact001890"
      unitRef="Pure">0.2010</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput
      contextRef="AsOf2026-01-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_DerivativeLiabilityMember"
      decimals="INF"
      id="Fact001891"
      unitRef="Pure">0.0342</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput
      contextRef="AsOf2026-01-31_us-gaap_MeasurementInputExpectedDividendRateMember_custom_DerivativeLiabilityMember"
      decimals="INF"
      id="Fact001892"
      unitRef="Pure">0.0700</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DividendsPreferredStockStock
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact001894"
      unitRef="USD">98458</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001896"
      unitRef="USD">195097</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact001898"
      unitRef="USD">101356</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="From2025-05-01to2026-01-31"
      decimals="0"
      id="Fact001900"
      unitRef="USD">162606</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockPaidinkind
      contextRef="From2025-11-012026-01-31"
      decimals="0"
      id="Fact001902"
      unitRef="USD">32491</us-gaap:DividendsPreferredStockPaidinkind>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-11-012026-01-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001904"
      unitRef="Shares">2234</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2025-11-012026-01-31_us-gaap_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact001906"
      unitRef="Shares">2358620</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:TreasuryStockTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001908">&lt;p id="xdx_801_eus-gaap--TreasuryStockTextBlock_z05biwOFw9D9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 11 &#x2013; &lt;span id="xdx_826_z0QudCCnAqA9"&gt;TREASURY STOCK&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2022, the Board authorized a share repurchase
program to acquire its outstanding common stock for up to $10 million. In January 2023, the Board authorized an additional share repurchase
program to acquire up to an additional $10 million of the Company&#x2019;s outstanding common stock. In conjunction with the share repurchase
programs, the Company selected a broker to repurchase shares on behalf of the Company. The amount of common stock repurchased on any given
trading day is determined by a formula, which is based on the market price of the common stock and average daily volumes. Shares repurchased
are held in treasury for general corporate purposes. The shares are treated as Treasury Stock using the cost method. As of April 2025,
the Company has paused the repurchase program.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 11, 2025, the Company granted the
directors of the Company &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20251210__20251211__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSCY3nNp30bd" title="Restricted stock"&gt;875,000&lt;/span&gt; shares of common stock in a restricted stock unit (&#x201c;RSU&#x201d;) transaction. The RSUs vested immediately
and the Company withheld &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20251210__20251211__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNKiFu3YEpSg" title="Restricted stock vested"&gt;393,750&lt;/span&gt; shares valued at $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_c20251210__20251211__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7MAV44xa0N4" title="Restricted units valued"&gt;401,625&lt;/span&gt; to cover the expected income tax effect of the grants. The Company recorded
stock based compensation expense to general and administrative expenses of $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensation_c20251210__20251211__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zzDtIa02IHR9" title="Stock issued for compensation"&gt;892,500&lt;/span&gt; related to the RSU grants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of January 31, 2026 and April 30, 2025, the
total number of shares held in Treasury Stock was &lt;span id="xdx_90D_eus-gaap--TreasuryStockCommonShares_iI_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--TreasuryStockCommonMember_zeharu2husK8" title="Treasury stock, common shares"&gt;15,270,066&lt;/span&gt; and &lt;span id="xdx_905_eus-gaap--TreasuryStockCommonShares_iI_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--TreasuryStockCommonMember_zJhKLAewAxmg" title="Treasury stock, common shares"&gt;14,876,316&lt;/span&gt;, respectively, shares at total costs of $&lt;span id="xdx_90A_eus-gaap--TreasuryStockCommonValue_iI_pp0p0_c20260131__us-gaap--StatementClassOfStockAxis__us-gaap--TreasuryStockCommonMember_z5eQUeKLUwfa" title="Treasury stock, value"&gt;45,009,541&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--TreasuryStockCommonValue_iI_pp0p0_c20250430__us-gaap--StatementClassOfStockAxis__us-gaap--TreasuryStockCommonMember_zGUTxHAJD8A1" title="Treasury stock, value"&gt;44,607,916&lt;/span&gt;,
respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:TreasuryStockTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2025-12-102025-12-11_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001910"
      unitRef="Shares">875000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2025-12-102025-12-11_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact001912"
      unitRef="Shares">393750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2025-12-102025-12-11_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001914"
      unitRef="USD">401625</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-12-102025-12-11_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact001916"
      unitRef="USD">892500</us-gaap:ShareBasedCompensation>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2026-01-31_us-gaap_TreasuryStockCommonMember266868390"
      decimals="INF"
      id="Fact001918"
      unitRef="Shares">15270066</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2025-04-30_us-gaap_TreasuryStockCommonMember266868390"
      decimals="INF"
      id="Fact001920"
      unitRef="Shares">14876316</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="AsOf2026-01-31_us-gaap_TreasuryStockCommonMember266868390"
      decimals="0"
      id="Fact001922"
      unitRef="USD">45009541</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="AsOf2025-04-30_us-gaap_TreasuryStockCommonMember266868390"
      decimals="0"
      id="Fact001924"
      unitRef="USD">44607916</us-gaap:TreasuryStockCommonValue>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001926">&lt;p id="xdx_80A_eus-gaap--FairValueDisclosuresTextBlock_zQasBjGXWRnl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 12 &#x2013; &lt;span id="xdx_829_z6jXmNqYPeQ5"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Fair value measurements discussed herein are based
upon certain market assumptions and pertinent information available to management as of and during the three and nine months ended January
31, 2026. The carrying amounts of cash equivalents, other current assets, accounts payable and accrued expenses approximate their face
values at January 31, 2026 due to their short-term nature. The fair value of the bifurcated embedded derivative related to the convertible
preferred stock was estimated using a probability-weighted scenario model, which uses as inputs the fair value of the Company&#x2019;s
common stock and estimates for the equity volatility and of the Company&#x2019;s common stock, the time to maturity of the convertible
preferred stock, the risk-free interest rate for a period of time that approximates the time to maturity, the maturity redemption premium
rate, the liquidation premium rate, the market discount rate, and the dividend rate. The fair value of the warrant liability was estimated
using the Black Scholes Merton Model which uses as inputs the following weighted average assumptions, as noted above: dividend yield,
expected terms in years, equity volatility and risk-free rate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Fair Value on a Recurring Basis&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company follows the guidance in ASC 820 for
its financial assets and liabilities that are re-measured and reported at fair at each reporting period, and non-financial assets and
liabilities that are re-measured and reported at fair value at least annually. The estimated fair value of the warrant liability and bifurcated
embedded derivative represent Level 3 measurements. The following table presents information about the Company&#x2019;s liabilities that
are measured at fair value on a recurring basis at January 31, 2026 and April 30, 2025, and indicates the fair value hierarchy of the
valuation inputs the Company utilized to determine such fair value:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zF9lBkc5Vir9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair value)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B6_zCx3vSGvWar2" style="display: none"&gt;Schedule of fair value of financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;April 30, 2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 55%; text-align: justify"&gt;Warrant liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20260131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_ztEgxCLFA8Yg" style="width: 11%; text-align: right" title="Warrant liabilities"&gt;13,657,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FinancialLiabilitiesFairValueDisclosure_pp0p0_c20250430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zpRAlvZ7ydcl" style="width: 11%; text-align: right" title="Warrant liabilities"&gt;338,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;Derivative liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20260131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zELHs1Gy564k" style="text-align: right" title="Warrant liabilities"&gt;1,136,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_d0_c20250430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zTB27IoUPQug" style="text-align: right" title="Warrant liabilities"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zl9Ml1eQruZh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table sets forth a summary of the
change in the fair value of the warrant liability that is measured at fair value on a recurring basis:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zjATpYIMOsv" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of warrant liability)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B4_zK9pFyzu0yq4" style="display: none"&gt;Schedule of change in the fair value warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three Months Ended January 31, 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%"&gt;Balance on October 31, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zPinaFMb2qVl" style="width: 13%; text-align: right" title="Fair value of the warrant liability at beginning"&gt;16,152,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issuance of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pp0p0_d0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zRj80Tmfx8Pb" style="text-align: right" title="Issuance of warrants"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Warrant exercises&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--WarrantExercises_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zGzvOXGHFIOg" style="text-align: right" title="Warrant exercises"&gt;(599,135&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ChangeInFairValueOfWarrantLiability_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability"&gt;(1,895,865&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance on January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zgCPiGJi7Emc" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of the warrant liability at ending"&gt;13,657,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; width: 83%"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center; width: 13%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nine Months Ended January 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Balance on April 30, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zid8xXInSDa1" style="text-align: right" title="Fair value, beginning"&gt;338,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issuance of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_z3f6fB8kM2Jf" style="text-align: right" title="Issuance of warrants"&gt;5,583,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Warrant exercises&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--WarrantExercises_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zGwMiBjNtHwk" style="text-align: right" title="Warrant exercises"&gt;(599,135&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiability_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability"&gt;8,335,135&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance on January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_z8ZefvQM88B" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value, ending"&gt;13,657,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_z03HtV5aCvE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following table sets forth a summary of the
change in the fair value of the derivative liability that is measured at fair value on a recurring basis:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zB3WdxHNSH4b" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of derivative liability)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BE_zBPBqzsLGbJ6" style="display: none"&gt;Schedule of change in the fair value derivative liability&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three Months Ended January 31, 2026&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance on October 31, 2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zz6jtwY1f8ia" style="text-align: right" title="Fair value of the warrant liability at beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,693,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 84%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance of Series C convertible preferred stock&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--IssuanceOfSeriesCConvertiblePreferredStock_pp0p0_d0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zmI71ikrL7jd" style="width: 13%; text-align: right" title="Issuance of Series C convertible preferred stock"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change in fair value of derivative liability&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ChangeInFairValueOfWarrantLiability_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zuPImSdAN83l" style="border-bottom: black 1pt solid; text-align: right" title="Change in fair value of derivative liability"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(557,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance on January 31, 2026&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zJtanI2USiFf" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value of the warrant liability at ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,136,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nine Months Ended January 31, 2026&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance on April 30, 2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_d0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zqDxowByTRS8" style="text-align: right" title="Fair value, beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 84%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance of Series C convertible preferred stock&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--IssuanceOfSeriesCConvertiblePreferredStock_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_pp0p0" style="width: 13%; text-align: right" title="Issuance of Series C convertible preferred stock"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,995,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change in fair value of derivative liability&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiability_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_pp0p0" style="border-bottom: black 1pt solid; text-align: right" title="Change in fair value of derivative liability"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(859,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance on January 31, 2026&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zV8ZJWF4fvzj" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,136,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zDmWku3XIn9f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of the convertible note receivable
was historically estimated using the income approach, which uses as inputs the fair value of debtor&#x2019;s common stock and estimates
for the equity volatility and volume volatility of debtor&#x2019;s common stock, the time to expiration of the convertible note, the discount
rate, the stated interest rate compared to the current market rate, the risk-free interest rate for a period that approximates the time
to expiration, and probability of default. Therefore, the estimate of expected future volatility is based on the actual volatility of
debtor&#x2019;s common stock and historical volatility of debtor&#x2019;s common stock utilizing a lookback period consistent with the time
to expiration. The time to expiration is based on the contractual maturity date. The risk-free interest rate is determined by reference
to the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration.
Probability of default is estimated using the S&amp;amp;P Global default rate for companies with a similar credit rating to debtor&#x2019;s.
At January 31, 2026, the fair value of the convertible note receivable was estimated to be equal to its principal value the note was near
its maturity and was expected to be fully settled in cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair values of financial instruments by class
as of January 31, 2026 and April 30, 2025 are as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zGaBW8wYEk61" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair values of financial instruments)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_zLyMlzDJddi8" style="display: none"&gt;Schedule of fair values of financial instruments by class&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;April 30, 2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Financial Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 55%; text-align: left"&gt;Marketable equity securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: center"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20260131__us-gaap--FinancialInstrumentAxis__custom--MarketableEquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 11%; text-align: right" title="Fair value of financial assets"&gt;372,251&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--MarketableEquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 11%; text-align: right" title="Fair value of financial assets"&gt;366,316&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Money market account&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;1&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20260131__us-gaap--FinancialInstrumentAxis__custom--MoneyMarketAccountMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Fair value of financial assets"&gt;2,081,636&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--MoneyMarketAccountMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Fair value of financial assets"&gt;76,287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible note receivable &#x2013; investment in debt security - Femasys&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_d0_c20260131__us-gaap--FinancialInstrumentAxis__custom--ConvertibleNoteReceivableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zC0yzOpRIE41" style="text-align: right" title="Fair value of financial assets"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--ConvertibleNoteReceivableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets"&gt;3,696,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Warrant asset - Femasys&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20260131__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetFemasysMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets"&gt;906,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetFemasysMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets"&gt;3,061,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Investment in preferred stock - QCLS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_c20260131__us-gaap--FinancialInstrumentAxis__custom--InvestmentInPreferredStockQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaBdqNmylt05" style="text-align: right" title="Fair value of financial assets"&gt;22,472,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--InvestmentInPreferredStockQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets"&gt;22,474,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Warrant assets - QCLS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_c20260131__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z8xXTGJ8HWue" style="text-align: right" title="Fair value of financial assets"&gt;10,242,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets"&gt;8,618,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_z3I6Soh50QTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Assumptions used in the valuation of the Level
3 assets include time to expiration, discount rate, risk-free rate, volatility and probability of default.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001932">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zF9lBkc5Vir9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair value)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B6_zCx3vSGvWar2" style="display: none"&gt;Schedule of fair value of financial liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: justify"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;April 30, 2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 55%; text-align: justify"&gt;Warrant liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20260131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_ztEgxCLFA8Yg" style="width: 11%; text-align: right" title="Warrant liabilities"&gt;13,657,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FinancialLiabilitiesFairValueDisclosure_pp0p0_c20250430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zpRAlvZ7ydcl" style="width: 11%; text-align: right" title="Warrant liabilities"&gt;338,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;Derivative liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_c20260131__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zELHs1Gy564k" style="text-align: right" title="Warrant liabilities"&gt;1,136,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pp0p0_d0_c20250430__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zTB27IoUPQug" style="text-align: right" title="Warrant liabilities"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2026-01-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact001934"
      unitRef="USD">13657000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2025-04-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact001936"
      unitRef="USD">338000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2026-01-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact001938"
      unitRef="USD">1136000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2025-04-30_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact001940"
      unitRef="USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001942">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zjATpYIMOsv" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of warrant liability)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B4_zK9pFyzu0yq4" style="display: none"&gt;Schedule of change in the fair value warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three Months Ended January 31, 2026&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%"&gt;Balance on October 31, 2025&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zPinaFMb2qVl" style="width: 13%; text-align: right" title="Fair value of the warrant liability at beginning"&gt;16,152,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issuance of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pp0p0_d0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zRj80Tmfx8Pb" style="text-align: right" title="Issuance of warrants"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Warrant exercises&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--WarrantExercises_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zGzvOXGHFIOg" style="text-align: right" title="Warrant exercises"&gt;(599,135&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ChangeInFairValueOfWarrantLiability_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability"&gt;(1,895,865&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance on January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zgCPiGJi7Emc" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value of the warrant liability at ending"&gt;13,657,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; width: 83%"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: center; width: 13%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nine Months Ended January 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Balance on April 30, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zid8xXInSDa1" style="text-align: right" title="Fair value, beginning"&gt;338,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Issuance of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_z3f6fB8kM2Jf" style="text-align: right" title="Issuance of warrants"&gt;5,583,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Warrant exercises&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--WarrantExercises_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_zGwMiBjNtHwk" style="text-align: right" title="Warrant exercises"&gt;(599,135&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiability_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value of derivative liability"&gt;8,335,135&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance on January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--WarrantLiabilityMember_z8ZefvQM88B" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value, ending"&gt;13,657,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2025-10-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact001944"
      unitRef="USD">16152000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
      contextRef="From2025-11-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact001946"
      unitRef="USD">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues>
    <PMCB:WarrantExercises
      contextRef="From2025-11-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact001948"
      unitRef="USD">-599135</PMCB:WarrantExercises>
    <PMCB:ChangeInFairValueOfWarrantLiability
      contextRef="From2025-11-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact001950"
      unitRef="USD">-1895865</PMCB:ChangeInFairValueOfWarrantLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact001952"
      unitRef="USD">13657000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2025-04-30_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact001954"
      unitRef="USD">338000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
      contextRef="From2025-05-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact001956"
      unitRef="USD">5583000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues>
    <PMCB:WarrantExercises
      contextRef="From2025-05-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact001958"
      unitRef="USD">-599135</PMCB:WarrantExercises>
    <PMCB:ChangeInFairValueOfWarrantLiability
      contextRef="From2025-05-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact001960"
      unitRef="USD">8335135</PMCB:ChangeInFairValueOfWarrantLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_WarrantLiabilityMember"
      decimals="0"
      id="Fact001962"
      unitRef="USD">13657000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001964">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zB3WdxHNSH4b" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Changes in fair value of derivative liability)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BE_zBPBqzsLGbJ6" style="display: none"&gt;Schedule of change in the fair value derivative liability&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Three Months Ended January 31, 2026&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance on October 31, 2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zz6jtwY1f8ia" style="text-align: right" title="Fair value of the warrant liability at beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,693,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 84%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance of Series C convertible preferred stock&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--IssuanceOfSeriesCConvertiblePreferredStock_pp0p0_d0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zmI71ikrL7jd" style="width: 13%; text-align: right" title="Issuance of Series C convertible preferred stock"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change in fair value of derivative liability&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ChangeInFairValueOfWarrantLiability_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zuPImSdAN83l" style="border-bottom: black 1pt solid; text-align: right" title="Change in fair value of derivative liability"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(557,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance on January 31, 2026&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20251101__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zJtanI2USiFf" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value of the warrant liability at ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,136,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Nine Months Ended January 31, 2026&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance on April 30, 2025&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iS_pp0p0_d0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zqDxowByTRS8" style="text-align: right" title="Fair value, beginning"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 84%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issuance of Series C convertible preferred stock&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--IssuanceOfSeriesCConvertiblePreferredStock_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_pp0p0" style="width: 13%; text-align: right" title="Issuance of Series C convertible preferred stock"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,995,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change in fair value of derivative liability&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ChangeInFairValueOfWarrantLiability_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_pp0p0" style="border-bottom: black 1pt solid; text-align: right" title="Change in fair value of derivative liability"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(859,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance on January 31, 2026&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iE_pp0p0_c20250501__20260131__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FinancialInstrumentAxis__custom--DerivativeLiabilityMember_zV8ZJWF4fvzj" style="border-bottom: black 2.25pt double; text-align: right" title="Fair value, ending"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,136,000&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2025-10-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact001966"
      unitRef="USD">1693000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <PMCB:IssuanceOfSeriesCConvertiblePreferredStock
      contextRef="From2025-11-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact001968"
      unitRef="USD">0</PMCB:IssuanceOfSeriesCConvertiblePreferredStock>
    <PMCB:ChangeInFairValueOfWarrantLiability
      contextRef="From2025-11-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact001970"
      unitRef="USD">-557000</PMCB:ChangeInFairValueOfWarrantLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact001972"
      unitRef="USD">1136000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2025-04-30_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact001974"
      unitRef="USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <PMCB:IssuanceOfSeriesCConvertiblePreferredStock
      contextRef="From2025-05-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact001976"
      unitRef="USD">1995000</PMCB:IssuanceOfSeriesCConvertiblePreferredStock>
    <PMCB:ChangeInFairValueOfWarrantLiability
      contextRef="From2025-05-012026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact001978"
      unitRef="USD">-859000</PMCB:ChangeInFairValueOfWarrantLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="AsOf2026-01-31_us-gaap_FairValueMeasurementsRecurringMember_custom_DerivativeLiabilityMember"
      decimals="0"
      id="Fact001980"
      unitRef="USD">1136000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="From2025-05-01to2026-01-31" id="Fact001986">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zGaBW8wYEk61" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details - Fair values of financial instruments)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B3_zLyMlzDJddi8" style="display: none"&gt;Schedule of fair values of financial instruments by class&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;January 31, 2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;April 30, 2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Financial Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 55%; text-align: left"&gt;Marketable equity securities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: center"&gt;1&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20260131__us-gaap--FinancialInstrumentAxis__custom--MarketableEquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 11%; text-align: right" title="Fair value of financial assets"&gt;372,251&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--MarketableEquitySecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 11%; text-align: right" title="Fair value of financial assets"&gt;366,316&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Money market account&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;1&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20260131__us-gaap--FinancialInstrumentAxis__custom--MoneyMarketAccountMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Fair value of financial assets"&gt;2,081,636&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--MoneyMarketAccountMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Fair value of financial assets"&gt;76,287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible note receivable &#x2013; investment in debt security - Femasys&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_d0_c20260131__us-gaap--FinancialInstrumentAxis__custom--ConvertibleNoteReceivableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zC0yzOpRIE41" style="text-align: right" title="Fair value of financial assets"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--ConvertibleNoteReceivableMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets"&gt;3,696,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Warrant asset - Femasys&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20260131__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetFemasysMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets"&gt;906,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetFemasysMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets"&gt;3,061,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Investment in preferred stock - QCLS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_c20260131__us-gaap--FinancialInstrumentAxis__custom--InvestmentInPreferredStockQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaBdqNmylt05" style="text-align: right" title="Fair value of financial assets"&gt;22,472,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--InvestmentInPreferredStockQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets"&gt;22,474,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Warrant assets - QCLS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FinancialInstrumentsOwnedAtFairValue_iI_pp0p0_c20260131__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z8xXTGJ8HWue" style="text-align: right" title="Fair value of financial assets"&gt;10,242,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FinancialInstrumentsOwnedAtFairValue_c20250430__us-gaap--FinancialInstrumentAxis__custom--WarrantAssetQCLSMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Fair value of financial assets"&gt;8,618,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:FinancialInstrumentsOwnedAtFairValue
      contextRef="AsOf2026-01-31_custom_MarketableEquitySecuritiesMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001988"
      unitRef="USD">372251</us-gaap:FinancialInstrumentsOwnedAtFairValue>
    <us-gaap:FinancialInstrumentsOwnedAtFairValue
      contextRef="AsOf2025-04-30_custom_MarketableEquitySecuritiesMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001990"
      unitRef="USD">366316</us-gaap:FinancialInstrumentsOwnedAtFairValue>
    <us-gaap:FinancialInstrumentsOwnedAtFairValue
      contextRef="AsOf2026-01-31_custom_MoneyMarketAccountMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001992"
      unitRef="USD">2081636</us-gaap:FinancialInstrumentsOwnedAtFairValue>
    <us-gaap:FinancialInstrumentsOwnedAtFairValue
      contextRef="AsOf2025-04-30_custom_MoneyMarketAccountMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact001994"
      unitRef="USD">76287</us-gaap:FinancialInstrumentsOwnedAtFairValue>
    <us-gaap:FinancialInstrumentsOwnedAtFairValue
      contextRef="AsOf2026-01-31_custom_ConvertibleNoteReceivableMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001996"
      unitRef="USD">0</us-gaap:FinancialInstrumentsOwnedAtFairValue>
    <us-gaap:FinancialInstrumentsOwnedAtFairValue
      contextRef="AsOf2025-04-30_custom_ConvertibleNoteReceivableMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001998"
      unitRef="USD">3696000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
    <us-gaap:FinancialInstrumentsOwnedAtFairValue
      contextRef="AsOf2026-01-31_custom_WarrantAssetFemasysMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact002000"
      unitRef="USD">906000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
    <us-gaap:FinancialInstrumentsOwnedAtFairValue
      contextRef="AsOf2025-04-30_custom_WarrantAssetFemasysMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact002002"
      unitRef="USD">3061000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
    <us-gaap:FinancialInstrumentsOwnedAtFairValue
      contextRef="AsOf2026-01-31_custom_InvestmentInPreferredStockQCLSMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact002004"
      unitRef="USD">22472000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
    <us-gaap:FinancialInstrumentsOwnedAtFairValue
      contextRef="AsOf2025-04-30_custom_InvestmentInPreferredStockQCLSMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact002006"
      unitRef="USD">22474000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
    <us-gaap:FinancialInstrumentsOwnedAtFairValue
      contextRef="AsOf2026-01-31_custom_WarrantAssetQCLSMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact002008"
      unitRef="USD">10242000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
    <us-gaap:FinancialInstrumentsOwnedAtFairValue
      contextRef="AsOf2025-04-30_custom_WarrantAssetQCLSMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact002010"
      unitRef="USD">8618000</us-gaap:FinancialInstrumentsOwnedAtFairValue>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2025-11-012026-01-31" id="Fact002011">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2025-11-012026-01-31" id="Fact002012">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2025-11-012026-01-31" id="Fact002013">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2025-11-012026-01-31" id="Fact002014">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
